PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (P

(51) International Patent Classification 6 :
A01N 37/18, 43/04, C12Q 1/00, 1/02, 1/68, C12N 5/00, 5/06, 15/00, 15/06, 15/09, 15/10, 15/11, G01N 33/53

A2

(11) International Publication Number: WO 9

(43) International Publication Date: 10 December 1998 (10.12.98)

(21) International Application Number: PCT/US98/11422

(22) International Filing Date: 4 June 1998 (04.06.98)

(30) Priority Data:

60/048,915	6 June 1997 (06.06.97)	US
60/048,882	6 June 1997 (06.06.97)	US

(Continued on the following page)

(71) Applicant (*for all designated States except US*): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): YOUNG, Paul [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). GREENE, John, M. [US/US]; 872 Diamond Drive, Gaithersburg, MD 20878 (US). FERRIE, Ann, M. [US/US]; 13203 L Astoria Hill Court, Germantown, MD 20874 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). HU, Jing-Shan [CN/US]; 1247 Lakeside Drive #3034, Sunnyvale, CA 94086 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; 14920 Mt. Nebo Road, Poolesville, MD 20837 (US). MOORE, Paul, A. [GB/US]; Apartment 104, 1908 Holly Ridge Drive, McLean, VA 22102 (US). SHI, Yanggu [CN/US]; 437 West Side Drive, Gaithersburg, MD 20878 (US). FLORENCE, Charles [US/US]; (US). FLORENCE, Kimberly [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). LAFLEUR, David, W. [US/US]; 1615 Q Street, N.W. #807, Washington, DC 20009 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). FAN, Ping [CN/US]; Apartment 302, 335 West Side Drive, Gaithesburg, MD 20878 (US). WEI, Ying-Fei [CN/US]; 13524 Straw Bale Lane, Darnestown, MD 20878 (US). FISCHER, Carrie, L. [US/US]; 5810 Hall Street, Burke, VA 22015 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). LI, Yi [CN/US]; 1247 Lakeside Drive #3034, Sunnyvale, CA 94086 (US). ZENG, Zhizhen [CN/US]; 13950 Saddleview Drive, Gaithersburg, MD 20878 (US). KYAW, Hla [MM/US]; 520 Sugarbush Circle, Frederick, MD 21703 (US). YU, Guo-Liang [CN/US]; 13524 Straw Bale Lane, Darnestown, MD 20878 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). DILLON, Patrick, J. [US/US]; 1055 Snipe Court, Carlsbad, CA 92009 (US). ENDRESS, Gregory, A. [US/US]; 972 Bagett Farm Drive, Potomac, MD 20854 (US). CART ... [US/US]; 11601 Brandy Hall Lane, N ..., MD 20878 (US).

(74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 10850 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority.

(54) Title: 207 HUMAN SECRETED PROTEINS

(Continued)

60/048,892	6 June 1997 (06.06.97)	US
60/048,901	6 June 1997 (06.06.97)	US
60/048,900	6 June 1997 (06.06.97)	US
60/048,893	6 June 1997 (06.06.97)	US
60/048,964	6 June 1997 (06.06.97)	US
60/048,884	6 June 1997 (06.06.97)	US
60/048,894	6 June 1997 (06.06.97)	US
60/048,971	6 June 1997 (06.06.97)	US
60/048,885	6 June 1997 (06.06.97)	US
60/049,375	6 June 1997 (06.06.97)	US
60/048,881	6 June 1997 (06.06.97)	US
60/048,880	6 June 1997 (06.06.97)	US
60/048,896	6 June 1997 (06.06.97)	US
60/049,020	6 June 1997 (06.06.97)	US
60/048,876	6 June 1997 (06.06.97)	US
60/048,895	6 June 1997 (06.06.97)	US
60/049,019	6 June 1997 (06.06.97)	US
60/048,916	6 June 1997 (06.06.97)	US
60/048,970	6 June 1997 (06.06.97)	US
60/048,972	6 June 1997 (06.06.97)	US
60/048,949	6 June 1997 (06.06.97)	US
60/048,974	6 June 1997 (06.06.97)	US
60/048,883	6 June 1997 (06.06.97)	US
60/048,897	6 June 1997 (06.06.97)	US
60/048,898	6 June 1997 (06.06.97)	US
60/049,373	6 June 1997 (06.06.97)	US
60/048,917	6 June 1997 (06.06.97)	US
60/048,962	6 June 1997 (06.06.97)	US
60/048,878	6 June 1997 (06.06.97)	US
60/049,374	6 June 1997 (06.06.97)	US
60/048,875	6 June 1997 (06.06.97)	US
60/048,899	6 June 1997 (06.06.97)	US
60/048,877	6 June 1997 (06.06.97)	US
60/048,963	6 June 1997 (06.06.97)	US

60/057,651	5 September 1997 (05.09.97)	US
60/057,769	5 September 1997 (05.09.97)	US
60/057,643	5 September 1997 (05.09.97)	US
60/057,645	5 September 1997 (05.09.97)	US
60/057,668	5 September 1997 (05.09.97)	US
60/057,635	5 September 1997 (05.09.97)	US
60/057,627	5 September 1997 (05.09.97)	US
60/057,667	5 September 1997 (05.09.97)	US
60/057,666	5 September 1997 (05.09.97)	US
60/057,764	5 September 1997 (05.09.97)	US
60/057,644	5 September 1997 (05.09.97)	US
60/057,765	5 September 1997 (05.09.97)	US
60/057,762	5 September 1997 (05.09.97)	US
60/057,775	5 September 1997 (05.09.97)	US
60/057,634	5 September 1997 (05.09.97)	US
60/057,777	5 September 1997 (05.09.97)	US
60/057,628	5 September 1997 (05.09.97)	US
60/057,776	5 September 1997 (05.09.97)	US
60/057,760	5 September 1997 (05.09.97)	US
60/057,761	5 September 1997 (05.09.97)	US
60/057,771	5 September 1997 (05.09.97)	US
60/057,770	5 September 1997 (05.09.97)	US
60/057,649	5 September 1997 (05.09.97)	US
60/057,774	5 September 1997 (05.09.97)	US
60/057,648	5 September 1997 (05.09.97)	US
60/057,642	5 September 1997 (05.09.97)	US
60/057,629	5 September 1997 (05.09.97)	US
60/057,778	5 September 1997 (05.09.97)	US
60/057,763	5 September 1997 (05.09.97)	US
60/057,584	5 September 1997 (05.09.97)	US
60/057,654	5 September 1997 (05.09.97)	US
60/057,646	5 September 1997 (05.09.97)	US
60/057,662	5 September 1997 (05.09.97)	US
60/057,650	5 September 1997 (05.09.97)	US
60/057,661	5 September 1997 (05.09.97)	US
60/057,647	5 September 1997 (05.09.97)	US
60/070,923	18 December 1997 (18.12.97)	US

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania
AM	Armenia
AT	Austria
AU	Australia
AZ	Azerbaijan
BA	Bosnia and Herzegovina
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CU	Cuba
CZ	Czech Republic
DE	Germany
DK	Denmark
EE	Estonia
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GH	Ghana
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IL	Israel
IS	Iceland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgyzstan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakstan
LC	Saint Lucia
LI	Liechtenstein
LK	Sri Lanka
LR	Liberia
LS	Lesotho
LT	Lithuania
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
MK	The former Yugoslav Republic of Macedonia
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
MX	Mexico
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SG	Singapore
SI	Slovenia
SK	Slovakia
SN	Senegal
SZ	Swaziland
TD	Chad
TG	Togo
TJ	Tajikistan
TM	Turkmenistan
TR	Turkey
TT	Trinidad and Tobago
UA	Ukraine
UG	Uganda
US	United States of America
UZ	Uzbekistan
VN	Viet Nam
YU	Yugoslavia
ZW	Zimbabwe

207 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoeitin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein , a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH_2PO_4; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking [illegible]

[illegible]

as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a

complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched , for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine,

formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

This gene is expressed primarily in melanocytes and, to a lesser extent, in testes, ovary, kidney and other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer, disorders of neural crest derived cells including pigmentation [illegible] immunological probes for differential identification of the tissue(s) or cell type(s) [illegible] a number of disorders of the above tissues or cells, particularly of the skin.

reproductive, and renal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating disorders that arise from alterations in the number or fate of neural crest derived cells including cancers such as melanoma and defects of the developing reproductive system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

This gene is expressed primarily in infant brain and fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental disorders of the brain or lung. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and pulmonary systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating or diagnosing disorders associated with abnormal proliferation of cells in the Central nervous system and developing lung.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

This gene is expressed primarily in breast lymph node and to a lesser extent in ovarian cancer and chondrosarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune responses such as inflammation or immune surveillance for

tumors. This gene may be important for inflammatory responses associated with tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 236 as residues: Lys-45 to Val-50, Lys-69 to Arg-76.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of immune responses including those associated with tumor-induced inflammation.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

This gene is expressed primarily in T-cells and T-cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunilogical diseases involving T-cells such as inflammation, autoimmunity, and cancers including T-cell lymphomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of T-cells and other cells of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating T-cell based disorders

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

This gene is expressed primarily in activated monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation, autoimmunity, infection, or disorders involving activation of monocytes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 238 as residues: Asp-19 to Arg-31.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing or treating diseases that result in activation of monocytes including infections, inflammatory responses or autoimmune diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

The translation product of this gene shares sequence homology with terminal deoxynucleotidyltransferase which is thought to be important in catalyzing the elongation of oligo- or polydeoxynucleotide chains.

This gene is expressed primarily in activated human neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, particularly those of the blood such as leukemia and deficiencies in neutrophils such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having

such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to terminal deoxynucleotidyltransferase indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and differential diagnosis of acute leukemia's. Alternatively, this gene may function in the proliferation of neutrophils and be useful as a treatment for neutropenia, for example, following neutropenia as a result of chemotherapy.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The contig exhibits a reasonable homology to the human chorionic gonadotropic (HCG) analogue-GT beta-subunit as disclosed in U.S. Patent No. 5,508,261 and PCT Publication No. WO 92/22568. There is a high degree of conservation of the structurally important cysteine residues in these identities.

This gene is expressed primarily in IL-1 and LPS induced neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 241 as residues: Ser-14 to Pro-22, Leu-43 to Val-53.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

This gene is expressed primarily in IL-1 and LPS induced neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 242 as residues: Tyr-22 to His-35.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth

factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

This gene is expressed primarily in activated T-cells and to a lesser extent in endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune dysfunctions including cancer of the T lymphocytes and autoimmune disorders and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of immune disorders particularly of T-cell origin and may act as a growth factor for particular subsets of T-cells such as CD4 positive cells which would make this a useful therapeutic for the treatment of HIV and other immune compromising illnesses.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

This gene is expressed primarily in fetal tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of many developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of thi[illegible]

[illegible] synovial fluid or spinal fluid) or another tissue or [illegible] sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a growth factor or differentiation factor for particular cell types in the developing fetus and may be useful in replacement or other types of therapy in cases where the gene is expressed aberrantly.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

This gene is expressed primarily in T-cells and to a lesser extent in tumor tissue including glioblastoma, meningioma, and Wilm's tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system including autoimmune conditions such as rheumatoid arthritis, inflammatory disorders and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 245 as residues: Thr-9 to Ser-14.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis/ modulation of immune function disorders, including rheumatoid arthritis and inflammatory responses.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

This gene is expressed primarily in placenta and to a lesser extent in fetal liver and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of hematological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

disorders of the above tissues or cells, particularly of the hematological and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a growth factor for hematapoietic stem cells or progenitor cells in the treatment of chemotherapy patients or kidney disease.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

This gene is expressed primarily in stromal cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of hematapoietic disorders including cancer, neutropenia, anemia, and thrombocytopenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematapoietic and immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a growth factor for hematapoietic stem cells or progenitor cells, in particular following chemotherapy treatment.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The translation product of this gene shares sequence homology with epsilon-COP from Bos taurus which is thought to be important as a component of coatomer, a complex of seven proteins that is the major [illegible]

MAPPAPGPASGGSGEVDELFDVKNAFYIGSYQQCINEAXXVKLSSPERDVERD

VFLYRAYLAQRKFGVVLDEIKPSSAPELQAVRMFADYLAHESRRDSIVAELDRE MSRSXDVTNTTFLLMAASIYLHDQNPDAALRALHQGDSLECTAMTVQILLKLD RLDLARKELKRMQDLDEDATLTQLATAWVSLATGGEKLQDAYYIFQEMADKCS PTLLLLNGQAACHMAQGRWEAAEGLLQEALDKDSGYPETLVNLIVLSQHLGKP PEVTNRYLSQLKDAHRSHPFIKEYQAKENDFDRLVLQYAPSAEAGPELSGP (SEQ ID NO:458); or RDVERDVFLYRAYLAQRKFGVVLDEIKPSSAPELQAVRMF ADYLAHESRRDSIVAELDREMSRSXDVTNTTFLLMAASIYLHDQNPDAALRALH QGDSLECTAMTVQILLKLDRLDLARKELKRMQDLDEDATLTQLATAWVSLATG GEKLQDAYYIFQEMADKCSPTLLLLNGQAACHMAQGRWEAAEGLLQEALDKD SGYPETLVNLIVLSQHLGKPPEVTNRYLSQLKDAHRSHPFIKEYQAKENDFDRL VLQYAPSA (SEQ ID NO:459).

This gene is expressed primarily in activated monocytes and T-cells, and to a lesser extent in multiple other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunomodulation, specifically relating to transport problems in these cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to epsilon-COP indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating /diagnosing problems with the cellular transport of proteins that may result in immunologic dysfunction.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

The translation product of this gene shares sequence homology with an RNA helicase which is thought to be important in polynucleotide metabolism. The translation product of this contig exhibits good homology to the LbeIF4A antigen of Leishmania braziliensis. The LbeIF4A antigen, or immunogenic portions of it, can be used to induce protective immunity against leishmaniasis, specifically L. donovani, L. chagasi,

L. infantum, L. major, L. braziliensis, L. panamensis, L. tropica and L. guyanensis. It can also be used diagnostically to detect Leishmania infection or to stimulate a cellular and/or humoral immune response or to stimulate the production of interleukin-12.

This gene is expressed primarily in colon cancer and to a lesser extent in pituitary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of cancers particularly of the colon. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 249 as residues: Glu-93 to Ala-98, Gln-150 to Leu-156, Leu-220 to Leu-231, Leu-268 to Arg-273, Val-324 to Pro-341, Arg-372 to Asn-380, Ser-405 to Gly-410, Phe-426 to Ala-433, Glu-458 to Asp-470, Arg-506 to Ser-547.

The tissue distribution and homology to RNA helicase indicates that polynucleotides and polypeptides corresponding to this gene are useful for development of diagnostic tests for colon cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The translation product of this contig has sequence homology to a cytoplasmic protein that binds specifically to JNK designated the JNK interacting protein-1 or JIP-1 in mice. JIP-1 caused cytoplasmic retention of JNK and inhibition of JNK-regulated gene expression.

This gene is expressed primarily in brain including pituitary cerebellum frontal cortex, fetal brain and to a lesser extent in the kidney cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification [illegible]

[illegible] schizophrenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological

probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Furthermore, the translation product of this contig may suppress the effects of the JNK signaling pathway on cellular proliferation, including transformation by the Bcr-Abl oncogene. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 250 as residues: Pro-6 to Ser-26, Ala-30 to Asp-41, Gly-55 to Ser-61, Gly-74 to Thr-80, Tyr-117 to Ala-123, Tyr-167 to Asp-172, Ala-212 to Cys-223, Pro-239 to Tyr-244.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for enhanced survival and/or differentiation of neurons as a treatment for neurodegenerative disease.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The translation product of this gene shares sequence homology with a liver stage antigen from a protozoan parasite.

This gene is expressed primarily in fetal tissue and to a lesser extent in activated T-cells and other immune cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities and diseases of immune function. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to a protozoan antigen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/immune modulation of parasitic infections.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

Preferred polypeptide encoded by this gene comprise the following polypeptide sequences:
MKAIGIEPSLATYHHIRLFDQPGDPLKRSSFIIYDIMNELMGKRFSPKD PDDDKFFQSAMSICSSLRDLELAYQVHGLLKTGDNWKFIGPDQHRNFYYSKFF DLICLMEQIDVTLKWYEDLIPSAYFPHSQTMIHLLQALDVANRLEVIPKIWER (SEQ ID NO:460); and/or KDSKEYGHTFRSDLREEILMLMARDKHPPELQVAF ADCAADIKSAYESQPIRQTAQDWPATSLNCIAILFLRAGRTQEAWKMLGLFRKH NKIPRSELLNELMDSAKVSNSPSQAIEVVELASAFSLPICEGLTQRVMSDFAINQ EQKEALSNLTALTSDSDTDSSSDSDSDTSEGK (SEQ ID NO:461). Polynucleotides encoding such polypeptides are also provided.

This gene is expressed primarily in stromal and CD34 depleted bone marrow cells and to a lesser extent in tissues of embryonic origin.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of hematologic origin including cancers and immune dysfunction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematapoietic and immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 252 as residues: Ser-28 to Gln-34.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a growth factor for hematopoietic stem cells or progenitor cells which may be [illegible]

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

Preferred polypeptide fragments can be found in an alternative open reading frame. These preferred polypeptides comprise the amino acid sequence: MSSDNESDIEDEDLKLELRRLRDKHLKEIQDLQSRQKHEIESLYTKLGKVPPAVIIPPAAPLSGRRRRPTKSKGSKSSRSSSLGNKSPQLSGNLSGQSAASVLHPQQTLHPPGNIPESGQNQLLQPLKPSPSSDNLYSAFTSDGAISVPSLSAPGQGTSSTNTVGATVNSQAAQAQPPAMTSSRKGTFTDDLHKLVDNWARDAMNLSGRRGSKGHMNYEGPGMARKFSAPGQLCISMTSNLGGSAPISAASATSLGHFTKSMCPPQQYGFPATPFGAQWSGTGGPAPQPLGQFQPVGTASLQNFNISNLQKSISNPPGSNLRTT (SEQ ID NO:462); IQDLQSRQKHEIESLYTKLGKVPPAVIIPPAAPLSGRRRRPTKSKGSKSSRSSSLGNKSPQLSGNLSGQSAASVLHPQQTLHPPGNIPESGQNQLLQPLKPSPSSDNLYSAFTSDGAISVPSLSAPGQGTSST (SEQ ID NO:463); TSDGAISVPSLSAPGQGTSSTNTVGATVNSQAAQAQPPAMTSSRKGTFTDDLH (SEQ ID NO:464); KGHMNYEGPGMARKFSAPGQLCISMTSNLGGSAPISAASATSLGHFTK (SEQ ID NO:465); QPLKPSPSSDNLYSAFTSDGAISVPSLSAPG (SEQ ID NO:466). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed in fetal liver and tissues associated with the CNS.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver and CNS diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver and CNS, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 253 as residues: Gln-26 to Lys-34.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for liver diseases such as hepatocellular carcinomas and diseases of the CNS.

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

In an alternative reading frame, this gene shows sequence homology to two recently cloned genes, karyopherin beta 3 and Ran_GTP binding protein 5. (See Accession Nos. gi|2102696 and gnl|PID|e328731.) The Ran_GTP binding protein is related to importin-beta, the key mediator of nuclear localization signal (NLS)-dependent nuclear transport. Based on homology, it is likely that this gene may activity similar to the RAN_GTP binding protein. Preferred polypeptide fragments comprise the amino acid sequence: VRVAAAESMXLLLECAXVRGPEYLTQMWHFMCDALIKA IGTEPDSDVLSEIMHSFAK (SEQ ID NO:467). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed in thymus tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

This gene is expressed primarily in prostate and osteoclastoma tissues. Preferred polypeptide fragments also comprise the amino acid sequence: MEINNQNCFIVIDLVRTVMENGVEGLLIFGAFLPESWLIGVRCSSEPPKALLLIL AHSQKRRLDGWSFIRHLRVHYCVSLTIHFS (SEQ ID NO:468). Also preferred are polynucleotide sequences encoding this polypeptide fragment.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification [illegible]

[illegible] bone and prostate tissues [illegible] particularly [illegible] prostate. Similarly, polypeptides and antibodies directed to these polypeptides are

useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bone and prostate systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 255 as residues: Met-1 to Ser-11.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for bone and prostate disorders, especially cancers of those systems.

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

This gene shares sequence homology with the FK506-binding protein (FKBP-13) family, a known cytosolic receptor for the immunosuppressants. Recently, another group has cloned a very similar gene, recognizing the homology to FK506-binding protein family, calling their gene FKBP23. (See Accession No. 2827255.)

This gene is expressed primarily in lymphoid tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample, especially for those susceptible to immune suppressant therapies and for diagnosis of diseases and conditions, which include, but are not limited to, immune suppressant disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 256 as residues: Ala-19 to Val-31, Arg-38 to Gly-49, Ala-61 to Lys-66, Tyr-68 to Pro-78, Gly-116 to Ala-121, Asp-154 to Ser-162, Glu-173 to Gln-186, Phe-194 to Gly-203, Pro-207 to Val-212.

The tissue distribution and homology to FKBP-12 and -13 indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for immune suppressant disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

This gene is expressed primarily in the brain and in the retina. This gene maps to chromosome 8, and therefore can be used in linkage analysis as a marker for chromosome 8.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological and ocular associated disease states. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the disorders of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 257 as residues: Cys-34 to Asp-40.

The tissue distribution in retina indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of eye disorders including blindness, color blindness, impaired vision, short and long sightedness, retinitis pigmentosa, retinitis proliferans, and retinoblastoma. Expression in the brain indicates a role in the is useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

This gene shows sequence homology to a newly identified class of proteins expressed in the nervous system called [illegible]

[illegible] phosphoprotein involved as a relay integrating various intracellular signaling pathways. These pathways affect cell proliferation and differentiation.

Preferred polypeptide fragments comprise the amino acid sequence: QDKHAEEVRKNKELKEEASR (SEQ ID NO:469); QQDLSPWAAPVGCPLXXASX TCHXLPLSGCLRRQSXSLPVVAXLCFWFSCPLASLFVPGQPCVTCPFPSLPFQD KHAEEVRKNKELKEEASR (SEQ ID NO:470). Also preferred are the polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntintons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

The polynucleotide sequence of this gene contains a domain similar to a Flt3 ligand peptide. Preferred polypeptide fragments comprise the amino acid sequence: PTRCCTTQPCRSSARRPCWVPMVPSPEGREXQPTCPS (SEQ ID NO:471). Thus, this gene may have activity as binding to Flt3 receptors, a process known to promote angiogenesis and/or lymphangiogenesis.

This gene is expressed in human tonsil, and to a lesser extent in teratocarcinoma, placenta, colon carcinoma, and fetal kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the tonsil, as well as cancers, such as colon, reproductive, and kidney cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful

in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the tonsils, colon, reproductive organs, and kidneys, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 259 as residues: Pro-22 to Glu-33.

The tissue distribution in tonsil and several cancers and fetal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the tonsil or colon, such as tonsillitis, inflammatory diseases involving nose and paranasal sinuses, especially during the infection of influenza, adenoviruses, parainfluenza, rhinoviruses. The gene may also be useful in the diagnosis and treatment of neoplasms of nasopharynx or colon origins.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

In an alternative reading frame exists a large open reading frame that encodes a preferred polypeptide. Preferred polypeptide fragments comprise the amino acid sequence:
MKRSLNENSARSTAGCLPVPLFNQKKRNRQPLTSNPLKDDSGISTPSDNYDFP
PLPTDWAWEAVNPEXAPVMKTVDTGQIPHSVSRPLRSQDSVFNSIQSNTGRSQ
GGWSYRDGNKNTSLKTWXKNDFKPQCKRTNLVANDGKNSCPMSSGAQQQK
QLRTPEPPNLSRNKETELLRQTHSSKISGCTMRGLDKNSALQTLKPNFQQNQY
KXQMLDDIPEDNTLKETSLYQLQFKEKASSLRIISAVIESMKYWREHAQKTVLL
FEVLAVLDSAVTPGPYYSKTFLMRDGKNTLPCVFYEIDRELPRLIRGRVHRCVG
NYDQKKNIFQCVSVRPASVSEQKTFQAFVKIADVEMQYYINVMNET (SEQ ID NO:472); SQDSVFNSIQSNTGRSQGGWSYRDGNKNTSLKTWXKNDFKPQCKR (SEQ ID NO:473); NKETELLRQTHSSKISGCTMRGLDKNSALQTLKPNF (SEQ ID NO:474):SSLRIISAVIESMKYWREHAQKTVLLFEVLAVLDSAVTPGPYYSKTFLM (SEQ ID NO:475); and PRLIRGRVHRCVGNYDQKKNIFQCVSVRPASVSEQKT FQAFV (SEQ ID NO:476).

This gene is expressed primarily [illegible]

[illegible] for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, male reproductive disorders, including cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a hormone with reproductive or other systemic functions; contraceptive development; male infertility of testicular causes, such as Kleinfelterís syndrome, varicocele, orchitis; male sexual dysfunctions; testicular neoplasms; and inflammatory disorders such as epididymitis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

This gene is expressed primarily in apoptotic T-cell.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases relating to T cells, as well as cancer in general. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the disorders of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders. Moreover, since the gene was isolated from an apoptotic cell and based on the understanding of the relationship of apoptosis and cancer, it is likely that this gene may play a role in the genesis of cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

This gene is expressed primarily in human tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, gastrointestinal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of gastrointestinal diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

The translation product of this gene shares sequence homology with C44C1.2 gene product of Caenorhabditis elegans with unknown function. Preferred polypeptide fragments comprise the amino acid sequence: GVFRPCVCGRPASLTCSPLDPEVGPYCDTPTMRTLFNLLWLALACSPVHTTLSK SDAKKAASKTLLEKSQFSDKPVQDRGLVVTDLKAESVVLEHRSYCSAKARDRH FAGDVLGYVTPWNSHGYDVTKVFGSKFTQISPVWLQLKRRGREMFEVTGLHD VDQGWMRAVRKHAKGLHIVPRLLFEDWTYDDFRNVLDSEDEIEELSKTVVQVA KNQHFDGFVVEVWNQLLSQKRVGLIHMLTHLAEALHQARLLALLVIPPAITPGT DQLGMFTHKEFEQLAPVLDGFSLMTYDYSTAHQPGPNAPLSWVRACVQVLDP KXKWRTKSSWGSTSMXWTXRXPXDARXPVVGXRXIQXLKDHXPRMVLDSK PQ (SEQ ID NO:477); TCSPLDPEVGPYCDTPTMRTLFNLLWLALACSPVHTTLS (SEQ ID NO:478); LVVTDLKAESVVLEHRSYCSAKARDRHFAGDVLGYVTPW NSHGYDVTKVFGSKF (SEQ ID NO:479); REMFEVTGLHDVDQGWMRAVRK HAKGLHIVPRLLFEDWTYDDFRNVLDSEDE (SEQ ID NO:480); [illegible] AHQPGPNAPLSWVRACVQVLDPKXKWRTKSSW GST (SEQ ID NO:482). Also preferred are polynucleotide fragments encoding these

polypeptide fragments. This gene maps to human chromosome 11, and therefore is useful in linkage analysis as a marker for chromosome 11.

This gene is expressed primarily in human T cells and to a lesser extent in human colon carcinoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and gastrointestinal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 263 as residues: Leu-21 to Ala-30, Ser-38 to Asp-47, Pro-87 to Asp-94, Leu-197 to Thr-204, Pro-256 to Ser-262, Thr-277 to Arg-282, Thr-293 to Trp-303.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders and gastrointestinal diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The translation product of this gene shares sequence homology with Ribosomal protein L11 of Caenorhabditis elegans. (See Accession No. 156201.) Preferred polypeptide fragments comprise the amino acid sequence:
ERGVSINQFCKEFNERTKDIKEGIPLPTKILVKPDRTFEIKIGQPTVSYFLKAAAG
IEKGARQTGKEVAGLVTLKHVYEIARIKAQDEAFALQDVPLSSVVRSIIGSARSL
GIRVVKDLSSEELAAF QKERAIFLAAQKEADLAAQEEAAKK (SEQ ID NO:483).
Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed in human embryo tissue and to a lesser extent in human epithelioid sarcoma and other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, development disorders and epithelial cell cancer. Similarly, polypeptides and antibodies

directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the embryonic and epithelial cell systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 264 as residues: Lys-34 to Gly-40.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of developmental disorders and epithelial cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

This gene is expressed primarily in resting T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory and general immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders of immune system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

This gene is believed to reside on [illegible]

[illegible] in prostate and to a lesser extent in [illegible] adult brain, human umbilical vein endothelial cells, and amniotic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, prostate-related disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the urinary system and nervous system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the diagnosis and treatment of disorders of the urinary and nervous systems.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

This gene shares sequence homology with R05G6.4 gene product. (See Accession No. gi|1326338.) This gene also shares sequence homology with the cyclophilin-like protein CyP-60. (See Accession No. 1199598, see also Biochem. J. 314 (1), 313-319 (1996).) Preferred polypeptide fragments comprise the amino acid sequence: AVYTYHEKKKDTAASGYGTQNIRLSRDAVKDFDCCCLSLQPCHDPVVTPDGYL YEREAILEYILHQKKEIARQMKAYEKQRGTRREEQKELQRAASQDHVRGFLEKE SAIVSRP LNPFTAKALSGTSPDDVQPGPSVGPPSKDKDKVLPSFWIPSLTPEAK ATKLEKPSRTVTCPMSGKPLRMSDLTPVHFTPLDSSVDRVGLITRSERYVCAVT RDSLSNATPCAVLRPSGAVVTLECVEKLIRKDMVDPVTGDKLTDRDIIVLQRGT (SEQ ID NO:484); YLYEREAILEYILHQKKEIARQMKAYEKQRGTRREEQKELQ RAASQDHVRGFLE (SEQ ID NO:485); and FTAKALSGTSPDDVQPGPSVGPP SKDKDKVLPSFWIPSLTPEAKATKLEKPSRTVTCPMSGKPL (SEQ ID NO:486). Also preferred are polynucleotide fragments that encode these polypeptide fragments.

This gene is expressed primarily in human testis and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male reproductive disorders and in particular testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system. Expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders of the male reproductive system and in particular of testicular cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

The translation product of this gene shares sequence homology with Lpe5p of Saccharomyces cerevisiae which is thought to be important in the metabolism of phospholipids.

This gene is expressed primarily in liver and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and nervous systems expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 268 as residues: Pro-14 to Leu-20, Lys-28 to Asn-38, Arg-109 to Arg-114, Lys-119 to Asn-124, Glu-152 to Leu-157, Pro-172 to Val-180.

The tissue distribution and homology to Lpe5p of Saccharomyces cerevisiae indicates that polynucleotides and polypeptides

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

This gene shares sequence homology with the nuclear ribonucleoprotein U (HNRNP U), encoded by *C. elegans* (See Accession gi|1703576.) Preferred polypeptide fragments comprise the amino acid sequence: MDTSENRPENDVPEPPMPIADQVSNDDRPEGSVEDEEKKESSLPKSFKRKISVVSATKGVPAGNSDTEGGQPGRKRRWGASTATTQKKPSISITTESLKSLIPDIKPLAGQEAVVDLHADDSRISEDETERNGDDGTHDKGLKICRTVTQVVPAEGQENGQREEEEEEKEPEAEPPVPPQVSVEVALPPPAEHEVKKVTLGDTLTRRSISQQKSGVSITIDDPVRTAQVPSPPRGKISNIVHISNLVRPFTLGQLKELLGRTGTLVEEAFWIDKIKSHCFVTYSTVEEAVATRTALHGVKWPQSNPKFLCADYAEQDELDYHRGLLVDRPSETKTEEQGIPRPLHPPPPPPVQPPQHPRAEQREQERAVREQWAEREREMERRERTRSEREWDRDKVREGPRSRSRSRXRRRKERAKSKEKKSEKKEKAQEEPPAKLLDDLFRKTKAAPCIYWLPLTDSQIVQKEAERAERAKEREKRRKEQEEEEQKEREKEAERERNRQLEREKRREHSRERDREREREREDRGDRDRDRERDRERGRERDRRDTKRHSRSRSRSTPVRDRGGR (SEQ ID NO:488). Also preferred are the polynucleotide fragments encoding this polypeptide fragments.

This gene is expressed primarily in epididymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the male reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of male reproductive disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 37

This gene is expressed primarily in amygdala.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory diseases and reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the amygdala, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of inflammatory diseases and reproductive disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

This gene shares sequence homology with human opsonin protein P35 fragment. (See Accession No. R94181.) The opsonin protein activates the phagocytosis of pathogenic microbes by phagocytic cells. Preferred polypeptide fragments comprise the amino acid sequence: GCDSCPPHLPREAFAQDTQAEGECSSRAERADMCPDAPPSQEVPEGPGAAP (SEQ ID NO:489). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed in immune-related tissues such as thymus, macrophage, T cells and to a lesser extent in many other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders and infectious disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and infectious disease, expression of this gene at significantly higher or lower [illegible]

[illegible] or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 271 as residues: Lys-9 to Arg-14, Met-38 to Asp-51.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders, as well as the treatment and/or diagnosis of infectious disease.

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

The translation product of this gene shares sequence homology with alpha-2 type I collagen which is thought to be important in tissue repair. (See, e.g., 211607.) Preferred polypeptide fragments comprise the amino acid sequence: PQLPSCGRPW PGTASVFQSHTQGPREDPDPCRAQGSAGTHCPISLSPPRQ (SEQ ID NO:490). Also preferred are the polynucleotide sequences encoding these polypeptide sequences.

This gene is expressed primarily in the brain and to a lesser extent in the kidney and thymus

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain, kidney, and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, kidney, and immune disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to alpha-2 type I collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of tissue repair, and brain, kidney, immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

The translation product of this gene shares sequence homology with mini-collagen which is thought to be important in tissue repair tumor metastasis. (See Accession No. gnl|PID|d1006976.) Preferred polypeptide fragments comprise the amino acid sequence: PGFRGPSGSLGCSFFPRSLGRVLPPGCQRPGAHAD

SSPPPTP (SEQ ID NO:491). Also preferred are polynucleotides encoding this polypeptide fragment.

This gene is expressed in ovarian cancer and to a lesser extent in dedritic cells and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumor metastasis and tissue repair. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the tumor metastasis and tissue repair, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 273 as residues: Asn-2 to His-11.

The tissue distribution and homology to mini-collegen gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of tumor metastasis and tissue repair.

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

This gene shares sequence homology with the HIV TAT protein. (See Accession No. 328416.) Preferred polypeptide fragments comprise the amino acid sequence: EDLKKPDPASLRAASCGEGKKRKACKNCTCGLAEELEKEK SREQMSSQPKSACGNCYLGDAFRCASCPYLGMPAFKPGEKVLLS (SEQ ID NO:492); EDLKKPDPASLRAASCGEGKKRKACKNCTCGLAEELEKEK SREQMSSQPKSACGNCYLGDAFRCASCPYLGMPAFKPGEKVLLSDSNLHD (SEQ ID NO:493); CGNCYLGDAFRCASCPYLGMPAFKPGEKVLLSDS (SEQ ID NO:494); SCGEGKKRKACKNCTCGLAEELEKE (SEQ ID NO:495); SQPKSAC GNCYLGDAFRCASC (SEQ ID NO:496); and REAGQNSERQYVS LSRD (SEQ ID NO:497). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

[illegible] testes

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain, testes and breast disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, testes and breast disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 274 as residues: Pro-7 to Val-15.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of brain, testes and breast, and other related disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

This gene is expressed primarily in the infant brain, human cerebellum, and to a lesser extent in medulloblastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain related disorders and medulloblastoma and other brain cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain related disorders and brain cancers, including medulloblastoma, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 275 as residues: Thr-41 to Glu-47.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of human brain related disorders, brain cancers, and medulloblastoma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

The translation product of this gene shares sequence homology with a phosphotyrosine-independent ligand for the lck SH2 domain which is thought to be important in signal transduction related to phosphotyrosine-independent ligand for the lck SH2 domain. (See Accession No. gi|1184951.) Preferred polypeptide fragments comprise the amino acid sequence: ESSGQARTLADPGPGWPRQQGMCFGSLT GLSTTPHGFLTVSAEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAAL DTIQYSKH (SEQ ID NO:498). Also preferred are polynucleotide fragments encoding this polypeptide fragment. It is likely that this gene is a new member of a family of phosphotyrosine-independent ligands for the lck SH2 domains.

This gene is expressed primarily in the placenta and to a lesser extent in endothelial cells and neutrophil.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive, cardiovascular, immune, and infectious diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular, reproductive, and immune system, and infectious diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to a phosphotyrosine-independent ligand for the lck SH2 domain indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cardiovascular, reproductive, and immune system diseases, as well as infectious diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

This gene is expressed primarily in the fetal brain, cerebellum and to a lesser extent in the placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal cell related disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuronal cell related disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 277 as residues: Thr-20 to Gly-28.

The tissue distribution and homology to proline-rich protein genes indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal cell related disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

The translation product of this gene shares sequence homology with precerebellin of human, which is thought to be important in synaptic physiology. (See Accession No. gi|180251.) It has been observed that cerebellin-like immunoreactivity is associated with Purkinje cell postsynaptic structures. Thus, it is likely that this gene also have synaptic activity. Preferred polypeptide fragments comprise the amino acid sequence: QEGSEPVLLEGECLVVCEPGRAAAGGPGGAALGEAPPGRVAFXAV RSHHHEPAGETGNGTSGAIYFDQVLVNEGGGFDRASGSFVAPVRGVYSFRFH VVKVYNRQTVQVSLMLNTWPVISAFANDPDVTREAATSSVLLPLDPGDRVSLR LRRGXSTGW (SEQ ID NO:499). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in cerebellum and infant brain. By Northern analysis, a single transcript of 2.4 kb was observed in brain tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, neuronal cell signal transduction and synaptic physiology. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuronal cell signal transduction and synaptic physiology expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to gene or gene family indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal cell related disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 46

This gene is expressed in fetal liver and spleen, and to a lesser extent in bone marrow, umbilical vein, and T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the immune system, particularly hematopoiesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoiesis and immune disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 279 as residues: Asp-30 to Glu-57.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hematopieotic and immune disorders

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The translation product of this gene shares sequence homology with a 12 kD nucleic acid binding protein of Feline calcivirus which is thought to be important in viral replication. (See Accession No. 59264)

This gene is expressed primarily in human cardiomyopathy and to a lesser extent in T helper cells, fetal brain and synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiomyopathy as well as viral infection. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 280 as residues: Trp-20 to Cys-26.

The tissue distribution in cardiomyopathy and homology to viral 12 kD nucleic acid binding protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of cardiomyopathy, including those caused by ischemic, hypertensive, congenital, valvular, or pericardial abnormalities. The gene expression pattern may be the consequence or the cause for these conditions.

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

The translation product of this gene shares sequence homology with tumor necrosis factor related gene product which is thought to be important in tumor necrosis, bacterial and viral infection, immune diseases and immunoreactions.

This gene is expressed primarily in colon and to a lesser extent in ovarian and breast cancers.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumors of colon, ovary or breast origins. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes

for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the colon, ovary and breast, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to Tumor necrosis factors indicates that polynucleotides and polypeptides corresponding to this gene are useful for intervention of cancers of colon, ovary and breast origins, because TNF family members are known to be involved in the tumor development.

FEATURES OF PROTEIN ENCODED BY GENE NO: 49

The translation product of this gene shares sequence homology with mucins, such as epithelial mucin, which is thought to be important in extracellular matrix functions such as protection, lubrication and cell adhesion (See for example Accession No. R68002). Preferred polypeptide fragments comprise the following amino acid sequence: PRSRPALRPGRQRPPSHSATSGVLRPRKKPDP (SEQ ID NO:500). Also preferred are polynucleotide fragments encoding these polypeptide fragments. Moreover, this gene maps to chromosome 22q11.2-qter, and therefore, can be used as a marker in linkage analysis for chromosome 22.

This gene is expressed primarily in corpus colosum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumors, especially of corpus colosum, as well as metastatic lesions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the corpus colosum and other solid tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample [illegible]

[illegible]

The tissue distribution and homology to mucins indicates that polynucleotides and polypeptides corresponding to this gene are useful for serum tumor markers or immunotherapy targets because tumor cells have greatly elevated level of mucin expression and shed the molecules into the epithelial tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

This gene is expressed primarily in CD34 depleted buffy coat cord blood and primary dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic disorders and immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in CD34 depleted buffy coat cord blood and primary dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hematopoietic and immune disorders. Secreted or cell surface proteins in the above tissue distribution often are involved in cell activation (e.g. cytokines) or molecules involved in cell surface activation.

FEATURES OF PROTEIN ENCODED BY GENE NO: 51

The translation product of this gene shares sequence homology with Interferon induced 1-8 gene encoded polypeptide which is thought to be important in binding to retroviral rev responsive element. Preferred polypeptide fragment comprise the following amino acid sequences: MTLITPSXKLTFXKGNKSWSSRACSSTLVDP (SEQ ID NO:501). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in CD34 positive cells and neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, retroviral infection, such as AIDS, and other immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 284 as residues: Gln-51 to Trp-62.

The tissue distribution and homology to interferon induced gene 1-8 indicates that polynucleotides and polypeptides corresponding to this gene are useful for intervention of retroviral infection including HIV. The factor may be involved in viral stability or viral entry into the cells. Alternatively, the virus/factor complex may elicit the cellular immune reaction.

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

This gene shares sequence homology to immunoglobulin lambda chain (See Accession No. 2865484). Therefore it is likely that this gene has activity similar to an immunoglobulin lambda chain. Preferred polypeptide fragments comprise the following amino acid sequence: GHPSPALSIAPSDGSQLPCDEVPYGEAHVTRYCKKPLTNS HLETEAQSSSL (SEQ ID NO:502). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, Hodgkin's lymphoma and other immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly [illegible]

[illegible] fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 285 as residues: Pro-27 to Thr-32.

The tissue distribution in Hodgkin's lymphoma and the sequence homology indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of Hodgkin's lymphoma, since the elevated expression and secretion by the tumor mass may be indicative of tumors of this type. Additionally the gene product may be used as a target in the immunotherapy of the cancer.Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

This gene has extensive homology to cDNA for Homo sapiens mRNA for the ISLR gene(See Accession No. AB003184). This protein is considered to be a new member of the Ig superfamily and contains a leucine-rich repeat (LRR) with conserved flanking sequences and a C2-type immunoglobulin (Ig)-like domain. These domains are important for protein-protein interaction or cell adhesion, and therefore it is possible that the novel protein ISLR may also interact with other proteins or cells. The ISLR gene was mapped on human chromosome 15q23-q24 by fluorescence in situ hybridization (See Medline Article No. 97468140). Homology to the ISLR gene has been confirmed by another independent group as well (See Accession No. Hs.102171)

This gene is expressed in a number of tissues including human retina, heart, skeletal muscle, prostate, ovary, small intestine, thyroid, adrenal cortex, testis, stomach, spinal cord, fetal lung and fetal kidney tissues, colon, tonsil and stomach cancer, and to a lesser extent in endometrial stromal cells treated with estradiol, breast tissue, synovium, lymphoma, and number of other tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumors of colon, ovary and breast origins. However, due to the wide range of expression in various tissues, protein may play a vital role in the development of cancer in other tissues as well, not just those mentioned above. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the colon, ovary and breast, expression of this gene at significantly higher or lower levels may be routinely

detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Additionally, this gene maps to chromosome 15q23-q24, and therefore, can be used as a marker in linkage analysis for chromosome 15.

The tissue distribution in tumors of colon, ovary, and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 54

Gene has homology to multidrug resistance gene 1 (See Accession No. P06795). Preferred polynucleotide fragments comprise the following sequence: GCTTCGTGTCCAACCCTCTTGCCCTTCGCCTGTGTGCCTGGAGCCAGTCCCA CCACGCTCGCGTTTCCTCCTGTAGTGCTCACAGGTCCCAGCACCGATGGCA TTCCCTTTGCCCTGAGTCTGCAGCGGGTCCCTTTTGTGCTTCCTTCCCCTCA GGTAGCCTCTCTCCCCCTGGGCCACTCCCGGGGGTGAGGGGGTTACCCCTT CCCAGTGTTTTTTATTCCTGTGGGGCTCACCCCAAAGTATTAAAAGTAGCTTT GTAA (SEQ ID NO:503). Also preferred are polypeptide fragments encoded by these polynucleotide fragments.

This gene is expressed primarily in lung, esophagus, leukemia (Jurkat cells) and breast cancers and to a lesser extent in macrophages treated with GM-CSF fetal tissues and wide range of tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer of wide range of origins. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the solid tumors, lung and leukemia, expression of this gene at significantly higher or lower [illegible]

[illegible] fluid or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Furthermore, due to the high expression level in lung tissue and the proposed function of the multidrug resistance protein 1 gene as the efflux pump responsible for low-drug accumulation in multidrug-resistant cells, protein as well mutants thereof, may also be beneficial as a target for gene therapy, particularly for the chronic patient. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 287 as residues: Met-1 to Lys-16.

The tissue distribution in wide range of cancers and fetal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection of cells in active proliferation, such as cancers. The gene products may be used for cancer markers or immunotherapy target.

FEATURES OF PROTEIN ENCODED BY GENE NO: 55

This gene maps to the X chromosome.

This gene is expressed primarily in the brain and to a lesser extent in the developing embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative disease states and developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders, including sex-linked disorders, of the above tissues or cells, particularly of the neurological, developmental systems, and cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Moreover, this gene maps to the X chromosome, and therefore, may be used as a marker in linkage analysis for this chromosome.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Klinefelter's, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental

disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 56

The translation product of this gene shares sequence homology with paxillin which is thought to be important in mediating signal transduction from growth factor receptors to the cytoskeleton. Preferred polynucleotide fragments comprise the following sequence: TGGCTCACTGTCTTACAATCACTGCTGTGGAATCATGA TACCACTTTTAGCTCTTTGCATCTTCCTTCAGTGTATTTTTGTTTTTCAAGAGG AAGTAGATTTTAACTGGACAACTTTGAGTACTGACATCATTGATAAATAAACT GGCTTGTGGTTTCAA (SEQ ID NO:506). Also preferred are polypeptide fragments encoded by these polynucleotide fragments. More preferably, polypeptide fragments comprise the amino acid sequence: LDELMAHLTEMQAKVAVRAD AGKKHLPDKQDHKASLDSMLGGLEQELQDLGIATVPKGHCASCQKPIAGKVI HALGQSWHPEHFVCTHCKEEIGSSPFFERSGLXYCPNDYHQLFSPRCAYCAAP ILDKVLTAMNQTWHPEHFFCSHCGEVFGAEGFHEKDKKPYCRKDFLAMFSPK CGGCNRPVLENYLSAMDTVWHPECFVCGDCFTSFSTGSFFELDGRPFCELHYH HRRGTLCHGCGQPITGRCISAMGYKFHPEHFVCAFCLTQLSKGIFREQNDKTY CQPCFNKLF (SEQ ID NO:507); KASLDSMLGGLEQELQDLGIATVPKGHC ASCQKPIAGKVIHAL (SEQ ID NO:508); CPNDYHQLFSPRCAYCAAPILDKVL TAMNQTWHPEHFFCSHCGEVFGAEG (SEQ ID NO:509); DKKPYCRKDFLAM FSPKCGGCNRPVLENYLSAMDTVWHPECFVCGDCFTSFSTGSFFELDGRPFCE L (SEQ ID NO:510); CGQPITGRCISAMGYKFHPEHFVCAFCLTQLSKGIFRE QNDKTYCQ (SEQ ID NO:511). Polynucleotide fragments encoding these preferred polypeptide fragments are also contemplated.

This gene is expressed primarily in brain, and to a lesser extent in the developing embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disease states and developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above

fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or

cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Moreover, since this gene shares homology with a gene that maps to chromosome 11, (See Accession No.T87404), gene as well as its translated product may be used for linkage analysis on chromosome 11.

The tissue distribution and homology to paxillin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and or detection of disease states associated with abnormal signal transduction in brain and/or the developing embryo. This would include treatment or detection of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder and also in the treatment and or detection of embryonic development defects.

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

This gene is expressed primarily in fetal spleen, brain, and to a lesser extent in six week old embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders, neurological disorders, and developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 290 as residues: Arg-28 to Gly-34.

The expression of this gene in fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/detection of immune disorders such as arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia. In addition the expression of this gene in the early embryo, indicates a key role in embryo development and hence the gene or gene product could be used in the treatment and or detection of embryonic development defects. This would include

treatment or detection of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntintons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder and also in the treatment and or detection of embryonic development defects.

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

The translation product of this gene shares sequence homology with the gene disrupted in the neurodegenerative disease dentatorubal-pallidoluysian atrophy. Moreover a long open reading fame exists in an alternative frame. Preferred polypeptide fragments comprise the following: MGSSQSVEIPGGGTEGYHVLRVQENSPGHRAGLEPFFDFIVSINGSRLNKDNDTLKDLLKXNVEKPVKMLIYSSKTLELRETSVTPSNLWGGQGLLGVSIRFCSFDGANENVWHVLEVESNSPAALAGLRPHSDYIIGADTVMNESEDLFSLIETHEAKPLKLYVYNTDTDNCREVIITPNSAWGGEGSLGCGIGYGYLHRIPTRPFEEGKKISLPGQMAGTPITPLKDGFTEVQLSSVNPPSLSPPGTTGIEQSLTGLSISSTPPAVSSVLSTGVPTVPLLPPQVNQSLTSVPPMNPATTLPGLMPLPAGLPNLPNLNLNLPAPHIMPGVGLPELVNPGLPPLPSMPPRNLPGIAPLPLPSEFLPSFPLVPESSSAASSGELLSSLPPTSNAPSDPATTTAKADAASSLTVDVTPPTAKAPTTVEDRVGDSTPVSEKPVSAAVDANASESP (SEQ ID NO:512); SVEIPGGGTEGYHVLRVQENSPGHRAGLEPFFDFIVSINGSRLNKDNDTLKDLLKXNVEKPVKMLIYSSKTLELRETSVTPSNLWGGQGLLGVSIRFCSFDGANENVWH (SEQ ID NO:513); ESNSPAALAGLRPHSDYIIGADTVMNESEDLFSLIETHEAKPLKLYVYNTDTDNCREVIITPNSAWGGEGSLGCGIGYGYLHRIPTRPFEEGKKISLPGQMAGTPITPLKDGFTEVQLSSVNPPSLSPPGTTGIEQSLTG LSISS (SEQ ID NO:514); RIPTRPFEEGKKISLPGQMAGTPITPLKDGFTEVQLSSVNPPSLSPPGTTGIEQSLTGLSISSTPPAVSSVLSTGVPTVPLLPPQVNQSLTSVPPMNPATTLPGLMPLPAGLPNLPNLNLNLPAPHIMPGVGLPELVNPGLPPLPSMPPRN (SEQ ID NO:516); PGLPPLPSMPPRNLPGIAPLPLPSEFLPSFPLVPESSSAASSGELLSSLPPTSNAPSDPATTTAKADAASSLTVDVTPPTAKAPTTVEDRVGDSTPVSEKPVSAAVDAN (SEQ ID NO:517).

This gene is expressed primarily in prostate cancer, and to a lesser extent in the pineal glands and in fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of [illegible]

[illegible] immunological probes for differential identification of the tissue(s) or cell type(s). For

a number of disorders of the above tissues or cells, particularly of the nervous, pulmonary, and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 291 as residues: Asn-9 to Leu-14.

The abundance of this gene in the pineal gland and its homology to a gene disrupted in the neurodegenerative disease state Dentatorubral-pallidoluysian atrophy indicates that this gene may be useful in the treatment and/or detection of other neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. The abundance of this gene in fetal lung would suggest that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung; that it may also be involved in predisposition to certain pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis; and thus the gen or the gene protein encoded by the gene could be used in the detection and/or treatment of these pulmonary disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 59

This gene is expressed primarily in the developing embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developmental system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression of this gene primarily in the embryo, indicates the gene plays a key role in embryo development and that the gene or the protein encoded by the gene could be used in the treatment and or detection of developmental defects in the embryo or in infants.

FEATURES OF PROTEIN ENCODED BY GENE NO: 60

This gene displays homology to nestin, an intermediate filament protein, the expression of which correlates with the proliferation of Central Nervous System progenitor cells and that is useful in the identification of brain tumors. This gene maps to chromosome 1, and therefore, may be used as a marker in linkage analysis for chromosome 1 (See Accession No. AA527348).

This gene is expressed primarily in kidney and to a lesser extent in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, renal disorders and neurodegenerative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the excretory and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 293 as residues: Thr-128 to Asn-135.

The tissue distribution and homology to nestin indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and/or treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition, its abundance in kidney indicates that it is useful in the treatment and detection of acute renal failure and other disease states associated with the kidney.

[illegible]

[illegible] homology with the latrophilin related protein [illegible] the calcium independent alpha-latrotoxin receptor. Preferred polypeptide fragments

comprise the following amino acid sequence: IYKVFRHTAGLKPEVSCFENIRSCARXXXXXXXXXXXXWIFGVLHVVHASVVTAYLFTVSNAFQGMFIFLFLCVLSRKIQEEYYRLFKNVPCC (SEQ ID NO:518); WIFGVLHVVHASVVTAYLFTVSNAFQGMFIFLFLCVLSRKIQEEYYRLFKNVPCC (SEQ ID NO:519). Also preferred are polynucleotide fragments encoding these polypeptide fragments. (See Accession No. 2213659) The translation product of this gene shares sequence homology with CD 97, a seven transmembrane bound receptor.

This gene is expressed primarily in infant brain and in endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders and hematopoeitic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurological and hematopoeitic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 294 as residues: Lys-13 to Leu-21.

The tissue distribution of this gene suggest that it may be useful in the detection and/or treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder, while its expression in hematopoietic cell types indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, asthma and immunodeficiency diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

This gene is expressed primarily in fetal liver and fetal spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematological and immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes

for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoetic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 295 as residues: Ser-91 to Lys-98.

The tissue distribution of this gene fetal liver and spleen indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, leukemia, asthma and immunodeficiency diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 63

Gene shares homology with human serum amyloid protein. Preferred polypeptide fragments comprise the following amino acid sequence: ALTRIPPGDWVINVTAVSFAGKTTARFFHSSPPSLGDQARTDPGHQRRD (SEQ ID NO:520) (See Accession No. W13671). Also preferred are polynucleotide fragments encoding these polypeptide fragments This gene maps to chromosome 9, and therefore, may be used as a marker in linkage analysis for chromosome 9 (See Accession No. AA004342).

This gene is expressed primarily in fetal liver and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid f

The tissue distribution of this gene in fetal liver-spleen indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, leukemia, asthma, and immunodeficiency diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

This gene maps to chromosome 3, and therefore, may be used as a marker in linkage analysis for chromosome 3 (See Accession No. AA219669).

This gene is expressed specifically in the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative disease states. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurological systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntintons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 65

Gene shares homology with a yeast protein. Preferred polypeptide fragments comprise the following amino acid sequence: LQEVNITLPENSVWYERYKFDIP VFHL (SEQ ID NO:521). Also preferred are polynucleotide fragments encoding these polypeptide fragments. (See Accession No. 1332638)

This gene is expressed primarily in fetal tissue (fetus and fetal liver).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver disorders and cancers (e.g. hepatoblastoma). Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 298 as residues: Asn-59 to Glu-64.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 66

Gene has homology with a B-cell surface antigen which may indicate gene plays a role in the immune response, including, but not limited to disorders and infections of the immune system. Preferred polynucleotide fragments comprise the following sequence: TAGCATGTAGCCAGTCGAATAACNTATAAGGACAAAGTGGAGTC CACGCGTGCGGCCGTCTAGACTAGTGGATCCCCCGGCTGCAGGATTCGGC ACGAG (SEQ ID NO:523). Also preferred are polypeptide fragments encoded by these polynucleotide fragments (See Accession No.T94535). Additionally, this gene shares homology with an interferon-gamma receptor. Preferred polypeptide fragments also comprise the following amino acid sequence: MQGSGSQFRACLLCLCFSCPC SPGGPRWNSRQGGRRFPKTCRAISQNLVFKYKTFCPVRYMQPHRSSLCLHFTS YVFILSTWGSLRTYSTDLKKKKKNSRGGPVPIRPKS (SEQ ID NO:522); MQGSGSQFRACLLCLCFSCPCSPGGPRWNSRQGGRRFPKTCRAISQNLVFK (SEQ ID NO:524); PVRYMQPHRSSLCLHFTSYVFILSTWGSLRTYSTDLKKKKK NSRGGPVPIRPKS (SEQ ID NO:525); and GEEQRDCSLGWRGVGMRATHCQAA RMFVLESLPKYAGL (SEQ ID NO:526).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological disorders and conditions (immunodeficiencies, cancer, leukemia, hematopoeisis). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and digestive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 299 as residues: Thr-41 to Gly-52.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune disorders including: leukemias, lymphomas, auto-immune disorders, immuno-supressive (transplantation) and immunodeficiencies (e.g. AIDS), inflammation and hematopoeitic disorders. The expression of this gene in gall bladder would suggest a possible role for this gene product in digestive disorders, particularly of the pancreas.

FEATURES OF PROTEIN ENCODED BY GENE NO: 67

This gene maps to chromosome 11, and therefore, may be used as a marker in linkage analysis for chromosome 11 (See Accession No. AA011622).

This gene is expressed primarily in a variety of fetal and developmental tissues (e.g. fetal spleen, infant brain).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental, immune or neurological abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing immune and central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 300 as residues: Ser-38 to Ser-43.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for developmental abnormalities or fetal deficiencies. The detection in infant brain would suggest a role in neurological disorders (both developmental and neurodegenerative conditions of the brain and nervous system, behavioral disorders, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia). In addition, the detection in spleen would similarly suggest a role in detection and treatment of immunologically mediated disorders (e.g. immunodeficiency, inflammation, cancer, wound healing, tissue repair, hematopoeisis).

FEATURES OF PROTEIN ENCODED BY GENE NO: 68

This gene is expressed primarily in spleen, T-cells, and fetal heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological deficiencies, including AIDSand cardiovascular disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and cardiovascular systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, autoimmune disorders, immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoeitic disorders. The [illegible]

[illegible] thrombosis).

FEATURES OF PROTEIN ENCODED BY GENE NO: 69

Gene shares homology with a human collagen protein. Preferred polypeptide fragments comprise the following amino acid sequence: MPRKTSKCRQLLCSGASRNADTAARQSTCSSHRPPGKIPSLGPRRXPGCXSVPSSRGEQSTGSPAAPRCGRRDAHRGLPGGAAMTPGDTWASFNPRAGHSKSQGEGQESSGASRQDRHPVSHWVERQREAWGAPRSSSAGGVKVAATTEREPEFKIKTGKA (SEQ ID NO:527); CSGASRNADTAARQSTCSSHRPPGKIPSLGPRRXPGCXSVPSSRGEQSTGSPAAPRCGRRDAHRGLPGGAAMTPGDTWASFNPRAGHS (SEQ ID NO:528); QGEGQESSGASRQDRHPVSHWVERQREAWGAPRSSSAGGVKVAATTEREPEFKIKTGKA (SEQ ID NO:529) (See Accession No. 124886). Also preferred are polynucleotide fragments encoding these polypeptide fragments

This gene is expressed primarily in fetal heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiovascular disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 302 as residues: Pro-32 to Ser-39.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cadiovascular disorders (e.g. heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis).

FEATURES OF PROTEIN ENCODED BY GENE NO: 70

The translation product of this gene shares sequence homology with a chicken single-strand DNA-binding protein. Preferred polypeptide fragments comprise the following amino acid sequence: MSPRYPGGPRPPLRIPNQALGGVPGSQPLLPSGMDPTRQQGHPNMGGPMQRMTPPRGMVPLGPQNYGGAMRPPLNALGGPGMPGMNMGPGGGRPWPNPTNAN

SIPYSSASPGNYVGPPGGGGPPGTPIMPSPADSTNSGDNMYTLMNAVPPGPNR PNFPMGPGSDGPMGGLGGMESHHMNGSLGSGDMDSISKNSPNNMSLSNQP GTPRDDGEMGGNFLNPFQSESYSPSMTMSV (SEQ ID NO:530); MSPRYPGG PRPPLRIPNQALGGVPGSQPLLPSGMDPTRQQGHPNMGGPMQRMTPPRGMVP LGPQNYGGAMRPPLNALGGPGMPGMNMGPGGGRPWPNPTNANSIPYSSASP GNY (SEQ ID. NO:531); LNALGGPGMPGMNMGPGGGRPWPNPTNANSIPYSS ASPGNYVGPPGGGGPPGTPIMPSPADSTNSGDNMYTLMNAVPPGPN (SEQ ID NO:532); GPMGGLGGMESHHMNGSLGSGDMDSISKNSPNNMSLSNQPGTPR DDGEMGGNFLNPFQSESYSPSMTMSV (SEQ ID NO:533); TCEHSSEAKAFHDY (SEQ ID NO:534). Also preferred are polynucleotide fragments encoding these polypeptide fragments. (See Accession No. 1562534)

This gene is expressed primarily in placenta and to a lesser extent in the fetal heart and a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities, fetal deficiencies, and particularly of the cardiovascular system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of developmental abnormalities or fetal deficiencies, ovarian and other endometrial cancers, reproductive dysfunction, cardiovascular disorders, and pre-natal disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 71

This gene is expressed primarily in fetal liver and to a lesser extent in the breast and testes.

biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, liver disorders (including hepatoblastomas) and reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). The expression in testes and breast indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of endocrine and reproductive disorders (e.g. sperm maturation, milk production, testicular and breast cancers).

FEATURES OF PROTEIN ENCODED BY GENE NO: 72

This gene maps to chromosome 1, and therefore, may be used as a marker in linkage analysis for chromosome 1 (See Accession No. W93595).

This gene is expressed primarily in smooth muscle and to a lesser extent in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiovascular and neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular and central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of restenosis, atherosclerosis, stroke, angina, thrombosis, wound healing and other conditions of heart disease. In addition, the expression in brain would suggest that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of developmental, degenerative and behavioral conditions of the brain and nervous system (e.g. schizophrenia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, addictive behavior and sleep disorders).

FEATURES OF PROTEIN ENCODED BY GENE NO: 73

Gene shares homology with human stromalin-2. Preferred polypeptide fragments comprise the following amino acid sequence: QAFVLLSDLLLIFSPQMIVGGRDFLRPLVFFPEATLQSELASFLMDHVFIQPGDL GSGA (SEQ ID NO:535); ACSYLLCNPEFTFFSRADFARSQLVDLLTDRFQQE LEELLQVG (SEQ ID NO:536),QKQLSSLRDRMVAFCELCQSCLSDVDTEIQEQV ST (SEQ ID NO:537); QVILPALTLVYFSILWTLTHISKSDAS (SEQ ID NO:538); STHDLTRWELYEPCCQLLQKAVDTGXVPHQV (SEQ ID NO:539). Also preferred are polynucleotide fragments encoding these polypeptide fragments (See Accession No.R65208) This gene maps to chromosome 7, and therefore, may be used as a marker in linkage analysis for chromosome 7 (See Accession No. D52585).

This gene is expressed primarily in the brain (infant brain, adult brain, pituitary, cerebellum, hippocampus, schizophrenic hypothalmus, amygdala).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental and neurodegenerative diseases of the brain and nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual

comprising a sequence shown in SEQ ID NO: 306 as residues: Thr-25 to Lys-36, Lys-55 to Ser-63.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of developmental, degenerative and behavioral conditions of the brain and nervous system (e.g. schizophrenia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, addictive behavior and sleep disorders).

FEATURES OF PROTEIN ENCODED BY GENE NO: 74

This gene is expressed primarily in the hypothalamus of a human suffering from schizophrenia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the CNS particularly schizophrenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS, such as schizophrenia expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 307 as residues: Gly-38 to Ala-44.

The tissue distribution indicates that the protein products of this gene are useful for the study, diagnosis and treatment of schizophrenia and other disorders involving the CNS.

FEATURES OF PROTEIN ENCODED BY GENE NO: 75

Preferred polypeptides of the invention comprise the following amino acid sequence encoded by this gene:
LAVSTSFICCADISTALPLGSSRPAPAPRHREHEHGHQARPPRLLXTSLMPLSTP
AAAQLLWTQLTPMGGRPGGRHSPPTLHTGPRALPPGPPHPSLHVAALSLLR
(SEQ ID NO:540). Polynucleotides encoding such polypeptides are also provided.

This gene is expressed primarily in endometrial tumor and to a lesser extent in amniotic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive and immune disorders particularly cancers of those systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 308 as residues: Ser-3 to Arg-9.

The tissue distribution indicates that the protein products of this gene are useful for study and treatment of immune and reproductive disorders particularly cancers of those systems.

FEATURES OF PROTEIN ENCODED BY GENE NO: 76

This gene is expressed primarily in kidney cortex and to a lesser extent in early stage human brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, renal disorders such as renal cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the kidney expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: [illegible]

[illegible] distribution indicates that the protein products of this gene are useful for study, treatment and diagnosis of renal diseases such as cancer of the kidney.

FEATURES OF PROTEIN ENCODED BY GENE NO: 77

This gene is expressed primarily in kidney medulla.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, metabolic and renal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and renal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for study, treatment and diagnosis of metabolic and renal diseases and disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 78

This gene is expressed in chronic synovitis and microvascular endothelium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, arthritis and atherosclerosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular and skeletal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for study, diagnosis and treatment of arthritic and other inflammatory diseases as well as cardiovascular diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 79

This gene is expressed in resting T-cells and activated monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the study and treatment of immune diseases such as inflammatory conditions.

FEATURES OF PROTEIN ENCODED BY GENE NO: 80

This gene is expressed in a variety of immune system tissues, e.g., neutrophils, T-cells, and TNF induced epithelial and endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, infectious and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and vascular systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising [illegible]

[illegible] protein products of this gene are useful for study and treatment of infectious diseases, immune and vascular disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 81

This gene is expressed in activated neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and other immune conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for study and treatment of immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 82

This gene is expressed in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory and other immune conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 315 as residues: Ala-83 to Thr-91.

The tissue distribution indicates that the protein products of this gene are useful for study and treatment of immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 83

This gene is expressed in human neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and inflammatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of disorders of the inflammatory and immune systems.

FEATURES OF PROTEIN ENCODED BY GENE NO: 84

This gene is expressed in human neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the inflammatory and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the inflammatory and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 85

This gene is expressed in activated neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and immune system diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and inflammatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of diseases of the inflammatory and immune systems.

FEATURES OF PROTEIN ENCODED BY GENE NO: 86

This gene is expressed in activated neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the inflammatory and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 319 as residues: Met-1 to Gly-6, Gly-32 to Pro-43, Leu-55 to Gln-60.

The tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of disorders of the immune and inflammatory system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 87

In specific embodiments, polypeptides of the invention comprise the sequence: EQVLALLWPRFELILEMNVQSVRSTDPQRLGGLDTRPHYITRRYAEFSSALVSINQTIPNERTMQLLGQLQVEVENFVLRVAAEFSSRKEQLVFLINNYDMMLGVLMERAADDSKEVESFQQLLNARTQEFIEELLSPPFGGLVAFVKEAEALIERGQAERLRGEEARVTQLIRGFGSSWKSSVESLSQDVMRSFTNFRNGTSIIQG (SEQ ID NO:541),ALLKYRFFYQFLLGNERATAKEIRDEYVETLSKIYLSYYRSYLGRLMKVQYEEVAEKDDLMGVEDTAKKGFXSKPSRSRNTIFTLGTRGSVISPTELEAPILVPHTAQR (SEQ ID NO: 542); EQRYPFEALFRSQHYXLLDNSCREYLFICEFFVVSGPXAHDLFHAVMGRTLSMTLKHLDSYLADCYDAIAVFLCIHIVLRFRNIAAKRDVPALDRYW (SEQ ID NO:543),GGLDTRPHYITRRYAEFSSALVSINQ (SEQ ID NO:544); SRKEQLVFLINNYDMMLGVL (SEQ ID NO: 545) and/or ALLKYRFFYQFLLGNERATAKEIRDEYVETLSKIYLSYYRSYLGRLMKVQYEEVAEKDDLMGVEDTAKKGFXSKPSLRSRNTIFTLGTRGSVISPTELEAPILVPHTAQRXEQRYPFEALFRSQHYXLLDNSCREYLFICEFFVVSGPXAHDLFHAVMGRTLSMTLKHLDSYLADCYDAIAVFLCIHIVLRFRNIAAKRDVPALDRYWEQVLALLWPRFELILEMNVQSVRSTDPQRLGGLDTRPHYITRRYAEFSSALVSINQTIPNERTMQLLGQLQVEVENFVLRVAAEFSSRKEQLVFLINNYDMMLGVLMERAADDSKEVESFQQLLNARTQEFIEELLSPPFGGLVAFVKEAEALIERGQAERLRGEEARVTQLIRGFGSSWKSSVESLSQDVMRSFTNFRNGTS (SEQ ID NO:546). Polynucleotides encoding these polypeptides are also encompassed by the invention. The translation product of this gene shares sequence homology with suppressor of actin mutation which is thought to be important in mutation suppression.

This gene is expressed primarily in fetal liver and to a lesser extent in a variety of other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver and mutations. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver or cancer, expression of this gene at significantly higher or lower levels may be [illegible] ... [illegible] tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level

in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 320 as residues: Val-53 to Arg-60, Thr-88 to Thr-94, Ala-142 to Ser-150, Gly-188 to Glu-196, Gly-208 to Ser-214, Thr-227 to Gly-232, Lys-279 to Phe-285.

The tissue distribution and homology to suppressor of actin mutation suggest that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and of liver disorder or cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 88

This gene maps to chromosome 9, and therefore can be used in linkage analysis as a marker for chromosome 9. In specific embodiments, polypeptides of the invention comprise the sequence: YEGKEFDYVFSIDVNEGGPSYKLPYNTSDDPWLTAYNFLQKNDLNPMFLDQVAKFIIDNTKGQMLGLGNPSFSDPFTGGGRYVPGSSGSSNTLPTADPFTGAGRYVPGSASMGTTMAGVDPFTGNSAYRSAASKTMNIYFPKKEAVTFDQANPTQILGKLKELNGTAPEEKKLTEDDLILLEKILSLICNSSSEKPTVQQLQILWKAINCPEDIVFPALDILRLSIKHPSVNENFCNEKEGAQFSSHLINLLNPKGKPANQLLALRTFCNCFVGQAGQKLMMSQRESLMSHAIELKSGSNKNI (SEQ ID NO: 547); HIALATLALNYSVCFHKD (SEQ ID NO: 548); HNIEGKAQCLSLISTILEVVQDLEATFRLLVALGTLISDDSNAVQLAKS (SEQ ID NO:549); LGVDSQIKKYSSVSEPAKVSECCRFILNLL (SEQ ID NO:550); and/or YEGKEFDYVFSIDVNEGGPSYKLPYNTSDDPWLTAYNFLQKNDLNPMFLDQVAKFIIDNTKGQMLGLGNPSFSDPFTGGGRYVPGSSGSSNTLPTADPFTGAGRYVPGSASMGTTMAGVDPFTGNSAYRSAASKTMNIYFPKKEAVTFDQANPTQILGKLKELNGTAPEEKKLTEDDLILLEKILSLICNSSSEKPTVQQLQILWKAINCPEDIVFPALDILRLSIKHPSVNENFCNEKEGAQFSSHLINLLNPKGKPANQLLALRTFCNCFVGQAGQKLMMSQRESLMSHAIELKSGSNKNIHIALATLALNYSVCFHKDHNIEGKAQCLSLISTILEVVQDLEATFRLLVALGTLISDDSNAVQLAKSLGVDSQIKKYSSVSEPAKVSECCRFILNLL (SEQ ID NO:551). Polynucleotides encoding these polypeptides are also encompassed by the invention. These polypeptides share significant homology with phospholipase A2 activating protein which is thought to be important in signal transduction (see, e.g., Wang et al., Gene 161(2):237-241 (1995)).

This gene is expressed primarily in endothelial cells, to a less extent in placenta, endometrial stromal cells, osteosarcoma, testis tumor, muscle, and infant brain that are likely to be rich in blood vessles.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders in vascular system, aberrent angiogenesis, tumor angiogenesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system or tumors, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene in endothelial cells and several potential highly vascularized tissues and its homology to phospholipase A2 activating protein suggest that this gene may be involved in transducing signals for endothelial cells in angiogenesis or vasculogenesis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 89

In specific embodiments, polypeptides of the invention comprise the sequence: YPNQDGDILRDQVLHEHIQRLSKVVTANHRALQIPEVYLREAPWPSAQSEIRTISAYKTPRDKVQCILRMCSTIMNLLSLANEDSVPGADDFVPVLVFVLIKANPPCLLSTVQYISSFYASCLSGEESYWWMQFTAAVE (SEQ ID NO:552); YPNQDGDILRDQVLHEHIQRLSKVVTANHRALQIPEVYLREAPWPSAQSEIRTISAYKTPRDKVQCILRMCSTIMNLLSLANEDSVPGADDFVPVLVFVLIKANPPCLLSTVQYISSFYASCLSGEESYWWMQFTAAVEFIKTI (SEQ ID NO:553); YPNQDGDILRDQVL (SEQ ID NO:554); EAPWPSAQSEI (SEQ ID NO:555); PVLVFVLIKANP (SEQ ID NO:560); SGEESYWWMQFTAAVEFIKTI (SEQ ID NO:556); ADDFVPVLVFVLIKANPP (SEQ ID NO:557); YKTPRDKVQCIL (SEQ ID NO:558); and/or GADDFVPVLVFVLIK (SEQ ID NO:559). The translation product of this gene shares sequence homology with human ras inhibitor and yeast VPS9p which is thought to be important in golgi vacuole transport.

This gene is expressed primarily in T cells and melanocytes and to a lesser extent in a variety of other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification [illegible]

[illegible] disorders involving T cells and melanocytes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to ras inhibitor indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating signal transduction; diagnosis and treatment of disorders involving T cells and melanocytes.

FEATURES OF PROTEIN ENCODED BY GENE NO: 90

This gene maps to chromosome 9 and therefore polypeptides of the invention can be used in linkage analysis as a marker for chromosome 9. The translation product of this gene shares sequence homology with neuronal olfactomedin-related ER localized protein which is thought to be important in influence the maintenance, growth, or differentiation of chemosensory cilia on the apical dendrites of olfactory neurons. In specific embodiments, polypeptides of the invention comprise the sequence: SARASTQPPAGQHPGPC (SEQ ID NO:561); MPGRWRWQRDMHPARKLLSLL FLILMGTELTQD (SEQ ID NO:562); SAAPDSLLRSSKGSTRGSL (SEQ ID NO:563); AAIVIWRGKSESRIAKTPGI (SEQ ID NO:564); FRGGGTLVLPPTHT PEWLIL (SEQ ID NO:567); PLGITLPLGAPETGGGD (SEQ ID NO:565); and/or CAAETWKGSQRAGQLCALLA (SEQ ID NO:566).

This gene is expressed in pineal gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological and endocrinological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurological or endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 323 as residues: Leu-20 to Ala-26, Arg-32 to Arg-39, Thr-104 to Gly-112.

The tissue distribution and homology to olfactomedin-related protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for maintenance, growth, or differentiation of neuron cells in pineal gland, therefore, may be useful for diagnosis and treatment of neurological disorders in pineal gland.

FEATURES OF PROTEIN ENCODED BY GENE NO: 91

This gene is expressed primarily in prostate and apoptotic T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, prostate disease and T cell dysfunction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate cancer, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detect abnormal activity in prostate and T cells or probably treatment of this abnormality.

FEATURES OF PROTEIN ENCODED BY GENE NO: 92

This gene is expressed primarily in prostate and to a lesser extent in smooth muscle cells, fibroblasts, and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders in prostate or vascular system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing [illegible] prostate or vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain

tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating function of prostate or highly vascularized tissues, e.g. placenta.

FEATURES OF PROTEIN ENCODED BY GENE NO: 93

This gene is expressed primarily in embryos and fetal tissues stage human and to a lesser extent in a wide variety of other proliferative tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders in embryonic development and cell proliferation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the embryonic tissues and proliferative cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of abnormalities in developing and proliferative cells and organs.

FEATURES OF PROTEIN ENCODED BY GENE NO: 94

The translation product of this gene shares sequence homology with transformation related protein which is thought to be important in transformation.

This gene is expressed primarily in female reproductive tissues, i.e., breast cancer cells, placenta, and ovary and to a lesser extent in fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, cancer or dysfunction of reproductive tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproduction system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 327 as residues: Ser-50 to Pro-61.

The tissue distribution and homology to transformation related protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of conditions caused by transformation, i.e. tumorigenesis in reproductive organs, e.g. breast, placenta, and ovary.

FEATURES OF PROTEIN ENCODED BY GENE NO: 95

This gene is expressed primarily in testes, rhabdomyosarcoma, infant brain and to a lesser extent in some tumors and highly vascularized tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumorigenesis, abnormal angiogenesis, and/or neurological disorders. , Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the tumor tissues or vascular tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 328 as residues: Arg-46 to Trp-54, Pro-60 to Ile-69, Asn-116 to Ala-122, Arg-147 to [illegible]

[illegible] indicates that polynucleotides and polypeptides corresponding to this gene are useful for a range of disease states including treatment of

tumor or vascular disorders and the treatment of neurological disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 96

This gene maps to chromosome 7 and therefore polynucleotides of the present invention can be used in linkage analysis as a marker for chromosome 7. The translation product of this gene is homologous to the Clostridium perfringens enterotoxin (CPE) receptor gene product and shares sequence homology with a human ORF specific to prostate and a glycoprotein specific to oligodendrocytes both of which are tissue specific proteins.(See e.g., Katahira et al., J Cell Biol. 136(6):1239-1247 (1997). PMID: 9087440; UI: 97242441.

This gene is expressed primarily in pancreas tumor and ulcerative colitis and to a lesser extent in several tumors and normal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, pancreatic disorder, ulcerative colitis, tumors and food poisoning. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system or tumorigenic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 329 as residues: Gly-147 to Met-152, Cys-177 to Lys-188.

The tissue distribution and homology to prostate and oligodendrocyte-specific protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for marker of diagnosis or treatment of disorder in pancreas, ulcerative colitis, and tumors. Furthermore, identity to the human receptor for Clostridium perfringenes entertoxin indicates that the soluble portion of this receptor could be used in the treatment of food poisoning associated with Clostridia perfringens by blocking the activity of perfringens enterotoxin.

FEATURES OF PROTEIN ENCODED BY GENE NO: 97

The translation product of this gene shares sequence homology with ATPase which is thought to be important in metabolism.

This gene is expressed primarily in testes and several hematopoietic cells and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, leukemia and hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 330 as residues: Leu-37 to Ala-42.

The tissue distribution and homology to ATPase indicates that polynucleotides and polypeptides corresponding to this gene are useful for marker of diagnosis and treatment of leukemia and other hematopoietic disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 98

In specific embodiments, polypeptides of the invention comprise the sequence: MRSARPSLGCLPSWAFSQALNI (SEQ ID NO:568); LLGLKGLAPAEISAVCE KGNFN (SEQ ID NO:569); VAHGLAWSYYIGYLRLILPELQARIR (SEQ ID NO:570); TYNQHYNNLLRGAVSQRC (SEQ ID NO:571); ILLPLDCGVPDNLSM ADPNIRFLDKLPQQTGDRAGIKDRVYSN (SEQ ID NO:572); SIYELLENGQRAGT CVLEYATPLQTLFAMSQYSQAGFSGEDRLEQ (SEQ ID NO:573); AKLFCRTLE DILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAV PSTSTMSQEPELLISGMEKPLPLRTDFS (SEQ ID NO:574); and/or LLGLKGLA PAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPEL (SEQ ID NO:57[illegible]

[illegible] in prostate BPH and to a lesser extent in bone marrow [illegible]

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, benign prostatic hypertrophy or prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male urinary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 331 as residues: Ile-60 to Asn-69, Leu-106 to Asp-112, Glu-130 to Gly-136, Phe-160 to Glu-167, Pro-184 to Cys-190, Glu-197 to Ser-202, Arg-215 to Glu-221, Thr-237 to Pro-242.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of benign prostatic hypertrophy or prostate cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 99

This gene is expressed primarily in salivary gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders or injuries of the salivary gland. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of glandular tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of disorders of, or injuries to the salivary gland or other glandular tissue.

FEATURES OF PROTEIN ENCODED BY GENE NO: 100

This gene maps to chromosome 15, accordingly, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 15. The translation product of this gene shares sequence homology with a *C.elegans* gene of unknown function. In specific embodiments, polypeptides of the invention comprise the sequence: DPRVRLNSLTCKHIFISLTQ (SEQ ID NO:583); TMKLLKLRRNIV KLSLYRHFTN (SEQ ID NO:576); TLILAVAASIVFIIWTTMKFRI (SEQ ID NO:577); VTCQSDWRELWVDDAIWRLLFSMILFVI (SEQ ID NO:578); MVLWR PSANNQRFAFSPLSEEEEEDEQ (SEQ ID NO:580); KEPMLKESFEGMKMRS TKQEPNGNSKVNKAQEDDL (SEQ ID NO:584); and/or KWVEENVPSSVTDVALP ALLDSDEERMITHFERSKME (SEQ ID NO:582). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in thyroid and to a lesser extent in osteoclastoma, kidney medulla, and lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, thyroid dysfunction or cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 333 as residues: Lys-107 to Leu-124, Glu-150 to Thr-159, Pro-173 to Asp-179, Ser-192 to Ser-201.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of thyroid dysfunction or cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 101

[illegible] chromosome [illegible] embodiments, polypeptides of the invention comprise the sequence:

IRHELTVLRDTRPACA (SEQ ID NO:585); and/or MDFXMALIYD (SEQ ID NO:586). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in kidney cortex and to a lesser extent in adult brain, corpus colosum, hippocampus, and frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of neurological disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 102

In specific embodiments, polypeptides of the invention comprise the sequence: MQEMMRNQDRALSNLESIPGGYNA (SEQ ID NO:587); LRRMYTDIQEPMLSA AQEQF GGNPF (SEQ ID NO:588); ASLVSNTSSGEGSQPSRTENRDPLPNPWAP QT (SEQ ID NO:589); SQSSSASSGTASTVGGTTGSTASGTSGQSTTAPNLVPGV GASMFNTPG MQSLLQQITENPQLMQNMLSAPY (SEQ ID NO:590); MRSMMQSLSQNPDLAAQMMLNNPLFAGNPQLQEQMRQQLPTFLQQ (SEQ ID NO:591); MQNPDTLSAMSNPRAMQALLQIQQGLQTLATEAPGLIPGFTPGLG ALGSTGGSSGTNGSNATPSENTSPTAGT (SEQ ID NO:592); TEPGHQQFI QQMLQALAGVNPQLQNPEVRFQQQLEQLSAMGFLNREANLQALIATGGDINAA IERLLGSQPS (SEQ ID NO:593); RNPAMMQEMMRNQDRALSNLESIPGGY NALRRMYTDIQEPMLSAA (SEQ ID NO:594); GNPFASLVSNTSS (SEQ ID NO:595); ENRDPLPNPWA (SEQ ID NO:595); GKILKDQDTLSQHGIHD (SEQ ID NO:597); GLTVHLVIKTQNRP (SEQ ID NO:598); SELQSQMQRQLLSNPEMM (SEQ ID NO:599); PEISHMLNNPDIMR (SEQ ID NO:600); and/or RQLIMANPQMQQLIQRNP (SEQ ID NO:601). Polynucleotides encoding these

polypeptides are also encompassed by the invention.

This gene is expressed primarily in breast.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of tumor systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of some types of breast cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 103

The translation product of this gene shares sequence homology with secreted serine proteases and lysozyme C precursor, which is thought to be important in bacteriolytic function. In specific embodiments, polypeptides of the invention comprise the sequence: NLCHVDCQDLLNPNLLAGIHCAKRIVS (SEQ ID NO:602); LDGFEGYSLSDWLCLAFVESKFN (SEQ ID NO:603); NENADGSFDYGLFQINSHYWCN (SEQ ID NO:604); and/or NLCHVDCQDLLNPNLLAGIHCAKRIVS (SEQ ID NO:605). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, infection. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of [illegible]

[illegible] detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 336 as residues: Ile-62 to Phe-70, Asn-78 to Asn-84.

The tissue distribution and homology to lysozyme C precursor indicates that polynucleotides and polypeptides corresponding to this gene are useful for boosting the moncyte-macrophage system and enhance the activity of immunoagents.

FEATURES OF PROTEIN ENCODED BY GENE NO: 104

This gene is expressed primarily in apoptotic T-cell.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of some immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 105

The translation product of this gene shares sequence homology with ARI protein of Drosophila (accession 2058299; EMBL: locus DMARIADNE, accession X98309), which is thought to be important in axonal path-finding in the central nervous system. In specific embodiments, polypeptides of the invention comprise the sequence IREVNEVIQNPAT (SEQ ID NO:606); ITRILLSHFNWDKEKLMERYF DGNLEKLFA (SEQ ID NO:607); NTRSSAQDMPCQICYLNYPNSYF (SEQ ID NO:608); TGLECGHKFCMQCWSEYLTTKIMEEGMGQTISCPAHG (SEQ ID NO:614); CDILVDDNTVMRLITDSKVKLKYQHLITNSFVECNRLLKWCPAPD CHHVVKVQYPDAKPV (SEQ ID NO:609); CDILVDDNTVMRLITDSK

VKLKYQHLITNSFVECNRLLKWCPAPDCHHVVKV (SEQ ID NO:610); GCNHMVCRNQNCKAEFCWVCLGPWEPHGSAWYNCNRYNEDDAKAARDAQERSRAALQRYL (SEQ ID NO:611); FYCNRYMNHMQSLRFEHKLYAQVKQKMEEMQQHNMSWIEVQFLKKAVDVLCQCRATLMYT (SEQ ID NO: 612); YVFAFYLKKNNQSIIFENNQADLENATEVLSGYLERDISQDSLQDIKQKVQDKYRYCESR (SEQ ID NO:613) Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in adult brain, and to a lesser extent in endometrial tumor, melanocytes, and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases or injuries involving axonal path development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to ARI protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of disease states or injuries involving axonal path development, including neurodegenerative diseases and nerve injury.

FEATURES OF PROTEIN ENCODED BY GENE NO: 106

The translation product of this gene shares sequence homology with cytochrome b561 [Sus scrofa] which is thought to be an integral membrane protein of neuroendocrine storage vesicles of neurotransmitters and peptide hormones.

This gene is expressed primarily in frontal cortex and to a lesser extent in rhabdomyosarcoma.

Therefore, polynucleotides and polypeptides of the [illegible]

[illegible] diagnosis of diseases and conditions which include, but are not limited to, neurological disorders. Similarly, polypeptides and antibodies directed to

these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 339 as residues: Ser-18 to Pro-24.

The tissue distribution and homology to cytochrome b561 [Sus scrofa] indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of neurological disorders. This gene may also be important in regulation of some types of cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 107

In specific embodiments, polypeptides of the invention comprise the sequence: MWGYLFVDAAWNFLGCLICGW (SEQ ID NO:615); MHFISSGNVSAIRSSILLL RXSLSYLGNCLRVSAIFVYFLLFLLLS (SEQ ID NO:616); and/or MDQALRGSPSE GFSTDPSPPQVGRQIPSFPPWRRLVLPKASGCFLEREWWLCVFKLRTRPGAEA HAYNSSILGGRGKGIT (SEQ ID NO:617). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in pancreas tumor and to a lesser extent in cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, pancreatic tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred

epitopes include those comprising a sequence shown in SEQ ID NO: 340 as residues: Pro-22 to Phe-33.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of pancreatic tumors.

FEATURES OF PROTEIN ENCODED BY GENE NO: 108

This gene maps to chromosome 17 and therefore polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 17. In specific embodiments, polypeptides of the invention comprise the sequence: MLPALASCCHFSPPEQAARLKKLQEQEKQQKVEFRKRMEKEVSDFIQDSGQIKKKFQPMNKIERSILHDVVEVAGLTSFSFGEDDDCRYVMIFKKEFAPSDEELDSYRRGEEWDPQKAEEKRNXKELAQRQ (SEQ ID NO:618); EEEAAQQGPVVVSPASDYKDKYSHLIGKGAAKDAAHMLQANKTYGCXPVANKRDTRSIEEAMNEIRAKKRLRQSGE (SEQ ID NO:619); PPRRPAQLPLTPGAGQGAGRDKAAAIRAHPGAPPLNHLLP (SEQ IDNO:620); AVPQAGGKQVFDLSPLELGYVRGMCVCV (SEQ ID NO:621) and/or MLPALASCCHFSPPEQAARLKKLQEQEKQQKVEFRKRMEKEVSDFIQDSGQIKKKFQPMNKIERSILHDVVEVAGLTSFSFGEDDDCRYVMIFKKEFAPSDEELDSYRRGEEWDPQKAEEKRNXKELAQRQEEEAAQQGPVVVSPASDYKDKYSHLIGKGAAKDAAHMLQANKTYGCXPVANKRDTRSIEEAMNEIRAKKRLRQSGE (SEQ ID NO:622). Polynucleotides encoding these polypeptides are also encompassed by the invention. The translation product of this gene shares sequence homology with FSA-1 which may play a role as a structural protein component of the acrosome.

This gene is expressed primarily in fetal kidney and sperm.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male reproductive disorders, especially involving acrosomal disfunction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid [illegible]

[illegible] healthy tissue or bodily fluid [illegible]

individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 341 as residues: Glu-8 to Asn-35.

The tissue distribution and homology to FSA-1 indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of infertility due to acrosomal disfunction of sperm.

FEATURES OF PROTEIN ENCODED BY GENE NO: 109

This gene is expressed primarily in pituitary and to a lesser extent in epididymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 342 as residues: Met-1 to Trp-6.

Because the gene is found in both pituitary and epididymus, this indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of male reproductive disorders. This may involve a secreted peptide produced in the pituitary targeting the epididymus.

FEATURES OF PROTEIN ENCODED BY GENE NO: 110

In specific embodiments, polypeptides of the invention comprise the sequence: LLCPVLNSGXSWNFPHPSQPEYSFHGFHSTRLWI (SEQ ID NO:623); and/or PSTPWFLFLLGLTCPFSTSHPRWDSIPP (SEQ ID NO:624). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in resting T-cells. .

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, T-cell disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of certain immune disorders, especially those involving T-cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 111

This gene is expressed primarily in cerebellum and whole brain and to a lesser extent in infant brain and fetal kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 344 as residues: Asp-48 to Gly-55.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurological disorders.

[illegible] this gene shares sequence homology with yeast mitochondrial ribosomal protein homologous to ribosomal protein s15 of E.coli which

is thought to be important in the early assembly of ribosomes (See Accession No. M38016). This gene maps to chromosome 1, and therefore, may be used as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in developmental tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, development of cancers and tumors in addition to healing wounds. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and developmental expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to ribosomalprotein s15 of E. coli indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases related to the assembly of ribosomes in the mitochondria which is important in the translation of RNA into protein. Therefore, this indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of multiple tumors as well as in healing wounds which are thought to be under similar regulation as developmental tissues. Protein, as well as, antibodies directed against the protein have utility as tumor markers, in addition to immunotherapy targets, for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 113

The translation product of this gene shares sequence homology with human poliovirus receptor precursors which are thought to be important in viral binding and uptake. Preferred polypeptide fragments comprise the following amino acid sequence: ELSISISNVALADEGEYTCSIFTMPVRTAKSLVTVLGIPQKPIITGYKSSLREKDT ATLNCQSSGSKPAARLTWRKGDQELHGEPTRIQEDPNGKTFTVSSSVTFQVTR EDDGASIVCSVNHESLKGADRSTSQRIEVLYTPTAMIRPDPPHPREGQKLLLHC EGRGNPVPQQYLWEKEGSVPPLKMTQESALIFPFLNKSDSGTYGCTATSNMGS YKAYYTLNVND (SEQ ID NO:625). Also preferred are polynucleotide fragments encoding these polypeptide fragments (See Accession No. gnl|PID|d1002627).

This gene is expressed almost exclusively in human brain tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, susceptibility to viral disease and diseases of the CNS especially cancers of that system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 346 as residues: Leu-26 to Asp-37, Lys-53 to Ser-59.

The tissue distribution and homology to poliovirus receptor precursors indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and prevention of diseases that involve the binding and uptake of virus particles for infection. It might also be helpful in genetic therapy where the goal is to insert foreign DNA into infected cells. With the help of this protein, the binding and uptake of this foreign DNA might be aided. In addition, it is expected that over expression of this gene will indicate abnormalities involving the CNS, particularly cancers of that system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 114

The translation product of this gene shares sequence homology with YO87_CAEEL hypothetical 28.5 KD protein ZK1236.7 in chromosome III of Caenorhabditis elegans in addition to alpha-1 collagen type III (See Accession No. gi|537432). One embodiment for this gene is the polypeptide fragment(s) comprising the following amino acid sequence: VPELPDRVHQLHQAVQGCALGRPGFPGGPTH SGHHKSHPGPAGGDYNRCDRPGQVHLHNPRGTGRRGQLHPTAGPGVHRRA CPSQQLPHRLGPGVPCPSPSLTPVLPSWTQSWCG LPGYTSSS (SEQ ID NO:630). An additional embodiment is the polynucleotide f

B and T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegeneration and imunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 347 as residues: Glu-34 to Glu-39, Gly-51 to Ser-72, Ala-88 to Glu-93, Gln-100 to Val-105.

The tissue distribution and homology to YO87_CAEEL hypothetical 28.5 KD protein ZK1236.7 in chromosome III of Caenorhabditis elegans as well as to a conserved alpha-1 collagen type III protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons' Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorders. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 115

The translation product of this gene shares sequence homology with alpha 3 type IX collagen which is thought to be important in hyaline cartilage formation via its ability to uptake inorganic sulfate by cells (See Accession No. gi|975657). One embodiment of this gene is the polypeptide fragment comprising the following amino acid sequence: SLRRPRSAAXQTLTTFLSSVSSASSSALPGSREPCDPRAPPPPR SGSAASCCSCCCSCPRRRAPLRSPRGSKRRIRQREVVDLYNGMCLQGPAGVPG RDGSPGANGIPGTPGIPGRDGFKGEKGECLRESFEESWTPNYKQCSWSSLNY GIDLGKIAECTFTKMRSNSALRVLFSGSLRLKCRNACCQRWYFTFNGAECSGP LPIEAIIYLDQGSPEMNSTINIHRTSSVEGLCEGIGAGLVDVAIWVGTCSDYPKG DASTGWNSVSRIIIEELPK (SEQ ID NO:634). An additional embodiment are the

polynucleotide fragments encoding this polypeptide fragment.

This gene is expressed primarily in smooth muscle and to a lesser extent in synovial tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias i.e., spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid and autoimmune disorders . Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to alpha 3 type IX collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of diseases associated with the mutation in this gene which leads to the many different types of chondrodysplasias. By the use of this product, the abnormal growth and development of bones of the limbs and spine could be routinely detected or treated in utero since the protein or muteins thereof could affect epithelial cells early in development and later the chondrocytes of the developing craniofacial structure.

FEATURES OF PROTEIN ENCODED BY GENE NO: 116

The translation product of this gene shares sequence homology with retrovirus-related reverse transcriptase which is thought to be important in viral replication. One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: TKKENCRPASLMNIDTKILNKILMNQ (SEQ ID NO:640). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments (See Accession No. pir|A25313|GNHUL1).

This gene is expressed primarily in human menin[illegible]

[illegible] present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, retroviral diseases such as AIDS, and possibly certain cancers due to transactivation of latent cell division genes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to retrovirus-related reverse transcriptase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of diseases and maladies associated with retroviral infection since a functional reverse transcriptase (RT) or RT-like molecule is an integral component of the retroviral life cycle.

FEATURES OF PROTEIN ENCODED BY GENE NO: 117

The translation product of this gene shares sequence homology with an unknown gene from *C. elegans*, as well as weak homolog with mammalian metaxin, a gene contiguous to both thrombospondin 3 and glucocerebrosidase, is known to be required for embryonic development. Preferred polypeptide fragments comprise the following amino acid sequence: MCNLPIKVVCRANAEYMSPSGKVPXXHVGNQ VVSELGPIVQFVKAKGHSLSDGLEEVQKAEMKAYMELVNNMLLTAELYLQWC DEATVGXITHXRYGSPYPWPLXHILAYQKQWEVKRKXKAIGWGKKTLDQVLE DVDQCCQALSQRLGTQPYFFNKQPTELDALVFGHLYTILTTQLTNDELSEKVKN YSNLLAFCRRI EQHYFEDRGKGRLS (SEQ ID NO:641); MCNLPIKVVCRANAE YMSPSGKVPXXHVGNQVVSELGPIVQFVK (SEQ ID NO:642),. Also preferred are polynucleotide fragments encoding these polypeptide fragments (See Accession No. gi|1326108).

This gene is expressed primarily in fetal tissues and to a lesser extent in hematopoietic cells and tissues, including spleen, monocytes, and T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer; lymphoproliferative disorders; inflammation; chondrosarcoma, and Gaucher disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification

of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and embryonic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression in embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation or cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and survival of hematopoietic cell lineages. Thus, this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 118

The translation product of this gene shares sequence homology with reverse transcriptase which is important in the synthesis of a cDNA chain from an RNA molecule, and is a method whereby the infecting RNA chains of retroviruses are transcribed into their DNA complements. One embodiment for this gene is the polypeptide fragment comprising the following amino acid sequence: MXXXNSHITIFTLNVNGLNAPNERHRLANWIQSQDQVCCIQETHLTGRDTHRL KIKGWRKIYQANGKQKK (SEQ ID NO:647). An additional embodiment is the polynucleotide fragments comprising polynucleotides encoding these polypeptide fragments (See Accession No. gi|2072964).

This gene is expressed primarily in skin and to a lesser extent in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, hematopoietic disorders; inflammation; disorders of immune surveillance. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential [illegible]

[illegible] of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and

wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to reverse transcriptase indicates that polynucleotides and polypeptides corresponding to this gene are useful for cancer therapy. Expression in the skin also indicates that this gene is useful in wound healing and fibrosis. Expression by neutrophils also indicates that this gene product plays a role in inflammation and the control of immune surveillance (i.e. recognition of viral pathogens). Reverse transcriptase family members are also useful in the detection and treatment of AIDS.

FEATURES OF PROTEIN ENCODED BY GENE NO: 119

The translation product of this gene shares sequence homology with reverse transcriptase which is important in the synthesis of a cDNA copy of an RNA molecule, and is a method whereby a retrovirus reverse-transcribes its genome into an inheritable DNA copy.

This gene is expressed primarily in the frontal cortex of brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer and neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS and peripheral nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to reverse transcriptase suggest that this is useful in the treatment of cancer and AIDS. The expression in brain indicates that it plays a role in neurodegenerative disorders and in neural degeneration.

FEATURES OF PROTEIN ENCODED BY GENE NO: 120

One embodiment of this gene has homology to a hypothetical protein in Schizosaccharomyces pombe (See Accession No. 2281980). Another embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: IYHLHSWIFFHFKRAFCMCFITMKVIHAHCSKLRKCXNAQISVFCTTLTASYPT (SEQ ID NO:651). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments. This gene maps to chromosome 18, and therefore, may be used as a marker in linkage analysis for chromosome 18.

This gene is expressed primarily in adult hypothalamus and to a lesser extent in infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative disorders; endocrine function; and vertigo. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, CNS and peripheral nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of neurodegenerative disorders; diagnosis of tumors of a brain or neuronal origin; treatments involving hormonal control of the entire body and of homeostasis, behavioral disorders, such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo.

FEATURES OF PROTEIN ENCODED BY GENE NO: 121

[illegible] important in binding to a [illegible] promoter element and thus regulating its transcription (See Accession No. gi|33969). This gene maps to

chromosome 1, and therefore, may be used as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in brain and breast and to a lesser extent in a variety of hematopoietic tissues and cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer of the brain and breast; lymphoproliferative disorders; neurodegenerative diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS, breast, and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cancer of the brain, breast, and hematopoietic system. In addition, it may be useful for the treatment of neurodegenerative disorders, as well as disorders of the hematopoietic system, including defects in immune competency and inflammation. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 122

The translation product of this gene shares sequence homology with an ATP synthase, a key component of the proton channel that is thought to be important in the translocation of protons across the membrane.

This gene is expressed primarily in T cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, T cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or

lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to ATP synthase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of defects in proton transport, homeostasis, and metabolism, as well as the diagnosis and treatment of lymphoma. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia

FEATURES OF PROTEIN ENCODED BY GENE NO: 123

This gene maps to chromosome 15, and therefore, may be used as a marker in linkage analysis for chromosome 15.

This gene is expressed primarily in a variety of fetal tissues, including fetal liver, lung, and spleen, and to a lesser extent in a variety of blood cells, including eosinophils and T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer (abnormal cell proliferation); T cell lymphomas; and hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetus and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the [illegible]

[illegible]

proliferation, apoptosis; or cell survival. Thus it may be useful in the management and

treatment of a variety of cancers and malignancies. In addition, its expression in blood cells suggest that it may play additional roles in hematopoietic disorders and conditions, and could be useful in treating diseases involving autoimmunity, immune modulation, immune surveillance, and inflammation..

FEATURES OF PROTEIN ENCODED BY GENE NO: 124

This gene is expressed primarily in placenta and to a lesser extent in pineal gland and rhabdomyosarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental, endocrine, and female reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the [insert system where a related disease state is likely, e.g., immune], expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 357 as residues: Leu-69 to Val-76.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders in development. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 125

This gene is expressed primarily in benign prostatic hyperplasia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of benign prostatic hyperplasia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive

system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of benign prostatic hyperplasia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 126

This gene is expressed primarily in apoptotic T-cells and to a lesser extent in suppressor T cells and ulcerative colitis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases involving premature apoptosis, and immunological and gastrointestinal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders involving inappropriate levels of apoptosis, especially in immune cell lineages. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases (such as AIDS), and leukemia

FEATURES OF PROTEIN ENCODED BY GENE NO: 127

This gene is expressed primarily in Raji cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and T cell autoimmune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 360 as residues: Asp-23 to Gly-29.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of inflammation and T cell autoimmune disorders. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases (such as AIDS), and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 128

The translation product of this gene shares sequence homology with an *C. elegans* coding region C47D12.2 of unknown function (See Accession No. gnl|PID|e348986). One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: EDDGFNRSIHEVILKNITWY SERVLTEISLGSLLILVVIRTIQYNMTRTRDKYLHTNCLAALANMSAQFRSLHQY AAQRIISLFSLLSKKHNKVLEQATQSLRGSLSSNDVPLPDYAQDLNVIEEVIRMM LEIINSCLTNSLHHNPNLVALLYKRDLFEQFRTHPSFQDIMQNIDLVISFFSSRLL QAGS (SEQ ID NO:657); EDDGFNRSIHEVILKNITWYSERVLTEISLGSLLILVV (SEQ ID NO:658); RTIQYNMTRTRDKYLHTNCLAALANMSAQFRSLHQYAAQ RIISLFSLLSKKHN (SEQ ID NO:659); KKHNKVLEQATQSLRGSLSSNDVPLPDY AQD (SEQ ID NO:661); SCLTNSLHHNPNLVYALLYKRDLFEQFRTHPSFQD IMQNIDLVISFFSSRLLQAGS (SEQ ID NO:660). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments. This gene maps to

chromosome 18, and therefore, may be used as a marker in linkage analysis for chromosome 18.

This gene is expressed primarily in smooth muscle and to a lesser extent in fetal liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, atherosclerosis and other cardiovascular and hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of circulatory system disorders such as atherosclerosis, hypertension, and thrombosis . In addition, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 129

The translation product of this gene shares sequence homology with a ribosomal protein which is thought to be important in cellular metabolism, in addition to the *C.elegans* protein F40F11.1 which does not have a known function at the current time (See Accession No. gnl|PID|e244552). Preferred polypeptide fragments comprise the following amino acid sequence:

[illegible]RKCLLLVLSVSIRGRHLSGVVLQDLDAEDHCHPPRLSALHPQVG
PLREAPQEHVCTPVPLLQGRPDR (SEQ ID NO:662); MKMQRTIVIRRDYLH

YIRKYNRFEKRHKNMSVHLSPCFRDVQIGDIVTVGECRPLSKTVRFNVLKVTK AAGTKKQFQKF (SEQ ID NO:663); MADIQTERAYQKQPTIFQNKKRVLLGET GK (SEQ ID NO:664); HCHPPRLSALHPQVQPLREAPQEHVCTPVPL LQGRPDR (SEQ ID NO:666); NIGLGFKDTPRRLLRGTYIDKKCPFTGNVSIRGRILSGVVTQ (SEQ ID NO:669); MKMQRTIVIRRDYLHYIRKYNRFEKRHKNMSVHLSP (SEQ ID NO:667); CFRDVQIGDIVTVGECRPLSKTVRFNVLKVTKAAGTKKQFQKF (SEQ ID NO:668). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in Wilm's tumor and to a lesser extent in thymus and stromal cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases affecting RNA translation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Wilm's tumors, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 362 as residues: Thr-11 to Asp-20.

The tissue distribution and homology to a ribosomal protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases affecting RNA translation.

FEATURES OF PROTEIN ENCODED BY GENE NO: 130

The translation product of this gene shares sequence homology with a yeast DNA helicase which is thought to be important in global transcriptional regulation (See Accession No. gnl|PID|e243594). One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: IFYDSDWNPTVDQQA MDRAHRLGQTKQVTVYRLICKGTIEERILQRAKEKSEIQRMVISG (SEQ ID NO:670); TRMIDLLEEYMVYRKHTYXRLDGSSKISERRDMVADFQNRNDI FVFLLSTRAGGLGINLTAXDTVHF (SEQ ID NO:671); TRMIDLLEEYMVYRK HTYXRLDGSSKISERRDM (SEQ ID NO:674); RRDMVADFQNRNDIFVFLL

STRAGGLGINLTAXDTVHF (SEQ ID NO:675) , IFYDSDWNPTVDQQAMD RAHRLGQTKQVTVYRLICKG (SEQ ID NO:676); RLICKGTIEERILQRAK EKSEIQRMVISG (SEQ ID NO:678). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in amygdala.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases and disorders of the brain. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to a DNA helicase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases affecting RNA transcription, particularly developmental disorders and healing wounds since the later are though to approximate developmental transcriptional regulation.

FEATURES OF PROTEIN ENCODED BY GENE NO: 131

This gene is expressed primarily in prostate and to a lesser extent in amygdala and pancreatic tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, prostate enlargement and gastrointestinal disorders, particularly of the pancreas and gall bladder. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this [illegible] plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to

the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of prostate diseases, including benign prostatic hyperplasia and prostate cancer. In addition, the tissue distribution in tumors of the pancreas indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tissues where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 132

This gene is expressed primarily in adult lung and to a lesser extent in hypothalamus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, pulmonary diseases and neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary and respiratory systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of pulmonary and respiratory disorders such as emphysema, pneumonia, and pulmonary edema and emboli. In addition, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental

disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 133

This gene is expressed primarily in human liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cirrhosis of the liver and other hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of liver disorders such as cirrhosis, jaundice, and Hepatitus. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 134

This gene is expressed primarily in fetal kidney and to a lesser extent in fetal liver and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, development and regeneration of liver and kidney and immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of [illegible]

[illegible] tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 367 as residues: Pro-70 to Arg-77, Tyr-102 to Thr-107.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the kidney and liver, such as cirrhosis, kidney failure, kidney stones, and liver failure, hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells. In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 135

This gene is expressed primarily in brain, bone marrow, and to a lesser extent in placenta, T cell, testis and neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative and immunological diseases and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 368 as residues: Met-1 to His-6.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition, the gene or gene product may also

play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 136

Translatation product of this gene is homologous to the human WD repeat protein HAN11. Preferred polypeptide fragments comprise the following amino acid sequence:
MSLHGKRKEIYKYEAPWTVYAMNWSVRPDKRFRLALGSFVEEYNNKVQLVG
LDEESSEFICRNTFDHPYPTTKLMWIPDTKGVYPDLLATSGDYLRVWRVGETET
RLECLLNNNKNSDFCAPLTSFDWNEVDPYLLGTSSIDTTCTIWGLETGQVLGRV
NLVSGHVKTQLIAHDKEVYDIAFSRAGGGRDMFASVGADGSVRMFDLRHLEH
STIIYEDPQHHPLLRLCWNKQDPNYLATMAMDGMEVVILDVRVPAHLXPGTTIE
HVSMALLGPHIHPATSALQRMTTRLSSGTSSKCPEPLRTLSWPTQLXGEINNVQ
WASTQPELSPSATTTAWRYSECSVGGAVPTRQGLLYFLPLPHPQS (SEQ ID NO:679); MSLHGKRKEIYKYEAPWTVYAMNWSVRPDKRFRLALGSFV
EEYNNKVQLVGLDEESSEFICRNTFDHPYPTTKLMWIPDTKGVYPDLLATSGDY
LRVWRVGETETRLECLLNNNKNSDFCAPLTSFDWNEVDPYLL (SEQ ID NO:680); SFDWNEVDPYLLGTSSIDTTCTIWGLETGQVLGRVNLVSGHVK
TQLIAHDKEVYDIAFSRAGGGRDMFASVGADGSVRMFDLRHLEHSTIIYEDPQH
HPLLRLCWNKQDPNYLATMAMDGMEVVILDVRVPAHLXPGTTI (SEQ ID NO:681); VGADGSVRMFDLRHLEHSTIIYEDPQHHPLLRLCWNKQDPNYLA
TMAMDGMEVVILDVRVPAHLXPGTTIEHVSMALLGPHIHPATSALQRMTTRLS
SGTSSKCPEPLRTLSWPTQLXGEINNVQWASTQPELSPSATTTAWRYSECSVG
GAVPTRQGLLYFLPLPHPQS (SEQ ID NO:682). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in placenta, embryo, T cell and fetal lung and to a lesser extent in endothelial, tonsil and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological and developmental diseases in addition to cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues [illegible]

[illegible] fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or

cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 369 as residues: Gly-19 to Gln-28, Pro-36 to Phe-42.

The tissue distribution in tumors of colon, ovary, and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 137

This gene is expressed primarily in TNF and INF induced epithelial cells, T cells and kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory conditions particularly inflammatory reactions in the kidney. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 370 as residues: Thr-67 to Gly-72, Gln-132 to Ala-145, Arg-150 to Pro-157.

The tissue distribution indicates that the protein products of this gene are useful for treating the damage caused by inflammation of the kidney.

FEATURES OF PROTEIN ENCODED BY GENE NO: 138

This gene maps to chromosome 1, and therefore, may be used as a marker in linkage analysis for chromosome 1 (See Accession No. D63485).

This gene is expressed primarily in breast cancer and colon cancer and to a lesser extent in thymus and fetal spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers, especially of the breast and colon tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors of colon and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 139

This gene maps to chromosome 17, and therefore, can be used as a marker for linkage analysis from chromosome 17.

This gene is expressed primarily in CD34 positive cells, and to lesser extent in activated T-cells and neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunologically related diseases and hematopoietic disorders. Similarly, [illegible]

[illegible] and hematopoietic system, expression of this gene at significantly higher or lower levels

may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in CD34, T-cell and neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of hematopoietic disorders and immunologically related diseases, such as anemia, leukemia, inflammation, infection, allergy, immunodeficiency disorders, arthritis, asthma, immune deficiency diseases such as AIDS.

FEATURES OF PROTEIN ENCODED BY GENE NO: 140

This gene was recently cloned by another group, who called the gene KIAA0313 gene. (See Accession No. d1021609.) Preferred polypeptide fragments comprise the amino acid sequence: LYATATVISSPSTEXLSQDQGDRASLDAADSGRGSWTSCSSGSHDNIQTIQ HQRSWETLPFGHTHFDYSGDPAGLWASSSHMDQIMFSDHSTKYNRQNQSRES LEQAQSRASWASSTGYWGEDSEGDTGTIKRRGGKDVSIEAESSSLTSVTTEETK PVPMPAHIAVASSTTKGLIARKEGRYREPPPTPPGYIGIPITDFPEGHSHPARKP PDYNVALQRSRMVARSSDTAGPSSVQQPHGHPTSSRPVNKPQWHKXNESDPR LAPYQSQGFSTEEDEDEQVSAV (SEQ ID NO:683); HMDQIMFSDHSTKYNRQ NQSRESLEQAQSRASWASSTGYWGE (SEQ ID NO:684); SVTTEETKPVPMP AHIAVASSTTKGLIARKEGRYREPPPTPPGYIGIPITD (SEQ ID NO:685); and VALQRSRMVARSSDTAGPSSVQQPHGHPTSSRPVNKPQW HKXNESDPRLAPYQSQGF (SEQ ID NO:686). Also preferred are polynucleotide fragments encoding these polypeptide fragments. This gene maps to chromosome 4, and therefore, may be used as a marker in linkage analysis for chromosome 4 (See Accession No. AB002311).

This gene is expressed primarily in ovarian cancer, tumors of the Testis, brain, and colon.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, ovarian, testicle, brain and colon cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male and female reproductive systems,

expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors of colon, ovary, testis, and brain origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 141

This gene is expressed primarily in spleen and colon cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, colon cancer and immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal trace and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors of colon, ovary, and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues

FEATURES OF PROTEIN ENCODED BY GENE NO: 142

Translation product is homologous to T cell translocation protein, a putative zinc finger factor (See Accession No. 340454), as well as to the G-protein coupled receptor TM5 consensus polypeptide (See Accession No. R50734). Preferred polypeptide fragments comprise the following amino acid sequence: CLLFVFVSLGMRCLFWTIVYNVLYLKHKCNTVLLCYHLCSI (SEQ ID NO:687); ACSKLIPAFEMVMRAKDNVYHLDCFACQLCNQRXCVGDKFFLKNNXXLCQTDYEEGLMKEGYAPXVR (SEQ ID NO:688). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in fetal brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders including brain cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Central Nervous System, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo.

FEATURES OF PROTEIN ENCODED BY GENE NO: 143

Translation product for this gene has significant homology to the Fas ligand, which is a cysteine-rich type II transmembrane protein/tumor necrosis factor receptor homolog. Mutations within this protein have been shown to result in generalized lymphoproliferative disease leading to the development of lymphadenopathy and autoimmune disease (See Medline Article No. 94185175). Preferred polypeptide

fragments comprise the following amino acid sequence: SALSEPGAPDRRRPCPESVPRRPDDEQWPPPTALCLDVAPLPPSS (SEQ ID NO:689). Also preferred are polynucleotide fragments encoding these polypeptide fragments (See Accession No. 473565).

This gene is expressed primarily in osteoblasts, lung, and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, osteoblast-related, pulmonary, neurological, and immunological diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 376 as residues: Trp-33 to Thr-40, Lys-45 to Ile-63.

The tissue distribution in osteoblasts, lung, and brain combined with its homology to the Fas ligand indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues. Because the Fas ligand gene is known to be expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including asthma, immune deficiency diseases such as AIDS and leukemia, and various autoimmune disorders including lupus and arthritis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 144

This gene shares sequence homology with a 21.5 KD transmembrane protein in the SEC15-SAP4 intergenic region of yeast (See Accession No. [illegible]

[illegible] RSHLMGRSCCHDGPGGLS SNRGRRFKWAIEL SGPGGGSRGRSDRGSGQGDSLYPVGYLDKQVPDTSVQETDRILVEKRCWDIAL

GPLKQIPMNLFIMYMAGNTISIFPTMMVCMMAWRPIQALMAISATFKMLESSSQ KFLQGLVYLIGNLMGLALAVYKCQSMGLLPTHASDWLAFIEPPERMEFSGG GLLL (SEQ ID NO:691); PVGYLDKQVPDTSVQETDRILVEKRCWDIALGPLKQ IPMNLFI (SEQ ID NO:693); and ATFKMLESSSQKFLQGLVYLIGNLMGLALAV YKCQSMGLLPTHASD (SEQ ID NO:692). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in osteoclastoma, hemangiopericytoma, liver, lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, osteoclastoma, hemangiopericytoma, liver and lung tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the above tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the lung and liver systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing osteoclastoma, hemangiopericytoma, liver and lung tumors.

FEATURES OF PROTEIN ENCODED BY GENE NO: 145

Translation product of this gene shares homology with the glucagon-69 gene which may indicate this gene plays a role in regulating metabolism. (See Accession No. A60318) One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: PTTKLDIMEKKKHIQIRFPSFYHKLVDSGRMRSKRETRREDSDTKHNL (SEQ ID NO:694). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in brain, kidney, colon, and testis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, brain, kidney, colon, and testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, neurological, circulatory, and gastrointestinal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors of brain, kidney, colon, and testis origins, indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 146

The translation product of this gene shares sequence homology with goliath protein which is thought to be important in the regulation of gene expression during development. Protein may serve as a transcription factor. One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: TEHIIAVMITELRGKDILSYLEKNISVQMTIAVGTRMPPKNFSRGSLVFVSISFIVLMIISSAWLIFYFIQKIRYTNARDRNQRRLGDAAKKAISKLTTRTVKKGDKETDPDFDHCAVCIESYKQNDVVRILPCKHVFHKSCVDPWLSEHCTCPMCKLNILKALGIV (SEQ ID NO:695); TEHIIAVMITELRGKDILSYLEKNISVQMTIAVGTRMPPKNFSRGSLVFVSISFIVLMIISSAWLIFYF (SEQ ID NO:[illegible] SISFIVLMII[illegible]

[illegible] VRILPCKHVFHKSCVDP

WLSEHCTCPMCKLNILKALGIV (SEQ ID NO:699). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments (See Accession No. 157535). Moreover, another embodiment is the polynucleotide fragments encoding these polypeptide fragments: MTHPGTEHIIAVMITELRGKDILSYLEKNISVQMTIAVGTRMPPKNFSRGS LVFVSISFIVLMIISSAWLIFYFIQKIRYTNARDRNQRRLGDAAKKAISKLTTRTV KKGDKETDPDFDHCAVCIESYKQNDVVRILPCKHVFHKSCVDPWLSEHCTCP MCKLNILKALGIVPNLPCTDNVAFDMERLTRTQAVNRRSALGDLAGDNSLGLE PLRTSGISPLPQDGELTPRTGEINIAVTKEWFIIASFGLLSALTLCYMIIRATASLN ANEVEWF (SEQ ID NO:696):MTHPGTEHIIAVMITELRGKDILSYLEKNISVQM TIAVGTRMPPKNFSRGSLVFVSISFIVLMIISSAWLIFYFIQKIRYTNARDRNQRR LGDAAKKAISKLTTRT (SEQ ID NO:700); AAKKAISKLTTRTVKKGDKE TDPDFDHCAVCIESYKQNDVVRILPCKHVFHKSCVDPWLSEHCTCPMCKLNIL KALGIVPNLPC (SEQ ID NO:701); TQAVNRRSALGDLAGDNSLGLEPLRTSGI SPLPQDGELTPRTGEINIAVTKEWFIIASFGLLSALTLCYMIIRATASLNANEVEW F (SEQ ID NO:702); PLHGVADHLGCDPQTRFFVPPNIKQWIALLQRGNCTF KEKISRAAFHNAVAVVIYNNKSKEEPVTMTHPGTEHIIAVMITELRGKDILSYLE KNISVQMTIAVGTRMPPKNFSRGSLVFVSISFIVLMIISSAWLIFYFIQKIRYTNA RDRNQRRLGDAAKKAISKLTTRTVKKGDKETDPDFDHCAVCIESYKQNDVVRI LPCKHVFHKSCVDPWLSEHCTCPMCKLNILKALGIVPNLPCTDNVAFDMERLT RTQAVNRRSALGDLAGDNSLGLEPLRTSGISPLPQDGELTPRTGEINIAVTKEW FIIASFGLLSALTLCYMIIRATASLNANEVEWF(SEQ ID NO:703); and HGVADHLGCDPQTRFFVPPNIKQWIALLQRGNCTFKEKISRAAFHNAVAVVIY NNKSKEE (SEQ ID NO:704). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments. When tested against Jurkat cell lines, supernatants removed from cells containing this gene activated the GAS pathway. Thus, it is likely that this gene activates immune cells through the JAKS/STAT signal transduction pathway.

This gene is expressed primarily in macrophage, breast, kidney and to a lesser extent in synovium, hypothalamus and rhabdomyosarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, schizophrenia and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and neural system, expression of this gene at

significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to zinc finger protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of schizophrenia, kidney disease and other cancers. The tissue distribution in macrophage, breast, and kidney origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of tumors within these tissues, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 147

The translation product of this gene shares sequence homology with HNP36 protein, an equilibrative nucleoside transporter, which is thought to be important in gene transcription as well as serving as an important component of the nucleoside transport apparatus (See Accession No. 1845345). One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: MSGQGLAGFFASVAMICAIASGSELSESAFGYFITACAVIILTIICYLGLPRLEFYR YYQQLKLEGPGEQETKLDLISKGEEPRAGKEESGVSVSNSQPTNESHSIKAILK NISVLAFSVCFIFTITIGMFPAVTVEVKSSIAGSSTWERYFIPVSCFLTFNIFDWLG RSLTAVFMWPGKDSRWLPSWXLARLVFVPLLLLCNIKPRRYLTVVFEHDAWFI FFMAAFAFSNGYLASLCMCFGPKKVKPAEAETAEPSWPSSCVWVWHWGLFS PSCSGQLCDKGWTEGLPASLPVCLLPLPSARGDPEWSGGFFF (SEQ ID NO:705); MSGQGLAGFFASVAMICAIASGSELSESAFGYFITACAVIILTIIC YLGLPRLEFYRYYQQLKLE GPGEQETKLDLISKGEEPRAGKEESGVSVSNSQ PTNESHSI (SEQ ID NO:706); SGVSVSNSQPTNESHSIKAILKNISVLAFSVCFI FTITIGMFPAVTVEVKSSIAGSSTWERYFIPVSCFLTFNIFDWLGRS (SEQ ID [illegible]

[illegible] NIKPRRYLTVVFEHDA (SEQ ID NO:708); FGPKKVKPAEAETAEPSWPSSCVWVWHWGLFSPCSGQLCDK

GWTEGLPASLPVCLLPLPSARGDPEWSGGFFF (SEQ ID NO:709). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in eosinophils and aortic endothelium and to a lesser extent in umbilical vein endothelial cell and thymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to HNP36 protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of blood neoplasias and other hematopoietic disease.

FEATURES OF PROTEIN ENCODED BY GENE NO: 148

This gene is expressed primarily in breast cancer cell lines, thymus stromal cells, and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, endocrine and female reproductive system diseases including breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of endocrine disorders. In addition, the tissue distribution in tumors of thymus, ovary, and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues

FEATURES OF PROTEIN ENCODED BY GENE NO: 149

Translation product of this gene has homology to pmt1 and pmt 2, two conserved schizosaccharomyces pombe genes. One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: DDDGFEIVPIEDPAKHRILDPEGLALGAVIASSKKAKRDLIDNSFNRYTFNEDEG ELPEWFVQEEKQHRIRQLPVGKKEVEHYRKRWREINARPIXXXXXXXXXXX XXXXXXLEQTRKKAEAVVNTVDIXRTRES (SEQ ID NO:710); DDDGFEIVPIEDPAKHRILDPEGLALGAVIASSKKAKRDLIDNSFNRYTF (SEQ ID NO:711); KRWREINARPIXXXXXXXXXXXXXXXXXLEQTRKKAE AVVNTVDIXRTRES (SEQ ID NO:712). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments (See Accession No. e1216734).

This gene is expressed primarily in retina and ovary and to a lesser extent in brreast cancer cell, epididymus and osteosarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal growth disorders, cancer and reproductive system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural and reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having [illegible]

[illegible] disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 382 as residues: Met-1 to Gly-7.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or treatment of reproductive system disease and cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 150

One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: MIKDKGRARTALTSSQPAHLCPENPLLHLKAAVKEKKRNKKKKTIGSPKRIQSPLNNKLLNSPAKTLPGACGSPQKLIDGFLKHEGPPAEKPLEELSASTSGVPGLSSLQSDPAGCVRPPAPNLAGAVEFNDVKTLLREWITTISDPMEEDILQVVKYCTDLIEEKDLEKLDLVIKYMKRLMQQSVESVWNMAFDFILDNVQVVLQQTYGSTLKVT (SEQ ID NO:713); MIKDKGRARTALTSSQPAHLCPENPLLHLKAAVKEKKRNKKKKTIGSPKRIQ (SEQ ID NO:714); KRIQSPLNNKLLNSPAKTLPGACGSPQKLIDGFLKHEGPPAEKPLEELSASTSGVPGLSSLQSDPAGCVRPPAPNLAGAVEFNDVKTLLREWITTISDPM (SEQ ID NO:715); TISDPMEEDILQVVKYCTDLIEEKDLEKLDLVIKYMKRLMQQSVESVWNMAFDFILDNVQVVLQQTYGSTLKVT (SEQ ID NO:716). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in 12 week embryo and to a lesser extent in hemangiopericytoma and frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, growth disorders and hemangiopericytoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circular and neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 383 as residues: Leu-4 to Lys-11.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of growth disorders, hemangiopericytoma and other soft tissue tumors.

FEATURES OF PROTEIN ENCODED BY GENE NO: 151

The translation product of this gene has been found to have homology to a human DNA mismatch repair protein PMS3. Preferred polypeptide fragments comprise the following amino acid sequence: FCHDCKFPEASPAMNCEP (SEQ ID NO:717). Also preferred are polynucleotide fragments encoding these polypeptide fragments (See Accession No. R95250).

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, lymphoma, immunodeficiency diseases, and cancers resulting from genetic instability. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 384 as residues: Met-1 to Lys-6.

The tissue distribution in neutrophils and the sequence homology indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of Hodgkin's lymphoma, since the elevated expression and secretion by the tumor mass may be indicative of tumors of this type. Additionally the gene product may be used as a target in the immunotherapy of the cancer. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia. Furthermore, its homology to a known DNA repair protein would suggest gene may be useful in establishing cancer predisposition and prevention in gene therapy applications.

FEATURES OF PROTEIN ENCODED BY GENE NO: 152

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, infectious diseases and lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of inflammation and infectious diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 153

One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence:
MASSVPAGGHTRAGGIFLIGKLDLEASLFKSFQWLPFVLRKKC
NFFCWDSSAHSLPLHPLSASCSAPACHASDTHLLYPSTRALCPSIFAWLVAPHS
VFRTNAPGPTPSSQSSPVFPVFPVSFMALIVCXLVCC (SEQ ID NO:720);
MASSVPAGGHTRAGGIFLIGKLDLEASLFKSFQWLPFVLRKKCNFFCWDSSAH
SLPLHPLSASCSAPACHA (SEQ ID NO:721);FAWLVAPHSVFRTNAPGPTPS
SQSSPVFPVFPVSFMALIVCXLVCC (SEQ ID NO:722). An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and infectious disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred

epitopes include those comprising a sequence shown in SEQ ID NO: 386 as residues: Ser-11 to Pro-17.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of infectious diseases and inflammation.

FEATURES OF PROTEIN ENCODED BY GENE NO: 154

This gene is expressed in multiple tissues including ovary, uterus, adipose tissue, brain, and the liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, uterine, ovarian, brain, and liver cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnostic or therapeutic uses in the treatment of the female reproductive system, obesity, and liver disorders, particularly cancer in the above tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 155

This gene maps to chromosome 3, and therefore, may be used as a marker in linkage analysis for chromosome 3 (See Accession No. D87452).

This gene is expressed in multiple tissues including brain, aortic endothelial cells, smooth muscle, pituitary, testis, melancytes, spleen, nertrophils, and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the [illegible]

[illegible]

[illegible] disorders including immunodeficiencies, cancers of the brain and the female reproductive system, as well as cardiovascular disorders, such as

atherosclerosis and stroke. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution suggest that polynucleotides and polypeptides corresponding to this gene are useful in treatment/detection of disorders in the nervous system, including schizophrenia, neurodegeneration, neoplasia, brain cancer as well as cardiovascular and female reproductive disorders including cancer within the above tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 156

The translation product of this gene shares sequence homology with the human gene encoding cytochrome b561 (See Accession No. P10897). Cytochrome b561 is a transmembrane electron transport protein that is specific to a subset of secretory vesicles containing catecholamines and amidated peptides. This protein is thought to supply reducing equivalents to the intravesicular enzymes dopamine-beta-hydroxylase and alpha-peptide amidase. Preferred polypeptides of the invention comprise the amino acid sequence:
MAMEGYWRFLALLGSALLVGFLSVIFALVWVLHYREGLGWDGSALEFNWHP
VLMVTGFVFIQGIAIIVYRLPWTWKCSKLLMKSIHAGLNAVAAILAIISVVAVFE
NHNVNNIANMYSLHSWVGLIAVICYLLQLLSGFSVFLLPWAPLSLRAFLMPIHV
YSGIVIFGTVIATALMGLTEKLIFSLRDPAYSTFPPEGVFVNTLGLLILVFGALIF
WIVTRPQWKRPKEPNSTILHPNGGTEQGARGSMPAYSGNNMDKSDSEL
NSEVAARKRNLALDEAGQRSTM (SEQ ID NO:724); as well as antigenic fragments of at least 20 amino acids of this gene and/or biologically active fragments. Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune system and metabolism related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological

probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product or RNA of this gene is useful for treatment or diagnosis of immune system and metabolic diseases or conditions including Tay-Sachs disease, phenylketonuria, galactosemia, various porphyrias, and Hurler's syndrome.

FEATURES OF PROTEIN ENCODED BY GENE NO: 157

The translation product of this gene shares sequence homology with collagen which is important in mammalian development. This gene also shows sequence homology with bcl-2. (See Accession No. P80988.) Preferred polypeptide fragments comprise the amino acid sequence: PGRAGPSPGLSLQLPAEPGHPAGNLAPL TSRPQPLCRIPAVPG (SEQ ID NO:725). Also preferred are polynucleotide sequences encoding this polypeptide fragment.

This gene is expressed primarily in HL-60 tissue culture cells and to a lesser extent in liver, breast, and uterus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological diseases, hereditary disorders involving the MHC class of immune molecules, as well as developmental disorders and reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and reproductive system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample [illegible]

comprising a sequence shown in SEQ ID NO: 390 as residues: Ser-39 to Gly-46, Leu-49 to Ala-62.

The tissue distribution and homology to collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hereditary MHC disorders and particularly autoimmune disorders including rheumatoid arthritis, lupus, scleroderma, and dermatomyositis, as well as many reproductive disorders, including cancer of the uterus, and breast tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 158

This gene is expressed primarily in the amygdala region of the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, a variety of brain disorders, particularly those effecting mood and personality. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and/or diagnosis of a variety of brain disorders, particularly bipolar disorder, unipolar depression, and dementia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 159

This gene is expressed in a variety of tissues and cell types including brain, smooth muscle, kidney, salivary gland and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers of a variety of organs including brain, smooth muscle, kidney, salivary gland and T-cells and cardiovascular disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders

of the above tissues or cells, particularly of the central nervous, urinary, salivary, digestive, and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain, smooth muscle, and T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of various neurological, and cardiovascular disorders, but not limited to cancer within the above tissues. Additionally the gene product may be used as a target in the immunotherapy of the cancer. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 160

The translation product of this gene shares sequence homology with collagen which is thought to be important in cellular interactions, extracellular matrix formation, and has been found to be an identifying determinant in autoimmune disorders. Moreover, this gene shows sequence homology with the yeast protein, Sls1p, an endoplasmic reticulum component, involved in the protein translocation process in Yeast Yarrowia lipolytica. (See Accession No. 1052828; see also J. Biol. Chem. 271, 11668-11675 (1996).) With mouse, this same region shows sequence homology with the heavy chain of kinesin. (See Accession No. 2062607.) Recently, suppression of the heavy chain of kinesin was shown to inhibits insulin secretion from primary cultures of mouse beta-cells. (See Endocrinology 138 (5), 1979-1987 (1997).) Moreover, kinesin was found associated with drug resistance and cell immortalization. (See 468355.) Thus, it is likely that this gene also act as a genetic suppressor elements.

This gene is expressed primarily in the greater omentum and to a lesser extent in a variety of organs and cell types including gall bladder, stromal bone marrow cells, lymph node, liver, testes, pituitary, and thymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the [illegible]

[illegible] including autoimmune disorders and cancers in a variety of organs and cell types.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and gastrointestinal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 393 as residues: Asn-27 to Leu-47, Gln-81 to Lys-88, Asp-93 to Lys-102, Asn-107 to Leu-116, Met-129 to Glu-141, Glu-150 to Asp-157, Lys-176 to Glu-185, Glu-333 to Tyr-349, Cys-393 to Leu-403, Gln-423 to Gly-429.

The tissue distribution in within various endocrine and immunological tissues combined with the sequence homology to a conserved collagen motif indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of various autoimmune disorders including, but not limited to, rheumatoid arthritis, lupus erthyematosus, scleroderma, dermatomyositis Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 161

This gene has homology to the tissue inhibitor of metalloproteinase 2. Such inhibitors are vital to proper regulation of metalloproteins such as collagenases (See Accession No. P16368). In addition, this gene maps to chromosome 17, and therefore, may be used as a marker in linkage analysis for chromosome 17 (See Accession No. P16368).

This gene is expressed primarily in several types of cancer including osteoclastoma, chondrosarcoma, and rhabdomyosarcoma and to a lesser extent in several non-malignant tissues including synovium, amygdala, testes, placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, various types of cancer, particularly cancers of bone and cartilage, as well as various autoimmune disorders. Similarly, polypeptides and antibodies directed

to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculoskeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in various cancers and the sequence homology to a collagenase inhibitor indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia

FEATURES OF PROTEIN ENCODED BY GENE NO: 162

This gene is homologous to the mitochondrial ATP6 gene and therefore is likely a homolog of this gene family (See Accession No. X76197).

This gene is expressed primarily in brain tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, a variety of brain disorders, including Down's syndrome, depression, Schizophrenia, and epilepsy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates this gene is useful for diagnosis of various neurological disorders [illegible]

[illegible]

disease, phenylketonuria and Hurler's Syndrome.

FEATURES OF PROTEIN ENCODED BY GENE NO: 163

This gene is expressed primarily in placenta, neutrophils, and microvascular endothelial cells and to a lesser extent in multiple tissues including brain, prostate, spleen, thymus, and bone.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neutropenea and other diseases of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis various female reproductive disorders. Additionally the gene product may be used as a target in the immunotherapy of various cancers. Because the gene is expressed in some cells of lymphoid and endocrine origin, the natural gene product may be involved in immune functions and metabolism regulation, respectively. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 164

This gene is expressed primarily in neutrophils, monocytes, bone marrow, and fetal liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune system disorders including, but not limited to, autoimmune disorders such as lupus, and immunodeficiency disorders . Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders

of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in various immune system tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of various immunological disorders such as Hodgkin's lymphoma, arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 165

The translation product of this gene shares sequence homology with dystrophin which is thought to be defective in both Duchene and Becker Muscular Dystrophy. Preferred polypeptide fragments comprise the following amino acid sequence: MKLLGECSSSIDSVKRLEHKLKEEEESLPGFVNLHSTETQTAGVIDRWELLQAQALSKELRMKQNLQKWQQFNSDLNSIWAWLGDTEEELEQLQRLELSTDIQTIELQIKKLKELQKAVDHRKAIILSINLCSPEFTQADSKESRDLQDRLXQMNGRWDRVCSLLEEWRGLLQDALMQCQGFHEMSHGLLLMLENIDRRKNEIVPIDSNLDAEILQDHHKQLMQIKHELLESQLRVASLQDMSCQLLVNAEGTDCLEAKEKVHVIGNRLKLLLKEVSRHIKELEKLLDVSSSQQDLSSWSSADELDTSGSVSPXSGRSTPNRQKTPRGKCSLSQPGPSVSSPHSRSTKGGSDSSLSEPXPGRSGRGFLFRVLRAALPLQLLLLLLIGLACLVPMSEEDYSCALSNNFARSFHPMLRYTNGPPPL (SEQ ID NO:726); MKLLGECSSSIDSVKRLEHKLKEEEESLPGFVNLHSTETQTAGVIDRWELLQAQALSKELRMKQNLQKWQQFNSDLNSIWAWLGDTEEELEQLQRLELSTDIQTIELQIK (SEQ ID NO:727); KLKELQKAVDHRKAIILSINLCSPEFTQADSKESRDLQDRLXQMNGRWDRVCSLLEEWRGLLQDALMQCQGFHEMSHGLLLMLENIDRRKNEIVPIDSNLDAEILQDHHKQLMQIKHELLESQLRVASLQDMSCQL (SEQ ID NO:728); QDMSCQLLVNAEGTDCLEAKEKVHVIGNRLKLLLKEVSRHIKELEKLLDVSSSQQDLSSWSSADELDTSGSVSPXSGRSTPNRQKTPRGKCSLSQPGPSVSSPHS (SEQ ID NO:729); DSSLSEPXPGRSGRGFLFRVLRAALPLQLLLLLLIGLACLVPMSEEDYSCALSNNFARSFHPMLRYTNGPPPL (SEQ ID NO:730). Also preferred are polynucleotide fragments encoding these polypeptide fragments. Furthermore [illegible]

[illegible] expressed in numerous [illegible] the heart [illegible] brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, musculoskeletal disorders including Muscular Dystrophy and cardiovascular diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscle tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to dystrophin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of Muscular Dystrophy and other muscle disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 166

This gene is expressed primarily in human cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the central nervous system, including Alzheimer's Disease, Parkinson's Disease, ALS, and mental illnesses. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 399 as residues: Pro-20 to Gly-26, Leu-37 to Pro-42, His-57 to Gly-63.

The tissue distribution indicates that the protein products of this gene are useful for treatment/diagnosis of diseases of the central nervous system and may protect or

enhance survival of neuronal cells by slowing progression of neurodegenerative diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 167

Preferred polypeptides encoded by this gene comprise the following amino acid sequence:
MKLLICGNYLAPSHSESSRRCCLLCFYPLCLEINFGMKVFLSMPFLVLFQ
SLIQED (SEQ ID NO:731). Polynucleotides encoding such polypeptides are also provided. This gene is believed to reside on chromosome 15. Therefore polynucleotides derived from this gene are useful in linkage analysis as chromosome 15 markers.

This gene is expressed primarily in human testes tumor and to a lesser extent in normal human testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the testes, particularly cancer, and other reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for treatment/diagnosis of testicular diseases including cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 168

This gene is expressed primarily in fetal liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, conditions affecting hem[illegible]

[illegible] immunological probes for differential identification of the tissue(s) [illegible] type(s). For a number of disorders of the above tissues or cells, particularly of the

hepatic system, and fetal hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 401 as residues: His-7 to Trp-17, Leu-19 to Lys-27, Pro-33 to Gly-44, Lys-68 to Gly-74, Lys-85 to Cys-95.

The tissue distribution indicates that the protein products of this gene are useful for treatment/diagnosis of diseases of the developing liver and hematopoietic system, and act as a growth differentiation factor for hematopoietic stem cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 169

The polypeptide encoded by this gene is believed to be a membrane bound receptor. The extracellular domain of which is expected to consist of the following amino acid sequence:
RILLVKYSANEENKYDYLPTTVNVCSELVKLVFCVLVSFCVIKKDHQSRNLKY
ASWKEFSDFMKWSIPAFLYFLDNLIVFYVLSYLQPAMAVIFSNFSIITTALLFRIV
LKXRLNWIQWASLLTLFLSIVALTAGTKTLQHNLAGRGFHHDAFFSPSNSCLL
FRNECPRKDNCTAKEWTFPEAKWNTTARVFSHIRLGMGHVLIIVQCFISSMANI
YNEKILKEGNQLTEXIFIQNSKLYFFGILFNGLTLGLQRSNRDQIKNCGFFYGH
S (SEQ ID NO:732). Thus, preferred polypeptides encoded by this gene comprise the extracellular domain as shown above. It will be recognized, however, that deletions of either end of the extracellular domain up to the first cysteine from the N-terminus and the first cysteine of the C-terminus, is expected to retain the biological functions of the full-length extracellular domain because the cysteines are thought to be responsible for providing secondary structure to the molecule. Thus, deletions of one or more amino acids from either end (or both ends) of the extracellular domain are contemplated. Of course, further deletions including the cysteines are also contemplated as useful as such polypeptides is expected to have immunological properties such as the ability to evoke and immune response. Polynucleotides encoding all of the foregoing polypeptides are provided.

This gene is expressed primarily in human osteoclastoma and to a lesser extent in hippocampus and chondrosarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, cancers, particularly those of the bone and connective tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 402 as residues: Met-1 to Cys-6, Ala-41 to Tyr-49, Lys-76 to Lys-84.

The tissue distribution indicates that the protein products of this gene are useful for diagnosis of cancers of the bone and connective tissues, and may act as growth factors for cells involved in bone or connective tissue growth.

FEATURES OF PROTEIN ENCODED BY GENE NO: 170

Preferred polypeptides encoded by this gene comprising the following amino acid sequence:
NSVPNLQTLAVLTEAIGPEPAIPRXPREPPVATSTPATPSAGPQPLPTGTV
LVPGGPAPPCLGEAWALLLPPCRPSLTSCFWSPRPSPWKETGV (SEQ ID NO:733). Polynucleotides encoding such polypeptides are also provided herein.

This gene is expressed primarily in hematopoietic progenitor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the blood including cancer and autoimmune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the blood/circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the [illegible]

[illegible] comprising a sequence shown in SEQ ID NO: [illegible] to His-32.

The tissue distribution indicates that the protein products of this gene are useful for diagnosis of diseases involving growth differentiation of hematopoietic cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 171

Preferred polypeptides encoded by this gene comprise the following amino acid sequences: ALQLAFYPDAVEEWLEENVHPSLQRLQXLLQDLSEVSAPP (SEQ ID NO:734); and/or CHPPALAGTLLRTPEGRAHARGLLLEAGGA (SEQ ID NO:735). Polynucleotides encoding such polypeptides are also provided. The protein product of this gene shares sequence homology with metallothionines. Thus, polypeptide encoded by this gene are expected to have metallothionine activity, such activities are known in the art and described elsewhere herein.

This gene is expressed primarily in kidney cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the kidney including cancer and renal dysfunction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 404 as residues: Ser-47 to Gln-52.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the kidney including kidney failure.

FEATURES OF PROTEIN ENCODED BY GENE NO: 172

This gene is expressed primarily in 12 week old early stage human.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for

differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing embryo, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 405 as residues: Gln-31 to Thr-43, Gly-51 to Ser-58, Pro-65 to Pro-72.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of developmental problems with fetal tissue. The gene may be involved in vital organ development in the early stage, especially hematopoiesis, cardiovascular system, and neural development.

FEATURES OF PROTEIN ENCODED BY GENE NO: 173

The translation product of this gene shares sequence homology with TGN38, an integral membrane protein previously shown to be predominantly localized to the trans-Golgi network (TGN) of cells.

This gene is expressed primarily in developing embryo and to a lesser extent in cancer tissues including lymphoma, endometrial, protate and colon.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 406 as residues: His-65 to Ser-7[illegible] [illegible]

[illegible] tissue distribution and homology to an integral membrane protein [illegible] that polynucleotides and polypeptides corresponding to this gene are useful for

diagnosis of cancers and developmental abnormalities where aberrant expression relates to an abnormality.

FEATURES OF PROTEIN ENCODED BY GENE NO: 174

The translation product of this gene shares sequence homology with a dnaJ heat shock protein from E. coli which is allelic to sec63, a gene that affects transit of nascent secretory proteins across the endoplasmic reticulum in yeast.

This gene is expressed primarily in Hodgkin's lymphoma and to a lesser extent in testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 407 as residues: Thr-13 to Trp-21, Arg-74 to Asp-81.

The tissue distribution and homology to dnaJ indicates that polynucleotides and polypeptides corresponding to this gene are useful as a diagnostic for cancer including Hodgkin's lymphoma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 175

This gene is expressed primarily in endothelial cells and to a lesser extent in bone marrow stromal cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases involving angiogenic abnormalities including diabetic retinopathy, macular degeneration, and other diseases including arteriosclerosis and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for treating diseases where an increase or decrease in angiogenesis is indicated and as a factor in the wound healing process.

FEATURES OF PROTEIN ENCODED BY GENE NO: 176

The translation product of this gene shares sequence homology with MAT8 (mouse) which is thought to be important in regulating chloride conductance in cells (particularly in the breast) by modulating the response mediated by cAMP and protein kinase C to extracellular signals.

This gene is expressed primarily in amniotic cells and hematopoeitic cells including macrophages, Neutrophils, T cells, TNF induced aortic endothelium and to a lesser extent in testes, TNF induced epithelial cells, and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory responses mediated by T cells, macrophages, and/or neutrophils particularly those involving TNF, and also cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 409 as residues: Thr-19 to Ala-33, Leu-51 to [illegible]

[illegible] tissue distribution and homology to MAT8 indicates that polynucleotides and polypeptides corresponding to this gene are useful for modifying inflammatory

responses to cytokines such as TNF and thus modifying the duration and/or severity of inflammation. Polynucleotides and polypeptides derived from this gene are thought to be useful in the diagnosis and treatment of cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 177

This gene is expressed primarily in endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, vascular restenosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating diseases associated with vascular response to injury such as vascular restenosis following angioplasty..

FEATURES OF PROTEIN ENCODED BY GENE NO: 178

One embodiment of the claimed invention comprises: MRPDWKAGAGPGGPPQKPAPSSQRKPPARPSAAAAAIAVAAAEEERRLRQRN RLRLEEDKPAVERCLEELVFGDVENDEDALLRRLRGPRVQEHEDSGDSEVENEA KGNFPPQKKPVWVDEEDEDEEMVDMMNNRFRKDMMKNASESKLSKDNLKK RLKEEFQHAMGGVPAWAETTKRKTSSDDESEEDEDDLLQRTGNFISTSTSLPRG ILKMKNCQHANAERPTVARISICAVPSRCTDCDGCWD (SEQ ID NO:737); or CLEELVFGDVENDEDALLRRLRGPRVQEHEDSGDSEVENEAKGNFPPQKKPV WVDEEDEDEEMVDMMNNRFRKDMMKNASESKLSKDNLKKRLKEEFQHAMG GVPAWAETTKRKTSSDDESEEDEDDLLQRTGNFISTSTSLPRGILKMKNCQHA NAERPTVARISICAVPSRCTDCDGC (SEQ ID NO: 738). LKEKIVRSFEVSPDGS FLLINGIAGYLHLLAMKTKELIGSMKINGRVAASTFSSDSKKVYASSGDGEVYV WDVNSRKCLNRFVDEGSLYGLSIATSRNGQYVACGSNCGVVNIYNQDSCLQE TNPKPIKAIMNLVTGVTSLTFNPTTEILAIASEKMKEAVRLVHLPSCTVFSNFPVI KNKNISHVHTMDFSPRSGYFALGNEKGKALMYRLHHYSDF (SEQ ID NO:739);

and/or KINGRVAASTFSSDSKKVYASSGDGEVYVWDVNSRKCLNRFVDEGSL YGLSIATSRNGQYVACGSNCGVVNIYNQDSCLQETNPKPIKAIMNLVTGVTSLT FNPTTEILAIASEKMKEAVRLVHLPSCTVFSNFPVIKNKNISHVHTMDFSPRSG YFALGNEKGKAL (SEQ ID NO:740).

This gene is expressed primarily in epidydimus and endometrial tumors and to a lesser extent in T cell lymphoma and cell lines derived from colon cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumors of the reproductive organs including testis and endometrial cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 411 as residues: Ser-67 to Lys-72, Val-87 to Leu-93, Tyr-128 to Pro-141, Asp-204 to Gly-210.

The tissue distribution indicates that the protein products of this gene are useful for treating tumors of the endometrium or epithelial tumors of the reproductive system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 179

Preferred polypeptides encoded by this gene comprise the following amino acid sequence:

MRILQLILLALATGLVGGETRIIKGFECKLHSQPWQAALFEKTRLLCGATLIAPR WLLTAAHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDH RNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTSCSFPAGAARPDPSYACLTPC DAPTSPSLSTRSVRTPTPATSQTPWCVPACRKGARTPARVTPGALWSVTSLFKA LSPGARIRVRSPESLVSTRKSANMWTGSRRR (SEQ ID NO:741); ETRIIKGFEC KLHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE GCEQTRTATESFPHPGFNNSLPNKDHRNDIML VKMASP[illegible]

[illegible] LSPGARIRVRSPESLVSTRKSANMWTG[illegible]

SRRR (SEQ ID NO:742); or CKLHSQPWQAALFEKTRLLCGATLIAPRWLLT AAHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNS (SEQ ID NO:743). The translation product of this gene shares sequence homology with neuropsin a novel serine protease which is thought to be important in modulating extracellular signaling pathways in the brain. Owing to the structural similarity to other serine proteases the protein products of this gene are expected to have serine protease activity which may be assayed by methods known in the art and described elsewhere herein.

This gene is expressed primarily in endometrial tumor and to a lesser extent in colon cancer, benign hypertrophic prostate, and thymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers of the endometrium or colon and benign hypertrophy of the prostate. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the urogenital or reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 412 as residues: Gly-12 to Ser-22, Pro-34 to Ser-53.

The tissue distribution and homology to serine proteases indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing or treating hperproliferative disorders such as cancer of the endometrium or colon and hyperplasia of the prostate.

FEATURES OF PROTEIN ENCODED BY GENE NO: 180

Preferred polypeptide encoded by this gene comprise the following amino acid sequence: VLQGRYFSPILEMRRLRPEGXXNLPGGSRAQKEPRQDLTLVLWPHC PHFAMTRSYVPTKQCMVQGSFYCIFIFKGPVQNWC (SEQ ID NO:744). Polynucleotides encoding such polypeptide are also provided.

This gene is expressed primarily in fetal brain

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, identifying and expanding stem cells in the CNS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for detecting and expanding stem cell populations in the (or of the) central nervous system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 181

This gene is expressed primarily in early stage human brain and a stromal cell line.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities of the CNS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 414 as residues: Gln-42 to Gln-47, Gln-51 to Pro-60.

are useful for diagnosing or treating developmental abnormalities of the central nervous system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 182

Preferred polypeptides encoded by this gene comprise the following amino acid sequence:
MPIIDQVNPELHDFMQSAEVGTIFALSWLITWFGHVLSDFRHVVRLYDF FLACHPLMPIYFAAVIVLYREQEVLDCDCDMASVHHLLSQIPQDLPYETLISRXE TFLFSFPHPNLLGRPLPNSKLRGRQPLLSKTLSWHQPSRGLIWCCGSGXRGLL RPEDRTKDVLTKPRTNRFVKLAVMGLTVALGAAALAVVKSALEWAPKFQLQL FP (SEQ ID NO:745); or CPEFFIPATLPCPFVFAFTSEASSRAYLTQRGPGGLAQ NLMPLPVGFWMGSLPPPWCWRKWVSEACSCFC (SEQ ID NO:746) These polypeptides are structurally similar to various TGF-beta family members. Thus, this polypeptide is expected to have a variety of activities in the modulation of cell growth and proliferation.

This gene is expressed primarily in osteoclastoma, microvascular endothelium, and bone marrow derived cell lines.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematological diseases particularly involving aberrant proliferation of stem cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 415 as residues: Ser-33 to Ala-39.

The tissue distribution indicates that the protein products of this gene is useful for treating disorders of the progenitors of the immune system. Applications include in vivo expansion of progenitor cells, ex vivo expansion of progenitor cells, or the treatment of tumors of the circulatory system, such as lymphomas.

FEATURES OF PROTEIN ENCODED BY GENE NO: 183

This gene maps to chromosome 17 and therefore, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 17. In specific embodiments, polypeptides of the invention comprise the sequence: GFGSVSAAGRRSGGTWQPVQ (SEQ ID NO:747); PGGLAVGSRWWSRSLT (SEQ ID NO:748); LEPSRQRRPRRRGGTSRPETDQRAKCWRQL (SEQ ID NO:749); and/or VCLRCQNRMEN (SEQ ID NO:750). In further specific embodiments, polypeptides of the invention comprise the sequence: MAACTARRPGRGQPLVVPVADXGPVAKAALCAAXAGAFSPASTTTTRRHLSSRNRPEGKVLETVGVFEVPKQNGKYETGQLFLHSIFGYRGVVLFPWQARLXDRDVASAAPEKAENPAGHGSKEVKGKTHTYYQVLIDARDCPHISQRSQTEAVTFLANHDDSRALYAIPGLDYVSHEDILPYTSTDQVPIQHELFERFLLYDQTKAPPFVARETLRAWQEKNHPWLELSDVHRETTENIRVTVIPFYMGMREAQNSHVYWWRYCIRLENLDSDVVQLRERHWRIFSLSGTLETVRGRGVVGREPVLSKEQPAFQYSSHVSLQASSGHMWGTFRFERPDGSHFDVRIPPFSLESNKDEKTPPSGLHW (SEQ ID NO:751); MAACTARRPGRGQPLVVPVADXGPVAKAALCAA (SEQ ID NO:752); VLETVGVFEVPKQNGKYETGQLFLHSIFGYRGVVL (SEQ ID NO:757); GLDYVSHEDILPYTST (SEQ ID NO:758); DVHRETTENIRVTVIPFYM (SEQ ID NO:759); WWRYCIRLENLDSDVVQLRER (SEQ ID NO:760); and/or PAFQYSSHVSLQASSGHMWGTFRFER (SEQ ID NO:761). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in gall bladder, prostate, and fetal brain, and to a lesser extent in a few tumor and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, growth related disorders such as cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate, gall bladder, and fetal brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of growth-related disorders, such cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 184

In specific embodiments, polypeptides of the invention comprise the sequence:SLCCPEGAEGC (SEQ ID NO:762) and/or QLKKTHYDRPCP (SEQ ID NO:763). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in stromal cell, tonsil, and glioblastoma and to a lesser extent in some other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune and inflammatory disorders and glioblastoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the stromal cells, tonsil, and glioblastoma expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Additionally, it is believed that the product of this gene regulates pancreatic cell differentiation into beta cells. Accordingly, polynucleotides and polypeptides of the invention are useful in the treatment of insulin-dependent diabetes mellitus and associated conditions e.g. pancreatic hypofunction and the prevention, as well as the treatment of undifferentiated type pancreatic cancers. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 417 as residues: Pro-27 to Ala-32.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune and inflammatory disorders and glioblastoma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 185

This gene is expressed primarily in hepatocellular carcinoma and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 418 as residues: Gly-32 to Lys-39.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of liver diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 186

This gene is expressed primarily in hippocampus and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neutronal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hippocampus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal disorders.

[illegible] expressed primarily in bone cancer and hippocampus, and to a lesser extent in osteoclastoma and other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, bone-related disorders and neuronal diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bone, ostoeclast, and hippocampus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of bone related disorders and neuronal diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 188

This gene maps to chromosome 4 and therefore polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 4.

This gene is expressed primarily in neuronal tissues such as hippocampus, spinal cord, and hypothalamus and to a lesser extent in a few other tissues such as ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuronal tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 189

This gene maps to chromosome 10, therefore, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 10.

This gene is expressed primarily in neuronal tissues and immune tissues, and to a lesser extent in a few other tissues such as skin tumor, lung etc.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal and immune-related disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuronal and immune-related tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 422 as residues: Pro-19 to Asp-25.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal and immune-related disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 190

The translation product of this gene shares sequence homology with human N33, a gene located in a homozygously deleted region of human metastatic prostate cancer which is thought to be important in prevention of prostate cancer. In specific embodiments, polypeptides of the invention comprise the sequence: AQRKKEMVLSEKVSQLMEWTNKRPVIRMNGDKFRRLVKAPPRNYSVIVMFTA LQLHRQCVVCKQADEEFQILANSWRYSSAFTNRIFFAMVDFDEGSDVFQMLNM NSAPTFINFPAKGKPKRGDTYELQVRGFSAEQIARWIADRTDVNIRVIRPPNMA ARWRFWCVSVT (SEQ ID NO:765); MVVALLIVCDVPSAS (SEQ ID NO:766); AQRKKEMVLSEKVSQL (SEQ ID NO:767); MEWTNKRPVIRMNGDKF (SEQ

[illegible] (SEQ ID NO:[illegible]); MVDFDEGSDVFQMLNMNSAPTFINFPAK GKP (SEQ ID NO:770); KRGDTYELQVRGFSAEQIARWIADRTDVNIRVIRPPN

(SEQ ID NO:771); and/or YAGPLMLGLLLAVIGGLVYLRRVIWNFSLIKLDGLLQLCVLCLL (SEQ ID NO:772). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in infant adrenal gland prostate cell line and to a lesser extent in a few other tissues like liver, smooth muscle etc.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, prostate cancer and endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate and adrenal gland, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 423 as residues: Pro-34 to Gly-43, Arg-113 to Pro-120.

The tissue distribution and homology to N33 indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for prostate cancer and endocrine disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 191

This gene is expressed primarily in T cell and to a lesser extent in fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue

or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 424 as residues: Trp-3 to Phe-9.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 192

This gene maps to chromosome 6, therefore, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 6. Neural activity and neurotrophins induce synaptic remodeling in part by altering gene expression. This gene is believed to be a glycosylphoshatidylinositol-anchored protein encoded by a hippocampal gene and to possess neural activity. This molecule is believed to be expressed in postmitotic-differentiating neurons of the developing nervous system and neuronal structures associated with plasticity in the adult. Message of this gene is believed to be induced by neuronal activity and by the activity-regulated neurotrophins BDNF and NT-3. The product of this gene is believed to stimulate neurite outgrowth and arborization in primary embryonic hippocampal and cortical cultures and to act as a downstream effector of activity-induced neurite outgrowth. In specific embodiments, polypeptides of the invention comprise the sequence: DAVFKGFSDCLLKLGDS (SEQ ID NO:773); CQEGAKDMWDKLRKESKNLN (SEQ ID NO:774); VLLVSLSAALATWLSF (SEQ ID NO:775); MGLKLNGRYISLILAVQIAYLVQAVRAAGKCDAVFKGFSDCLLKLGDS (SEQ ID NO:776); PAAWDDKTNIKTVCTYWEDFHSCTVTALTDCQEGAKDMWDKLRKESKNLNIQGSLFELCGSGNGAAGSLLPAFPVLLVSLSAALATWLSF (SEQ ID NO:777); and/or MGLKLNGRYISLILAVQIAYLVQAVRAAGKCDAVFKGFSDCLLKLGDSXXXXXPAAWDDKTNIKTVCTYWEDFHSCTVTALTDCQEGAKDMWDKLRKESKNLNIQGSLFELCGSGNGAAGSLLPAFPVLLVSLSAALATWLSF (SEQ ID NO:778). Polynucleotides encoding this polypeptide are also encompassed by the invention.

This gene is expressed primarily in human placenta, endometrial tumor and tissues of the central nervous system (CNS).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, relating to reproductive disorders, cancers and neurological diseases. Similarly, polypeptides and antibodies directed to the [illegible]

[illegible] disorders of the above tissues or cells, particularly of the reproductive and neurological disorders, expression of this gene at significantly higher

or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 425 as residues: Asp-47 to Asp-63, His-75 to Tyr-80, Pro-83 to Tyr-89.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of reproductive disorders such as endometrial tumors. Expression of this gene in tissues of the CNS and its strong homology to Neuritin suggest that the protein product from this gene may also be used in the treatment and diagnosis of neurological disorders and in the regeneration of neural tissues, e.g., following injury.

FEATURES OF PROTEIN ENCODED BY GENE NO: 193

The translation product of this gene shares sequence homology with tenascin which is thought to be important in development. The translation product of this gene is believed to be a ligand of the fibroblast growth factor family. FGF ligand activity is known in the art and can be assayed by methods known in the art and disclosed elsewhere herein.

This gene is expressed primarily in endometrial tumors, and other types of tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cancer tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 426 as residues: Gly-29 to Glu-34, Arg-71 to Arg-76, Thr-176 to Cys-182, Gly-184 to Glu-199.

The tissue distribution and homology to tenascin indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 194

In specific embodiments, polypeptides of the invention comprise the sequence: MNSAAGFSHLDRRERVLKLGESFEKQPRCASTLC (SEQ ID NO:779). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal human lung and neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, lung development and respiratory disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the respiratory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal lung and neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of lung and immunity related diseases, for example, lung cancer, viral, fungal or bacterial infections (e.g. lesions caused by tuberculosis), inflammation (e.g. pneumonia), metabolic lesions etc.

FEATURES OF PROTEIN ENCODED BY GENE NO: 195

This gene is expressed primarily in breast lymph node.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunal disorders. Similarly, polypeptides and antibo[illegible] number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at

significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immunal disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 196

This gene maps to chromosome 5 and accordingly, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 5. The translation product of this gene shares sequence homology with human M-phase phosphoprotein 4 which is thought to be important in phosphorylation and signal transduction processes. In specific embodiments, polypeptides of the invention comprise the sequence: TIYPTEEELQAVQKIVSITERALKLVSD (SEQ ID NO:780); RALKGVLRV GVLAKGLLLRGDRNVNLVLLC (SEQ ID NO:781); ALAALRHAKWFQARAN GLQSCVIIIRILRDLCQRVPTWS (SEQ ID NO:782); GDALRRVFECISSGIIL (SEQ ID NO:783); LAFRQIHKVLGMDPLP (SEQ ID NO:784); and/or TIYPTEEELQAVQ KIVSITERALKLVSDSLSEHEKNKNKEGDDKKEGGKDRALKGVLRVGVLAKG LLLRGDRNVNLVLLCSEKPSKTLLSRIAENLPKQLAVISPEKYDIKCAVSEAAIIL NSCVEPKMQVTITLTSPIIREENMREGDVTSGMVKDPPDVLDRQKCLDALAALR HAKWFQARANGLQSCVIIIRILRDLCQRVPTWSDFPSWAMELLVEKAISSASSP QSPGDALRRVFECISSGIILKGSPGLLDPCEKDPFDTLATMTDQQREDITSSAQFA LRLLAFRQIHKVLGMDPLPQMSQRFNIHNNRKRRRDSDGVDGFEAEGKKDKK DYDNF (SEQ ID NO:785). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in Human Hippocampus and to a lesser extent in Prostate, Human Frontal Cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders related to reproductive system and nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system and nervous system, expression of this gene at significantly higher or lower

levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to human M-phase phosphoprotein 4 indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of reproductive and nervous system disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 197

In specific embodiments, polypeptides of the invention comprise the sequence: MGSQHSAAARPSSCRRKQEDDRDG (SEQ ID NO:786); LLAEREQEEAIAQFPYVEFTGRDSITCLTC (SEQ ID NO:787); and/or QGTGYIPTEQVNELVALIPHSDQRLRPQRTKQYV (SEQ ID NO:788). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in Human Primary Breast Cancer and to a lesser extent in Human Adult Spleen, Hodgkin's Lymphoma I, Salivary Gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer and immunal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cancer and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 430 as residues: Ser-126 to Gly-138.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and immunal disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 198

This gene is expressed primarily in monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, blood cell disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of blood cell disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 199

This gene is expressed primarily in Human Ovary and Synovia and to a lesser extent in Human 8 Week Whole Embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive and developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and developmental system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of reproductive and developmental disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 200

This gene maps to chromosome 8 and therefore polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 8. The translation product of this gene shares limited sequence homology with collagen proline rich domain.

This gene is expressed primarily in CNS.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 433 as residues: Pro-35 to Asp-41.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurological diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 201

Translation product of this gene shares homology with a mammalian histone H1a protein. One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: ARLNVGRESLKREMLKSQGVKVSESPMGAR HSSWPEGAAFCKKVQGAQMQFPPRR (SEQ ID NO:789); ARLNVGRESLKR EML (SEQ ID NO:790); LKSQGVKVSESPMGARHSSW (SEQ ID NO:791); AFCKKVQGAQMQFPPRR (SEQ ID NO:792). An additional embodiment is the polynucleotide fragments encoding these polypeptide (See Accession No. pir|S24178) fragments.

This gene is expressed primarily in neutrophils

[illegible] differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders. Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in vital immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 202

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders. Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 203

This gene is expressed primarily in Neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, infectious disorders, immune disorders, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 436 as residues: Thr-31 to Lys-36.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of infectious disorders, immune disorders, and cancers. Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 204

This gene maps to chromosome 16 and therefore polynucleotides of the invention can be used in linkage analysis as markers for chromosome 16. The translation product of this gene shares sequence homology with lactate dehydrogenase which is thought to be important in lactate metabolism.

This gene is expressed primarily in human tonsils and to a lesser extent in Spleen, and Neutrophils.

Therefore, polynucleotides and polypeptides of the invention [illegible]

[illegible] diseases and conditions, which include, but are not limited to, immune disorders, infectious disorders, and cancers. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune disorders, infectious disorders, and cancers, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 437 as residues: Gly-7 to Ser-12.

The tissue distribution and homology to lactate dehydrogenase gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders, infectious disorders, and cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 205

The translation product of this gene shares sequence homology with Gcap1 protein which is developmentally regulated in brain.

This gene is expressed primarily in placenta and endometrial tumor and to a lesser extent in several other tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, vasculogenesis/angiogenesis and tumorigenesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system and tumors, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to Gcap1 protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorder or dysfunction of vascular system of tumorigenesis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 206

In specific embodiments, polypeptides of the invention comprise the sequence MPYAQWLAENDRFEEAQKAFHKAGRQREA (SEQ ID NO:799); VQVLEQLTNNAVAESRFNDAAYYYWMLSMQCLDIAQD (SEQ ID NO:794); PAQKDTMLGKFYHFQRLAELYHGYHAIHRHTEDP (SEQ ID NO: 795); FSVHRPETLFNISRFLLHSLPKDTPSGISKVKILFT (SEQ ID NO:800); LAKQSKALGAYRLARHAYDKLRGLYIP (SEQ ID NO:796); ARFQKSIELG TLTIRAKPFHDSEELVPLCYRCSTNN (SEQ ID NO: 797); and/or PLLNNLGNVC INCRQPFIFSASSYDVLHLVEFYLEEGITDEEAISLIDLEVLRPKRDDRQLEICKQQ LPDSCG (SEQ ID NO:798). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male reproductive and endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of male reproductive and endocrine disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 207

This gene is expressed in fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of [illegible]

[illegible] for differential identification of the tissue(s) or cell type(s). For a number of disorders

of the above tissues or cells, particularly of the respiratory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 440 as residues: Tyr-49 to Cys-54.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of disorders associated with developing lungs particularly in premature infants where the lungs are the last tissues to develop. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of lung tumors since the gene may be involved in the regulation of cell division, particularly since it is expressed in fetal tissue. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
1	HLHDS67	97979 03/27/97	Uni-ZAP XR	11	2526	427	2526	458	458	234	1	30	31
2	HLHDZ58	97979 03/27/97	Uni-ZAP XR	12	1131	1	1131	129	129	235	1	14	15
3	HLMMJ13	97979 03/27/97	Lambda ZAP II	13	941	39	941	62	62	236	1	44	45
3	HLMMJ13	97979 03/27/97	Lambda ZAP II	218	941	39	941	245	245	441	1	35	36
4	HLTEI25	97979 03/27/97	Uni-ZAP XR	14	843	1	843	155	155	237	1	19	20
5	HMSJX24	97979 03/27/97	Uni-ZAP XR	15	1018	1	1018	90	90	238	1	18	19
6	HNFED65	97979 03/27/97	Uni-ZAP XR	16	661	1	661	76	76	239	1	28	29
7	HNHDX07	97979 03/27/97	Uni-ZAP XR	17	553	1	553	106	106	240	1	23	24
8	HNHGC82	97979 03/27/97	Uni-ZAP XR	18	869	1	869	101	101	241	1	21	22
9	HNHGO09	97979 03/27/97	Uni-ZAP XR	19	959	1	959	176	176	242	1	21	22
10	HOUBE18	97979 03/27/97	Uni-ZAP XR	20	1446	1	1446	101	101	243	1	27	28
11	HOUDL69	97979 03/27/97	Uni-ZAP XR	21	1471	579	1460	692	692	244	1	31	32

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
12	HPMFI71	97979 03/27/97	Uni-ZAP XR	22	1402	242	1402	401	401	245	1	32	33	60
13	HPMGQ55	97979 03/27/97	Uni-ZAP XR	23	1047	1	1047	164	164	246	1	26	27	35
14	HPQAC69	97979 03/27/97	Lambda ZAP II	24	990	1	988	82	82	247	1	20	21	37
15	HPTBB03	97979 03/27/97	Uni-ZAP XR	25	1208	350	1173	398	398	248	1	29	30	210
16	HPTWA66	97979 03/27/97	pBluescript	26	1922	1381	1922	24	24	249	1	33	34	547
16	HPTWA66	97979 03/27/97	pBluescript	219	575	1	575	148	148	442	1	22	23	65
17	HPTWC08	97979 03/27/97	pBluescript	27	1951	1422	1874	219	219	250	1	19	20	299
18	HRGCZ46	97979 03/27/97	Uni-ZAP XR	28	3989	2635	3989		2748	251	1	16	17	39
19	HSAVU34	97979 03/27/97	Uni-ZAP XR	29	3735	2966	3735	272	272	252	1	30	31	594
19	HSAVU34	97979 03/27/97	Uni-ZAP XR	220	3018	1929	3018	26	26	443	1	1	2	156
20	HSDFW61	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	30	1667	59	1625	138	138	253	1	32	33	130
21	HSDGP60	97974 04/04/97	Uni-ZAP XR	31	1408	1	1408	285	285	254	1			20

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		209080 05/29/97											
22	HSOAJ55	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	32	2031	1273	2031	1285	1285	255	1	29	30
23	HSQEO84	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	33	971	13	971	91	91	256	1	19	20
23	HSQEO84	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	221	968	8	968	86	86	444	1	20	21
24	HSXAM05	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	34	1792	369	1792	470	470	257	1	26	27
25	HSXAS67	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	35	896	1	896	96	96	258	1	32	33
26	HTDAF28	97974 04/04/97 209080 05/29/97	pSport1	36	912	1	912	38	38	259	1	22	23
27	HTEGQ64	97974	Uni-ZAP XR	37	1382	67	1382	271	271	260	1		

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		04/04/97 209080 05/29/97												
28	HTGEU09	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	38	872	1	872	74	74	261	1	18	19	28
29	HTOAM21	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	39	812	1	812	41	41	262	1	30	31	43
30	HTPBW79	209511 12/03/97	Uni-ZAP XR	40	1515	118	1507	302	302	263	1	24	25	362
30	HTSEV09	97974 04/04/97 209080 05/29/97	pBluescript	222	1404	1	1265	92	92	445	1	19	20	415
31	HJPCD40	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	41	704	22	704		117	264	1	18	19	127
32	HTWBY48	97974 04/04/97 209080 05/29/97	pSport1	42	1094	1	1094	32	32	265	1	34	35	53
33	HTWCI46	97974 04/04/97	pSport1	43	1821	892	1647	56	56	266	1	26	27	28

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		209080 05/29/97											
34	HTXGI75	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	44	1024	30	1024		167	267	1	20	21
35	HWTBF59	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	45	983	779	983	85	85	268	1	30	31
35	HWTBF59	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	223	707	488	707	514	514	446	1	41	42
36	HADAE74	97974 04/04/97 209080 05/29/97	pSport1	46	2421	664	1587	710	710	269	1		
37	HAGFB60	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	47	840	1	840	97	97	270	1	30	31
38	HATEF60	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	48	2432	1193	2246	1491	1491	271	1	17	18
39	HBMSN25	97974	Uni-ZAP XR	49	1742	1165	1742	1207	1207	272	1	23	24

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		04/04/97 209080 05/29/97												
40	HCDAR68	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	50	1487	181	1455	325	325	273	1	35	36	56
41	HCE3J79	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	51	1328	251	1328	525	525	274	1			21
42	HMDAN54	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	52	1856	725	1853	928	928	275	1	33	34	50
43	HCECA49	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	53	1558	310	1408	393	393	276	1			1
44	HCEEC15	97974 04/04/97 209080 05/29/97	Uni-ZAP XR	54	948	1	948	9	9	277	1	23	24	65
45	HCESF40	97974 04/04/97 209080 05/29/97	pBluescript	55	990	99	990	193	193	278	1	32	33	256

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
45	HCESF40	97974 04/04/97 209080 05/29/97	pBluescript	224	1384	99	1384	193	193	447	1	32	33
46	HCFMV39	97974 04/04/97 209080 05/29/97	pSport1	56	1603	1	1296	96	96	279	1	29	30
47	HCMSX86	97975 04/04/97 209081 05/29/97	Uni ZAP XR	57	1052	5	786	12	12	280	1	28	29
48	HCNAP62	97975 04/04/97 209081 05/29/97	Lambda ZAP II	58	814	1	558	93	93	281	1	22	23
49	HCRAF32	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	59	1215	257	1215		356	282	1	19	20
50	HCUDC07	97975 04/04/97 209081 05/29/97	ZAP Express	60	478	1	478	147	147	283	1	36	37
51	HCWBB42	97975 04/04/97 209081	ZAP Express	61	618	1	618	212	212	284	1	35	36

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		05/29/97												
52	HDTAB05	97975 04/04/97 209081 05/29/97	pCMVSport 2.0	62	751	1	751	257	257	285	1	21	22	32
53	HE2AV74	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	63	780	283	780		433	286	1			16
54	HE2AY71	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	64	588	21	588	169	169	287	1			16
55	HE2GS36	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	65	774	272	774	445	445	288	1			37
56	HE2OF09	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	66	1866	1313	1866	1596	1596	289	1			11
57	HE6EU50	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	67	1152	117	686	237	237	290	1	20	21	34
58	HE9HU17	97975 04/04/97	Uni-ZAP XR	68	2483	1577	2448	1620	1620	291	1			14

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		209081 05/29/97											
59	HE9ND48	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	69	536	1	536	83	83	292	1	36	37
60	HEBBW11	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	70	865	647	865		388	293	1	30	31
61	HELDY74	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	71	932	1	932	201	201	294	1	17	18
62	HEMAE80	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	72	996	1	945	12	12	295	1	24	25
63	HFEBA88	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	73	785	464	785	356	356	296	1	29	30
64	HFGAB89	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	74	1069	196	1047	295	295	297	1	32	33
65	HFVHY45	97975	pBluescript	75	831	1	831		89	298	1	30	31

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		04/04/97 209081 05/29/97												
66	HGBAJ93	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	76	590	1	590	233	233	299	1	38	39	94
67	HGBBQ69	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	77	1274	1	1273	105	105	300	1	24	25	43
68	HHFCF08	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	78	1133	4	1042	175	175	301	1	23	24	30
69	HHFHJ59	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	79	661	1	661	192	192	302	1	29	30	112
70	HHFHR32	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	80	1378	1	1378		358	303	1			13
71	HHGCN69	97975 04/04/97 209081 05/29/97	Lambda ZAP II	81	1440	298	1440	532	532	304	1	23	24	34

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
72	HHGDO13	97975 04/04/97 209081 05/29/97	Lambda ZAP II	82	1381	766	1371	993	993	305	1	23	24
73	HHPFD63	97975 04/04/97 209081 05/29/97	Uni-ZAP XR	83	1706	182	1644	257	257	306	1	24	25
74	HHSEG23	97976 04/04/97	Uni-ZAP XR	84	573	1	573	160	160	307	1	18	19
75	HJPAV06	97976 04/04/97	Uni-ZAP XR	85	684	199	684	323	323	308	1	27	28
76	HKIXL73	97976 04/04/97	pBluescript	86	1036	591	1036	690	690	309	1	32	33
77	HKMNC43	97976 04/04/97	pBluescript	87	908	1	908	139	139	310	1	18	19
78	HMEJE31	97976 04/04/97	Lambda ZAP II	88	655	1	655	165	165	311	1	33	34
79	HMSKS35	97976 04/04/97	Uni-ZAP XR	89	1102	1	1102	228	228	312	1	26	27
80	HNFAE54	97976 04/04/97	Uni-ZAP XR	90	1533	665	1518	347	347	313	1	26	27
81	HNFJH45	97976 04/04/97	Uni-ZAP XR	91	575	1	575	275	275	314	1	30	31
82	HNGBT31	97976 04/04/97	Uni-ZAP XR	92	639	1	639	224	224	315	1	28	29

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
83	HNGIN60	97976 04/04/97	Uni-ZAP XR	93	744	1	744	225	225	316	1	43	44	70
84	HNGJG84	97976 04/04/97	Uni-ZAP XR	94	526	1	526	268	268	317	1	29	30	38
85	HNHDW42	97976 04/04/97	Uni-ZAP XR	95	426	1	426	168	168	318	1	28	29	71
86	HNHFL57	97976 04/04/97	Uni-ZAP XR	96	844	1	844	98	98	319	1	25	26	61
87	HOGAR52	97977 04/04/97 209082 05/29/97	pCMVSport 2.0	97	1985	453	1985	533	533	320	1	17	18	285
88	HOSBZ55	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	98	1416	69	1416	246	246	321	1	32	33	54
89	HOSDI92	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	99	1935	141	772		274	322	1	20	21	58
90	HPBCU51	97977 04/04/97 209082 05/29/97	pBluescript SK-	100	599	1	599	86	86	323	1	27	28	119
91	HPCAL49	97977 04/04/97 209082	Uni-ZAP XR	101	784	1	784		280	324	1	18	19	43

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		05/29/97											
92	HPFCR13	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	102	1035	602	1035	859	859	325	1	32	33
93	HPHAC83	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	103	2218	840	2182	1035	1035	326	1	17	18
94	HPMBQ32	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	104	1351	1	1351	18	18	327	1	23	24
95	HPWAN23	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	105	2066	51	2052	270	270	328	1	29	30
95	HPWAN23	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	226	2057	1	1954	220	220	449	1	29	30
96	HRDFB85	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	106	1705	23	1697	233	233	329	1	21	22
97	HRGBR28	97977 04/04/97	Uni-ZAP XR	107	1167	611	1167	53	53	330	1	1	2

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		209082 05/29/97												
98	HSKGN81	97977 04/04/97 209082 05/29/97	pBluescript	108	1907	151	1432	353	353	331	1	23	24	260
98	HSKGN81	97977 04/04/97 209082 05/29/97	pBluescript	227	2084	335	2084	537	537	450	1	19	20	23
99	HSPAH56	97977 04/04/97 209082 05/29/97	pSport1	109	611	1	576	229	229	332	1	25	26	47
100	HE8EU04	209746 04/07/98	Uni-ZAP XR	110	2632	294	2632	337	337	333	1	25	26	333
100	HSXBT86	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	228	2143	53	1096	235	235	451	1			9
101	HSXCS62	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	111	2249	1	1953	90	90	334	1	18	19	199
102	HTEFU09	97977 04/04/97 209082	Uni-ZAP XR	112	2198	228	2158	400	400	335	1			23

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		05/29/97											
103	HTEKM35	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	113	1043	40	1043	320	320	336	1	20	21
104	HTGEP89	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	114	703	1	703	285	285	337	1	29	30
105	HTGEW91	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	115	3684	526	1338	584	584	338	1	24	25
106	HTOEY16	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	116	1965	127	1915	202	202	339	1	27	28
107	HTPCN79	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	117	503	1	503		1	340	1	7	8
108	HTSGM54	97977 04/04/97 209082 05/29/97	pBluescript	118	1133	316	1069		423	341	1	12	13
109	HTSHE40	97977 04/04/97	pBluescript	119	1101	118	956	218	218	342	1	31	32

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		209082 05/29/97												
110	HTWAF58	97977 04/04/97 209082 05/29/97	Lambda ZAP II	120	282	1	282	137	137	343	1	25	26	48
111	HTWBY29	97977 04/04/97 209082 05/29/97	pSport1	121	2635	1593	2489	1654	1654	344	1	25	26	55
112	HUKFC71	209007 04/28/97 209083 05/29/97	Lambda ZAP II	122	994	1	932		272	345	1	15	16	221
113	HCE3Q10	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	123	1542	1	1542	143	143	346	1	25	26	63
114	HCEVR60	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	124	1390	82	1390	127	127	347	1	32	33	153
115	HDTAW95	209007 04/28/97 209083 05/29/97	pCMVSport 2.0	125	1288	412	1288	571	571	348	1			16
116	HE6EL90	209007	Uni-ZAP XR	126	1517	1	1452	243	243	349	1			9

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		04/28/97 209083 05/29/97											
117	HELBU29	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	127	1073	198	1073		776	350	1		
118	HERAH36	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	128	300	155	300	202	202	351	1		
119	HFXBW82	209007 04/28/97 209083 05/29/97	Lambda ZAP II	129	1275	1	1275	56	56	352	1	23	24
120	HHPTD20	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	130	472	51	472		243	353	1		
121	HIBED17	209007 04/28/97 209083 05/29/97	Other	131	1950	284	1927	395	395	354	1	72	73
122	HLTER03	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	132	990	1	990	78	78	355	1	22	23

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
123	HOABL56	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	133	1720	565	1720	660	660	356	1	18	19	21
124	HPMCJ92	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	134	705	28	705	106	106	357	1	28	29	98
125	HPWAZ95	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	135	323	1	323	88	88	358	1	27	28	78
126	HRGBR18	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	136	582	1	582		16	359	1	17	18	30
127	HSUBW09	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	137	1021	1	1021	153	153	360	1	32	33	56
128	HUKCO64	209007 04/28/97 209083 05/29/97	Lambda ZAP II	138	1777	439	1777		521	361	1			2
129	H6EAA53	209007 04/28/97 209083	Uni-ZAP XR	139	643	303	643		313	362	1	7	8	31

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		05/29/97											
130	HAGAI11	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	140	1220	1	1220		127	363	1	16	17
131	HAGAO39	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	141	721	1	721		415	364	1		
132	HALSK07	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	142	1468	125	1468	210	210	365	1	29	30
133	HALSQ59	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	143	300	4	300	101	101	366	1	22	23
134	HAIBP89	unknown 05/18/98	Uni-ZAP XR	144	2243	173	2243	311	311	367	1	27	28
134	HBGCB91	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	229	1025	409	1025	624	624	452	1	20	21
135	HBMTD81	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	145	1082	163	1082	357	357	368	1		

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
136	HBXGK12	209008 04/28/97 209084 05/29/97	ZAP Express	146	4313	1153	4313	1313	1313	369	1	18	19	42
137	HFKFJ07	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	147	1183	1	1183	149	149	370	1	41	42	254
138	HCQAI40	209008 04/28/97 209084 05/29/97	Lambda ZAP II	148	734	1	734	285	285	371	1			19
139	HCWHZ24	209008 04/28/97 209084 05/29/97	ZAP Express	149	1405	1	1405	108	108	372	1	34	35	63
140	HE2GT20	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	150	2890	1178	2890	1178	1178	373	1	31	32	39
141	HE8EY43	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	151	2399	1181	2399	1265	1265	374	1	30	31	34
142	HFCEB37	209008 04/28/97 209084	Uni-ZAP XR	152	802	352	802		487	375	1			10

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		05/29/97											
143	HFTCT67	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	153	461	24	461	145	145	376	1	37	38
144	HGLAM46	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	154	2388	818	2388	648	648	377	1		
145	HHGBR15	209008 04/28/97 209084 05/29/97	Lambda ZAP II	155	642	322	642	400	400	378	1		
146	HJAAU36	209008 04/28/97 209084 05/29/97	pBluescript SK-	156	1251	583	1251		933	379	1	16	17
147	HUSIT49	209008 04/28/97 209084 05/29/97	pSport1	157	2127	247	2127	383	383	380	1	47	48
148	HKLAB16	209008 04/28/97 209084 05/29/97	Lambda ZAP II	158	1625	817	1625	1012	1012	381	1	18	19
149	HLMMU76	209008 04/28/97	Lambda ZAP II	159	1687	1307	1687	1296	1296	382	1	28	29

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		209084 05/29/97												
150	HMSKQ35	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	160	1842	172	1463	319	319	383	1	30	31	33
151	HNHED86	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	161	770	1	770	30	30	384	1	31	32	46
152	HNHEJ88	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	162	519	1	519	242	242	385	1	17	18	24
153	HNHFQ63	209008 04/28/97 209084 05/29/97	Uni-ZAP XR	163	753	1	753	164	164	386	1	17	18	67
154	HOECU83	209009 04/28/97	Uni-ZAP XR	164	1400	189	1400		508	387	1	22	23	33
155	HPTRC15	209009 04/28/97	pBluescript	165	2153	594	2153		611	388	1			13
156	HSKCP69	209009 04/28/97	Uni-ZAP XR	166	1251	219	1120			389	1			
156	HSKCP69	209009 04/28/97	Uni-ZAP XR	230	1250	223	1250	393	393	453	1	32	33	171
157	H6EAE26	209009	Uni-ZAP XR	167	882	48	882	155	155	390	1	33	34	153

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
		04/28/97											
158	HAGBX03	209009 04/28/97	Uni-ZAP XR	168	1208	1	1208	182	182	391	1		
159	HAGDQ47	209009 04/28/97	Uni-ZAP XR	169	1307	1	1307	44	44	392	1	22	23
160	HAICP19	209009 04/28/97	Uni-ZAP XR	170	1624	89	1483	128	128	393	1	18	19
161	HAUAE83	209009 04/28/97	Uni-ZAP XR	171	2003	889	2003	1080	1080	394	1		
162	HBHAD12	209009 04/28/97	Uni-ZAP XR	172	786	1	786		176	395	1	17	18
163	HBMTY28	209009 04/28/97	Uni-ZAP XR	173	1758	962	1758	1184	1184	396	1	27	28
164	HBMVP04	209009 04/28/97	Uni-ZAP XR	174	888	330	862		546	397	1		
165	HCDDB78	209009 04/28/97	Uni-ZAP XR	175	2379	750	2379	901	901	398	1	18	19
166	HCEQA68	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	176	1348	1	1348	12	12	399	1	28	29
167	HCEZS40	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	177	1502	178	1502	315	315	400	1		
168	HCFNF11	209010	pSport1	178	1637	26	1607	152	152	401	1	44	45

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		04/28/97 209085 05/29/97												
169	HCRBL20	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	179	2911	1103	2858	192	192	402	1	32	33	424
169	HCRBL20	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	231	1811	20	1811	93	93	454	1	36	37	95
170	HCUBL62	209010 04/28/97 209085 05/29/97	ZAP Express	180	519	1	519	57	57	403	1	28	29	32
171	HDSAP81	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	181	968	320	968	476	476	404	1	27	28	79
172	HE2CT29	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	182	1128	1	1128	111	111	405	1	26	27	94
173	HE8MG65	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	183	2276	48	2276	88	88	406	1	37	38	257

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
173	HE8MG65	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	232	2271	56	2232	79	79	455	1	43	44
174	HE9FB42	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	184	2500	76	1693	518	518	407	1	1	2
175	HEMAM41	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	185	1337	60	1328	175	175	408	1	39	40
175	HEMAM41	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	233	1338	33	1327	175	175	456	1	32	33
176	HEMCV19	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	186	941	33	931	79	79	409	1	23	24
177	HEMDX17	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	187	654	1	654	137	137	410	1		
178	HETAR54	209010 04/28/97 209085	Uni-ZAP XR	188	1848	454	1848	948	948	411	1	14	15

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
		05/29/97												
179	HETBX14	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	189	1146	157	1146		74	412	1	14	15	53
180	HFGAB48	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	190	906	156	906	245	245	413	1	30	31	32
181	HFKFI40	209010 04/28/97 209085 05/29/97	Uni-ZAP XR	191	1941	120	1002	213	213	414	1	18	19	218
182	HFXHN68	209010 04/28/97 209085 05/29/97	Lambda ZAP II	192	2118	777	2118	966	966	415	1	23	24	50
183	HGBFO79	209011 04/28/97	Uni-ZAP XR	193	1538	259	1538	273	273	416	1	23	24	49
184	HGLAM56	209011 04/28/97	Uni-ZAP XR	194	1098	68	1098		185	417	1	28	29	69
185	HHLBA89	209011 04/28/97	pBluescript SK-	195	1001	1	1001	324	324	418	1	25	26	39
186	HHPDW05	209011 04/28/97	Uni-ZAP XR	196	1443	1	1443	246	246	419	1	21	22	21
187	HHPSD37	209011 04/28/97	pBluescript	197	1282	66	1282	171	171	420	1	19	20	37

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion
188	HHPSF70	209011 04/28/97	pBluescript	198	951	26	951		162	421	1	16	17
189	HHSAK25	209011 04/28/97	Uni-ZAP XR	199	1740	1390	1740	1534	1534	422	1	19	20
190	HIASB53	209011 04/28/97	pBluescript	200	1707	401	1195	652	652	423	1	26	27
191	HJABZ65	209011 04/28/97	pBluescript SK-	201	779	1	779	23	23	424	1	26	27
192	HJPBB39	209011 04/28/97	Uni-ZAP XR	202	1617	188	1605	182	182	425	1	28	29
193	HLHSK94	209011 04/28/97	pBluescript	203	1974	1	1794	112	112	426	1	26	27
194	HLHTC70	209011 04/28/97	pBluescript	204	1057	229	1057	365	365	427	1	23	24
195	HLMIW92	209011 04/28/97	Lambda ZAP II	205	721	1	721	244	244	428	1	25	26
196	HLTCY93	209011 04/28/97	Uni-ZAP XR	206	2465	988	2465	1225	1225	429	1		
197	HLTDB65	209011 04/28/97	Uni-ZAP XR	207	1480	1	1480		371	430	1	15	16
198	HMSHM43	209011 04/28/97	Uni-ZAP XR	208	872	1	872	35	35	431	1	18	19
199	HMSHQ24	209011 04/28/97	Uni-ZAP XR	209	1779	16	1779	148	148	432	1	24	25
200	HNFAH08	209011 04/28/97	Uni-ZAP XR	210	2110	592	2110	611	611	433	1	18	19

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
201	HNGAO10	209011 04/28/97	Uni-ZAP XR	211	938	1	938	107	107	434	1	27	28	30
202	HNGBE45	209011 04/28/97	Uni-ZAP XR	212	1551	1	1551	114	114	435	1	21	22	100
203	HNHAZ16	209011 04/28/97	Uni-ZAP XR	213	997	1	997	202	202	436	1	24	25	36
204	HNHCM59	209011 04/28/97	Uni-ZAP XR	214	1496	1	1132		165	437	1	28	29	41
205	HOSFM22	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	215	1308	501	1308		809	438	1			1
206	HPHAC88	97977 04/04/97 209082 05/29/97	Uni-ZAP XR	216	1705	384	1705	549	549	439	1	23	24	24
207	HCDEO95	209007 04/28/97 209083 05/29/97	Uni-ZAP XR	217	999	608	999	273	273	440	1	22	23	54

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly , the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby [illegible]

[illegible] generate antibodies which bind specifically to the [illegible] protein encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus [illegible]

[illegible] signal sequence from a secreted protein [illegible]

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown inTable 1, the ORF (open reading frame), or any fragement specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the presence invention can be determined conventionally using known computer programs. A preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identiy are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization

Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the lenght of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is becuase the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignement of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide [illegible] alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query

amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is becuase the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. [illegible]

[illegible] (1993), reported variant KGF proteins having heparin binding activity even after

deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the

carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Particularly, N-terminal deletions of the polypeptide of the present invention can be described by the general formula m-p, where p is the total number of amino acids in the polypeptide and m is an integer from 2 to (p-1), and where both of these integers (m & p) correspond to the position of the amino acid residue identified in SEQ ID NO:Y.

Moreover, C-terminal deletions of the polypeptide of the present invention can also be described by the general formula 1-n, where n is an integer from 2 to (p-1), and again where these integers (n & p) correspond to the position of the amino acid residue identified in SEQ ID NO:Y.

The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of SEQ ID NO:Y, where m and n are integers as described above.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

...genic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an

epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).)

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of specifically binding to protein. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the

polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, [illegible]

[illegible] purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D.

Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance

genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the [illegible]

[illegible] well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein

after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are

more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation [illegible]

[illegible] Both techniques are effective in model

systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of

unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

112In, 99mTc), a radio opaque substance, or a material detectable by nuclear magnetic

resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat [illegible] [illegible] hemophilias), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can

decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic

shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

[illegible] infectious agent. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases

may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox , hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Menigococcal), Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS

related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure [illegible]

[illegible] organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal

or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors),or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypepti[illegible]

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity , and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, caricadic rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method

comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

two nucleotide sequences, wherein at least one sequence in said panel is at least 95%

identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein [illegible]

[illegible] said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide

comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 [illegible]

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

Vector Used to Construct Library	Corresponding Deposited Plasmid
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSport 2.0	pCMVSport 2.0
pCMVSport 3.0	pCMVSport 3.0
pCR®2.1	pCR®2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1

Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide [illegible]

[illegible] Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).)

The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 µl of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 µM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P^{32} using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. [illegible]

[illegible] procedures

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 ($O.D.^{600}$) of between 0.4 and 0.6. IPTG

(Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA

insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfuidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 μm membrane filter with appropriate surface area

(e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 μg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five μg of a plasmid containing the polynucleotide is co-transfected with 1.0 μg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One μg of BaculoGold™ virus DNA and 5 μg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm

tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 µCi of ^{35}S-methionine and 5 µCi ^{35}S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

A typical mammalian expression vector contains a promoter element, which mediates

the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the

polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μg of the expression plasmid pC6 is cotransfected with 0.5 μg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μM, 2 μM, 5 μM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by [illegible] HPLC [illegible]

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:
GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCCAAAACC
CAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC

AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCA
GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the

described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a

working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2 x 10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl2 (anhyd); 0.00130 mg/L $CuSO_4$-$5H_2O$; 0.050 mg/L of $Fe(NO_3)_3$-$9H_2O$; 0.417 mg/L of $FeSO_4$-$7H_2O$; 311.80 mg/L of Kcl; 28.64 mg/L of $MgCl_2$; 48.84 mg/L of $MgSO_4$; 6995.50 mg/L of NaCl; 2400.0 mg/L of $NaHCO_3$; 62.50 mg/L of NaH_2PO_4-H_20; 71.02 mg/L of Na_2HPO4; .4320 mg/L of $ZnSO_4$-$7H_2O$; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of

Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H_20; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H_20; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H_20; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalainine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tryrosine-2Na-$2H_20$; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B_{12}; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proxial region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the [illegible]

[illegible] identified.

Ligand	tyk2	JAKs Jak1	Jak2	Jak3	STATS	GAS(elements) or ISRE
IFN family						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
gp130 family						
IL-6 (Pleiotrohic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
Il-11(Pleiotrohic)	?	+	?	?	1,3	
OnM(Pleiotrohic)	?	+	+	?	1,3	
LIF(Pleiotrohic)	?	+	+	?	1,3	
CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrohic)	?	+	?	?	1,3	
IL-12(Pleiotrohic)	+	-	+	+	1,3	
g-C family						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
gp140 family						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
Growth hormone family						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
Receptor Tyrosine Kinases						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is: 5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCG AAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':<u>CTCGAG</u>ATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATG
ATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGC
CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC
CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT
TGCAAA<u>AAGCTT</u>:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively [illegible] the SV40 [illegible]

[illegible] systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, Il-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml genticin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1 x 10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2x10e^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $Na_2HPO_4.7H_2O$, 1 mM $MgCl_2$, and 675 uM $CaCl_2$. Incubate at 37^{O}C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37^{O}C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting $1x10^8$ cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of $5x10^5$ cells/ml. Plate 200 ul cells per well in the 96-well plate (or $1x10^5$ cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37^{O}C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by

growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as $5x10^5$ cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to $1x10^5$ cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF-κB (Nuclear Factor κB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-κB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF-κB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κB is retained in the cytoplasm with I-κB (Inhibitor κB). However, upon stimulation, I- κB is phosphorylated and degraded, causing NF- κB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-κB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-kB would be useful in treating

diseases. For example, inhibitors of NF-κB could be used to treat those diseases related to the acute or chronic activation of NF-kB, such as rheumatoid arthritis.

To construct a vector containing the NF-κB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-κB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:
5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCA
TCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACT
AATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTC
CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:
3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-κB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-κB/SV40/SEAP cassette is removed from the above NF-κB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the

Once NF-κB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1,1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 µl of 2.5x dilution buffer into Optiplates containing 35 µl of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 µl Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 µl Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6

23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000 - 20,000 cells/well in a Co-star black [illegible] HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is incubated at 37°C in a CO_2 incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10^6 cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford,MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford,MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na3VO4, 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boeheringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many

determining its ability to phosphorylate a tyrosine residue on a specific substrate (a

biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg_{2+} (5mM ATP/50mM $MgCl_2$), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM $MgCl_2$, 5 mM $MnCl_2$, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavadin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phospotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other

phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer [illegible]

[illegible] labeled at their [illegible] polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies).

The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Manheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10.

The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 μg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 μg/kg/hour to about 50 μg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally,

intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence [illegible]

Example 27: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide of the present invention. A polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the encoded polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) Cardiovasc. Res. 35(3):470-479, Chao J et al. (1997) Pharmacol. Res. 35(6):517-522, Wolff J.A. (1997) Neuromuscul. Disord. 7(5):314-318, Schwartz B. et al. (1996) Gene Ther. 3(5):405-411, Tsurumi Y. et al. (1996) Circulation 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs of the present invention may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). These polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs of the present invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the present invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is [illegible]

[illegible] either circular or linear, is either used as naked DNA or complexed with

liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA of the present invention.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference.

Sequence Listing

(1) GENERAL INFORMATION:

(i) APPLICANT: Human Genome Sciences, Inc., et al.

(ii) TITLE OF INVENTION: 207 Human Secreted Proteins

(iii) NUMBER OF SEQUENCES: 800

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Human Genome Sciences, Inc.

(B) STREET: 9410 Key West Avenue

(C) CITY: Rockville

(D) STATE: Maryland

(E) COUNTRY: USA

(F) ZIP: 20850

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage

(B) COMPUTER: HP Vectra 486/33

(C) OPERATING SYSTEM: MSDOS version 6.2

(D) SOFTWARE: ASCII Text

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Kenley K. Hoover

(B) REGISTRATION NUMBER: 40,302

(C) REFERENCE/DOCKET NUMBER: PZ007PCT

(vi) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (301) 309-8504

(B) TELEFAX: (301) 309-8439

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 733 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```
GGGATCCGGA GCCCAAATCT TCTGACAAAA CTCACACATG CCCACCGTGC CCAGCACCTG    60
AATTCGAGGG TGCACCGTCA GTCTTCCTCT TCCCCCCAAA ACCCAAGGAC ACCCTCATGA   120
TCTCCCGGAC TCCTGAGGTC ACATGCGTGG TGGTGGACGT AAGCCACGAA GACCCTGAGG   180
TCAAGTTCAA CTGGTACGTG GACGGCGTGG AGGTGCATAA TGCCAAGACA AAGCCGCGGG   240
AGGAGCAGTA CAACAGCACG TACCGTGTGG TCAGCGTCCT CACCGTCCTG CACCAGGACT   300
GGCTGAATGG CAAGGAGTAC AAGTGCAAGG TCTCCAACAA AGCCCTCCCA ACCCCCATCG   360
AGAAAACCAT CTCCAAAGCC AAAGGGCAGC CCCGAGAACC ACAGGTGTAC ACCCTGCCCC   420
CATCCCGGGA TGAGCTGACC AAGAACCAGG TCAGCCTGAC CTGCCTGGTC AAAGGCTTCT   480
ATCCAAGCGA CATCGCCGTG GAGTGGGAGA GCAATGGGCA GCCGGAGAAC AACTACAAGA   540
CCACGCCTCC CGTGCTGGAC TCCGACGGCT CCTTCTTCCT CTACAGCAAG CTCACCGTGG   600
ACAAGAGCAG GTGGCAGCAG GGGAACGTCT TCTCATGCTC CGTGATGCAT GAGGCTCTGC   660
ACAACCACTA CACGCAGAAG AGCCTCTCCC TGTCTCCGGG TAAATGAGTG CGACGGCCGC   720
GACTCTAGAG GAT                                                      733
```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Trp Ser Xaa Trp Ser
1 5

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 86 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCGCCTCGAG ATTTCCCCGA AATCTAGATT TCCCCGAAAT GATTTCCCCG AAATGATTTC 60

CCCGAAATAT CTGCCATCTC AATTAG 86

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCGGCAAGCT TTTTGCAAAG CCTAGGC 27

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 271 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

AAATATCT[illegible] 120

GCCCCTAACT CCGCCCAGTT CCGCCCATTC TCCGCCCCAT GGCTGACTAA TTTTTTTTAT 180

TTATGCAGAG GCCGAGGCCG CCTCGGCCTC TGAGCTATTC CAGAAGTAGT GAGGAGGCTT 240

TTTTGGAGGC CTAGGCTTTT GCAAAAAGCT T 271

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GCGCTCGAGG GATGACAGCG ATAGAACCCC GG 32

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GCGAAGCTTC GCGACTCCCC GGATCCGCCT C 31

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGGGACTTTC CC 12

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 73 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GCGGCCTCGA GGGGACTTTC CCGGGGACTT TCCGGGGACT TTCCGGGACT TTCCATCCTG 60

CCATCTCAAT TAG 73

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 256 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

CTCGAGGGGA CTTTCCCGGG GACTTTCCGG GGACTTTCCG GGACTTTCCA TCTGCCATCT 60

CAATTAGTCA GCAACCATAG TCCCGCCCCT AACTCCGCCC ATCCCGCCCC TAACTCCGCC 120

CAGTTCCGCC CATTCTCCGC CCCATGGCTG ACTAATTTTT TTTATTTATG CAGAGGCCGA 180

GGCCGCCTCG GCCTCTGAGC TATTCCAGAA GTAGTGAGGA GGCTTTTTTG GAGGCCTAGG 240

CTTTTGCAAA AAGCTT 256

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2526 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GACAGGCTAT CCGAGAATCT GAGAGCTGGG CCCGGCAATT CCTCCAGTTA CCCTTGTGAC 60

CTAAGTCCAG TCACACATTT CCCAAAGTTT CTCTTTGTCA TAACCCTGGT CTGGCTGGTT 120

TTGRGGRCTT GAGAATGGGT CAGGGACTCC AGGCCAAGTC CAACAGAGAC CCCAAACCCA 180

CCACACACCA GCAGCCACAA CCTCACCACC AACAAAGAGG ACTTTTGTGG GGCCACAAGT 240

[illegible]

[illegible]

GGTGCTCAAT CATCTTTTTC TGGCCAAGGT TCTCATTATG CTTAGTACTG GAACAGAGGT 480

GGCCAGGCCC CCAGCGACTC TTCTTGGCCT GATGTTTGTC CTCACAGGCA TGCCACGTGG 540

CCTGAGATGA TTCAGAACAA ATCATGCTAA CTTTGAATCC ATCCAGCCAC TTGCAAATGA 600

TAATCAGAAG TCAGCTTGTT CACTGTTAGA AAGAAACTAA CAAAAGAGAA CCCAGAGCAA 660

TCTAGAATCT TTGAGTGCTT GGCTTTCCAA GGATACTGCG GAGATTCTGG CCAAGCTGAT 720

GAMCTTCTGA ARTGTCACTG GCACCATATG CAACAAGAAC CACCATTCAC TGAGTAGCTA 780

ATGGGTTTGG GGCCTGGGAC ATTCCATCTG AGGTCCTTCC TGAACATGTC ACTCCACAGC 840

AGAGGACCGG TTGCAGCTTA CCCAGAACCA CTCCTCCAGG AGAGCTGGAT GTTTTGCGTG 900

CAACACCTTG AGCACTGACT GCTATTGTTC AAAAAAAGCC TTTGCTGCAT TCGGAGGACT 960

GCCCCGTGCC CTGAGGTGAC TTCCTAACTA TGTGGTTTCA TTAGCGAATT TATTTTTTGT 1020

GCTGGGTGGA CATTTGTATT TTGTTAGGTT GCTGTTTAAG CTCAAGTTTG CTGTGCTCTC 1080

TGCAGCTACA AAACATCTTG GCATATTTAA GAKTGGCTTT TATAAATAGC TTTATTCTGA 1140

TATTAATCAG ATTCCCAACT TTACTGAGAA TTAAGGACTG GGCTACTTTA AAGAAATGCA 1200

AATAGCAATT GAAGAACCAC TGCTGCAGGT GGTAGCCCTG GCTAGACTGA ATTACACTAG 1260

AAATCAGCCA GAAGGAAGCG TCCTTGGGAT CCCAGATCAC TCTTTTTTTT TTTTTTTTTA 1320

AAAGCGGCAG CCCCTTGATG GCTCATCTCT CTGAATAACA GTTACGTCTT CATATCGATA 1380

CCAGATGCCT TCTTCATCAT GCCACTGAAG CCACTCACCA CCTTCAAGAA CATGCCAACC 1440

TCTGTCAGAT TCACTTACCC ACAAACAAGG AGGCACGTTT GGCACAAAGT GTTGTCCTCC 1500

AGGTCCAAGT GGACTCTACA GAGTGCTTGA CCTCAACACA CTGGATTCCA GGTGGACTGG 1560

ACCAAGAGCA GGCAAAGACA CGGGAACTGA AAAACTCCAC AGGGTTTGGA GAATAGAAAT 1620

GAAAAGCCAC GTCATATAAC TCAAGAATAA ATGGTGTTTT GGAAATTTTA AAATTATCAT 1680

CGAAGGTGGT GAAACTATTT CAGGCCCAAA TGAAAGGAAA TCGCCAGTTG GGGATGAAAT 1740

CACAGAGCCT GTGTTTTATG ATATGGTTGG ATGTCCACTG ATGAAATTTT AAAGGAGTTT 1800

CATTTTTAAA AGTGCGCATG ATTCTACATA TGAGAATTCT TTAGGCCAAG AAACTGTCCT 1860

TGGCTCAGAG GTGTTGGGAA TTAAAGCAGA GAGAAGCCAT TCGTGATGCT TAGAACCAAG 1920

GATGGTCATG TACACAAAGA CCATCGAGAC GGCCATTCTT GTTTACAAAA CACTTACCAA 1980

GAAAGCACTT TGTAGGGGAA CTTTAGTAAG TTCTTCTCAT TTCATTATGT TTCTTCCAAG 2040

GAAACAGGAG AGACTGAATT AATAATTCTC TCTTTCCTCT TAAGCACTTT TAAAATAATA 2100

AAGTACATCT TGAAATTTGG GGGGGCATCT CTGATTTAAA AAAAGAAAAA GGCTGCTTGA 2160

TGTATGTTAT GCAGAGACAC TCTGCCTCTG GTGGCTGCAG AGCAATACCC AAGCCTCATT 2220

TGGAAGGCTC AACATTTGGA ATTGCACTTT AATTGATTAA TCCTCAATTC ATGTGGCCTT 2280

ACGGGATGGT GGGTCTGGGA CCCCAATTCA TTCTTATCTG CCAAAGAATT ATCTAGAAGC 2340

ACATCAAATA CCAGCACCCC ACCTGCACAA TGGGGGTGGA AAACTTTTGT ATCCCTAAGC 2400

ATATTATTTT ATAGTGTCTG CCATGCCATG TGGAAATACT TTATTTTTAA CCTCAGGATT 2460

TAAATAAAGT AAACACTATG ACATTTAAAA AAAAAAAAAA AAAACTCGAG GGGGGCCCGG 2520

TACCCA 2526

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CACTGCACCA GCTTTGTTAT CTGTAAAATG ATGATAATAC CAACACCTTC TTCTTGGGGT 60

ACTGAAGATG AGAGAACATG ATATGTGTAA AGTGCCTTCC ACAATACCCA GAACATAGCA 120

AACATGTAAT GAATGTAGTA ATAGTAATTA TTTTATTTTC TTTTGATTCA GTTGGGACTA 180

TGTTCAGCTG TAACAGAATA CCCAAAATAA CTGTTTTAAA CAAATTAAAG TTTWGTTGTG 240

AAGTTTTGTT ACGAATTCAG ACAATCCAGG GCTTTTATAG ATGCACCAGG ATCAGCAGGT 300

ACAAAGGCAT CTTTCCTGAT TTCTGCCAGT CTCAATGCAT GGGTTGCAAT CCAGARTCCA 360

RGATGGCAGT TCCAGCCCTG GTTACGCCCA TATTAGCACA CAGAAAGAAA GAGAAAGGGA 420

TGTGCCTCTT CACTTTAATC ATAGCTCCCA CTAGATGCAC CCACTACTTC TGCTGATACT 480

CCATTAGCTA ATGCTTGCTT ACATGGTCAC ACTTAGTTTC CAGAGAGACA TGTCTGGACA 540

GTCATGTGCT CAATTAATAT CCAAGTGTCC AATTACTGAG AAAAAAAGAA ACTAGCACCT 600

TTGCTTGGTT GCATTCCTCT TAGCATAAGC CACATTCTTT TTATGAAGTT GTCCTCAGTT 660

ACTTGGATGC CTCAGTTGTC CTTTCAWTTA GAAAWGCYCC TKGGACAYCC TGAAWCTGAC 720

TTCTTTTGTC ATCAGCACCA TCACTACCAC TGCCYTCTTC AAAGCCACCA CGTTCTGTCC 780

CCAGGATGGT TGCAACAACC ACCATAGGGA CTTTTTGCCT TCTACTTCCA CACAATAGNC 840

CAGAGTAAGC TTTTGAAAAT GTAGGTCAGA TCATGTCTCT CTCTTCCTCT TCAAAACCCT 900

[illegible]

TATTTGCACT TAAAATAGAA AAAAAAAAAA AAAAAAAACT CGAGGGGGGC C 1131

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 941 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GGCACGAGTA GCATTTCATT TAATCTGCAG GTATATTCTC CCAACAGTTT ATTGTCATGT 60

GATGTCCTCA GCCAAGATTG TRAGGCAGAG AGGAGCTGTC CCAACCTACT ATACCACCGA 120

GGCTGGAGAG ATCATATTTT TGGTATTAAA CTGGAGTCTC TCCATCCTTC ACATTGTTGA 180

TGTCCTCTGT AGCAAACCGG AAAAGTCAGT GACAGAAGAT GCCGCTAGCG GTTTGAGCCA 240

GAGAATGACA GCTCTGGTTT GGAGAAAAGG GCCGGATGGT GGCTCTAGAA AGCCCATCCT 300

TCTGCTCTTC TTTTTTCTCC CCCTTATATT GTGCTTTCAT TCATTCATTC ATTCATCAAA 360

CATTTGTTGA GCACCTATTA TGTGTCAAGC TCTGTGCTAG CCTCTGGAAA ACCTGCCCTC 420

ATGTAGCTCA CTGTGGAGTA GGAGAAACAA TGACTACACT ATGATAAGCA CGGGTTGTCA 480

GGGTCTCACA GAGCAGTGGC CCCTCATCCA GACCGATGAG GTCAAAGAAG GCATCCAGGC 540

GAGGATGGTG TCAGAGCTAA CTGAAGAATG AGAGGGAGCT GCACCASCAG GGGTTGGAAC 600

TGAAGGTGGC AGTGCCTGGA GTCTTGATTC CAGCAGAGGG AGAGCAGTCT GTGAAAAGGC 660

ACCAAGGGTG GGAGAGGGCA GAGCACATGG AGGAACTTCA GGTAGTTCTG GATGGCSCTG 720

GGGCAAAGCT AGAGAGGTAA GAAGAATCTA CAAATGTTCC TCGAGTTACA TGAACTTCCA 780

TCCCAATAAA CCCATTGGAA ACGAAAAATT TAAGTCAGAA GTGCATTTAA GGCTGGTCCG 840

AGTAGAATGA TTTTTACAAC GAATTGATCA CAACCAGTTA CAGATGTCTT TGTTCCTTCT 900

CCACTCCCAC TGCTTCACCT GACTAGCCTT TAAAAAAAAA A 941

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 843 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

```
CNAGGGATAA CCCCAAAGNT GGGAAATAAA CCCTCAATTA AAGGGGGAAC CAAAAAGCTG     60
GGAAGTTCCC CCCCGCGGTG GCGGCCNGNT CTAGGAACTA GTGGAATCCC CCGGGGCTGC    120
AGGGAATTCG GCACGGAGTG GGAATGTTGT TTGTATGATA CTATTTCCAC AAWATGCATT    180
GAGACTTGGT KTGTGGCCTA GGACATGGTC AATTCTTTYT AAATATTCCG TGAATTTCTT    240
TAGTGCATAT TCTCCGATGG GGGCTGTGGG GACAGAGTTC TAAATATGCC CATTAGATTA    300
AATCTCTTCA TTCTGTTGCT CACATCTTCT ATATCCTTAT TAATCTGTCA ATCTCTTCAA    360
GAGAGGTGTT ATTAAAATCT CTCACTGTAT GTGTCACTTT GCCCTTAAAA TTCTGATGAT    420
TTGCTTTATA AATGGTTATA ACCATTTTCC AGGAAGAACA TTAAAGAACT TTCCATTGGC    480
ATTATCCAGT TTCCCTCAAA ATACTGGTTT TTTTTATTTT GGCTNCTAAG CAGCTATGAA    540
TCCAGTTTCT CAGAAGCCCT TGTCTCAAGG CATTTGTTTC CAGATTACCT TGTTAGCATC    600
CACACTATGG GCTATTTTAG AAAAACAAAA AAAGTATCAA AATCATATAG CTATGATTTT    660
CCTGTGCTTG AAGGAGCCTT AAAGCTCATC TAGTCCAGCC AGTATTTGTT CATCCAAATT    720
CTGCCAAGAA ATCTCTATTG TCAAGATATT CTTTACCATC TTTGGGACAT TCTCATTATT    780
AGAAACAAAT CCTAAGAAGA AATTCTGCCA TAKACAACCC ATCCGTTCTT TAAAAAAAAA    840
AAA                                                                  843
```

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1018 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

```
CTGTAATTTT TAATTTTCAT ATACCGTGCT TTGATTCTAA TTTTATTTTT TGAGTTCTCT     60
GAAGGTTACA TATACAGAGT GCTTCAGGAA TGATCATTTT GTTATTATTC ATGCTTCTTA    120
ACAATGTTGT TTTACTCCAA GAAGATAATT GCCAGAGAAA GAATACAGTG CAGGAAAGAA    180
GARGCTGGAG CCAGTGGTGA AGARGGATTG AGARGACAGA CATTGTGGGA ATGAAATCAT    240
GAATAATCGT GTTTTTGAAT TGTCCAAAAA CTTCTACAAA CCATGAAATG TTGGAGTTTA    300
[illegible]
[illegible]
```

```
TGGCTATCTA ATTTGGTGCC AAATACTTAA TGTGCTTGAA TTTAAAAACA GCAAACATGT      600
AGAAAGGTAA TTATAATTAT GAGGCCAGTT CTTTAAGCTA GCTTTTTTTC CCCTCTCAAA      660
CAGCATATTG GCTTGGATGT CAGCAGGAGA AAGTGTTTTT TGCAATACAC ATAATGCATA      720
TATGGTCCTG TTAGCAATCT ATAGAAAATA GATATTGCTC ATTAAGGTAA ATATTTTTGT      780
TGATGAATGA TCTGGAATGG TCTGGACTTG TTGTGTGAAC AGGAAATTGC TCTGTAGGCT      840
TTGACTTGTG AGGTAAAGAG TGAGGCTGGT AAGATTAATT AAAGTAAATA CTGTGACAAT      900
ACGATGTCAA AACCAAAAAC GTGTTTCTGA AACTCAAGGA ATTAATGACA CATAGGGAAG      960
TTTTTGCCAT ATTAAGCATA GAGTAGGAGA GGCAAGTCAA GAATAAAAAA AAAAAAA        1018
```

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 661 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

```
TTTAAGAAAT TAGTGAATCC CCGGNTGCAG GGAATTCGGC ACGAGGAGGA GGCCGTCAGC      60
TGGCAGGAGC GCAGGATYGC AGCTGYTCCC CCGGGTTGCA CCCCCCCAGY TCTGCTGGAC      120
ATAAGYTGGT TAACAGAGAG CCTGGGAGCT GGGCAGCCTG TACCTGTGGA GTGCCGGCAC      180
CGCCTGGAGG TGGCTGGGCC AAGGAAGGGG CCTCTGAGCC CAGCATGGAT GCCTGCCTAT      240
GCCTGCCAGC GCCCTACGCC CCTCACACAC CACAACACTG GCCTMTCCGA GCTGCTGGAG      300
CATGGAGTGT GTGAGGAGGT GGAGAGAGTT CGGCGCTCAG AGAGGTACCA GACCATGAAG      360
GTGCGCAGGG CAGGGCTGGG ACCTACCCCA GGAATGTCCT GCCCTGGGAA TGACAACACA      420
GTCCACACCA TGCACGGGGA GGCAAACAGG GGCAGCTGAC CCAGCCCAGG GGTCAGANGA      480
GGTCTTGCCG AGGAAGTGGC AGCTAAGCTG ATACCTGATA TGCACWAGKC AGCCARGYGG      540
AGACAGGCAA GGAAGAAGCT TGTTTTGAGG ACAGAATTTT CTAGATCACT CAGCACCATC      600
TGGCTTTTGG GGCTTTTTGT TTTATTTTGT TTTTGAGACG GGTCTCGCT CTGTCGCCCA      660
N                                                                 661
```

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 553 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ II NO: 17:

```
GGCACAGGGC TATTTGCCCC TCTCTCCACA TGACAGAACT GCTCTAAGTT TCTTTGCTGC      60
TCTTCTCAGC TGTCAGACGG CTTGCTGCTT GTTTTCCACA CCACCATGTC TATTCTTTGC     120
TGTCCTTWAC TCTGCCTGTT TTTTTCCTTT TGTATTTCTT CTGGCTCTTG TCCCTTTTCC     180
CACGTGTCWC AGCTTTCCTT TATTGCCACT TTCAGTCAGA GCAGTCCTGT GCTTCTGGTG     240
CCGGCATACA ATACTTACTT GAGTTTCTTG GCTTTTCTTG ACTGTGCATC TCTTACTTCA     300
ACATAGGAAT AGCCTGTCAT AGAATTTCTC CAGTTCCAGG GCTCAAGAGG GAGAGTGCCA     360
GAAAATTGAG ACTGTTTTCC CTGTCTTGGA TTGAATTCAT AAAGCAAAAC CAGTCTTTGT     420
GTGAGGGTTT GCTGTGTCAT GCCTATAGGT TGTTTGGGTG CAAACCTATA GAATCCAGCC     480
TGCGAAAAGA AAGRAACCAG AGAATANCAG CATCAGAACA ATGCTTGACA TCATTTCTCA     540
ATCAAGCAGT CCA                                                        553
```

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 869 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

```
GGCACGAGCT GCCAACACTG AGGTCTTCGT GGCTTCTCAC ATCTAGATGT ATCCCTCTCA      60
AATCTATCCT CTATCCAGGC ACCAGATTGA GGTATCTAAA ATGTCAACTT TCCAGTTACT     120
CCTTCTTATA CTAGCCCAAT CAACTTACAA GATAAAGTCC AAGCCCCTTC ATATGACAAA     180
CCACACCCTG CTTAACTCTC CAGGTTTGAA TCCTTCATCT CCTACTTTAA ACTTTAAAAC     240
CCAGCAGCAC GAAAGTGTCT CCTATGCATG TTGCCATATG CGTTCTCTCC ATCATGCATT     300
TGCCTGAGCA AGATGTCTTG AGTTAACATC TTATTCTTTA AGACTCATTG TGGTGGTAGA     360
CAGCCTTTAA TAACGGATCC TTGGCCAGGC ACAGTGACTC ACACCTGTAA TCCCAGAACT     420
```

[illegible]

CAAGGCTGCA GTGAACCATG ATCAGAACAT TGCANTCCAG CTTGGGTAAC AGAGTGAGAC 660

CTTAGGTCAG AAAAATGAAT AAATAAGCAT AAAATTTTAA AAACTTAGCC AGGCATGGTG 720

GCACACATCT GTGGTCCCTG CTACTTAGGA GGCTGAGGTG AGAGGATCCT TGAGCCCAGG 780

AGGTCAACAC TACAGTGAGC TATGATTGTG CCACTAAACT CCAACCTGGG TGAAAAAGCA 840

AAACCCTGCC AAAAAAAAAA AAAAAAACT 869

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 959 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GGCGAGCCGA GATCGTGCCA TTGCACTCCA GCCTGGGCAA CAAGAGTGAA ACTCTGTCTC 60

AAAAAAAAAA AATTATAATA CTATATGCCA TAAAATGACA TTTCATATTT AAAGAGTTTT 120

TTAAAACTCT TGTATTCACA TGCCATAATT TGAAACCCTA TTTCACTGAA TGAGAATGGT 180

ATCTGTTGTC CTCATTTTTT CATTTTTATC CTTAACAATT TCCACCACAG CCAGTGCATA 240

TAATGGCAAT GACACCCAGG GATGGAATGA TAAGTTCCAT CRCMGCTCAG TCAAGACGCA 300

GACTTGATGT GGCCCCAACA ACAGTCAATA ATGGAGTCTC CAAAATAAAG CTCTATAGGA 360

AAGGTAAATA CCCGCTGCAC AAGAAACCAC AGCATCTAGG TTCTAACCCC ATCTCTATGA 420

AGAGCTTGCT GGGAGAGTTT TGACATTWAA CAATCTGTCT GATKGCCAAT TTTYTTCTTC 480

TATAAAATGA TAATGTTKGA YTCAAAGATC CAAAGTCAAT TCATGGTCTA AAACTTAATG 540

ATTTTTTTAG GTTTTGKGAC ATTTCACTGT ACACTGTAGT AATTTATATC TTATTTTCCC 600

ACTAATTTAG AAAAATATYT AAATGATCCT TAATTGGCAA TGGGTCCTAA GAATTTTGTT 660

TTAAATCCCT GTTACCCAAA AGAGCCCTTT TTTGTATCTC GCAGTAGTTA CAAGGATCTT 720

TCTAAATCTT AAAAAAAAAA AAAAAAGAAA GAAAGAAAAG AAAAGAAAAA AAGTCAGCCG 780

GGCGTGGTGG CTCATGCCTG TAATCCCAGC ACTTTGGGAG CAAGGTGGAC AGATCACGAG 840

GTCAGGAGAT GGAGACCATC CCGGCCAACA TGGAGAAACC CTGTCTCTAC TAAAAAAAAA 900

AAAAACTCGA GGGGGGCCCG GTACCCAATN CGCCGGCTAG TGGTCGTAAA ACAATCAAA 959

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1446 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

```
CGGGGCAGGG CTGTGTGGCA CCGCCAGGGA GCGGGCCCAC CTGAGTCACT TTATTGGGTT     60
CAGTCAACAC TTTCTTGCTC CCTGTTTTCT CTTCTGTGGG ATGATCTCAG ATGCAGGGGC    120
TGGTTTTGGG GTTTTCCTGC TTGTGCCAAG GGCTGGACAC TGCTGGGGGG CTGGAAAGCC    180
CCTCCCTTCC TCTCCTTCTG TGGCCTCCAT CCCCTCATGG GTGCTGCCAT CCTTCCTGGA    240
GAGAGGGAGG TGAAAGCTGG TGTGAGCCCA GTGGGTTCCC GCCCACTCAC CCAGGAGCTG    300
GCTGGGCCAG GACCGGGAGA GGGAGCACTG CTGCCCTCCT GGCCCTGCTC CTTCCGCAGT    360
TAGGGGTGGA CCGAGCCTCG CTTTCCCCAC TGTTCTGGAG GGAAGGGGAA GGAGGGGGTC    420
TTCAGGCTGG AGCCAGGCTG GGGGTGCTGG GTGGAGAGAT GAGATTTAGG GGGTGCCTCA    480
TGGGGTGGCC AGGCCTGGGG TGAAATRAGA AAGGCCCAGA ACGTGCAGGT CTGCGGAGGG    540
GAAGTGTCCT GACTGAAGGA GGGCACTCCC ATCCTGGGGG ATGCTGGGAG TGAGTGAGTG    600
AGATGGCTGA GTGAGGGTTA TGGGGAGCCT GAGGTTTTAT GGGCCTGTGT ATCCCCTTCT    560
CCCGGCCCCA GCCTGCCTCC CTCCTGCCTG CCTGGCCCAC AGGTCTCCCT CTGGTCCCTG    720
TCCCTCTGGT GGTTGGGGAT GGAGCGGCAG CAAGGGGTCT AATGGGGCTG GGTTCTGTCT    780
TCTACAGGCC ACCCCGAGGT CCTCAGTGGT TGCCTGGGGA GCCGGACGGG GCTCCTGAGG    840
GGTACAGGTT GGGTGGGCCC TCCCTGAGGG TCTGGGGTCA GGCTTTGGCT CTGCTGCCTC    900
TCAGTCACCA AGTCACCTCC CTCTGAAAAT CCAGTCCCTT CTTTGGATGT CCTTGTGAGT    960
CACTCTGGGC CTGGCTGTCG TCCCTCCTCA GCTTCTTGTT CCTGGGACAA GGGTCAAGCC   1020
AGGATGGGCC CAGGCCTGGG ATCCCCCACC CCAGGACCCC CAGGCCCCCT CCCCTGCTCC   1080
TTTGCCGGGG GCAGGGCAGA AATGGACTCC TTTTGGGTCC CCGAGGTGGG GTCCCCTCCC   1140
AGCCCTGGAT CCTCCGTGCC GTAGACCTGC TCCCCAGAGG AGGGGCCTTG ACCCATAGGA   1200
CGTGTGGTGG CGCCTGGCAC TCAGGGACCC CCAGCTGCCC CAGCCCTGGT CTCTGGCGCA   1260
TCTCTTCCCT CTTGTCCCGA AGATCTGCGC CTCTAGTGCC TTTTGAGGGG TTCCCATCAT   1320
CCCTCCCTGA TATTGTATTG AAAATATTAT GCACACTGTT CATGCTTCTA CTAATCAATA   1380
```

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1471 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

```
CAAAAAATAA TAATGATAAT TTAAAATAAA TAAGTAACTA ATAAAAAGAT TTTATATCCC     60
AGTCTTATGA TGTTGGTTGG CAAGGCTAGA TAAAAAGATG TTAGAATGAA AGAACATATT    120
TTTAGTGATA TGTAAATGAA GGATTCTACA ATAGTCATAT ATTTTTATAT GAATGAATGT    180
TGGGTTGGGC TGGAGAGGTA TGTGTGTGTA AATATAAAGG TCTCACATTC AGAGTATAGC    240
TCTGAAATAA TGGAACTCAT GTCTACAATT CAACATGCAT CTGTATAGTT ACATCTCATG    300
TAAATATACA CAGACATATT TTGCAGCCAG TAATTGACAG TTAATGTCCA AAACAGGTGA    360
TTGATAGGTA ACAGAAATTA GATAACCACC AATTTTGCCC AAGAGAAAGA CTAGAAGGAC    420
TAAAAGCAGT TGAATGTATG GTACTGACAT TGTCATAAGC AGTCTGATAA CCAGTTTATT    480
GAAACGTGTG CATTAACAGA GAATTTAATT TTAAACCCAT AATTTCTCCT ATCCATTAAA    540
ATATTATAAT TGTTAGTAGT ATGAAACCAA CAGGAAATGT TTTTTAATCA TTTAGTGAGG    600
TGATTCATTT GTTTCATGGG CAAACACTAT CCAGGAAAAG CCTTGCTTGC CTGTTTCCCA    660
AAGAGCTCTA AGAAATACAA TCAAGTGTAA AATGGTTCAG ACCATTCAGG ATTTCTTGTC    720
ACTCTTCTCA ACCCCGATCT TCCTGTTATT ACTGATGTTT GAAACCCTGT CATTAGCCCC    780
GGCCTGGTTA AAGCCCCTCA GAGTCACCTC TCATTCATAG CAATAGAATT CAACCCCAAG    840
TGGTTGATGG TGTCCCCAGC ACAGCCGAGA GACCTGATCT CTGGATTCAG TGCTTTTAGC    900
TCTTCGAGTT TACCCTAAGA TACCTTCGGG CAATATTTTT AACCAACCCA AAAGCTCTTC    960
AGGTCATTTC TGAAGAGGAC AAGGTGAATC TTGGCTTGGA ACACCATTTT TGGGCTCTTG   1020
CTACTGAATG AATCAGAAAG GAATTTTTTC TGAAGAGCAT TAGAAAGTAA AGGAGATGTT   1080
AAAATAAGTT CTTGAAGTAT GTTTTATATT TATCTAAAAC ACTGATTTTA AAAGTTTACA   1140
TTCAAATGTG TATTCAAAAG AAGTACTGAT TTGTAATTAT TATAGTTTGT GTGTATCATC   1200
CCCTTTTAAC CGTGCCTAAC AACTGTACTT AAATTTTGTT TTCCTAGTGT AACAAATGTT   1260
TCCCATAAGA TTTTCTAGAG CCAAATAATG GGAGTGAAAA ATTCCTTAAG TGTTATATAA   1320
GAAAATATAT TAGAAAATCA GCTTTGGATT ATACGATTTC TAAAATATAC TAATACAGAA   1380
TCCTCAGTAA TATGTTTTGA ATTGGATTTT TTCTCAGAAC TGTTACATAA TAAATAATAC   1440
ATCAACCAGA AAAAAAAAAA AAAAAAATTN C                                  1471
```

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1402 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

```
AGGGACGTCT TGCCTGAGGA GATGCCCATT TCTGTCCTGG RTTACCCTCA CTGCGTGGTG     60
CATGAGCTGC CAGAGCTGAC GGCGGAGAGT TTGGAAGCAG GTGACAGTAA CCAATTTTGC    120
TGGAGGAACC TCTTTTCTTG TATCAATCTG CTTCGGATCT TGAACAAGCT GACAAAGTGG    180
AAGCATTCAA CGACAATGAT GCTGGTGGTG TTCAAGTCAG CCCCCATCTT GAAGCGGGCC    240
CTAAAGGTGA AACAAGCCAT GATGCAGCTC TATGTGCTGA AGCTGCTCAA GGTACAGACC    300
AAATACTTGG GGCGGCAGTG GCGAAAGAGC AACATGAAGA CCATGTCTGC CATCTACCAG    360
AAGGTGCGGC ATCGGCTGAA CGACGACTGG GCATACGGCA ATGATCTTGA TGCCCGGCCT    420
TGGGACTTCC AGGCAGAGGA GTGTGCCCTT CGTGCCAACA TTGAACGCTT CAACGCCCGG    480
CGCTATGACC GGGCCCACAG CAACCCTGAC TTCCTGCCAG TGGACAACTG CCTGCAGAGT    540
GTCCTGGGCC AACGGGTGGA CCTCCCTGAG GACTTTCAGA TGAACTATGA CCTCTGGTTA    600
GAAAGGGAGG TCTTCTCCAA GCCCATTTCC TGGGAAGAGC TGCTGCAGTG AGGCTGTTGG    660
TTAGGGGACT GAAATGGAGA GAAAAGATGA TCTGAAGGTA CCTGTGGGAC TGTCCTAGTT    720
CATTGCTGCA GTGCTCCCAT CCCCCACCAG GTGGCAGCAC AGCCCCACTG TGTCTTCCGC    780
AGTCTGTCCT GGGCTTGGGT GAGCCCAGCT TGACCTCCCC TTGGTTCCCA GGGTCCTGCT    840
CCGAAGCAGT CATCTCTGCC TGAGATCCAT TCTTCCTTTA MTTCCCCCAM CCTCCTCTCT    900
TGGATATGGT TTGTTTTGGC TCATTTCACA ATCAGCCCAA GGYTGGGAAA GCTGGAATGG    960
GATGGGAACC CCTCCGCCGT GCATCTTAAT TTCAGGGGTC ATGCTGATGC CTCTCGAGAC   1020
ATACAAATCC TTGCCTTTGT CAGCTTGCAA AGGAGGAGAG TTTAGGATTA GGGCCAGGGC   1080
CAGAAAGTCG GTATCTTGGT TGTGCTCTGG GGTGGGGGTG GGGTGTTTCT GATGTTATTC   1140
CAGCCTCCTG CTACATTATA TCCAGAAGTA ATTGCGGAGG CTCCTTCAGC TGCCTCAGCA   1200

[illegible]
```

ATAAAAAAAA AAAAAAAAAA CT 1403

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1047 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

```
GGCACAGGGG ACTACAGGCA CCCACGACCA TACCCAGCTA ATTTTTGTAT TTTTTTGTAG     60
AGATGGGGTT TCACGATGTC GCCCAGGCTG GTCTTGAACT CCTGGGCTTG AGCGATCTTC    120
CCATCTTTCC ATCTTGGCCT CCTAAAGTGC TGGGACTGCA GGCATGAGCC ACCATGCCCA    180
GCCAAGATTC TTATTGATTA CCATGTTGCT TCAAGAAGCC AAGCCAGTTT CCAATATTCC    240
CCATTTGCTG GAGTCTTGGT ACTTTGGGTA GAAGCAACTG GTAAATTGTT AATTGGAACA    300
NTTGGTGGTG TAGATAACCA CGTATGGCCA AACCTAGAGC ATCTAGGCTC ACAATTACTA    360
TCCTGACTTG ATAACAAGTG TTCTGATATT AACCTGAAAA TGGGAATAAT GCCAAATCTG    420
TGTAACTTAA CATCTATATA CACAGTGGGG AGAACTGAAG TTATTAAACC TGGAATCTCT    480
GTGATCAAGG CTAACAGTAG TTATCTAAGA AGCAAAGGAC CTACAATTCT TAGACTTGGA    540
GTCATATTCT TTAAGGACGT GTTCTGAAAC TATATCAAGC ATCTGGTTTC CACGTATTTC    600
TCCCTCAGAA ATTATGAAGT ACAAGTAAAA ATGAAGGTAC AGGGTAAGAC ACATGCTGCT    660
TTCTTGCTCT TGAGTGGAGA CAGTTTTCCA GCCATCTTAA CCCCTTWACA CAAAACAATT    720
TGTGTTTTAT AGCAAATAAG TGACTCAACA TAATTTCAAT ATGATGTTTA TCCACCAGTA    780
CTTTCCTTTC AGCTTCTAGT CCCATAARTG GTTTGTGAAG TCATCGGTTA CATTAGCCAA    840
GATAGGCCTA GACTTGAAGT CTAGAATGTT TTTCCCACTA TATGCCAAAG TAGAATGTGG    900
GTATCTCAGG GTCATTTTTG TTGTTCAATT TCCCACCTGT ACAGTTGTTA TGATTCACTT    960
TCCTTATGTG TCTAATAAAT CTTGTTCCAT GAAATGATCA AAAAAAAAAA AAAAAAAACT   1020
CGAGGGGGGG CCCGGTACCC AAATCGC                                       1047
```

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 990 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

```
TTGGAAAGGG TCTAGCTCTT TCTCATTCAC CAACTATATT AGAAGCACTT GAGGGAAATT    60
TACCACTCCA AATCCAAAGC AATGAACAGT CTTTTCTGGA TGATTTTATT GCCTGTGTCC   120
CAGGATCAAG TGGTGGAAGG CTTGCAAGGT GGCTTCAGCC AGATTCATAT GCGGATCCTC   180
AGAAAACATC TTTGATCCTG GAATAAGGAT GATATTCGTT GTGGTTGGCC TACCACCATA   240
ACTGTTCAAA CAAAAGACCA GTATGGGGAT GTGGTACATG TTCCCAATAT GAAGGTAATT   300
ATAACTGGAT TAAATTAGGA GACATCTATA TACTGGCTGC AATGACTGAT AAAATTTTAG   360
AAATGCCAAG TGCTGAGRGT CCATTTGTTC TACCCTCTTT ATATAAACGG TGATGCTGAA   420
AGTTTGTTTA AATGACTTGT TTATATTAAT TAGTCCCCAA GTGTCCAAGT TACACCTGTT   480
TTTTTTGTGA GTTTGTTCTT TACATTTTGC TACCTGTTAC GGGGACTCAA AGGAGGGATA   540
AGAAAGTATC CATCTAAAGA GTGCTAGACA CATACAGTGA AGCCCCTCAA TATGTATTGA   600
TTGAATAAAT GCATGAAAGA ATACATTTTT AAATTTTGTG TATAGTTTTG AAAGACTCAA   660
GTACGTTCTG TGTTTGGTAT TACTGAAACC ACATTTTAAA AATAACACTC ATTAAGTTAG   720
AAATATATGA GTTTAGATTG TAAAAGAATG AGGAATTGAA ATAGTTGTAT ACCATATTGA   780
TGAATATAGA GTTTTTAGGA TACCTCTTAC CTGAAATATT AATAATAATG TTTNCAGAGC   840
ATATTATACA TAATTATTTG TGATTTAATC TGTTAATATG AATATCTCAT TTAAAACTTT   900
TATTTCTGAA AAAATTATAT TGAATAAAAT TTTATATAGG CAGTCCCCAG CCCTTTCCTC   960
CTTCAAAGTT GTCTTATAGA GTGATTGGTT                                     990
```

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1108 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25.

```
TAATCGCTAC TATAGGGAAA GCTGGTCGCT GCAGGTACCG GTCCGGAATT CCGGGTCGAC    60
[illegible]                                                          120
[illegible]                                                          300
```

```
CTCCTCGGCC CCTGAGCTCC AGGCCGTGCG CATGTTTGCT GACTACCTCG CCCACGAGAG    360
TCGGAGGGAC AGCATCGTGG CCGAGCTGGA CCGAGAGATG AGCAGGAGCK TGGACGTGAC    420
CAACACCACC TTCCTGCTCA TGGCCGCCTC CATCTATCTC CACGACCAGA ACCCGGATGC    480
CGCCCTGCGT GCGCTGCACC AGGGGACAG CCTGGAGTGC ACAGCCATGA CAGTGCAGAT    540
CCTGCTGAAG CTGGACCGCC TGGACCTCGC CCGGAAGGAG CTGAAGAGAA TGCAGGACCT    600
GGACGAGGAT GCCACCCTCA CCCAGCTCGC CACTGCCTGG GTCAGCCTGG CCACGGGTGG    660
TGAGAAGCTG CAGGATGCCT ACTACATCTT CCAGGAGATG GCTGACAAGT GCTCGCCCAC    720
CCTGCTGCTG CTCAATGGGC AGGCGGCCTG CCACATGGCC CAGGGCGCT GGGAGGCCGC    780
TGAGGGCCTG CTGCAGGAGG CGCTAGACAA GGATAGTGGC TACCCRGAGA CGCTGGTCAA    840
CCTCATCGTC CTGTCCCAGC ACCTKGGCAA GCCCCCTGAG GTGACAAACC GATACCTGTC    900
CCAGCTGAAG GATGCCCACA GGTCCCATCC CTTCATCAAG GAGTACCAGG CCAAGGAGAA    960
CGACTTTGAC AGGCTGGTGC TACAGTACGC TCCCAGCGCT GAGGCTGGCC CAGAGCTGTC    1020
AGGACCATGA AGCCAGGACA GAGGCCAGGA GCCAGCCCTG CAGCCCTCCC CACCCGGCAT    1080
CCACCTGCAT CCCTCTGGGG CACGAGCCCA CCCCCAGCAC CCCCATCTGT TAATAAATAT    1140
CTCAACTCCA RGGTGTTCCA CCTGAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA    1200
AAAAAAAA                                                             1208
```

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1922 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

```
GTGCTGCGCT ACTGAGCAGC GCCATGGAGG ACTCTGAAGC ACTGGGCTTC GAACACATGG    60
GCCTCGATCC CCGGCTCCTT CAGGCTGTCA CCGATCTGGG CTGGTCGCGA CCTACGCTGA    120
TCCAGGAGAA GGCCATCCCA CTGGCCCTAG AAGGGAAGGA CCTCCTGGCT CGGGCCCGCA    180
CGGGCTCCGG GAAGACGGCC GCTTATGCTA TTCCGATGCT GCAGCTGTTG CTCCATAGGA    240
AGGCGACAGG TCCGGTGGTA GAACAGGCAG TGAGAGGCCT TGTTCTTGTT CCTACCAAGG    300
AGCTGGCACG GCAAGCACAG TCCATGATTC AGCAGCTGGC TACCTACTGT GCTCGGGATG    360
TCCGAGTGGC CAATGTCTCA GCTGCTGAAG ACTCAGTCTC TCAGAGAGCT GTGCTGATGG    420
```

AGAAGCCAGA TGTGGTAGTA GGGACCCCAT CTCGCATATT AAGCCACTTG CAGCAAGACA 480
GCCTGAAACT TCGTGACTCC CTGGAGCTTT TGGTGGTGGA CGAAGCTGAC CTTCTTTTTT 540
CCTTTGGCTT TGAAGAAGAG CTCAAGAGTC TCCTCTGTCA CTTGCCCCGG ATTTACCAGG 600
CTTTTCTCAT GTCAGCTACT TTTAACGAGG ACGTACAAGC ACTCAAGGAG CTGATATTAC 660
ATAACCCGGT TACCCTTAAG TTACAGGAGT CCCAGCTGCC TGGGCCAGAC CAGTTACAGC 720
AGTTTCAGGT GGTCTGTGAG ACTGAGGAAG ACAAATTCCT CCTGCTGTAT GCCCTGCTCA 780
AGCTGTCATT GATTCGGGGC AAGTCTCTGC TCTTTGTCAA CACTCTAGAA CGGAGTTACC 840
GGCTACGCCT GTTCCTGGAA CAGTTCAGCA TCCCCACCTG TGTGCTCAAT GGAGAGCTTC 900
CACTGCGCTC CAGGTGCCAC ATCATCTCAC AGTTCAACCA AGGCTTCTAC GACTGTGTCA 960
TAGCAACTGA TGCTGAAGTC CTGGGGGCCC CAGTCAAGGG CAAGCGTCGG GGCCGAGGGC 1020
CNAAAGGGGA CAAGGCCTCT GATCCGGAAG CAGGTGTGGC CCGGGGCATA GACTTCCACC 1080
ATGTGTCTGC TGTGCTCAAC TTTGATCTTC CCCCAACCCC TGAGGCCTAC ATCCATCGAG 1140
CTGGCAGGAC AGCACGCGCT AACAACCCAG GCATAGTCTT AACCTTTGTG CTTCCCACGG 1200
AGCAGTTCCA CTTAGGCAAG ATTGAGGAGC TTCTCAGTGG AGAGAACAGG GGCCCCATTC 1260
TGCTCCCCTA CCAGTTCCGG ATGGAGGAGA TCGAGGGCTT CCGCTATCGC TGCAGGGATG 1320
CCATGCGCTC AGTGACTAAG CAGGCCATTC GGGAGGCAAG ATTGAAGGAG ATCAAGGAAG 1380
AGCTTCTGCA TTCTGAGAAG CTTAAGACAT ACTTTGAAGA CAACCCTAGG GACCTCCAGC 1440
TGCTGCGGCA TGACCTACCT TTGCACCCCG CAGTGGTGAA GCCCCACCTG GGCCATGTTC 1500
CTGACTACCT GCTTCCTCCT GCTCTCCGTG GCCTGGTRCG CCCTCACAAG AAGCGGAAGA 1560
AGCTGTCTTC CTCTTGTAGG AAGGCCAAGA GAGCAAAGTC CCAGAACCCA CTGCGCAGCT 1620
TCAAGCACAA AGGAAAGAAA TTCAGACCCA CAGCCAAGCC CTCCTGAGGT TCTTGGGCCT 1680
CTCTGGAGCT GAGCACATTG TGGAGCACAG CCTTACACCC TTCCTGGACA GCCGAGGCTC 1740
TGGTGCTTAC TGCACAGCCT GAACAGACAG TTCTGGGGCC GGCAGTGCTG GCCCCTTTAG 1800
CTCCTTGGCA CTTCCAAGCT GGCATCTTGC CCCTTGACAA CAGAATAAAA ATTTTAGCTG 1860
CCCCAAAAAA AAAAAAAAAA AAAAAAACTC GAGGGGGGGC CCGTACCCAA TTCGCCCTAT 1920
AA 1922

(A) LENGTH: [illegible] base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

```
TCGTCCCCAG AGCGGGCTGA GCCCCAGGCG GAGGGTGGCG GGGGAGCCTG GGGGAGCCGC     60
CGCCACCTCC ACGGGCCTCT CTGAGCTCGG ACACCAGCGC CCTGTCCTAT GACTCTGTCA    120
AGTACACGCT GGTGGTAGAT GAGCATGCAC AGCTGGAGCT GGTGAGCCTG CGGCGTGCTT    180
CGGAGACTAC AGTGACGAGA GTGACTCTGC CACCGTCTAT GACAACTGTG CCTCCGTCTC    240
CTCGCCCTAT GAGTCGGCCA TCGGAGAGGA ATATGAGGAG GCCCCGCGGC CCCAGCCCCC    300
TGCCTGCCTC TCCGAGGAAC TCCACGCCTG ATGAACCCGA CGTCCATTTC TCCAAGAAAT    360
TCCTGAACGT YTTCATGAGT GGCCGCTCCC GCTCCTCCAG TGCTGAGTCC TTCGGGCTGT    420
TCTCCTGCAT CATCAACGGG GAGGAGCAGG AGCAGACCCA CCGGGCCATA TTCAGGTTTG    480
TGCCTCGACA CGAAGACGAA CTTGAGCTGG AAGTGGATGA CCCTCTGCTA GTGGAGCTCC    540
AGGCTGAAGA CTACTGGTAC GAGGCCTACA ACATGCGCAC TGGTGCCCGG GGTGTCTTTC    600
CTGCCTATTA CGCCATCGAG GTCACCAAGG AGCCCGAGCA CATGGCAGCC CTGGCCAAAA    660
ACAGTGACTG GGTGGACCAG TTCCGGGTGA AGTTCCTGGG CTCAGTCCAG GTTCCCTATC    720
ACAAGGGCAA TGACCTCCTC TGTGCTGCTA TGCAAAAGAT TGCCACCACC CGCCGGCTCA    780
CCGTGCACTT TAACCCGCCC TCCAGCTGTG TCCTGGAGAT CAGCGTGCGG GGTGTGAAGA    840
TAGGCGTCAA GGCCGATGAC TCCCAGGACG CCAAGGGGAA TAAATGTAGC CACTTTTTCC    900
AGTTAAAAAA CATCTCTTTC TGCGGATATC ATCCAAAGAA CAACAAGTAC TTTGGGTTCA    960
TCACCAAGCA CCCCGCCGAC CACCGGTTTG CCTGCCACGT CTTTGTGTCT GAAGACTCCA   1020
CCAAAGCCCT GGCAGAGTCC GTGGGGAGAG CATTCCAGCA GTTCTACAAG CAGTTTGTGG   1080
AGTACACCTG CCCCACAGAA GATATCTACC TGGAGTAGCT GTGCAGCCCC GCCCTCTGCG   1140
TCCCCCAGCC CTCAGGCCAG TGCCAGGACA GCTGGCTGCT GACAGGATGT GGCACTGCTT   1200
GAGGAGGGGC ACCTGCCACC GCCAGAGGAC AAGGAAGTGG GGCGCTGGCC CAGGGTAGGG   1260
GAGGGTGGGG CAATGGGGAG AGGCAAATGC AGTTTATTGT AATATATGGG ATTAGATTCA   1320
TCTATGGAGG GCAGAGTGGG CTGCCTGGGG ATTGGAGGGG ACAGGCTTCG GGGAGCAGGT   1380
CTCTGGCAGA GAAGGATGTC CGTTCCAGGA GCACACGGCC CTGCCCCATC CTGGGCCTTA   1440
CCTCCCCTGC CAGGGCTCGG GCGCTGTGGC TCCTGCCTTG ATGAAGCCCG TGTCCTGCCT   1500
TGATGAAGCC TGTGCCACCT GCAAGTGCCC GCCCTGCCCC TGCCCCAACC CCCACCGAAG   1560
AGCCCTGAGC TCAGGCTGAG CCCAGCCACC TCCCAAGGAC TTTCCAGTGA GGAAATGGCA   1620
ACACGTGGAG GTGAAGTCCC TGTTCTCAGC TCCGTCATCT GCGGGGCTTC TGGGTGGCTC   1680
```

CTGCCACTGA CCTCACCGGC ATGCTGGCCT GTGGCAGGCC TAGGACCTCA GGCGGGGAGG 1740

AGGAGCTGCC GCAAGGCCCT GTCCCAGCAG AAGAGGGAGG CTTCCTGACT GACACAGGCC 1800

AGCCCCATCT TGGTCCTGTC ACCCTGGCCC CAACTATTAA AGTGCCATTT CCTGTCAAAA 1860

AAAAAAAAAA AAAATCGGGG GGGGCCCGGA ANCCAATTTC CCCCAAAAAG GGGGGTTATA 1920

AAAATTCCCN GGCNGTGTTT TTAAAAATTC G 1951

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3989 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GGCACAGGCC GCAGGGNACC TATGGGCGCA TATAGGTTGT AATGAAACTG TAGTCTCAGT 60

TGGAAGCCTA GACATGAAAT GGGTCAGTGA GCAAGGCTCT ATTCCTAGTC TCCAGCCATG 120

CCTGTGGAAC CTGARCCCRC TCTCAGCACA TTGGACCCAG GCAGATGYAA AAAATTCACA 180

GAACTATGAT TTGGACTCAA GGGTTTGTAG ATTTCCTCCT TCATTCTAAT TTCAGTGTCT 240

AAAATTCTTG CATCCRTGAA CGAGCTGGGC ATTTGATGAG ACAGGGCYGA ATACTGCAGT 300

TTTCCTCCTA GAAATCATCT GGGGCATTTT CTTTGAACTG ATGGGAACAA TAAGGCATAA 360

CTGTTTGCAC AAACTTGGGA TAARTGATTT TGGGATAACG ATCTACCAGA ATGGGGATAT 420

TTCACCCTTG GTTCTGAGAT GCAAACCAAA GAATATCATG ACCAGCTTTC AGGCCTCCTG 480

AAGTATATCT CTCACATTGT CCTGTTCTCA TGCTGAGGAG CCTGAGATCC CTGTGTGGGG 540

ATTAGATAGT GGACTGTTAT GGGTGTAGGT GAATTGGCTT ATTTTGTCTG TCCCTCTCTG 600

AATGTATTGC AGGAAYTAAA AAGCACCAAG AAGAGGAAGA AGACCAAGGC CCACTATGCC 660

CCAGGCCCAG CAGGGAGCTG CTGGAGGTAG TAGAGCCTGA AGTCTTGCAG GACTCACTGC 720

ATAGATGTTA TTCAACTCCT TCCAGTTGTC TTGAACAGCC TGACTCCTGC CAGCCCTATG 780

GAAGTTCCTT TTATGCATTG GAGGAAAAAC ATGTTGGCTT TTCTCTTGAC GTGGGAGAAA 840

TTGAAAAGAA GGGGAAGGGG AAGAAAAGAA GGGGAAGAAG ATCAAAGAAG GAAAGAAGAA 900

[illegible]

GGAGCAACAG CATGTTGGCT TGGCTGTTGA CATGGATGAA ATTGAAAAGT ACCAAGAAGT 1140
GGAAGAAGAC CAAGACCCAT CATGCCCCAG GCTCAGCAGG GAGCTGCTGG ATGAGAAAGA 1200
GCCTGAAGTC TTGCAGGACT CACTGGATAG ATGTTATTCG ACTCCTTCAG GTTATCTTGA 1260
ACTGCCTGAC TTAGGCCAGC CCTACAGCAG TGCKGTTTAC TCATTGGAGG AMCAKTACCT 1320
TGGCTTKKCT CTTGACGTGG ASAAATTGAA AAGAAGGGGA AGGGGAARAA AAGAAGGGGA 1380
AGAAGATCAA AGAAGGAAAG AAGAAGGGGA AGAAAAGAAG GGGAAGAAGA TCAAAACCCA 1440
CCATGCCCCA GGCTCAGCAG GGAGCTGCTG GATGAGAAAG GGCCTGAAGT CTTGCAGGAC 1500
TCACTGGATA GATGTTATTC AACTCCTTCA GGTTGTCTTG AACTGACTGA CTCATGCCAG 1560
CCCTACAGAA GTGCCTTTTA YRTATTGGAG CAACAGYGTG TTGGCTTGGC TGTTGACATG 1620
GATGAAATTG AAAAGTACCA AGAAGTGGAA GAAGACCAAG ACCCATCATG CCCCAGGCTC 1680
AGCAGGGAGC TGCTGGATGA GAAAGAGCCT GAAGTCTTGC AGGACTCACT GGATAGATGT 1740
TATTCGACTC CTTCAGGTTA TCTTGAACTG CCTGACTTAG GCCAGCCCTA CAGCAGTGCT 1800
CTTTACTCAT TGGACGAACA GTACCTTGGC TTGGCTCTTG ACGTGGACAG AATTAAAAAG 1860
GACCAAGAAG AGGAAGAAGA CCAAGGCCCA CCATGCCCCA GGCTCAGCAG GGAGCTGCTG 1920
GAGGTAGTAG AGCCTGAAGT CTTGCAGGAC TCACTGGATA GATGTTATTC AACTCCTTCC 1980
AGTTGTCTTG AACAGCCTGA CTCCTGCCAG CCCTATGGAA GTTCCTTTTA TGCATTGGAG 2040
GAAAAACATG TTGGCTTTTC TCTTGACGTG GGAGAAATTG AAAAGAAGGG GAAGGGGAAG 2100
AAAAGAAGGG GAAGAAGATC AAMGAAGRAA AGAAGAAGGG GAAGAAAAGA AGGGGAAGAA 2160
GATCAAAACC CACCATGCCC CAGGCTCAAC GGCGTGCTGA TGGAAGTGGA AGAGCSTGAA 2220
GTCTTACAGG ACTCACTGGA TAGATGTTAT TCGACTCCGT CAATGTACTT TGAACTACCT 2280
GACTCATTCC AGCACTACAG AAGTGTGTTT TACTCATTTG AGGAACAGCA CATCAGCTTC 2340
GCCCTTTACG TGGACAATAG GTTTTTTACT TTGACGGTGA CAAGTCTCCA CCTGGTGTTC 2400
CAGATGGGAG TCATATTCCC ACAATAAGCA GCCCTTASTA AKCCGAGAGA TGTCATTCCT 2460
GCAGGCAGGA CCTATAGGCA MGTGAAGATT TGAATGAAAG TACAGTTCCA TTTGGAAGCC 2520
CAGACATAGG ATGGGTCAGT GGGCATGGCT CTATTCCTAT TCTCAAACCA TGCCAGTGGC 2580
AACCTGTGCT CAGTCTGAAG ACAATGGACC CACGTTAGGT GTGACACGTT CACATAACTG 2640
TGCAGCACAT GCCGGGAGTG ATCAGTCRGA CATTTTAATT TGAACCACGT ATCTCTGGGT 2700
AGCTACAAAA TTCCTCAGGG ATTTCATTTT GCAGGCATGT CTCTGAGCTT CTATACCTGC 2760
TCAAGGTCAK TGTCATCTTT GTGTTTAGCT CATCCAAAGG TGTTACCCTG GTTTCAATGA 2820
ACCTAACCTC ATTCTTTGTG TCTTCAGTGT TGGCTTGTTT TAGCTGATCC ATCTGTAACA 2880

```
CAGGAGGGAT CCTTGGCTGA GGATTGTATT TCAGAACCAC CAACTGCTCT TGACAATTGT    2940
TAACCCGCTA GRCTCCTTTG GTTAGAGAAG CCACAGTCCT TCAGCCTCCA ATTGGTGTCA    3000
GTACTTAGGA AGACCACAGC TAGATGGACA AACAGCATTG GGAGGCCTTA GCCCTGCTCC    3060
TCTCRATTCC ATCCTGTAGA GAACAGGAGT CAGGAGCCGC TGGCAGGAGA CAGCATGTCA    3120
CCCAGGACTC TGCCGGTGCA GAATATGAAC AAYGCCATGT TCTTGCAGAA AACGCTTAGC    3180
CTGAGTTTCA TAGGAGGTAA TCACCAGACA ACTGCAGAAT GTRGARCACT GAGCAGGACA    3240
GCTGACCTGT CTCCTTCACA TAGTCCATRT CACCACAAAT CACACAACAA AAACGAGARG    3300
AGATATTTTG GGTTCAAAAA AAGTAAAAAG ATAATGTAGC TGCATTTCTT TAGTTATTTT    3360
GARCCCCAAA TATTTCCTCA TCTTTTTGTT GTTGTCATKG ATGGTGGTGA CATGGACTTG    3420
TTTATAGAGG ACAGGTCAGC TGTCTGGCTC AGTGATCTAC ATTCTGAAGT TGTCTGAAAA    3480
TGTCTTCATG ATTAAATTCA GCCTAAACGT TTTGCCGGGA ACACTGCAGA GACAATGCTG    3540
TGAGTTTCCA ACCTYAGCCC ATCTGCGGGC AGAGAAGGTC TAGTTTGTCC ATCASCATTA    3600
TCATGATATC AGCACTGGTT ACTTGGTTAA GGAGGGGTCT AGGAGATCTG TCCCTTTTAG    3650
AGACACCTTA CTTATAATGA AGTATTTGGG AGGGTGGTTT TCAAAATTAG AAATGTCCTG    3720
TATTCCRATG ATCATCCTGT AAACATTTTA TCATTTATTA ATCATCCCTG CCTGTGTCTA    3780
TTATTATATT CATATCTCTA CGCTGGAAAC TTTCTGCCTC AATGTTTACT GTGCCTTTGT    3840
TTTTGCTAGT GTGTGTTGTT GAAAAAAAAA ACATTCTCTG CCTGAGTTTT AATTTTTGTC    3900
CAAAGTTATT TTAATCTATA CAATTAAAAG CTTTTGCCTA TCAAAAAAAA AAAAAAAAAA    3960
AAAAAAAAAA AAAAAGCGGA CCCGTGGGC                                      3989
```

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3735 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

```
CTGCTGTTCG CTGGCTGGGC TCCGCAGCAG GCTTGGCCAG CGGCTGACGG GTCGGCGGGC      60
[illegible] CCCTCTCAAA                                                120
[illegible] TTTCAAGATG [illegible] AATCTCGTTT                         [illegible]
```

ATTTTTACTG GCAAAGAAAT CCGGGGAGAA TGTGGCCAAG TTTATTATTA ATTCATACCC 360
CAAATATTTT CAGAAGGACA TAGCTGAACC TCATATACCG TGTTTAATGC CTGAGTACTT 420
TGAACCTCAG ATCAAAGACA TAAGTGAAGC CGCCCTGAAG GAACGAATTG AGCTCAGAAA 480
AGTCAAAGCC TCTGTGGACA TGTTTGATCA GCTTTTGCAA GCAGGAACCA CTGTGTCTCT 540
TGAAACAACA AATAGTCTCT TGGATTTWTT GTGTTACTAT GGTGACCAGG AGCCCTCAAC 600
TGATTACCAT TTTCAACAAA CTGGACAGTC AGAAGCATTG GAAGAGGAAA ATGATGAGAC 660
ATCTAGGAGG AAAGCTGGTC ATCAGTTTGG AGTTACATGG CGAGCAAAAA ACAACGCTGA 720
GAGAATCTTT TCTCTAATGC CAGAGAAAAA TGAACATTCC TATTGCACAA TGATCCGAGG 780
AATGGTGAAG CACCGAGCTT ATGAGCAGGC ATTAAACTTG TACACTGAGT TACTAAACAA 840
CAGACTCCAT GCTGATGTAT ACACATTTAA TGCATTGATT GAAGCAACAG TATGTGCGAT 900
AAATGAGAAA TTTGAGGAAA AATGGAGTAA AATACTGGAG CTGCTAAGAC ACATGGTTGC 960
ACAGAAGGTG AAACCAAATC TTCAGACTTT TAATACCATT CTGAAATGTC TCCGAAGATT 1020
TCATGTGTTT GCAAGATCGC CAGCCTTACA GGTTTTACGT GAAATGAAAG CCATTGGAAT 1080
AGAACCCTCG CTTGCAACAT ATCACCATAT TATTCGCCTG TTTGATCAAC CTGGAGACCC 1140
TTTAAAGAGA TCATCCTTCA TCATTTATGA TATAATGAAT GAATTAATGG GAAAGAGATT 1200
TTCTCCAAAG GACCCGGATG ATGATAAGTT TTTTCAGTCA GCCATGAGCA TATGCTCATC 1260
TCTCAGAGAT CTAGAACTTG CCTACCAAGT ACATGGCCTT TTAAAAACCG GAGACAACTG 1320
GAAATTCATT GGACCTGATC AACATCGTAA TTTCTATTAT TCCAAGTTCT TCGATTTGAT 1380
TTGTCTAATG GAACAAATTG ATGTTACCTT GAAGTGGTAT GAGGACCTGA TACCTTCAGC 1440
CTACTTTCCC CACTCCCAAA CAATGATACA TCTTCTCCAA GCATTGGATG TGGCCAATCG 1500
GCTAGAAGTG ATTCCTAAAA TTTGGAAAGA TAGTAAAGAA TATGGTCATA CTTTCCGCAG 1560
TGACCTGAGA GAAGAGATCC TGATGCTCAT GGCAAGGGAC AAGCACCCAC CAGAGCTTCA 1620
GGTGGCATTT GCTGACTGTG CTGCTGATAT CAAATCTGCG TATGAAAGCC AACCCATCAG 1680
ACAGACTGCT CAGGATTGGC CAGCCACCTC TCTCAACTGT ATAGCTATCC TCTTTTTAAG 1740
GGCTGGGAGA ACTCAGGAAG CCTGGAAAAT GTTGGGGCTT TTCAGGAAGC ATAATAAGAT 1800
TCCTAGAAGT GAGTTGCTGA ATGAGCTTAT GGACAGTGCA AAAGTGTCTA ACAGCCCTTC 1860
CCAGGCCATT GAAGTAGTAG AGCTGGCAAG TGCCTTCAGC TTACCTATTT GTGAGGGCCT 1920
CACCCAGAGA GTAATGAGTG ATTTTGCAAT CAACCAGGAA CAAAAGGAAG CCCTAAGTAA 1980
TCTAACTGCA TTGACCAGTG ACAGTGATAC TGACAGCAGC AGTGACAGCG ACAGTGACAC 2040
CAGTGAAGGC AAATGAAAGT GGAGATTCAG GAGCAGCAAT GGTCTCACCA TAGCTGCTGG 2100

AATCACACCT GAGAACTGAG ATATACCAAT ATTTAACATT GTTACAAAGA AGAAAAGATA 2160

CAGATTTGGT GAATTTGTTA CTGTGAGGTA CAGTCAGTAC ACAGCTGACT TATGTAGATT 2220

TAAGCTGCTA ATATGCTACT TAACCATCTA TTAATGCACC ATTAAAGGCT TAGCATTTAA 2280

GTAGCAACAT TGCGGTTTTC AGACACATGG TGAGGTCCAT GGCTCTTGTC ATCAGGATAA 2340

GCCTGCACAC CTAGAGTGTC GGTGAGCTGA CCTCACGATG CTGTCCTCGT GCGATTGCCC 2400

TCTCCTGCTG CTGGACTTCT GCCTTTGTTG GCCTGATGTG CTGCTGTGAT GCTGGTCCTT 2460

CATCTTAGGT GTTCATGCAG TTCTAACACA GTTGGGGTTG GGTCAATAGT TTCCCAATTT 2520

CAGGATATTT CGATGTCAGA AATAACGCAT CTTAGGAATG ACTAAACAAG ATAATGGCAG 2580

TTTAGGCTGC ACAACTGGTA AAATGACTGT AGATAAATGT TGTAATTAGT GTACACGTTT 2640

GTATTTTTGT TAATATAGCC CCTGCCATAG TTTTCTAACT TGAACAGCCA TGAATGTTTC 2700

ATGTCTCCCT TTTTTTTTTG TCTATAGCTG TTACCTATTT TAGTGGTTGA AATGAGAGCT 2760

AGTGATGACA GAAGGATGTG CAATGTCTTC TTGACATCAT TGTGTATTGC TGGTAATCAA 2820

GTTGGTAACG ACTACTTCTA GCAGCTCTTA CCACTATGAC TTAAGTGGTC CTGGAAGGCA 2880

GTAAGTGGAG GTTTGCAGCA TTCCTGCCTT CATGAGGGCT TCTACCACTG ACCACTTTGC 2940

ACGTACCTGG CTCCCAGATT TACTTAGGTA CCCCACGAGT CGTCCACATA AGCAGCTTCA 3000

TCTTTACCTT GCCAGAGTTG ACAATTATGG GATACTCTAG TCTACTTATA CTTGTGTTCC 3060

CATCTGTCTG CCATCCTCTG AAGGCCAGGA CCCAGTCATA CATCCTTAGA AACCAAAGTA 3120

TGGTTTTTGT TTTCTCTTGG AATGTCAGGT CTTAAGGCAT TTAATTGAGG GACAAAAAAA 3180

AAAAAAAGCC GATATAGTAG CTAGCTACTT AAGCATCCAT GGGTATTGCT CCATATCAAA 3240

GCAGATTTGC AGGACAGAAA GAGTAAATTA GCCTTCAGTC TTGGTTTACA GCTTCCAAGG 3300

AGAGCCTTGG CCACCTGAAA TGTTAACTCG GTCCCTTCCT GTCTCTAGTT CATCAGCACC 3360

TGCAGATGCC TGACTCTTGT TAGCCTTACT ATTCAATACA GTCCTTAGAT TCACGGTATG 3420

CCTCTTCCTA TCCAGGCACC TATTCTGAAT CACCATGTTG CTCTGCAGCT AGAGTTGATA 3480

GGAGAAAATC CATTTGGGTA GATGGCCTAT GAATTTGTAG TAGACTTTCA AAATGAGTGA 3540

TTTGTTAGCT TGGTACTTTT AAGTTTGTGG TACAGATCCT CCAAACCCAT ACTCTGAGCA 3600

ATTAACTGCC TTGAACATAG AGAAAATTAA GGCCTCACAG GATGAGTCTC CATTCTCTGT 3660

[illegible]

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1657 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

```
TAGTAATTCA TTTAACTCCT CTTACATGAG TAGCGACAAT GAGTCAGATA TCGAAGATGA     60
AGACTTAAAG TTAGAGCTGC GACGACTACG AGATAAACAT CTCAAAGAGA TTCAGGACCT    120
GCAGAGTCGC CAGAAGCATG AAATTGAATC TTTGTATACC AAACTGGGCA AGGTGCCCCC    180
TGCTGTTATT ATTCCCCCAG CTGCTCCCTT TTCAGGGAGA AGACGACGAC CCACTAAAAG    240
CAAAGGCAGC AAATCTAGTC GAAGCAGTTC CTTGGGGAAT AAAAGCCCCC AGCTTTCAGG    300
TAACCTGTCT GGTCAGAGTG CAGCTTCAGT CTTGCACCCC CAGCAGACCC TCCACCCTCC    360
TGGCAACATC CCAGAGTCCG GGCAGAATCA GCTGTTACAG CCCCTTAAGC CATCTCCCTC    420
CAGTGACAAC CTCTATTCAG CCTTCACCAG TGATGGTGCC ATTTCAGTAC CAAGCCTTTC    480
TGCTCCAGGT CAAGGAATCA GCAGCACAAA CACTGTTGGG GCAACAGTGA ACAGCCAAGC    540
CGCCCAAGCT CAGCCTCCTG CCATGACCTC CAGCAGGAAG GGCACATTCA CAGATGACTT    600
GCACAAGTTG GTAGACAATT GGGCCCGAGA TGCCATGAAT CTCTCAGGCA GGAGAGGAAG    660
CAAAGGGCAC ATGAATTATG AGGGCCCTGG AATGGCAAGG AAGTTCTCTG CACCTGGGCA    720
ACTGTGCATC TCCATGACCT CGAACCTGGG TGGCTCTGCC CCCATCTCTG CAGCATCAGC    780
TACCTCTCTA GGTCACTTCA CCAAGTCTAT GTGCCCCCCA CAGCAGTATG GCTTTCCAGC    840
TACCCCATTT GGCGCTCAAT GGAGTGGGAC GGGTGGCCCA GCACCACAGC CACTTGGCCA    900
GTTCCAACCT GTGGGAACTG CCTCCTTGCA GAATTTCAAC ATCAGCAATT TGCAGAAATC    960
CATCAGCAAC CCCCCAGGCT CCAACCTGCG GACCACTTAG ACCTAGAGAC ATTAACTGAA   1020
TAGATCTGGG GGCAGGAGAT GGAATGCTGA GGGGGTGGGT GGGGGTGGGA AGTAGCCTAT   1080
ATACTAACTA CTAGTGCTGC ATTTAACTGG TTATTTCTTG CCAGAGGGGA ATGTTTTTAA   1140
TACTGCATTG AGCCCTCAGA ATGGAGAGTC TCCCCCGCTC CAGTTATTGG AATGGGAGAG   1200
GAAGGAAAGA ACAGCTTTTT TGTCAAGGGG CAGCTTCAGA CCATGCTTTC CTGTTTATCT   1260
ATACTCAGTA ATGAGGATGA GGGCTAGGAA AGTCTTGTTC ATAAGGAAGC TGGAGAACTC   1320
AATGTAAAAT CAAACCCATC TGTAATTTCG AGTGGGTGGA GCTCTTGCTT TTGGTACATG   1380
CCCTGAATCC CTCACTCCCT CAAGAATCCG AACCACAGGA CAAAAACCAC CTACTGGGCT   1440
CTCTCCTACC CTGCCCTCCT CCCTTTTTTT TACCCCTCTC TTTTTTATTT TTTCTTTGCT   1500
```

CTTTAGAACC CAGTGAAAAA TACCAGGGTA CTGGGGTGCA ACTCTTTCTT ATGATAGGTC 1560

ATTAGTGCTT TAAGCAAAAG ATATTAGCAG CTTTGACTGC AGCATTAGCA ATTAGGRAAA 1620

AAAAAAANWA AAAACTCGAG GGGGGGCCCG GTTACCCAAT TCGCCCT 1667

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1408 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

ATTACACACC TGAGCACTGT GCCTGGCAAG ACCTGTCTTA ATAGATTAGA GAACCACTGA 60

TAGATGGTCA GCTTTCTGTA GCAGTGAGAA CCCTACATTT CAAATGTGGA TAGCACCTTT 120

GCGGGGAAAC ATCACTTGGC ACATCTGCAT TCTTTTTTGA CACAGGGTCT CACTCTGTTG 180

CCCAGGCTAG AGTGCATGGC ACGATCTTAG CTCACTGCAA CCTCCACCTC CCAAGTTCAA 240

GCGATTCTTC TGCCTCAGCC TCCTGAGCAG CTGGGATCAC AGACATGCGC TACCATGCCC 300

AGCTAATTTT TTGTATTTTT TGTKTGTTTG TTTTTGTTTK TAAGTAGAGA CGGGCTTTCA 360

CCACGTTGGS CAGGCAGGTC TCGAACTCCT GAMCTCAGGT GATCCACCCA CATCTGCGTT 420

CCAATATCTT TCTCAACATA ATGATAGCCG TAATTAATAT TTTCCAGTAC ATTTTTATGC 480

CTTTACACAC GAGAGTGGTA GACAGACACA AACCCAGATC TGTCTGACTC CAAAGCCCGT 540

TTGTCATCAT TCCTTTTACG GTATCCTATA GTGGTATCCT TTACAGAAAG ACAGCTTTTA 600

CCCAACAAAG ACTTAACTTC CCAGGATGCC AGAAGGACAA AGCGGGATTG CTTTTAAGRA 660

GRAAGTTATC AAGAMCTTAT TTTATAAATG AGATTAGATA GGGAAAGGCA ATTTATCTTT 720

ATTAAAAACT GAAAAGGCCA GCATAGGGAA GGAGGTCCTT CGGTGGTCTT TTTCAGGGAA 780

ATACTTCACT TGCTTTTATT AGAAACAGAT AGTACCTAAG GTTTTGAGGT AGGWACAGCT 840

TAAGGCATGC TAATGKTCAT GGGTCCTTCC ATAGTCATTT TKGTATTTTG GTTWACATTT 900

GAGCAATAGG CAGCCCTTCA CTGCTGCTGG AYTCATTCCT GCCAYTATTA CAGGTGACAG 960

AGGAGACAGG AGGTATGTCT TTTCTATTTT TAWACATGCT TTATATTTAA CACAAGCTCT 1020

TGGGTATCTT AGATAAACAG AAGTTGCCTA GCACTCCTTT TAGTGCATTG AACCCTTTAA 1080

[illegible] TTATGTGTGA [illegible]

AGATTCAGAC GTCCTCTCAG AAATAATGCA TTCTTTTGCA AAGGTGAATA TTTTTCTCTT 1320

AAAAAATATG TATAAGGTGG TATGTTCATT TATTAGTCTT GCTAAAAAAA AAAAAAAAAA 1380

ACTTNGAGGG GGGGNCCGGT ACCCAATT 1408

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2031 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

AGGATATGCA TGATTCTTAA CCAGGCTATA TGTTAAAAAA AAATTGGAAA ATGCAATACA 60

TTTTTTATTA TACAAACTAC AGAATGAGTA TGCAAGTTTT ATTTATCAAA ATGTAATGGA 120

TTTTTAAAGG CTGAGAAATT TTCCTTATAC CTACCTTTTC AGTTATTTTA ATTATACCAA 180

ATTATCAACT AGAATAGCTT CATCCATATG AAATATAAAA TGAAGAGACA CCTAGGCTCT 240

ATCAGGCTTA GGATTCTTTG AACTTATTTC CACTTTAATT TCTCAGTGGA AGTTAAGAGG 300

GGTGAGAAAA CAAAGAAGGG GAAAAACTGA CAACTAACAA AACCAGCACC ACATCGCTAG 360

GTGGTGCTTA CTAATTACCT TCTCAGGATT TTCCTCAGAT TGAAAAGCTT ATGAGGATTT 420

CTTGGGAGTC TTAATAACCT GCCTGTTAGT ACAGAGCTTT CCTGATGATA TTTACTCTTG 480

AGCACATGTG GTTGTAAAAC CTTAACTTTC TTTCTCCAGG AGGGTGGTGA TAGAAACAGA 540

TGGTAGTATT TATGAACTGA TGTTCTCGTG AAATGTTGAG GGTGGGGAGA AAAGACTTTA 600

AGGGAGGAGA GCCATCTATT TTGTTCCTAA AGCCACCTCT CAGCAGAATC GTCATGTTTT 660

TCTGATGCAC CGCTCTGCTT CATGCCCAAG ATGACTTGCG AGGCAATCTC AGGAGCTGTG 720

GACTTAACCR TTGCAAAGCA CACTGTCTTT CTCAGCGTTC TCTGCAAGTC AGTAGGTGTT 780

AGTATGGTTG CAAAGTTCAC TGTCTCAGCA AAGTTGAACT GGGCTACCTC TCTACAGCTG 840

TTTCCTCAGA GGGAAAAATC TTGAGACCAG ATGGTGGAGC TCTGGAGTCA GAGGAAATGG 900

GTGTCTTCAG CACAAAGCTG CTGCTTTTAC TTCAGCCACT TCTGACATTT TTACATACCG 960

AGCCTGAGAT TRTGTGATTA TCTCAAATCA AATCACTTTG ATGGAGATAA ATAATCAAAA 1020

CTGTTTTATA GTCATTGATT TGGTGAGAAC AGTAATGGAA AATGGTGTTG AAGGACTTCT 1080

CATTTTTGGA GCTTTCCTTC CAGAGTCCTG GCTGATTGGT GTTCGCTGTT CATCTGAGCC 1140

CCCAAAAGCA TTATTACTGA TACTTGCACA CAGTCAAAAG CGCAGACTGG ATGGATGGTC 1200

TTTTATAAGG CATTTAAGGG TACACTACTG TGTTTCACTG ACCATACATT TTTCTTAGCC 1260

CCTCAAGTAA TATAGCACAG AGTTATGAAT GACAATTCCC CTAACCATTC CTCTTCATAT 1320

CTGCCTCTTC CCCTTACCAT CGTAATTCTC CAAACTGGTC ATAAAGGCAC TCTGTGAAGA 1380

TATTGGGGAC TGACATCTTA AGCTCTCACC TGGCTGCAGT AGGAAAGGCC AAACTGACGA 1440

CAAAAAAAAA ATTCTTTATA AAGATGATAT GGTAACATGT ATCTTTGCCC TGGGTCTGGG 1500

TGGGTCCAGT CAGTCTCAGA TTTACAAGCA TTTAGGAGCC TAGGTAAAAG CTGCTAGTAT 1560

TCTTTTAAAA GTTACATTTA TGACTTGCAA TGATAGAAAA CTCCTTCCAA TTAAATGGCA 1620

TTTTATAATA TTATGTGTGT ACTTCACAGT GTTAAAAATA CCCTCATACG TTATTGCATT 1680

TGATCTTCAC AGAAAGTGCA TTTTAACCAG TACTCTGGGT GCAATAAATA ATATGTAGAA 1740

ATTTAAGTCC TCCAATTCCA GCATATCCAG TGAGTTTTGA CAGTGTGTTT ATGTGGAATG 1800

TTTAAGGATA TACAATTGTA CTTTATATAA ATTGGTTCTT GTTCTTCTTA AATGTGACAT 1860

GAAATAATTG TGCTGCTACA TTATACTGGA AATTAACAGG GGAAAAGGGA AGAGCTCTTG 1920

GCTCCCTTGA GGTTCTGCTA GTGGTGTTAG GAGTGGTTAC AACTGAGCTT TTAGTAACCA 1980

TTTAACCGTA TGTAAACTTG GTTTCTAATT AAAAAAAAAT TTCTTTTTCC A 2031

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 971 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

CGCGTCGGAA CTCGGCCGCG GGACATCCAC GGGGCGCGAG TGACACGTGG GAGGGAGAGC 60

AGTGTTCTGC TGGAGCCGAT GCCAAAAACC ATGCATTTCT TATTCAGATT CATTGTTTTC 120

TTTTATCTGT GGGGCCTTTT TACTGCTCAG AGACAAAAGA AAGAGGAGAG CACCGAAGAA 180

GTGAAAATAG AAGTTTTGCA TCGTCCAGAA AACTGCTCTA AGACAAGCAA GAAGGGAGAC 240

CTACTAAATG CCCATTATGA CGGCTACCTG GCTAAAGACG GCTCGAAATT CTACTGCAGC 300

CGGACACAAA ATGAAGGCCA CCCCAAATGG TTTGTTCTTG GTGTTGGGCA AGTCATAAAA 360

GGCCTAGACA TTGCTATGAC AGATATGTCC CCTGGAGAAA AGCGAAAAGT AGTTATACCT 420

[illegible]

CAAAGGGAAT TTGAAAAAGA TGAGAAGCCA CGTGACAAGT CATATCAGGA TGCAGTTTTA 660

GAAGATATTT TTAAGAAGAA TGACCATGAT GGTGATGGCT TCATTTCTCC CAAGGAATAC 720

AATGTATACC AACACGATGA ACTATAGCAT ATTTGTATTT CTACTTTTTT TTTTTAGCTA 780

TTTACTGTAC TTTATGTATA AAACAAAGTC ACTTTTCTCC AAGTTGTATT TGCTATTTTT 840

CCCCTATGAG AAGATATTTT GATCTCCCCA ATACATTGAT TTTGGTATAA TAAATGTGAG 900

GCTGTTTTGC AAACTTAAAA AAAAAWAAAA AAAACTSGAG GGGGGCCCGT ACCCAANTCG 960

CCGNATATGA T 971

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1792 base pairs
(B) TYPE nucleic acid
(C) STRANDEDNESS. double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

GAACCCCCTT TCTCCTGGTA AAGGGTAAGG GGGGGGATAA TGTTTACCAC AGGTACGAAA 60

TAGTCACTTT AACATTGAGA CCTCTGCCTC ATTGAATTCA GGTTTTTTAA GTACTTGAAA 120

CTCTTCAGAT TCTCCTTATT TTAGTTTCTT TTTACATTTA TGAAGTAGAA AGCATTGTTT 180

TGTAAACTGT TTTGAAAATA AATAGCCTAG TCTCTTATCC TCTTTAGCGT GGATTAAAGG 240

TGAAGTTCTG CAAATGGGAG AGTGTTCACA GTAGATAGCT CAGATTGATT GAACACATTT 300

GAGGAAGAGA CTCCTGCATG AGATACCAGC ATTTTTACAA ATACTTTTTA TGTACATTCT 360

TTATTTTGTC ATTTTGTCAA CCCTCTCCCC AAGCACATCT TCTTTCCTTT TACTATGTCT 420

ATGTAGGGAA AAACAAAACA AAAAATTGCA CTTACGTTAC ACTCCCAAAA TGTGGGTAAT 480

CCGTGTCTTT CAAAAAACAT TTCTGTTTTT TGTTTTGTTT TGGTCAGTCC ATTGCATAAG 540

TGACAAGTTT GGGTGCTTGT GGCACGTATG TATGAAGCGG GAGGGGGATG ASAATTGCCT 600

GTCCTTCAGT ARGCTGTAAA AGTAATTTAC ATGTAAGTAA AAAGGGAAAA TAGAATAGAT 660

GCCAAAGTCA TTTATTCAGT CCTTAGTTTT CTTATGTGGC ATTACTGCAT CTGCTAGTTA 720

GTGAGAAAGC ACCCTCAGCT TTTACTGCTC CCCTCCCTGC CTGCCAACAC ACTTGATGTG 780

TGCAAACAGC CCTCAAGTAT CTGTCAGATG ACCTATATAA GGTATTGAAT AAGGTATTCT 840

TGTCAGTTTA GAAATGGACT GGATAAAACT TACTTGGTTG TCATTATTTT ATCTCATTTG 900

TCCTGTTACA TGCCCTATGT TAAGATAATT ATATTGCCAC TAATAATCAA GATGCTAAAT 960

```
GAGTATTACA ACTGGCTAAT ATCATTTTTT ATATACAAGG GTATGTGTAT ATTTGGAATT      1020
GRTATGAGAA ACTCATTTGT ACCCATTTGA GTGATATTGC ACAACAAACA CAGATAYCTA      1080
CAGACTCCGT TTTCATTTTC TCGTGTTCTT TATGATAATG ATCTTTGTAG ATTGGTTATT      1140
TCTGTACTTT ATCTGTAATA AACTTTGTAG ATCCTGTGAA CCATTACTTT GCCTAAATCA      1200
CTTGAGACTT GAGTCTTTAA TAACAAAGCA TCAATATTCA CTAAAGTCAA TCTCTTTTGA      1260
GTTTCTGTGA CTTGGCTAGA AGCTCTTGAC ACTAAGGGAT TAGTGTTAAT TTTCCCTGGG      1320
GGTGTTCCAC TAGGGCATTA CTGTATAATG ACTTGATGTT GCCACATAGA CTTCAAGATA      1380
TATAATATTT TGAGGATTTT GTTGATTGGC CTATGTTTTA TTGCATAGTG TGAAACGTGT      1440
AAAGCTTGGT TAACCTGTAT ATAGATAGCT TATTGTTGAC TAGTTATAGT GTATTTAGGG      1500
TTGCCTGTAA TATTTAAGCT TCTTTACTGA TGTGTGTGCT GGTAGGAACA TATAATTTTT      1560
GTACATTATA TTTACTGAGA TGTTGCCTTT TTTATTTTAC AAATACTTTG GAATTCCAAT      1620
GTGTTTTTTG CTTCCGTGAG GATTAATTTG GAAAGGTTTT TAATGACATT CCACTGATTT      1680
CAGATTTTGC TTGAGATTGA CTTCAATAAA TTGTCCTGTA TGTTCCAAAA AAAAATTAAA      1740
AAACTCGAGG GGGGGCCCGGT ACCCAANNCG CCGGATATGA TCGTAAACAA TC             1792
```

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 896 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

```
AGTTGNANAC AACAGGACCT GAGTCCTTGG GCAGCACCAG TAGGTTGCCC CYTGCYTCYT        60
GCCAGCYTCA CYTGCCACYT TYTGCCCCTY TCGGGATGCC TTCGCAGACA GAGYTYTTCG       120
CTGCCTGTGG TGGCCAYTCT TTGCTTTTGG TTYTCTTGCC CCTTGGCCTC CCTTTTTGTC       180
CCCGGGCAGC CTTGTGTGAC CTGCCCTTTT CCCTCCCTTC CTTTCCAGGA CAAGCACGCC       240
GAGGAGGTGC GGAAAAACAA GGAGCTGAAG GAAGAGGCCT CCAGGTAAAG CCTAGAGGCC       300
AAAGAACTTT CCAGGTCAGC CGGACAGCTC CAGCAGCTCC ACGTTCCAGG CAGCCTCGMC       360
[illegible]                                                            420

[illegible]                                                            600
```

ACATTGAGCC TCCCAGGCAC CATGTTGAGG AGAGATGAAA ACCAGGGCGG TAGAACTTCA 660

GGGTGAAGGA CAGAGTCCTG GGTGGGGCAG CGGCTGCAGG GCGCACCAGA GAACCCAGCC 720

AGAGGGGGTG TGAGTACCAG TGGTGTTGCT TCCACCCTGC AGCAGGTGGG ATGAGGTCTG 780

TGTGTGTGTG TGAACCATCA TTTTTTGATC ATCATGACCA ATGAAACATT GAAAAAAAAA 840

AAAAAAACTG GAGGGGGCCC CGTACCCAAN TCGCCGNATA GTGATCGTAA ACAATC 896

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 912 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

TCGACCCACG CGTCCGGTCA GCCAGTCGCA TCCAGCCATG ACAGCCTTCT GCTCCCTGCT 60

CCTGCAAGCG CAGAGCCTCC TACCCAGGAC CATGGCAGCC CCCCAGGACA GCCTCAGACC 120

AGGGGAGGAA GACGAAGGGA TGCAGCTGCT ACAGACAAAG GACTCCATGG CCAAGGGAGC 180

TAGGCCCGGG GCCAKCCGCG GCAGGGCTCG CTGGGGTCTG GCCTACACGC TGCTGCACAA 240

CCCAACCCTG CAGGTCTTCC GCAAGACGGC CCTGTTGGGT GCCAATGGTG CCCAGCCCTG 300

ARGGCAGGGA AKGTCAACCC ACCTGCCCAT CTGTGCTGAG GCATGTTCCT GCCTACCATC 360

CTCCTCCCTC CCCGGCTCTC CTCCCAGCAT CACACCAGCC ATGCAGCCAG CAGGTCCTCC 420

GGATCACYGT GGTTKGGTGG AGGTCTGTCT GCACTGGGAG CCTCARGARG GCTCTGCTCC 480

ACCCACTTGG CTATGGGAGA GCCAGCAGGG GTTCTGGAGA AAAAAACTGG TGGGTTAGGG 540

CCTTGGTCCA GGAGCCAGTT GAGCCAGGGC AGCCACATCC AGGCGTCTCC CTACCCTGGC 600

TCTGCCATCA GCCTTGAAGG GCCTCGATGA AGCCTTCTCT GGAACCACTC CAGCCCAGCT 660

CCACCTCAGC CTTGGCCTTC ACGCTGTGGA AGCAGCCAAG GCACTTCCTC ACCCCYTCAG 720

CGCCACGGAC CTYTYTGGGG AGTGGCCGGA AAGCTCCCSG GCCTYTGGCC TGCAGGGCAG 780

CCCAAGTCAT GACTCAGACC AGGTCCCACA CTGAGCTGCC CACACTCGAG AGCCAGATAT 840

TTTTGTAGTT TTTATKCCTT TGGCTATTAT GAAAGAGGTT AGTGTGTTCC CTGCAATAAA 900

CTTGTTCCTG AG 912

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1382 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

```
AATTCGGCAC GAGCGGAGGC GAGGGAAACT RAGGGCGAAA GTTGTGTGTC GTGTTGGCAG     60
GAGGGCCTAG AAGGGAAAGA CTGTCTAGTG GGACAATGTC ATATTATAAA TTTGGAATGC    120
TGAATAGAAA ATTATAGATT TTGATATTGA AGGAAATGAA GCGAAGCYTA AATGAAAATT    180
CAGCTCGAAG TACAGCAGGC TGTTTGCCTG TTCCGTTGTT CAATCAGAAA AAGAGGAACA    240
GACAGCCATT AACTTCTAAT CCACTTAAAG ATGATTCAGG TATCAGTACC CCTTCTGACA    300
ATTATGATTT TCCTTCTCTA CCTACAGATT GGGCCTGGGA AGCTGTCAAT CCACACTTKG    360
CTCCTGTAAT GAAAACAGTG GACACCGGGC AAATACCACA TTCAGTTTCT CGTCCTCTGA    420
GAAGTCAAGA TTCTGTCTTT AACTCTATTC AATCAAATAC TGGAAGAAGC CAGGGTGGTT    480
GGAGCTACAG AGATGGTAAC AAAAATACCA GCTTGAAAAC TTGGRATAAA AATGATTTTA    540
AGCCTCAATG TAAACGAACA AACTTAGTGG CAAATGATGG AAAAAATTCT TGTCCAATGA    600
GTTCGGGAGC TCAACAACAA AAACAATTAA GAACACCTGA ACCTCCTAAC TTATCTCGCA    660
ACAAAGAAAC CGAGCTACTC AGACAAACAC ATTCATCAAA AATATCTGGC TGCACAATGA    720
GAGGGCTAGA CAAAAACAGT GCACTACAGA CACTTAAGCC CAATTTTCAA CAAAATCAAT    780
ATAAGANACA AATGTTGGAT GATATTCCAG AAGACAACAC CCTGAAGGAA ACCTCATTGT    840
ATCAGTTACA GTTTAAGGAA AAAGCTAGTT CTTTAAGAAT TATTTCTGCA GTTATTGAAA    900
GCATGAAGTA TTGGCGTGAA CATGCACAGA AAACTGTACT TCTTTTTGAA GTATTAGCTG    960
TTCTTGATTC AGCTGTTACA CCTGGCCCAT ATTATTCGAA GACTTTTCTT ATGAGGGATG   1020
GGAAAAATAC TCTGTCTTGT GTCTTTTATG AAATCGATCG TGAACTTCCG AGACTGATTA   1080
GAGGCCGAGT TCATAGATGT GTTGGCAACT ATGACCAGAA AAAGAACATT TTCCAATGTG   1140
TTTCTGTCAG ACCGGCGTCT GTTTCTGAGC AAAAAACTTT CCAGGCATTT GTCAAAATTG   1200
CAGATGTTGA GATGCAGTAT TATATTAATG TGATGAATGA AACTTAAGTA GTGATAAAAG   1260
GAAGTTTAGC ATAAATTATA GCAGTTTTCT GTTATTGCTT AATTTACCAT CTCCATAGTT   1320
[illegible]                                                         1380
```

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 872 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

```
GGGCTACTTC AAAGCCCTGG GCCTTATTTC TTCAGGTAAA AAAATATAAA GTCAGATCTC      60
ATCCCGGCTG GCCATGCTGT TAGACCCTTT CATCCTTCTC TTCTGCCTCT TCTCAACAGC     120
TGCCCAGTCC TCTTTGGAAT TCATATACAT ACAGTTCTAA TACTGATGTA TTTACCCTCA     180
TAAGCCACTC AACCCAGAAT CTTATTTGAA TTATAATCCA GAAACATCAG GTGACGTGTG     240
AGACTACTGT ATGAGAAAGA GACAGTTTAA GGGTCAGTCC AATGGAAAAA AGAGTTCTCA     300
GAGCTTTCTT TAGCTTATTC TCATCAAAGA GCTTTCTCTG CAGAAGGAAC CTACTGGTTC     360
CTCCTTTCCA GTCCTAGAAA TCCTGACCTA GAGTGGCTTA ATCCTGCTAG CACCTCTCTC     420
TCCCACTCTG GTGCCAAATG ACTCCAGGAA CTGGGCCATG ATGTGGTGGG AATGACCTTA     480
CCCTGAGCAT GTCACTCATG CATTGAACAA CAGCTAAGAG CAGAGCTTAG AGCTTAGAGC     540
TGGGCCCTGT AAGGTGAGAG GAATCACATC CTGCAGAAGT CTGTCCTGAG AAGCAGGTAC     600
TCCTGTCACA GCAGAGACAC AGTGGATACC TGAGTAACAA TAATACAAGA CAGGACGTGG     660
CMACAGCAAA AGATTTGGGT GTCAGAAGAR GCCGAGAACA CTTYCAGGCA GGAACATTCA     720
RARTTCTTCT TGGAGGAART AGGCMCSAAG GCTGGGCAGG ATTTCMCGGG GCAGAGATGG     780
AGCAAGCAAT TGAAATGAAA GCCATGGCAT GGGAAAAGGA GCACTGGCCA CAGGGAGTGC     840
AACGTTGTGA TGCAAGGCCA CTGTGGAGCC AT                                   872
```

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 812 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

```
GGCAGAGGCT CACCCCAGCA GAGATTGAGG GGGAACCGTG ATGAAATTTT TAAGTATTCT      60
GCTTGATGAT AATAATTTTY CTCTTATGTT AATGTTGGCT CCGTTTGGGT GTTTAGCTTT     120
TGAAAGGAGT ATGAAAATGC GGAATGGGGC TTTGGGGCTT GAGGAGGTGT GATCTCTAGT     180
GTTTAAAAAA TTTAATTGCA CAAATAGAAA TAATTCACCC ACATTATTGA ACCCCACTAA     240
```

```
AGCATATCCT TTTTGTCCAT ATTCCTTTCC TGCTGCCCTC GTGTGTACCA TTATTACTCA     300
GTTGTGATTT GAGCTCGTTC CACTTAAAGT CATTCATAGA TACTTTTGCG TCGTGTTKGA     360
ATATTTATTG AATTTCTATT CTGTGTTTTA CTTAATTACT TTATTATGGA ACCTTTACAC     420
AGGTCTGGTG TACTTGTTCT TTGAAAAGTC TTATGTTGAC CACCATCACT GAGCATATAG     480
CTTTTTCCTT ATTTCCTTGG GATAATTACC CGAAGTGGAA ATACCGAATC AAACTTCTGT     540
TTTCTTTCTT TGGCACTATT ATATAAATTG TTTTCCAAAC AAGGCATGTT TACAATAGAC     600
ATTTTTCAAA ATCTGGGTAT TTCTCCTATT TTGCTCTCTG TATGCAGAAT TCAGCGGGGT     660
GCCAAGTCGT TTTCTGTGTG GGTTGAGAGA CAGGCTGTGC AGCCCACTGT TGCATAGGAC     720
TAACTACTAC AAATCATGCT GAGACCGAGC TATTTTTGCT GCTTAGARGC TTTGCAGCCT     780
TGAGTAAGTT TCGNCATCTG GAAACNTTGN AA                                   812
```

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1515 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

```
AATTCGGCAC GAGGGAAATT CAAGCACTTT TCCTAAAAGA AGGGGGAATG GATGCTGAAA      60
CAACACGTNT CCCACAAAGG GAGCAGACAC TGGGCTTGTG AAGCTGCCCC ATACCTTCCC     120
CACAGAACTG GGGTCCGGCC TCCCTGACAT GCAGATTTCC ACCCAGAAGA CAGAGAAGGA     180
GCCAGTGGTC ATGGAATGGG CTGGGGTCAA AGACTGGGTG CCTGGGAGCT GAGGCAGCCA     240
CCGTTTCAGC CTGGCCAGCC CTCTGGACCC CGAGGTTGGA CCCTACTGTG ACACACCTAC     300
CATGCGGACA CTCTTCAACC TCCTCTGGCT TGCCCTGGCC TGCAGCCCTG TTCACACTAC     360
CCTGTCAAAG TCAGATGCCA AAAAAGCCGC CTCAAAGACG CTGCTGGAGA AGAGTCAGTT     420
TTCAGATAAG CCGGTGCAAG ACCGGGGTTT GGTGGTGACG GACCTCAAAG CTGAGAGTGT     480
GGTTCTTGAG CATCGCAGCT ACTGCTCGGC AAAGGCCCGG GACAGACACT TTGCTGGGGA     540
TGTACTGGGC TATGTCACTC CATGGAACAG CCATGGCTAC GATGTCACCA AGGTCTTTGG     600

[illegible]
```

CCGGAACGTC TTAGACAGTG AGGATGAGAT AGAGGAGCTG AGCAAGACTG TGGTCCAGGT 840

GGCAAAGAAC CAGCATTTCG ATGGCTTCGT GGTGGAGGTC TGGAACCAGC TGCTAAGCCA 900

GAAGCGCGTG ACCGACCAGC TGGGCATGTT CACGCACAAG GAGTTTGAGC AGCTGGCCCC 960

CGTGCTGGAT GGTTTCAGCC TCATGACCTA CGACTACTCT ACAGCGCATC AGCCTGGCCC 1020

TAATGCACCC CTGTCCTGGG TTCGAGCCTG CGTCCAGGTC CTGGACCCGA AGTCCAAGTG 1080

GCGAAGCAAA ATCCTCCTGG GGCTCAACTT CTATGGTATG GACTACGCGA CCTCCAAGGA 1140

TGCCCGTGAG CCTGTTGTCG GGGCCAGGTA CATCCAGACA CTGAAGGACC ACAGGCCCCG 1200

GATGGTGTGG GACAGCCAGG YCTCAGAGCA CTTCTTCGAG TACAAGAAGA GCCGCAGTGG 1260

GAGGCACGTC GTCTTCTACC CAACCCTGAA GTCCCTGCAG GTGCGGCTGG AGCTGGCCCG 1320

GGAGCTGGGC GTTGGGGTCT CTATCTGGGA GCTGGGCCAG GGCCTGGACT ACTTCTACGA 1380

CCTGCTCTAG GTGGGCATTG CGGCCTCCGC GGTGGACGTG TTCTTTTCTA AGCCATGGAG 1440

TGAGTGAGCA GGTGTGAAAT ACAGGCCTTC ACTCCGTTAA AAAAAAAAAA AAAAAAAAAA 1500

AAAAAAAAAA AAAAA 1515

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 704 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

AAGATGGTGG CGCCCAGAGC TTCGCTCTAT GCTGCTCCCC TGAGAGAGGC GTTTCCATCA 60

ACCAGTTTTG CAAGGAGTTC AATGAGAGGA CAAAGGACAT CAAGGAAGGC ATTCCTCTGC 120

CTACCAAGAT TTTAGTGAAG CCTGACAGGA CATTTGAAAT TAAGATTGGA CAGCCCACTG 180

TTTCCTACTT CCTGAAGGCA GCAGCTGGGA TTGAAAAGGG GGCCCGGCAA ACAGGGAAAG 240

AGGTGGCAGG CCTGGTGACC TTGAAGCATG TGTATGAGAT TGCCCGCATC AAAGCTCAGG 300

ATGAGGCATT TGCCCTGCAG GATGTACCCC TGTCGTCTGT TGTCCGCTCC ATCATCGGGT 360

CTGCCCGTTC TCTGGGCATT CGCGTGGTGA AGGACCTCAG TTCAGAAGAG CTTGCAGCTT 420

TCCAGAAGGA ACGAGCCATC TTCCTGGCTG CTCAGAAGGA GGCAGATTTG GCTGCCCAAG 480

AAGAAGCTGC CAAGAAGTGA CCCTTGCCCC ACCAACTCCC AGATTTCAAA GGAGGTAGTT 540

GCAAAAGCTG TGCCCAAGGG GAGGAAGGAG GTCACACCAA TATGATGATG GTTTTCATGA 600

CTTTGAATGA TATATTTTTG TACATCTAGC TGTATCGAGG CATCAGGCCT GAATAAACAT 660

CCTTTCTTAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAA 704

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1094 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

GGCAGCTTTC TTACAAACCC ATCCTTCTGA AATGTTGCTT CAAATTCATC CTCTGCTCCC 60

CAGTCCCACT ATTCCACACA TACTGTTACT GTTTCTTTAT CCTACTTTCT CAATTTTGGA 120

ACATAGTTGC AGTTACTGCA TTGAATACCT GTGGGTTTGC CTGTTGTTCT GTCTGTCTCT 180

GTGGTTCTTG TAATANTGGA TCCCAGAGAT AAAATGGACA GTTGTNATGC ACAGTTAATT 240

CAGAAACTAG ACCTTACTTG CTGTGTGAAA TACCAACTAA ATTCTCAGTG AACTCAGCTG 300

ANCTTTATCT CCTTTTGTTT CCCCAATTTA TAATTTCAGT TCAGGCCCAG AAAGATGGAA 360

TCCCAGCTAA GAAATACAAG TTACACCCTG TACTAGCAGC CCATGTGTGC ATGTTCTTTA 420

AGTGCTCTTG CAGCTATGTC ATTTATATTG ATTTCCCTGT ATTATTATAA GCAAAGCAAA 480

TTTGAGGAAA AAAACCCATA ATACCACACC TCATTTTTTT CAAGTAATAG GGTCATAAGT 540

CTCATYCTYC ATATAATATG TTGAGTATGC AGTATATTAT GTGTTAGGCT CTGGANAGGC 600

AGAGGTTAGA TCATGTWACA GATQATATCK GATTAGGCAG ATAAACAGTA TTTTAACCTT 660

TTCCTTATTA TATGTAACTT GCTTTCAGGT TTTTTAATGT TACTATTATG TCTTTAATAT 720

ATTATCTTTA TTTGTACTTT TGTATACAGA GTGATTTTCC TTTTTTAAAA AAAATTGTGT 780

CTTTAGGATG GATTCCAAAG ATGTGGAATC AGTAGGTTTA AGGAATATGG ATATTTTGGC 840

TGGCAAGGTG CCTCACACCT GTAATCCCAG CACTTTGGGA GGCTGAGGTG GGTGGATCAC 900

CTGAAGTCAG GAGTTCGAGA CCAGCCTGAC CAACATGGCG AAACCCTGTT TNTACTAAAG 960

ACACACWWAA AATTRGCCAG TGGTGGTGGC ATGTGCTTGT AGTCCCACTT AGCTACTCGA 1020

GAGGCTGAGG CAGGAGAATC GCTTGAACCC GGGAGGCAGA GGTTGCAGTG AGGCAAGATG 1080

GCACCTCTAC ACTC 1094

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1321 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

```
TGGCTTAGGC CATCACCCTT CCCTTGGCTG GAACTACTGG ACAGACCCTT TTGAGATGTG   60
CCTGTGGTGC TGTGGAGATG TGTGTAGTGG TCTTAGCTCT TTGTTGAGCT TGTGTGTGTG  120
TTGTGTAGTC TTAGCTGTAT GCTGAAATTG GGCGTGTGTT GGAGGGCTTC TTAGCTCTTT  180
GGTGAGATTG TATTTCTATG TGTTTGTATC ASCTGAATGT TGCTGGAAAT AAAACCTTGG  240
TTTGTMAAGG CTCTTTTTTG TGGGAAGTAA GTAGGGGAAA AGGTCTTTGA GGGTTCCTAG  300
GCTCCTTTGT ACAACAGGAA AATGCCTCAA AGCCTTGCTT CCCAGCAACC TGGGGCTGGT  360
TCCCAGTGCC TGGTCCTGCC CCTTCCTGGT TCTTATCTCA AGGCAGAGCT TCTGAATTTC  420
AGGCCTTCAT TCCAGAGCCC TCTTGTGGCC AGGCCTTCCT TTGCTGGAGG AAGGTACACA  480
GGGTGAAGCT GATGCTGTAC TTGGGGATC TCCTTGGCCT GTTCCACCAA GTGAGAGAAG  540
GTACTTACTC TTGTACCTCC TGTTCAGCCA GGTGCATTAA CAGACCTCCC TACAGCTGTA  600
GGAACTACTG TCCCAGAGCT GAGGCAAGGG GATTTCTCAG GTCATTTGGA GAACAAGTGC  660
TTTAGTACTA GTTTAAAGTA GTAACTGCTA CTGTATTTAG TGGGGTGGAA TTCAGAAGAA  720
ATTTGAAGAC CAGATCATGG GTGGTCTGCA TGTGAATGAA CAGGAATGAG CCGGACAGCC  780
TGGCTGTCAT TGCTTTCTTC CTCCCCATTT GGACCCTTCT CTGCCCTTAC ATTTTTGTTT  840
CTCCATCTAC CACCATCCAC CAGTCTATTT ATTAACTTAG CAAGAGGACA AGTAAAGGGC  900
CCTCTTGGCT TGATTTTGCT TCTTTCTTTC TGTGGAGGAT ATACTAAGTG CGACTTTGCC  960
CTATCCTATT TGGAAATCCC TAACAGAATT GAGTTTTCTA TTAAGGATCC AAAAAGAAAA 1020
ACAAAATGCT AATGAAGCCA TCAGTCAAGG GTCACATGCC AATAAACAAT AAATTTTCCA 1080
GAAGAAATGA AATCCAACTA GACAAATAAA GTAGAGCTTA TGAAATGGTT CAGTAAGGAT 1140
GAGTTTGTTG TTTTTTGTTT TGTTTTGTTT TGKTTTTTTA AAGACGGAGT CTCGCTCTGT 1200
CACTCAGGCT GGAGTGCAGT GGTATGATCT TGGCTCACTG TAACCTCCGC CTCCCGGGTT 1260
CAAGCCATTC TCCTGCCTCA GTCTCCTGAG TAGCTGGGAT TACAGGTGCG TGCCACCATG 1320
CCTGGCTAAT TTTTGTGTTT TTAGTAGAGA CAGGGTTTCA CCATGTTGGT CGGGCTGGTC 1380
TCAAACTCCT GACCTCTTGA TCCGCCTGCC TTGGCCTCCC AAAGTGATGG GATTACAGAT 1440
GTGAGCCACC CGTGCCCTAG CCAAGGATGA GATTTTTAAA GTATGTTTCA GTTCTGTGTC 1500
ATGGTTGGAA GACAGAGTAG GAAGGATATG GAAAAGGTCA TGGGGAAGCA GAGGTGATTC 1560
ATGGCTCTGT GAATTTGAGG TGAATGGTTC CTTATTGTCT AGGCCACTTG TGAAGAATAT 1620
```

GAGTCAGTTA TTGCCAGCCT TGGAATTTAC TTCTCTAGCT TACAATGGAC CTTTTGAACT 1680

GGAAAACACC TTGTCTGCAT TCACTTTAAA ATGTCAAAAC TAATTTTTAT AATAAATGTT 1740

TATTTTCACA TTGAAAAAAA AAAAAAATTT AAAAACYCGG GGGGGGCCCS GWACCCTATT 1800

NGCCCCTAAG GGGGGGGGTT T 1821

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1024 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

GGGGCACAGT TGAAGAAGCG ACCGAGGGAC TGGGAGTCGT TAGTGAGGAT GACGCCGCAT 60

GGCAAGAACT GCACCGCAGG GCCGTCTACA CCTACCACGA GAAGAACAAG GACACAGCGG 120

CCTCGGGCTA TGGGACCCAG AACATTCGAC TGAGCCGGGA TCCCGTGAAG GACTTCGACT 180

GCTGTTGTCT CTCCCTGCAG CCTTGCCACG ATCCTGTTGT CACCCCAGAT GGCTACCTGT 240

ATGAGCGTGA GGCCATCCTG GAGTACATTC TGCACCAGAA GAAGGAGATT GCCCGGCAGA 300

TGAAGGCCTA CGAGAAGCAG CGGGGCACCC GGCGCGAGGA GCAGAAGGAG CTTCAGCGGG 360

CGGCCTCGCA GGACCATGTG CGGGGCTTCC TGGAGAAGGA GTCGGCTATC GTGAGCCGGC 420

CCCTCAACCC TTTCACAGCC AAGGCTCTCT CGGGCACCAG CCCAGATGAT GTCCAACCTG 480

GGCCCAGTGT GGGTCCTCCA AGTAAGGACA AGGACAAAGT GCTGCCCAGC TTCTGGATCC 540

CGTCGCTGAC GCCCGAAGCC AAGGCCACCA AGCTGGAGAA GCCGTCCCGC ACGGTGACCT 600

GCCCCATGTC AGGGAAGCCC CTGCGCATGT CGGACCTGAC GCCCGTGCAC TTCACACCGC 660

TAGACAGCTC CGTGGATCCC GTGGGGCTCA TCACTCGCAG CGAGCGCTAC GTGTGTGCCG 720

TGACCGGCGA CAGCCTCAGC AACGCCACCC CCTGCGCTGT GCTGCAGTCC TCTGAGGCTG 780

TGGTCACCCT CGAATGCGTG GAGAAGCTGA TTCGGAAGGA CATGGTGGAC CCTGTGACTG 840

GAGACAAACT CACAGACCGC GACATCATCG TGCTGCAGCG GGGCGGTACC GGTTCGCGGG 900

CTCCGGAGTG AAGCTGCAAG CGGAGAAATC ACGGCCGGTG ATGCAGGCCT GAGTGTGTGC 960

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 983 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

CGACACGGCT GCGAGAAGAC GACAGAAGGG CCCGACCGCG AGCCGTCCAG GTCTCAGTGC 60

TGTGCCCCCC CCAGAGCCTA GAGGATGTTT CATGGGATCC CAGCCACGCC GGGCATAGGA 120

GCCCCTGGGA ACAAGCCGGA GCTGTATGAG GAAGTGAAGT TGTACAAGAA CGCCCGGGAG 180

AGGGAGAAGT ACGACAACAT GGCAGAGCTG TTTGCGGTGG TGAAGACAAT GCAAGCCCTG 240

GAGAAGGCCT ACATCAAGGA CTGTGTCTCC CCCAGCGAGT ACACTGCAGC CTGCTCCCGG 300

CTCCTGGTCC AATACAAAGC TGCCTTCAGG CAGGTCCAGG GCTCAGAAAT CAGCTCTATT 360

GACGAATTCT GCCGCAAGTT CCGCCTGGAC TGCCCGCTGG CCATGGAGCG GATCAAGGAG 420

GACCGGCCCA TCACCATCAA GGACGACAAG GGCAACCTCA ACCGCTGCAT CGCAGACGTG 480

GTCTCGCTCT TCATCACGGT CATGGACAAG CTGCGCCTGG AGATCCGCGC CATGGATGAG 540

ATCCAGCCCG ACCTGCGAGA GCTGATGGAG ACCATGCACC GCATGAGCCA CCTCCCACCC 600

GACTTTGAGG GCCGCCAGAC GGTCAGCCAG TGGCTGCAGA CCCTGAGCGG CATGTCGGCG 660

TCAGATGAGC TGGACGACTC ACAGGTGCGT CAGATGCTGT TCGACCTGGA GTCAGCCTAC 720

AACGCCTTCA ACCGCTTCCT GCATGCCTGA GCCCGGGGCA CTAGCCCTTG CACAGAAGGG 780

CAGAGTCTGA GGCGATGGCT CCTGGTCCCC TGTCCGCCAC ACAGGCCGTG GTCATCCACA 840

CAACTCACTG TCTGCAGCTG CCTGTCTGGT GTCTGTCTTT GGTGTCAGAA CTTTTGGGCC 900

GGGCCCCTCC CCACAATAAA GATGCTCTCC GACCTTCAAA AAAAAAAAAA AAAAAAAAGR 960

KGSGGCCGGT CCCCANTCCC CCC 983

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2421 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

CCGGCTGATC GCTGCCGCTC CGCCAATACA ATAGAGCCAK CCACTACCAG CAGCCTGGCC 60

```
CTCTTCCTCC TTCTCCAGAG AGACCAATCC AGCCGAACTC GGGGTTTGCC TGAGGAGAAG   120
GAGGAAGTGA CCATGGACAC AAGTGAAAAC AGACCTGAAA ATGATGTTCC AGAACCTCCC   180
ATGCCTATTG CAGACCAAGT CAGCAATGAT GACCGCCCGG AGGGCAGTGT TGAAGATGAG   240
GAGAAGAAAG AGAGCTCGCT GCCCAAATCA TTCAAGAGGA AGATCTCCGT TGTCTCAGCT   300
ACCAAGGGGG TGCCAGCTGG AAACAGTGAC ACAGAGGGGG GCCAGCCTGG TCGGAAACGA   360
CGCTGGGGAG CCAGCACAGC CACCACACAG AAGAAACCTT CCATCAGTAT CACCACTGAA   420
TCACTAAAGA GCCTCATCCC CGACATCAAA CCCCTGGCGG GCCAGGAGGC TGTTGTGGAT   480
CTTCATGCTG ATGACTCTCG CATCTCTGAG GATGAGACAG ACCGTAATGG CGATGATGGG   540
ACCCATGACA AGGGGCTGAA AATATGCCGG ACAGTCACTC AGGTAGTACC TGCAGAGGGC   600
CAGGAGAATG GCCAGAGGGA AGAAGAGGAA GAAGAGAACG AACCTGAAGC AGAACCTCCT   660
GTACCTCCCC AGCTGTCAGT AGAGGTGGCC TTGCCCCCAC CTGCAGAGCA TGAAGTAAAG   720
AAAGTGACTT TAGGAGATAC CTTAACTCGA CGTTCCATTA GCCAGCAGAA GTCCAGAGTT   780
TCCATTACCA TTGATGACCC AGTCCGAACT GCCCAGGTGC CCTCCCCACC CCGGGGCAAG   840
ATTAGCAACA TTGTCCATAT CTCCAATTTG GTCCGTCCTT TCACTTTAGG CCAGCTAAAG   900
GAGTTGTTGG GGCGCACAGG AACCTTGGTG GAAGAGGCCT TCTGGATTGA CAAGATCAAA   960
TCTCATTGCT TTGTAACGTA CTCAACAGTA GAGGAAGCTG TTGCCACCCG CACAGCTCTG  1020
CACGGGGTCA AATGGCCCCA GTCCAATCCC AAATTCCTTT GTGCTGACTA TGCCGAGCAA  1080
GATGAGCTGG ATTATCACCG AGGCCTCTTG GTGGACCGTC CCTCTGAAAC TAAGACAGAG  1140
GAGCAGGGAA TACCATGGCC CCTGCACCCC CCACCCCCAC CCCCGGTCCA CCCACCACAG  1200
CACCCCCGGG CAGAGCAGCG GGAGCAGGAA CGGGCAGTGC GGGAACAGTG GGCAGAACGG  1260
GAACGGGAAA TGGAGCGGCG GGAGCGGACT CGATCAGAGC GTGAATGGGA TCGGGACAAA  1320
GTTCGAGAAG GGCCCCGTTC CCGATCAAGG TCCCGTRACC GCCGCCGCAA GGAACCTGCG  1380
AAGTCTAAAG AAAAGAAGAG TGAGAAGAAA GAGAAAGCCC AGCAGGACCC ACCTGCCAAG  1440
CTCCTGGATG ACCTTTTCCG AAAGACCAAG GCAGCTCCCT GCATCTATTG GCTCCCACTG  1500
ACTGACAGCC AGATCGTTCA GAAAGAGGCA GAGCGGGCCG AACGGGCCAA GGAGCGGGAG  1560
AAGCGGCGAA AGGAGCAAGA AGAAGAAGAG CAAAAGGAGC GGGAGAAGGA AGCCGAGCGG  1620
GAACGGAACC GACAGCTGGA GCGAGAGAAA CGTCGGGAGC ACAGTCGGGA GAGGGACAGG  1680

[illegible]
```

AGGTACCAGC CACTCGGCCC CAGGGGGTTA TGGCCACAGA GGGATAGGCA CAGTTTCCAC 1920

CACCCTGGAG CCAAGGGTCT TTCACATCAC CTATCCCTAC ATACATACCA AATGGAAAAG 1980

TGGCCATCCT TTTCCCCCCA AACACACCCC CTTAACCTAT CTCTTGGGAC TTAGCCCGAC 2040

CCTCCCTCTC ATTTCCCATT AAGTCTGAGA GGCAAGAGCT AGGTTAGGCA AGGAGGTGGT 2100

TGGCCAGAGA TGGGGAACAG CCAGGTGCCC CAGTCCTCTG ATTTTTCCTC CATCCTGCTT 2160

ACCACCTCCC TGGGTACTTA CAGCCTTCTC TTGGGAACAG CCGGGGCCAG GACTGGGTCA 2220

CCTATGAGCT GAATCAGCAT CTCCTCCTGA GTCCCAGGGC CCCTGCAGTT CCCAGTCTCT 2280

TCTGTCCTGC AGCCCTTGCC TCTTTCCCAC AGGTTCCACT TTATATCCAC CTTTTCCTTT 2340

TGTTCAATTT TTATTTTTAT TTTTTTTATT ATTAAATGAT GTGGTCTATG GAAAAAAAAA 2400

TAAAAATCTG ACTTAGTTTT A 2421

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 840 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

CTCAAACTCC TGAGCTGAAG CGATCTACCT GCCTCAGCTA GGATTACAGG TGTGAGCCAC 60

CGCACCCAAC CTCAATAAGC KTATTTGATA AAAKATATGC AAGCTCCCTT TATKCACTTT 120

TCATTCAGAA TGTTTAGTAA TTTGTATTGT TTTTCAGATT TTCAGCCCAA TATATCTCCY 180

TGCCCACTGT GTCACTGTAT TCTACCTAWA CATCATCACG TGTTTCTGCT ATTGGCTGTA 240

TGATGGAACA CTGCGGCTCA TTTTCCTGAA AACTGCCGAT AGTGCATAGA RTGCTGGGAT 300

GGAAACCAGA ARCTTTGAAT TCAAGCCTTG GTTCTGCCTT GTTTTTGCTT GGGTGGCCTT 360

GAGTCAGCCA CATACCTTTT AAAATCTCAA TTTATTAGAA ATTATTCCAA ATCAAAATCA 420

AATGAGAAGG TATATACAAA AGTGCTTTAT CCCACAATAA ACTATTCAAG AGAGAGCAAA 480

GGAGAGGACA TTTACTCAAC ACCTCCTAAA AGGCAGCCAG TGAAATTAGG CATTTTATTT 540

AATCCTCCTG GCAACTCTGA GAGTAAAGCA TTATTAATCC CATTTTGGCT GTTTAAAGAA 600

ATTATTTGCA CTAGATTCCA GCTGTAGTTT AGYTTCAGAA AAAAAAATCC TGAGATGTGA 660

ATTCACAGCT TTCTGGGTTT AAAGCCCAAG CTCTATCACA TCATGCTATT ATTGTTACAT 720

TACTGCTAGT TCTATGAAAA GAAATACTAA TTTATGAAAT ACATCTTATC CAAAAAAAAA 780

AAAAAAAAAC TGGGAGGGGG GGCCCGTACC CAAATCGCCG GATAGTGATC GTAAACAATC 840

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2432 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

GGCACGAGGC CCGGAACGCT GAGGAAGGGC CCGTCCCGCC TTCCCCGGCG CGCCATGGAG 60

CCCCGGGCGG TTGCAGAAGC CGTGGAGACG GGTGAGGAGG ATGTGATTAT GGAAGCTCTG 120

CGGTCATACA ACTAGGAGCA CTCCCAGAGC TTCACGTTTG ATGATGCCCA ACAGGAGGAC 180

CGGAAGAGAC TGGCGGACTG CTGGTCTCCG TCCTGGAACA GGGCTTGCCA CCCTCCCACC 240

GTGTCATCTG GCTGCAGAGT GTCCGAATCC TGTCCCGGGA CCGCAACTGC CTGGACCCGT 300

TCACCAGCCG CCAGAGCCTG CAGGCAYTAG CCTGYTATGY TGACATCTCT GTCTCTGAGG 360

GGTCCGTCCC AGAGTCCGCA GACATGGATG TTGTACTGGA GTCCCTCAAG TGCCTGTGCA 420

ACCTCGTGCT CAGCAGCCCT GTGGCACAGA TGCTGGCAGC AGAGGCCCGC CTAGTGGTGA 480

AGCTCACAGA GCGTGTGGGG CTGTACCGTG AGAGGAGCTT CCCCCACGAT GTCCAGTTCT 540

TTGACTTGCG GCTCCTCTTC CTGCTAACGG CACTCCGCAC CCATGTGCCC CANAGCTGTT 600

TCAGGAGCTG AAAGGAGTGC GCCTGCTAAC TGACACACTG GAGCTGACGC TGGGGGTGAC 660

TCCTGAAGGG AACCCCCCAC CCACGCTCCT TCCTTCCCAA GAGACTGAGC GGGCCATGGA 720

GATCCTCAAA GTGCTCCTCA ACATCACCCT GGACTCCATC AAGGGGGAGG TGGACGAGGA 780

AGACGCTGCC CTTTACCGAC ACCTGGGGAC CCTTCTCCGG CACTGTGTGA TGATCGCTAC 840

TGCTGGAGAC CGCACAGAGG ACTTCCACGG CCACGCAGTA ACCCTCCTGG GGAACTTGCC 900

CCTCAAGTGT CTGGATGTTC TCCTCACCCT GGAGCCACAT GCAGACTCCA CGGACTTCAT 960

GGGAGTGAAT ATGGATGTGA TTCGTGCCCT CCTCATCTTC CTAGAGAAGC GTTTGCACAA 1020

GACACACAGG CTGAAGGAGA GTGTAGCTCC CGTGCTGAGC CTGCTGACTG AATGTGCCCG 1080

GATGCACCGC CCAGCCAGGA AGTTCCTGAA GCCCCAGGTG CTGCCCCCTC TGCGGGATGT 1140

CAGGACACGG CCTGAGGTTG GGGAGATGCT GCGGAACAAG CTTGTCCGCC TCATGACACA 1200

[illegible]

ATGAGTACAA GGAAGCCAAA GCCAGCATAA ACCCTGTGAC CGGGAGGGTG GAGGAGAAGC 1440
CGCCTAACCC TATGGAGGGC ATGACAGAGG AGCAGAAGGA GCACGAGGCC ATGAAGCTGG 1500
TGACCATGTT TGACAAGCTC TCCAGGAACA GAGTCATCCA GCCAATGGGG ATGAGTCCCC 1560
GGGGTCATCT TACGTCCCTG CAGGATGCCA TGTGCGAGAC TATGGAGCAG CAGCTCTCCT 1620
CGGACCCTGA CTCGGACCCT GACTGAGGAT GGCAGCTCTT CTGCTCCCCC ATCAGGACTG 1680
GTGCTGCTTC CAGAGACTTC CTTGGGGTTG CAACCTGGGG AAGCCACATC CCACTGGATC 1740
CACACCCGCC CCCACTTCTC CATCTTAGAA ACCCCTTCTC TTGACTCCCG TTCTGTTCAT 1800
GATTTGCCTC TGGTCCAGTT TCTCATCTCT GGACTGCAAC GGTCTTCTTG TGCTAGAACT 1860
CAGGCTCAGC CTCGAATTCC ACAGACGAAG TACTTTCTTT TGTCTGCCCC AAGAGGAATG 1920
TGTTCAGAAG CTGCTGCCTG AGGGCAGGGC CTACCTGGGC ACACAGAAGA GCATATGGGA 1980
GGGCAGGGGT TTGGGTGTGG GTGCACACAA AGCAAGCACC ATCTGGGATT GGCACACTGG 2040
CAGAGCMANT GTKTTGGGGT ATGTGCTCCA CTTCCCAGGG AGAAAACCTG TCAGAACTTT 2100
CCATACGAGT ATATCAGAAC ACACCCTTCC AAGGTATGTA TGCTCTGTTG TTCCTGTCCT 2160
GTCTTCACTG AGCGCAGGGC TGGAGGCCTC TTAGACATTC TCCTTGGTCC TCGTTCAGCT 2220
GCCCACTGTA GTATCCACAG TGCCCGAGTT CTCGCTGGTT TTGGCAATTA AACCTCCTTC 2280
CTACTGGTTT AGACTACACT TACAACAAGG AAAATGCCCC TCGTGTGACC ATAGATTGAG 2340
ATTTATACCA CATACCACAC ATAGCCACAG AAACATCATC TTGAAATAAA GAAGAGTTTT 2400
GGACAAAAAA AAAAAAAAAA AAAAAAAAAA AA 2432

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1742 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

GTCCTGCAGG AGCTGCACGC GGCCGAGGTG CGCANGAACA AGGAGCAGCG AGAAGAGATG 60
TCGGCCTAAG GGCCCGGSAC GRGSGGCGCC CATCCTGCGA CGGAACACGT TCGGGTTTTG 120
GTTTTGTTTC GTTCACCTCT GTCTAGATGC AACTTTTGTT CCTCCTCCCC CACCCCAGCC 180
CCCAGCTTCA TGCTTCTCTT CCGCACTCAG CCGCCCTGCC CTGTCCTCGT GGTGAGTCGC 240
TGACCACGGC TTCCCCTGCA GGAGCCGCCG GGCGTGRAGA CGCGGTCCCT CGGTGCAGAC 300
ACCAGGCCGG GCGCGGCTGG GTCCCCCGGG GGCCCTGTGA GAGAGGTGGY GGTGACCGTG 360

```
GTAAACCCAG GGCGGTGGCG TGGGATCRCG GGTCCTTACG CTGGGCTGTC TGGTCAGCAC     420
GTGCAGGTCA GGGCAGGTCC TCTGAGCCGG CGCCCCTGGC CAGCAGGCGA GGCTACAGTA     480
CCTGCTGTCT TTCCAGGGGG AAGGGGCTCC CCATGAGGRA GGGGCGACGG GGGAGGGGGG     540
TGATGGTGCC TGGGAAGCCT GCKTGTGCAN CCGGTGCTTG TTGAACTGGC AGGCGGGTGG     600
GTGGGGGCTG CAGCTTTCCT TAATGTGGTT GCACAGGGGT CCTCTRAGAC CACCTGGCGT     660
GAGGTGGACA CCCTGGGCCT TCCTGGAAGC CTGCAGTTGG GGGCCTGCCC TGAGTCTGCT     720
GGGGAGTGGG CATTCTCTGC CAGGGACCCA TGAGCAGGCT GCATGGTCTA GAGGTTGTGG     780
GCAGCATGGA CAGTCCCCCA CTCAGAAGTG CAAGAGTTCC AAAGAGCCTC TGGCCCAGGC     840
CCCTCCGTGG GACAGCCCCG CCGCCCCTCC CCACCAGGGC TTTGCAGATG TCCTTGAAAG     900
ACCCACCCTA GAGCCCTTTG GAGTGCTGGC CCCTCCTGTG CCCTCTGCCC TGGTGGAAGC     960
GGCAGCACAA GTCCTCCTCA GGGAGCCCCA AGGGGGATTT TKTGGGACCG CTGCCCACAG    1020
ATCCAGGTGT TGGAAGGGCA GCGGGTAAGG TTCCCAAGCC AGCCCCAACA CCCTTCCCAC    1080
TTGGCACCCA GAGGGGGCTG TGGGTGGAGG CCTGACTCCA GGCCTCTCCT GCCCACACCC    1140
TCTGGGCTGA GTTCCTTCTT TCCCTTGGAC GCCCAGTGCT GGCCTTGGAG GACGGTCAGC    1200
TGGAGGATGG CGGTGGGGGA GGCTGTCTTT GTACCACTGC AGCATCCCCC ACTTCTCCAC    1260
GGAAGCCCCA TCCCAAAGCT GCTGCCTGGC CCCTTGCTGT AAAGTGTGAA GGGGGCGGCT    1320
GAGTTCTCTT AGGACCCAGA GCCAGGGCCC TCAACTTCCA TCCTGCGGGA GGCCTTGGCC    1380
GGGCACTGCC AGTGTCTTCC AGAGCCACAC CCAGGGACCA CGGGAGGATC CTGACCCCTG    1440
CAGGGCTCAG GGGTCAGCAG GGACCCACTG CCCCATCTCC CTCTCCCCAC CAAGACAGCC    1500
CCAGAAGGAG CAGCCAGCTG GGATGGGAAC CCAAGGCTGT CCACATCTGG CTTTTGTGGG    1560
ACTCAGAAAG GGAAGCAGAA CTGAGGGCTG GGATATTCCT CATGGTGGCA GCGCTCATAG    1620
CGAAAGCCTA CTGTAATATG CACCCATCTC ATCCACGTAG TAAACTGAAC TTAAAAATTC    1680
AATCAAATGA ACAATTAAAT AAACACCTGT GTGTTTAAGA AAAAAAAAAA AAAAAAACTG    1740
CG                                                                   1742
```

(2) INFORMATION FOR SEQ ID NO: 50:

TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

```
GGCACGAGCC TCCGTGAACT GTGGAGTCGG CGGAGGGCTG GAATCAGCGT GGGCTCCAGG      60
TCGCTGGCAG CCGGGTGGCA GAACTCTTCC GAGGCTCCTT GGGAAGAAGC TACACCCGAG     120
GGAGCCGGAT GGGCCTCGAA AACCTGGCCC GCTCTGGTTC TGTACCATTG CAAGGGGAAC     180
CGTAAACTGA GCTTTTCTAA CGTGGGTTTC TGCCAAGTAC TTTTCCAGCT GCCCCCTTCC     240
CCCCAGCACA CAGGAGAGCC TCTGTGTAGC CAGCGCTTGA CAGTCGTTAG GTAGGTTGTA     300
CTGTGTAGGG AGGAGCTCAA GATCATGAAT GGTTGTCACA GGAGAAAGCG GTTGCATCTT     360
TGCAAAACTA TATACCTGCT GTGGTTTGTG TTTTCTTTTC TGCTGAGTAA TGAAGTTGTA     420
AGTTCACACT GGCACATTCT CAGGGCTGTG CAGATTATTT GCACTTTATT TCATAGGTGR     480
ATAAGTGCTT TTTAGCTTTC TTTGTATATT GAGTTGCTTT TGAATTGCTT CCCATATTTT     540
TATTTCATAC AAACTGAACA ATTGTGGCCC CTCTATTTTA TTTATAAAGG TTCAGTGTAT     600
CTTTGCCTGC CTACATCAAT CTGCAAGGGA GTTGCAGAAA GCCTCATGTT CATCGAGCCG     660
TGAGTCACAA CCAATTTCTA AGCTGTTATA ACAAAAAAGT GTTTGCTTTT TTTCACAAGT     720
AACTTTAAAA GTGTAGTTTA GAAAGAAAAC ATTTTCAATA AAAAGACACT ACATTAATCC     780
TGGATGCTTG CAAATCCTAA AATMTATTCC TCCTCTAGCG TTGCACAGCT CTGTGTTGTA     840
TACACAGACT AGCTTTAAAA TTTGTCACAT ACCACTTTAC CTTTACTTTT ATGTATCATT     900
CCCCCGACTT CCTTACTGCA GGTGTGGGCA AGAAAACTTT TCCTTTAACA CTTTTCAACA     960
GCGGGCATAA AATTCTGCAG CTGAGGTCTT GAAGAATGCA GATGGGTACA GTATGTGTTG    1020
GAGCTCACAG TGTGTATTGA CTAACCTAGT TCCTTTTTTG CTTTTTTTGG TATTGTCTTG    1080
TTAAAAGTGA CTCCCAGGTA GCAACTCTCT TTTTTAAGGG TGGGAACGAA AGGGACGTAG    1140
GAAGAATAGA TCTAGATTAT TTAACAGTCT TCGATAGAGT TTGAAAGCTT TCTTCTTCAT    1200
TCAATTTTGG GCAAAATACT GCCTCTGCAT TTGTTCATAA CAAAAAGATT AGATTAATAA    1260
GTAGCTTTTG TTGGTGGAAA TTACCAGCTC TATAAGTCAC CCTTGGTGGT TCATGGACCT    1320
CTGATTAGCT TGGGTTTTGC AGTCTCATTG CCACATGTAT ATGTGGAGCC AATGGCCTTT    1380
TGGTGCTCAG CTGTTTACGT CTGACTCCTT GACTTCTTTG GTACAGTGAT GGAGTCAGAT    1440
CTCATTAAGT GTGATTCTCC ATGGATATAA CCAGCCCCAA AAAAANG                   1487
```

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1328 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

```
GGCACGAGCT CGTGCCGAAT TCGGCACGAG AGAAGATTTG AAGAAGCCAG ATCCAGCTTC     60
CCTGCGGGCT GCTTCTTGTG GGGAAGGGAA AAAGAGGAAG GCCTGTAAGA ACTGCACCTG    120
TGGCCTTGCC GAAGAACTGG AAAAAGAGAA GTCAAGGGAA CAGATGAGCT CCCAACCCAA    180
GTCAGCTTGT GGAAACTGCT ACCTGGGCGA TGCCTTCCGC TGTGCCAGCT GCCCCTACCT    240
TGGGATGCCA GCCTTCAAAC CTGGGGAAAA GGTGCTTCTG AGTGATAGCA ATCTTCATGA    300
TGCCTAGGAG GTTCCTGACA TGGGACCCAT CTGCTCCTCC AGCCAACTCC TGTCCCTCAC    360
ATCCCACCAT GGTGGCTCCT CCCACCTCCT CTGGATTTGT TCACTCTGAG ATCTGTTTGC    420
AGAGTGGGTG CTTAGCAGAC AGAGTGAAGC TGGCTGGGGG GCACAGTGGT GTGTAGTGCT    480
GCTGTGTATC AAAAGACCAA GGTATTATGG GACCTGGTTT CAGAATGGGA TGGGTTTCTT    540
CACCTCATGT TAAGAGAAGG GAGTGTGTCC TGAAGAAGCC CTTCTTCTGA TGTTAAAATG    600
CTGACCAGAA CGCTCTTGAG CCCAGGCATC GTTGAGCATT AACACTCTGT GACAGAGCTG    660
CAGACCCCTG CCTTGAGTCT CATCTCAGCA ATGCTGCCAC CCTCTTGTCT TTCAGAGTTG    720
TTAGTTTACT CCATTCTTTG TGACACGAGT CAAGTGGCTC ACAACCTCCT CAGGGCACCA    780
GAGGACTCAC TCACTGGTTG CTGTGATGAT ATCCAGTGTC CCTCTGCCCC CTTCCATCCC    840
CAACCACATT TGACTGTAGC ATTGCATCTG TGTCCTGTTG TCATTTATGT TAACCTTCAG    900
GTATTAAACT TGCTGCATAT CTTGACATAT CTTGAGATTC TGCATGTCTT GTAAAGAGAG    960
GGGATGTGCA TTTGTGTGTG ATGTTGGATA GTCATCCACG CTCAGTTTGG ACCATTGGAG   1020
GAACTTAGTG TCACGCACAA ATGGGGCTAT TCCTACGCTT AGAATAGGGC TTGTCTGCCC   1080
ACTTTAGAAG AGTCCCAGGT TGGTGAGCAT TTAGAGGGAA GCAGGGCAGA ACTCTGAACG   1140
ACAATACCTC TCTCTGAGCA GAGACCCCTT TGTTCTTGTT ATCCACCCAT ATGGACTTGG   1200
AATCAATCTT GCCAAATATT TGGAGAGATT GTGTGGATTT AAGAGACCTG GATTTTTATA   1260
TTTTACCAGT AAATAAAAGT TTTCATTGAT ATCTGTCCTT GAAAAAAAAA AAAAAAAAAA   1320
AAACTCGA                                                            1328
```

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

```
GAATTCGGCA CGAGCTTTGC AACATTGCAA ATGAACTTGC AGTCGAGGGT TCCGCTGCCC      60
CCTAGATTAA ATTTCCCGGG CTGAAACTGA CTTGCAGATT TAGAATATCA TATTTTAAAT     120
TGCTGTCTTC AATTAAACCA TTTATGACCA TAACTAATTT TCAGGATGTC GATGCATGCT     180
TTTCCAGGCC TTCCTTCTTT GTACAAAAGT AAATGTCCAT AAAGCCTTTC ACTTATATTC     240
TTCAAACATG ATGCTAATTT AAATTAATTA CTTCCTATGA TATGTTATTA TTCCTATGAT     300
TTTGCCACTG TTATTAGTTC TCTCAAAAAT ACATCTAGGG AAGAGGATTA TTTTAAGTRA     360
TTTGATTATC TTTCTATCTC TTTTATTTAT TTCTCATTTA CTTAAGAAAT TCGTTCCATT     420
GGTTGGCATT GATACAGTAA ATTTGTAAAT GAGGAGACAA TATAAAAAAT CTAAATTACT     480
TGTGCTTAAT GACTGTAGCA GAATSCCTTT TCTCTAAATC AGATTGTCTT TCTTGCAGTT     540
TAGTTTGATA GATTTGCAAG CTATGCTGCT TCCATGAAGT TAGTTGCGCT GGTAGGAACG     600
CAGGCTTCTT TGTCTCTGGT TGTAGCTTGC ATGATCGCCC CATTAGGCAG ACAACGTAGC     660
CGGAGATCAC AAATCAGGTC CTTGGTGTAG TTGCTAGTGT GTGGAGGTGC AGAGAGGTTG     720
GCAGAAACTG ACCTCACTGG GCAAGGGTGG CCATGGACCT GATTCTTTAA TGCACTCTAT     780
GTGTTCAGGA AGCCACAGGC CATATTTGAC TCTGACAAAG AAAACAAGAG GAAAAACCCC     840
ACAAAGTATA ACAACCCCTT AAGATACATC TATTTTAAAG TGAAATTAAT TTTTCAGTTT     900
ATACCATTGG CCAATTACAA GATAAAAATG TTCAATTTCT TTAAGAATCC TTTGTTGACT     960
TGTCTTTTCA TCTCTTGCTA TTTATATTTG TCACTGTTAG TGAACAAAGT CTTATTTGCT    1020
GAGGAAGGAC TTTGCTGCAC TTACTGTACC ACATCAAACA CTGGGGAGGG TGGTGTTTAA    1080
CTTTTTAAAA AATGTTATTC TGATTATAAC AATAATATTG GCTTTTTTCA TGAAAAGAGC    1140
GCCACCTTGC AAGGTTTAGT GAGATTTATG GAAGTTGAAT ACCTAAGCAG GAATTGCTGC    1200
TAGCTCCAAA AATTTGCGAA GCAAAAGCTA GCCCCAATTG GTTTGGAAGT TTGAAACTGA    1260
TTAACAGATT TGCATTTGAA GTGACTCCAG ACATTAGGTC CAGACATTAG TTAAAAATAG    1320
AAAGAGGAAT AAAGACATCT YTTCTCTCTA GAAAAGATAA CACCRCAATT AATAATCCTT    1380
CCCACTTTCA TTGAGATCAG CTTGTCTGAT AACCTGATAT GAGTGTGATA ATGATAAACA    1440
TGATAATAGT GGTACTTTTG TAATTTTGCT GGTGCATTTA AGAAGATAGT AAAHGATGAG    1500
TTCAYCTTTT CTYCGAACAT YCCTATYCCT AGATGTAGTT TACCTCAAAT TGGGAATTAT    1560
AACTGTCCTA ATTTTTGTTG TGTACCCTGA TGCCCCTTTT GCTTTAATAC CCACAGTGTA    1620
ACAATTAAAT ATCACACTAT GACATATGAT TTAAGTAGGA TATTTTAAAG ATAAATTTTA    1680
```

GGGGTAAATG TTTACTTCAA AATGACTCCA TATTTCAAAT ATCTGTTTAG ACTGTGAAGG 1740

GCAAATAATT TTTAAGAAAA CATTTGAAGA GTAGTGTGTT TGCATTTGTG AATAATCTTA 1800

CTCACAGCAA GTAAACGTAA TAAAAGCCAA CATTTAAGCC AAAAAAAAAA AAAAAA 1856

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1558 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

TGGGTATCCA TTCCTGNAAT TACTTTACTT AGGATAATGG CCTCCAGCTC CGTCCAAGTT 60

GCTGCAAAAG GTATTATTTC GTTCCTTTTT GTGGCTGAGT AGTATTCCAT GGTGTATATA 120

TACCACATTT TCTTTATCCA CTCATTGCTT GATGGGCAGT TAGGTTGGTT CCACATCTTT 180

GCAATTGTGA GTTGTGCTGC TCCAGATATC ATCTTTAACT CCTTTGCCTT CTCCACATAC 240

ATTTCCAAGT CCTGTTCATT CTACCTCCAA AATGTATCTT GTATCCATTC ATCTCTCTCC 300

ATCTTCAATC TATTTCAATG CCCCATCATC TCTTGCATGG AGGAGTGTAA TAATTGGCTA 360

ACTGGCCTGT TCTTACATTT TAAAATCAAA AGATGTGACA GGTGAAATGC CTATTTCAGT 420

GTCCATTGAT GGTTCTGCTT ACACACCACC TGGCTGCCTG GTGTCGCAGT GGCAGAGTTG 480

AGCAGTGTGA AAAAGACTGC TTGGCCCTTT ACAGGGAAAG CAGGTCCACT GTGGCCTGTG 540

AGGACGAGAG CTCTGGGCAG GCTCGGACAC TGGCAGACCC TGGTCCTGGC TGGCCAAGGC 600

AGCAGGGTAT GTGTTTCGGG TCACTCACAG GGCTCAGCAC CACTCCTCAT GGCTTCCTTA 660

CTGTTTCGGC AGAGGCTGAC CCGCGGCTGA TTGAGTCCCT CTCCCAGATG CTGTCCATGG 720

GCTTCTCTGA TGAAGGCGGC TGGCTCACCA GGCTCCTGCA GACCAAGAAC TATGACATCG 780

GAGCGGCTCT GGACACCATC CACTATTCAA AGCATCCCCC GCCGTTGTGA CCACTTTTGC 840

CCACCTCTTC TGCGTGCCCC TCTTCTGTCT CATAGTTGTG TTAAGCTTGC GTAGAATTGC 900

AGGTCTCTGT ACGGGCCAGT TTCTCTGCCT TCTTCCAGGA TCAGGGGTTA GGGTGCAAGA 960

AGCCATTTAG GGCAGCAAAA CAAGTGACAT GAAGGGAGGG TGCCTGTGTG TGTCTGTGCT 1020

[illegible]

[illegible] 12[illegible]

TTGTCAGCAG GCAGGCTGGG GAGGCCAGTG TTGTGGCCTT CCTGCTGGGA CTGAGAAGGC 1320

TCACGAAGGG CATCCGCAAT GTTGGTTTCA CTGAGAGCTG CCTCCTGGTC TCTTCACCAC 1380

TGTAGTTCTC TCATTTCCAA ACCATCAGCT GCTTTTAAAA TAAGATCTCT TTGTAGCCAT 1440

CCTGTTAAAT TTGTAAACAA TCTAATTAAA TGGCATCAGC ACTTTAACCA AAAAAAAAAA 1500

AAAAAAAAAA AAANAAAAAA AAAAGGGGGC CGCTCTAGAG GTCCAAGTTA NGACGNGG 1558

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 948 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

TAAAAATCAT GCTCTGTACC ATCCTCACCG TAGTCATCAT CATCGCCGCG CAGACCACGA 60

GAACTACTGG GATCCCTAAA AACGCCCCTG GTCCGGCCCC ACTCTGCGCC CCTCGATCTC 120

CCAGGCTCTT TCTGCAGWCA TACCGCGGAC CCAATGGGCG CCCTGCACAC CCGTTTCTGG 180

GGCCGTCAGA CTTGGATACA TCGTAAACTC CGCCTCCACG GAACGTCTCG CCTKGCGAGC 240

AAGMTCGGAA TCCAGTTCCT CAGGAACCCC TCCAAAACCC ACACCCCCAG GGACGCCGCT 300

TTCCGGATCC CCGGGCAAAC GCCGGACCCT CAGTCGCTCC AGGCCCCCTC ACCCTCAAAG 360

TGTAGCGCCC CCAACCGAGC AACCTCGGTT TGGTCCCTAA AACCCCGCCT CCTCTATANG 420

CACCGCCCCA GCTCTGACAA AACCCCGCCT CCAGGTCGGC AGGCTCCGCT TCTTTTCTTC 480

TCCGCGGGGT GATTCAGTCC AGTGATTGGG TTTGTGGCTC CAGGCCTCGC CCACAGACGG 540

ACAGACCCCT CCCTTTCTTC CGGCAAAAGG ACCGAGCCCT GGGGTAGTAA GGSCCCCACA 600

CTCCTGTTTT TTGCAAGTAC ATTTTTGTCC YTCCTCCACC CAGGTATCTG CCTATTTTCT 660

TGCTAATCCC AGAACCTTTC CTTTTGCTTT TTTTAAGGAC ATTTGGGAAG TTCCTGGTGT 720

AGGACCCTTC TCCCTGGGAT AAGAAACCTG CCTGTAAACG CTCTGTAAAT ACTCCCTTCC 780

ACCCATCCCA GCCCCTGGGC AGCCGGGCAG AAGGGAATCC AGGCTATGGA CCTCCCAAGT 840

CCCCGCTCCC CGCTCCCCTC GGCGGCCCCG CCTTGTTCTG ATCTGTGTGT GAGTGTGTGT 900

GAACTTCTGA AAGACAATAT TAAAGAGACT TAGTTGAAAA AAAAAAAA 948

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 990 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

```
GGGGAACTCC AGTGACAGCA GGAGTAAGAG TGGGAGGCAG GACAGAGCTG GGACACAGGT     60
ATGGAGAGGG GGTTCAGCGA GCCTAGAGAG GGCAGACTAT CAGGGTGCCG GCGGTGAGAA    120
TCCAGGGAGA GGAGCGGAAA CAGAAGAGGG GCAGAAGACC CGGGCACTTG TGGGTTGCAG    180
AGCCCCTCAG CCATGTTGGG AGCCAAGCCA CACTGGCTAC CAGGTCCCCT ACACAGTCCC    240
GGGCTGCCCT TGGTTCTGGT GCTTCTGGCC CTGGGGGCCG GGTGGGCCCA GGAGGGGTCA    300
GAGCCCGTCC TGCTGGAGGG GGAGTGCCCG GTGGTCTGTG AGCCTGGCCG AGCTGCTGCA    360
GGGGGGCCCG GGGGAGCAGC CCTGGGAGAG GCACCCCCTG GGCGAGTGGC ATTTGYTGCG    420
GTCCGAAGCC ACCACCATGA GCCAGCAGGG GAAACCGGCA ATGGCACCAG TGGGGCCATC    480
TACTTCGACC AGGTCCTGGT GAACGAGGGC GGTGGCTTTG ACCGGGCCTC TGGCTCCTTC    540
GTAGCCCCTG TCCGGGGTGT CTACAGCTTC CGGTTCCATG TGGTGAAGGT GTACAACCGC    600
CAAACTGTCC AGGTGAGCCT GATGCTGAAC ACGTGGCCTG TCATCTCAGC CTTTGCCAAT    660
GATCCTGACG TGACCCGGGA GGCAGCCACC AGCTCTGTGC TACTGCCCTT GGACCCTGGG    720
GACCGAGTGT CTCTGCGCCT GCGTCGGGGG NAATCTACTG GGTGGTTGGA AATACTCAAG    780
TTTCTCTGGC TTCCTCATCT TCCCTCTCTG AAGGACCCAA GTCTTTCAAG CACAAGAATC    840
CAGCCCCTGA CAACTTTCTT CTGCCCTCTC TTGCCCCANA AACAGCANAA GCAGGANANA    900
NACTCCCTCT GGCTCCTATC CCACCTCTTT GCATGGGAAC CTGTGCCAAA CACCCAAGTT    960
TAAGAAAAAA ATAAAACTGT GCCATCTCCA                                     990
```

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1603 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

```
CCGCCGTCCT AGCCGCTGCT GTCTTCGTGG GAGCCGCCGT GAGTTCGCCG CTGGTGGCTC     180
CGGACAATGG GAGCAGCCGC ACATTGCACT CCAGAACAGA GACGACCCCG TCGCCCAGCA     240
ACGATACTGG GAATGGACAC CCAGAATATA TTGCATACGC GCTTGTCCCT GTGTTCTTTA     300
TCATGGGTCT CTTTGGCGTC CTCATTTNGC CAMCTNGCTT NAAGAAGAAA GGCTATCGTT     360
GTACAACAGA AGCAGAGCAA GATATCGAAG AAGAAAAAGG TTGAAAAGWT AGRATTGAAT     420
GACAGTGTGA ATGAAAACAG TGACACTGTT GGGCAAATCG TCCACTACAT CATGAAAAAT     480
GAAGCGAATG CTGATGTYTT AAAGGCGATG GTAGCAGATA ACAGCCTGTA TGATCCTGAA     540
AGCCCCGTGA CCCCCAGCAC ACCAGGGAGC CCGCCAGTGA GTCCTGGGCT TTGTCACCAG     600
GGGGGACGCC AGGGAAGCAC GTCTGTGGCC ATCATCTGCA TACGGTGGGC GGTGTWGTCG     660
AGAGGGATGT GTGTCATCGG TGTAGGCACA AGCCGTGGCA CTTTATAAAG CCCACTAACA     720
AGTCCAGAGA GAGCAGACCA CGGCGCCAAG GCGAGGTCAC GGTCCTTTCT GTTGGCAGAT     780
TTAGAGTNAC AAAAGTGGAG CACAAGTCAA ACCAGAAGGA ACGGAGAAGC CTGATGTCTG     840
TTAGTGGGGC TGAAACCGTC AATGGGGAGG TGCCGGCAAC ACCTGTGAAG AGAGAACGCA     900
GTGGCACAGA GTAGCAGGTG AGCCGTGGTT TTGGTGACAT TGGGGGCAGA GTGGTGCAGG     960
GTGAGGAGAA GGTACTTGGA GCCTCCCAGG TGCTGTGGCA GCATAGGAAT GGTATTTGAC    1020
AGGGAAGTGG GAGAGCTTTC CTTGACCCAG GAAGACTGAG GGGGACTGAA CATGATTACT    1080
TGTCTGCCTA GAGCTTCTTG TAAAGAAGTC ACAAACTTAG TGCCTCCAGG GGCTTGGCTG    1140
TGTGATAATG AGGATAGAGG ATTACTTGTG AGGCAATGTG GCATGGTGGG GATTGTGGCA    1200
AACTAGAATT CACATCACCC ACCATATAGG GCTTGCATTA CCACGAGGCA GAAAGCACCT    1260
AGTGTTGCTG CATCTTCTTA CGCAAAAAAG ACAAAATCCA GACTTCTAAA ATGTAAAATC    1320
ACTGATTTTC GATATTGGCA GCTTACTTTT TTTTTTTAAA CAACCATGCA GGCCAAATGA    1380
CTTGTAATCT TGTCACCATT TTTAGGTAAA CTGTGACTTG AAAAAGTCTG GAGCAAACAA    1440
ACCAATGCTT TTTCCTTTTA TTCTGTTGGR AACCAGTTTT CTTTGTGTCA CAGTTYTGAA    1500
ACCTCAATAC GAATATTTCT CTTCCCACCA AATATTTTGA GGCAATTGAA AAGCCACAGT    1560
GATTTATTTC TTGATTTGGC AATTTTAATT TTGCAAGACA ATT                      1603
```

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1052 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

```
TACAGCTCAG GATGCCTGTA ACATTGTCAT CTCTGGGCTT CTGGGTCCTG CTTAGCCTGC      60
TTTTTCCCTG GAGGACTGAC CAGGGATGCG GCCCAGCAAC ATGTTACTAA ATCATACTCT     120
GCTCCCTACC TTTCCCAGAC CTCTCACTCC TGCCTGGTGT TCCAACCCGT TCTGTGGCCA     180
GAGTATACAT TTTGGAACCT CTTCGAGGCC ATCCTGCAGT TCCAGATGAA CCATAGCGTG     240
CTTCAGCAGN AAGGCCCGAG ACATGTATGC AGAGGAGCGG AAGAGGCAGC AGCTGGAGAG     300
GGACCAGGCT ACAGTGACAG AGCAGCTGCT GCGAGAGGGG CTCCAAGCCA GTGGGGACGC     360
CCAGCTCCGA AGGACACGCT TGCACAAACT CTCGGCCAGA CGGGAAGAGC GAGTCCAAGG     420
CTTCCTGCAG GCCTTGGAAC TCAAGCGAGC TGACTGGCTG GCCCGTCTGG GCACTGCATC     480
AGCCTGAATG AGGCTGGCCA CCTGCCACTT TGCCCTGCCC TCTGCCTCCA GGGCTCCMCT     540
MYCCTTCCTT TTCTTGGTGA AAGGCACCTC CTTTCCTGAT AATGAATGGT GTTCCCTTTG     600
CTTGGCTGGG GAGCCCCCCA GGCCAGGTTT GCTGGCCATA GATACCTTTG GGCTGCCTGR     660
GACAGGCTCC TGAGGAGGAT TGAGGGTGAA AGTCTCCCAC GAGTACACTA AACCTAGGTC     720
TGGTCACCAA TAGGGTTTGG AGAGCAAAGG GCCACAACTC ATCAGCTGCC TGTCTCTTAG     780
ATGCACTTTC TTTTTCCACC AGCACATCCT TCAACACACA GAATTTCAGG GAAGAGTTCT     840
CCCCAAAACC CTAGCTCTTT ACCCTTCCAT TTTAGCCTTC CACCCAGCTT CCACAAAAGA     900
TTTGGCTCTA CCTTGGATCT GCTAGTAAAT AACTAATAGG CAGGCAGTTA TTTGGGTAAG     960
GAAAAAAGGG GTGGGAGAGA CAGAAAATTT GCCCACTGCT GCTCCTCCCC TTGGSTYTCC    1020
ACCTGGGATT TGCTATTGAA TCTCTACCCT NN                                  1052
```

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 814 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

```
ACNCCNTGGC GGCCGCTCTA GAACTAGGGG ANCCCCCGGG CTGCAGGAAT TCGGCACGAG      60
[illegible]
```

```
ACTGCAACCT GGGAGGCAGA GGTTGCAGTG AGTCGAGATG GTGCCATTGC TCTCGTTTGG    300
GCAACAAGAG TGAAACTCTT GTCTCAAAAA AAAAAAAAAA ATGAGGTTTA AGACAGTTTT    360
GTCATTACTG GTGGGATCTG GTCACACAAG ATAGCATTAA ACGTGACATG GCACATAAAA    420
TTGGTTAAAA AATTTTGTTT TTTAATTACG TAATGTAAAA GCCCAACAAA CACTTTATGC    480
AAGATTGGAA TGTATCTTCA AATTCAGATT TAATAAACAT GTAAAGATCC TCTGTATATA    540
AAAGTTGTAT TTAATCCCTT GTGCCCCAAG AATGCTATAA AAGATCCCAA GAATGTTATC    600
TATGAAAAGA TAGCAATAGG GAATGGTGAA CAAATAATTT AATTTGCCAA TTCTAAAAAA    660
CATGGACTTA AACCCCATGA AAACTTGGTT CCATAGTTTT AACTGTTTTA TGGTTCCAAT    720
ACAAAACCAG AGTGGTTTAC ATTCCACAAT NACCAAATTT GCATCCAATN TTGGGGTAAT    780
TTTNGGTATT TGCCATGGGA TACTATTCAT TTTT                                814
```

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1215 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

```
AGAGGAAGTC TTTTGCCAAG CCTGTTCTCT GGACTAACGC CATCCAGGCT GGGAGGGGAA     60
GAGTGCTCTG CTACACTCGT CCCCCTCCTG CCTCATCTTC CTTCTCAGCC TTGGTTCCTG    120
ATGGGAACAG AATGGAGGGC CTGAGAACAT ACTTTCTAAA TGCCTTTGAC CCAGGAACCG    180
ATTATCTATA TTTGTTCCCA TTTTCCTTCA CCGTGACATT CCAGCATTGT CTGACTGTGA    240
GGTGGGCCTT TGAGAGCCTC CAGGTTCCTC AAAACAGGCC TGAGCGATGG GCATCACACC    300
CTCTGCCTAC CCACRTGCCT GCTTACCTGC CAGATAACCA AGTGNAGATG TCTGCGAGTG    360
GCTAGTTTTC ACATTCTTAC TAGTGTTTGG YTCACCTTTG GGCAAAGGCC CCCTCTAGGC    420
CTTGCCCCAC CTCCATCAAA CGCAGACACT GTAGTCAGAC CTCAGYAATA TAGGAGGCAA    480
TAATCTTTTA ACAGTGTTTT GCAAACAAAC AAAAAGAGAA AAATCCCAGC CAGGGGAACT    540
CGCCACCTGC CCACGCTAGT TCCATCCACG CTCAAGACCC GCCCTTAGAC CAGGCAGGCA    600
AAGGCCCCCA TCACACTCGG CCACTAGTGG GGTCCTGAGG CCAAGAAAGA AACCAGACCC    660
TGTATGACAA GTTGGGKTCT TTCCAGAACA CGACAGAAAC AGGGGGGGCC CCTTGTTAAT    720
GCCACTCCAT ACTCCAGAAG CATTATTCCT TATTTGGGAC AGCCAAGGGC AGATTCACAG    780
GTTATTGTAG GAATAAAGAC TAGTTTACAA AGGARAAAGA GSCCCTGGAC TTCCCMAGGA    840
```

AAGGTCAGGT TAGGGCTCCT GTACCCATTC TGTTCCACCA CTGTTTGATC TCTCTGGCCT 900

CCCACCAGGA ATGCCGTTTC CTTTTTATGG ATCTGTTGGG AACCAGAGAG AATCAACAGA 960

TCAATGACAT AGGATCCGAA GTGCAATCAT AGTCACTTCT AGTTTGGCAT TTCACAAACT 1020

CTGNACAGCA AGGTATTGGT AGGTTACTCA ATTTCAAAAG GGCCCCATGC CCAAATATGT 1080

TTAGGAACCG CTGTTTGNAT TTCTTTTTTT GGAGACGCAT TGTATATAAT ATATGTCAAA 1140

GGCTTTCGGA ATTCCTGCAG GAAAGAAATC AGCTTTGTTA AATCCNAAAA AAAAAAAAAA 1200

AAAAAAATAG ACTCG 1215

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 478 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

ATTTCTTATG ACATGGGGGT TTGAATTGGT TGGCAAATGT TTAATTTTAA TATCCATAAT 60

CAGTGAGGTC CTGCTGGCTG TAATCATTAA TTGTGAAATC TAAGGAGCTT AGTTCATGGC 120

TCTAGAATTT CACAGAAAAR TGYCMTATGA TACGAGCATT AAGTTTATTT CTTCTGATCT 180

TTGATGCAGC TTTGTTCAGT TTATCTGTTT TTGTATTTAT TGGTCAPCTA CTTCCCATGC 240

CAAAAGGGAC TGGTCTACAT AGCTGCGCTA AACACCTGAT CAAATCACTA AAAGAAAATG 300

TGTTACCTCT AATGAATTAT CCTGATTGTA AGTTAAAAAT CAATATTTCC CCGTAGTGAG 360

GTTTGCTTTT TAAAAAGAAK KCTTAAAAAA AAAAAAAAAA AAACGAGTTN AAGAAAAGGA 420

AGCAAGCTCA GGTAAGGTGC ACACATTGGG CTAAGGAAGC TAGAGCCTGT GGAGANGC 478

(2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 618 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
[illegible]

[illegible]

TTC[illegible]GCT TGCAGTTTGA [illegible]ACTAGTGGA T[illegible]CAAAGAA TT[illegible] [illegible]TATAATGA 12[illegible]

GCTACTAGGT AAGCCTTCTG GGACTTTTCAG ATATTTTGGG GAAGATTGAT TTTTGTTCTT 180

ACATGCTGTG GACCCTTGGC CATCAAATGG TATGGGGAAG CTCATCCGTC TGTCTGTGAT 240

GGTCATGTCA GTCAGGCGTC TTTTTAGTAT TTACTGGGTG CTCAGTACTG TGCCAGATGC 300

TGTCGGGAGC CGTGGTGGTA TGGAGGAGGA GTGCTCCAGA GGACTCTGCT GTGTGGCAGG 360

CCAGCATAAA CAAGCCAAGG GGAAAAGGCA GGCATGGAAT AAAGGGGGAG AATACCAGTG 420

TGTGACTTAC TGCTGACTGT GTGGATTAGC CTATCAGCAG TAATCAAGCA GGGCGGAGCG 480

CATTATCTTT GAGTCAGAAG AGTGAGCACT GGGCCGAGGG TGGAGCATCA AGAGGCGGTG 540

TAGGACCNCA AGGCTTCTTN CNGGGGAGAC AACGTCAATA AGCNGTCAGT AGTCACCGAC 600

AGTTTTGGGA AGCAAGGG 618

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 751 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

TCGACCCACG CGTCCGAGGA GCTGGACTTC TGAGACAGCC ATTCTCCTTG CATAGCACTG 60

TCTGCTGCTA CAGCTCATAG AAGTCAACAA TTTTCTTCAA CACTGGTAGG CAGCCTCTAA 120

ATGGCCCTGA TCACCCTCAC CTCCTGCCAT TCACACCNNT GTAAAATTCC ACCCCTGGAC 180

CTAGTGACTC ACTTCTAACA ANGAGAATAC AGCAAAAGTA ACATCGCTTC TGAGGTGAGG 240

CTACAAGGAG ACTACGATGC CTGCCTTGGT CACCCTTCTC CTGCTCTTTC CATTGCTCCC 300

TCTGATGGAA GCCAGTTGCC ATGTGATGAG GTGCCCTATG GAGAGGCCCA CGTGACAAGG 360

TATTGTAAAA AGCCTCTGAC CAATAGCCAT CTAGAAACGG AGGCCCAGTC CAGCAGCCTC 420

TGAGATGAAT CCTGCCAACC TGAGCTTGGA GACAGATTCT CTCCCTATCC TGCCTTGGGA 480

TGATCACAGC CACCACCAAC ACCTTCACTG CCTGGTGAGA GGCCAAGCCA GTGAACCCAA 540

GGTAAACTGG ACAGAATCCT GACCCACAGA AACTGAGATA ATGTTTGTTA TTTTAAGCTG 600

CTCAGTTTGT TACAGAGCAA TAGATAACTA ACTCAAACAC CATAAAATTC TAATATTTTA 660

TTCTATCACA CAAACCAGGT AATACCAAGT AAATGCCATT ACTATACACA TATTTTTGTA 720

ACACAATTAC ATGTGATTTT TTAAGAAGGC T 751

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 780 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

CNGNCAGTCA CNGTCCCCGA TTCCCGGCTC GACCCACGCG TCCGGGTTGG CAACTCCTGA 60
GGCCTGCATG GTTGACTTCA CATTTTCCTA CCTCTCCTTC TAATCTCTTC TAGAGCACCT 120
GCTATTCCCA ACTTCTAGAC CTGCTCCAAA CTAGTGACTA GGATAGAATT TGATCCCCTA 180
ACTCACTGTC TGCGGTGCTC ATTGCTGCTA ACAGCATTGC CTGTGCTCTC CTCTCAGGGG 240
CAGCATGCTA ACGGGCGAC GTCCTAATCC AACTGGGAGA AGCCTCAGTG GTGGAATTCC 300
AGGCATTCTG ATTCTCAAGC TGGCAAGGGC CAGGATTGGG GGAATGGAGC TGGGGCTTAG 360
CTGGGAGGTG GTCTGAAGCA GACAGGGAAT GGGAGAGGAG GATGGGAACT AGACAGTGGC 420
TGGTATGCCT CTGAGGCTCC CTGGGGCCTG CTCAAGCTCC TCCTGCTCCT TGCTGTTTTC 480
TGATGATTTG GGGCCTGGG AGTCCCTTTG TCCTCATCTG AGACTGAAAT GTGGGGATCC 540
AGGATGGCCT TCCTTCCTCT TACCCTTCCT CCCTCAGCCT GCAACCTCTA TCCTGGAACC 600
TGTCCTCCCT TTCTCCCCAA CTATGCATCT GTTGTCTGCT CCTCTGCAAA GGCCAGCCAG 660
CTTGGGAGCA GGAGAGAAAT AAACAGCATT TCTGATGCCA AAAAAAAAAA AAAAAAAACC 720
GCGGCCGAAA GCTTATTNCC CTTTAAGTAA GGGGTTAATT TTTAGCTTGG GCACTNGGCC 780

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 583 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

TTCCGAATTA ATCGACTCAC TATAGGAAWT GCCGTCGCCA TGACCCGCGG TAACCAGCGT 60
GAGCTCGCCC GCCAGAAGAA TATGAAAAAG CAGAGCGACT CGGTTAAGGG AAAGCGCCGA 120

AGTGCTCACA GGTCCCAGCA CCGATGGCAT TCCCTTTGCC CTGAGTCTGC AGCGGGTCCC 360
TTTTGTGCTT CCTTCCCCTC AGGTAGCCTC TCTCCCCCTG GGCCACTCCC GGGGGTGAGG 420
GGGTTACCCC TTCCCAGTGT TTTTTATTCC TGTGGGGCTC ACCCCAAAGT ATTAAAAGTA 480
GCTTTGTAAT TCCAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 540
AAAAAAAAAA AAAAAAAAAA AAAANNCGGG GGGGGGCCCC CCCCCCCC 588

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 774 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

TTTAAAGATG AAGAAATGAC AAGGGAGGGA GATGAGATGG AAAGGTGTTT GGAAGAGATA 60
AGGGGTCTRA GAAAGAAATT TAGGGCTCTG CATTCTAACC ATAGGCATTC TCGGGACCGT 120
CCTTATCCCA TTTAATTAAT TTCTCTGACA ATTCAATTAT TTTCTGTTAT TAATGTTGCC 180
ACTGCTTTCT GTTTGTCTGC ACTTTCTTGA TAAATATTTG CTATCGTTTT ACTCCAGTCA 240
TTCGATGTTG CTGAGATTTA CATATGACTC TTGTCAACAT CTCATCTTTT GACCCAATCT 300
TATTCATTTA ATAAGAGGTC TCATTCATTT GCATGGAAAA ATGCTCATTG TATATTGCAA 360
AGTGAAAATA ACGAGTTGCA AAACAGTGTA TACATATATG TGTGTATATA TGTACACTTT 420
ATTTGTACAT TTCTATGTGA CATAATGCAA AGGAAAGTGT CTGATTTTAT TATACACCAA 480
AGGTTAACAG TGAATCTCTG TGTGATCTCT TTTTTTTTCT TTTTGCCTAT CTGCATCTTC 540
TCACTTGCCA AAAAATGAAT ATATGTTTAT GTGTGTATAT TACTTGTGTC ACAAAAAACC 600
CTAAAGTAGA CAGTAAAAGA ACTTGTCAAT CGCCTTTGGA AGGCAATGAA ACACTTAATA 660
AACTCTCAAT AACAGAAGCG TAAAAATGAA ATGTAAACCT CCAATTACCT CTGGATCTCT 720
TAGCCAGAGT AATAAACTGG TAATTATTAC AGATAAAAAA AAAAAAAAAA AANA 774

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1866 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

```
ACCCACGCGT CCGGTCCTCT TCTTCAGCAC ATGCCAAAGC TGTTCCTCAC GGCCTGTGAG      60
ACAAGAGCAT CTTGGATGTA GGACAATGGA AGAGTTAGAT GCCTTATTGG AGGAACTGGA     120
ACGCTCCACC CTTCAGGACA GTGATGAATA TTCCAACCCA GCTCCTCTTC CCCTGGATCA     180
GCATTCCAGA AAGGAGACTA ACCTTGATGA GACTTCGGAG ATCCTTTCTA TTCAGGATAA     240
CACAAGTCCC TTGCCGGCGC ANTCGTGTAT ACTACCAATA TCCAGGAGCT CAATGTCTAC     300
AGTGAAGCCC AAGAGCCAAA GGAATCACCA CCACCTTCTA AAACGTCAGC AGCTGCTCAG     360
TTGGATGAGC TCATGGCTCA CCTGACTGAG ATGCAGGCCA AGGTTGCAGT GAGAGCAGAT     420
GCTGGCAAGA AGCACTTACC AGACAAGCAG GATCACAAGG CCTCCCTGGA CTCAATGCTT     480
GGGGGTCTSG AGCAGGAATT GCAGGACCTT GGCATTGCCA CAGTGCCCAA GGGCCATTGT     540
GCATCCTGCC AGAAACCGAT TGCTGGGAAG GTGATCCATG CTCTAGGGCA ATCATGGCAT     600
CCTGAGCATT TTGTCTGTAC TCATTGCAAA GAAGAGATTG GCTCCAGTCC CTTCTTTGAG     660
CGGAGTGGCT TGGNCTACTG CCCCAACGAC TACCACCAAC TTTTTTCTCC ACGCTGTGCT     720
TACTGCGCTG CTCCCATCCT GGATAAAGTG CTGACAGCAA TGAACCAGAC CTGGCACCCA     780
GAGCACTTCT TCTGCTCTCA CTGCGGAGAG GTGTTTGGTG CAGAAGGCTT TCATGAGAAG     840
GACAAGAAGC CATATTGCCG AAAGGATTTC TTAGCCATGT TCTCACCCAA GTGTGGTGGC     900
TGCAATCGCC CAGTGTTGGA AAACTACCTT TCAGCCATGG ACACTGTCTG GCACCCAGAG     960
TGCTTTGTTT GTGGGGACTG CTTCACCAGT TTTTCTACTG GCTCCTTCTT TGAACTGGAT    1020
GGACGTCCAT TCTGTGAGCT CCATTACCAT CACCGCCGGG GAACGCTCTG CCATGGGTGT    1080
GGGCAGCCCA TCACTGGCCG TTGTATCAGT GCCATGGGGT ACAAGTTCCA TCCTGAGCAC    1140
TTTGTGTGTG CTTTCTGCCT GACACAGTTG TCGAAGGGCA TTTTCAGGGA GCAGAATGAC    1200
AAGACCTATT GTCAACCTTG CTTCAATAAG CTCTTCCCAC TGTAATGCCA ACTGATCCAT    1260
AGCCTCTTCA GATTCCTTAT AAAATTTAAA CCAAGAGACG AGAGGAAAGG CTAAATTTTC    1320
TGTTACTCAC CTTCTGCTTA ATAGTCTTAT AGAAAAAGGA AACGTGATGA GCAAATAAAG    1380
GAACTTCTAG ACTTTACATG ACTAGGCTGA TAATCTTATT TTTTAGGCTT CTATACAGTT    1440
AATTCTATAA ATTCTCTTTC TCCCTCTCTT CTCCAATCAA GCACTTGGAG TTAGATCTAG    1500
GTCCTTCTAT CTCGTCCCTC TACAGATGTA TTTTCCACTT GCATAATTCA TGCCAACACT    1560

[illegible]
```

TTTTGTTTTT CAAGAGGAAG TAGATTTTAA CTGGACAACT TTGAGTACTG ACATCATTGA 1800

TAAATAAACT GGCTTGTGGT TTCAATAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1860

AAAAAA 1866

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1152 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

CTCAAGGATG TAAAGGCTCT GCAGATTTCG GGAGGCCTGT CTCCCAGCAC CTGATGGGAC 60

ACTTTTTGCC CCACTGTAAA TTCTGGGTGT ATCCTCCACT GTATGCTGTC ACCCCAAGGG 120

CAAGCACTGC ATCTGCTTAG TGAAGGATTT ATTGTTCGGA AGATACATTT TCCCCTTKAG 180

CAGAGAGTGG CGTATCCTGG CAGTCTTCGG TGAGCCAGTT GTACCAGGAT TATGAAATGC 240

AGATGTTTAC TGTGTCATTG TTGCTGTCAT TGCTACTGAG GAGTACTGAC CAGAATCATC 300

TGCAACTYTT AGTTGGCAGA GAGGACCACT ATGGCGGGTA GCTCTTTTCT TTCCTGCCAT 360

TGTGGGGATG ATTCCAGGCC AAAGATGATG GARAAGTATG GAAATCATCT GAAAGGTTGA 420

AGCTTGGCAC GTGAAGCCAT TCATGACTTT GTAAGGCAGT TTTGCTGAAG GCCAGTTCTG 480

CCCTGGGAGG GACGGAGGTG AATCCTCCTG AGTACCTGTG GTTTTCTTAC TTCCTGCTGA 540

ATTTACCTAA GTGCCTGTTG TTTGCTTGCT GTGGAGGCTT TCTGGTATTT CATTTCAGGT 600

GCAGATGCCT TCACTTTCCC ACCRAAAAAA CCCCMACCAA ACCTAAGACC TTACTGCAAC 660

TAAGTYTNCC AAGTACTTTT TAACCCAATG GGATGAACAG CCTGTGGTCT GCTCAGATCA 720

CCCTGAGTGC GTGTGAGAAG GCMTNGGCTT TGCCAGGAAA TCCAGGAAGG CAGGGCCGGG 780

CTGTGTTGGA AGCTGGCTTA GCTGGTGGGG CAGCCTTATT TCAATTAAAA GGGCATTGAC 840

TGGGAGCAGC AGTCCTGGAG TTTGTTGCAT TTCCTATTGC CCTCAAAATG AGAAACCAGG 900

AAAATAGCAG ATTGGAGCCT TCGAGAAGGC AGTAAATGGC TGTTTTTATT GACAAAAGGA 960

AAACATTTTA CTGCCATCTC ACTGATGGCA TCTCACTGAC TTAAAATGAA GGCANGTTGT 1020

AGTAAAAAAA AAAGTCTACA TTTTTCCACC GCCACGTTCT TATATCCTGT TTGTCAGCCA 1080

CTGCTCANAA GGGCATGTTG TCTTGCGGAN TANAGGCGCT CTCCTTCCCT CGTTTTCCCT 1140

ATAGGTTGGG TG 1152

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2433 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

```
AGCAGGCGGT GCGCTGGGGG CGGGAGCAGC GCGKAGCCCG GCTCGGCCAC ACCGATCGCC      60
CGCCGCCATG GGCTCCTGGC AAAGCGTCGA GATCCCGGGC GGGGGCACCG AGGGCTACCA     120
CGTTCTGCGG GTACAAGAAA ATTCCCCAGG ACACAGAGCT GGTTTGGAGC CTTTCTTTGA     180
TTTTATTTGTT TCTATTAATG GTTCAAGATT AAATAAAGAC AATGACACTC TTAAGGATCT     240
GCTGAAAGCA AACGTTGAAA AGCCTGTAAA GATGCTTATC TATAGCAGCA AAACATTGGA     300
ACTGCGAGAG ACCTCAGTCA CACCAAGTAA CCTGTGGGGC GGCCAGGGCT TATTGGGAGT     360
GAGCATTCGT TTCTGCAGCT TTGATGGGGC AAATGAAAAT GTTTGGCATG TGCTGGAGGT     420
GGAATCAAAT TCTCCTGCAG CACTGGCAGG TCTTAGACCA CACAGTGATT ATATAATTGG     480
AGCAGATACA GTCATGAATG AGTCTGAAGA TCTATTCAGC CTTATCGAAA CACATGAAGC     540
AAAACCATTG AAACTGTATG TGTACAACAC AGACACTGAT AACTGTCGAG AAGTGATTAT     600
TACACCAAAT TCTGCATGGG GTGGAGAAGG CAGCCTAGGA TGTGGCATTG GATATGGTTA     660
TTTGCATCGA ATACCTACAC GCCCATTTGA GGAAGGAAAG AAAATTTCTC TTCCAGGACA     720
AATGGCTGGT ACACCTATTA CACGTCTTAA AGATGGGTTT ACAGAGGTCC AGCTGTCCTC     780
AGTTAATCCC CCGTCTTTGT CACCACCAGG AACTACAGGA ATTGAACAGA GTCTGACTGG     840
ACTTTCTATT AGCTCAACTC CACCAGCTGT CAGTAGTGTT CTCAGTACAG GTGTACCAAC     900
AGTACCGTTA TTGCCACCAC AAGTAAACCA GTCCCTCACT TCTGTGCCAC CAATGAATCC     960
AGCTACTACA TTACCAGGTC TGATGCCTTT ACCAGCAGGA CTGCCCAACC TCCCCAACCT    1020
CAACCTCAAC CTCCCAGCAC CACACATCAT GCCAGGGGTT GGCTTACCAG AACTTGTAAA    1080
CCCAGGTCTG CCACCTCTTC CTTCCATGCC TCCCCGAAAC TTACCTGGCA TTGCACCTCT    1140
CCCCCTGCCA TCCGAGTTCC TCCCGTCATT CCCCTTGGTT CCAGAGAGCT CTTCTGCAGC    1200
AAGCTCAGGA GAGCTGCTGT CTTCCCTCCC GCCCACCAGC AACGCACCCT CTGACCCTGC    1260

GCTTTTTTCT GCGGTGTGG ATACCAATGC TTCTGAGTTA CCTTAACTTT CAACCATTCT     1440
```

TTGGAATTGG CGTGGTATAT TTAACCACGG GAGCGTGTCT GGAAACGCAA ACTATCATTA 1500

ATTTCATACT AGTTTGTACC GTATCTGTAG GCATCCTGTA AATAATTCCA AGGGGAAAAC 1560

TAAACGAGGA CGTGGGTTGT ATCCTGCCAG GTTGAGTGGG GCTCACACGC TAGGGTGAGA 1620

TGTCAGAAAG CGCTTGTATT TTAAACAACC AAAAAGAATT GTAAGGGTGG CTTGCTGCCA 1680

GGCTTGCACT GCCGTTCCTG GGGGTGTGCA TCTTCGGGAA AGGTGGTGGC GGGGCGTCCA 1740

CTAGGTTTCC TGTCCCCTGC TGCTCCTTCC GTAAGAAAAT GAAATATTCT ATGCCTAATA 1800

CTCACACGCA ACATTTCTTG TACTTTGTAA GTCGTTTGCG AGAATGCAGA CCACCTCACT 1860

AAACTGTAAA CGGTAAAGAG ATTTTTACTT TTGGTCTCCG TGAGTCGCAT CTCTACTAAG 1920

GTTTACACAG GAATTCCACC TGAAGACTTG TGTTAAAGTT CTACAGCGCG CACTGTTAAC 1980

TGAACGTCTT TTTCTTCAGC CTATACGCGG ATCCTTGTTT TGAGCTCTCA GAATCACTCA 2040

GACAACATTT TGTAACTGCT GCTGTTGCTT TCTACATACA CCTTATAAAG TGACATTTCA 2100

AAAGAAATAA GGTGCCACAG TTTTAAACCA GAAGGTGGCA CTCTGTGGCT CCTTGTAGTA 2160

TTATAGCTAT ACTGGGAAAG CATAGATACA GCAATAAAGT ACAGTAATTT TACTTTTTTT 2220

CTTGTGTTAC ATCTAAATTA CAACCCTTAA TTGCCACGTG TGCACTTACT ACTCTCCAGT 2280

ATGTCTTATT ACTCTCCAGT ATGTCACGCA TCTTTAACTT TTCACGTCCT ATGTTTGCTT 2340

TCTCCCATTT TTAAGAGATG GTAAGTTAAC TGGAATTGAT TTACTGAATG AAATTAAATG 2400

CAGATATCCC TGTTTTTGAA ATAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2460

AAAAAAAAAA AAAAAAAAAA AAA 2483

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 536 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

GAGAAATGGA GCTTTGTTAG ATAAAAATTT TTTCAACGCA AACAGTCATT TTCCAGTGAA 60

AGGAGAGCGT ATCCGCCGTA GGATGGACTT AGATCGTGTA AAAGCTGAGG CCACCGAGGA 120

TATAACCTCC GGGGTCCTTT GCCTCCTTTT CCTTAGACTC CCTCCAAACT CGTGTATCTT 180

TCCTTCAGCA GTACTGGGCT CCACGCGAAC CTAGTCCTTT GTCTTTACCC TATTACCTTT 240

CATAACATCC TAGTTGAAAA GTARTTATTC AACCGCGTTT GAAAATGAGA ACAGGTTCAC 300

AGARGCTAGG TTACTTGCGA AGGTCGTTCA ATTAGTAACC AGTAACGCCA GGACTGCCAG 360

TTTCTTGCTT CCGAATTCTC ATGGTAGCTT TCACCARGCT CCCCGTCMAA TGCTAACGTC 420

AACTACTGAA CTAGATTAGC AAAAAGGTCT TTTAACAGAA TTCCTGGTTT TCAGAGAGAG 480

TTTCTTTCAT GAAGCGCCCC ATTTCTACAG AGGAAAATAA ACTCCAAGCA GCCAGT 536

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 865 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

CCACGCGTCC GGCCTTTCTT GGCCAGAGGC GCCGGTTGGA CTCACGGGCG GGGCATGATG 60

GGTAACAGGA CCGGTGGGGT CCCCAGGAAG TCCTAGAGGG GGTCGGGGTT TGGGTGGACA 120

AGCTTTCCTC GTCCTCTCCC GACAGAGCTG ACGTGTCCTG GGTTCCACCG GGAGCGGGCA 180

TTTCCACCGG ACGGGAGGGT TCGGGGTGTC CGGGGCTGGG GAATACGTAG GGGTTGCCGC 240

GCGGTGTGGG GAGTTGGGGC GTGTGGCTGC AGTCCCGGGA GTTCTTGGAG GGGGTCGGCC 300

CACCGAGCTT CCGGACCGGC TGATCTGCCC GTAGCTTGCC GGANGGARGG CGGAGCTGAC 360

TCTCCGTCCC TTCTCCCATC CCCTCCAGTG GTGGGTACGG GCACCTCGCT GGCGCTCTCC 420

TCCCTCCTGT CCCTGCTGCT CTTTGCTGGG ATGCAGATGT ACAGCCGTCA GCTGGCCTCC 480

ACCGAGTGGC TCACCATCCA GGGCGGCCTG CTTGGTTCGG GTCTCTTCGT GTTCTCGCTC 540

ACTGCCTTCA ATAATCTGGA GAATCTTGTC TTTGGCAAAG GATTCCAAGC AAAGATCTTC 600

CCTGAGATTC TCCTGTGCCT CCTGTTGGCT CTCTTTGCAT CTGGCCTCAT CCACCGAGTC 660

TGTGTCACCA CCTGCTTCAT CTTCTCCATG GTTGGTCTGT ACTACATCAA CAAGATCTCC 720

TCCACCCTGT ACCAGGCAGC AGCTCCAGTC CTCACACCAG CCAAGGTCAC AGGCAAGAGC 780

AAGAAGAGAA ACTGACCCTG AATGTTCAAT AAAGTTGATT CTTTGTAAAA AAAAAAAAAA 840

AAAAAAAAAA AAAAAAAAAA AAAAA 865

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

TCATCATATA CAAAGTTTTT CGTCACACTG CAGGGTTGAA ACCAGAAGTT AGTTGCTTTG 60

AGAACATAAG GTCTTGTGCA AGAGGAGCCC TCGCTCTTCT GTTCCTTCTC GGCACCACCT 120

GGATCTTTGG GGTTCTCCAT GTTGTGCACG CATCAGTGGT TACAGCTTAC CTCTTCACAG 180

TCAGCAATGC TTTCCAGGGG ATGTTCATTT TTTTATTCCT GTGTGTTTTA TCTAGAAAGA 240

TTCAAGAAGA ATATTACAGA TTGTTCAAAA ATGTCCCCTG TTGTTTTGGA TGTTTAAGGT 300

AAACATAGAG AATGGTGGAT AATTACAACT GCACAAAAAT AAAAATTCCA AGCTGTGGAT 360

GACCAATGTA TAAAAATGAC TCATCAAATT ATCCAATTAT TAACTACTAG ACAAAAAGTA 420

TTTTAAATCA GTTTTTCTGT TTATGCTATA GGAACTGTAG ATAATAAGGT AAAATTATGT 480

ATCATATAGA TATACTATGT TTTTCTATGT GAAATAGTTC TGTCAAAAAT AGTATTGCAG 540

ATATTTGGAA AGTAATTGGT TTCTCAGGAG TGATATCACT GCACCCAAGG AAAGATTTTC 600

TTTCTAACAC GAGAAGTATA TGAATGTCCT GAAGGAAACC ACTGGCTTGA TATTTCTGTG 660

ACTCGTGTTG CCTTTGAAAC TAGTCCCCTA CCACCTCGGT AATGAGCTCC ATTACAGAAA 720

GTGGAACATA AGAGAATGAA GGGGCAGAAT ATCAAACAGT GAAAAGGGAA TGATAAGATG 780

TATTTTGAAT GAACTGTTTT TTCTGTAGAC TAGCTGAGAA ATTGTTGACA TAAAATAAAG 840

AATTGAAGAA ACACATTTTA CCATTTAAAA AAAAAAAAAA ACTNGAGGGG GGCCCGGTAC 900

CCAAATCGCC GCATAGTGAT CGTAAACAAT CT 932

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 996 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

CGCCTGGCAC CATGAGGACG CCTGGGCCTC TGCCTGTGCT GCTGCTGCTC CTGGCGGGAG 60

CCCCCGCCGC GCGGCCCACT CCCCCGACCT GCTACTCCCG CATGCGGGCC CTGAGCCAGG 120

AGATCACCCG CGACTTCAAC CTCCTGCAGG TCTCGGAGCC CTCGGAGCCA TGTGTGAGAT 180

ACCTGCCCAG GCTGTACCTG GACATACACA ATTACTGTGT GCTGGACAAG CTGCGGGACT 240

TTGTGGCCTC GCCCCCGTGT TGGAAAGTGG CCCAGGTAGA TTCCTTGAAG GACAAAGCAC 300

GGAAGCTGTA CACCATCATG AACTCGTTCT GCAGGAGAGA TTTGGTATTC CTGTTGGATG 360

ACTGCAATGC CTTGGAATAC CCAATCCCAG TGACTACGGT CCTGCCAGAT CGTCAGCGCT 420

AAGGGAACTG AGACCAGAGA AAGAACCCAA GAGAACTAAA GTTATGTCAG CTACCCAGAC 480

TTAATGGGCC AGAGCCATGA CCCTCACAGG TCTTGTGTTA GTTGTATCTG AAACTGTTAT 540

GTATCTCTCT ACCTTCTGGA AAACAGGGCT GGTATTCCTA CCCNGGAACC TCCTTTGAGC 600

ATAGAGTTAG CAACCATGCT TCTCATTCCC TTGACTCATG TCTTGCCAGG ATGGTTAGAT 660

ACACAGCATG TTGATTTGGT CACCTAAAAA GAAGAAAAGG ACTAACAAGC TTCACTTTTA 720

TGAACAACTA TTTTGAGAAC ATGCACAATA GTATGTTTTT ATTACTGGTT TAATGGAGTA 780

ATGGTACTTT TATTCTTTCT TGATAGAAAC CTGCTTACAT TTAACCAAGC TTCTATTATG 840

CCTTTTTCTA ACACAGACTT TCTTCACTGT CTTTCATTTA AAAAGAAATT AATGCTCTTA 900

AGATATATAT TTTAYGTAGT GCTGACAGGA CCCACTCTTT CATTGAAAGG TGATGAAAAT 960

CAAATAAAGA ATCTCTTCAC ATGARAAAAA AAAAAA 995

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 785 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

GGCACGAGGG GCTTTGCGTA CACAATAGCT GCTAGGAGTA CCCAAAGCCT GARTACARCC 60

TGCTGGTGTC ATGGCCACGT GTGAGCAGGC CAGCGTCAMA CGGCTCGCTG TGACCCGTCC 120

CGRAGACTGA AATGGGCCTG GGTCTTCTCC TKGTCCTGTG ATWAAAGTCC TCTCTTGAAA 180

GTGGAGAGCA AAGGCACACA GAGGTGCGCG CTCACAAGAA TTCCTCCCGG TGACTGGGTA 240

ATCAATGTTA CTGCTGTTTC CTTTGCAGGA AAGACCACAG CAAGATTTTT TCATTCGTCT 300

CCTCCTAGCC TGGGGGACCA GGCTCGAACT GACCCTGGAC ATCAAAGGAG GGATTATGTG 360

GCTGCTAAAG CCATCGGCCC ACAGCCCTGT TCACRTCTTG GTGCTTCTCT TTCCCAGAGG 420

CTGGTCCCAG CCAGGCACAC ACAAAAGGCA GATTCTCGTA AACSCAGCCT CCCTCCCTGG 480

AGGCTGCCTC CTGCCCTGGA TCTGGAGTGG AGCTGCTCTG AGATTTTGAG TTCTTCTGCA 540

[illegible]

TAAATGTAAT GGATTTTTTT TTTGTAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 780

AAAAA 785

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1069 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

TCCTCACCAT TCCCCTAGGN CAGGTCCCTG CAGGTCCCAC ACTTCTCCCA GGTCCCTAAA 60

CTTGGGTCGG TCCTTTCCCT GGAGTAGCTG GNTCCTCCAG TCGAGGTCCC TGTTCAGTCG 120

GTTCTTAGGC TCCTGCACAT GAAGGTGTGT GCCTGTGGTG TGTGGGCTGC TCTAGGAGCA 180

GATACAGGCT GGTATAGAGG ATGCAGAAAG GTAGGGCAGT ATGTTTAAGT CCAGACTTGG 240

CACATGGCTA GGGATACTGC TCACTAGCTG TGGAGGTCCT CAGGAGTGGA GAGAATGAGT 300

AGGAGGGCAG AAGCTTCCAT TTTTGTCCTT CCTAAGACCC TGTTATTTGT GTTATTTCCT 360

GCCTTTCCGA GTCCTGCAGT GGGCTGCCCT GTACCCTGAA CCTCATGAGC CTCTAAGGGA 420

AAGGAGGAAC AATTAGGACG TGGCAATGAG ACCTGGCAGG GCAGARTACA AGCCCAGCAC 480

CAGTGTCCCA GCCTTACTGG GTCCTTACCC TGGGCCAAAC AGGGAGGGCT GATACCTCCT 540

TGCTCTTCCT AGATGCCCAC CTCCTACAAT CTCAGCCCAC AAGTCCTCTC CACCCTAGGG 600

GGCTTGCTGC ATGGCAATAA CTCATAATCT GATTTGGAGG TTTGCCCTTT ACAGGGGCAG 660

ATTTTCTGCT CAGTTCAACA ATGAAATGAA GAGGAACTCC CTCTTTCTAC AGCTCACTTC 720

TATCAGAGGC CCAGGTGCCT CAGAGCCACA TTGAGTTGCT TTTTCTGGGA TGAGGAAGTA 780

GGGTTAAACT CCCCAGTTTC CTGAGGGAGG CTCCTGACAG GTGCCCTTTG TCAGACCCTA 840

CCACAGCCTG GATAGGCAGC CACATTGGTC CTCGCCCTTG CTCGGNACTC CGTGGTGGTC 900

CTGCCCTTCT CCCTGCATGC CTGTGGGTCT GCTCTGGTGT GTGAAGGTCG GTGGGTTAAC 960

TGTGTGCCTA CTGAACCTGG CAAATAAACA TCACCCTGCA AAGCCAAAAA AAAAAAAAAA 1020

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 1069

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 831 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

```
GGACATTAGA TCACTGTGGA CCTAAAACAA ACAAACAACT ATAAGGAAAA TGGCATTAGA      60
AATGGTCTGG GGATCAGTTT ATCACTGCAG TTGTTACATC ACCCCATGGT CTAAAATACA     120
GAGCTTTAGT CTGTCTCTGT TTCAGTTCAT TTTACAGGAG GTGAACATCA CACTTCCAGA     180
AAACTCTGTC TGGTATGAAA GGTATAAATT TGATATTCCT GTCTTTCACT TGAATGGCCA     240
GTTTCTGATG ATGCATCGAG TAAACACCTC AAAACTTGAA AAACAGCTCC TGAAACTTGA     300
GCAGCAAAGT ACTGGARGCT GACTGATGCC CTCATGATTT TCCACCCTCT CTTCCCATAA     360
AGCATCTTCC TAAGGAAATG AMCATGGCCT GATACTCATT TTGTCACTTG TACAGAGCCC     420
TAAGGATGTT CTGAATTCAG TGGTGCCAAA TAAATGTTGA CATTCCCCTT TTGGTTGATG     480
GAAGTATCAG TGTGGGAACT GTTTGCTTAA TGGCATTTTA TAAAATAAKA AKAKCATATT     540
AGCAGGGAGG GAGATGATGG AGGGAGGGAG AAGTCCATTT GTCTTATTTA TCCTTTTTGT     600
ATTAATAGAG AAGCACTTCA CAGTCACTGG CAATGCCATT TATAGGAAGA AGGTTCTGCA     660
TTCCTGCTGC TCCCGGAGGG CTTAACTTTT TAATGAAAGA ATAAATGCTC TTCCACTCAG     720
TAGATAAAGT GAAATGTGAA TTGTTAATAA CTGTGCACGG TCAATAAAGC GATGTTTTAA     780
GGAATACAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAACTCG A              831
```

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 590 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

```
TATATATAGA CNGTTAATAG TCGTGANTGN TGTGNACGAA CATTAACGGA AGTAGCATGT      60
AGCCAGTCGA ATAACNTATA AGGACAAAGT GGAGTCCACG CGTGCGGCCG TCTAGACTAG     120
TGGATCCCCC GGCTGCAGGA TTCGGCACGA GCTGCCAGGT GAGGAGCAGA GAGACTGTTC     180
CCTTGGGTGG AGAGGTGTGG GCATGAGAGC CACCCATTGC CAAGCAGCAA GAATGTTCGT     240

[illegible]
```

CTTTTTGTCC TGTAAGATAT ATGCAGCCTC ACAGAAGCAG CCTCTGCCTC CACTTTACCA 480

GCTACCGTTT TATCTTAAGC ACATGGGGCT CCCTTAGAAC TTACTCCACT GATTTAAAAA 540

AAAAAAAAAA AAACTCGAGG GGGGGCCCGG TACCCATTCG CCCTAAAGT 590

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1274 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

GAGCCACCAC ACCTGGCCTG GAAGGAACCT CTTAAAATCA GTTTACGTCT TGTATTTTGT 60

TCTGTGATGG AGGACACTGG AGAGAGTTGC TATTCCAGTC AATCATGTCG AGTCACTGGA 120

CTCTGAAAAT CCTATTGGTT CCTTTATTTT ATTTGAGTTT AGAGTTCCCT TCTGGGTTTG 180

TATTATGTCT GGCAAATGAC CTGGGTTATC ACTTTTCCTC CAGGGTTAGA TCATAGATCT 240

TGGAAACTCC TTAGAGAGCA TTTTGCTCCT ACCAAGGATC AGATACTGGA GCCCCACATA 300

ATAGATTTCA TTTCACTCTA GCCTACATAG AGCTTTCTGT TGCTGTCTCT TGCCATGCAC 360

TTGTGCGGTG ATTACACACT TGACAGTACC AGGAGACAAA TGACTTACAG ATCCCCCGAC 420

ATGCCTCTTC CCCTTGGCAA GCTCAGTTGC CCTGATAGTA GCATGTTTCT GTTTCTGATG 480

TACCTTTTTT CTCTTCTTCT TTGCATCAGC CAATTCCCAG AATTTCCCCA GGCAATTTGT 540

AGAGGACCTT TTTGGGGTCC TATATGAGCC ATGTCCTCAA ACCTTTTAAA CCTCCTTGCT 600

CTCCTACAAT ATTCAGTACA TGACCACTGT CATCCTAGAA GGCTTCTGAA AAGAGGGGCA 660

AGAGCCACTC TGCGCCACAA AGGTTGGGGT CCATCTTCTC TCCGAGGTTG TGAAAGTTTT 720

CAAATTGTAC TAATAGGSTG GGGCCCTGAC TTGGCTGTGG GCTTTGGGAG GGGTAAGCTG 780

CTTTCTAGAT CTCTCCCAGT GAGGCATGGA GGTGTTTCTG AATTTTGTCT ACCTCACAGG 840

GATGTTGTGA GGCTTGAAAA GGTCAAAAAA TGATGGCCCC TTGAGCTCTT TGTAAGAAAG 900

GTAGATGAAA TATCGGATGT AATCTGAAAA AAAGATAAAA TGTGACTTCC CCTGCTCTGT 960

GCAGCAGTCG GGCTGGATGC TCTGTGGCCT TTCTTGGGTC CTCATGCCAC CCCACAGCTC 1020

CCAGGAACCT TGAAGCCAAT CTGGGGGACT TTCAGATGTT TGACAAAGAG GTACCAGGCA 1080

AACTTCCTGC TACACATGCC CTGAATGAAT TGCTAAATTT CAAAGGAAAT GGACCCTGCT 1140

TTTAAGGATG TACAAAAGTA TGTCTGCATC GATGTCTGTA CTGTAAATTT CTAATTTATC 1200

ACTGTACAAA GAAAACCCCT TGCTATTTAA TTTTGTATTA AAGGAAAATA AAGTTTTGTT 1260

TGTTAAAAAA AAAA 1274

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1133 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

AGGATTTTTC CTTGTTCAAC CAAAATCTGA GCATTCTTTC TATGTTGAAA ACACTGAAAA 60

ACTAATTTWA GTTAATGAAC TAGAAAGAAT ATTGATTTTW AAGAAACAGA AAAATACTAC 120

TTATTTTCCT TCTCAAATAA CGTTTCTTTC AAAAACTTCT GGCTGAAGTA TAACATGCTG 180

GTAGTTAACA TAAATCTTGT CTTTCTCTTG TTCTTTATCT TTCTTTGTTA TTTAGATGCT 240

TGTATAAATG TCTTTTGTTT TTATTAAGTG CCTAATTGAC AGAGCTTAAT TTGAAGAAGT 300

GCCCTAATTT ATTGACCACT TAAGAATTGC CTTTATTGGG GTATTTTATT TGTTCCTGCG 360

TCTTTTTGAT GTTGTTCAGT CTATTCATCC CTGTGAGTAT GTGTGGGGGA CAGCTGATAG 420

AAGGGAGGAG AGTGTGTCTA TGCTCAGGAT TGCCCTTTAG CCACTCAGCC AGAGATCCAC 480

AGGGAGCAAC AAGGACAGTT TCACATGCTT AGACTTTCTT GGAAGAAACA GTGAGGAGGA 540

GTAAGTCGTG AGTAGTGTCA AGCTGGATGT AGAATTGTCC TAAGGCAGTT GACCCCACCT 600

TCCAACATGT TTTCACTTTA TTTGCCCCTC CCTACATTTG GGTTAGGTTC CATTTGGATT 660

TGCAGCAATA ATGACTTTAT TTCTCTCTTG GTCAGGATTT GGCACATAAA ATCCTTTTAT 720

TATAGAACTA GCTATTTTAG TTACATAGTA ATGTAACTAA TGGAGAGATT TATAGAGAAT 730

TTTGKTTTTG CTCTCATATA TGTCCATTTT GGAGACAGAT ATGATAGAAC TAGAAATTAA 840

GTTGCATTTC TGCAAGTGCC ATTTGAATGA ACTTCAAGTA TCTTCTTAAT TATTAAATTT 900

TCTGATGAAG GCATTCTAAC AAATATATAG TATTATTAAA TCTAATTAAT ATTTGGAAAT 960

ATTAATAAAT AGGTATTTTA TTTACTGTAA AAAGTCAAAC TTCATTATGT AGATAAATCT 1020

TATTCTTTTC ATTCTTTCCC CTGTTTACAT CCTTTTTACA AAGCTTAGTC ACCAATTAAA 1080

GCTTTCCTAT CAAAAAAAAA AAAAAAAAAA ACTCGAGACT AGTTCTCTCT CCT 1133

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 661 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

```
GAATTCGGCA CGAGGGGAAA AGGATGCTGA ACGAGAGCAG AAAGCCTCTT TCCTTTGCTT      60
CACGCCTTTC CAGTCTTTAT TTTAAACTCG GGTTCCCTTT CTGTGGTCGC AGCAACCTTT     120
ACTCCACCTG CACTGCTGCT CCTGGGGGCT CCCCAGGCCT CCCTCTGCCT TTCTACCCAG     180
TGGCTGACGG GATGCCTGTC TTGCCTGGAC GCACCACTGC TCTCCTGTCC CTCACCTTGG     240
CTTTTGCTGT GCCCTGCTCT GGGGTTGAAG CTGGCCCATG TGTCCCCCGG AGTCATGGCT     300
GCTCCTCCTG GGAGGCCTCT GTGTGCGTCA CGTCTTCCAC ACCTGGGGGC AGCTGGCGAG     360
CCCGTGCTCT GTTCCCCTCG GCTGCTTGGC ACAGAGYTGC AGCCTGGGAY TCTCCGTGGA     420
CCCAGACTGG GGATTTTGCC AGGGGGGCGA TGGGAGGAGC AGGTGCTTTG CCTGGCGGCT     480
GTGTCTGCAT TTCTGGACGC CCCAGAGCAC AGAAGTTGCC GGCACTTTGA GGTCTTCCTC     540
GGCATGTGCC AGATTACATG AGTGACGGCT GGGAATATGT TTTCTTTTTT GTAATGGAGG     600
CGTGTTTCAC ATATAGTAAA GCTCACCAAA AAGTAAAAAA AAAAAAAAAA AAAAAACTCG     660
A                                                                     661
```

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1378 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

```
ATTGGGTACC GGGCCCCCCC TCGAAGTTTT TTTTTTTTTT TTTTAATGAA AGCTCTCAAA      60
TAAGCGATTT TATTCCTATC CATGATTGCA GACATTTACA AAACCATAAC ATCTGAGTTC     120
ACCTTAAAAA ATAACTTATA TAAAGCAGTG ATATACACAG CACAAAATAG TTCAGGGAGG     180
GGGCAGGAGC AACTTGTAAT AATTAAAATG TAAACGTGAA AAAAAGGATG GAATAAAAGT     240
CCCTACTTAT TTCTACTTAA GATGTCATGT GATAATATTT TACAATGTCC TGTGGGTCAA     300
TGTATGTATG TGTATATGTC TGTATAACAT ACACATATAC AGTACATTCT CTTTCCCACA     360
CATATACATA CACACATAAT TATTTGCAGT TCAGTTTAGG GCAATTCTAA TATGCCACTC     420
CGTACAGTTG TTTGAATCAC ATTTGGACCC GCTTTCTTCA CAAAAGAGGG GAGAGAGCAG     480
```

GAAATAAAAA GGTTGGTTTG GTGTGACTGA GATTCCTTTG TTTAACTGTA CACTGTGATG 540

AATAATTTTC TTCCGTAGTA GTTCTGTGAA GGGCTGACTC ACTGTGGTTT TCATGAGGAG 600

ACTTGGTAAT GGATCACACG CTCATTGTCA TGCTAGGGGA GTAACTCTCA CTCTGAAAAG 660

GATTTAAGAA ATTTCCCCCC ATTTCGCCAT CATCCCTTGG AGTGCCCGGT TGATTACTCA 720

GGCTCATATT ATTGGGAGAA TTCTTGGAAA TACTGTCCAT ATCTCCTGAG CCTAAAGAGC 780

CATTCATGTG ATGTGACTCC ATTCCTCCTA ATCCACCCAT GGGACCATCT GACCCAGGRC 840

CCATTGGAAA ATTAGGTCTG TTAGGTCCAG GAGGTACTGC ATTCATTAAA GTATACATGT 900

TATCACCAGA GTTGGTTGAA TCTGCTGGAC TAGGCATGAT GGGTGTTCCT GGTGGCCCTC 960

CACCTCCTGG AGGACCTACA TAATTCCCAG GAGATGCTGA GGAGTATGGT ATTGAATTGG 1020

CATTTGTTGG GTTTGGCCAA GGTCTACCAC CACCTGGACC CATGTTCATT CCAGGCATTC 1080

CAGGGCCACC TAAAGCATTC AGTGGGGGTC TTATTGCACC TCCATAGTTC TGTGGTCCTA 1140

AGGGCACCAT TCCTCTTGGA GGAGTCATTC TCTGCATTGG CCCACCCATA TTTGGATGTC 1200

CTTGTTGTCG AGTTGGATCC ATTCCACTGG GGAGTAATGG CTGACTTCCT GGGACACCTC 1260

CAAGTGCCTG ATTAGGTATC CTCAATGGGG GCCTTGGACC TCCAGGGTAC CGAGGTGACA 1320

TAAAAGGGTA ATCATGGAAG GCTTTTCCTT CACTTGAGTG TTCACATGTT TCACGTCT 1378

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1440 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

ACTTTGTCCA AATGTGTCTG TCACATGTAG TCAGCTGNAG NAATTTAAAA TGAATTGCCA 60

AGTGAAGAGT CTGTGGATTA ATTGGCCGTT AATTAACAGG CTTTATCAAT GTGTCCTCAA 120

GGGAGAGGCC CAACCCTAAT TAAGGAGCTA AACTTCCTGA GTGAGGGGCT GTGAGGATGG 180

AGGTGGAGGA GGCATCTGGG GCGGGTGGTG GCCGGGCCAG CAGATGGCGC CTCCCTGGCT 240

GAGCTGCCCG CACCGCCAGT TCCCTCATTT CCACTCAGGA AGGCAGAGAA GGCAGAGTGA 300

[illegible] 360

[illegible]

[illegible] 540

```
TTTTTTTTTA GTTTTTACCT TTTCTTAATT ACCCTTATTC CGAATGGACG AACACTTTCT     600
ACCACTGCTG ACCATTGTAA AATACCGTGT ATATAAATCC CATTGAAATA ATGCCCTGGA     660
ATAGAACATC TCAAATGCTG CTTAATTACA GACTCAGGTC GATTACTTGT ATTTCATGTA     720
ATGTTCCTCC AAGTTAGACA TCTGGTGCAA GACCAACCGG GAGACCATGG AATTGTCAAA     780
AGTACAAACT GACAGTGTGT ATATTTAATT TAAAGACTTA TTTAAAAACT CACAAGCTCT     840
CACCTAGACT TTGGAGAGCA GTCTGTTTTC TGTAATGTCT GATACTAGAA ACTAATTTGC     900
TTATTTTAGT TGTATTCAAG ATTTGAAGAT GTATTTTATA GACAAGTTCT GTTTTTGAAC     960
TTTGTGGAAC TGTTCCAATC AATCAATTTC CCAGTTATGA TGAGTATTTA CATTATGAAT    1020
GTATAACCCA GACATGATTT GTAAAGCCGA CAGTATGTTT CTATTACACA ACACTTTTTG    1080
ATACAGCGTC TCTTGTCTTC ACTGATACTG GAGTCTCCGT TGTCTGGNNG GTCCCTTCGA    1140
GTTTCTAGTT ACAGACACAA TCATACTGTG ATTTTATTTT TAATATGGAT ATGCTATCAA    1200
ACTGTGATAC ACTTATAATT CACTGGTCCT GCATCAGGAG ATGGAGTGGG GAAAACTGTA    1260
TTTAATACAG TTTGTATCTG AATAATCTGT ATGGTTTATA CAGTTTGTGT TGTTCAGAGA    1320
TGTTTAAAGT TTGATCTTTG TTTTTCTAAA GATTAAAAAA GCACTTGCCC CACTGTAAAT    1380
ATACAGCATG TAAAATTTCT RTAGTATATA AATGGCAGCA AATCACAAAA AAAAAAAAAN    1440
```

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1381 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

```
CCCGGGCTGC AGGAATTCGK YACGAGGCCA GCAGTTGCTC CCAGTTCAGG AGGTGCTCCT      60
GTACCCTGGC CACAGCCCAA TCCTGCCACT GCTGACATCT GGGGAGACTT TACCAAATCT     120
ACAGGATCAA CTTCCAGCCA GACCCAGCCA GGCACAGGCT GGGTCCAGTT CTGACCTGAG     180
CACGGTTTTT CCTCATGTGA CTTCTGGGAA GGCGCTCCCT CATCTGGGCC AAAGGAAGGA     240
GGACGAAGCC CTCCTCAGCT GGCCTGTGTT TGGGGCATGA ATCTCTCCTC TCCTCCTTGT     300
CTGGCTCTGT TGACAAACCG GGCATGTTTG GCAGTAAATT GGCACCGTGT CACACTGTTT     360
CCTGGGATTC AAGTATGCAA CCAGAACACA GGAGAAGAAA AGCTCCAGGA TCCCTGTCCC     420
CATCTGTCCT CTTGATGTGA GAGAGACTCT GAGACTTCTT CCATCGCAAT GACCTGTATT     480
```

```
AAACACAAGC CCCCCAAGCA AAAGAAGAGG TTGAGTTTGC TGCCAGGATT CAGATCAGCC      540

CTTCCCAGGG TCTGCAGGTG TCACATGATC ACAGTTCAGC GGGAGGCTTT CCGTACCCAC      600

ACTGGCTGTA GCACTTCAGT CCATCTGCCC TCCAGAGGAG GGTTTCTTCC TGATTTTTAG      660

CAGGTTTAGA GGCTGCAGCT TGAGCTACAA TCAGGAGGGA AATTGGAAGG ATTAGCAGCT      720

TTTAAAAATG TTTAAATATT TTGCTTTGCT AATGTGCTGA TCCGCACTAA CTCATCTTTG      780

CAAAAGGAAC TGCTCCCTCG GCGTGCCCCA GCTGGGCCT CTGAAGGGAT TCCTCACTGT      840

GGGCAGCTGC CCTGAGCTTC AGGCAGCAGT GTTCATCTCT GGCCAGTTGT CTGGTTTCCA      900

TGTATTCTAG GCCAGGTAGG CAACACAGAG CCAAGGCGGG TGCTGGAAGC CAGACGGAAC      960

AGTGTTGGGG CAGGAAGGTG GATGCTGTTG TCATGGAGCT GTGGGAGTTG GCACTCTGTC     1020

TGCTGGTGGC CCTCTCGGCT CACATGTTCA CAGTGCAGCT CCTGGCAGAC TTGGGTTTTC     1080

TCTTTGGTGG TTTCTAAAGT GCCTTATCTG CAAACAACTT CTTTTCTCCT TCAGGAACTG     1140

TGAATGGCTA GAAGAAGGAG CTCAGTAAAC TAGAAGTCCA GGGTTGCTTG GTTTACTGGT     1200

TTATAAGAAA TCTGAAAGCA CCTCTGACAT TCCTTTTATT AACTCACCTC TCAGTTGAAA     1260

GATTTCTTCT TTGAAAGGTC AAGACCGTGA ACTGAAAAAA GTGTTGGCCT TTTTGCGGGA     1320

CCAGATTTTT AAGATAAAAT AAATATTTTT ACTTCTGTCA AAAAAAAAAA AAAAAAATNT     1380

C                                                                     1381
```

(2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1706 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:

```
ACTGCACCAC TGCCCAGGTC TCCCGGCTGG ATGAAGACGT GGTCCATGAG GAAGCTGGCT       60

AGCTCAGACT GGAGAGTAGC TTCAGGAAAA AAGACAAGTG GCCTAAGGAA ATCACGGCCC      120

CCAACTATCA TCTGAGGGCT AAAGATGAGA AGTAGATCAC TTAATAAGAC AAAAGCCTGT      180

AGGGGGAAAA GAAAGGATGT TTAAAAGGAC AGAATGTTTC CCAAGGTAGA AATGACACTG      240

[illegible]

[illegible]

GGGGAAGAAT GAAGACACAG ACT[illegible] T[illegible]CTATTAT[illegible] CCATCTAAGA C[illegible]CACACT[illegible]A      [illegible]
```

```
CCTGGGGAAG CATCTGATTT AGAAATGTGG GTTAGTGTCC AGAGAATGGA AAAATAGACA   540
AGAGTCAAGG CTGGCAGGAT AACCTGTAAC AACAAAGGGT TTGAAAAATG AGGTTTGGGT   600
TAGGAGAGGG AGAGACAGAT AGCCAGAAAC ACACCAGTGA AGAGGAGAGA AAATGAGTAA   660
AGGGAGAGCT AATTCCTTTT CCAGTGGAAA ATGAGTGATA TTCTGGACAT TCTTCAGAGG   720
CATCTACACG AAGTAGAAAT GTCACCGCTC CCTAATTTAC TCTACGTCTT CTAGAATCCC   780
TCAATATTAT CCTTGGCTTC CAGGAAATCC AAGAAGACCC TGGAAGTAGA GTCCACCTTC   840
TAAGAGAGGA ATGTAAGAGG TGACCCCCAC CCACCTGATC TTCCTCGCTT TGTCCACTCC   900
ACGCACTGAG ACTTGACACA CCTAGTGGCC ACCTAGAACG TAGGTCCTTA AAATYTAGCC   960
CCCCAGCCCC CAACCCATCT CTAGCCTGTC CACTCACCTG GTGAGGAACY TYTCCTGTGT  1020
CCACAGCYTT CTGCAGGAGT TGGCAACATG GCTCATAGAG CTCCCAGCGA GTCAGGTCAT  1080
GAGTGCTTTG GGGGAGAAAG GGGAATGTTA TACTGGAAAA GAACAGAGGG AACCAACTCC  1140
ACAGACACCA GTAAAAACGG GGATGGGAAG AGGAGGAAAG CCACTCACTT GTAGAAGGCA  1200
GAGAGGCGTT TCAGAGTGGC TGCCAGATTA TATACCTCAT CCTCATCTAG GAAGGACGAC  1260
TGAGAAGGAA AGAAGATCCA CAATAGCATT TCCCCCAGAA CTCATCAGTC CACATCCCCC  1320
GTCTTGCAGC CCCTCCCACC CTTGTTTGGG GTGTCCCATT GTCCAGCCCC AGCTCCTACC  1380
TGTAACAGCT CTTCAAGCTC CTGCTGGAAR CGGTCAGTCA GCAAATCTAC TAGCTGGCTG  1440
CGGGCAAAGT CCGCCCGGCT GAAGAAAGTG AATTCGGGAT TACAGAGCAG GTAAGAGCAT  1500
GCGCCCCAGC CTCAAGCACC GCTGGCTCTG CATGCTTCAC CACCACCTCC TGGAGTTGCT  1560
GCAGGAACAG CTCCAGGTGC TGAGAAGAAA AGGCAGAAGA TGGTGTGCTG TGGGGATGGG  1620
AGGAGGACAC TCTTCTGGCG GGAAGTGGAA CGGGGTTAAA AGCATTAAAC TTCAAGGATA  1680
AGATGCCTAA RAAAAAAAAA AAAAAA                                       1706
```

(2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 573 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

```
GAATTCGGCA CGAGCTTGGT AGCCTTAGAA CTGCATGAGC TGCTTTACCA CTGGGAAACA    60
CGAGCACAGC CTAGCTTGAT TTTGTATGTG GTATCAGATC TAAGGTGGAT GGAATTCAGG   120
```

```
ACTTCCTGTC TACTCTTTGA TTTTGTTTTA TTTTTAGAAA TGTTTTATTT TGTTTTATTC     180
ATTTATTCAT CTTCAGAGAC ATGGTCTGGC TCTGTTGCCC AGGATGGAGT GCATGGTGTG     240
ATCATAGGCC ACTGCAGTGT TGAGCTCCCG GCCTCAGGCG ATCCTCCTGC CTCAGCTYCC     300
TTAGTAGCTG GGACTATAGG CACATGCCCT ACCATGCCTG GCTTTGTCTA CTTTTTGAAT     360
GATGTCYCAA ACTAGAAGGT CTATTAATTT AAAAAATTAA GGATAGCATG CCATAATTAA     420
AAATAATAAC AGTGGGAAAA GGCACCTTCC AATGATTCAG ACATCAACTT GTGATTTAAA     480
AAAACGAAAA ATAAATAATA GGAAAAAAAG GGGAAAAAGT TAAATAAAAA TAAAATTAAA     540
AAAAAAAAAA AAAAACTCGA GGGGGGCCCG GTA                                  573
```

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 684 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

```
CTCTTTGGCT GTGTCTACCT CCTTCATCTG CTGCGCCGAC ATAAGCACCG CCCTGCCCCT      60
AGGCTCCAGC CCTCCCGCAC CAGCCCCCAG GCACCGAGAG CACGAGCATG GGCACCAAGC     120
CAGGCCTCCC AGGCTGCTCT YCACGTCCCT TATGCCACTA TCAACACCAG CTGCYGCCCA     180
GCTACTTTGG ACACAGCTCA CCCCCATGGG GGGCCGTCCT GGTGGGCGTC ACTCCCCACC     240
CACGCTGCAC ACCGGCCCCA GGGCCCTGCC GCCTGGGCCT CCACACCCAT CCCTGCACGT     300
GGCAGCTTTG TCTCTGTTGA GAATGGACTC TACGCTCAGG CAGGGGAGAR GCCTCCTCAC     360
ACTGGTCCCG GCTCACTCTT TTTCCCTGAC CCTCGGGGGC CCAGGGCCAT GGAAGGACCC     420
TTAGGAGTTC GATGAGAGAG ACCATGAGGC CACTGGGCTT TCCCCCTCCC AGGCCTCCTG     480
GGTGTCATCC CCTTACTTTA ATTCTTGGGC CTCCAATAAG TGTCCCATAG GTGTCTGGCC     540
AGGCCCACCT GCTGCGGATG TGGTCTGTGT GCGTGTGTGG GCACAGGTGT GAGTGTGTGA     600
GTGACAGTTA CCCCATTTCA GTCATTTCCT GCTGCAACTA AGTCAGCAAC ACAGTTTCTC     660
TGAAAAAAAA AAAAAAAAAA AAAC                                            684
```

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1036 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

TGGAGGCAGA TGCACAGGAG AAAGGTTCCC GTCCGCACCC TCTCAGACCT GAGGCTGAGC 60

TTGCAGTGAG GGCTTCTCCT CGGCCCCTCG CCCGCCCCCA GAGCTGCCAT CCCTGCTGTT 120

ACAAGCCAGA GGAGCCCGGA TGTGAGGCCC CAGATCACCT CCAGGGACTT GGGGTTCCCA 180

TCTGAAATCC TTTATTTTTG TACCATGGGG TGGGCCCCGG GCTGAGAAGG AAGAAGCACC 240

CTCTCCCCGG CCTCCTCTGT CTGCACCCGT GGGGCTGTGA CTTACTCCTG CCTCCAGGGG 300

CGGGGCGGGG CCCCCTGGGA CCTCTTAAGG CCCAAGGTGG GCCCCAGGAC CTYTGGGCAG 360

AGTGGAYTGC TCATGGCAGA TGTGTGGCAA TGTCTGGCTG WGTCTTTCCG GCAMCTGCGT 420

YCCCTYTCCC GGGYTCCCCT GCTGCATGGT GGATGTGCTC CTTCCTGGCC CGGTCACATT 480

GCCTCCTTGA GCCTTAGTCC AGGGGGTCAC TYCTCCCACC CCACCTACCT CACAGGGTTG 540

TTGTGAGGGT GCACAGAGGA GCAAAGTCCC TGAAGGCCCT CAGGCAGTAT ATAGGGGCCG 600

CCCACCTTCA GCTGCCCTGG GATGGGAAGG ACCCAGCCCG ACCCCTGGGC ATAACACTGT 660

GTTTGCAAAT GGAGATTCAG GTATTGGGGA TGCAGGTTGT GGGGAGCTGG CCTGGCAGAG 720

TAGGGGTAGT TGGCTTGGCC TTCTCTTTGG TGATCCCACC CCCAGCCATT TGCATTGCTG 780

GCCCAGCGCC TGGCCTGGGG GGCGGGGAGA GGCAGCAGAA GGGGCTGGGC AGGGGCGGTG 840

GAGGACTCAG GAACTGCCCG GGGAGAGTGG GTATGGCGGC TGAGCCAGGG GCCCTCCTGT 900

GTTTGACTTC CCGGGATGGG TCCTTGCTTC TCAGCTGTGT CCGACCCCAC CATGTAATAA 960

AACCCAAAGG AACAGCAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAN 1020

CCCNGGGGGG GNCCCG 1036

(2) INFORMATION FOR SEQ ID NO: 87:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 908 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

TTAAACAAAT GGAATCATGC AATATGTGAC CTTTTGCGTC TGGCTTATTT TATTTAGCAT 60

AATGTTTTTG AGGTTCATCC AAGCTGTAGC ATGTATCAGC ACCTCATTTC TTTTTCTGGC 120

TGAATATTAT TCCATTATAT GGATTTACCA CAATTCATTT ACCTATTCAT CTTTTGTTTC 180

TGCTGTCTGG CTATTGTGAA TAATGCTTCG ATAAACATTC ATATACAAGT TTCTATGTGG 240

CTTTATGTTT TCATTTCTCT TGGCTATCTA CATGGGAGTA GAATTCTAGG TCATAATATA 300

ATTTTATGTT TAACTTCTCA AAGAATTGCC AAAAGGTTTT TCATAGTGGC TGCATCATTT 360

ACATTCCCAC CGGCAATGTA CAAGGATTTC TATTTTTCCA TATCCTTGCA CTTACCAACA 420

CTTCTTTTTK GTWATWATTT TGTTTTTTCA TTATTGCCAC CCTAGTGGAT GTGAAATGGC 480

ATCTTATTGT TTTGATTTGC ATTTCTCTAA TGACAAATGA TATCATACTT TTTTTATGTG 540

CTTACGGATC AAAGGTATTT CCTTGGAGAA ATGTCCCTTC AAGTCCTTTG CCATTTCAAA 600

ATTTGGTTAT TTGTCTTTTA TTATTCAGTT TTAAGAAATT CTGGCCAGGC GCAGTGGCTC 660

ACCTGTAATC MTAGCACTTT GGGAGGCCAA GGCGGGCAGA TCACTTGAGK TCAGGACTTC 720

GAGACCAGCC TGGCCAACAT GGTGAAACCC CATCTTACTA AAAATACAAA AATTAGCTGG 780

GCGTGGTGGC AGGTGCATGT AATCNTATCT ACTCAGGAGG CTGAGGCAGG AGAATCGCTT 840

GAACCCAGGA GGCGGAGGCT GCAGTGAGCC AAGATCACGC CATTGCACTC TAGCCTGGGT 900

GACACAGA 903

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 655 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

TGCACTGGTT CCTTCTCCCC AGCAAATACT GCCTTCTTGT TTTTCTCTGA TGTGGCAGGT 60

GACTACAAAA TCCGCCTTGG TATTCTTCAA ATGCATATAT ATTCCTTTCT TGTCAGCTCC 120

CTCTCTTCCT AGATTAGAAA ACTGCCTCAT TTTCTGCTCA CTGGATGTCC AGTCCCAGCT 180

TGTCTTCCTC TCCTCCCCCC CTGTTGCAGG TGTTCTTTTT TTTTTTCTTC TTTCCCCACT 240

GGGCAGCAAA AGTTGTTCCA CAGTGGAAAW TTAGGCATCC TCAAGTTTCY TCCCAGCTTC 300

TGCTGTGTTT TCTTAGAGTA AATTGCCAAT TTCTGTTTTT ACAGGAAATC CTTTTTTAAA 360

AATGGAATCA GTGTGGTCCC CATCTACTCT GCAAAAATTG CATTTTTCTT TATTTTCAAA 420

[illegible]

AAAAAAAAAA AAAAAAAACY GRACGGGGGC CCGGTACCAA TTCGCCCTAT AATGA 655

(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1102 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

```
TTTTTTTTTT ACCATTTAAA ATAAAATGAA AGTGACCTTC TGTTTATAAA AATCTTTGTC      60
TGCATCTCTG CTTATTTCCT TAGAAGAGAT TCCAAGAAGC GGTGAGTGAT TTCACGGCAG     120
CAGAGGGTTG GGACATATTA CGGGCGCGGA TCCCTCTTGG AGTGAGATGA CTCTCCGGAG     180
AGATTTAGTC GTCACCCTCG CGTGTGAGGC TGCGTCACAC CCCAGGGATG TGTCTATCAA     240
GATGGAAGAT CTTTTACACG CTCTTGATTT TGTTTGSCTY TTTTTCTATT ACTAGTGAGA     300
AKGAAACTTT TTATATGATT ATTATCCATC ATAATCCAAC ACAAATTACT GCTTCATGTT     360
CTTTTACTTT CCTGTGAAGG TTTTAGTGCC TTTTAAAAAT TGCTATATAT TAAGCTTGTT     420
AATACTTCCA TGCTGTATTT GTGGSCATCA RTTTCCCCGG GNACAGGCNT GCACATTTTG     480
CCTTCACACG CTGGGTGGTT TTTCATTTTC AMTTCTATTT CTCGTTCTTC TATCGTTTTA     540
TGTTCAGACG GGTTTCTCCG TGTAGAAAGC AGTTTATGAA GATTTACTTT CGACAGTCTT     600
CTCTCTACTT TCTACAGTGA ATTCTCTGAT GTGTCTGGGA GTTTGGGGGT CTGGGTAAGA     660
RTCCTCCTCT CACCCTATTC TCTATTACGA TCCACAGCCT CATGCTTTAT GARATTGGTG     720
GCCGGGARCG GGGGAGATTT GCGGATCCCC CAAGCCAGAC TTTATCCCCC TATCCCTGCC     780
TCTGGATCCC ACGTACAGGC CTGGGAACTC CCTGTGGGTA GGGGCCAATG GTCTCGCACT     840
CTCACCTGTA CCCCAGGGCT GGCACAGGAT GGTCAAGGAG AGAGGCTGCC CAAGCGCATC     900
CYTCTGGTGT CCCCCTGACA CGCCTCCAAA GTGAGCAGGT AGGTTTCAAC AGCCCCACGT     960
TGCAGGTGGG AGATGAAGCT CAGGGTGGAG ACCAGTATCT CACAGTTCTC TTTGCATGGC    1020
CGGGTACTTG TTAGTCAACT GATCAAGTGA AAATTCTAGC CCCAGAGGCA GGAGGAATCCG   1080
GAACAAAATT AAACCAGCCA GG                                            1102
```

(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1533 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

```
GGCACGAGCC GNCACGGGCA GCGCCCCATA GCGCCAGGGA CCCCCTGGCA GCGGGAGCCG     60
CGGGTCGAGG TTATGGATCC AGCGGGCGGC CCCCGGGGCG TGCTCCCGCG GCCCTGCCGG    120
TGNCTGGTGC TGCTGAACCC GCGCGGCGGC AAGGGCAAGG CCTTGCAGCT CTTCCGGAGT    180
CACGTGCAGC CCCTTTTGGC TGAGGCTGAA ATCTCCTTCA CGCTGATGCT CACTGAGCGG    240
CGGAACCACG CGCGGGARCT GGTGCGGTCG GAGGAGCTGG GCCGCTGGRA CGCTCTGGTG    300
GTCATGTYTG GAGACGGGCT GATGCACGAG GTGGTGAACG GGCTTCATGG AGCGGCCTGA    360
CTGGGAGACC GCCATCCAGA AGCCCCTGTG TAGCCTCCCA GCAGGCTCTG GCAACGCSCT    420
GGCAGCTTCC TTRAACCATT ATGCTGGCTA TRAGCAGGTC ACCAATGAAG ACCTCCTGAC    480
CAACTGCACG CTATTGCTGT GCCGCCGGCT GCTGTCACCC ATGAACCTGC TGTCTCTGCA    540
CACGGCTTCG GGGCTGCGCC TCTTCTCTGT GCTCAGCCTG GCCTGGGGCT TCATTGCTGA    600
TGTGGACCTA GAGAGTGAGA AGTATCGGCG TCTGGGGGAG ATGCGCTTCA CTCTGGGCAC    660
CTTCCTGCGT CTGGCAGCCC TGCGCACCTA CCGCGGCCGA CTGGCCTACC TCCCTGTAGG    720
AAGAGTGGGT TCCAAGACAC CTGCCTCCCC CGTTGTGGTC CAGCAGGGCC CGGTAGATGC    780
ACACCTTGTG CCACTGGAGG AGCCAGTGCC CTCTCACTGG ACAGTGGTGC CCGACGAGGA    840
CTTTGTGCTA GTCCTGGCAC TGCTGCACTC GCACCTGGGC AGTGAGATGT TTGCTGCACC    900
CATGGGCCGC TGTGCAGCTG GCGTCATGCA TCTGTTCTAC GTGCGGGCGG GAGTGTCTCG    960
TGCCATGCTG CTGCGCCTCT TCCTGGCCAT GGAGAAGGGC AGGCATATGG AGTATGAATG   1020
CCCCTACTTG GTATATGTGC CCGTGGTCGC CTTCCGCTTG GAGCCCAAGG ATGGGAAAGG   1080
TGTGTTTGCA GTGGATGGGG AATTGATGGT TAGCGAGGCC GTGCAGGGCC AGGTGCACCC   1140
AAACTACTTC TGGATGGTCA GCGGTTGCGT GGAGCCCCCG CCCAGCTGGA AGCCCCAGCA   1200
GATGCCACCG CCAGAAGAGC CCTTATGACC CCTGGGCCGC GCTGTGCCTT AGTGTCTACT   1260
TGCAGGACCC TTCCTCCTTC CCTAGGGCTG CAGGGCCTGT CCACAGCTCC TGTGGGGGTG   1320
GAGGAGACTC CTCTGGAGAA GGGTGAGAAG GTGGAGGCTA TGCTTTGGGG GGACAGGCCA   1380
GAATGAAGTC CTGGGTCAGG AGCCCAGCTG GCTGGGCCCA GCTGCCTATG TAAGGCCTTC   1440
```

(2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 575 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

```
ATCCTCTGGA ATCTAGGTGG AAGCCACCAA GCCTTCTTCA CACTTGCGTT CTGAGCATCT     60
GCAGACTTAA CCCCATGTGG CAATCACCAA GGCTTATGGC TTGTGTCCTC CAGAACTGTG    120
GCCAGAGCTG TACCTGGGCC CCTTTGAGCT GAGGCTGAAG CCAGAGTCTG AAGCTCAGCA    180
GGGCAGTARG GCCCTGGGCC TGGCCCCTGA AACCATTCTT TTCTCCTAAG CCTCTGGGCC    240
TTTGATGGGA RGGGCTGTCC TCAAGATTTT TGAAATGCCT TTGGAGGGTT TTTGCCTTGT    300
CTTGGATATT GGCTTCCTTT TAGTTATGCT CATCTCTCTA GCAAGTGAAT GTTTCACAAC    360
CTGCTTGGAT TCTTTCTCTA CCACAGARCC AGGCTGCAAA TTTTACAAAC TTTTACACTC    420
TGTTTCCCTT TTAAATATAA ATTTCAATGT TAAGTCACTT CTTTGCTCCC ATATCTGATT    480
TAGGTTGCTG GAAGTAGCCA AGTCACCTCT TGAATGCTTT GCTGCTTAGA AATTTCCTCT    540
ACTAGGTAGC CTGGGTCATC ACACTTAAGT TCAAA                               575
```

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 639 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

```
TCCTTTCATC TTAAGCACCA CCCGACAGGG CAGGTACTAT TACCATCTCC GTTTGACAGA     60
TNAGGAACCT GGCACAGGAA GCATTTAAGT GGATTCCCCA GGATCGCCCC ACTGTCAGGA    120
GCAGANTCAG AATGGGCCTC AGCATCAGGC TCCCAATCCT GGCTTCTAAC TGCTGCGCTC    180
TGCCCTTCYC TCWCCCCACC TCCCCACTCC AGTGCCTTTG GTCATGCCAC TGCAGCTTTC    240
AGGCCAATAC TGGATTAGCC TCTTAGTGTT CTTGTCCCTG CAGCCATTTC CCCAGGCAGC    300
AATTCCATGT GCCCTCACTG ATGTAGGTGG CTCTTGTGTC ATTTGTCACA TCCTATTGAA    360
TTGTTTATGC ATCTTGTTCA CACTCACAGC ACCCTCCCTC TCACACGTCC TCCTTATAAA    420
AATGTCCCTC AGTGTCTGCT ATGAGCCAGG TGCAGACTTA AGTGACAGGG CTGCTACGGG    480
```

AAATAAAAAA TTAACAAGGA GCACCTGCCT CTTAATGCAC AGTAACAAAC TATGTTAAGT 540

GTCAGGAAGG AAAGGTTAAG GATGCCAGGA AGGCTTTTAA TAAATAACCT GACTTAGATG 600

GGCAGGTGGT GCTGARGATT AAGAACGTGT TCTTCTCGA 639

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 744 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

GAATTCGGCA CGAGAGTGGC TGGAGTCTGG CTGCAGAGGG AAGACATCAG CAGGGAGGGA 60

GCCAGGGCCT GTCACATCTT TCCTCTGGCC ATTGTCCTGG TCTTTGTAAG CCCAGAATCT 120

CCCCTTCCCT GAAGGGAGGC CAGCACCCCA GGAGGGCAGC AGGTGTGCTG TGAGGGTTGG 180

AGTAGTGTGA GAGGTCAGGG TACACTAGAA TGGCCATGGA CACCATGTGG GGGTGCTCTG 240

GGCTGGGCCA CAGAACAGTG TCCTTCCTGC TGCTCCTCCC CTGCAGCTTC CCCCGACCTT 300

GTNGTTTATT TGGTTTGATA CCAATCAGCA GACCCTGCAA GGTGGAAGCT CCCAGGCTCT 360

CAGTCCCACS ACTCTCATGT GCCAGTCACC CNTACTGTAA CTGCCCAATG AGTACTTCTT 420

GCCCACTGCC AAGATAGAGC CAGTTTACCA AGACAGGGGA ATTGCAGTAG AGAAAGAGTT 480

GAATATACAT AGAGCCAGCT AAATGGGAGA GTGGAGTTTT CTTATTACTT AAATCAGCCT 540

CCCYTAAAAT TCAGAGGTGA GAATTTTTCA AGGACAGTTT GGTGGSCAGG CCTAGGGAAT 600

GGATGCTGCT GATTGGCTAG GGATGCAATC ATAGGGGTGT AGAAAAGTWC CTTGTGCACT 660

GAGTCCACTT TTGGTGAGAG CTACCAAGGA GCTGCTGGTC TGCTGGTCCC GGTAGAGCCA 720

TCTGGTGTCA GGAATGAAA AGTG 744

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 526 base pairs
(B) TYPE: nucleic acid

[illegible]

AAGCCCATAA GTGCTGGCCT GTTGGGACAA ATGAGAGAAA TCCCATAGGG TGGTGATGAC 120

AGCGCAYTCA GCCATCYTAY TCCTGGGGAA AATGAAACTT GTGCTCCTAT CAAATGCTCA 180

GTTGTAAAAC TGGAAAAAAA TTTTAGAAGA CATCTTGTCC AGCATCTGTG TTTATGTCTA 240

TAAAATGTAG AAAACTAAAG CACAGAGATG TTAAATGTTT TGTCCAAGGT CCAACAGCTG 300

GTTAGCARGC TTGGTCTGGT GACCTTTCTA CTGAACCACA GTGCCGCTGG GGGAAGTCCT 360

CAGCACAGAT GGCTGCTGCT ATAGCTGGGG TATGGCAGT ATTAGTAGTT AACCAGTCAA 420

CCCAAGTTCC CATAGTCTAG GTTCTGCTTC AGCTGGAGGT TAGGGAAAAA CACAAGAAAA 480

TCCCTTACCA CTCTACCAGT GCTGGGGGAT GTACTAAGAG ATCCCC 526

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 426 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

GGCACAGGGC AGGAGAGACT TGGTCCATGG GGAGAAGCCT GCAGTATAGA TGGGACCTCC 60

AGGAGCCCAA GTAGCATAGA CCCTGCTGAT CCGGGGCCAT TGAGCCAGAG GATTTGGGCT 120

GAATGTCCCC AGAGACAAAA GGGAAAGGTA GATCCTTTCC CTTAAAGATG AAAGCCATCG 180

CCCGGGCTTG CTTATTGCTC TCTCTCCTGG TCCTTCCACA TGTTGTTTCT GAACATTTGT 240

TCTGGCATCA CAATCCCCGT CATCCTGTCA TCTGGCCCTT CCCACCTTTC CACCTTATCT 300

CTTGCAGTGT CTCCGCGTCG ACCTGGCACC TGGGTGAARG CTTGCTCTTG CTGGTGCCCA 360

TAGCCCCCAG TGTATGGTCT TGAMCTCCCC AGCCATATGG ARACCCACCT CAGGAGGGCC 420

CCTCGA 426

(2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 844 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

GGCACAGCGG CACGAGATAG GAAGCTTGGC AGGGGCAGCT CCCCCAGTGC GCATTGCCCT 60

GTAACTCGAG CGCCTGGGAG TGGGGAGAGG CTTGGAAATG GAGCAGGGTG GTGGACCTCG 120

TCTTCTCCTG CTCATCCCAG GCCTCCTCCA TAACACCTAC CTAGCACGGC CTGGGGACTT 180

CCCAGCCCAA GGAACAACTG AGAATACTGA GTGCCAGGGT AGCCCTAGCC CCATTTCACA 240

CCTGGGCAAA GTGAGGTCAC TGGATTCAAA CACTCAGATT TAAACCTCCT CTGTGTCTGC 300

AGCACCTGTA TATAACTGCC AGCCTCTGCT GCCCCTCTCC AAAAAGTCTC TGCCCTTGTC 360

TTTGGCACCT GTCTCTGTCC TCCCCATTCT CTGCTCCTCC TTTCTCCAAC TCAGANTCAC 420

CCTGTTAGTT CAGCAAATGT TCATCGAGCT CCATAATGTA GCAGGACAGG NCTGTCTAAC 480

AGATTCTGGN CTTGCAAGCG TGAGACAAGT ACTCTCCATC TTTCTCTCAT CTTCACAGAT 540

GGTCTGCTCA ACAACTTTGC ACTGAATTGT AAATAATTGA TACTGCATAA AACATTGATG 600

TTCTTTAAGG GTAGCCCAGC AAGGTGGCAA GTCTTATAAT GATAACTGCT CAAGGATCTC 660

TCAGTGAAGC ATTTGGGGGT GCTAGCTCTG CCTATGGGTG AGGTCAGCTA TCTCACGCCA 720

TCTACTTCCA CNTGCCCCCC CATGCCAGGC TCACCCTGAG CTGAGATGCC TGAGCAGGTG 780

GCAGAAAGGA GCCACCTGGT TTATGCTTCG GGACCACAAA CTCCTCTATC CAGANGACAG 840

TTTT 844

(2) INFORMATION FOR SEQ ID NO: 97:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1985 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:

AGCCCTGCTG AAGTACAGGT TCTTCTATCA GTTTCTGTTG GGCAATGAAC GAGCAACAGC 60

AAAGGAGATT AGGGATGAAT ATGTGGAGAC CCTGAGCAAG ATTTACCTGT CTTACTACCG 120

CTCTTACCTG GGCGGGCTCA TGAAGGTGCA GTATGAAGAA CTCGGTGAGA AAGATGATCT 180

AATGGGTGTG GAAGATACAG CAAAGAAAGG ATTCTYCTCA AAGCCATCGC TCCGCAGCAG 240

GAACACCATT TTCACCCTAG GAACCCGCGG CTCTGTCATC TCCCCCACTG AACTTGAGGC 300

CCCCATCCTG GTGCCTCACA CAGCGGAGCG GNAGAGCAGA GGTATCCATT TGAGGCCCTC 360

[illegible] 540

[illegible] 600

```
GTTCCTGCCC TGGACAGGTA CTGGGGAACA GGTGCTTGCC TTGCTATGGC CACGGTTTGA     660
ACTGATCCTG GAGATGAATG TTCAGAGCGT CCGAAGCACT GACCCCCAGC GCCTAGGGGG     720
GTTGGATACT CGGCCCCACT ATATCACACG CCGCTATGCA GAGTTCTCCT CCGCTCTTGT     780
CAGTATCAAC CAGACAATTC CTAATGAACG GACCATGCAA TTGCTGGGAC AGCTGCAGGT     840
GGAGGTGGAG AATTTTGTCC TCCGAGTGGC AGCTGAGTTC TCCTCAAGGA AGGAGCAGCT     900
TGTGTTTCTG ATCAACAACT ATGACATGAT GCTGGGTGTG CTGATGGAGC GGGCTGCAGA     960
TGACAGCAAA GAGGTTGAGA GCTTCCAGCA GCTGCTCAAT GCTCGGACAC AGGAATTCAT    1020
TGAAGAGTTG CTGTCTCCCC CTTTTGGGGG TTTAGTGGCA TTTGTGAAGG AGGCTGAGGC    1080
TTTGATTGAG CGTGGACAGG CTGAGCGACT TCGAGGGGAA GAAGCCCGGG TAACTCAGCT    1140
GATCCGTGGC TTTGGTAGTT CCTGGAAATC ATCAGTGGAA TCTCTGAGTC AGGATGTAAT    1200
GCGGAGTTTC ACCAACTTCA GAAATGGCAC CAGTATCATT CAGGGAGCGC TGACCCAGCT    1260
GATCCAGCTC TATCATGGCT TCCACCGGGT GCTGTCCCAG CCGCAGCTCC GAGCCCTCCC    1320
TGCCCGGGCT GAGCTCATCA ACATTCACCA CCTTATGGTG GAGCTCAAGA AGCATAAGCC    1380
CAACTTTCGA TGTGCCAGAA ACCGCCCTGA GATCTGCCGG TCATCTCCAT GGACTTCTGC    1440
ACCCCATTCC ATACCCTTCT TCACCTGGGG TACCCCTTCC AGTTTTCCCC TTGCTTCCCA    1500
GGCCCTTGAC ATGGCTTACC TGCCTTCACT CCCAGCACCT TGCCCAACAG GATAAGCTGG    1560
ATCCCCTTGG CCTTCTGAAT ATCCCAGTGT CTTCAGGTTT CCCAAGACCA CTTCCCTGTG    1620
GGCTTCCAAA ATGGCCTTTA TCATTTCTCC AGTCTGTCAC CCTCCTTTCC TGCTCCCATA    1680
CACCCAAGGC TTGTTTCTTC CCCTGTAAAA ACCACTGCCT CAATCTCTGG TTCACTCAAC    1740
TAGTCACCAT GTCCTGAGGC ATGAAGCCTC CTCAGCTCTT GGAATTGCTG GCAAGGGGTG    1800
ACTGCCTCTG AGTCATTGTG TTTTTCAAAG TGATTTCTTT TCTGTAGCTT TTTGACCTAA    1860
GATCTCAGCA ATTTGAACAC TAACCTCTCC CCTCCTGGCT CAAGAATTAC TCCGAAGTCA    1920
GTCTGCAGAA AATAAATATT TAGTATGACA TGAAAAAAAA AAAAAAAAAA AAAAAAAAAA    1980
AAAAA                                                                1985
```

(2) INFORMATION FOR SEQ ID NO: 98:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1416 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

```
ATATGAAGGG AAAGAATTTG ATTATGTTTT CTCAATTGAT GTCAATGAAG GTGGACCATC      60
ATATAAATTG CCATATAATA CCAGTGATGA CCCTTGGTTA ACTGCATACA ACTTCTTACA     120
GAAGAATGAT TTGAATCCTA TGTTTCTGGA TCAAGTAGCT AAATTTATTA TTGATAACAC     180
AAAAGGTCAA ATGTTGGGAC TTGGGAATCC CAGCTTTTCA GATCCATTTA CAGGTGGTGG     240
TCGGTATGTT CCGGGCTCTT CGGGATCTTC TAACACACTA CCCACAGCAG ATCCTTTTAC     300
AGGTGCTGGT CGTTATGTAC CAGGTTCTGC AAGTATGGGA ACTACCATGG CCGGAGTTGA     360
TCCATTTACA GGGAATAGTG CCTACCGATC AGCTGCATCT AAAACAATGA ATATTTATTT     420
CCCTAAAAAA GAGGCTGTCA CATTTGACCA AGCAAACCCT ACACAAATAT TAGGTAAACT     480
CAACCAACTT AATGGAACTG CACCTGAAGA GAAGAAGTTA ACTGAGGATG ACTTGATACT     540
TCTTGAGAAG ATACTGTCTC TAATATGTAA TAGTTCTTCA GAAAAACCCA CAGTCCAGCA     600
ACTTCAGATT TTGTGGAAAG CTATTAACTG TCCTGAAGAT ATTGTCTTTC CTGCACTTGA     660
CATTCTTCGG TTGTCAATTA AACACCCCAG TGTGAATGAG AACTTCTGCA ATGAAAAGGA     720
AGGGGCTCAG TTCAGCAGTC ATCTTATCAA TCTTCTGAAC CCTAAAGGAA AGCCAGCAAA     780
CCAGCTGCTT GCTCTCAGGA CTTTTTGCAA TTGTTTTGTT GGCCAGGCAG GACAAAAACT     840
CATGATGTCC CAGAGGGAAT CACTGATGTC CCATGCAATA GAACTGAAAT CAGGGAGCAA     900
TAAGAACATT CACATTGCTC TGGCTACATT GGCCCTGAAC TATTCTGTTT GTTTTCATAA     960
AGACCATAAC ATTGAAGGGA AAGCCCAATG TTTGTCACTA ATTAGCACAA TCTTGGAAGT    1020
AGTACAAGAC CTAGAAGCCA CTTTTAGACT TCTTGTGGCT CTTGGAACAC TTATCAGTGA    1080
TGATTCAAAT GCTGTACAAT TAGCCAAGTC TTTAGGTGTT GATTCTCAAA TAAAAAAGTA    1140
TTCCTCAGTA TCAGAACCAG CTAAAGTAAG TGAATGCTGT AGATTTATCC TAAATTTGCT    1200
GTAGCAGTGG GCAAGAGGGA CGGATATTTT TAATTGATTA GTCTTTTTTT CCTCACATTT    1260
GACATGACTG ATAACAGATA ATTAAAAAAA GAGAATACGG TGGATTAAGT AAAATTTTAC    1320
ATCTTGTAAA GTGGTGGGGA GGGGAAACAG AAATAAAATT TTTGCACTGC TGAAAAAAAA    1380
AAAAAAAAAA AAAAGGAAAC TCGAGGGGGG GCCCGG                              1416
```

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

```
NTCTACCCTA ATCAAGATGG GGACATACTT CGCGACCAGG TTCTTCATGA ACATATCCAG     60
AGATTGTCTA AAGTAGTGAC TGCAAATCAC AGAGCTCTTC AGATACCAGA GGTTTATCTT    120
CGAGAAGCAC CATGGCCATC TGCACAATCA GAAATCAGGA CAATAAGTGC TTATAAAACC    180
CCCCGGGACA AAGTGCAGTG CATCCTGAGA ATGTGCTCTA CGATTATGAA CCTCCTGAGC    240
CTGGCCAATG AGGACTCTGT CCCTGGAGCG GATGACTTTG TTCCTGTGTT GGTGTTTGTG    300
TTGATAAAGG CAAATCCACC CTGTTTGCTG TCTACTGTGC AGTATATCAG TAGCTTTTAT    360
GCTAGCTGTC TGTCTGGAGA GGAGTCCTAT TGGTGGATGC AGTTCACAGC AGCAGTAGAA    420
TTCATTAAAA CCATCGATGA CCGAAAGTGA CCAAGACCAA GGCCCACCAA GGCAGCAGAC    480
TGTTAATCAG ACAAACAGAT CTCTGAGAAG GTGCATCAGC TGCTTTGAAG GCTGAAGATT    540
GTTTTGTATG ATACTGCACA GCATCAGGCA TTTTAAAGCA GATCTTTACT AAACAGGTTA    600
ATGAGCTAAC AAGCAGGTTC TCTCGTCTTT GGGCTCTTTC CTTTCTGAGT TGCATATTCT    660
ATTTTCTTGT CCCCAAGTAG AGACTAGTAC TACAAAAAGG GACCACATTT TTCAAGTATT    720
TCTAAGTATA AAAAACAAAA CAAAAATCTC TTAGGAAATG TCTAGACCTC CATTCTTGGA    780
TTCCCTTTCT TTCCTTTTAT TTTAAAAAAG AACAGTACCC CTCTTTTAAG ATGCTGTCTT    840
ACATTAATGA GCATCTAATG GAAAGAAGGT ATGAGTTGCA CTGAGGATTA GAATAGTGGT    900
GCGTTAGTGG CATTATCTAT AAATACACTC ACCTAAATTG AAAGCTAAGA AGGAAATGTA    960
AATATAATAT ATATTTATAT TTGATGTAAT ATGGACATCT GCAGATTCTA ATAAACAAGG   1020
ACTATTGCTG ATAGTAGGCT GTGACATACT GTCTTGTGAA ATGGTTTCCT TGACAAAATT   1080
TAAGCTGAGC TTAAAAGCAA AAAAACAAAA AGTACACAGA AATATTTATT AAAATGTAAT   1140
ACAGTTTATT GAACTTTCTA GGTATGGAGT TTGATGGACA GGCTGCCTY TAATGAGTGT   1200
GAAGGTCACT AAGTCACTTA GACATCTCAC CGTGGAAGTT TGTGAGCCTG CATTAGGAGA   1260
TAGACTGATT ACCATACATG ACATAAAAAG GAACAGTGGA TAGCTCATAC TTTATGGTGG   1320
TTCTTCTCCT CCGAAATAAT ATACTGCAGA AATCCCAGAC AGAGCTCCTT ACAAACCTTT   1380
AATTGTAATA TATTTTTGAT GATTATTCAC ATTGAATGCA CAGACCAAGA ATTCAGTGAA   1440
TGTCATTTTT TAAAAAACTA ATTTGTATTG TCTGCTCTAG TGATACAAGT TTTACTAGTG   1500
ATAAACTATT TTAATCAACC ATACTATTCT TATGGAAAAA AATATCTATT TTGGCAGGTT   1560
TCTGTGCCTT TATTTCCCTC TTCTGAAAAA AAGTCTGTGT TTTCATAGTT TGGTTTGCAT   1620
TGTATATCAA TAATTAATCA GGAATGGGTT TTGGTGCCTG AAAAATTGGC CATGGAGGCA   1680
CACCAAAGCT TCAAGCACAA GTCTTGTACA TGGGCCATCA CTGTCTGGTT TCACTTCGTG   1740
```

TGTTTCCTAA ACACATTTAG CTGCTTTTTT AACAAACTCA GCCCCATACT TGAGTCCCTT 1800

GTTGTTGGGA GCATTTCCAG GCATCTTTTA AGGGAACTGT GACAAACAGC CTCGGGCAGA 1860

TGAACACGGA GGCTCTCTGT TGTCTGTCTC TGAGATCTTT GTGTCTGGGA ATGCCTAAAG 1920

NTTTTGNTTT TTTTT 1935

(2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 599 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

GAATTCGGCA CGAGCGTCCA CGCAGCCGCC GGCCGGCCAG CACCCAGGGC CCTGCATGCC 60

AGGTCGTTGG AGGTGGCAGC GAGACATGCA CCCGGCCCGG AAGCTCCTCA GCCTCCTCTT 120

CCTCATCCTG ATGGGCACTG AACTCACTCA AGACTCCGCT GCCCCCGACT CCCTGCTGAG 180

AAGTTCAAAG GGCAGCACGA GGGGGTCTTT GGCTGCTATT GTCATCTGGA GGGGGAAGAG 240

TGAGAGCCGG ATAGCCAAGA CCCCAGGCAT TTTCAGAGGT GGCGGGACCT TAGTCCTACC 300

CCCAACACAC ACCCCTGAGT GGCTCATCCT CCCTTTGGGC ATAACGCTGC CCTTGGGGGC 360

TCCAGAAACA GGCGGTGGGG ATTGTGCCGC TGAGACCTGG AAGGGCAGCC AGCGTGCCGG 420

CCAGCTGTGT GCATTGCTGG CTTAATATGC AGGGCTTGGG GGGCTGTGGC CACATGCCCG 480

GCAGGAGGTG AGTGAGGAGC CCTGTGGCGT GCTGGTGTGG GGATCGTGGG CATTTCAAAC 540

GGGCTTGTCG TACCCTGAAC AATGTATCAA TAGAGAAAAA AAAAAAAAAA AAAACTCGA 599

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 784 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

[illegible]

[illegible]

```
CACTTTGCAC ATCCACTTGT CACCAAATCK RGTTCATTCT GCATCCTAAG TAAGTCCTTT     240
GATTCCTCCA GTTGTTCATT AGTAATGTCT CAARTGTAAT TTTTTCTAGT AGTTTTCAGC     300
CTGTCTTTCC KGCCTTCAGT CTTAACTTCT CCAGTACATA KGCCACATTG TTGTCAGCAK     360
GATCAWATTT TATTTAAAAA TACTTTACAW AKGTTTATKG CCAAATATTA GRAAATACAG     420
ATTCATGGAA AGAAAAATCA CTGTCCCAAG GAGGTCACTG GCATGGTGAG GTTAAGGGGT     480
GATTTTAATT TTTAAAAATG TATATTTTTT CCTGTGTAGA GTAGTAACAC CCTTGAAAAC     540
ACAWTCCCTT GTAAAGTCTC TAATTCTGTA CTCCGCATCT AGSTGRTCTC TTCTTTCTCA     600
GATATTTTAC AATTTCATTT ATCACCACCT TTCTCTAGCC TTTACCCGTC TCTTCAATAT     660
TWACATATGC AGAAGTTTCT CCTAACAAAC ACCTGCCTCT GCCTCAGTTC TGCTACCACC     720
CTGTTGCTTT CTTTCCCTTC ACAATCAAAT TTAAGAGTGT CAAAAAAAAA AAAAAAAAAC     780
TCGA                                                                  784
```

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1035 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

```
AGAGGCCTGG CTGCGTTGCC CTATCTCCGT CTCCGCCACC CACTTAGCGT TTTAGGCATC      60
AATTACCAGC AGTTTCTCCG CCACTATCTG GAAAATTACC CGATTGCTCC CGGCAGAATA     120
CAAGAGCTTG AAGAACGCCG CAGTTGCGTG GAAGCCTGCA GAGCAAGGGA AGCAGCGTTT     180
GATGCCGAAT ATCAGCGAAA TCCTCACAGG GTGGACCTCG ATATTTTAAC CTTTACGATA     240
GCTCTGACTG CCTCTGAAGT TATCAACCCT CTGATAGAAG AACTTGGTTG CGATAAGTTT     300
ATCAATAGAG AATAGTTAGG TGGTGACACT ACTTCAAGAG AACCTCTGCA TTCCAGTCAT     360
ACCAATCCTG CAACTTGATT TTCAGAAGTC AAGAGTATAT CGCGATAAGA CAGTGCACAG     420
GTGGAGGGGA AAAAAAGGGG GAGGGGGAAG CTTATCTTGA AAAAGCATCA CAGAAGTAGA     480
AAAAAATGTC GAAAGCATTA TAACTGTAAC GTTCTTTGAG TTTGTGATTG ATCCACATTT     540
TTCCCCCTGC ATTATGGAAA ATGTCTCTCA GCATTGCTTT ATTACAAAGT AAAGGATGGT     600
TTTATAAAAT TGAGACTGAT GAAACATCAA TACTAGAGCC CATGAGGATG AAAGAAATTA     660
TCAAATAGTG CTGAACAGAA TAAGATGTTA ACGCTGAGTT ATTAGGACTG GAAGGCTATG     720
```

AAAAGAACTT GAAATTGTCG GAATATGTGC TCTCTTCATG TCATATTCAA TAGAAGTTTC 780

TAGTTTAAGA TTGATTTTGT GTTTTCTTAG GCATTTCAAG TGACAAGCAA AGTAAATGTA 840

TATATTATGT GATAAATCAT GTTTTCAAGA ACGTCAAATT TCTGGACTTT TTTCTTTCAA 900

TTTTTAATTT TTAAAGTTTT TTTGGTATTA AAAAATCYAT TCACAAGCCA AAAAATWTWT 960

WAAATWTWCM GCGAAAAGCC AAAAAAAAAA AAAAMMAGGG GGGGCCGGGC CCCATCCCCC 1020

CAAGGGGGTC CNGNT 1035

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2218 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

AGGTATTAGG CCCTTTTGTG GGAGCCCCAT GTTTTGTTTT TCTGAGTTGG TGGGGAGGGA 60

SGGAGGGGGA GGGCTGAATT GTTTTGCAGA GGAAGATGGC ATCTGTGCTT TAAATTTCTC 120

ATTACTGGGT TAGAAAACAA AGAGGGAKTG CCCTGCACAT TTTCTTTTGT GCTTTTAAAT 180

GTTTCTTAAG TTGGAACAGG TTTCCTCGGG CCTGTTTTGA CTGATTGCTG GAGTGCATTT 240

GATAGTTAAA AATTACTAAT TGGTTTTATT TCCCTTCACA CTCTGCCTCC CCACTTCTCC 300

CCCCGTTACT GAAAAATAAC CATTTTAGTG TCAGGCTAGA AATTGAATTG CTGAGTTTTG 360

TGTATCCTTT AAATTAAAAA CCACAAGTGT TTATTGTAGT GGTTAAACTG TAGCATCTCA 420

GCATCTGGGT GGAAGCTGCC TATATTTCTT CCCAGTTTAA CTGGGGACCA TCTGTGAAAT 480

TAATTTTCCA TCCAGACAGC TGCTGTGAGC AAATGAACAT AAATGCTCGC TGGAAATTTA 540

CTAACCAGTT TTTATATTGA CCTGCAGTGT AAAAAGCACA TTTAATTATA AACAATATAT 600

TCAAAATGGG CAAATTTTAT TTTCAAATGC AGTGTAGAGC TAGATTAAAA GCAACTCTTT 660

GCCACCTACT CTGCCCTTTT GGCAAAGTTA CCTTGAACAA AGAATCTTAA GGGTTTATTA 720

AGAACTCTTT ATTTTCTTCA TACCCTGTTC TCTGCAGTGC TTTCTAACAG CTTCTGGGTG 780

CAGATTTTCT TCGGCATCCT TTTGCACTCA GCTTATTACA GGTAGGTAGT GCTTAAGAAA 840

[illegible]

[illegible] 1080

```
GCAGTTGAAG GGGGAAGGCT CCACTGCATT CTTTGGCTAA GGCCTGAATG CTTGCTCATC    1140
TGTAAGATCT ATACTCGAGG TTTTGTTTTC CTTTTAAAAT TCTTTAGGGA GAGAGGGATG    1200
GTTTCTGAGG GCTTCTGAAA GTATGATTCA ATGTGCAACA TACAGGTAGG TCTTCAGCAT    1260
AAGCTGAAAT ATATGCATGT AAAAACTTTG ACATCTTTTT TTTTAATTTT CCACTTTCTT    1320
CTTAACTTTA CTTCTCTTTT TGTCCCCCCC CCATCTTACA GAAGTTGAGG CCAAGGGAGA    1380
ATGGTAGGCA CAGAAGAAAC ATGGCAAACT GCTCTGTGCT TTCAAACCAA AGTGTTCCCC    1440
CCAACCCCAA ATTTGTCTAA GCACTGGCCA GTCTGTTGTG GGCATTGTTT TCTACAACCA    1500
AATTCTGGGT TTTTTTCTTC TTTCTTTAAA CATAGAGGTA CCACCACAAG GGATGCCCTA    1560
CTCTCTTGCA GCTCTTGAAA GCATCTGTTT GAGGGAAAGG TCTCTGGGCA AGCAAGTGGT    1620
TATTTGGATT GCTTGCTTCC CTTTTTCCAC CTGGGACATT GYAATCATAA AATAACAGTA    1680
AATTCCAAAC CTCAAAAACT ATTATGGCCT GAGCACAGCT GAAATCTAGC AGAGTTTAAC    1740
TCTTCTGCCT CCATGTCTGT CACTTATAAT TCAGGTTCTG CTGTTGGCTT CAGAACATGA    1800
GCAGAAGAAT CGTTTTATGC TAGTTATTGC ATTCATGGTT GAAACTCAAC TTAGGGAAAG    1860
GGTTCCAATG TATTAAGCAA TGGGCTGCTT CTCCCCAATC CTCCCTAACA ATTCGTTGTG    1920
TGGACTTCTC ATCTAAAAGG TTAGTGGCTT TTGCTTGGGA TCAGTGCTCT CTATTGATGT    1980
TCTTGCTGGT CTCCAGACAC ATTCCTGTTG CATTAAGACT TGAAAGACTT GTAGATGTGT    2040
GATGTTCAGG CACAGGATGC TGAAAGCTAT GTTACTATTC TTAGTTTGTA AATTGTCCTT    2100
TTGATACCAT CATCTTGTTT TCTTTTTGTA GGTATAAATA AAAACACTGT TGACAATAAA    2160
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAA      2218
```

(2) INFORMATION FOR SEQ ID NO: 104:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 1351 base pairs
   (B) TYPE nucleic acid
   (C) STRANDEDNESS: double
   (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

```
CTTCACAGAC TGACAGAATG GTTTTGTTTT GTTTTGTTTT GTTTTGTTTT GTTTTGAGA    60
TGGACTCTAG CTCTGTCACC CAGGCTGGAG TGCAGTGGTG CGATCTCGGC TCACTGCAAG    120
CTCCGCCTCC CGGGTTCTCA CCATTCTCCT GCCTCAGCCT CCCGAGTAGC TGGGACTACA    180
GGCGCCCACC ACCACGCCCG GCTAATTTTT TGTATTTTTT AGTAGAGACG GGGTTTCACC    240
```

```
ATGTTAGCCA GGATGGTCTC GATCTCCTGA CCTCGTGATC CGCCCGCYTC GGCCTCCCAA    300
AGTGCTGGGA TTACAGGCGT GAGCCACCGT GCCTGCCCCA GAATGGTTTT TAAAGCCACA    360
GTTGAGARGC CACCCATTGC CCGGCGCCTG GATAGTGATC ATCTTGTTCA TCTTGTTCAG    420
TCCTTTCTTG TGTGATTGGA ATTATTCATC CCCTTTGAAA GATGAGAAGG TTGAGATGCA    480
AAGAGTCTAC CTTTCCAAGT TCTCACTGCT GGAAAGARCT AGAAGCACAG TTCAAAGTTC    540
TGGNTTCTGG ACTCTGCAGT CCAGGTYTCC CTTYTCCCAC TTGCCTATCC TCAATGCCAC    600
ACTGTTTTTG AAGTGGCCCA TAACTTGAAG GRAAAGTTTA AAGATAGTTT AATTTAATCA    660
TCAGRATGCA TTCTTTTTTT TTTCGGARAC GGAKTTTCAC TCTTGCTGCC CAGGCTGGAG    720
TGCAATGGTG CAATGATCTC GGCTCACTGC AACCTATGCC TCCTGGGTTC AAGNGATTAT    780
CCAGCCTCAG CCTCCCGAGT AGCTGGGATT ATGGGCGCCC ACCACCATGC CCAGCTAATT    840
TTTGTATTTT TTTTTTTAGT AGAGATGGGG TTTCGCCAGG TTGGCCAGGC TGKTCTTGTG    900
AAYTCCTGGC YTCAGGTGAT YTGCCCACYT CATCYTCCAA AAGTGCTGGG ATTACAGGCA    960
TGAGCCACTG CGCCTGGCYT CAGAATGCAT TCTTACACAT CTATCCTAGA CATTTATAAG   1020
CACTCTAATG GATAACAATC CAAGAATAAA TGATTGTAAA AGATGATGCC GAAGAGTTGA   1080
TGTCAATCTT TTTTTCCTAA GAAAAAAAGT CCGCGAGTAT TAAATATTTA GATCAATGTT   1140
TATAAAATGA TTACTTTGTA TATCTCATTA TTCCTATTTT GGAATAAAAA CTGACCTTCT   1200
TTAATCATAT ACTTGTCTTT TGTAAATAGC AGCTTTTGTG TCATTCTCCC CACTTTATTA   1260
GTTAATTTAA ATTCGAAAAA ACCCTCAAAC TAATATTCTT GTCTGTTCCA GTCTTATAAA   1320
TAAAACTTAT AATGCATGTA AAAAAAAAAA A                                  1351
```

(2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2066 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:

```
GGCACGAGGC GGCGGAGGGC CACAATCACA GCTCCGGGCA TTGGGGGAAC CCGAGCCGGC     60
[illegible]
[illegible]
CAAAAATGGC TGTTGCAATT ATAAAAAATA TGAGCATAAA GAAGTGTGCT ATTTTTGGTG    300
```

GGATTCTGCT CGTGTTCCAA ATCATCGCCT TTCTGGTGGG AGGCTTGATT GCTCCAGGGC 360
CCACAAGGGC AGTGTCCTAC ATGTCGGTGA AATGTGTGGA TGCCCGTAAG AACCATCACA 420
AGACAAAATG GTTCGTGCCT TGGGGACCCA ATCATTGTGA CAAGATCCCA GACATTGAAG 480
AGGCAATTCC AAGGGAAATT GAAGCCAATG ACATCGTGTT TTCTGTTCAC ATTCCCCTCC 540
CCCACATGGA GATGAGTCCT TGGTTCCAAT TCATGCTGTT TATCCTGCAG CTGGACATTG 600
CCTTCAAGCT AAACAACCAA ATCAGAGAAA ATGCAGAAGT CTCCATGGAC GTTTCCCTGG 660
CTTACCGTGA TGACGCATTT GCTGAGTGGA CTGAAATGGC CCATGAAAGA GTACCACGGA 720
AACTCAAATG CACCTTCACA TCTCCCAAGA CTCCAGAGCA TGAGGGCCGT TACTATGAAT 780
GTGATGTCCT TCCTTTCATG GAAATTGGGT CTGTGGCCCA TAAGTTTTAC CTTTTAAACA 840
TCCGGCTGCC TGTGAATGAG AAGAAGAAAA TCAATGTGGG AATTGGGGAG ATAAAGGATA 900
TCCGGTTGGT GGGGATCCAC CAAAATGGAG GCTTCACCAA GGTGTGGTTT GCCATGAAGA 960
CCTTCCTTAC GCCCAGCATC TTCATCATTA TGGTGTGGTA TTGGAGGAGG ATCACCATGA 1020
TGTCCCGACC CCCAGTGCTT CTGGAAAAAG TCATCTTTGC CCTTGGGATT TCCATGACCT 1080
TTATCAATAT CCCAGTGGAA TGGTTTTCCA TCGGGTTTGA CTGGACCTGG ATGCTGCTGT 1140
TTGGTGACAT CCGACAGGGC ATCTTCTATG CGATGCTTCT GTCCTTCTGG ATCATCTTCT 1200
GTGGCGAGCA CATGATGGAT CAGCACGAGC GGAACCACAT TGCAGGGTAT TGGAAGCAAG 1260
TCGGACCCAT TGCCGTTGGC TCCTTCTGCC TCTTCATATT TGACATGTGT GAGAGAGGGG 1320
TACAACTCAC GAATCCCTTC TACAGTATCT GGACTACAGA CATTGGAACA GAGCTGGCCA 1380
TGGCCTTCAT CATCGTGGCT GGAATCTGCC TCTGCCTCTA CTTCCTGTTT CTATGCTTCA 1440
TGGTATTTCA GGTGTTTCGG AACATCAGTG GGAAGCAGTC CAGCCTGCCA GCTATGAGCA 1500
AAGTCCGGCG GCTACACTAT GAGGGGCTAA TTTTTAGGTT CAAGTTCCTC ATGCTTATCA 1560
CCTTGGCCTG CGCTGCCATG ACTGTCATCT TCTTCATCGT TAGTCAGGTA ACGGAAGGCC 1620
ATTGGAAATG GGGCGGCGTC ACAGTCCAAG TGAACAGTGC CTTTTTCACA GGCATCTATG 1680
GGATGTGGAA TCTGTATGTC TTTGCTCTGA TGTTCTTGTA TGCACCATCC CATAAAAACT 1740
ATGGAGAAGA CCAGTCCAAT GGAATGCAAC TCCCATGTAA ATCGAGGGAA GATTGTGCTT 1800
TGTTTGTTTC GGAACTTTAT CAAGAATTGT TCAGCGCTTC GAAATATTCC TTCATCAATG 1860
ACAACGCAGC TTCTGGTATT TGAGTCAACA AGGCAACACA TGTTTATCAG CTTTGCATTT 1920
GCAGTTGTCA CAGTCACATT GATTGTACTT GTATACGCAC ACAAATACAC TCATTTAGCC 1980
TTTATCTCAA AATGTTAAAT ATAAGGAAAA AAGCGTCAAC AATAAATATT CTTGAGTATA 2040
AAAAAAAAAA AAAAAAAAAA AAAAAA 2066

(2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1705 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

AATTCGGCAR AGGGCAGCTG TCGGCTGGAA GGAACTGGTC TGCTCACACT TGCTGGCTTG 60

CGCATCAGGA CTGGCTTTAT CTCCTGACTC ACGGTGCAAA GGTGCACTCT GCGAACGTTA 120

AGTCCGTCCC CAGCGCTTGG AATCCTACGG CCCCCACAGC CGGATCCCCT CAGCCTTCCA 180

GGTCCTCAAC TCCCGYGGAC GCTGAACAAT GGCCTCCATG GGGCTACAGG TAATGGGCAT 240

CGCGCTGGCC GTCCTGGGCT GGCTGGCCGT CATGCTGTGC TGCGCGCTGC CCATGTGGCG 300

CGTGACGGCC TTCATCGGCA GCAACATTGT CACCTCGCAG ACCATCTGGG AGGGCCTATG 360

GATGAACTGC GTGGTGCAGA GCACCGGCCA GATGCAGTGC AAGGTGTACG ACTCGCTGCT 420

GGCACTGCCG CAGGACCTGC AGGCGGCCCG CGCCCTCGTC ATCATCAGCA TCATCGTGGC 480

TGCTCTGGGC GTGCTGCTGT CCGTGGTGGG GGGCAAGTGT ACCAACTGCC TGGAGGATGA 540

AAGCGCCAAG GCCAAGACCA TGATCGTGGC GGGCGTGGTG TTCCTGTTGG CCGGCCTTAT 600

GGTGATAGTG CCGGTGTCCT GGACGGCCCA CAACATCATC CAAGACTTCT ACAATCCGCT 660

GGTGGCCTCC GGGCAGAAGC GGGAGATGGG TGCCTCGCTC TACGTCGGCT GGGCCGCCTC 720

CGGNCTGCTG CTCCTTGGCG GGGGGCTGCT TTGCTGCAAC TGTCCACCCC GCACAGACAA 780

GCCTTACTCC GCCAAGTATT CTGCTGCCCG CTCTGCTGCT GCCAGCAACT ACGTGTAAGG 840

TGCCACGGCT CCACTCTGTT CCTCTCTGCT TTGTTCTTCC CTGGACTGAG CTCAGCGCAG 900

GCTGTGATCC CAGGAGGGCC CTGCCACGGG CCACTGGCTG CTGGGGACTG GGGACTGGGC 960

AGAGACTGAG CCAGGCAGGA AGGCAGCAGC CTTCAGCCTC TCTGGCCCAC TCGGACAACT 1020

TCCCAAGGCC GCCTCCTGCT AGCAAGAACA GAGTCCACCC TCCTCTGGAT ATTGGGGAGG 1080

GACGGAAGTG ACAGGGTGTG GTCGTGGAGT GGGGAGCTGG CTTCTGCTGG CCAGGATGGC 1140

TTAACCCTGA CTTTGGGATC TGCCTGCATC GGTGTTGGCC ACTGTCCCCA TTTACATTTT 1200

[illegible] TTTAGAGGGG [illegible] TAAA [illegible]

CAGGTTTGGG CAGTGGTGGG GGAGGGGGCC AGAGAGGCGG CTCAGGTTGC CCAGCTCTGT 1440

GGCCTCAGGA CTCTCTGCCT CACCCGCTTC AGCCCAGGGC CCCTGGAGAC TGACCCCCTC 1500

TGAGTCCTCT GCCCCTTCCA AGGACACTAA TGAGCCTGGG AGGGTGGCAG GGAGGAGGGG 1560

ACAGCTTCAC CCTTGGAAGT CCTGGGGTTT TTCCTCTTCC TTCTTTGTGG TTTCTGTTTT 1620

GTAATTTAAG AAGAGCTATT CATCACTGTA ATTATTATTA TTTTCTACAA TAAATGGGAC 1680

CTGTGCACAG GRAAAAAAAA AAAAG 1705

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1167 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

TGCAGGAATT CGGCAGAGGT TTTCCGCTAG ACTCTGGCAG TTGGTGAGCA TCATGGCAAC 60

CGTTACAGCC ACAACCAAAG TCCCGGAGAT CCGTGATGTA ACAAGGATTG AGCGAATCGG 120

TGCCCACTCC CACATCCGGG GACTGGGGCT GGACGATGCC TTGGAGCCTC GGCAGGCTTC 180

GCAAGGCATG GTGGGTCAGC TGGCGGCACG GCGGGCGGCT GGCGTGGTGC TGGAGATGAT 240

CCGGGAAGGG AAGATTGCCG GTCGGGCAGT CCTTATTGCT GGCCAGCCGG GCACGGGGAA 300

GACGGCCATC GCCATGGGCA TGGCGCAGGC CCTGGGCCCT GACACGCCAT TCACAGCCAT 360

CGCCGGCAGT GAAATCTTCT CCCTGGAGAT GAGCAAGACC GAGGCGCTGA CGCAGGCCTT 420

CCGGCGGTCC ATCGGCGTTC GCATCAAGGA GGAGACGGAG ATCATCGAAG GGGAGGTGGT 480

GGAGATCCAG ATTGATCGAC CAGCAACAGG GACGGGCTCC AAGGTGGGCA AACTGACCCT 540

CAAGACCACA GAGATGGAGA CCATCTACGA CCTGGGCACC AAGATGATTG AKTCCCTGAC 600

CAAGGACAAG GTCCAGGCCG GGGACGTGAT CACCATCGAC AAGGCGACGG GCAAGATCTC 660

CAAGCTGGGC CGCTCCTTCA CACGCGCCCG CGAACTACGA CGCTATGGGC TCCCAGACCA 720

AGTTCGTGCA GTGCCCAGAT GGGGAGCTCC AGAAACGCAA GGAGGTGGTG CACACCGTGT 780

CCCTGCACGA GATCGACGTC ATCAACTCTC GCACCCAGGG CTTCCTGGCG CTCTTCTCAG 840

GTGACACAGG GGAGATCAAG TCAGAAGTCC GTGAGCAGAT CAATGCCAAG GTGGCTGAGT 900

GGCGCGAGGA GGGCAAGGCG GAGATCATCC CTGGAGTGCT GTTCATCGAC GAGGTCCACA 960

TGCTGGACAT CGAGAGCTTC TCCTTCCTCA ACCGGGCCCT GGAGAGTGAC ATGGCGCCTG 1020

TCCAGCAGGT CTATGGGGAT GCCGTGAGGG CTCTGGTAGC TGGTGCCCCG GATTCGCGTG 1080

ATGCCACGGT TGGTGGCCTC GTGCCGAATT CCTGCAGCCC GGGGGATCCA CTAGTTCTAG 1140

AGCGGCCGCC ACCGCGGTGG ANCTCCN 1167

(2) INFORMATION FOR SEQ ID NO: 108:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1907 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

GGCACAGGGG AATCATCGTG TGATGTGTGT GCTGCCTTTG TGAGTGTGTG GAGTCCTGCT 60

CAGGTGTTAG GTACAGTGTG TTTGATCGTG GTGGCTTGAG GGGAACCCTT GTTCAGAGCT 120

GTGACTGCGG CTGCACTCAG AGAAGCTGCC CTTGGCTGCT CGTAGCGCCG GGCCTTCTCT 180

CCTCGTCATC ATCCAGAGCA GCCAGTGTCC GGGAGGCAGA AGGTACCGGG GCAGCTACTG 240

GAGGACTGTG CGGGCCTGCC TGGGCTGCCC CCTCCGCCGT GGGGCCCTGT TGCTGCTGTC 300

CATCTATTTC TACTACTCCC TCCCAAATGC GGTCGGCCCG CCCTTCACTT GGATGCTTGC 360

CCTCCTGGGC CTCTCGCAGG CACTGAACAT CCTCCTGGGC CTCAAGGGCC TGGCCCCAGC 420

TGAGATCTCT GCAGTGTGTG AAAAAGGGAA TTTCAACGTG GCCCATGGGC TGGCATGGTC 480

ATATTACATC GGATATCTGC GGCTGATCCT GCCAGAGCTC CAGGCCCGGA TTCGAACTTA 540

CAATCAGCAT TACAACAACC TGCTACGGGG TGCAGTGAGC CAGCGGCTGT ATATTCTCCT 600

CCCATTGGAC TGTGGGGTGC CTGATAACCT GAGTATGGCT GACCCCAACA TTCGCTTCCT 660

GGATAAACTG CCCCAGCAGA CCGGTGACCG TGCTGGCATC AAGGATCGGG TTTACAGCAA 720

CAGCATCTAT GAGCTTCTGG AGAACGGGCA GCGGGCGGGC ACCTGTGTCC TGGAGTACGC 780

CACCCCCTTG CAGACTTTGT TTGCCATGTC ACAATACAGT CAAGCTGGCT TTAGCGGGGA 840

GGATAGGCTT GAGCAGGCCA AACTCTTCTG CCGGACACTT GAGGACATCC TGGCAGATGC 900

CCCTGAGTCT CAGAACAACT GCCGCCTCAT TGCCTACCAG GAACCTGCAG ATGACAGCAG 960

CTTCTCGCTG TCCCAGGAGG TTCTCCGGCA CCTGCGGCAG GAGGAAAAGG AAGAGGTTAC 1020

TGTGGGCAGC TTGAAGACCT CAGCGGTGCC CAGTACCTCC ACGATGTCCC AAGAGCCTGA 1080

[illegible]

```
GGACTTGACA TCTTAAGATG CGTCTTGTTC CCTTGGGCCA GTCATTTCCC CTCTCTGAGC   1320
CTCGGTGTCT TCAACCTGTG AAATGGGATC ATAATCACTG CCTTACCTCC CTCACGGTTG   1380
TTGTGAGGAC TGAGTGTGTG GAAGTTTTTC ATAAACTTTG GATGCTAGTG TACTTAGGGG   1440
GTGTGCCAGG TGTCTTTCAT GGGGCCTTCC AGACCCACTC CCCACCCTTC TCCCCTTCCT   1500
TTGCCCGGGG ACGCCGAACT CTCTCAATGG TATCAACAGG CTCCTTCGCC CTCTGGCTCC   1560
TGGTCATGTT CCATTATTGG GGAGCCCCAG CAGAAGAATG GAGAGGAGGA GGAGGCTGAG   1620
TTTGGGGTAT TGAATCCCCC GGCTCCCACC CTGCAGCATC AAGGTTGCTA TGGACTCTCC   1680
TGCCGGGCAA CTCTTGCGTA ATCATGACTA TCTCTAGGAT TCTGGCACCA CTTCCTTCCC   1740
TGGCCCCTTA AGCCTAGCTG TGTATCGGCA CCCCCACCCC ACTAGAGTAC TCCCTCTCAC   1800
TTGCGGTTTC CTTATACTCC ACCCCTTTCT CAACGGTCCT TTTTTAAAGC ACATCTCAGA   1860
TTAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAGGG CGGCCGC                 1907
```

(2) INFORMATION FOR SEQ ID NO: 109:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 611 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

```
ATGAATTAAC GCCAAGCTNT NAATAGGGAC TCACTATGGG GGAAAGNTGG GTAACGCCTG     60
CAGGTACCGT TCCGGAATTC CCGGGTCGAC CCACGCGTCC GATGGGGCTT TAGTAAATCA    120
GGCTTGCAGG CTCAAAGCTG CAATCTGCCC ACTCTCAGGT ACTGAGACTT TGTGGGCCTC    180
AGACACCAGG AAGAAAGTTG GGATACAGTC ATTTGAGTTA AAAAGGGAAT GACCCCTCAG    240
AAACCCGCAT TAGCAGTGTT ACTCTTGGAA GTGCCTTTAC TTTTAACGCT CTCTGTTCTG    300
AAAAAGAGGT GTTTGGTTAC GTGTGAGCCA ACATCACGTT TTGTTAGCTG TGATTTACCT    360
TTGTCCGTTT AAAAGACTTC ACGGAGCCAT TCTGTATACA AGGTGTGCTC TTTCCAATGT    420
AGAAGGGGTT ATGGAAAAGG GTGCGATCCT TTGCTGTAAA CTGGAGAGAC CAGTCCCAAA    480
CAGAGGGGAA TTTTAAGCCC TTCTCATCAC CCAATTGGAT GTTTTTGCTT ATAGCAAATT    540
CCTGCAAAAT AAATAAATAA ATATTTGCAA AACTAAAAAA AAAAAAAAAA AAAAAAAAAA    600
GGGGGGNCCN C                                                         611
```

(2) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2632 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110:

TCCCAGCTCT CAGGACAAGG GCCCTGGGCG ATCTTTTAAA AAAGCCGATT GGGTGTCTTT 60

CTAAAANTAC AACCAGTACT TCATCGTCAA GTTTCTGGGA AGGGAGTCCC CTCCAGATTC 120

TCATGGAGTG ACAAATCTTG ACTCTTGCTC CTGGAATTTT TCAGGCCCAA ACTAGCGTTT 180

CTACAATGAT TTATTTGGCA AATTTGTCTT GATTATGGGT GGCTGATGAG GAACGTGCTT 240

TTGTTAGGAA CCGAAACTGG GCGGCGGTGA GGGCGTGTAC GCAATGAGTC CGGAAGAGGG 300

TGAAATGCTT TCGGTAGGCA CTCCACGGCT GTGAAGATGG CGGCGGCTGC GTGGCTTCAG 360

GTGTTGCCTG TCATTCTTCT GCTTCTGGGA GCTCACCCGT CACCACTGTC GTTTTTCAGT 420

GCGGGACCGG CAACCGTAGC TGCTGCCGAC CGGTCCAAAT GGCACATTCC GATACCGTCG 480

GGGAAAAATT ATTTTAGTTT TGGAAAGATC CTCTTCAGAA ATACCACTAT CTTCCTGAAG 540

TTTGATGGAG AACCTTGTGA CCTGTCTTTG AATATAACCT GGTATCTGAA AAGCGCTGAT 600

TGTTACAATG AAATCTATAA CTTCAAGGCA GAAGAAGTAG AGTTGTATTT GGAAAAACTT 660

AAGGAAAAAA GAGGCTTGTC TGGGAAATAT CAAACATCAT CAAAATTGTT CCAGAACTGC 720

AGTGAACTCT TTAAAACACA GACCTTTTCT GGAGATTTTA TGCATCGACT GCCTCTTTTA 780

GGAGAAAAAC AGGAGGCTAA GGAGAATGGA ACAAACCTTA CCTTTATTGG AGACAAAACC 840

GCAATGCATG AATCATTGCA AACTTGGCAA GATGCACCAT ACATTTTTAT TGTACATATT 900

GGCATTTCAT CCTCAAAGGA ATCATCAAAA GAAAATTCAC TGAGTAATCT TTTTACCATG 960

ACTGTTGAAG TGAAGGGTCC CTATGAATAC CTCACACTTG AAGACTATCC CTTGATGATT 1020

TTTTTCATGG TGATGTGTAT TGTATATGTC CTGTTTGGTG TTCTGTGGCT GGCATGGTCT 1080

GCCTGCTACT GGAGAGATCT CCTGAGAATT CAGTTTTGGA TTGGTGCTGT CATCTTCCTG 1140

GGAATGCTTG AGAAAGCTGT CTTCTATGCG GAATTTCAGA ATATCCGATA CAAAGGARAA 1200

TCTGTCCAGG GTGCTTTGAT CCTTGCAGAR CTGCTTTCAG CAGTGAAACG CTCACTGGCT 1260

CGAACCCTGG TCATCATAGT CAGTCTGGGA TATGGCATCG TCAAGCCACG CCTGGAGTCA 1320

[illegible] [illegible] TGTGGATAT [illegible] [illegible] [illegible] 15[illegible]

TAAAACTTCG GAGGAACATT GTAAAACTCT CTTTGTATCG GCATTTCACC AACACGCTTA 1560

TTTTGGCAGT GGCAGCATCC ATTGTGTTTA TCATCTGGAC AACCATGAAG TTCAGAATAG 1620

TGACATGTCA GTCGGACTGG CGGGAGCTGT GGGTAGACGA TGCCATCTGG CGCTTGCTGT 1680

TCTCCATGAT CCTCTTTGTC ATCATGGTTC TCTGGCGACC ATCTGCAAAC AACCAGAGGT 1740

TTGCCTTTTC ACCATTGTCT GAGGAAGAGG AGGAGGATGA ACAAAAGGAG CCTATGCTGA 1800

AAGAAAGCTT TGAAGGAATG AAAATGAGAA GTACCAAACA AGAACCCAAT GGAAATAGTA 1860

AAGTTAACAA AGCACAGGAA GATGATTTGA AGTGGGTAGA AGAGAATGTT CCTTCTTCTG 1920

TGACAGATGT AGCACTTCCA GCCCTTCTGG ATTCAGATGA GGAACGAATG ATCACACACT 1980

TTGAAAGGTC CAAAATGGAG TAAGGAATGG GAAGATTTGC AGTTAAAGAT GGCTACCATC 2040

AGGGAAGAGA TCAGCATCTG TGTCAGTCTT CTGTACGGCT CCATGGGATT AAAGGAAGCA 2100

ATGACATCCT GATCTGTTCC TTGATCTTTG GGCATTGGAG TTGGCGAGAG GTGTCAGAAC 2160

AAAGAGAACA TCTTACTGAA AACAAGTTCA TAAGATGAGA AAAATCTACG AGCTTCTTAT 2220

TTACAACACT GCTGCCCCCT TTCCTCCCAG ACTCTGACAT GGATGTTCAT GCAACTTAAG 2280

TGTGTTGTTC CTGAACTTTC TGTAATGTTT CATTTTTTAA ATCTGACAAA CTAAAAAGTT 2340

TAACGTCTTC TAAAAGATTG TCATCAACAC CATAATATGT AATCTCCAGG AGCAACTGCC 2400

TGTAATTTTT ATTTATTTAG GGAGTTACAT AGGTGATGGG GGAAATTGTT AACTACCTTT 2460

CATTTTCCTG GGAAGTCAAG GTTACATCTT GCAGAGGTTG TTTTGAGAAA AAAGGGCCCT 2520

TCTGAGTTAA GGAGCCATAG TTCTATCAAT GATCAAAAGA AAAAAAAAAA AACTCGATCG 2580

GCACGAGGGG GGGCCCGGTA CCCAATTCGC CCTATGGGAN TCGAATGAGA CC 2632

(2) INFORMATION FOR SEQ ID NO: 111:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2249 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111:

GAATTCGGCA CGAGCTCACC GTGCTGCGTG ACACAAGGCC AGCCTGCGCC TACGAGCCCA 60

TGGACTTTKT RATGGCCCTC ATCTACGACA TGGTACTGSW TGTGGTCACC CTGGGGCTGG 120

CCCTCTTCAC TCTGTGCGGC AAGTTCAAGA GGTGGAAGCT GAACGGGGCC TTCCTCCTCA 180

TCACAGCCTT CCTCTCTGTG CTCATCTGGG TGGCCTGGAT GACCATGTAC CTCTTCGGCA 240

ATGTCAAGCT GCAGCAGGGG GATGCCTGGA ACGACCCCAC CTTGGCCATC ACGCTGGCGG 300

CCAGCGCTGG GTCTTCGTCA TCTTCCACGC CATCCCTGAG ATCCACTGCA CCCTTCTGCC 360

AGCCCTGCAG GAGAACACGC CCAACTACTT CGACACGTCG CAGCCCAGGA TGCGGGAGAC 420

GGCCTTCGAG GAGGACGTGC AGCTGCCGCG GGCCTATATG GAGAACAAGG CCTTCTCCAT 480

GGATGAACAC AATGCAGCTC TCCGAACAGC AGGATTTCCC AACGGCAGCT TGGGAAAAAG 540

ACCCAGTGGC AGCTTGGGGA AAAGACCCAG CGCTCCGTTT AGAAGCAACG TGTATCAGCC 600

AACTGAGATG GCCGTCGTGC TCAACGGTGG GACCATCCCA ACTGCTCCGC CAAGTCACAC 660

AGGAAGAMAC CTTTGGTGAA AGACTTTAAG TTCCAGAGAA TCAGAATTTC TCTTACCGAT 720

TTGCCTCCCT GGCTGTGTCT TTCTTGAGGG AGAAATCGGT AACAGTTGCC GAACCAGGCC 780

GCCTCACAGC CAGGAAATTT GGAAATCCTA GCCAAGGGGA TTTCGTGTAA ATGTGAACAC 840

TGACGAACTG AAAAGCTAAC ACCGACTGCC CGCCCCTCCC CTGCCACACA CACAGACACG 900

TAATACCAGA CCAACCTCAA TCCCCGCAAA CTAAAGCAAA GCTAATTGCA AATAGTATTA 960

GGCTCACTGG AAAATGTGGC TGGGAAGACT GTTTCATCCT CTGGGGGTAG AACAGAACCA 1020

AATTCACAGC TGGTGGGCCA GACTGGTGTT GGTTGGAGGT GGGGGGCTCC CACTCTTATC 1080

ACCTCTCCCC AGCAAGTGCT GGACCCCAGG TAGCCTCTTG GAGATGACCG TTGCGTTGAG 1140

GACAAATGGG GACTTTGCCA CCGGCTTTGC CTGGTGGTTT GCACATTTCA GGGGGTCAG 1200

GAGAGTTAAG GAGGTTGTGG GTGGGATTCC AAGGTGAGGC CCAACTGAAT CGTGGGGTGA 1260

GCTTTATAGC CAGTAGAGGT GGAGGGACCC TGGCATGTGC CAAAGAAGAG GCCCTCTGGG 1320

TGATGAAGTG ACCATCACAT TTGGAAAGTG ATCAACCACT GTTCCTTCTA TGGGGCTCTT 1380

GCTCTAGTGT CTATGGTCAG AACACAGGCC CCGCCCCTTC CCTTGTAGAG CCATAGAAAT 1440

ATTCTGGCTT GGGGCAGCAG TCCCTTCTTC CCTTGATCAT CTCGCCCTGT TCCTACACTT 1500

ACGGGTGTAT CTCCAAATCC TCTCCCAATT TTATTCCCTT ATTCATTTCA AGAGCTCCAA 1560

TGGGGTCTCC AGCTGAAANS CCCTCCGGGA GGCAGGTTGG AAGGCAGGCA CCACGGCAGG 1620

TTTTCCGCCA TGATGTCACC TAGCAGGGCT TCAGGGGTTC CCACTAGGAT GCAGAGATGA 1680

CCTCTCGCTG CCTCACAAGC AGTGACACCT CGGGTCCTTT CCGTTGCTAT GGTGAAAATT 1740

CCTGGATGGA ATGGATCACA TGAGGGTTTC TTGTTGCTTT TGGAGGGTGT GGGGGATATT 1800

TTGTTTTTGCT TTTTCTGCAG GTTCCATGAA AACAGCCCTT TTCCAAGCCC ATTGTTTCTG 1860

[illegible]

AGATACTCTA ATCACTACAT TGCTTTTTCT ATAAAACTAC CCATAAGCTT TTTACTTTTA 2100

AAGAAAAATG AAAAACGTTA CTTTTTGGGG GCCGGGGGAG GACTGACCGC TTCATAAGCC 2160

AGTACGTCTG AGCTGAGTAT TTTTCAATAA ACCTTTTGAT ATTTCTCAAA AAAAAAAAAA 2220

AAAAANCCCG GGGGGGGGCC CGTACCTGG 2249

(2) INFORMATION FOR SEQ ID NO: 112:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2193 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

GATACTATAA GGCAAGTGAC TCACGGGTGC GCCGTTAGAC TAGTGGATCC CGGGTGCAGG 60

AATTCGGCAG AGTGCTGCCG GAGCCGAAGT GCTGGCGCCC CCGCGGCCGC TGCCTCCGCG 120

GANCCCAAAA TCATGAAAGT TACCGTGAAG ACCCCGAAGA AAAGGAGGAA TTCGCCGTGC 180

CCGAGAATAG CTCCGTCCAG CAGTTTAAGG AAGAAATCTC TAAACGTTTT AAATCACATA 240

CTGACCAACT TGTGTTGATA TTTGCTGGAA AAATTTTGAA AGATCAAGAT ACCTTGAGTC 300

AGCATGGAAT TCATGATGGA CTTACTGTTC ACCTTGTCAT TAAAACACAA AACAGGCCTC 360

AGGATCATTC AGTTCAGCAA ACAAATACAG CTGGAAGCAA TGTTACTACA TCATCAACTC 420

CTAATAGTAA CTCTACATCT GGTTCTGCTA CTAGCAACCC TTTTGGTTTA GGTGGCCTTG 480

GGGGACTTGC AGGTCTGAGT AGCTTGGGTT TGAATACTAC CAACTTCTCT GAACTACAGA 540

GTCAGATGCA GCGACAACTT TTGTCTAACC CTGAAATGAT GGTCCAGATC ATGGAAAAWC 600

CCYTTGTTCA GAGCATGCTC NTCAAATCCT GACCTGATGN AGACAGTTAA TTATGGCCAA 660

TCCACAAATG CAGCAGTTGA TACAGAGAAA TCCCAGAAAT TAGTCATATG TTGAATAATC 720

CAGATATAAT GAGACAAACG TTGGAACTTG CCCAGGAATC CAGCAATGAT GCAGGAGATG 780

ATGAGGAACC AGGACCGAGC TTTGAGCAAC CTAGAAAGCA TCCCAGGGGG ATATAATGCT 840

TTAAGGCGCA TGTACACAGA TATTCAGGAA CCAATGCTGA GTGCTGCACA AGAGCAGTTT 900

GGTGGTAATC CATTTGCTTC CTTGGTGAGC AATACATCCT CTGGTGAAGG TAGTCAACCT 960

TCCCGTACAG AAAATAGAGA TCCACTACCC AATCCATGGG CTCCACAGAC TTCCCAGAGT 1020

TCATCAGCTT CCAGCGGCAC TGCCAGCACT GTGGGTGGCA CTACTGGTAG TACTGCCAGT 1080

GGCACTTCTG GGCAGAGTAC TACTGCGCCA AATTTGGTGC CTGGAGTAGG AGCTAGTATG 1140

TTCAACACAC CAGGAATGCA GAGCTTGTTG CAACAAATAA CTGAAAACCC ACAACTTATG 1200

```
CAAAACATGT TGTCTGCCCC CTACATGAGA AGCATGATGC AGTCACTAAG CCAGAATCCT      1260
GACCTTGCTG CACAGATGAT GCTGAATAAT CCCCTATTTG CTGGAAATCC TCAGCTTCAA      1320
GAACAAATGA GACAACAGCT CCCAACTTTC CTCCAACAAA TGCAGAATCC TGATACACTA      1380
TCAGCAATGT CAAACCCTAG AGCAATGCAG GCCTTGTTAC AGATTCAGCA GGGTTTACAG      1440
ACATTAGCAA CGGAAGCCCC GGGCCTCATC CCAGGGTTTA CTCCTGGCTT GGGGGCATTA      1500
GGAAGCACTG GAGGCTCTTC GGGAACTAAT GGATCTAACG CCACACCTAG TGAAAACACA      1560
AGTCCCACAG CAGGAACCAC TGAACCTGGA CATCAGCAGT TTATTCAGCA GATGCTGCAG      1620
GCTCTTGCTG GAGTAAATCC TCAGCTACAG AATCCAGAAG TCAGATTTCA GCAACAACTG      1680
GAACAACTCA GTGCAATGGG ATTTTTGAAC CGTGAAGCAA ACTTGCAAGC TCTAATAGCA      1740
ACAGGAGGTG ATATCAATGC AGCTATTGAA AGGTTACTGG GCTCCCAGCC ATCATAGCAG      1800
CATTTCTGTA TCTKGAAAAA ATGTAATTTA TTTTTGATAA CGGCTCTTAA ACTTTAAAAT      1860
ACCTGCTTTA TTTCATTTTG ACTCTTGGAA TTCTGTGCTG TTATAAACAA ACCCAATATG      1920
ATGCATTTTA AGGTGGAGTA CAGTAAGATG TGTGGGTTTT TCTGTATTTT TCTTTTCTGG      1980
AACAGTGGGA ATTAAGCCTA CTGCATGCAT CACTTCTGCA TTTATTGTAA TTTTTTAAAA      2040
ACATCACCTT TTATAGTTGG GTGACCAGAT TTTGTCCTGC ATCTGTCCAG TTTATTTGCT      2100
TTTTAAACAT TAGCCTATGG TAGTAATTTA TGTAGAATAA AAGCATTAAA AAGAAGCAAA      2160
AAAAAAAAAA AAAAATTCCT GCGCCCGCGA ATTCTTCT                            2198
```

(2) INFORMATION FOR SEQ ID NO: 113:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1043 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:

```
CTGAAGTGTA TGTGGTGAGG AAGAAGAGGC TCCTACTGTA GACAGCCTTG TTCTACAGAT        60
CCTCCCAGAA ATCTCTGGGC CAGGTGGAAC CCAGGGTCAG AGAGGGATGG GAGAGAGGTT       120
TAATTTTTCA TGATAAATAA AAATCTATAA AATAATAAAC AAGAGAAAAG AGATTGGAAA       180

[illegible]
TGCCCTAAAT CAGGCCAGCC TCATCAGTCG CTGTGACTTG GCCCAGGTGC TGCAGCTGGA       420
```

RGACTTGGAT GGGTTTGAGG GTTACTCCCT GAGTGACTGG CTGTGCCTGG CTTTTGTGGA 480

AAGCAAGTTC AACATATCAA AGATWAATGA AAATGCAGAT GGAAGCTTTG ACTATGGSCT 540

CTTCCAGATC AACAGCCACT ACTGGTGCAA CRATTATAAG AGTTACTCGG AAAACCTTTG 600

CCACGTAGAC TGTCAAGATC TGCTGAATCC CAACCTTCTT GCAGGCATCC ACTGCGCAAA 660

AAGGATTGTG TCCGGAGCAC GGGGGATGAA CAACTGGGTT AGAATGGAAG KTTGCACTGT 720

TCAGGCCGGC CACTCTTCTA CTGGCTGACA GGATGCCGCC TGAGATKAAA CARGGTGCGG 780

GTGCACCGTG GARTCATTCC AAGACTCCTG TCCTCACTCA RGGATTCTTC ATTTCTTCTT 840

CCTACTGCCT CCACTTCATG TTATTTTCTT CCCTTCCCAT TTACAACTAA AACTGACCAG 900

AGCCCCAGGA ATAAATGGTT TTCTTGGCTT CCTCCTTACT CCCATCTGGA CCCAGTCCCC 960

TGGTTCCTGT CTGTTATTTG TAAACTGAGG ACCACAATAA AGAAATCTTT ATATTTATCG 1020

AAAAAAAAAA AAAAAAAACT CGA 1043

(2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 703 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114:

GAATTCGGCA CGAGTGCGCG GGCACCACGG CGGTTTTTCG ACGCTGGCGG TGGACGCAGG 60

CAGCATGGAC CACGGTTGCT GGGCGGATGG GGAGCGTCTA TGGTCAGTTG CCTTAGAAGT 120

GGTGAGATGG GAAGCTGCAG TTGGAAGACC CTGGAGGATG CCTGACAAGG GGATGTCTGA 180

CACATGATTG GAGCTCTTTT TGAAATGTTT CTTGCCCTTC CTGGAGCAGA GGAGCCATTA 240

TTTATGCAGG TACATCGAAG TCTTTTGACC TCCATACAGT GATTATGCTT GTCATCGCTG 300

GTGGTATCCT GGCGGCCTTG CTCCTGCTGA TAGTTGTCGT GCTCTGTCTT TACTTCAAAA 360

TACACAACGC GCTAAAAGCT GCAAAGGAAC CTGAAGCTGT GGCTGTAAAA AATCACAACC 420

CAGACAAGGT GTGGTGGGCC AAGAACAGCC AGGCCAAAAC CATTGCCACG GAGTCTTGTC 480

CTGCCCTGCA GTGCTGTGAA GGATATAGAA TGTGTGCCAG TTTTGATTCC CTGCCACCTT 540

GCTGTTGCGA CATAAATGAG GGCCTCTGAG TTAGGAAAGG TGGGCACAAA AATCTTCATG 600

AGCAATACTT CTTAGTAGAT TGTTTTGTTA TTCAAATCAA GTTCTAGTGT TTTTATGTGA 660

GATTATATAA TTTACAGTGT TGTTTTATAT ACTTTTGAAT AAA 703

(2) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3684 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115:

```
GGCAGAGGGG GCATGAGCAG GAGGAGGATT ACCGCTACGA GGTGCTCACG GCCGAGCAGA      60
TTCTACAACA CATGGTGGNA ATGTATCCGG GAGGTCAACG AGGTCATCCA GAATCCAGCA     120
ACTATCACAA GAATACTCCT TAGCCACTTC AATTGGGATA AAGAGAAGCT AATGGAAAGG     180
TACTTTGATG GAAACCTGGA GAAGCTCTTT GCTGAGTGTC ATGTAATTAA TCCAAGTAAA     240
AAGTCTCGAA CACGCCAGAT GAATACAAGG TCATCAGCAC AGGATATGCC TTGTCAGATC     300
TGCTACTTGA ACTACCCTAA CTCGTATTTC ACTGGCCTTG AATGTGGACA TAAGTTTTGT     360
ATGCAGTGCT GGAGTGAATA TTTAACTACC AAAATAATGG AAGAAGGCAT GGGTCAGACT     420
ATTTCGTGTC CTGCTCATGG TTGTGATATC TTAGTGGATG ACAACACAGT TATGCGCCTG     480
ATCACAGATT CAAAAGTTAA ATTAAAGTAT CAGCATTTAA TAACAAATAG CTTTGTAGAG     540
TGCAATCGAC TGTTAAAGTG GTGTCCTGCC CCAGATTGCC ACCATGTTGT TAAAGTCCAA     600
TATCCTGATG CTAAACCTGT TCGCTGCAAA TGTGGGCGCC AATTTTGCTT TAACTGTGGA     660
GAAAATTGGC ATGATCCTGT TAAATGTAAG TGGTTAAAGA AATGGATTAA AAAGTGTGAT     720
GATGACAGTG AAACCTCCAA TTGGATTGCA GCCAACACAA AGGAATGTCC CAAATGCCAT     780
GTCACAATTG AGAAGGATGG TGGTTGTAAT CACATGGTCT GTCGTAACCA GAATTGTAAA     840
GCAGAGTTTT GCTGGGTGTG TCTTGGCCCA TGGGAACCAC ATGGATCTGC CTGGTACAAC     900
TGTAACCGCT ATAATGAGGA TGATGCAAAG GCAGCAAGAG ATGCACAGGA GCGATCTAGG     960
GCAGCCCTGC AGAGGTACCT GTTCTACTGT AATCGCTATA TGAACCACAT GCAGAGCCTG    1020
CGCTTTGAGC ACAAACTATA TGCTCAGGTG AAACAGAAAA TGGAGGAGAT GCAGCAGCAC    1080
AACATGTCCT GGATTGAGGT GCAGTTCCTG AAGAAGGCAG TTGATGTCCT CTGCCAGTGT    1140
CGTGCCACAC TCATGTACAC TTATGTCTTC GCTTTCTACC TCAAAAAGAA TAACCAGTCC    1200

[illegible]

AAAGATCTGT GGGAGTACAT TGAGGACTGA GAATGGCCCT GCATAAAATG AACTCTGAAA    1440
```

ACTTTACCAT CTAGAGTGCT CATGCAATTA AAACAAAACA AACACAAACA AGGAGGCACT 1500
AAGCCTATTC TGACACCACT GGTCTGTAGT ACCAGAATTG TTTTGTTAAT GGAAAGTTTA 1560
AGTAAATTAT ATTGTAATAA AAAGGTAGAT AAACCATTGT ACAACAGTAT TCTAGGCCGC 1620
CAACAAAAGT GTGACAGACA CACTAAAAGC CCTCCAACTT TAACTTGTAA CGTAGCTTCA 1680
TTCTCAAAGC TGACTCCTTT TTTTTCTTTT TCCTTTTCCT GAGTGTAGTA CAGTTAAAAT 1740
TTCAAACAGC TCCTTGACAC TGCTTTTCAT GTTCAAACCA GCCATTTTGT TGTACTTTGG 1800
TAAAGGACCT CTTCCCCTTC CTCCCCTACA CATACAGATA CACCCACACA CAGACTGACT 1860
CTCTTTCTCT CATACCCCAA GGTCATGAGT GAATGATGCT TAGTTCCTTG TAAAGAAAAT 1920
CTTGGGATGG GGAAAGGGGT AGGCAGCAAG AGGATTCAAC AAACGAAAAA CATAAAAACT 1980
TTGTATATGA CTTTTAAAAC AAGAGGACAA CACAGTATTT TTCAAAATTG TATATAGCGC 2040
ATATGCATGG ACAAAGCAAG CGTGGCACGT GTTTGCATAA TGTTTAATTA CAAAAAAATA 2100
TTTATTCTTT AAAAATCTTC AAGATTATGT CTATTTGCTG TGCATTTTCT TTCAGTTTGC 2160
TTATCTTTCC CGGGTTGGGG TTGGGATAAA GGTGTGTCGG TTTAGCACCT CTGGAAGACC 2220
TATCTAGAGC TCTTTCACTT TCCTGAGGTT ATTTTGCCCY TTCTGGTGTT GGTATGTCTG 2280
TTGCCGGCCA TGGGCTNCAY GCCTTGAATT CCTGCTCTTG ATCAGGGACA AGGGAGGTCA 2340
AGCTCTGACT AATGCCATGA CCTGATTAAG GGGTACAGCA GGGAGTTTTG TTGCTACAGC 2400
TCATGAATTA ACCTGTCCCA ACCTAATCCC CCTCCATGGC ATCATGCCTC TACCCAAGCC 2460
TTTGTGTGCC CATGTTATGC ACACAGCTGT AGGCATTCTT AAGTCCCCTG TCGCATCCAG 2520
TGGAAGCATT TTAAAATTTC TTTTACTTTT TGGTTTTCCC TTAATTGCTG CTTTTCAGAT 2580
TTTAGTTATG GCTCGTCTGC TCACCCCTTC TCTACATTAG GGTGTCAAAG AGAATGTTTT 2640
GCTTTAAATA TAAATAGCCA TTCATTTAGT CTCAGATTGT GAATTTAAAA TGGTGGATAC 2700
CGAAATTGCT TGTGTGTGTT GCTGTGGGTT TGGTTTGAAG GCAAACACCC CTAGAACATG 2760
ATATTCCCAT CTAGTGCATT TAAATAGAAA TCACTGAGTT TGCTGCTTTT TTATTGTCAG 2820
CAGATAGGAG AATTAATAAT GCATTTTAGC TGTGATGTCC ATTTTTATGA AATTCCTACT 2880
AAGAGCTATG TTAAAAGTAA AGGATGGTGG TGGTTGTATT AACTATATAC CTGTTTAGGC 2940
CATTCTGGCT GTGGTATTTT TCAATAGGTC AGCATCTGTA AATCTGTCAG TTTTATACAG 3000
GAGTGCAGAG TGAACTAGGC AACTAGATTA AGAGGTCTAA ATATGAAATA CCAGTTGAGG 3060
CTGAGGACCT CTTCGTCTTC CTTTAAATGT CTTTTGCCTA GGGAGTGTTT ACCATTTGTG 3120
AGGCAGCTTT GTCTGCTCTT ACACTGTACA TCCTATTACT CCATTGGGAA GTAGGTTCAC 3180
TTTCCTCTGG CCTTTTGCCT AAGTTAGGCT TTGCTGAATC AACCCTACTT TTCCTTTTAG 3240

AAAAGGTTGT TACAGGAGAT TTACTGGCAA CTGTTCTTTT CCCATCAAAA ATCAGTGAAT 3300

GTTTGCTGAG TATAAATGCT GCTTCCTTAA ACCACTTGTC GCTTTAGGAT CAACTTTATC 3360

TGTACCTTTT CTCCTTTCCT CCCTTGCCAC CTCAGGTGCA AATCTGAACT CAGTGTCTGC 3420

TTCTTCCATT TTCTCGTCTC TCTCCCCTCT TCCCCCATTA TCCATATGAC ATTATTTTAC 3480

TTCAAATGAC AGCATCAATC TTAAAAAGAT ATACATTAAA ACTAAGGAGT TTTTTTAAAG 3540

AAAGCCTGAA TAAGTTCCTT TCCCTGGTAA CTTTGAAAAG CAGTCAGAGT TGCTATATAG 3600

ATATATGTGG CTCCTTTAAA ATGCTTTGTG TATGTGTGGT GTTTAAAAAA AAAAAAAAAA 3660

TTCGGGGGGG GGCCCGGTNC CCAT 3684

(2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1965 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116:

AAGAAAGGCT ATTAAAATTC TAGATCACAT ATGGACCCGG GAAGGTTTTT NACCCTCTGT 60

TAGTGACATC GAGTCTCCCA CTAGACAAAA TAGGTGGAAA AATCTCTCGA GGGCTCACAT 120

TGTTTTGTCA TCTTCAGGAA AAACACCACC AGGCCATACC ACAGCCTGCC CAGTGAGGCG 180

GTCTTTGCCA ACAGCACCGG GATGCTGGTG GTGGCCTTTG GGCTGCTGGT GCTCTACATC 240

CTTCTGGCTT CATCTTGGAA GCGCCCAGAG CCGGGGATCC TGACCGACAG ACAGCCCCTG 300

CTGCATGATG GGGAGTGAAG CAGCAGGAAG GGGCTCCCAA GAGCTCCTGG TGGTGCAGCC 360

TGTGCTCCCC TCAGAAGCTC TGCTCTTCCC AGGGCTCCCG GCTGGTTTCA GCAGGCGACT 420

TTCTTCCAAT GCTGGGCCCA GACTTCTTGC CTGGGTGCTG GCCTGCCCTC TCCGGNCCGC 480

TTGCTGCCTG TCTGCTTTCC TTGGTGGYTT TGCTGGGTGC TGGGCCTGCC CTCTCCGGCC 540

GCTTGCTGCC TGTCTGCTTT CCTTGGTGGC TTTGCTGGGT GCTGGGCCTG CCTTCTCTGG 600

CTGCTTGCTG CCTGTCTGCT TTCCTTGGTG GCTTTGGCTT CTGCACTCCT TGGCGTCAGC 660

TCTCAGGTCC TCCATTCACA CGAGGTCCTC CTCGCTCTGG CCGCTCTTGC TGCTCCTGTC 720

AAGGTGTGCA TTTCAGTTAG GCTGCCCCTC CACAGAGCAG GCTTCATCTG CTTTTGCCAT 960

CAGCCCCATC TGGATGTGAG GTGGGGTGGA GACATCATGG GGTGATTGCA GAAAGGGGGA 960

GTGGCGGCCC ACGCAGCTTC TGCTGAGGAG CTGACCGCTC TGAGCTGTTC TGTTTCGTAT 1020

TGCTGCTCTG TGTCTGCATG TATTGTGACC GTGCGGCTCC ACCTCTTCCA GCTGCTGCTA 1080

CAGCTGAGGC CTGGATCCCG GCCTTTCCCT GTGACTTACG TGTCTGTCAC CGGCANGCAG 1140

CCCTACAAAT CCTGGTGACC TGCTCTCCCA AGAACAGAGC CTGTCCCCAG ATGTCCCAGT 1200

AGCGATGAGT AACAGAGGTG GCTGTGGACT TCCTCTACTT CTCCTTGCTG GATCAGGGCC 1260

TTCCTGCCTC CCGCTGGGCA GGTCTGGCCT TGCTCTCTTG GCAGGGCCCC AGCCCCTCTG 1320

ACCACTCTGC AGCTCACCAT GCAGCTGATG CCAAAGTTGT GGTGTCCAGT GTGCAGCAGC 1380

CCTGGGAGCC ACTGCCACCT TCAGAGGGGT TCCTTGCTGA GACCCACATT GCTTCACCTG 1440

GCCCCACCAT GGCTGCTTGC CTGGCCCAAC CTAGCGTTCT GTGCCATGCT AGAGCTTGAG 1500

CTGTTGCTCT TCTTCAGGGG AGGAAATAGG GTGGAGAGCG GGAAGGGTCT TGCTCCTAAG 1560

TGTTGCTGCT GTGGCTTTTT TGCCTTCTCC AAAGACGCAC TGCCAGGTCC CAAGCTTCAG 1620

ACTGCTGTGC TTAGTAAGCA AGTGAGAAGC CTGGGGTTTG GAGCCCACCT ACTCTCTGGC 1680

AGCATCAGCA TCCTACTCCT GGCAACATCA GGCCAACGTC CACCCCAGCC TCACATTGCC 1740

AGATGTTGGC AGAAGGGCTA ATATTGACCG TCTTGACTGG CTGGAGCCTT CAAAGCCACT 1800

GGGATGTCCT CCAGGCACCT GGGTCCCATG ACCAGCTCCC CGTCTCCATA GGGGTAGGCA 1860

TTTCACTGGT TTATGAAGCT CGAGTTTCAT TAAATATGTT AAGAATCAAA GCTGTCTTTG 1920

TTCAGGCTGC TATAACAAAA ATATAATAGC CTGGGTGGCT TAAAC 1965

(2) INFORMATION FOR SEQ ID NO: 117:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 503 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

AGTGATCCCC TTGCCTCGGC CTCCCAAAAT GCTGGAATTG TAAGCGTGGG CCTCTGCACC 60

CGGCCTGGTC CGCAATTTAA AAACGCACAG CCACCATTCC CTYTCCAGAA AGCACCCAGA 120

TGCCTTTGGG AGAACCAGCC TCCTCCATGG AGGAAAGCTT GGGATCTGCC TTCCCACCTG 180

GGGAGGAGAG GGATCTGTGG AAAATCCTTC TGACGGACTT CCCCTCAGTG CCTGATCCAT 240

ACTCAATAGT AGAAAAAGTA AGAAATATAC AAAGATAGCA GATACACGGA GACAGTTCCC 300

CAAATAGCTG AGCGAWTAGC GCAGAAGCAA TATTGAAGAC CTAATAGTTG AGACATTTCC 360

```
AGAACTGATA AAGTGCATCC AGCCACAGAT CAAGCAGCCC AGAAAATTCC AGGCAGCATC      420

AACAAATAAA TAGCCCCACA TGCACCCGTG AAAATGCAGA AGACCAAACA AAAAAGTCCG      480

GTCAACAGCC AGAGTTAAAG AGG                                              503
```

(2) INFORMATION FOR SEQ ID NO: 118:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1133 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

```
GGCACAGCTT GGAATGAACC CCTGTGGATA AGGGGGACTA TTAGATAGAA TAAACATCAA       60

TAAATGCTTG ATGAATAAAC GCTAATCCTA CCTTCCCAGC CTGACACCTC CCAGTGGACA      120

CCACACTTCA CTTGAAGCCT TAGAAACCTT TCCCACCCAT GCTTCCAGCC CTGGCTTCAT      180

GTTGCCATTT CTCACCCCCA GAACAGGCCG CCCGCCTGAA GAAACTACAA GAGCAAGAGA      240

AACAACAGAA AGTGGAGTTT CGTAAAAGGA TGGAGAAGGA GGTGTCAGAT TTCATTCAAG      300

ACAGTGGGCA GATCAAGAAA AAGTTTCAGC CAATGAACAA GATCGAGAGG AGCATACTAC      360

ATGATGTGGT GGAAGTGGCT GGCCTGACAT CCTTCTCCTT TGGGGAAGAT GATGACTGTC      420

GCTATGTCAT GATCTTCAAA AAGGAGTTTG CACCCTCAGA TGAAGAGCTA GACTCTTACC      480

GTCGTGGAGA GGAATGGGAC CCCCAGAAGG CTGAGGAGAA GCGGAACNTG AAGGAGCTGG      540

CCCAGAGGCA ANGAGGAGGA GGCAGCCCAG CAGGGGCCTG TGGTGGTGAG CCCTGCCAGC      600

GACTACAAGG ACAAGTACAG CCACCTCATC GGCAAGGGAG CAGCCAAAGA CGCAGCCCAC      660

ATGCTACAGG CCAATAAGAC CTACGGCTGT KTGCCCGTGG CCAATAAGAG GGACACACGC      720

TCCATTGAAG AGGCTATGAA TGAGATCAGA GCCAAGAAGC GTCTGCGGCA GAGTGGGGAA      780

GAGTTGCCGC CAACCTCCTA GGCGCCCCGC CCAGCTCCCT TTGACCCCTG GGGCAGGGCA      840

GGGGGCAGGG AGAGACAAGG CTGCTGCTAT TAGAGCCCAT CCTGGAGCCC CACCTCTGAA      900

CCACCTCCTA CCAGCTGTCC CTCAGGCTGG GGGAAAACAG GTGTTTGATT TGTCACCGTT      960

GGAGCTTGGA TATGTGCGTG GCATGTGTGT GTGTGTGTGA GAGTGTGAAT GCACAGGTGG     1020
```

(2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1101 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119:

```
GGGCACAGCT GAAGCTGCAG ACCTCCCCAG GGGATGGCTC CTCTCCCCCA GGAGCCCCGA      60
GGCAGGGGAG GCAGAAAGCC TGGGCTCTGG GGGGTGGCCT GCGGACAGCT GTGCTGTGGG     120
CCGGGGGCTG GGCCTGTCCC ACAGGGNCGT GGAGCTCGTG GTTCTGAGCA GCCAGCTGGG     180
TGGTGTCTGG GGATACCTGG GAGGCACAGC GGCTGCCATG TGGGACTGGG ACTGGAGTGC     240
TCCCTGGTCT TGGCCTCTGT GGCTCAGCCT TGCTCTGGTC TGCCTGAGTG CAGGGGCCAA     300
GGGGCACAGG GCCAGTGAGG CCGGCCACCC TCGGGCCCTC ACCTGTGAGA TGGGGTCGGA     360
ATTTKACACA GCCTANGGCT TGGTTCTTGG TKGTNGAMCG TGGACTYCTK AGAACGGGAG     420
TGCTGGTCCT GAAAGGCGTG GTTGGAGACC AGCTGCTTTT CTCGCTGTTT TTCTCTTAGG     480
AGATTAAACA AAAACAGAAA GCACAAGACG AACTCAGTAG CAGACCCCAG ACTCTCCCCT     540
TGCCAGACGT GGTTCCAGAC GGGGAGACGC ACCTCGTCCA GAACGGGATT CAGCTGCTCA     600
ACGGGCATGC GCCGGGGGCC GTCCCAAACC TCGCAGGGCT CCAGCAGGCC AACCGGCACC     660
ACGGACTCCT GGGTGGCGCC CTGGCGAACT TGTTTGTGAT AGTTGGGTTT GCAGCCTTTG     720
CTTACACGGT CAAGTACGTG CTGAGGAGCA TCGCGCAGGA GTGAGGCCCA GCCGCCGAGA     780
CCCAAGGCGC CACTGAGGGC ACCGCGCACC AGAGCGTGAC CTCGGCAGGC TGGACACACT     840
GCCCAGCACA GGCAGACCCA CCAGGCTCCT AGGTTTAGCT TTTAAAAACC TGAAAGGGGA     900
AGCAAAAACC AAAATGTGTG ACTGGGCTTT GCAGGAGACT GGAGCCTCAG CCCTGTCCTG     960
GCCACGGGCC GCTGGGGCTG GTGTGGGTGG GCCTTGTGTG CTGGATTTGT AGCTTATCTT    1020
CCGTGTTGTC TTTGGACCTG TTTTAGTAAA CCCGTTTTTC ATTTTAAAAA AAAAAAAAAA    1080
AAACTTTGGG GGGGGGCCCC N                                              1101
```

(2) INFORMATION FOR SEQ ID NO: 120:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 282 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120:

```
AGCTTCTCTG TCCAGTCTTG AACTCTGGGS TCTCTTGGAA CTTTCCTCAC CCCTCTCAGC    60
CTGAATATTC CTTTCATGGA TTCCACTCAA CCAGACTTTG GATCTGTGCC TACTTAATCA   120
ACCTTATCTT TGCAATATGT TCCGGCCCAC CTTCCACTCC TTGGTTCTTG TTCCTCCTTG   180
GCCTAACTTG TCCCTTCTCC ACTTCACATC CCCGGTGGGA CAGCATTCCT CCTTCCTCCC   240
AACCTCCCTC CGTCTCARAA AAAAAAAAAA AAAAAAAAAA TT                      282
```

(2) INFORMATION FOR SEQ ID NO: 121:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2635 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121:

```
TAAGGGGGTG TGTGCTCACC TCCTCCTGAC CCTTAACACT CCTGTCCTGC CCAGACCAAC    60
AGAGAGAGCT GTCCCTGAGA CCCGGAGAG AAGCAGCTGC CGAAAGCTGC AGCCTTTCCG   120
CACTCTGAGA CCATGATCTT CCTCCTGCCA GGGGAGAGCC ACCCACAGGC CATGTCCAGC   180
CCCACTTCCC TCAGCCCCCA GGGYTTCCTT CTGGCCCCTC TGAGGATTCC CTAGGGCTGC   240
CCCGCAGAGG GGYTTCCCCA AGCTCTGTTT TGAAGCCTGC AATGTGGAAA AGTGAGAAGT   300
CAGAGGGAAC AGGACAGGTG CAGCCGGGCT CTGAGGCCAC ACCTCACACC TCGCTGTTCC   360
CCAACATCCC CTGAGCAGTG TGAGCTCATC TCACCAGATG AGAAGAGGCC CTGTGCATTT   420
YTTTTGTTTG TTTGTTGCTG TTTTCCCCCA CCCATCCAGT TCTCCTCAGC AAAGCAAATT   480
CCTTAACACC TTTGGTGGAG AATTTCTTAC CCAGACTTGG GGCTGTGATG CCCTTCAGTG   540
CGTGGTGAGT GCAGCGTGTG TGCGTGTGCC TGTGTGTGAA CCTGGGGGCC ATCCTGGTGG   600
CCTGGGAGCG TGAGGAGAGG CCCCCTGTGT GCTGGGTGAG TGGTGGGTGT GGGGTCAATG   660
CAGTGAGGCT CTCTGGGTGA GGCTCCCAAC CTGGCAGTCC CCAGCCTCCC AGCATCTGTG   720
AGCGTCTGTT GGACTTTACA GAAGAGCCTC ATCCYGTCTG CCCCTCACTC TGCCCTGGAA   780
TCAACATCTT CCGAGTCCTT CTTGGGGGAA ATAGCAGAGC CCCACTTAAC TCCATAAACT   840

[illegible]
CGGAGCTACT TGAAACTTCT GCTCTTGCTA GGATTGGAGT CTACCTATCT CTTTCATTTG  1080
```

TCCCAGCTGG AGTTCTGGAA CTTTCCTCCT CGGGGTGGGG GTGGGGGTTG TTAAGGATGC 1140

TGGGGGGCCT GGGGAAGGAA GGAGTTCAGA GGAAGGGTGT CCCCTGTCCT CTTGATGTCA 1200

CCCTCCGCTC CTGGGACACG TGCTCTCTCT GTCTCTGGGT CTTCTGGCTG TGCACGTTTG 1260

TGTGTCCTTG TAAATATGTT TTAGGAAGAA AGCAAAAGGG ACTGAACTAG CCTTTGGTAG 1320

GATTGCAGGG GTCCAGCCTT GCCTGTTTCC GAAGCCCCCA CACTGCTTTT CGCCCCACTG 1380

AGACTGGTCC CCTCAAAAGG TAGACAAAAC AGCAGCTCCC TGTGGAGCTG AAGGGCGGCC 1440

TCAAAGTGGC TTTTTGTTAG ACAAGGTTAA GGTTTTCTCA TGAGCAAGCT TGCAGATCGG 1500

TCCTTCCTCA GCTCCTTGAT TTGTGACCTT GACCAAGGGG CCTGCCACCC AGCCCCTCCA 1560

GTGCCCTCTC CTCGATGCCT CGCTCCTTCC TGCCCCCACT CCCCTGGCTT AGGCAGGTAG 1620

GGGAATTAGG GCCATGCTGG AAGAAGCTTA ACCATGTGTT CAAAGAACGG TTTCTTGCTT 1680

GCTTGGTCCT GGAACTCCCC TTGGCTGCCC CAGGCCTCCT TGGCCCATGG GTGCTGGGGG 1740

AGGTGGATGT CAGATCTGGT AGGTTGCAGC AGAGAAAATA AATGTGCCTT GAGAGACCAC 1800

TCAGAGAGGG TCCAAGCGTG ATGGAGAAGG AAGCATGGCC TGGGAGCTTG GAAGGGARGG 1860

GTGGTGGGTG GTGGCATCTT GACTGCCCCC TGTTCTCCCA CACGTGGGGG GTGGTCACCC 1920

CYCTTCACTC CAGCCCGCCT GCCTTCAGCC TTCCATGAGC TTCACCTGCT TCCAACTTCA 1980

CTTTGGAGGG GGTGGGGTCC GTTGGCATCA ACACGGGGAC CCTCTGCTTC ACCAAAGCCC 2040

GAGCCCTCAG CTCCTGGGGA GAACAAATGG CTGAGCTTTG ATACCTGGGG TCGTCGAGAG 2100

GCTGCGGGCT GGCGGCAGTC CCAGGGGAGA GACACCACAG AAGGAGACCC AGACATCCCG 2160

AGGAAGTTCC CAGCAGAGCA AACTGCTTTC CAGCCTGAAG CCTGCTTAAA CTGTGTGATG 2220

TGCAATAACT GAGCTTAGAG TTAGGAATTG TGTTCAAGTG CTTGGATTTC CGTCTGTAGA 2280

TTTAACTGCT GAAATTGTAT CTCTCAGTAA TTTTAGATGT CTTTTAAAAA ATTGAAAAAC 2340

AAAGTGTTAG ACTGTGTGCG TGTGCGTTGA TGGGCACTCA AGAGTCCCGT GAGTCATCCA 2400

GCCCTGCCTT TCCCCTGCGC CCCCATCCTC TCACGTCCCG CCCYGCCTCC ACTTGGGGAC 2460

CCTGCCTCGT GTCGTCTTTA TCTGCCTATT ACTCAGCCTA AGGAAACAAG TACACTCCAC 2520

ACATGCATAA AGGAAATCAA ATGTTATTTT TAAGAAAATG GAAAATAAAA ACTTTATAAA 2580

CACCAAAAAA AAAAAAAAAA ACCCNGGGGG GGGGCCCGTA ACCCATTTCG CCTAA 2635

(2) INFORMATION FOR SEQ ID NO: 122:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 994 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:

```
GAATTCGGCA GAGGTTCGGC GAAGATAGGG AATAAGGAAG CACAGGAGTA GGGGAGAAGG      60
AAGCACAGGA GTAGGGGAGA TATACAGCGG TCAGGATAAG GGGGAAAGGG CGGTGGTTGC     120
GCAAGAGGTG AAACAAGATG TGAGAGACAA GGGGTAGGGA AGAAATGGGG CAGCGGTTAG     180
GTTCAGAAGC GCATAGACCG TGGCGGACGG GCAATGCGAG GGGCACAGAA AGGAACTGAG     240
GGGTGGGCTA TTTTAARGGA GATGGTCCTT CAGCCCTCTT YTTTTCTGCG TAGTTCTCCT     300
CCTCCAGGCC GCGCGCGGAT ATGTCGTCCG GAAACCAGCC CAGTCTAGGC TGGATGATGA     360
CCCACCTCCT TCTACGCTGC TCAAAGACTA CCAGAATGTC CCTGGAATTG AGAAGGTTGA     420
TGATGTCGTG AAAAGACTCT TGTCTTTGGA AATGGCCAAC AAGAAGGAGA TGCTAAAAAT     480
CAAGCAAGAA CAGTTTATGA AGAAGATTGT TGCAAACCCA GAGGACACCA GATCCCTGGA     540
GGCTCGAATT ATTGCCTTGT CTGTCAAGAT CCGCAGTTAT GAAGAACACT TGGAGAAACA     600
TCGAAAGGAC AAAGCCCACA AACGCTATCT GCTAATGAGC ATTGACCAGA GGAAAAAGAT     660
GCTCAAAAAC CTCCGTAACA CCAACTATGA TGTCTTTGAG AAGATATGCT GGGGGCTGGG     720
AATTGAGTAC ACCTTCCCCC CTCTGTATTA CCGAAGAGCC CACCGCCGAT TCGTGACCAA     780
GAAGGCTCTG TGCATTCGGG TTTTCCAGGA GACTCAAAAG CTGAAGAAGC GAAGAAGAGC     840
CTTAAAGGCT GCAGCAGCAG CCCAAAAACA AGCAAAGCGG AGGAACCCAG ACAGCCCTGC     900
CAAAGCCATA CCAAAGACAC TCAAAGACAG CCAATAAATT CTGTTCAATC ATTTAAAAAA     960
AAAAAAAAAA AAAAAAAAAA AAAAAGGGGA GGGG                                 994
```

(2) INFORMATION FOR SEQ ID NO: 123:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1542 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123:

```
GCTGTTCGCT TCCTGCTG[illegible] CCTCCGGCGG GGCCAACCTC TCCCAGGA[illegible] ACAGCCAGCC     240
```

CTGGACATCT GATGAAACAG TGGTGGCTGG TGGCACCGTG GTGCTCAAGT GGCAAGTGAA 300

AGATCACGAG GACTCATCCC TGCAATGGTC TTAACCCTGC TCAGCAGACT CTCTACTTTG 360

GGGAGAAGAG AGCCCTTCGA GATAATCGAA TTCAGCTGGT TAMCTCTACG CCCCACGAGC 420

TCAGCATCAG CATCAGCAAT GTGGCCCTGG CAGACGAGGG CGAGTACACC TGCTCAATCT 480

TCACTATGCC TGTGCGAACT GCCAAGTCCC TCGTCACTGT GCTAGGAATT CCACAGAAGC 540

CCATCATCAC TGGTTATAAA TCTTCATTAC GGGAAAAAGA CACAGCCACC CTAAACTGTC 600

AGTCTTCTGG GAGCAAGCCT GCAGCCCGGC TCACCTGGAG AAAGGGTGAC CAAGAACTCC 660

ACGGAGAACC AACCCGCATA CAGGAAGATC CCAATGGTAA AACCTTCACT GTCAGCAGCT 720

CGGTGACATT CCAGGTTACC CGGGAGGATG ATGGGGCGAG CATCGTGTGC TCTGTGAACC 780

ATGAATCTCT AAAGGGAGCT GACAGATCCA CCTCTCAACG CATTGAAGTT TTATACACAC 840

CAACTGCGAT GATTAGGCCA GACCCTCCCC ATCCTCGTGA GGGCCAGAAG CTGTTGCTAC 900

ACTGTGAGGG TCGCGGCAAT CCAGTCCCCC AGCAGTACCT ATGGGAGAAG GAGGGCAGTG 960

TGCCACCCCT GAAGATGACC CAGGAGAGTG CCCTGATCTT CCCTTTCCTC AACAAGAGTG 1020

ACAGTGGCAC CTACGGCTGC ACAGCCACCA GCAACATGGG CAGCTACAAG GCCTACTACA 1080

CCCTCAATGT TAATGACCCC AGTCCGGTGC CCTCCTCCTC CAGCACCTAC CACGCCATCA 1140

TCGGTGGGAT CGTGGCTTTC ATTGTCTTCC TGCTGCTCAT CATGCTCATC TTCCTTGGCC 1200

ACTACTTGAT CCGGCACAAA GGAACCTACC TGACACATGA GGCAAAAGGC TCCGACGATG 1260

CTCCAGACGC GGACACGGCC ATCATCAATG CAGAAGGCGG GCAGTCAGGA GGGGACGACA 1320

AGAAGGAATA TTTCATCTAG AGGCGCCTGC CCACTTCCTG CGCCCCCCAG GGCCCTGTGG 1380

GGACTTGCTG GGGCCGTCAC CAACCCGGAC TTGTACAGAG CAACCGCAGG GGCCGSCCCT 1440

CCCGNTTGTT CCCCAGCCCA CCCACCCCCT TGTTACAGAA TGTYTKGTTT GGGGTGCGGT 1500

TTTGTWATTG GTTTNGGATN GGGGAAGGGA GGGANGGCGG GG 1542

(2) INFORMATION FOR SEQ ID NO: 124:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1390 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124:

CAAGCTCTAA TACGACTCAC TATAGGGAAA GCTGGTACGC CTGCAGGTAC CGGTCCGGAA 60

TTCCCGGGTC GACCCACGCG TCCGGGCCTC AGGGTGGACG CATGGTTCTG CACTGAGGCC 120

CTCGTCATGG TGGCGCCTGT GTGGTACTTG GTAGCGGCGG CTCTGCTAGT CGGCTTTATC 180

CTCTTCCTGA CTCGCAGCCG GGGCCGGGCG GCATCAGCCG GCCAAGAGCC ACTGCACAAT 240

GAGGAGCTGG CAGGAGCAGG CCGGGTGGCC CAGCCTGGGC CCCTGGAGCC TGAGGAGCCG 300

AGAGCTGGAG GCAGGCCTCG GCGCCGGAGG GACCTGGGCA GCCGCCTACA GGCCCAGCGT 360

CGAGCCCAGC GGGTGGCCTG GGCAGAAGCA GATGAGAACG AGGAGGAAGC TGTCATCCTA 420

GCCCAGGAGG AGGAAGGTGT CGAGAAGCCA GCGGAAAYTC ACCTGTCGGG GAAAATTGGA 480

GCTAAGAAAC TGCGGAANNT GGAGGAGAAA CAAGCGCGAA AGGCCCAGCK TGAGGCAGAG 540

GAGGCTGAAC GTGARGWGCG GAAACGACTC GAGTCCCAGC GCGAATGAGT GGAAGAAGGA 600

GGAGGAGCGG CTTCGCCTGG AGGAGGAGCA GAAGGAGGAG GAGGAGAGGA AGGCCCGCGA 660

GGAGCAGGCC CAGCGGGAGC ATGAGGAGTA CCTGAAACTG AAGGAGGCCT TTGTGGTGGA 720

GGAGGAAGGC GTAGGAGAGA CCATGACTGA GGAACAGTCC CAGAGCTTCC TGACAGAGTT 780

CATCAACTAC ATCAAGCAGT CCAAGGTTGT GCTCTTGGAA GACCTGGCTT CCCAGGTGGG 840

CCTACGCACT CAGGACACCA TAAATCGCAT CCAGGACCTG CTGGCTGAGG GGACTATAAC 900

AGGTGTGATT GACGACCGGG GCAAGTTCAT CTACATAACC CCAGAGGAAC TGGCCGCCGT 960

GGCCAACTTC ATCCGACAGC GGGGCCGGGT GTCCATCGCC GAGCTTGCCC AAGCCAGCAA 1020

CTCCCTCATC GCCTGGGGCC GGGAGTCCCC TGCCCAAGCC CCAGCCTGAC CCCAGTCCTT 1080

CCCTCTTGGA CTCAGAGTTG GTGTGGCCTA CCTGGCTATA CATCTTCATC CCTCCCCACC 1140

ATCCTGGGGA AGTGATGGTG TGGQCAGGCA GTTATAGATT AAAGGCCTGT GAGTACTGCT 1200

GAGCTTGGTG TGGCTTGGTG TGGCAGAAGG CCTGGCCTAG GATCCTAGAT AAGCAGGTGA 1260

AATTTAGGCT TCAGAATATA TCCGAGAGGT GGGGAGGGTC CCTTGGAAGC TGGTGAAGTC 1320

CTGTTCTTAT TATGAATCCA TTCATTCAAG AAAATAGCCT GTTGCAAAAA AAAAAAAAAA 1380

AAAAACTCGA 1390

(2) INFORMATION FOR SEQ ID NO: 125:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1288 base pairs

[illegible]

[illegible] TGAAAGCCTC ATTGATGCAG CCTGGGCCCG [illegible] [illegible] [illegible]

GACGCTGACC ACGTTCCTCT CCTCGGTCTC CTCCGCCTCC AGCTCCGCGC TGCCCGGCAG 120

CCGGGAGCCA TGCGACCCCA GGGCCCCGCC GCCTCCCCGC AGCGGCTCCG CGGCCTCCTG 180

CTGCTCCTGC TGCTGCAGCT GCCCGCGCCG TCGAGCGCCT CTGAGATCCC CAAGGGGAAG 240

CAAAAGGCGC ATCCGGCAGA GGGAGGTGGT GGACCTGTAT AATGGAATGT GCTTACAAGG 300

GCCAGCAGGA GTGCCTGGTC GAGACGGGAG CCCTGGGGCC AATGGCATTC CGGGTACACC 360

TGGGATCCCA GGTCGGGATG GATTCAAAGG AGAAAAGGGG GAATGTCTGA GGGAAAGCTT 420

TGAGGAGTCC TGGACACCCA ACTACAAGCA GTGTTCATGG AGTTCATTGA ATTATGGCAT 480

AGATCTTGGG AAAATTGCGG AGTGTACATT TACAAAGATG CGTTCAAATA GTGCTCTAAG 540

AGTTTTGTTC AGTGGCTCAC TTCGGCTAAA ATGCAGAAAT GCATGCTGTC AGCGTTGGTA 600

TTTCACATTC AATGGAGCTG AATGTTCAGG ACCTCTTCCC ATTGAAGCTA TAATTTATTT 660

GGACCAAGGA AGCCCTGAAA TGAATTCAAC AATTAATATT CATCGCACTT CTTCTGTGGA 720

AGGACTTTGT GAAGGAATTG GTGCTGGATT AGTGGATGTT GCTATCTGGG TTGGCACTTG 780

TTCAGATTAC CCAAAAGGAG ATGCTTCTAC TGGATGGAAT TCAGTTTCTC GCATCATTAT 840

TGAAGAACTA CCAAAATAAA TGCTTTAATT TTCATTTGCT ACCTCTTTTT TTATTATGCC 900

TTGGAATGCT TCACTTAAAT GACATTTTAA ATAAGTTTAT GTATACATCT GAATGAAAAG 960

CAAAGCTAAA TATGTTTACA GACCAAAGTG TGATTTCACA TGTTTTTAAA TCTAGCATTA 1020

TTCATTTTGC TTCAATCAAA AGTGGTTTCA ATATTTTTTT TAGTTGGTTA GAATACTTTC 1030

TTCATAGTCA CATTCTCTCA ACCTATAATT TGGGAATATT GTTGTGGTCT TTTGTTTTTT 1140

CTCTTAGTAT AGCATTTTTA AAAAAATATA AAAGCTACCA ATCTTTGTAC AATTTGTAAA 1200

TGTTAAGAAT TTTTTTTATA TCTGTTAAAT AAAAATTATT TCCMACAACC TTAAAAAAAA 1260

AAAAAAAAAA AAAAAAAAAA AAAAANAA 1288

(2) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1517 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126:

AGTGGCTTAA AGGCATCGTT TTAGGGATTA CTGGGAAGTA TCTTCAAAGT AATACATGAG 60

AAACATTCCT TCCTAAATCC TTTATTATAT TGAATATCGT ATTAATTGGT TTTCAGAGGT 120

TAAATTAACC ATGTATTCCT GCAATAAATG TCACTTGTNT CTTGTATATA ATCTTTTTTA 180

TATATTACCG GATTGATTCA TTAGTATTTT GTTGAGGATT TTTGTGTCTA TATTCATAAG 240

AGATGCTGGT CTGCAGTTTT CTTTTTTTGT GATAATCTGG TTTTTGTATC AGTAATACAG 300

GCCCCATGAA ACGAGTTGGG AAGTGTTCAC CTCTCTTGTA TTTTTTCAAG AGTTTGTGAA 360

GAATTGCTAT TAATTCTTTA AATGTTTGGT AGAATCTACC ATTGAAATCA TGTGTCCTGG 420

GCTTTTTTTT GAGGGAAGTG TTCTGATAAC TAATTCAGTA TCTACTTTTT ATAGCTCTGT 480

TCAGATTTTG CTTCTTCCTG AGTTAGTTTT GGTAATTTGT GTATCTCTAG GARTTTGTCC 540

ATTTCATTTA TCTCATTTGT TGGCATAAAT TAAACTAAAT TTGGCCTGAG CCTACCTGTA 600

TATCTTGAGT CCCTCTGTAA GGAACTGTAG CCTAACTTGT ACATAAACAA ACTGAAATCC 660

TAAATTAGGA ATGTAGTTTT TGTAACAGCT CCTGAGTCTC AGGCAGTCAC AGCAGYCAAG 720

TCTGTCAATT GCAGGCTGCT AACTAAGCAG CCCATGSTCA AATGAGGCAA AAACCTTTGC 780

TTTTAACACA TAGTATAGCT TTGTAATCCT TTTCTTGCAC ACTCGGGTAA TTTCTTCCTT 840

TTTCATTCCC KGWATTTTCC AKGAATATGA RTCTYCCTTT TTTCCCCTCC TGTCAGTCTA 900

GCTAATGGTT TGTCAATTTT GTTGATCTTT TGAARAACAA ACCTTTGGTT CCACTTTCTT 960

GTTGCATATG CTGARTATTC TCATAATTGG AGTGGAAAGC TGATCTTTGA TTACTTATTT 1020

TACTTAGGGC TGAGGAGTTC ATGGACTTCG CAAAACCTCC TTGAATCTAA ATTGCATCTT 1080

CTTTCCTGGT TTCTGGGCTG AAACATGTTT TTTCCCATCT WANAWACCCT TGGTCTTTTC 1140

ATKGGGGATT AAGACTAGAG AAAGTTCTAG ATMCCTTGTC CTTTTATGCT GTCATTTTGT 1200

TTAAAGGCTT TCTATGTAGT AAAACTATCT ATATAGACAA AATAGAGCCT TGAGTTGTGG 1260

TCTTGAATTT GATCAACATG ATTTACCACA TTCTGTACTG GATATTTCTT CACCTGCTGC 1320

TACTGTAAAC CATTTTATTC TTGGATCTTC TGTAGAGTAT ATTATCACAG GTACTTTTTA 1380

CAGGGGTGTC TAATCTTTTG GCTTCCCTGG GCACATTGAA AGAAGAAGAA TTGTCTTGGG 1440

CCACACATCA AATACGCTAA CACTAATAAT AGTTGATGAG CTAAAAAAAA AAAAAAAAAG 1500

GCAAAAAAGN CCCAAAA 1517

(2) INFORMATION FOR SEQ ID NO: 127:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

```
TGAATCTATT CTTTGAACAT TCTACAACAA GAATTACATT ATACTGTTAT ACCAGAGTAC    60
TTCTGCAGTG TGAAATAGAT TGGTTTGGAA AATGAACCTG GCTTTGCTAT AAATTACATT   120
CACAGGCCTT TTTGCAAATG TGTAACTTGC CTATCAAAGT AGTTTGTAGG GCAAATGCAG   180
AATATATGTC TCCATCTGGT AAAGTACCTT WTAYTCATGT GGGAAATCAA GTAGTATCAG   240
AACTTGGTCC AATAGTCCAA TTTGTTAAAG CCAAGGGCCA TTCTCTTAGT GATGGGCTGG   300
AGGAAGTCCA AAAAGCAGAA ATGAAAGCTT ACATGGAATT AGTCAACAAT ATGCTGTTGA   360
CTGCAGAGCT GTATCTTCAG TGGTGTGATG AAGCTACAGT AGGGRMGATC ACTCATGMTA   420
GGTATGGWTC TCCTTACCCT TGGCCTCTGW WTCATATTTT GGCCTATCAA AAACAGTGGG   480
AAGTCAAACG TAAGNTGAAA GCTATTGGAT GGGGAAAGAA GACTCTGGAC CAGGTCTTAG   540
AGGATGTAGA CCAGTGCTGT CAAGCTCTCT CTCAAAGACT GGGAACACAA CCGTATTTCT   600
TCAATAAGCA GCCTACTGAA CTTGACGCAC TGGTATTTGG CCATCTATAC ACCATTCTTA   660
CCACACAATT GACAAATGAT GAACTTTCTG AGAAGGTGAA AAACTATAGC AACCTCCTTG   720
CTTTCTGTAG GAGAATTGAA CAGCACTATT TTGAAGATCG TGGTAAAGGC AGGCTGTCAT   780
AGAGTTATGT GTTAGTCTCA GGAGTCTTAA CTTTTGAAAT ATGTTTTACT TGAATGTTAC   840
ATTAGATATT GGTGTCAGAA TTTTAAAACC AAATTACTGC TTTTTGAAAC CTCAAATTAT   900
ATAATGTATC TTATGTATGT GCTTTATATT GTTATTTGTG TATACATTAA AATAATTCTG   960
AATTATTTAA TCTGATATGT TGTATTCTGT ATCTTGAAAT TTTTGTTTCC TTGAAACATG  1020
CATGCATTTA AAAATAAAGC TTAAACAACT GTAAAAAAAA AAAAAAAAAA CTC         1073
```

(2) INFORMATION FOR SEQ ID NO: 128:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 300 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128:

```
CAACCCCTGC CTTTTTTTTG TTTTCCATTT GCTTGGTAGA TCTTCCTCCA TCCCTTTATT    60
TTGAGCCTAT GTGTGTCTCT GCCCGTGAGA TGAGTCTCCT GAATACAGCA CACTTACTGG   120
TCTTGACTCT GTATCCAATT TGCCAGTCTG TGTCTTTCAT TTGGAGCATT TAGCCCATTT   180
ACATTTAAGG TKAATATTGT TATGTGTGAA TTTRATCYTR TCATTATGWT GTTAGCTGGT   240
TATTTTGCTT GTTAGTTGAT GCAGTTTCTT CCNGGCATCA ATGGTCTTTA CAANTTGGCA   300
```

(2) INFORMATION FOR SEQ ID NO: 129:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1275 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129:

```
GGCAGAGCCT GTCCCTGCTG CCCCTGCAAA AAAAACCCCC TCTGGTGTGA GCAGGATGGT     60
TGGAGGTTAT GTGAGCTCCT TCTCCTTTCC TCCAGTTTCC TCTTCCCTTC TCCTCCCTGC    120
CTCTTTTGCT TTTCCCTTTC TTCCTGGTAC CCCCTGCCCA TTCCTGTATT TTCTCCCATC    180
GCCATTCTCC CCTCTCCCAC TGTCCCTAAC CCGTTCAAAC TCTTTCCTCT TAAATGGTTG    240
AGATTTTCTC TCACCAAGCA CACCCCAGTA TTAATTAAAC TAGCTGCAAA CAGGCAGCAA    300
GTGGTCTACC ATGACAGATG GGTTTTGTGT GTGTGTGTGT GTGTGTAATT GTAATAAAAC    360
ATATTGARTC ACTCAATAAA CACAGAGTGT CTACTACATG TATCARGCAC TATCATAGAT    420
GCTAATTAAC GAAACTGAAA TGGCCAGGCC CTCACAGTGG CTCATGCCTA TAATCCCAGC    480
ACTTTGGGAG GATGAGGCAG GAGGATCACT TGAGGCCGGG AGTTCAAGAC CAGCCTGGGC    540
AACATAGTAA GACTCCATCT CTACAAAAAA AAAATTTTTT TTATTATACT TTAAGTTTTG    600
GGTTACATGT GCAGAACGTG TAGTTTTGTT ACATAGGTAT ATACGTGCCC TGGTAGTTTG    660
CTGCACCCAT CAACCCATCA CCTACATTAG GTATTTCTCC TAATGTTACC CCTCTCCTAG    720
CCCCCCACCC CGTGACAGCC CCTGGTGTGT GATGTTCCCC TCCCTGTGTC CATGTGTTCT    780
CATTGGTCAA CTCTCACCTA TGGAGTGAGA ACATGTGGTA TTTGGTTTTC TGATCTTGTG    840
ATAGCTTGCT GAGAATGTKG GTTTCCAGCT TTATCCACGT CCCTGCAAAG GGCATAAACT    900
CATCCCTTTT TATGGCTGCA TAGTGTTCCA TGGTGTATAC GTGCCACATT TTCTTAATCT    960
ATCATTGATG GACAAGTTTT GCTATTGTGA ATAGTGCCAC AATAAACATA CGTGTGCGTG   1020
TGTCTTTATA GCAGCATGAT TTATAATCCT TTGGGTATAT ACCCAGTAAT GGGATCACTG   1080
AGTCAAATGG TATTTCTCGT TCTAGATCCG TAAGGAATTG CCACACTGTC TTCCACAATG   1140
TTTGAACTAA TNTACACTCC CACCAACAGT GTAAAAGTGT TTCTATTTTT CCACAACCTC   1200
```

(2) INFORMATION FOR SEQ ID NO: 130:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 472 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130:

```
CNGAAACCCC GTGAACCCTC CCCGGGTTAA AAAGCCCCCC CTAAATGGGG GGAACGCYTC    60
ACACGTTATA AAAAAGCACT AGAATGTTTT GAAAGCGAGA AACAACAGCT GTGTAGGGTA   120
GCTAGCAGTT AGTGTTGTAC AGAAGACAGA TATTTGTGCA TTTYTGCATT TTCTAAGTTT   180
GCTGCAATGA GCATGTATTA CTTTCATAGT TATAAAACAC ATGCAAAATG CCCTTTTAAA   240
ATGAAAAAAA ATCCATGAGT GTAAGTGATA TATATGCTTT GGAAAGCCTG GCACGGTCAT   300
TGTTTACTCT CAATAGTATG TGTTTGCCTT TGTCTTTTTG AGACATTTTG TTTTAATCTG   360
TTGATGACAA TAACCTGTTG ATAATATAAC TTGATAACAA ATAAAATGAC TTATGATTGA   420
AWMAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA NN           472
```

(2) INFORMATION FOR SEQ ID NO: 131:

(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 1950 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131:

```
ACCTCTCAGA ATCTTCTCTC AGCAACCTGA GTCTTCGCCG TTCCTCAGAG CGCCTCAGTG    60
ACACCCCTGG ATCCTTCCAG TCACCTTCCC TGGAAATTCT GCTGTCCAGC TGCTCCCTGT   120
GCCGTGCCTG TNATTCGCTG GTGTATGATG AGGAAATCAT GGCTGGCTGG GCACCTGATG   180
ACTCTAACCT CAACACAACC TGCCCCTTCT GCGCCTGCCC CTTTNTGCCC CTGCTCAGTG   240
TCCAGACCNT TGATTCCCGG CCCAGTGTCC CCAGCCCCAA ATCTGCTGGT GCCAGTGGCA   300
GCAAAGATGC TCCTGTCCCT GGTGGTCCTG GCCCTGTGCT CAGTGACCGA AGCTCTGCCT   360
TGCTCTGGAT GAGCCCCAGC TCTGCAACGG GCACATGGGG GGAGCCTCCC GGCGGGTTGA   420
GAGTGGGGCA TGGGCATACC TGAGCCCCCT GGTGCTGCGT AAGGAGCTGG AGTCGCTGGT   480
AGAGAACGAG GGCAGTGAGG TGCTGGCGTT GCCTGAACTG CCCTCTGCCC ACCCCATCAT   540
CTTCTGGAAC CTTTTGTGGT ATTTCCAACG GCTACGNCTG CCCAGTATTC TACCAGGCCT   600
GGTGCTGGCC TCCTGTGATG GGCCTTCGMA CTCCCAGGCC CCATCTCCTT GGCTAACCCC   660
```

```
TGATCCAGCC TCTGTTCAGG TACGGCTGCT GTGGGATGTA CTGACCCCTG ACCCCAATAG   720
CTGCCCACCT CTCTATGTGC TCTGGAGGGT CCACAGCCAG ATCCCCCAGC GGGTGGTATG   780
GCCAGGCCCT GTACCTGCAT CCCTTAGTTT GGCACTGTTG GAGTCAGTGC TGCGCCATGT   840
TGGACTCAAT GAAGTGCACA AGGCTGTGGG GCTCCTGCTG GAAACTCTAG GGCCCCCACC   900
CACTGGCCTG CACCTGCAGA GGGGAATCTA CCGTGAGATA TTATTCCTGA CAATGGCTGC   960
TCTGGGCAAG GACCACGTGG ACATAGTGGC CTTCGATAAG AAGTACAAGT CTGCCTTTAA  1020
CAAGCTGGCC AGCAGCATGG GCAAGGAGGA GCTGAGGCAC CGGCCGGCGC AGATGCCCAC  1080
TCCCAAGGCC ATTGACTGCC GAAAATGTTT TGGAGCACCT CCAGAATGCT AGAGACCTTA  1140
AGCTTCCCTC TCCAGCCTAG GGTGGGGAAG TGAGGAAGAA GGGATTCTAG AGTTAAACTG  1200
CTTCCCTGTT GCCTTCATGG AGTTGGGAAC AGGCTGGGAA GGATGCCCAG TCAAAGGCTC  1260
CAAGCGAGGA CAACAGGAAG AGGGATCCAC TGTTACCAAA AGTCCTGATT CCCCCATCAC  1320
CAACCTACCC AGTTTGTTCG TGCTGATGTT GGGGGAGATC TGGGGGGAGT TGGTACAGCT  1380
CTGTTCTTCC CTTGTCCTAT ACCGGGAACT CCCCTCCAGG GTACCCACAG ATCTGCATTG  1440
CCCTGGTCAT TTTAGAAGTT TTTGTTTTAA AAAACAACTG GAAAGATGCA GAGCTACTGA  1500
GCCTTTGCCC TGAATGGGAG GTAGGGATGT CATTCTCCAC CAATAATGGT CCCTCTTCCC  1560
TGACGTTGCT GAAGGAGCCC AAGGCTCTCC ATGCCTTTCT ACCTAAGTGT TTGTATTTTA  1620
TTTTAAATTA TTTATTCTGG AGCCACAGCC CCCTTGCTTA TGAGGTTCTT ATGGAGAGTG  1680
AGAAAGGGAA GGGAAATAGG GCACCATGGT CCGGTGGTTT GTAGTTCCTT CAAAGTCAGG  1740
CACTGGGAGC TAGAGGAGTC TCAAGCTCCC CTTAGGAAGA ACTGGTGCCC CCTCCAGTCC  1800
TAATTTTTCT TGCCTGCCCC GCCTTGGGGA ATGCCTCACC CACCCAGGTC CTGACCTGTG  1860
CAATAAGGAT TGTTCCCTGC GAAGTTTTGT TGGATGTAAA TATAGTAAAA GCTGCTTCTG  1920
TCTTTTTTAA AAAAAAAAAA AAAAAAAACT                                   1950
```

(2) INFORMATION FOR SEQ ID NO: 132:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 990 base pairs

(B) TYPE: nucleic acid

TTAAAGATTT AAAATAGTTT TTATATTTTT TTTAAATATG AATATATAAA TTTTAATAAA

CTTGAGTCCT TATTATTATG AAATTTTCCT TATTATTTCT ACCAATGCTT CTTATATTAA 120

AGCCTGATCT TTTTCATATT AGTATATGTA CATTAGCTGC CTGTGGATTA ACATTTCCAT 180

GAAATGTATT TTTGCATTGT TTGATCTTAA ACTTTTTGTG TCTTTATATA AGGTATGCTY 240

CTTTTAAGCA TGATATTTTT AACCACAATA GTTGAAAGAC AATCTYCACC TTTTACTTGT 300

ATATTTACAT GTAATGTAAT TTTTGATGCA TATTACGTCT TATTATTTAA CCAACCTATT 360

TTATTTTATC TAGGGCATTT TTCAGAAAGC CTTATTTTCT TGTATTAATC AAATATTTTT 420

AYCATTGTAT TTTCCYCTAT TAGTTAGKAA TACGKTACYC YAAATATATA TTGTGGSTAT 480

TTTCAGAATT GCAATATGCC TCCTTAATTT ATTAGAGGCT AACCTAAATT ATTACTTTTA 540

CCACTTACTT GAAAATTCTG GAACTTTAGA ACATTTATTG TTTTATGCAT TTTAATTCTA 600

CTTGTATTTT TACTACTCCT AAACATTATT ATTGTTTTAG ACAAGCCAAA ATATATNTTG 660

TTATTATCTT ATYCTCCATT TCTTTCTGTA TTTTTATGCC ACTATGTATG CTCAATTTCC 720

TTCTATGTGA TGAACCTAAT TCAGTACTTT TGTTTTTTAA TCTGTGCAGG TAGCCTGGCC 780

ATTAAATTTT TATTTTTGGT TTGCTGAAAA AATTGTGTTT ATTTCTATAT GCATACTTAT 840

GCATATAGAA TNCTAGGTNG ACATATTTTT AGTATTTATA AATGTAAAGT CATTWATTKG 900

GCTTCTATCA TTTCKGTKGA GAAATCAATT GTCAGCCCAA TAGTTTTTCA TTTTAAATTA 960

CNGAATTTTT TCATGTCTCT GCTTTTAGGA 990

(2) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1720 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133:

GTCTGATAAG CGACTGTGGT TATTCCCCTA AAGTTTACTT CAGCACTAAC ACTAGTGCTT 60

CCGCTGGAGT TTGCAGTTTT CCAGCTTTAT ACAGGATTTT CCTTTGACTG GAAGAGTCAA 120

GGATATAGAG ACTCAACAGT GACATTTATT GTACAACATC AAGGGGAATA GGATACTCAT 180

CAAACTGGGA TTATTCTTAT CAAAACATGG TCTTCTTTGA ATAAGAAAAA TACATAGTTG 240

GTTATTATGG ACTTAAAACT GTGTTAAATG GATATTCTGA TAAAATATTT GCTGCTCTGT 300

AGAGTGTGGA AAATCTGAGA ATATTAGCTT TACTCATCTT GAGCTTTGAG GATGTTCTCT 360

GTACGCCGAT GGTTTCATAT TAACTAAAAA AGCTGGGTAT TGTAAAATCT CATTTATAAA 420

AACTCAGATG AGAAGAAAAT TTTCTTTGAT GGTGAGACTG TTGTCTTAGT TCAGGAAATT 480

ATTTAATAAT CCTTTGTTAC CTGTGAATGA AGGAACTTTG TAATTCTGAT TTATCGTAAA 540

ACATGAGCCT TTCCAGAGTC AGCTTAGACA CTGTTGTCGC AAATAGCCAT GCTTTGCCTT 600

ATGCCAAGGA GGCCCAGAGG GAGGGCCTAG TCTTCCTCTG TTGCTGTACA TATATTGAAA 660

TGCTTTTTTT TTTTATTTTG CATTTGTTAT CTATAATGAG CTTTCTGAGC CCTGATATTA 720

TGTGAGACAA ACAGGAGTTA TTGATGTTAT ACACTCCCTT CCATTCAGGA TTTTCTGCTT 780

GGAGGGAAAT ATGTTGACCT TAGAGAATTG TGAATATTGT TGCAATTCTT GAATATATTA 840

CCATGTGAAT AATAGAGACT GTGTTGCTCT CTAGTATAAG CTATATTTAT TTTTCATTCA 900

TTTGAATTAC TAGTTATAAC TGGAGAAATT TTGTTACCTC TATCCTGGCT TGCCTGACTG 960

GCTGTATAAT AGCAGCAGCC TCTTTTAGAG CATCTTAATG AAAACATGGA TGAAAGGAAT 1020

TAATGATGAT ATCTGCAGAC TGCGTAGAAA ATGGCTTTTG TTCCCAGCGT TAACATTTTC 1080

TTCTCAATCA CATTTCAATG TTTGTGGAGA GTGGCAGATT CACACCAGAA ACACTAGGTG 1140

TTCATATCCA TAGCATGGAT GCAGAATAAG CAGTTGGGAG AGAAGCTTCT TCCTACCTGG 1200

TACTCCTCCC ATTCACCTCA GCCCAGCCCC AGACAGGCGT TAGCATTCAG TGTGGGCCCT 1260

CAGGCAGCCC TGAAGCCTGG CTGGGTCATC AGATGGGGGC AGCCTGTGAC GGGCACCAGC 1320

GGCCTGATTC CAGGGAAGAG TTCCTGGAGG GTGTTGGCTG TTTTTGTTAG CTCAGTTTTT 1380

TTCTGGGCTC CACCATTCCT AACTCCAGGT AGACAAGATA GATGTCACAC ACAACAATTT 1440

TAAAGTATTT TGCTTAGTGC ATTTTGTTTA TGATTGCAGT GTTTGTTTCT TATTTAATAG 1500

GCTTTTTACT TCATTCTATT AAATTTTAGT GTTTAGAAGA GGCGGGTACT GTCACTGTGT 1560

AAAATATGTA ATATTTTATA TGTTATACCA TGTCATATAT ACTTGCAATA TCAGACCTTG 1620

CATTCAATAT ACAATGCAAT TGACTCTTTG CAGACCTGCA TTTTTCAGTG AACAATAAAA 1680

AGATTGTCTG GCACTCCAAA AAAAAAAAAA AAAAAAAAAA 1720

(2) INFORMATION FOR SEQ ID NO: 134:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 705 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

GTGGAATCAC AGACACTCCT AGAGGAGAAT GCTGTTCAAG GAACAGAACG TACTCTTGGA 180

TTAAATATAG CACCTTTTAT TAACCAGTTT CAGGTACCTA TACGTGTATT TTTCGACCTA 240

TCCTCATTGC CCTGTATACC TTTAAGCAAG CCAGTGGAAC TCTTAAGACT AGATTTAATG 300

ACTCCGTATT TGAACACCTC TAACAGAGAA GTAAAGGTAT ACGTTTGTNA AATCTGGGAA 360

GACTTGACTG CTATTCCATT TTGGGTATCA TATGTACCTT GATGAAGANG ATTAGGTTGG 420

GATACTTCAA GTGAAGCCTC CCACTGGAAA CAAGCTGCAG TTGTTTTAGA TAATCCCATC 480

CAGGTTGAAA TGGGAGAGGA ACTTGTACTC AGCATTCAGC ATCACAAAAG CAATGTCAGC 540

ATCACAGTAA AGCAATGAAG AGCAGTTTTC CAATGAAAAC TGTGTAAATA GAGCATCAAC 600

AAGTACAAAA TTCTTGTCTT AATTAGTGGG GGTATATAAA AATTCCTTGT AATGGTCAAA 660

TATTTTTTAA AATTGACATT AATAAAGCAT ATTTTAAAAG TTTCT 705

(2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 323 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135:

AGCACACACC TCCTTTAGTT GCTCCTAAGG TCATGTTCAA CATTCGTGGA GTGCATTTTC 60

TGCTCAGGGA GCTTTCCCAG ACCCGGAATG TTTGGTGCTC ACAGACYCTG GCAAGGATCG 120

GTATTGCTGT TCCTCAGTTT TGCCTGGGGA AATGGAGGST CAGTGACGTT CAGTGACGTG 180

CCCAGAGTCA TGCCATTGGC GGGTGGCCCA GKGMTCCAGG TCTCCAGCAC CCCTCGGCCC 240

CCTCCTCACC AGGTCACATC ATCTCCTGGA TTAGAATCTG CTCACATAGT CTGTCCTGAA 300

AGGAAAAAAA AAAAAAAAAA AAC 323

(2) INFORMATION FOR SEQ ID NO: 136:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 582 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136:

GGACGGAATG GTGCAACCCT CCTWAMTTTT CTKGKGCTGT TGACAACAGA GGGAGGGAGG 60

GAAAACATTT TTYGTGGGAG AATCCTACYT CTGCAGSGGA GCCCTTAAGC GATKGATTTT 120

GAATCTKGAC CCTTTACCAA CTAATTTTGA AGGAAGATAC CTTGGAAATA TTTGGCATTC 180

AGTGGGTTAC TGAAACAGCA TTAGTGAATT CATCTAGAGA ACTCTTTCAT TTATTCAGGC 240

AACAACTGTA CAACTTGGAA ACCTTGTTAC AGTCCAGTTG TGATTTTGGG AARGTATCAA 300

CTCTACACTG CAAAGCAGAC AATATTAGGC AGCAGTGTGT ACTATTTCTC CATTATGTTA 360

AAGTTTTCAT CTTCAGGTAT CTGAAAGTAC AGAATGCTGA GAGTCATGTT CCTGTCCATC 420

CTTATGAGGC TTTGGAGGCT CAGCTTCCCT CAGTGTTGAT TGATGAGCTT CATGGATTAC 480

TCTTGTATAT TGGACACCTA TCTGAACTTC CCAGTGTTAA TATAGGAGCA TTTGTAAATC 540

AAAACCAGAT TAAGGTTTGA CTGGTTTCAT TTGATTTTTA AG 582

(2) INFORMATION FOR SEQ ID NO: 137:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1021 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137:

TTCGGCAGAG CCCTTGCGCG CTCTTGAATA CCTGCKTTCT GTAGCGCTAG TTCTCTTCAA 60

GATTTGCTTA GTGTCATTTC ATTTCGGTTT CTTTTCTCGC CATGTTTTTC TGTCGGAATT 120

ACGGTTCGTT TTGGTTCTAT GTACTCTCTA AAATGTTATC GTTTTTCATT TGTCTACTAA 180

TTTTCGTGCA TTTGTTACTA CTGAGTTTCT TAATATCTGA CTGGCCTCCG CCCACGGGCT 240

CTGCAGANCA TAAAATACTC AGGCTGATGG TAGTGCAGAG ACTCTCCCTC CTTGATCAGC 300

GCAAACGTTG GTTTGAGGCT TGAGGGATGG AGCAACATTT TCTTGGCTGT GTGAAGCGGG 360

CTTGCGATTC CGCAGAGGTG GCGCCAGAGC CCCAGCCTCC ACCTATTGTG AGTTCAGAAG 420

ATCGTGGGCC GTGGCCTCTT CCTTTGTATC CAGTACTAGG AGAGTACTCA CTGGACAGCT 480

GTGATTTGGG ACTGCTTTCC AGCCCTTGCT GGCGGCTGCC CGGAGTCTAC TGGCAAAACG 540

GACTCTCTCC TGGAGTCCAG AGCACCTTGG AACCAAGTAC AGCGAAGCCC ACTGAGTTCA 600

GTTGGCCGGG GACACAGAAG CAGCAAGARG CACCCGTAGA AKARGTGGGG CAGGCAGARG 650

[illegible]

[illegible]

[illegible]

AGCCTTAGAT AGCAGCAGAA GGCTTTTTGG ATTCTCCTCC TTGAAAAGAT TCTCAGTTAC 960

CAAACGTCTC CACCTAGAAA ATAAAAATAC ATTAAGATGT TGANAAAAAA AAANAAAAAA 1020

A 1021

(2) INFORMATION FOR SEQ ID NO: 138:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1777 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:

CGGAAGATGA TGGCTTCAAC AGATCCATTC ATGAAGTGAT ACTAAAAAAT ATTACTTGGT 60

ATTCAGAACG AGTTTTAACT GAAATCTCCT TGGGGAGTCT CCTGATCCTG GTGGTAATAA 120

GAACCATTCA ATACAACATG ACTAGGACAC GAGACAAGTA CCTTCACACA AATTGTTTGG 180

CAGCTTTAGC AAATATGTCG GCACAGTTTC GTTCTCTCCA TCAGTATGCT GCCCAGAGGA 240

TCATCAGTTT ATTTTCTTTG CTGTCTAAAA AACACAACAA AGTTCTGGAA CAAGCCACAC 300

AGTCCTTGAG AGGTTCGCTG AGTTCTAATG ATGTTCCTCT ACCAGATTAT GCACAAGACC 360

TAAATGTCAT TGAAGAAGTG ATTCGAATGA TGTTAGAGAT CATCAACTCC TGCCTGACAA 420

ATTCCCTTCA CCACAACCCA AACTTGGTAT ACGCCCTGCT TTACAAACGC GATCTCTTTG 480

AACAATTTCG AACTCATCCT TCATTTCAGG ATATAATGCA AAATATTGAT CTGGTGATCT 540

CCTTCTTTAG CTCAAGGTTG CTGCAAGCTG GGAGCTGAGC TGTCAGTGGA ACGGGTCCTG 600

GAAATCATTA AGCAAGGCGT CGTTGCGCTG CCCAAAGACA GACTGAAGAA ATTTCCAGAA 660

TTGAAATTCA AATATGTGGA AGAGGAGCAG CCCGAGGAGT TTTTTATCCC CTATGTCTGG 720

TCTCTTGTCT ACAACTCAGC AGTCGGCCTG TACTGGAATC CACAGGACAT CCAGCTGTTC 780

ACCATGGATT CCGACTGAGG GCAGGATGCT CTCCCACCCG GACCCCTCCA GCCAAGCAGC 840

CCTTCAAGTT CTTTTATTTC TGGGTAACAG AAGTAGACAG ACAGGTTACT TGGTGTATCT 900

TCTGTTAAAG AGGATTGCAC GAGTGTGTTT TCCTCACACA CTTTGATTTG GAGAATTGGT 960

GCTAGTTGGC AATAGATAAC TCAGCGTAGA TAGTATTGCA AAAAGGGGAG GAAATACACA 1020

ACAATAATAA ATGTAAAAAC CTGCTATTCA ACATGCAGTT TTATTTCGAR GCCAAAAATC 1080

TAGAGCTTTC CCAAGATCCT GTTGCCTTAG GCACATNCAC ACTTCAACAG TGCACACTAT 1140

CCAACAGTGC ACACTATTCA ACAGTGCACA CTATTCAAAA GCGTAGACTA TTTTTTTGCA 1200

```
TGTTCAAGAT ATTTGTTTTG GTCTTATGTG TGTGTGAGAG AGAGAGATTC CTTTGACATT   1260
AAGGAGCATC AATGAGAAAA GATGATGAGG CAGGAATTAA TAAAGAAATG AAGTCGTGTG   1320
TGTTTGGTTG CCTGTCAGAG GGCACACAAT TTCATAAACA CCATGCCTGG ACAATTTGAT   1380
ATTAATATTT AACACCTCTG CATCTTTTTC TTAAAAAAGA ATATGGGCCA GATACAGTGG   1440
CTCACATTTG TAATCCCAGC ACTTTGGGGA GCCAAGTTAG CAGAATCCCT TGAGCACAGG   1500
AATCTGAAAC CAGCTTGGGC AACATAGTGA GATCCCATCT NTACAAAAAA CTTAAAAATT   1560
AGCCAGGCAT GATGGCACAT TCCTGTAGTC CTAGCTACTC AGGAGGCTAA GGTAGGAGGA   1620
TTGCCTGAGC CCAGGAGTTC AAGGCTGCAG TGAGCTAAGN ACGTGCCAGT ACACTCCAGC   1680
CTGAGCCACA AAGTGAGACC CTGTCTCGCA AAAAAAAAAN TTAAAAAGTC GGGGGGGGGC   1740
CCGGTACCCA AATCGCCGGA TATGATCGTA AACAATC                            1777
```

(2) INFORMATION FOR SEQ ID NO: 139:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 643 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139:

```
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTGGG AATGAGAAAA TAACTTTATT   60
TTCATTGTGG GGAGCGGGCC GATGTCCAGC CTCAGAACTT CTGGAACTGC TTCTTGGTGC   120
CGGCAGCCTT GGTGACCTTG AGCACGTTGA AGCGCACTGT CTTGCTCAGA GGCCGGCACT   180
CGCCCACTGT GACGATGTCA CCGATCTGGA CGTCCCTGAA GCAGGGGGAC AGGTGTACAG   240
ACATGTTCTT GTGGCGCTTC TCCAAGCGGT TGTACTTGCG GATGTAGTGC AGATAGTCTC   300
GGCGGATGAC AATGGTCCTC TGCATCTTCA TCTTGGGTCA CCACGCCAGA GAGGATCCGC   360
CCTCGAATGG ACACATTACC AGTGAAGGGG CATTTCTTCT CAATGTAGGT GCCCCTCAAT   420
AGCCTCCTTG GCGTGTCTTT GAAGCCCAGA CCGATGTTCT TGTTAGTAAC CCGCGGGAGC   480
TTCTCCTTGC CAGTTTCTCC CAGCAGGACC CTCTTCTTGT TTTGAAAGAT GGTCGGCTGC   540
TTTTGGTAGG CACGCTCAGT CTGAATGTCC GCCATCTTCT CGTGCCGMAY TCCTGCAGCC   600
```

(2) INFORMATION FOR SEQ ID NO: 14

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1220 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140:

```
GGCACGAGGA TGATAGACCT ACTGGAGGAA TACATGGTTT ACAGGAAGCA TACCTACATR      60
AGGCTTGATG GCTCATCCAA GATCTCGGAG AGGCGAGACA TGGTTGCTGA TTTTCAGAAC     120
AGGAATGACA TCTTTGTGTT CCTGTTAAGC ACACGAGCTG GAGGACTGGG TATCAATCTC     180
ACTGCTGMAG ACACAGTGCA TTTTCTATGA TAGCGACTGG AACCCCACTG TGGACCAGCA     240
GGCCATGGAC AGGGCCCACC GCTTAGGGCA GACAAAGCAG GTTACTGTGT ACCGGCTCAT     300
CTGTAAAGGC ACCATTGAAG AACGCATTCT GCAAAGAGCC AAGGAGAAGA GTGAGATTCA     360
GCGGATGGTG ATTTCAGGTG GGAACTTCAA ACCAGATACC TTGAAACCCA AAGAGGTGGT     420
TAGTCTTCTT CTAGACGACG AAGACTTGGA GAAGAAACCT ATGTACTCTA AACCTCTATA     480
CACTCCCCTC ACGTATCTGA GAATGGAAGA GGTACTTGGG TGTGTGCCAA CGGTTAGGCA     540
AAGCCAGAGG CTGTATTTAG GGAAAGTATT TTTGTGCTCA TATTTTATAT AAAAACCCAA     600
ACAAGAATGT GTTTGTAGGC CAGGCGTGGT GGCTCGCGCC TCTAGTCTCA GCATTTCGGG     660
ARGCCAAAGT GGGCAGATCA CCTGARGTCA GGARTTTGAG TTTGARACCA GCCTGGCCMA     720
CGTTGTGAAA CCCCACCTCT ACTARGARTA CSGAAAATTG GTTGGGCATG GTGGCGGGCA     780
CCTGTAATTC CAGCACTTTG GGAGGCTGGG GCAGAANAAT TGCTTGAGCC CAGGAGGTGG     840
AGATTGCGGT GAGCCGAGAT YGTGCCATTG CAMTCCAGCC GGGGCAATAA GAGTGAAAYT     900
CCATCTTTTA AAAACAAACA AAAACAAAAA ACACAAGACG GCTCACACCT GTAATCCCAG     960
CACTTTGGGA RGCCGARGCA GGTGGATCAC GARGTCAGGA GTTCCAAGAC TAGCCTGGCC    1020
AACCTGGTGA AGCCCCGTCT CTACTAAAAA TACMAATATT AGTCGGGCGT GGTGGTGGGC    1080
ACGTGTAATC CCAGCTACTC GGGAGGCTGA GGCAGGAGAA TCCCTTGAAG CTAGGAGGCA    1140
GAGGTTGCAG TGAGCCAGGA TCGTGCCATT GCACTCCAGC CTGGACAACA AGAGCAAGAT    1200
TCCATCTCAA AAAAAAAAAA                                                1220
```

(2) INFORMATION FOR SEQ ID NO: 141:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 721 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141:

```
AATTCGGCAC GAGCCAGGTT AGCTGGAAGG GCAGCTCTCC AGGCCCTGCC CACCCCACAG    60
GGGGCTCCTT ATGCACAGCG GGGTGTCTCC TTGTGGCCAT AGAAACGGAA CTGGCTCTTT   120
TCAACAGTGC TGCAAGAGGA TGGTTATTTA ACGCTGGCCC CCAAGGAGGA AAGGCACAGA   180
CYTTCCTCCC TCCTGGAACA TCCAAGGGCA CTGGATCCTC TGTGTCCCTC TGAGATGGGG   240
TGCCACTCCA GCAAGAGCAC CACGGTGGCA GCTGAGTCCC AGAAGCTTGA AGAAGAGYGC   300
GAGGGAAGAG AGCCAGGTCT GGAGACCGGC ACCCAGGCAG CAGACTGCAA GGATGCCCCG   360
CTGAAGGATG GAACCCCTGA GCCAAAGAGC TGAAATGCCT CTCTCCAGAG TCGGACCCTC   420
ACCTCYTTCC TGGAACTGCC TTTGGCCCCA GAACCATGAG ACAATCCCCA CCCTGAGAAG   480
CTCCGATCAC TGGGAGGAGA GAGAAAGCCT CCAGCTTTGG GATTCAGGCT TCAGAAGTTT   540
TTAGCAGCCT TTGCTCATTG GAGAGGTGGG GAAAGGATAA AGTTCTTATA AGGAAATCCC   600
TAATTTCCCC CAGCTCCTCC CCNCCNGAAG AAGGAACNAA AGAAAGTTCC TTCCACACGT   660
TTTGTTGGAA ACTTTTCCCT TGCCAACTTT CCTTGGATTG CCAGAACAAA GCCCTCCAGA   720
A                                                                   721
```

(2) INFORMATION FOR SEQ ID NO: 142:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1468 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142:

```
ATGAATTAAT GTTTATAAAT GACTGTACTG AATTTAAAAC CGTACAGTTT CATTTGCATT    60
TTGACATTAC TTTATTATAC ATTTTGCATT TAAAAGGCTG CACCAGTTGG CTTTTTCTTCT  120
GTTTTATTCT CAAAATATAG AGATTCTGTG ATTTATTTGC CCTGTTTATG GATTAAAAAG   180
AAAATTCTAA TATAAAGCAT TTCAATAGGA TGCATAGGTA TATTACGTTT TTTAAATGCT   240
TTAGATCTGT GATTCTTGAC TTACTATTTA TTTTATCCCC TTTAAGTCAG GGATGCTTTA   300
TTCTATTTTA AAGCACTTAT GAGTTACATG TTGTAATCAA GTTTGCACAA TATATTTATC   360
[illegible]
ACACAGTTAT TAAACACTGT TGACAGTAAA ATTCTCTTTG ATAAATATAG ACAATTAATG   540
```

GAAAAAAAAA TTCTCATTAT TTGCAAAGAA TGAACAAGTT AATGAACAAA CAAACTAGAT 600

TTGGTATGTT TTCAGCTTTT GTATCATGTT TAATTGTTTA ATTTGGTTGA AAAACTGCAG 660

TTGAGAAATC AGATAGCAAT ATAGACATTC ACAGCAGCTC TGTGGATACC ATGTAATTGT 720

CAGGTAATTT CAGAATGTTG AAAATTATTC AGTGCAGCCC TCATAGTATC ATACTTGAAG 780

AAATTGATTA CAGTTCCACT AAATTGTTGA AGATAAATTA TTTTTAAAGG TTATGAAAAC 840

TAAGTTATAT TAATTCATAT GTTTGATTTT TAAATCCCAC CTCCTCAAGC TATCCAATTT 900

NCTGACTTTG AAAATAACCA TGAGAGATGC CACATTTCTC TCTGGGAAAC TACCACTCAA 960

AGAATAATTG TTAAAAATTA AGCTTTTAGG TATTAGAAGC TGTTATAAAG TATAAAATTA 1020

AGATATAAGC AGATCACATG TAAATCATTC CTAAAGCACA AGAAAAGAAT GTGCCTTGAT 1080

GTACATATAT TACTAAGTTG CCTCTCCCAG TTTACTTTAA AAATGGCTTT AAGGATAAAG 1140

AATAAATGTG ATAGCTGTGC ATGCATTATA TATTTGCATT TGCAAATTTC CCATTGTTTT 1200

AACAGCTGTG TGGCTGACTT TCAATTTTAA GACGTGAATT GACATACAGC CCATAACTTT 1260

ATAATGGCTG CTCATTTATC TTATCTTTCA GTTAGTGGAA AAACATTTCA ACCTGACTAA 1320

AATTTGGAAT TGTGTCTTTT ATGTTCCATC CTCTGTTGTT ACTAGATTTA GTTTAAAAAT 1380

TGTGTATGAC CATTAATGTA TGTCATAAAC ATGTAAATAA AAGATGTTGA ATCTTGTTGA 1440

AAAGCAWRAA AAAAAAAAAA AAACTCGA 1468

(2) INFORMATION FOR SEQ ID NO: 143:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 300 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143:

TGAATTTTTT GCCAAACTTA GTAACTCTGT TAAATATTTG GAGGATTTAA AGAACATCCC 60

AGTTTGAATT CATTTCAAAC TTTTTAAATT TTTTTGTACT ATGTTTGGTT TTATTTTCCT 120

TCTGTTAATC TTTTGTATTC RCTTATGCTC TCGTACATTG AGTACTTTTA TTCCAAAACT 180

AGTGGGTTTT CTCTACTGGA AATTTTCAAT AAACCTGTCA TTATTGCTTA CTTTGATTAA 240

AAAAAAAAAA AAAAAAAAAA AAACCCCNAG GGGGGGGCCG GGTNCCCAAT CCCCCCCAAA 300

(2) INFORMATION FOR SEQ ID NO: 144:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2243 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144:

```
TGCCTCCCTT CCTGCAGATT GTGGACAGTA GTTCCTCAGC CTGCACCCTG GATTCCTTCT      60
TCCCCTTCCT AGCTCCATGG GACTCGCCCC AAGACTGTGG CTTCAAGGAC CACCAGCCCC     120
TTACTCTTCA AGCCCTGACT GTGGAGTTGG TAGATGCCTT TGATCCTCAG TATTCTCTCT     180
GGCAATGTTC CACCGCTTCT CCTTCCTGGG AGCTGGCTCC ATAACTTGAT TTTCCCCAAA     240
CGTGTTGCAA TCCCTGCTGC CCCTTAGCCA CCCAGGGTCT TGTGTGGGTA TGAGTGTAGA     300
GGATGGGGGT ATGCCAGGCC TGGGCCGTCC CAGGCAGGCC CGCTGGACCC TGATGCTACT     360
CCTATCCACT GCCATGTACG GTGCCCATGC CCCATTGCTG GCACTGTGCC ATGTGGACCG     420
CCGAGTGCCC TTYCGGCCCT CCTCAGCCGT GCTGCTGACT GAGCTGACCA AGCTACTGTT     480
ATGCGCCTTC TCCCTTCTGG TAGGCTGGCA AGCATGGCCC CAGGGGCCCC CACCCTGGCG     540
CCAGGCTGCT CCCTTCGCAC TATCAGCCCT GCTCTATGGC GCTAACAACA ACCTGGTGAT     600
CTATCTTCAG CGTTACATGG ACCCCAGCAC CTACCAGGTG CTGAGTAATC TCAAGATTGG     660
AAGCACAGCT GTGCTCTACT GCCTCTGCCT CCGGCACCGC CTCTCTGTGC GTCAGGGGTT     720
AGCGCTGCTG CTGCTGATGG CTGCGGGAGC CTGCTATGCA GCAGGGGGCC TTCAAGTTCC     780
CGGGAACACC CTTCCCAGTC CCCCTCCAGC AGCTGCTGCC AGCCCCATGC CCCTGCATAT     840
CACTCCGCTA GGCCTGCTGC TCCTCATTCT GTACTGCCTC ATCTCAGGCT TGTCGTCAGT     900
GTACACAGAG CTGCTCATGA AGCGACAGNG GCTGCCCCTG GCACTTCAGA ACCTCTTCCT     960
CTACACTTTT GGTGTGCTTC TGAATCTAGG TCTGCATGCT GGCGGCGGCT CTGGCCCAGG    1020
GCTCCTGGAA GGTTCCTCAG GATGGGCAGC ACTGGTGGTG CTGAGCCAGG CACTAAATGG    1080
ACTCCTCATG TCTGCTGTCA TGAAGCATGG CAGCAGCATC ACACGCCTCT TTGTGGTGTC    1140
CTGCTCGCTG GTGGTCAACG CCGTGCTCTC AGCAGTCCTG CTACGGCTGC AGCTCACAGC    1200
CGCCTTCTTC CTGGCCACAT TGCTCATTGG CCTGGCCATG CGCCTGTACT ATGGCAGCCG    1260
CTAGTCCCTG ACAACTTCCA CCCTGATTCC GGACCCTGTA GATTGGGCGC CACCACCAGA    1320
TCCCCCTCCC AGGCCTTCCT CCCTCTCCCA TCAGCAGCCC TGTAACAAGT GCCTTGTGAG    1380

A[illegible]AAGTTGT TT[illegible]AGACTAA AGAATTAAGG TAACATCAAT A[illegible] [illegible]    [illegible]
```

CCCATCCTTG TTGGGCAGCT CCCTGCTTTG TCCTGCATGA ACAGAGTTGA TGAAAGTGGG 1620

GTGTGGGCAA CAAGTGGCTT TCCTTGCCTA CTTTAGTCAC CCAGCAGAGC CACTGGAGCT 1680

GGCTAGTCCA GCCCAGCCAT GGTGCATGAC TCTTCCATAA GGGATCCTCA CCCTTCCACT 1740

TTCATGCAAG AAGGCCCAGT TGCCACAGAT TATACAACCA TTACCCAAAC CACTCTGACA 1800

GTCTCCTCCA GTTCCAGCAA TGCCTAGAGA CATGCTCCCT GCCCTCTCCA CAGTGCTGCT 1860

CCCCACACCT AGCCTTTTGTT CTGGAAACCC CAGAGAGGGC TGGGCTTGAC CCATCTCAGG 1920

GAATGTAGCC CCTGGGCCCT GGCTTAAGCC GACACTCCTG ACCTCTCTGT TCACCCTGAG 1980

GGCTGTCTTG AAGCCCGCTA CCCACTCTGA GGCTCCTAGG AGGTACCATG CTTCCCACTC 2040

TGGGGCCTGC CCCTGCCTAG CAGTCTCCCA GCTCCCAACA GCCTGGGGAA GCTCTGCACA 2100

GAGTGACCTG AGACCAGGTA CAGGAAACCT GTAGCTCAAT CAGTGTCTCT WTAACTGCAT 2160

AAGCAATAAG ATCTTAATAA AGTCTTCTAG GCTGTAGGGT GGTTCCTACA ACCACAGCCA 2220

AAAAAAAAAA AAAAAAACTC GAG 2243

(2) INFORMATION FOR SEQ ID NO: 145:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1082 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145:

GCCAAGCTCT AATACGACTC ACTATAGGGA AAGCTGGTAC GCCTGCAGKT ACCGGTTCCG 60

GGAATTCCCG GGTCGACCCA CGCGTCCGCT TCCGTGTGTC AAAATCCTCA CCTCCTTCAT 120

AACCATCTCC CACAATTAAT TCTTGACTAT ATAAATTTAT GGTTTGATAA TATTATCAAT 180

TTGTAATCAA TTGAGATTTC TTTAGTGCTT GCTTTTCTGT GACTCAACTG CCCAGACACC 240

TCATTGTACT TGAAAACTGG AACANCTTGG GAATGCCATG GGGTTTGATA ATCTGCCAGG 300

GACATGAAGA GGCTCAGCTT CCTGGGACCA TGACTTTGGC TCAGCTGATC CTGNACATGG 360

GAGAACAACC ACATTTTTCT TTGTGTGTGC TTCTAGCAGC TGTTCGGGAG GACCKTGACC 420

CAAYAGTGTT CCCATGCTGT TTCTTGTGAA ATGCTCTCGG CTATGTAGCA GCTTTTGATT 480

CCCTGCATAC CCTAGGCTGC TGCCCCTATC CTGTCCCTTG TTTATAACAT TGAGAGGTTT 540

TCTAGGGCAC ATACTGAGTG AGAGCAGTGT TGAGAAGTCG GGGAAAATGG TGACTACTTT 600

TAGAGCAAGG CTGGGCATCA GCACCTGTCC AGCTCTACTT GTGTGATGTT TCAGGAACTC 660

AGCCCCTTTT TCTGCCTAGG ATAAGGAGCT GAAAGATTAA CTTGGATCTY CTAATGGTCC 720

```
AAATCTTTTG GTCACAATAA AGAGTCTCCA AATTAGAGAC TGCATGTTAG TTCTGGATGG     780

ATTTGGTGGC CTGACATGAT ACCCTGCCAG CTGTGAGGGG ACCCCGTTTT TAAGATGCAT     840

GGCCAAGCTC TCTGCAAATG GAAATGCTTA CACTGGGTGT TGGGGATGTT TGCTACCTCC     900

TGCTATTTTT GTGGTTTTGG TTCTCCCACT ATGGTAGGAC CCCTGGCCAG CATTGTGGCT     960

TGTCATGTCA GCCCCATTGA CTACCTTTTC ATGCTCTGAG GTACTACTGC CTCTGCAGCA    1020

CAAATTTCTA TTTCTGTCAA TAAAAGGAGA TGAAAATAAA AAANAAAAAA AAAAAACTCG    1080

NG                                                                   1082
```

(2) INFORMATION FOR SEQ ID NO: 146:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4313 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146:

```
CAAGCTGGTT TGAAACTAGG GGTCGGGCTC GGCCGTCGTC GTTGTTTGTC GCCGCATCCC      60

CGCTTCCGGG TTAGGCCGTT CCTGCCCGCC CCCTCCTCTC CTCCCTTCGG ACCCATAGAT     120

CTCAGGCTCG GCTCCCCGCC CGCCGCAGCC CACTGTTGAC CCGGCCCGTA CTGCGGCCCC     180

GTGGCCACCA TGTCCCTGCA CGGCAAACGG AAGGAGATCT ACAAGTATGA AGCGCCCTGG     240

ACAGTCTACG CGATGAACTG GAGTGTGCGG CCCGATAAGC GCTTTCGCTT GGCGCTGGGC     300

AGCTTCGTGG AGGAGTACAA CAACAAGGTT CAGCTTGTTG GTTTAGATGA GGAGAGTTCA     360

GAGTTTATTT GCAGAAACAC CTTTGACCAC CCATACCCCA CCACAAAGCT CATGTGGATC     420

CCTGACACAA AAGGCGTCTA TCCAGACCTA CTGGCAACAA GCGGTGACTA TCTCCGTGTG     480

TGGAGGCTTG GTGAAACAGA GACCAGGCTG GAGTGTTTGC TAAACAATAA TAAGAACTCT     540

GATTTCTGTG CTCCCCTGAC CTCCTTTGAC TGGAATGAGG TGGATCCTTA TCTTTTAGGT     600

ACCTCAAGCA TTGATACGAC ATGCACCATC TGGGGGCTGG AGACAGGGCA GGTGTTAGGG     660

CGAGTGAATC TCGTGTCTGG CCACGTGAAG ACCCAGCTGA TCGCCCATGA CAAAGAGGTC     720

TATGATATTG CATTTAGCCG GGCCGGGGGT GGCAGGGACA TGTTTGCCTC TGTGGGTGCT     780

[illegible]
```

CTGTSGCCAG GTTAAACAAC CATCGAGCAT GTGTCAATGG CATTGCTTGG GCCCCACATT 1020

CATCCTGCCA CATCTGCACT GCAGCGGATG ACCACCAGGC TCTCATCTGG GACATCCAGC 1080

AAATGCCCCG AGCCATTGAG GACCCTATCC TGGCCTACAC AGCTGNAAGG WGAGATCAAC 1140

AATGTGCAGT GGGCATCAAC TCAGCCCGAA YTGTCGCCAT CTGCTACAAC AACTGCCTGG 1200

AGATACTCAG AGTGTAGTGT TGGTGGCGCT GTGCCCACGA GGCAGGGGCT TTTGTATTTC 1260

CTGCCTCTGC CCCACCCCCA AAGTAAGAAG AAACATGTTT CCAGTGGCCA GTATGTCTTT 1320

CATTGCTTTG CACCCACTGT TACCAGAAGC TGCTCTAGGA GTTCCTGGCC AGTCACCCCA 1380

TCGCCCTCTG TGGCAGACTC AGTGCTGTGT GGCGCCTCCT CAGCCCAGGG CTGAGTTTTA 1440

AGATTTTCTC TCCTTTCCTC TTCTCCTTTG GTTCCTCAAT TAAAAAATGT GTGTATATTT 1500

GTTTGTCAGG CGTTGTGTTG AGGAGCAGTT CACGCACTGG CTGTGTCTAT TCCTCTGCCC 1560

AGGTGTCTCT GTTTGCTGCC CAAKGYWKKT TTTCATGTCT CGTCCATGTC CATGTTCGTG 1620

TTAGCACTWA CGTGGGAACA AATACCAATT TGTCTTTTCT CCTAGTATCA GTGTGTTTAA 1680

CAAATTTTAA CTTTGTATAT TTGTTATCTA TCAGGCTAAT TTTTTTATGA AAAGAATTTT 1740

ACTCTCCTGC TTCATTTCTT TGTCTTATAG TCCTCCCTCT TTGCACCTTC TTCTCTTCCC 1800

TCAGTGCCTG GAGCTGGTAC TGGGCCCCTG GCCCCATGAG CAGTTTGCCT TCTTGAGTCA 1860

CTGCCTGTGT AGTACATACC TGACCGGGAG TCCAAACCAC CTTGGTGCTC TGAAGTCCAC 1920

TGACTCATCA CACCTTTCTT AGCCTGGCTC CTCTCAAGGG CATTCTGGGC TTGTAAACAG 1980

ACATAGGAAG CCTCTGTTTA CCCTGAAGCA CCACTGTCCA GCCCATTGGT TCCCACTGGC 2040

AGCATGGTAG AGCTGAGAGA AACAGGCTCT CAGGGTACCT GACTTGAGGG GAATCGTTTC 2100

ATGAAGCTGA ACTTCAAGCA TATTTCCAGT ACATTCTTTC AGAGTCTGTT TTTCCATCCA 2160

AATATAAGCC CCAGGCCATT CCACTTAGTG TCTTTTCAAT GATAGGCAAG AATGATATCT 2220

GAGTTGAACT TCGGTGCTTC TGTTGTTTGA GTTTACTGTG CCTGGTGGTA TATTGGGCAT 2280

TCTTTGGATT GAGTGTTCTG AGGTGAGAGA GTCTTCCCGA GGCATCCTGT CTGTGCTTCC 2340

AACCCTGAAC AAGACCTTAC ATGAGAGATG GACTGATGGA CTGCGGCAAT CCTGGGCTGT 2400

CAAGTGGATA GATAGTTAAA AAGCATTATA CTGTGGGTAA TGAAAAGGGA GGAAAAAAAA 2460

AGAAGGAAAA GGAATTATAG ACCCCCAGGG TCAGCCAGTT AAGAGCTCTA CCCACACCTG 2520

TCAACCCCTC TCTCCCCCAG TTTAGGTTCT GAGCAGTATT GGACTTGTAG CCTGCAGTTG 2580

TCTTTTGACT TGCAGGCCGC AGTGTCTTTC TGTTATGTGA ATGAGTTCCA TGGAGGGGCA 2640

TATGTGTGAT TCCACCGTTA GATGAGCCCT TGGGGCAGGC AGTTTGGGAT GTGCTCTTGG 2700

GGGAAAGTTG GCTGTTTCCT TGCGCTCTGC TCCTACCCGA AGTTTTTAAG TCCCTCTGAA 2760

```
TTGCTCATCT GAGATTAGTA GAGTAGCAGG CCTGAAGGAT GATGGTTTTG TCCTCTTTGG   2820
TTCTCACCTG CTTGAGAAGT AAAACAGTAA CTTTGTTCTT CTGGGCCCTT AAGCTTTTTT   2880
GGTTAAGTCT TCCTTTTCAG AAGTAGATGT CATTATATGC CAAAAGTCTA GCTCTTTGCT   2940
TTACCATACA GGGACCTGTC CCAAAGAAAA AGGCTCTTTT TTTAGCCAGC ATATTTCCCC   3000
TTCTACCCTT TTACTTTGTT GTTCTGATTT TAGGACTCTG GCTGGCCATG TGCTTGTGGT   3060
TGCCTCTCCT GCATTTGCCA CTGGATTTGC ACTGCATCGT TTGGAGATAC AAAGCGAGCA   3120
GTTCTTGGTC AGAACCCTCC TCTGCTTTTC ATTGTGTTTG ATAATCGTTA CTGGGTCCTT   3180
CTCTCAAGGG TAGCAAGGCC AAGCTGATGG CTGCTTGTTT AGGAGGCCAT CAGTTCCTTC   3240
CTGTGGAGAA GGGTCTGAAA TGGAAGTCAG TGGTAGAAGG GGCTGGTCTG CTGGGCAGGG   3300
CTTACATCCA CTGAGTTCTA AGATTCCTTT CCTGATCTGC ACCTACGGCT GGTCTGTATG   3360
GTGGAATTTG TCAGCTGGAA CTCAGAAACA ACAACTTGAA AAAAAAATAA TAATTAGAAC   3420
ATATTTGCAT AAGATAGCTA TTTACTCTGG AAACCAACAA CTTTTGAGAT TTCCCTTGCC   3480
CTGTGGACGC CCAGCTCCTG TCATCCTTCC TTAGGTCCTG CACTACAGTC TTCCCCTGAA   3540
TGCCACCGGG GACCCAGGGG GACTCCACCC CCCTAAGCAA GCACACACAT ACTCACAGTT   3600
GATGAGTTGC TGGTCTTTGA GTCCCAGCTC TCTTACCCTC CCTTTACTCC ACCAGCCCGA   3660
CGACCCATGA CTGAGGAGGG GATTTCTACA GTCTCAGGAT TTAGAAAGTC TGTAAGCCAT   3720
CCATGCTCCA GAAAGCACCG ATCTGTTGTA CTTGCAAAAA CAACTCTGTA ATTTGTTGAG   3780
GTTCTCAAAC TGACAGCCAG CGAGACTGGG TGGGAGGCCC TGGATCTGTT CTCCCTGACT   3840
GCGGGAGGAG CAGCCACTAG GACTTTAGCA GGAAGCCCAC ATGGAGGCTC CGCCAGGCTG   3900
TGGCCCAGCT GGTGATGGCC CTTTTGCTCC TGGCAGCCTG AGCCACAGCT GCCTGTATTG   3960
TCCTCATCTG TTCTGACTGA AGGATGGAGG TGCTGAATAA ATTAGGCCTC AGGCTTCTAC   4020
CACCAGAGAG CTGGAGAATG GGTCCACGTC ATTCAAGGAC CTGAATTTTT TATGCTCAGG   4080
AGCATTGGAA TCCTCTTCTT CCAGGGAGGA ATTAGCCTGC AAGGTTAGGA CTTCAAGAGG   4140
GAAGGTATTT AATAACTGGG CGAGGATGGG TGTGGTGGCT CACACCTGTA ATCCCAGCAT   4200
TTTGGGAGGC TGAGGTGGCC AGATCCCAAG GTCAGAAGAT CGAGACCATC CTGGCTAACA   4260
TGGTGAAACC CCATCTCTAC TAAAAATACA AAATTAAATT GGCCGGGCGT GAA          4313
```

SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1183 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147:

```
GGCAGAGCCT CAAGCTGACT TGGATTATGT GGTCCCTCAA ATCTACCGAC ACATGCAGGA      60
GGAGTTCCGG GGCCGGTTAG AGAGGACCAA ATCTCAGGGT CCCCTGACTG TGGCTGCTTA     120
TCAKWYGGGG AGTGTCTACT CAGCTGCTAT GGTCACAGCC CTCACCCTGT TGGCCTTCCC     180
ACTTCTGCTG TTGCATGCGG AGGGCATCAG CCTTGTGTTC CTGCTTCTGT TTCTGCAGAG     240
CTTCCTTCTC CTACATCTGC TTGCTGCTGG GATACCCGTC ACCACCCCTG GTCCTTTTAC     300
TGTGCCATGG CAGGCAGTCT CGGCTTGGGC CCTCATGGCC ACACAGACCT TCTACTCCAC     360
AGGCCACCAG CCTGTCTTTC CAGCCATCCA TTGGCATGCA GCCTTCGTGG GATTCCCAGA     420
GGGTCATGGC TCCTGTACTT GGCTGCCTGC TTTGCTAGTG GGAGCCAACA CCTTTGCCTC     480
CCACCTCCTC TTTGCAGTAG GTTGCCCACT GCTCCTGCTC TGGCCTTTCC TGTGTGAGAG     540
TCAAGGGCTG CGGAAGAGAC AGCAGCCCCC AGGGAATGAA GCTGATGCCA GAGTCAGACC     600
CGAGGAGGAA GAGGAGCCAC TGATGGAGAT GCGGCTCCGG GATGCGCCTC AGCACTTCTA     660
TGCAGCACTG CTGCAGCTGG GCCTCAAGTA CCTCTTTATC CTTGGTATTC AGATTCTGGC     720
CTGTGCCTTG GCAGCCTCCA TCCTTCGCAG GCATCTCATG GTCTGGAAAG TGTTTGCCCC     780
TAAGTTCATA TTTGAGGCTG TGGGCTTCAT TGTGAGCAGC GTGGACTTCC TCCTGGGCAT     840
AGCTTTGCTG ATGAGAGTGG ATGGTGCTGT GAGCTCCTGG TTCAGGCAGC TATTTCTGGC     900
CCAGCAGAGG TAGCCTAGTC TGTGATTACT GGCACTTGGC TACAGAGAGT GCTGGAGAAC     960
AGTGTAGCCT GGCCTGTACA GGTACTGGAT GATCTGCAAG ACAGGCTCAG CCATACTCTT    1020
ACTATCATGC AGCCAGGGGC CGCTGACATC TANGACTTCA TTATTCWATR ATTCAGGACC    1080
ACAGTGGAGT ATGATCCCTA ACTCCTGATT TGGATGCATC TGAGGGACAA GGGGKCGGT     1140
STCCGAACTG GAATAAAATA GGCGGGCGTG GTGACTTGCA CCT                      1183
```

(2) INFORMATION FOR SEQ ID NO: 148:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 734 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148:

```
GAATTCGGCA GAGTGAAGCA TTAGAATGAT TCCAACACTG CTCTTCTGCA CCATGAGACC      60
```

```
AACCCAGGGC AAGATCCCAT CCCATCACAT CAGCCTACCT CCCTCCTGGC TGCTGGCCAK     120
GATGTCGGCA GCATTACCTT CCACTGCCTT TCTCCCTGGG AAGCAGCACA GCTGACACTG     180
GGCACCAGGC CACCTCTGTT GGGACCCACA GGAAAGAGTG TGGCAGCAAC TGCMTGGCTG     240
ACCTTTCTAT CTTCTCTAGG CTCAGGTACT GCTCCTCCAT GCCCATGGYT GGGCCCGTGGG    300
GAGAAGAAGC TCTCATACGC CTTCCCACTC CCTCTGGTTT ATAGGACTTC ACTCCCTAGC     360
CAACAGGAGA GGAGGCCTCC TGGGGTTTCC CCRRGGCAGT AGGTCAAACG ACCTCATCAC     420
AGTCTTCCTT CCTCTTCAAG CGTTTCATGT TGAACACAGC TCTCTCCRCT CCCTTCTGAT     480
TTCTGAGGGT CACCACTGCC ARCCTCAGGC AACATAGAGA GCCTCCTGTT CTTTCTATGC     540
TTGGTCTGAC TGAGCCTAAA GTTGAGAAAA TGGGTGCCAA GGCCAGTGCC AGTGTCTTGG     600
GGCCCCTTTG GCTCTCCCTC ACTCTCTGAG GCTCCAGCTG GTCCTGGGAC ATGCAGCCAG     660
GACTGTGAGT CTGGGCASGT CCAAGGCCTG CACCTTCAAG AAGTGGAATA AATGTGGCCT     720
TTGCTTCTAT TTAA                                                       734
```

(2) INFORMATION FOR SEQ ID NO: 149:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1405 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:

```
GGCACAGTGG ACTCCAGATT CCCTCTCCGC CTTTCTCTGC CTGGGGAGAC CCACTGTGTG      60
CATGGCATCA CTGACTCCCA TACCTCTGGC TATCAAAGGT TTCTGCCATG GCCACCCTGG     120
AAGGAAACCA GAGGGAGGTA GATAGGGAGA TCAGGTCCCT TCTACTCTGG TTCCTGCTCT     180
GTGAAATTGT CTCAGGCTGG CTCTGTCCAG ARGGTCCCTG GTTCTCTCAR GGATGCCAAA     240
TCTACAAGAA TCTCTCCTCT TCCAGTTCCT ATAACCTCTC CTTCCTTTTG TCTCTTTAGA     300
CCTTGGAGTA GTAGCAGCCA GGTTCTTTCT ATCTCTGGGT TAGTGCATTA TCTCTGGTGG     360
CTCCCTTACC CAGGACTTTG GGAATGGTCT TTTTGTAATA CATTCTCCTC AAATAATTCA     420
ATTTTGAGTG TTCTGTATGT ATCCTGCTGG GAGGTTGTTA TATACAAATC ACTGTGCCCG     480
[illegible]
AATCAATAAA TGTTGGCTGA TGACAAACAT GTTTTTTTTG TTGATTAGTT ATATTGATTA     720
```

TGTTCTAAAT AACTCCMACA AGGAARTCAG CACATTTGGA ATATCAWTAT CTTTCCATGA 780

TAATATCTTT CCMYGGAAAG AWAACGATAT TCCMAACTGG GAGTGTCCCW ACCARATCTG 840

ANTCTGTGTA TTGGCCCTGG GGTGGGCCAG CCCCTTAGAC TCTATGGTCT CATTCTCTTT 900

GTTTACAAAA TTGAGATAAG GCCTTATTCT CTCCCCACCC CACCCATCCA TATTGTTTTG 960

AGAATAAAAT GAGAGGATGT GTGTCAAGGG TGTATTTTGG CAATAGTCTC TGAGCCATTT 1020

TCTGAGCACC TCCATACTGT TGACACTCAA GTAATATTTC ATCAGCATTC CATTCAGGNT 1080

CCTCCCTTAA TGAGGTGTGC GATGTACAAG AGTYGTGACG TGGCAAAGGA TGGGCTCCTG 1140

AGGAAACACT TAGGAAACTG GGCTTTCTGC CATTAAAAGA GACAAACCTT TGTGGTGACC 1200

TAATTAAAGT TTTTAAAATT CAATTTGGAA AGTTAGCAAG CTAGCTCCTK TCCAGGWAAA 1260

ATAAGGAGTC AGTGCATGAC CTAACCGGTC CCGGGCTGCT TGCCATTCCA AACAACTGCA 1320

GTAAGTTTAT CACNTTCTTT CAGGCACTCA GGTTTCCAGG CACAGACTTG GATAAGGAAG 1380

GATGTCCTAT GGGGTCACAT TGATC 1405

(2) INFORMATION FOR SEQ ID NO: 150:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2890 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150:

TTATATGCTA CAGCTACAGT AATTTCTTCT CCAAGCACAG AGGANCTTTC CCAGGATCAG 60

GGGGATCGCG CGTCACTTGA TGCTGCTGAC AGTGGTCGTG GGAGCTGGAC GTCATGCTCA 120

AGTGGCTCCC ATGATAATAT ACAGACGATC CAGCACCAGA GAAGCTGGGA GACTCTTCCA 180

TTCGGGCATA CTCACTTTGA TTATTCAGGG GATCCTGCAG GTTTATGGGC ATCAAGCAGC 240

CATATGGACC AAATTATGTT TTCTGATCAT AGCACAAAGT ATAACAGGCA AAATCAAAGT 300

AGAGAGAGCC TTGAACAAGC CCAGTCCCGA GCAAGCTGGG CGTCTTCCAC AGGTTACTGG 360

GGAGAAGACT CAGAAGGTGA CACAGGCATA ATAAAGCGGA GGGGTGGAAA GGATGTTTCC 420

ATTGAAGCCG AAAGCAGTAG CCTAACGTCT GTGACTACGG AAGAAACCAA GCCTGTCCCC 480

ATGCCTGCCC ACATAGCTGT GGCATCAAGT ACTACAAAGG GGCTCATTGC ACGAAAGGAG 540

GGCAGGTATC GAGAGCCCCC GCCCACCCCT CCCGGCTACA TTGGAATTCC CATTACTGAC 600

TTTCCAGAAG GGCACTCCCA TCCAGCCAGG AAACCGCCGG ACTACAACGT GGCCCTTCAG 660

AGATTGCGGA TGGTCGCACG ATCCTCCGAC ACAGCTGGGC CTTCATCCGT ACAGCAGCCA 720

CATGGGCATC CCACCAGCAG CAGGCCTGTG AACAAACCTC AGTGGCATAA AYCGAACGAG 780

TCTGACCCGC GCCTCGCCCC YTATCAGTCC CAAGGGTTTT CCACCGAGGA GGATGAAGAT 840

GAACAAGTTT CTGCTGTTTG AGGCACAGAC TTTTCTGGAA GCAGAGCGAG CCACCTGAAA 900

GGAGAGCACA AGAAGACGTC CTGAGCATTG GAGCCTTGGA ACTCACATTC TGAGGACGGT 960

GGACCAGTTT GCCTCCTTCC CTGCCTTAAA AGCAGCATGG GGSTTCTTCT CCCCTTCTTC 1020

CTTTCCCCTT TGCATGTGAA ATACTGTGAA GAAATTGCCC TGGCACTTTT CAGACTTTGT 1080

TGCTTGAAAT GCACAGTGCA GCAATCTTCG AGCTCCCACT GTTGCTGCCT GCCACATCAC 1140

ACAGTATCAT TCCAAATTCC AAGATCATCA CAACAAGATG ATTCACTCTG GCTGCACTTC 1200

TCAATGCCTG GAAGGATTTT TTTTAATCTT CCTTTTAGAT TTCAATCCAG TCCTAGCACT 1260

TGATCTCATT GGGATAATGA GAAAAGCTAG CCATTGAACT ACTTGGGGCC TTTAACCCAC 1320

CAAGGAAGAC AAAGAAAAAC AATGAAATCC TTTGAGTACA GTGCTTGTCC ACTTGTTTAC 1380

AATGTCCTCC TTTTAAAAAA AAAAAAATGA GTTTAAAGAT TTTGTTCAGA GAGTAAATAT 1440

ATATCCATTT AATGATTACA GTATTATTTT AAACCTTAAG TAGGGTTGCC AGCCTGGTTT 1500

CTGAAAAACC AAATATGCCG GACAGGGTGT GGCCACACCA AGAAGACGGG AAGACCTGGC 1560

TTGTGACCCT GGCTTCCCAT GTCCTTCTGG TCTCACCGGC GAAGTGCCCT ATCCTGGAAG 1620

TATGAAATGT TAGCCAATTA ATACCAAGAC ACCTCATCTG CTCCTTCCCC AGTGGATGGG 1680

GTTCTTCTGT AAAACTGTTT GCACATGGCC AGGGGAGGGA ACTAGGACCC TTGTGTCCTG 1740

TCTGAGCCTT ATGGAGGCAG GACGGTGTCA TTGGCGGATG TGTCCTGCTC CATTGAGATG 1800

GATGGCAAAC CCCATTTTTA AGTTATATTT CTTTGGATTTT TGTTAATTTA GAGGTGTAGG 1860

TTTTGTTTTT TGTTTTTTTG TTTTTTTTTA AGAGAAACAT TTATAACTGG ATAGCATTGC 1920

AGTGAAAGCA GCTTGGGATG TTGGAGCTAA TGCCAGCTGT TTATACTGCT CTTTCAAGAC 1980

AGCCTCCCTT TATTGAATTG GCATTAGGGA ATAAACAAGC CTTTAAACGT GATAAAAGAT 2040

CAAAAACCTG GTTAGACATG CCAGCCTTTG CAAGGCAGGT TAGTCACCAA AGACTAACCT 2100

CCAAGTGGCT TTATGGACGC TGCATATAGA GAAGGCCTAA GTGTAGCAAC CATCTGCTCA 2160

CAGCTGCTAT TAACCCTATA ATGACTGAAA TGACCCCTCC ACTCTATTTT TGTGTTGTTT 2220

TGCACAGACT CCGGAAAAGT GAAGGCTGCC AATCTGAGTA GTACTCAAAT GTGAGGAACT 2280

TAGTGCTTTA TTTAATAATT CTCTTTTTTA TTATAAATT TGTCTACTTG CTTATTACAT 2460

TGTCAATTAT GCATTTGTAA TTTTACATGT AATATGCATT ATTTGCCAGT TTTATTATAT 2520

AGGCTATGGA CCTCATGTGC ATATAGAAAG ACAGAAATCT AGCTCTACCA CAAGTTGCAC 2580

AAATGTTATC TAAGCATTAA GTAATTGTAG AACATAGGAC TGCTAATCTC AGTTCGCTCT 2640

GTGATGTCAA GTGCAGAATG TACAATTAAC TGGTGATTTC CTCATACTTT TGATACTACT 2700

TGTACCTGTA TGTCTTTTAG AAAGACATTG GTGGAGTCTG TATCCCTTTT GTATTTTTAA 2760

TACAATAATT GTACATATTG GTTATATTTT TGTTGAAGAT GGTAGAAATG TACTATGTTT 2820

ATGCTTCTAC ATCCAGTTTG TACAAGCTGG AAAATAAATA AATATAACAT AAAAAAAAAA 2880

AAAAAAAAAA 2890

(2) INFORMATION FOR SEQ ID NO: 151:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2399 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 151:

GAACTTTTCC ATCTGGCAAA CCGGAAACTC CATCCCCATT AAACCAACTC CCCCTTTTGG 60

TTTCCCCCCC AGNGGAATAG AATTTGGACN CCCATATAAA TCCAGGAAAC CACCTAAATT 120

CTTTAGTNGT TTGTGTTTGC AAGATCTAAG GTCATGGTAA ACATTAAGTT CTTAAAATTT 180

TTGGGAGGGA CCAGTGCACC TCTCCCTCTG AATTGTTCNC CAATTTAAAA TTGGAGTAAG 240

GTTTTAAAAT GTCTNATTCC ATTGGAAGGG TNTGTTATTT CATTTTGAGC CCAGAGGGGA 300

GAGGCACATT TTAAATATCA GAATTAGATT AGCTTTGAGT TTGTACAATT GGGAACATAA 360

TAGATTTTCA TAAATTATGT GTGCCTTGTT GGAAGTGTCA ACTGTCTTTA TGTCTGCTTG 420

TAAAAGTTTC AAAATATGTT TTCCCTCAAA AAGGCAACGT TACTTCATTT GCTTGAATAT 480

TATGATAGGA ATGCTTACTG ATATTACTTG ATAGTCATAT ATAGCCTAGG AAATTTAACA 540

TATATATAAC TATAGCAGTA TTAATAATGA TAGTTGTACT TCTTTAAAAC ATTAAATTTG 600

AGGAAACTTT AATGCTGTCT CGTGTACATT GCTTTACTAC AGTGAGGGGG AATATCCTTT 660

AGATTGAGCC TCAATTTACT GGTTAGTAGT ATGTGAACTC TGGTATAAAA ACGTAAACTA 720

GACAGTAGAG CCGATGAATT AAAATTGTAA ATTGCTACAT TGGCATTTTC TACCTCCTTT 780

TCTGTCAGAG TATTACTTTT TCCAGCATTT ATTCTTATTT GTGAGTAAAG AGGAAATGGG 840

AACCTGAGGT TAAAATTGAC ATTTTTGTTT CATTGAGAAT TTAAGCAGTA GGTACAGGAG 900

AAGTGACTTG TCACATTAAT TTGGTGCCTA AATCTGTAAC TACAAGTTGT GATCGACATG 960

TACAAAATGT CTAAGAAAGG TCATATGCTG AATATTTTAC TTTTCCTGTA TAGTCTGCAT 1020
GATTTGTTTC ATAAACCCAG CTTATTTCCT CCAAAAAGCA AAATGGTCCT GTAATTTTTA 1080
AAGTAAAATA AACGTGCCAT TTTGTCTGCA ATCTATAATT TCAGGAAGTT ATTGRAAGTT 1140
CTGACTCAGG GCTTTTTAAC AGTTCAAGCA ATTGTCAGTT ATATTTTGGA AACTCCATCT 1200
GTGTAATTCT CCAGTGCCTT GAAAGAATTA TTAACTTGGC AACACTATTA AAACTTTATA 1260
AAAGATGGTC TTTAGTGCAC GTGTATCATT ATATACACGT TTTAAAGTCA TATTGCTTAG 1320
CTTGTTAATA ATGATTCTGC ATGTGTGCTG GGTTTGGGTA ATTCTTTAAA GGAAGTTTTC 1380
TAGATTTGCA CTTGATGTTT GTTTTTTAAA AACTGATTAT TTATGGCCGT GACACTGTTA 1440
CCAGAAAAGT AATTCTAATT AAGTTATTAT GCAAAGTCAT CTATAAGTAG CATCTGGGAA 1500
GAGGAGATGG AGGCCACAGT TTGCTATTTT AGTATGAAAG GAGGATCTGT TTGGGAAACA 1560
TAGATTGTCT TCCCCTCAAA TGAGGGGAAA AAAAAAGACC CTTTGTTCAA ATGGATTCTG 1620
TTGTAAAAAA TTATTTTTAA AGGAAATCAC AAATTGTATG TCATTCTTAA TGCTAGTCTT 1680
ATAGAATAAA TCCATAAAAT TGTTTTTATG TTCAGTATGT TTATGTCATT CTAAATGCAG 1740
CAAATTCAAT GATAGCAGTT CAATTGACTC ATAGCAGTGT TTTGTATTTT TTCTAATTCT 1800
TTAGCTTTCA ATATTGGATT AAAGTCTTGT TTGTGAATAT AGTTTCCGTA TGGCAAATGA 1860
TTTCTTGCTT ATTAGCTTTT GTTAAAGAAT GCTTAGTAAG AGCTAAGCTT TTAAAAGTAA 1920
TGCAAACATT TATCGTTAAT AAAACCTATG GTGTAATATC ATATAATGCT TTTCTTTGAT 1980
CTTTGGAGAA TTATTCTTTT ATAGTAGTAT ACATGAATTT TGATTTTTAA AGCATTTAAA 2040
AACAAATCTC AATACATTAA AAAACCTGTT ATTGTTAAAA RGGAAATTAC CATGCCTTTA 2100
AGAAACAAGG ATGTACATCT TCAATTCAGC ATRAGTGTCC ACATCTAGAA GGCTCTCATT 2160
GCAGTTGTTT ACAGTTAAGG TACCTCTATC TAAAGGGCCA AAGAAGCATT TCATAYTTTA 2220
ACACCTCACA TTCTTTCAGG ATTAAGACAT ATGAAAATAG TCTGAATAGG ATAAATTTGG 2280
ATACGAAGTA ACTTAACCAG TCTGGGAAGA TTCAGGCTTT TTCTATKAAA AAGCTTATTC 2340
CTCTTCACAA CTCNGGTGGT AGGNTTTCAT TTTTCAAGAG GGTAGATATT TTAAAGCCA 2399

(2) INFORMATION FOR SEQ ID NO: 152:

[illegible]
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152:

CGTGCCTGTA GTAAGCTCAT CCCTGCCTTT GAGATGGTGA TGCGTGCCAA GGACAATGTT 60
TACCACCTGG ACTGCTTTGC ATGTCAGCTT TGTAATCAGA GATTNTGTGT TGGAGACAAA 120
TTTTTCCTAA AGAATAACWT GAYCCTTTGC CARACGGACT ACGAGGAAGG TTTAATGAAA 180
GAAGGTTATG CACCCCMGGT TCGCTGATCT ATCAACATCA CCCCATTAAG AATACAAAGC 240
ACTACATTCT TTTATCTTTT TTGCTCCACA TGTACATAAG AATTGACACA GGAACCTACT 300
GAATAGCGTA GATATAGGAA GGCAGGATGG TTATATGGAA TAAAAGGCGG ACTGCATCTG 360
TATGTAGTGA AATTGCCCCA GTTCAGAGTT GAATGTTTAT TATTAAAGAA AAAAGTAATG 420
TACATATGGC TGGATTTTTT TGCTTGCTAT TCGTTTTTGT GTCACTTGGC ATGAGATGTT 480
TATTTTGGAC TATTGTATAT AATGTATTGT AATATTTGAA GCACAAATGT AATACAGTTT 540
TATTCTGTTA CCATTTGTGT TCCATTTGCT YCTTTGTATT GTTGCATTTA GTACAATCAG 600
TGTTTAAACT TACTGTATAT TTATGCTTTC TGTATTTACC AGCTATTTTA AATGAGCTGT 660
AACTTTCTAG TAAAGAATTG AAAAGCAAAT CCTCACTAAA GGATACACAG GATAGGATAA 720
AGCCAAGTCN CATCAACATT AAAAAATACT AAAANANAAA ACACAAAAAA AAAAAANCCC 780
GGGGCGGGCC CGGAACCCAT TC 802

(2) INFORMATION FOR SEQ ID NO: 153:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 461 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153:

CTAGGAGCAC CGAGCAGCTT GGCTAAAAGT AAGGGTGTCG TGCTGATGGC CCTGTGCGCA 60
CTGACCCGCG CTCTGCNCTC TCTGAACCTG GCGCCCCCGA CCGTCGCCGC CCCTGCCCCG 120
AGTCTGTTCC CCGCCGCCCA GATGATGAAC AATGGCCTCC TCCAACAGCC CTCTGCCTTG 180
ATGTTGCTCC CCTGCCGCCC AGTTCTTACT TCTGTGGCCC TTAATGCCAA CTTTGTGTCC 240
TGGAAGAGTC GTACCAAGTA CACCATTACA CCAGTGAAGA TGAGGAAGTC TGGGGGCCGA 300
GACCACACAG GTGGGAACAA GGACAGGGGG ATTTAAGCAG TCAAAAGGAA AAACATGTTA 360
AGACCCTAGA CTTGTATATT GACACACTTG TACCTTGTAA GGCAGAGGAA TGTAATTAAA 420
AAGCACTTAT TTGGCWNAAA AAAAAAAAAA AAAAAAAAAA C 461

(2) INFORMATION FOR SEQ ID NO: 154:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2388 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154:

GCCCACGCGT CCGAAAGCGG AGAACGCTGG TGGGCCTGTT GTGGAGTACG CTTTGGACTG 60

AGAAGCATCG AGGCTATAGG ACGCAGCTGT TGCCATGACG GCCCAGGGGG GCTGGTGGCT 120

AATCGAGGCC GGCGCTTCAA GTGGGCCATT GAGCTAAGCG GGCCTGGAGG AGGCAGCAGG 180

GGTCGAAGTG ACCGGGGCAG TGGCCAGGGA GACTCGCTCT ACCCAGTCGG TTACTTGGAC 240

AAGCAAGTGC CTGATATCAG CGTGCAAGAG ACAGACCGGA TCCTGGTGGA GAAGCGCTGC 300

TGGGACATCG CCTTGGGTCC CCTCAAACAG ATTCCCATGA ATCTCTTCAT CATGTACATG 360

GCAGGCAATA CTATCTCCAT CTTCCCTACT ATGATGGTGT GTATGATGGC CTGGCGACCC 420

ATTCAGGCAC TTATGGCCAT TTCAGCCACT TTCAAGATGT TAGAAAGTTC AAGCCAGAAG 480

TTTCTTCAGG GTTTGGTCTA TCTCATTGGG AACCTGATGG GTTTGGCATT GGCTGTTTAC 540

AAGTGCCAGT CCATGGGACT GTTACCTACA CATGCATCGG ATTGGTTAGC CTTCATTGAG 600

CCCCCTGAGA GAATGGAGTT CAGTGGTGGA GGACTGCTTT TGTGAACATG AGAAAGCAGC 660

GCCTGGTCCC TATGTATTTG GGTCTTATTT ACATCCTTCT TTAAGCCCAG TGGCTCCTCA 720

GCATACTCTT AAACTAATCA CTTATGTTAA AAAGAACCAA AAGACTCTTT TCTCCATGGT 780

GCGGTGACAG GTCCTAGAAG GACAATGTGC ATATTACGAC AAACACAAAG AAACTATACC 840

ATAACTCAAG GCTGAAAATA ATGTAGAAAA CTTTATTTTT GTTTCCAGTA CAGAGCAAAA 900

CAACAACAAA AAAACATAAC TATGTAAACA AGAGAATAAC TGCTGCTAAA TCAAGAACTG 960

TTGCAGCATC TCCTTTCAAT AAATTAAATG GTTGAGAACA ATGCATAAAA AAAGTTGCAC 1020

AAGTTCCTTA TTTTCCTTAA TATTTCACTT CTATTTAATA CAAGCTGGGA CATAAAAATT 1080

CTGTTGGGGA TACCTGGGGG AAGATGTGAG AAACTAATGC TGAATTCAGC TTATACATGA 1140

TGAAAAGAAA AACCAGACAA AAGGAGCACA TAAATATGCA TACAGTGTAA CTGTTATTAT 1200

TTTAATA[illegible] A[illegible]ATAAGGG ATTTTTGTTA GCATGTTTAG GGGGAACGAG GATTGGTGGG 1260

ATA[illegible] AA[illegible] GTCAGCA[illegible]A GCATGTGTAT TTCTAAT[illegible]TA [illegible]GGTAAA 144[illegible]

GTCATAGGTA AGACTCAAAA GCGGGATCTT ATTCAAAAGG CAGGTATTTC CTTTGTTTTC 1500

TGTCTTGAAA TAGCCCCTTC CCCTAAGGTG CATTCTCTCA AGTTTTCAGT ATTGCTTTAT 1560

TTGCAGTGAT TAAAAGAGAT GAGAGACTTT GGAGACAGAC AACGTAAGCA ACACATACAC 1620

ACATGAAATA CTCTAGACAG AGATGAATAT AAATCTGGCC TAATAACCAG TTTTCCATGT 1680

AACAGTGATT TTGTGTTTCG GGCTGAAGCA GTGGTTATAT TAAAAGCCAC TAATTCCCTT 1740

ATCCCTTTAA AAGATTTTTA CAATTCTCCA ACCACAAACA GCACTTCTAA AACTAACTTT 1800

ACTTTCTGCC CATAATTTGT TCTACATGGA AAAAAAAAAT ATTACTTTGG CCAGGGGTGT 1860

GTGTAAATGT GGCAGAATTC CTAGGCAGGC TGACCTTTAC AGTATGGGCC TTTAAGATAC 1920

TGGATCCTGG TTGGGCAACA AGTGTCACGC CTGAAGTTTC TGAAAACAAA TTAGAAGACT 1980

GTTGGCTTGG CTAATCTCGT AGTTCAGGGC CAAGTTTCTG TAGTCAGAAT GAAGAATAAA 2040

ATTGAAAGAA AAAGGGGGAA ATGCTTATAC TTGGCATTAA GTTGAATGCC TCAAGTCTTA 2100

ACTATGGCTT TGTAGATGAG GCAAAAGATT TCTTAGTGGT AAAATTTCTT CAACAGGTCA 2160

ATGCCAATCT GTATGCCATT TTAGTAAAGT AGGTAAGGAG AGTAGCCGCT CAGTAACTTT 2220

GGCACTAAAG AAAGAGTGTG GCTCTAGAAC TTCCAATCCC ATTGCTAGAT GTGCCCTTTA 2280

AAAGATGGTC CAGTGCTTTC AGGGAAGGAT GTTTAGCCAG TTTTCCTAGT ATTTGTTCCT 2340

TAAGATTTTT TGACCTGTGC TTAATAAGAC GGACGCGTGG GTCGACCC 2388

(2) INFORMATION FOR SEQ ID NO: 155:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 642 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155:

AAAACAGACC ATTTAAAAAC TCAGACAAGA TTATATTTAA TATATTAATT ACTAAAAAGG 60

CACAAGATTA CACTGAACAT ATTAGCTACT AAAAAGGCAC TGCTAAGACA TTCAAGCAAA 120

TAGCTATTAC ACACTACTGC AGATTTTACA GGTTTCTAAT TCTAACATAT GTTTGAAAAA 180

TCCGTGAGTA TTCCAAAATA TATTTAATAA TGGAATATCT GCATTAATAT ACCATCCATG 240

TGTTTTTACC ATTTGCCTTA ATATTGAATA TACTGTTTAC CTCACACTAA AAAGAAAACC 300

AGAAGCCTTA TTTGTGATTT TGGGAGTGGA AGCTTCCATT TTTGTGTCAA AAATGAATCC 360

TGATTCTTAT GGAAATCTCT GTTATTAAGA TATTTCAAGA TGAGACAACA CTGAAGATCA 420

AATTGTGTTT AGTATCACTA TCTTCTCTCC TCGTTTCTCT CTTACTCCTC ATCCTCCCAG 480

AATCTACCAG TTTATGGTAG AAAGATGGGA ACCTTATTTG AATGTGTTTT TTTTTTTCCA 540

TGATGTCCAA TTTTGTTGTG GGAAAGGATT TGGATAAAAT TTTTGTTTAA ATTTTGGTAG 600

ATTTTTATCT ATACAAATTT AAATAAAATT ATGTTTTGTA AG 642

(2) INFORMATION FOR SEQ ID NO: 156:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1251 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156:

GCCGCTGCCC CTCCACGGAG TTGCTGATCA TCTGGGCTGT CATCCACAAA CCCGGTTCTT 60

TGTCCCTCCT AATATCAAAC AGTGGATTGC CTTGCTGCAG AGGGGAAACT GCACGTTTAA 120

AGAGAAAATA TCACGGGCCG CTTTCCACAA TGCAGTTGCT GTAGTCATCT ACAATAATAA 180

ATCCAAAGAG GAGCCAGTTA CCATGACTCA TCCAGGCACT GAGCATATTA TTGCTGTCAT 240

GATAACAGAA TTGACGGGTA AGGATATTTT GAGTTATCTG GAGAAAAACA TCTCTGTACA 300

AATGACAATA GCTGTTGGAA CTCGAATGCC ACCGAAGAAC TTCAGCCGTG GCTCTCTAGT 360

CTTCGTGTCA ATATCCTTTA TTGTTTTGAT GATTATTTCT TCACCATGGC TCATATTCTA 420

CTTCATTCAG AAGATCAGGT ACACAAATGC ACGCGACAGG AACCAGCGTC GTCTCGGAGA 480

TGCAGCCAAG AAAGCCATCA GTAAATTGAC AACCAGGACA GTAAAGAAGG GTGACAAGGA 540

AACTGACCCA GACTTTGATC ATTGTGCAGT CTGCATAGAG AGCTATAAGC AGAATGATGT 600

CGTCCGAATT CTCCCCTGCA AGCATGTTTT CCACAAATCC TGCGTGGATC CCTGGCTTAG 660

TGAACATTGT ACCTGTCCTA TGTGCAAACT TAATATATTG AACGCCCTGG GAATTGTGCC 720

GAATTTGCCA TGTACTGATA ACGTAGCATT CGATATGGAA AGGCTCACCA GAACCCAAGC 780

TGTTAACCGA AGATCAGCCC TCGGCGACCT CGCCGGCGAC AACTCCCTTG GCCTTGAGCC 840

ACTTCGAACT TCGGGGATCT CACCTCTTCC TCAGGATGGG GAGCTCACTC CGAGAACAGG 900

AGAAATCAAC ATTGCAGTAA CAAAAGAATG GTTTATTATT GCCAGTTTTG GCCTCCTCAG 960

TGCCCTCACA CTCTGCTACA TGATCATCAG AGCCACAGCT AGCTTGAATG CTAATGAGGT 1020

TTTATTTTTT TATAAAATTG TTAATGAAAA AGTTTTGTAT TAAAAGAAAT AAATAATAAA [illegible]

ATAAAAAAAA AAAAACCCCG GGGGGGGCCC GGTCCCCAAT TGGCCCTATG G 1251

(2) INFORMATION FOR SEQ ID NO: 157:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2127 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157:

CCGGCGGGAG AGGGAAGCTG CAGGGAGAGG CGCGGATCTC AGCGGGGGAG CAGTGCTTCT 60

GCGGCAGGCC CCTGAGGGAG GGAGCTGTCA GCCAGGGAAA ACCGAGAACA CCATCACCAT 120

GACAACCAGT CACCAGCCTC AGGACAGATA CAAAGCTGTC TGGCTTATCT TCTTCATGCT 180

GGGTCTGGGA ACGCTGCTCC CGTGGAATTT TTTCATGACG GCCACTCAGT ATTTCACAAA 240

CCGCCTGGAC ATGTCCCAGA ATGTGTCCTT GGTCACTGCT GAACTGAGCA AGGACGCCCA 300

GGCGTCAGCG CNCCCTGCAG CACCCTTGCC TGAGCGGAAC TCTCTCAGTG CCATCTTCAA 360

CAATGTCATG ACCCTATGTG CCATGCTGCC CCTGCTGTTA TTCACCTACC TCAACTCCTT 420

CCTGCATCAG AGGATCCCCC AGTCCGTACG GATCCTGGGC AGCCTGGTGG CCATCCTGCT 480

GGTGTTTCTG ATCACTGCCA TCCTGGTGAA GGTGCAGCTG GATGCTCTGC CCTTCTTTGT 540

CATCACCATG ATCAAGATCG TGCTCATTAA TTCATTTGGT GCCATCCTGC AGGGCAGCCT 600

GTTTGGTCTG GCTGGCCTTC TGCCTGCCAG CTRACACGGC CCCCATCATG AGTGGCCAGG 660

GCCTAGCAGG CTTCTTTGCC TCCGTGGCCA TGATCTGCGC TATTGCCAGT GGCTCGGAGC 720

TATCAGAAAG TGCCTTCGGC TACTTTATCA CAGCCTGTGC TGTHATCATT TTGACCATCA 780

TCTGTTACCT GGGCCTGCCC CGCCTGGAAT TCTACCGCTA CTACCAGCAG CTCAAGCTTG 840

AAGGACCCGG GGAGCAGGAG ACCAAGTTGG ACCTCATTAG CAAAGGAGAG GAGCCAAGAG 900

CAGGCAAAGA GGAATCTGGA GTTTCAGTCT CCAACTCTCA GCCCACCAAT GAAAGCCACT 960

CTATCAAAGC CATCCTGAAA AATATCTCAG TCCTGGCTTT CTCTGTCTGC TTCATCTTCA 1020

CTATCACCAT TGGGATGTTT CCAGCCGTGA CTGTTGAGGT CAAGTCCAGC ATCGCAGGCA 1080

GCAGCACCTG GGAACGTTAC TTCATTCCTG TGTCCTGTTT CTTGACTTTC AATATCTTTG 1140

ACTGGTTGGG CCGGAGCCTC ACAGCTGTAT TCATGTGGCC TGGGAAGGAC AGCCGCTGGC 1200

TGCCAAGCTG GNTGCTGGCC CGGCTGGTGT TTGTGCCACT GCTGCTGCTG TGCAACATTA 1260

AGCCCCGCCG CTACCTGACT GTGGTCTTCG AGCACGATGC CTGGTTCATC TTCTTCATGG 1320

CTGCCTTTGC CTTCTCCAAC GGCTACCTCG CCAGCCTCTG CATGTGCTTC GGGCCCAAGA 1380

```
AAGTGAAGCC AGCTGAGGCA GAGACCGCAG AGCCATCATG GCCTTCTTCC TGTGTCTGGG   1440
TCTGGCACTG GGGGCTGTTT TCTCCTTCCT GTTCCGGGCA ATTGTGTGAC AAAGGATGGA   1500
CAGAAGGACT GCCTGCCTCC CTCCCTGTCT GCCTCCTGCC CCTTCCTTCT GCCAGGGGTG   1560
ATCCTGAGTG GTCTGGCGGT TTTTTCTTCT AACTGACTTC TGCTTTCCAC GGCGTGTGCT   1620
GGGCCCGGAT CTCCAGGCCC TGGGGAGGGA GCCTCTGGAC GGACAGTGGG GACATTGTGG   1680
GTTTGGGGCT CAGAGTCGAG GGACGCGGTG TAGCCTCGGC ATTTGCTTGA GTTTCTCCAC   1740
TCTTGGCTCT GACTGATCCC TGCTTGTGCA GGCCAGTGGA GGCTCTTGGG CTTGGAGAAC   1800
ACGTGTGTCT CTGTGTATGT GTCTGTGTGT CTGCGTCCGT GTCTGTCAGA CTGTCTGCCT   1860
GTCCTGGGGT GGCTACGAGC TGGGTCTGAC CGTTGTATGG TTTGACCTGA TATACTCCAT   1920
TCTCCCCTGC GCCTCCTCCT CTGTGTTCTC TCCATGTCCC CCTCCCAACT CCCCATGCCC   1980
AGTTCTTACC CATCATGCAC CCTGTACAGT TGCCACGTTA CTGCCTTTTT TAAAAATATA   2040
TTTGACAGAA ACCAGGTGCC TTCAGAGGCT CTCTGATTTA AATAAACCTT TCTTGTTTTT   2100
TTCTCCATGG AAAAAAAAAA AAAAAAA                                       2127
```

(2) INFORMATION FOR SEQ ID NO: 158:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1625 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158:

```
CAAAAGATCT ATAATCAGGA CATTGTTTAT GTAAGTTGGA CAANAAAAAT TCTTCCCCTT     60
TATGTCCACC CTTCCTATGA TTGCAAGACA AAATTTCCCT CCTTTACCTC ATCCCTATAA    120
CATGGGAGGC TGAGAAAAAT GAGGGGAGAT GGAACCAGAT ACAAGGAGAT CCAATAAGAG    180
AAGCTTATTT AAATATTGTG AAATAAAGGA AGAMCCAAAG CATTTTTTTA AGTGGGGAAT    240
CCTTTTGAAC AGTTATTATT TATCCATATT ATTAAYAACA TCTTTTCTGA CAAAATCCAT    300
CAGATGAAGT GTAAATGGAT AATCTTTTAA TGGATCTAAA CCTAGAAAGT TTCACTTACT    360
[illegible] [illegible] [illegible] [illegible] [illegible] AAGTTCTTCT    420
[illegible]
TTATATTGAA [illegible] TTTAATTCTT [illegible] ATATTTTTAA [illegible]    [illegible]
```

```
TTGAAGTCTC AGTCACCAGA CACAGGTTCT ATACAATTAA TGATGAGCTG GAGAAGTAAT     660
ATGTAGCTAA TTTTTCAAAA GCATTGAATA TACTTTCCGG AAAGAAAACA GAAATTAAAT     720
ATTGCCACAT CTTGCCAGAA TCCCATCTGA CACCTTAACT TTGTCAGGTT TCCTACAACT     780
TGCTAATCAA GTTTTATACA TTCTAAATCT CCCCAGTTTC TTTGGGGCTG GAAGATGCAA     840
CTTCCATTTA ATAGAAACTT TGAAATCTTG GGGTAAGGGA GCAGTGGGGG GACTAGGGAG     900
AAGGATAAGA AATAGAATTA TTGAAAAGCC CCCACCAGGG ACCTTCCTGG CCAGAATATG     960
CAGAGTAATT CCTGCTGGCT TCACCTTTGA AAGTCCCTCG AAACTATGCA GATGAAACTG    1020
AGTCTGTTTT TGATATTGTC AGATGTATTC TACCTTGGAA GTCCCNACAC CTAAACTGGA    1080
ATTCTTGTAT TTACATCTCC TCCACTGTCC CCCACACCAC CCCTCAATTC CTGCTGCCCC    1140
TGCTAATGTT AAGCATTTTT CTCTTGTTAT CATCAGGTTC ACATTAAAAM CAGRTACTTA    1200
CAAACTGACT TGAAGCACAG ATACTTTTAC GAATGTGATA AAATATTTTC TTAAGAAAAG    1260
GAAAGAGGAT GTGGGTCAAA TAAAACACCG CATGGATGTT GATTGGTGAA TACTGGTGTA    1320
AGAAAAGGGA GCTCAGGAAT TTTTATTACT GTATTTGTAA ATGAGTTTGA AGGAATTTGT    1380
AAATGCCACT GGTACATTTT TAAGGTGACA CATTTGCTCC TTATAAAGTT ATTAAAAATT    1440
ACAGGGTAAG CTTAAATGAC GTTTGCCAGT AGTTTTACTT TATATAATCA ATATTGATAT    1500
TGTTGCTGAA CTATGTAACT TTATGATGCA TTTTTCAGTC CCTTTTCAGA GCAAATGCTT    1560
TTGCAATGGT AGTAATGTTT AGTTTAAATT GACTTAATAA ATTMTTACCT GAGCAAAAAA    1620
AAAAA                                                                1625
```

(2) INFORMATION FOR SEQ ID NO: 159:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1687 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 159:

```
CGGGGTCACC AGTTATTAGA GGAAGTAACA CAAGGGGATA TGAGTGCAGC AGACACATTT      60
CTGTCCGATC TGCCAAGGGA TGATATCTAT GTGTCAGATG TTGAGGACGA CGGTGATGAC     120
ACATCTCTGG ATAGTGACCT GGATCCAGAG GAGCTGGCAG GAGTCAGGGG ACATCAGGGT     180
CTAAGGGACC AAAAGCGTAT GCGACTTACT GAAGTGCAAG ATGATAAAGA GGAGGAGGAG     240
GAGGAGAATC CACTGCTGGT ACCACTGGAG GAAAAGGCAG TACTGCAGGA AGAACAAGCC     300
AACCTGTGGT TCTCAAAGGG CAGCTTTGCT GGGNATCGAG GACGATGCCG ATGAAGGCCC     360
```

```
TGGAGATCAG TCAGGCCCAG CTGTTATTTG AGAACCGGYG GAAGGGACGG CAGCAGCAGC    420
AGAAGCAGCA GCTGCCACAG ACACCCCCTT CCTGTTTGAA GACTGAGATA ATGTCTCCCC    480
TGTACCAAGA TGAAGCCCCT AAGGNAACAG AGGCTTCTTC GGGGACAGAA GCTGCCACTG    540
GCCTTGAAGG GGAAGAAAAG GATGGCATCT CAGACAGTGA TAGCAGTACT AGCAKTGAGG    600
AAGAAGAGAG CTGGGAACCC TCCGTGGTAA GAAGCGAASC GTGGGCCTAA AGTCAGATGA    660
TGACGGGTTT GAGATAGTGC CTATTGAGGA CCCAGCGAAA CATCGGATAC TGGACCCCGA    720
AGGCCTTGCT CTAGGTGCTG TTATTGCCTC TTCCAAAAAG GCCAAGAGAG ACCTCATAGA    780
TAACTCCTTC AACCGGTACA CATTTAATGA GGATGAGGGG GAGCTTCCGG AGTGGTTTGT    840
GCAAGAGGAA AAGCAGCACC GGATACGACA GTTGCCTGTT GGTAAGAAGG AGGTGGAGCA    900
TTACCGGAAA CGCTGGCGGG AAATCAATGC ACGTCCCATC AAGAAGGTGG CTGAGGCTAA    960
GGCTAGAAAG AAAAGGAGGA TGCTGAAGAG GCTGGAGCAG ACCAGGAAGA AGGCAGAAGC   1020
CGTGGTGAAC ACAGTGGACA TCTNCAGAAC GAGAGAAAGT GGCACAGCTG CGAAGTCTCT   1080
ACAAGAAGGC TGGGCTTGGC AAGGAGAAAC GCCATGTCAC CTACGTTGTA GCCAAAAAAG   1140
GTGTGGGCCG CAAAGTGCGC CGGCCAGCTG GAGTCAGAGG TCATTTCAAG GTGGTGGACT   1200
CAAGGATGAA GAAGGACCAA AGAGCACAGC AACGTAAGGA ACAAAAGAAA AAACACAAAC   1260
GGAAGTAAGC AGAGCTGCCA GGCTCCCAGG AGAGCATGGG GACTAGGAGG AAGGGTGTGG   1320
CATGGCTCAG TCTGGCCCCC TTGATTACCG GCCTAGCCCC TGCTCACATC ACAGCTGTCT   1380
GAAGAACAGT GAGGTGGAGT GCCTAGAACT CCCGTGGTGG TCCTGAGCAG AGAGGAGGAT   1440
GTCCTCCTGC CTGCCTGAAG GTCTCCCATG AAAACACTGC TGAACTGTGT TGACACTCAT   1500
GACCCTTTTT TTAAACCGTT AAAGGGAAGT TCGGTGTTGG AGCGATACTC AATGTAGTCA   1560
GTCTACACCT GGACGTGTGG GCCACTTAAG CCCTCCCCAC CCCCATCCTA TTCCTRAATA   1620
AAACCAGGAT AATGGAARAA AAAAAAAAAA AAAAAAAAAG GGGGGGCCCN TAAAGGGNCC   1680
CANNTTT                                                             1687
```

(2) INFORMATION FOR SEQ ID NO: 160:

(i) SEQUENCE CHARACTERISTICS:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160:

GGATGACAGA TTGCGACANA GATTTGTGAC CCTTCCTGCT GAACTTCAGA GGGAGCTGAA 60
ANCAGCGTAT GATCAAAGAC AAAGGCAGGG CGAGAACAGC ACTCACCAGC AGTCAGCCAG 120
CGCATCTGTG CCCCGAGAAT CCTTTACTTC ATCTAAAGGC AGCAGTGAAA GAAAAGAAAA 180
GAAACAAGAA GAAAAAAACC ATTGGTTCAC CAAAAAGGAT TCAGAGTCCT TTGAATAACA 240
AGCTGCTTAA CAGTCCTGCA AAAACTCTGC CAGGGGCCTG TGGCAGTCCC CAGAAGTTAA 300
TTGATGGGTT TCTAAAACAT GAAGGACCTC CTGCAGAGAA ACCCCTGGAA GAACTCTCTG 360
CTTCTACTTC AGGTGTGCCA GGCCTTTCTA GTTTGCAGTC TGACCCAGCT GGCTGTGTGA 420
GACCTCCAGC ACCCAATCTA GCTGGAGCTG TTGAATTCAA TGATGTGAAG ACCTTGCTCA 480
GAGAATGGAT AACTACAATT TCAGATCCAA TGGAAGAAGA CATTCTCCAA GTTGTGAAAT 540
ACTGTACTGA TCTAATAGAA GAAAAAGATT TGGAAAAACT GGATCTAGTT ATAAAATACA 600
TGAAAAGGCT GATGCAGCAA TCGGTGGAAT CGGTTTGGAA TATGGCATTT GACTTTATTC 660
TTGACAATGT CCAGGTGGTT TTACAACAAA CTTATGGAAG CACATTAAAA GTTACATAAA 720
TATTACCAGA GAGCCTGATG CTCTCTGATA GCTGTGCCAT AAGTGCTTGT GAGGTATTTG 780
CAAAGTGCAT GATAGTAATG CTCGGAGTTT TTATAATTTT AAATTTCTTT TAAAGCAAGT 840
GTTTTGTACA TTTCTTTTCA AAAAGTGCCA AATTTGTCAG TATTGCATGT AAATAATTGT 900
GTTAATTATT TTACTGTAGC ATAGATTCTA TTTACAAAAT GTTTGTTTAT AAAGTTTTAT 960
GGATTTTTAC AGTGAAGTGT TTACAGTTGT TTAATAAAGA ACTGTATGTA TATTTGGTAC 1020
RGGCTCCTTT TKGTGAAYCC TTAAAAACTC AACTCTAGGA RGCAACTACT GTTTATTATA 1080
CTAAARGGCT GAAAAMCCTC CAGGCCAGAC TGCTAAGCTC TGAAATYCCT GAGAGGTCTC 1140
AGACCGGGAT TCTACTTGTT CCAAGAAAGG GTAAAGCTTC TAAACCATCT TATTCTTGTC 1200
TCCAAGCATG AACACAGGAG CATGTYAAGA AAATCTTTAC TACTTTCTYC CATGCGGAGA 1260
AATCTACATA TTTTGAATTA GAAACACCCT CACACCCACT TGAAGATTTT TTTCCTGGGA 1320
ACATTATGTC CCGTAGATCA GAGGTGGTGT TGTCTTTTTG CTTCTACTGG CCATTGAGAA 1380
ACTTTGATGA TAAAAAAGAA CGGTATAGAT TTTTCAAACG TATATAAAAT ATTTTTATGT 1440
TATATGTTAT GCCATAACTT TAAAATAAAA ATAGTTTAAA ATTCTATGCT AGTGGATATT 1500
TGGAACTTTT TCCTCAAACA AACACCCCAC ACTGACTTCA GCAAAACCCT AAAACTAGCT 1560
ACAGATTACT ACTACGAATG AATCATYAAG TTTTGTGTCT GCAACAATTT AGAAGCACTA 1620
AGCCCAAATA TCAGGAAATG TGTGTATGAT GGAATTTTCT AGGACAAAAC AGATCAAGAT 1680
TAAAACAGGA TCAAGGATTA ATGGTATAAA AATGGTCTAC TAAAACAGGA TCAAGGATTA 1740
AAACAGGATC AAGGATTAAT GGTATAAAAA TCTCTACTGG TTACCGGGTG GCNGGGCCAT 1800

ACAGGGTAGT GGTGGATGGA TAGTTTAGTT TGGNAAGGGT AA 1842

(2) INFORMATION FOR SEQ ID NO: 161:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 770 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 161:

GGCACGAGCC CTATGCTGTT CTTGTGATAA TGAGTGAGTC TCACAAGATC TGGTGGTGTT 60

ATAGGCATCT GGCATTTCCC CTGCTGACGC TCATTCTCTA TCCTGCCACC CTGGGAAGAA 120

GTGTCTTCTG TCATGATTGT AAGTTTCCTG AGGCCTCCCC AGCTATGTAG AACTGTGAGC 180

CAATTAAACC TCTTTTCTCT ATAAATTATC CAGTCTTATA TATTTCTTCA TAGCAGTGTG 240

AGAACAGATA ATACCGTAAA TTGGTATCAC AGAGAGTGGG GTGTTGCTAT AAACACATCT 300

GAAAATGTTA AAGCAAATTT GGAACTGGGT AACAGGCAAA GGCTGGAACA GTTKGAAGAA 360

CAGTTAAGAA GAAGACAGGA AAATATGAGA AATCTTGAAA CTTCCTAGAG TCTTAAAGGT 420

CTCAGAAGAC ATGAAGATGT GGGAAGCTTT GGAACTTCCT AGAGACTTGT TTGAATGGCT 480

TTGACCAAAA TGCTGATAGT GATATGGACA ATGAAGTCCA GGCTGAGCTT ATCCAGACAG 540

ACATAAGAAG CTCGCTGGGA ACTTGAGTAA AGATCACTCT TGCTAGGCAA AGAGACTGGT 600

GGCCTTTTTT CCTCTGCCCT AGAGATCTGT GGAAATCTGA ACCTGAGAGA GATGATTTAG 660

GGTATCTGGC AGAAGAAATA TCTAAGCGGC AAAACCTTCM AGAGGAAGCA GAGCATAAAC 720

GTTTGAAAAA TTTGCAGCCT GACNATGGGA GACCAAAGTT AAACCCAATT 770

(2) INFORMATION FOR SEQ ID NO: 162:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 519 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162:

[illegible]

ATGGAGCTGT TTGTGAAGGT TAAATGGGAA GACATAAAGC ACTTAGCCCA GAGCCAAGGA 240

CATGCTGAAT AGGATAATGG TGGCCTCCTT TGGCGCTGTG CTGGTGCAGG TGTGCCGAGG 300

AAYTGGGCAG GGGTGACAGA TACCTCTTCT AACCTAGTTC CTTTCCAAGA ACCTAATTGG 360

TGTCTCTCCC TCCCCCAGGC AATTGGAAGG AGGAGGCTGG GCCCCAGCCC CAGAATACGG 420

GAGGTTTCTC ACCGTGGTAG GGAAATTGCT GGGTTGGGGG TGTGGGCAAC CACAGTGATC 480

GTCTCTCTGC AGGACGGATG AGGCTTTGCT GACAGAGGC 519

(2) INFORMATION FOR SEQ ID NO: 163:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 753 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163:

GGCACGAGCG GCACGAGCAG CCAGTTGCTG ACTGGCACAT GGCCTCCAGC GTCCCGGCTG 60

GTGGGCACAC TAGAGCCGGA GGGATCTTCT TAATTGGTAA ATTGGATCTT GAAGCTTCAC 120

TGTTTAAATC TTTTCAGTGG CTTCCCTTTG TACTTAGAAA AAAATGCAAC TTCTTCTGCT 180

GGGACTCATC CGCTCACAGC CTTCCCCTCC ACCCTCTCTC TGCCTCATGC TCTGCCCCTG 240

CCTGCCATGC CTCCGATACT CACCTTTTGT ACCCCAGCAC CCGTGCCCTC TGCCCCTCGA 300

TCTTTGCCTG GCTGGTTGCT CCTCACTCAG TGTTCAGGAC AAATGCTCCT GGCCCTACCC 360

CATCTAGCCA GTCTAGCCCG GTCTTCCCTG TCTTCCCTGT TTCATTCATG GCTCTTATTG 420

TTTGTTWACT TGTGTGCTGT TGACTTTTAA CTCTCTCAGT CCCCACTGGA ATGCAAGCGA 480

TCTCCCAAGC TCCTAGAATT GTTCCTGCCT CTTCACAGGC CCTTACGCTG TGTGTGCTCG 540

TGCCGAATTC GGCACGAGGG TATGTGCACT TGCTGGTATG TATGTAGGTG TTTGCTAACA 600

CATACGTGCA CACGCAGAAT GCTTCCAGGG GACTGCACAG CCTCTAGTTC GCAGCCCCCA 660

CCCCTCCCTT TGGCCCTGCA CTCTCCCCTC TCTGAGCTGC ATTCGCATGA AAGGGTGCAN 720

GGTTCCTGAN CCCGCNAGCG NCACCTCCTG GGA 753

(2) INFORMATION FOR SEQ ID NO: 164:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1400 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164:

```
GGCACAGTTT ATTAATACCT ATTATGGGAA AGTCACTTTG GTTGGCATTG AAAATTACAT      60
CATCTTTAAA GCAGTATTTG TCCCCAGATG GACTCATCAC TAGCAAAGAC TAGGTTCATT     120
GGAAGGCATA GGGTGAGAGA ATGGGAAGAT GRAGTGGAGG CGGGTTGTTA AAGTGCTGTC     180
AGTGAGTGAT TTTGTCTACT TGAATAATGG TCCATGTTTG GGGGCATATT GTGTTTCATA     240
AGAAGTGAAA GGTATTTGCA AAGTAAGCTA CAAATGACCC ATAAATCTGT TAACAACAGT     300
CCTTAATATG CAAAGATGAA AAACAAGCAT TACTGCTACC CAAAGGGAAC TGGTGCTTGG     360
TGATGTGCAG ATGGGGCTGT TGGTTAAGAG AGCTATTACA GGTTTTCTCT CTTAGGTTTC     420
ATAGGAGGTA GTTACTGAGA TGAGATTGTT TTATCTTTTT GAATACAGAT CTCTTGTCTT     480
GAGTTAGTTC TGAGGATGGG AGTAATAAAG GAGTTTTTTG TTTTTTTGTT TGTTTGTTTG     540
TTTTGGCTCC TTAGTAATAC TCCTCTGACA TTTATTTCTA TTATTCTTCA AAGAAAGGAA     600
ACCAACTGAA ATGTTTGCTT TAACAAACAT TTTAATAAGT TCTCTGGGTT TTTTTTTCCC     660
CTTTTAAAAA AATTAGCATA TACCATAGCA ATAAAAGAAC TAATGTTAAC TATTGTATGC     720
TACAACTTAA GTGATTTTTC TAAAGAAGCA CAATGTCATT GRAAGTATTA TTGAAAAGGA     780
TCATAGTCAC ATTGAATTTG TGAAGGCCAA AGAAATTGAA GGGAGTGATA TTTTCATTTT     840
ATGATATTCA CATATTTAGT AAATTTTGTG TACAACAATA CCAGGCAGAG TGTTTTACCC     900
ATGGAAACAG GTTTCAGATT ACTTTGTTTT TACTGTTAGA GTCTCAAGTT TAGAAATGCT     960
AACACTTAAA TCAGTTTTTT TCTCACTATA CTTGAAGATT GTTAATATTT TGATATCTTC    1020
CTAGCTTGAT GGAATTTAAA CATATCTTCA GATCTGTGAC AGTGACAGCC AATAGGACTG    1080
ATAATATTAG CTTCAAACCA ATAATATCCA GGGTTAAAAT AAAAATCATA GTGAAAGTAC    1140
GATTGTAAAA TTATGCTATA TTAACTTTTA AGTCTGTAAT AACTTGACAT CAAAATGTTA    1200
TGTAATTACC ATAAATAATG GCTAGCGAGA ACATCTTTGG AAATTCTCAA ATTACCTTTC    1260
TTACTACACT GTTTGCAGAA TGAATGTAGA AATGATCCTG TTAGCTTTCT GAATGTTCTG    1320
TGGTTGAATG TGTTTTTGCT TAAATAAAGC TTTTGGTATT TGTTTAAATW ACAAAAAAAA    1380
AAAAAAAAAA AAAAACTCGA                                                1400
```

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: [illegible] base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165:

```
CAGGCCTCAG GGCCTCTGGT GGCTCTGGCC CAGACAGTAT TTGCAGTTCT TGTGCTATGG    60
GTGGAGTCTT TCTTCCTCAA GTTTCGGCAG CTGTGCTGTG NCTGGATGGG CTGCTCCTCC   120
CAGGGCTCAA GGGCTGTGGT CCGCTCAGGG TCTCATTTCC CCAGGCCAAG TTCAAGGCAG   180
CAGCCCTTTG TGAGGCGCTC TTGGCCCTGG GCTGGAGGGA GAACTTTAAG CTTTTTTGCT   240
CACAGGGACG TGGTATGGGC CCTGGGTGCA GGTGCCCACA TTCTGCTAAT GAGAGCTTTG   300
TCTGATCAGT CCTGGGTCCA TCAGTTTGTC CATGTGTCCG GCTGCCAGCC CGTCCCTTGG   360
GATCCTTCCC CTGGGGTGTA GCCTTGTTCA TTAGTATATA CTCATTCCTT CATGCTTTCC   420
TCAGCAGAAC ACTTCCACTT CTGAGGTGAG CTTTTGCCCC RTGCCCTTCC TCCACAGGTG   480
TTGCCTTTTT ATAAAGACCT GATAGCAGAA TAAATTGGTG TTTCCCTGTT GACCCAGCAC   540
CATTTCTGTG GGCCTAGAAT ATGGCCCTCA ACCCTTAGAG TGGGGCAGTG AGGGCTTGAG   600
GAGTGACCCT TCCTTTCTCA TGGTTTTAGT CATTTTGGCT GCCAGCCCTT AATGGCACAG   660
ATCTGCTGCT TCTAACAGAT GGCCAGGAGG TGACACCGAT TTCAGCCATT GCCAAGGTTA   720
GCACCCTCTC CTTTGAGCCT AGGGCCACAC TGTTCATTGT CACTTTAGGC AAGTGCCTGT   780
TTGGCTTTAA AGGTAAGCCT GCCAGCTGTG AGAAGCCTTG GTAACTGATG GACTCATTTC   840
CTGGTCCTTA AAGATGCAGC CTCTTAAGGG CTCCTTGATG GATGCCATCT CTCCTAGCCC   900
CCAGCCCTGG TGCCACTGGT GGGCAGGTTC CCATTCTTTG GGGCTGGGAG GGACAGCTTG   960
CCTGTTTCTG GTCACAAATT ACAGTCTTCT CTCCTGTACC ATTCTGTGGC TTCAGCATGG  1020
GGGCAGTAGC CTTTCATTAG TGTAGATAGT CATTCCCTGG TAGGGTGGAG GGTAAGACAT  1080
AGGGTCTGGA ACTGTTTGGG ACCTTTTGGG GATGTCCTGT GCCTCCCAGA TTCCTMGATT  1140
CTGGGAGGAG AGGCTGCCGC ATTCTGCTGC TCCTCACAGC GAGCAAAGCT GCACCCACTT  1200
ACATTCAGTA TTTTCCTGGC ACTACAAAGA GTGGGAAGGC CTGGGATTTG CTGCTGCTCC  1260
CTTAGAGCAG GGCCCCTYTT TTCAGCACTT TGGACACCTG GAGACCCAGC CCTGTTATTT  1320
AATGGTAGTG GGCAAGTGTG TGTGCATACT GTCTGCCACT GCTTTCTCCC TGCCCCATGC  1380
CAGAGAGCCC TGTCCCTGCC AGGCCCAGCC TTCTTAGCCC CAACTTGGGA ACAAAGTGCA  1440
ACATGGGATC ATGGGTTGGG GTGCTCAGGT GAGCCCTCTC TATAGTGCTT CCCTGGGCCA  1500
AGCTGACACC AGCCCCTGAG GGTGGGGTGG GACGGGTGGT GCTTAAAAGA GGAAGGGGAC  1560
CAGTGTAGCA ACTTGCCAGG GACCCCACCC CTCCCTCTCT GGGCCTGTGC AGTGAGCATG  1620
GGGATTCCCA TCAAGGGGCC TGGCACCTGT GCTAGTTACG TAGCCGCTGN TCACGCGCTC  1680
```

ACTCCTGACC ACATGCACGT TCCCTAGATG CAGACTGCTT TGAACTTTAA AGCTGTACAA 1740

TTTGGTTATG TTTGTGCTGA CTTAAAATAT ATTTTAATGA GGAAAAAATA ATGGAGAACC 1800

CTGGGAAGGA CCTGGTTCTT TTGCTTCTCG GGGAACTGTA AGCCCTCGCG TTCTGGGAAT 1860

CGCTCTCTGC TGCTCTTTCC TGGAAGCTAA GCCTGTCTCC ACCGCCCGAG GCCTGCGCCG 1920

GTGCTCCCGC CGCAGTTGCG TTTGCTTTGG ACCTTGCGTG CGGGGGAGGG GCTGCTCGGT 1980

CCGAGCCCGC TCCTTTCTGT ACACCTAGCG CTGCCCGCCC CGCTTGTGTC TGAGGTCGTG 2040

TATGTCAAAA ATAAAGCCGC TAGAAACGGA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2100

AAACTCGAGG GGGGGCCCGT ACCCAATTAA CCCNNTATGA TCTATAAAGC GTC 2153

(2) INFORMATION FOR SEQ ID NO: 166:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1251 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166:

GCCCACGCGT CCGCCCACGC GTCCGGCGGT GCGGAGTATG GGGCGCTGAT GGCCATGGAG 60

GGCTACTGGC GCTTCCTGGC GCTGCTGGGG TCGGCACTGC TCGTCGGCTT CCTGTCGGTG 120

ATCTTCGCCC TCGTCTGGGT CCTCCACTAC CGAGAGGGGC TTGGCTGGGA TGGGAGCGCA 180

CTAGAGTTTA ACTGGCACCC AGTGCTCATG GTCACCGGCT TCGTCTTCAT CCAGGGCATC 240

GCCATCATCG TCTACAGACT GCCGTGGACC TGGAAATGCA GCAAGCTCCT GATGAAATCC 300

ATCCATGCAG GGTTAAATGC AGTTGCTGCC ATTCTTGCAA TTATCTCTGT GGTGGCCGTG 360

TTTGAGAACC ACAATGTTAA CAATATAGCC AATATGTACA GTCTGCACAG CTGGGTTGGA 420

CTGATAGCTG TCATATGCTA TTTGTTACAG CTTCTTTCAG GTTTTTCAGT CTTTCTGCTT 480

CCATGGGCTC CGCTTTCTCT CCGAGCATTT CTCATGCCCA TACATGTTTA TTCTGGAATT 540

GTCATCTTTG GAACAGTGAT TGCAACAGCA CTTATGGGAT TGACAGAGAA ACTGATTTTT 600

TCCCTGAGAG ATCCTGCATA CAGTACATTC CCGCCAGAAG GTGTTTTCGT AAATACGCTT 660

GGCCTTCTGA TCCTGGTGTT CGGGGCCCTC ATTTTTTGGA TAGTCACCAG ACCGCAATGG 720

[illegible]

ACCATGTAAA ATGTTGTAGA GATAGAGCCA TATAACGTCA CGTTTCAAAA CTAGCTCTAC 960

AGTTTTGCTT CTCCTATTAG CCATATGATA ATTGGGCTAT GTAGTATCAA TATTTACTTT 1020

AATCACAAAG GATGGTTTCT TGAAATAATT TGTATTGATT GAGGCCTATG AACTGACCTG 1080

AATTGGAAAG GATGTGATTA ATATAAATAA TAGCAGATAT AAATTGTGGT TATGTTACCT 1140

TTATCTTGTT GAGGACCACA ACATTAGCAC GGTGCCTTGT GCAKAATAGA TACTCAATAT 1200

GTGAATATGT GTCTACTAGT AGTTAATTGG ATAAACTGGC AGCATCCCTG A 1251

(2) INFORMATION FOR SEQ ID NO: 167:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 882 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167:

GACSMTCTAG AACTATGGTC CCCCGGGACT GCAGGAATTC GGCACAGCGG CTGCGGGCGC 60

GAGGTGAGGG GCGCGAGGTT CCCAGCAGGA TGCCCCGGCT CTGCAGGAAG CTGAAGTGAG 120

AGGCCCGGAG AGGGCCCAGC CCGCCCGGGG CAGGATGACC AAGGCCCGGC TGTTCCGGCT 180

GTGGCTGGTG CTGGGGTCGG TGTTCATGAT CCTGCTGATC ATCGTGTACT GGGACAGCGC 240

ACGCGCCGCG CACTTCTACT TGCACACGTC CTTCTCTAGG CCGCACACGG GGCCGCCGCT 300

GCCCACGCCC GGGCCGGACA GGGACAGGGA GCTCACGGCC GAYTCCGATG TCGACGAKTT 360

TCTGGACAAK TTTCTCAGTG CTGGCGTGAA GCAGAGTGAC YTTCCCAGAA AGGAGACGGA 420

GCAGCCGCCT GCGCCGGGGA GCATGGAGGA GAGCGTGAGA RGCTACGACT GGTCCCCGCG 480

CGAMGCCCGG CGCACCCAGA CCAGGGCCGG CAGCARGCGG ANCGGAGGAR CGTGCTGCGG 540

GGCTTCTGCG CCAAYTCCAG CCTGGCCTTC CCCACCAAGG AGCGCGCATT CRACGACATC 600

CCCAACTCGG AGCTGAGCCA CCTGATCGTG GACGACCGGC ACGGGGCCAT CTACTGCTAC 660

GTGCCCAAGG TGGCCTGCAC CAACTGGAAG CGCGTRATGA TCGTGCTGAG CGGAAGCTGT 720

GCACCGCGTG CGCCTACCGC GACCCGYTGC GNTCCCGCGC GAGCACGTGC ACAACGCCAG 730

CGCGCACTGA CTTCAACAAT TCTGGCGCCG CTACGGGAAG TCTCCCCCAC CTCATGAAGT 840

CAAGCTCAAG AATACACCAA TTCTTTCTGC GCGACCCTTC TG 832

(2) INFORMATION FOR SEQ ID NO: 168:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1208 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168:

```
GGGAAACTCA AAAGGATGAT GGAATGGTTG ATGGAGCCAG AGCCTAGAAG TRAAGGGATA      60
CAGAGTGAAG ATAGAGGTAT TTACGTATAT TTWAATATTA GCTTTGGAAT TACGTAGGGA     120
TTCTTAAGAA AAGATCATGA CAGGACAGCC ACATTTGGTA AAATGTCAGG GCAGCCAGTG     180
CATGGTCCTC CTGGGGCTCC TCAGTTGACG GGTTTAAATC ATTTCCTGAT CCCCCTGCCC     240
TGGTTTGAGG AATGCATACA GTACGTGAAA TGCCTGTGGT ATGAGTTGCA ATGGGCAATC     300
AACCTGGGTA AATCCAAGAT TAATGATTAG TTCTAAAGAT CCAGTTGAAG TTCTAGAGTG     360
GGAATTTTCC GTCAAGCARC TCAGCACAGC TTTATGCCTG TTCCTCTAAT AACGATAGGT     420
AACAAATAGC TGTGTKTWCA CAGCTAGGAR GATAACCAAA TCTAGAGTTC TTGARTCTCA     480
TTTAATAAAT AAKTATTATG AGTACCAACT GCATATTTCA GGCACTGCAT TTGACTCTGT     540
TAAATACTGA TYCCTTAKGA CMSCCACWTC AGAWAACMTT AATCTGTCTG ATCAATAAAC     600
AGCTTGACTT AGAGRGGTAA AATAGCTTGC CACAGGTWAC CCAATTAGTA GGTAACAGCG     660
ACAGAATAAC AGTGCAGTTA AAATCTTAGA CTGGAGACTA ATTGCATAAG TTTGAATTTC     720
AGTTCTGCTA TGTAAATTTG GGTGAGTACC TTAATTYACC TGAGTCTCGG TCTTTATATC     780
TGTAGAATGG AGCTAATGAT ATTACTTAAT TTGCTTTATG TGAGATTAAA TGTACTAATA     840
TATGTAAATC ACTTACAACA GCATTTGACA TATTTGACAT ACTTAATATA TTTGCTACTA     900
ATACTATTAG CAACAGCATT CTGATTTTCC AAGTTGAAAT TCAGTGTTTT CTTTTTTACT     960
TTGCCATAAT TTACAATGTT GTGCTCTGTA AACCATAAAT TTCCCTGAGG TGTTGTCAGG    1020
TTAAAAAAAA ATCACTATGG CCCCCARNMA CTTGCAAAAT AGAAATGAGA CCAGCTTCAT    1080
CTATATTCTT TACTGCAAAT AACTTAGAAT TGTAATAGGC TAATATGTAC TGGGACTTCC    1140
AATTTGGGAA TATGACAAAA ATAATACTAT TTAGCTAAAA CATATACAGA ACTTATTTTT    1200
CCTCTGAA                                                             1208
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169:

```
GGCACGAGAG AAAAGAGGTT GAGAATGTTT TCTAGCAGGC AGAATGTGCA TACATGTTTT      60
CATGARTGTC CTTTGGGTGC TGTTTCTTTT AAATCCTCTG TGCACAGGGC TCTGGCCTTT     120
ARTAAACTGT TTTTCTGTCT TACGTCATGC TGACTGGGTG CTAGGGGCTG ATTACAAAGG     180
GGAAGAGTTG AACAGACATC AGGGGCCGAT GAAACCAAAG GACTAGGAGT CAGGAGAACA     240
AGTCAGGGAT TAGGAGACAG CGGTTTGGTT TATTGTTATC CAGCTGGAGG ACTCCTAGGG     300
GCAGCAGCAG GAGGAATACC AGGGCCACGG AGGGGCAGGA GTCTCACAGT GGAGGGCAGA     360
CTCTAACAGA TGCCAGCTGA ACGCTCGCTG GCCCTGGATG TCATACGAGT TGGGGACCAG     420
AAATCTGGGC TCAGAGAACC CGTCCAGGGA GATTTGAAGC CATGGGTTAT CTTCTAGAGT     480
TGATACTGAT AATATATTTT AATTTTTATT GATGTTTAAT ACCTTCTGAA ACAGGAGGGT     540
AAGATCAGAT GGGAAGCCCY TCTGTTGAAG GATCTTGGGA ACCTTGGTGG TTTTTTTTTT     600
TTGGTTTTTT TTTTTTTGAT CGAGCTGTGG ACATCCTTCT TAATTCGATT NTGAGGATTT     660
GTTTAACTAA AAAGTTCCCA AACACAGAAA GGGCCTCCCC ACCTGCTTTG GGGAGCTGTC     720
TGTSCTGGGA GTGCCAGGCA TCCSATGGGA CCCATCACTG CCAGTGTCTG TGCCTCCCAG     780
AGGTCAGCCC TGTGTCTGCC CTGGCTCTGT CTCCTCTGTG ACAGGGCAGA GCATTTCTGG     840
TCAGTTTCTC CATGGTGCCT CCCACCCCTT TGTAAAGTGG ATGGACATGA TGGAATTCAG     900
TTGTCTCACC CTGATAGCCT GGGTGTTGAT ATTCACTTTA CCCGCACTCA GACACAGGCG     960
ACCTTGAAGC AGTTCTCGGT GTGTAGAGTC CACGTGACAG TCCCCACAGC CTCCCCAGAT    1020
AGCTGTGTGC CTGTGCGCTA CTGCTGTGCC ATTTTCCCAA CTTNGGCGTT TCACTAAATG    1080
CAGCTGATCT CTCTCTCTGT GCACTCGTGA TCCATGTTGA ACAATACATG TAGGTTCTTT    1140
TTCCACGCAA TGTAAGAACA TGATATACTG TACGTTGGAA AGCATTTACC TTATTTATAT    1200
ACCTGAATGT TCCTACTACA CAAATAAACA TATATTAAAT WCTAAAAAAA AAAAAAAAAA    1260
CTGGAGGGGG GGCCCGGTAC CCAAATCGCC GGATAGTGAT CGTAAAC                  1307
```

(2) INFORMATION FOR SEQ ID NO: 170:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1624 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170:

GGCACGAGGT CGCCGCCGCG GCCGCCTGGA ATTGTGGGAG TTGTGTCTGC CACTCGGCTG 60

CCGGAGGCGA AGGTCCCTGA CTATGGCTCC CCAGAGCCTG CCTTCATCTA GGATGGCTCC 120

TCTGGGCATG CTGCTTGGGC TGCTGATGGC CGCCTGCTTC ACCTTCTGCC TCAGTCATCA 180

GAACCTGAAG GACTTTGCCC TGACCAACCC AGAGAAGAGC AGCACCAAAG AAACTGAGAG 240

AAAAGAAACC AAAGCCGAGG AGGAGCTGGA TGCCGAAGTC CTGGAGGTGT TCCACCCGAC 300

GCATGAGTGG CAGGCCCTTC AGCCAGGGCA GGCTGTCCCT GCAGGATCCC ACGTACGGCT 360

GAATCTTCAG ACTGGGGAAA GAGAGGCAAA ACTCCAATAT GAGGACAAGT TCCGAAATAA 420

TTTGAAAGGC AAAAGGCTGG ATATCAACAC CAACACCTAC ACATCTCAGG ATCTCAAGAG 480

TGCACTGGCA AAATTCAAGG AGGGGGCAGA GATGGAGAGT TCAAAGGAAG ACAAGGCAAG 540

GCAGGCTGAG GTAAAGGGGC TCTTCCGCCC CATTGAGGAA CTGAAGAAAG ACTTTGATGA 600

GCTGAATGTT GTCATTGAGA CTGACATGCA GATCATGGTA CGGCTGATCA ACAAGTTCAA 660

TAGTTCCAGC TCCAGTTTGG AAGAGAAGAT TGCTGCGCTC TTTGATCTTG AATATTATGT 720

CCATCAGATG GACAATGCGC AGGACCTGCT TTCCTTTGGT GGTCTTCAAG TGGTGATCAA 780

TGGGCTGAAC AGCACAGAGC CCCTCGTGAA GGAGTATGCT GCGTTTGTGC TGGGTGCTGC 840

CTTTTCCAGC AACCCCAAGG TCCAGGTGGA GGCCATCGAA GGGGGAGCCC TGCAGAAGCT 900

GCTGGTCATC CTGGCCACGG AGCAGCCGCT CACTGCAAAG AAGAAGGTCC TGTTTGCACT 960

GTGCTCCCTG CTGCGCCACT TCCCCTATGC CCAGCGGCAG TTCCTGAAGC TCGGGGGGCT 1020

GCAGGTCCTG AGGACCCTGG TGCAGGAGAA GGGCACGGAG GTGCTCGCCG TGCGCGTGGT 1080

CACACTGCTC TACGACCTGG TCACGGAGAA GATGTTCGCC GAGGAGGAGG CTGAGCTGAC 1140

CCAGGAGATG TCCCCAGAGA AGCTGCAGCA GTATCGCCAG GTACACCTCC TGCCAGGCCT 1200

GTGGGAACAG GGCTGGTGCG AGATCACGGC CCACCTCCTG GCGCTGCCCG AGCATGATGC 1260

CCGTGAGAAG GTGCTGCAGA CACTGGGCGT CCTCCTGACC ACCTGCCGGG ACCGCTACCG 1320

TCAGGACCCC CAGCTCGGCA GCACACTGGC CAGCCTGCAG GCTGAGTACC AGGTGCTGGC 1380

CAGCCTGGAG CTGCAGGATG GTGAGGACGA GGGCTACTTC CAGGAGCTGC TGGGCTCTGT 1440

CAACAGCTTG CTGAAGGAGC TGAGATGAGG CCCCACACCA GGACTGGACT GGGATGCCGC 1500

TAGTGAGGCT GAGGGGTGCC AGCGTGGGTG GGCTTCTCAG GCAGGAGGAC ATCTTGGCAG 1560

TGCTGGCTTG GCCATTAAAT GGAAACCTGA AGGCCAAAAA AAAAAAAAAA AAAAAAAAAA 1620

(2) INFORMATION FOR SEQ ID NO: 171:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2003 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171:

```
GGCACGAGCC AGCTTGCAGG AGGAATCGGT GAGGTCCTGT CCTGAGGCTG CTGTCCGGGG     60
CCGGTGGCTG CCCTCAAGGT CCCTTCCCTA GCTGCTGCGG TTGCCATTGC TTCTTGCCTG    120
TTCTGGCATC AGGCACCTGG ATTGAGTTGC ACAGCTTTGC TTTATCCGGG CTTGTGTGCA    180
GGGCCCGGCT GGGCTCCCCA TCTGCACATC CTGAGGACAG AAAAAGCTGG GTCTTGCTGT    240
GCCCTCCCAG GCTTAGTGTT CCCTCCCTCA AAGACTGACA GCCATCGTTC TGCACGGGGC    300
TTTCTGCATG TGACGCCAGC TAAGCATAGT AAGAAGTCCA GCCTAGGAAG GGAAGGATTT    360
TGGAGGTAGG TGGCTTTGGT GACACACTCA CTTCTTTCTC AGCCTCCAGG ACACTATGGC    420
CTGTTTTAAG AGACATCTTA TTTTTCTAAA GGTGAATTCT CAGATGATAG GTGAACCTGA    480
GTTGCAGATA TACCAACTTC TGCTTGTATT TCTTAAATGA CAAAGATTAC CTAGCTAAGA    540
AACTTCCTAG GGAACTAGGG AACCTATGTG TTCCCTCAGT GTGGTTTCCT GAAGCCAGTG    600
ATATGGGGGT TAGGATAGGA AGAACTTTCT CGGTAATGAT AAGGAGAATC TCTTGTTTCC    660
TCCCACCTGT GTTGTAAAGA TAAACTGACG ATATACAGGC ACATTATGTA AACATACACA    720
CGCAATGAAA CCGAAGCTTG GCGGCCTGGG CGTGGTCTTG CAAAATGCTT CCAAAGCCAC    780
CTTAGCCTGT TCTATTCAGC GGCAACCCCA AAGCACCTGT TAAGACTCCT GACCCCCAAG    840
TGGCATGCAG CCCCCATGCC CACCGGGACC TGGTCAGCAC AGATCTTGAT GACTTCCCTT    900
TCTAGGGCAG ACTGGGAGGG TATCCAGGAA TCGGCCCCTG CCCCACGGGC GTTTTCATGC    960
TGTACAGTGA CCTAAAGTTG GTAAGATGTC ATAATGGACC AGTCCATGTG ATTTCAGTAT   1020
ATACAACTCC ACCAGACCCC TCCAACCCAT ATAACACCCC ACCCCTGTTC GCTTCCTGTA   1080
TGGTGATATC ATATGTAACA TTTACTCCTG TTTCTGCTGA TTGTTTTTTT AATGTTTTGG   1140
TTTGTTTTTG ACATCAGCTG TAATCATTCC TGTGCTGTGT TTTTTATTAC CCTTGGTAGG   1200
TATTAGACTT GCACTTTTTT AAAAAAAGGT TTCTGCATCG TGGAAGCATT TGACCCAGAG   1260
TGGAACGCGT GGCCTATGCA GGTGGATTCC TTCAGGTCTT TCCTTTGGTT CTTTGAGCAT   1320
CTTTGCTTTC ATTCGTCTCC CGTCTTTGGT TCTCCAGTTC AAATTATTGC AAAGTAAAGG   1380
ATCTTTGAGT AGGTTCGGTC TGAAAGGTGT GGCCTTTATA TTTGATCCAC ACACGTTGGT   1440
CTTTTAACCG TGCTGAGCAG AAAACAAAAC AGGTTAAGAA GAGCCGGGTG GCAGCTGACA   1500
GAGGAAGCCG CTCAAATACC TTCACAATAA ATAGTGGCAA TATATATATA GTTTAAGAAG   1560
```

GCTCTCCATT TGGCATCGTT TAATTTATAT GTTATGTTCT AAGCACAGCT CTCTTCTCCT 1620

ATTTTCATCC TGCAAGCAAC TCAAAATATT TAAAATAAAG TTTACATTGT AGTTATTTTC 1680

AAATCTTTGC TTGATAAGTA TTAAGAAATA TTGGACTTGC TGCCGTAATT TAAAGCTCTG 1740

TTGATTTTGT TTCCGTTTGG ATTTTTGGGG GAGGGGAGCA CTGTGTTTAT GCTGGAATAT 1800

GAAGTCTGAG ACCTTCCGGT GCTGGGAACA CACAAGAGTT GTTGAAAGTT GACAAGCAGA 1860

CTGCGCATGT CTCTGATGCT TTGTATCATT CTTGAGCAAT CGCTCGGTCC GTGGACAATA 1920

AACAGTATTA TCAAAGAGAA AAAAAAAAAA AAAAAACTCG NGGGGGGGCC CGGTACCCAA 1980

TTCGCCCTAT AGTGAGCCNA TTC 2003

(2) INFORMATION FOR SEQ ID NO: 172:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 786 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172:

GGCACAGCGG CACGAGAAGA CTTTGGTGTT TAAGAGATTA ATGTGTTAGC CAGAACAACT 60

CATTTCTCTA CCMGTGTGTA GTCCATTTAT CTTTAAAGAT TTTCTATTGG AATAATTTTG 120

AAATTACTTT CTTAGTTTTC TTCATTAAAA ACTAAGAAAA TGCTTTGTTT ATTATGAATT 180

GCTATTTCTC TTGATTATTA TTCTTGGAGA AAGTCTATCA GACGTAATTC TTCTGATTTG 240

CTTCTAGGCT AGAGGAAAAT GTGAAAGATG ACAAATGAAA ATTTCAAAGG TTGTCAGTAG 300

TATGACTTCT TTTATCGTTT GTCATTATCA CAAATATATC AACATAGGAC TTTTAAAAGA 360

TATTTTGTAC ATATTGGGCC TTAGTAGGAT TTTGCATGAA TTTTTTTTTT CTTTTATGCC 420

CAGAGAGAAA GAGCAAAGAA ATAACCAAGG GTGATGTACT CGTATTGAAG GTTTACCAAA 480

TAAGGACTGC TTTTATTATG AACTATAGTC TATATTCTAA GTAAATCAAT TTTTCTATTA 540

TGTGTTTTTT GTTCCTGCAG GCAAGATCTC TGAACTTTAT GCAGAGGGTT CTTTTAAAAA 600

AACAAAGTTG AATTTTTTTA TTTCTTGGAA TATTTTTTTT CATTGATTTC TCCCAAGTAG 660

AGCAGATTCA AATCTCCTTT GTACCCTATG TCTTTTTTGT TTTGCTATTA GCTCAGTATT 720

(2) INFORMATION FOR SEQ ID NO: 173:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1758 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173:

```
GGGACGAGCC CTGCCCACCT CCTGCAGCCT CCTGCGCCCC GCCGAGCTGG CGGATGGAGC     60
TGCGCACGGG GAGCGTGGGC AGCCAGGCGG TGGCGCGGAG GATGGATGGG GACAGCCGAG    120
ATGGCGGCGG CGGCAAGGAC GCCACCGGGT CGGAGGACTA CGAGAACCTG CCGACTAGCG    180
CCTCCGTGTC CACCCACATG ACAGCAGGAG CGATGGCCGG GATCCTGGAG CACTCGGTCA    240
TGTACCCGGT GGACTCGGTG AAGACACGAA TGCAGAGTTT GAGTCCAGAT CCCAAAGTCC    300
AGTACACAAG TATCTACGGA GCCCTCAAGA AAATCATGCG GACCGAAGCT TCTGGAGGCC    360
CTTGCGAGGC GTCAACGTCA TGATCATGGG TGCAGGGCCR GCCCATGCCA TGTATTTTGC    420
CTGCTATGAA AACATGAAAA GGACTTTAAA TGACGTTTTC CACCACCAAG GAAACAGCCA    480
CCTAGCCAAC GGTATTTTGA AAGCGTTTGT CTGGAGTTAG AAAGTTCTCT TCTTCAACAC    540
GTCCCTCCCC AGGGTGTTCC TCCCTGTGAC CCAGCCGCCT CGACTTCGGC CCGCTTGCTC    600
ACGAATAAAG AACTCAGAGT TGTGTGTGCA ATGCACACCC AGACACACGC ACGCACACAC    660
ACGCGCGCGC ACACACATGC TTTTTTCTGT TCCCCTCCGC TTTCTGAAGC CTGGGGAGAA    720
ATCAGTGACA GAGGTGTTTT GGTTTTATTG TTATGTGGGT TTTCTTTTGT ATTTTTTTTG    780
TTTGTTTTGT TTTTAAACAT TCAAAAGCAA TTAATGATCA GACATAGGAG AAACCCTGAA    840
TAGAAACAAA ACTTTTGAAT GCTGGATTCA AAAAAAAAAA AAAGTTATCT GGACAGCTTC    900
TTTGAGACTA TTTAAAAACT GGTACAACAG GTCTCTACAA CGCCAAGATC TAACTAAGCT    960
TTAAAAGGTC AAGAAGTTTT ATGGCTGACA AAGGACTCGC GCAACGCAGA AGGCCTTTCC   1020
CACCTTAAGC TTCCGGGGAT CTGGGAATTT TACCCCCATT CTCTTCTGTT TGTCTGAGTC   1080
TCATCTCTCT GCAAGCAAGG GCTGAAATCA TTTTGTTTGG TTGTTTTGAG GGAGAGAGGC   1140
GGGGTGGGGG GGTGCAAATC TGCCAGCAGC TCTTACGTAA GGCATGTTTT ATTGGGGAGG   1200
GCTGAGCTTT TATTTTCTCC TCTCCAGTGG GGTTGGCTTT TATTGTTTCT TGTTTGGGTT   1260
TGGAATGGAA ATATGGATAG CAGCATAAAG TACTTTTATT TTGACAAAAT TCATTTTTTT   1320
CAACAATGGA GACATAGATT TGACCCACAA TAACTTCTCC CCCTCTCTTT TTACTCTGCT   1380
CAAAAAGCAT CTCTCCTCCC ATTACCCAAC CTTGGTCATA AGTGTGCCTG GCTGGTTTGC   1440
AGATATTTGT TCTGCTTTGT AAAAATTGGC CATTAGTGCA TTTATTGAGA TGATCTCTAA   1500
```

AGAGCTATGC CCTGACCTAC CCCTGATTCT ATGACATTGG GGCCCTTCTT TTGCTGAAAC 1560

TGCCTTACGT AATGGTTTTA CTCCTTGAAA GAGATTTGAC GGAATCCATT TTATGCCAAG 1620

TGCTGCCCTG CACTGTTTCT GCAATATGTG GTGTATGCTG TGGTGATCTT GCTGGGAATG 1680

ATTATAAGTG TGTGTGTGGT GGGGGAGTGG GTATTACATG CATTGCTGAA GAGTCAAAAA 1740

AAAAAAAAAA AAACTCGA 1758

(2) INFORMATION FOR SEQ ID NO: 174:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 888 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174:

CTGTTAGAAT GCCCAGTTTA CCTGGATGGC AACCCAACAG TGCTCCTGCC CACCTGCCCC 60

TCAATCCTCC TAGAATTCAG CCCCCAATTG CCCAGTTACC AATAAAAACT TGTACACCAG 120

CCCCAGGGAC AGTCTCAAAT GCAAATCCAC AGAGTGASMC ACCACCTCGG GTAGAATTTG 180

ATGACAACAA TCCCTTTAGT GAAAGTTTTC AAGAACGGGA ACGTAAGGAA CGTTTACGAG 240

AACAGCAAGA GAGACAACGG ATCCAACTCA TCCAGGAGGT AGATAGACAA AGAGCTTTGC 300

AGCAGAGGAT GGAAATGGAG CAGCATGGTA TGGTGGGCTC TGAGATAAGT AGTAGTAGGA 360

CATCTGTGTC CCAGATTCCC TTCTACAGTT CCGACTTACC TTGTGATTTT ATGCAACCTC 420

TAGGACCCCT TCAGCAGTCT CCACAACACC AACAGCAAAT GGGGCAGGTT TTACAGCAGC 480

AGAATATACA ACAAGGATCA ATTAATTCAC CCTCCACCCA AACTTTCATG CAGACTAATG 540

AGCGAGGCAG GTAGGCCCTC CTTCATTTGT TCCTGATTCA CCATCAATCC CTGTTGGAAG 600

CCCAAATTTT TCTTCTGTGA AGCAGGGACA TGGAAATCTT TCTGGCACCA GCTTCCAGCA 660

GTCCCCAGTG AGGCCTTCTT TTACACCTGC TTTACCAGCA GCACCTCCAG TAGCTAATAG 720

CAGTCTCCCA TGTGGCCAAG ATTCTACTAT AACCCATGGA CACAGTTATC CGGGATCAAC 780

CCAATCGCTC ATTCAGTTGT ATTCTGATAT AATCCCAGAG GAAAAAGGGN AAAAAAAARA 840

AMAARAAARA ARAAAGGAGA TGATGATCCA GAATTCCACC AAGGCTCC 888

(2) INFORMATION FOR SEQ ID NO: 175:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2379 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175:

```
GGCAGAGCTA GTGTGGACTC CATCCCCCTG GAGTGGGATC ACGNCTATGA CCTCAGTCGG     60
GACCTGGAGT CTGCAATGTC CAGAGCTCTG CCCTCTGAGG ATGAAGAAGG TCAGGATGAC    120
AAAGATTTCT ACCTCCGGGG AGCTGTTGGC TTATCAGGGG ACCACAGTGC CCTAGAGTCA    180
CAGATCCGAC AACTGGGCAA AGCCTGGATG ATAGCCGCTT TCAGATACAG CAAACCGAAA    240
ATATCATTCG CAGCAAAACT CCCACGGGGC CGGAGCTAGA CACCAGCTAC AAAGGCTACA    300
TGAAACTGCT GGGCGAATGC ACTAGCAGTA TAGACTCCGT GAAGAGACTG GAGCACAAAC    360
TGAAGGAGGA AGAGGAGAGC CTTCCTGGCT TTGTTAACCT GCATAGTACC GAAACCCAAA    420
CGGCTGGTGT GATTGACCGA TGGGAGCTTC TCCAGGCCCA GGCATTGAGC AAGGAGTTGA    480
GGATGAAGCA GAACCTCCAG AAGTGGCAGC AGTTTAACTC AGACTTGAAC AGCATCTGGG    540
CCTGGCTGGG GGACACGGAG GAGGAGTTGG AACAGCTCCA GCGTCTGGAA CTCAGCACTG    600
ACATCCAGAC CATCGAGCTC CAGATCAAAA AGCTCAAGGA GCTCCAGAAA GCTGTGGACC    660
ACCGCAAAGC CATCATCCTC TCCATCAATC TCTGCAGCCC TGAGTTCACC CAGGCTGACA    720
GCAAGGAGAG CCGGGACCTG CAGGATCGCT TGTCGCAGAT GAATGGGCGC TGGGACCGAG    780
TGTGCTCTCT GCTGGAGGAG TGGCGGGGCC TGCTGCAGGA TGCCCTGATG CAGTGCCAGG    840
GTTTCCATGA AATGAGCCAT GGTTTGCTTC TTATGCTGGA GAACATTGAC AGAAGGAAAA    900
ATGAAATTGT CCCTATTGAT TCTAACCTTG ATGCAGAGAT ACTTCAGGAC CATCACAAAC    960
AGCTTATGCA AATAAAGCAT GAGCTGTTGG AATCCCAACT CAGAGTAGCC TCTTTGCAAG   1020
ACATGTCTTG CCAACTACTG GTGAATGCTG AAGGAACAGA CTGTTTAGAA GCCAAAGAAA   1080
AAGTCCATGT TATTGGAAAT CGGCTCAAAC TTCTCTTGAA GGAGGTCAGT CGTCATATCA   1140
AGGAACTGGA GAAGTTATTA GACGTGTCAA GTAGTCAGCA GGATTTGTCT TCCTGGTCTT   1200
CTGCTGATGA ACTGGACACC TCAGGGTCTG TGAGTCCCAY ATCAGGAAGG AGCACCCCAA   1260
ACAGACAGAA AACGCCACGA GGCAAGTGTA GTCTCTCACA GCCTGGACCC TCTGTCAGCA   1320
GTCCACATAG CAGGTCCACA AAAGGTGGCT CCGATTCCTC CCTTTCTGAG CCARGGCCAG   1380
GTCGGTCCGG CCGCGGCTTC CTGTTCAGAG TCCTCCGAGC AGCTCTTCCC CTTCAGCTTC   1440
TCCTGCTCCT CCTCATCGGG CTTGCCTGCC TTGTACCAAT GTCAGAGGAA GACTACAGCT   1500
GTGCCCTCTC CAACAACTTT GCCCGGTCAT TCCACCCCAT GCTCAGATAC ACGAATGGCC   1560
CTCCTCCACT CTGAACTAAG CAGATGCCAT CTGCAGAAGT GCTGGTAGCA TAAGGAGGAT   1620
```

CGGGTCATAA GCAATCCCAA ACTACCAACA AGAGGACCTT GATCTTGGCG AAAGCCMTCG 1680

GTGTGGCAGC TTTAGCCTCC TCCAGATCAC ATGTGTGCAA ATTATGGCTT CAGAGGTGGA 1740

AGATAAACAG TGACGGGGGA ACAAACAGAC AACAAGAAGG TTTGGAAGAA ATCTGGTTTG 1800

AGACTCTGAA CCTTAGCACT AAGGAGATTG AGTAAGGACC TCCAAAGTTC CCCGGACTCA 1860

TGAATTCTGG GCCCTTGGCC NATTCTGTGC ACAGCCAAGG ACTTCAGTAG ACCATCTGGG 1920

CAGCTTTCCC ATGGTGCTGC TCCAACCATC AGATAAATGA CCCTCCCAAG CACCATGTCA 1980

GTGTCGGTACA ATCTACCAAC CAACCAGTGC TGAAGAGATT TTAGAACCTT GTAACATACA 2040

ATTTTTAAGA GCTTATATGG CAGCTTCCTT TTTACCTTGT TTTCCTTTGG GGCATGATGT 2100

TTTAACCTTT GCTTTAGAAG CACAAGCTGT AAATCTAAAA GGCACTTTTT TTTAGAGGTA 2160

TAAAGAAAAA CTAGATGTAA TAAATAAGAT CATGGAAGGC TTTATGTGAA AAAAGTTGAA 2220

TGTTATAGTA AAAAAAAAAG ATATTTATGT ATGTACAGTT TGCTAAAGCC AAGTTTTGTT 2280

TGTATTGATT TCTTTGCATT TATTATAGAT ATTATAAAAT AAAAAAAAAA AAAAAAAAAC 2340

TCGAGGGGGG GCCCGGTACC CAATTCGCCC TATAGTGAG 2379

(2) INFORMATION FOR SEQ ID NO: 176:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1348 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 176:

GCGCCTTCAC GATGCCGGCG GTCAGTGGTC CAGGTCCCTT ATTCTGCCTT CTCCTCCTGC 60

TCCTGGACCC CCACAGCCCT GAGACGGGGT GTCCTCCTCT ACGCAGGTTT GAGTACAAGC 120

TCAGCTTCAA AGGCCCAAGG CTGGCATTGC CTGGGGCTGG AATACCCTTC TGGAGCCATC 180

ATGGAGGTGA GGGGCAGGGG TGGGGACCGC TATGCCCAGG GTCCCTCAAA GTGCTGGAGG 240

GGCTGTRACT TGGTGGGGAG TGGGTCTGTC ACAGCCATCC TCTGTCCAGG GTGGGGCAAG 300

GCCTGGGACA GTGCCAGGCA CCCCAGGACC CCTTCCAGGC TTGTCTCCTG CTCCACCGCC 360

[illegible] [illegible] CCAAGCTGTT TCTCCTCTGC CTCTCTNNTT [illegible] 420

[illegible]

CTGGGGGCTA CCTGGAGGGA AGCATCCTCA TCCCAGGTGA GTGGGCACCA GCCCTTCCCT 660

GTATGTGTGT TGTGGGTGGA AGTAGGCATG AGAGCATCTT AGCCCATAGG TTTGTATTCA 720

GGGACTTCCA AACCCAGACC TACAAAGAGT GTGTCTTCTA CCAGATCTTG TTCAAAAAAG 780

GGTTTGTGAT GATGGAACTA CACGATAGAG GGAGTGAGCA AGAACAATGA GGATTAGAGT 840

GGAGCGTGAA ATAGTCTAGG AGCATGGCTT CCAAAACATA TGCTGTGAGG TCTGTCCACC 900

TGAGAGTTGG GCCATGGATT TAATTCTGAG CCTCTTAGCA GGCAAAGCAA AGACAGAAAG 960

CAGATCGGCT GTGGATTTCT GTCTATAAAA TGTGAGTTCT TGGCCGGCTG CGGTGGCTCA 1020

CGCCTGTAAT CCCGGCGCTT TGGGAGGCCA GGGCGGATGG GTCGCGAGGT CAGGAGGTTG 1080

GAAACCATCC TGGCCGGAAT GGCGAAGCCC TGACTCTACT AGAAGTGCAA AGATTGGCTG 1140

GGTGTGGTGG CGTGCGCCTG TGGTCCCAGC TTCTCGGGAG GCTGAGGCGG GAGAGTTGCT 1200

TGGGCCCGGG AGGCCGAGGT TGCGGTGAGC TGAGATCCTG CCATTGCACT TCAGCCTGGG 1260

CACAGAGCCA GACTCTGGCT CAAAAAAAAA AAAAAAAAAA ACTCGAGGGG GGCCCGTACC 1320

CAATTCGCCG NATATGATCG TAAACAAT 1348

(2) INFORMATION FOR SEQ ID NO: 177:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1502 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 177:

CTCAAAATAA ATAAATAAAT AAAAATTTGT ATTCCATTGA TTTGGGTAGA CACCAGGAAT 60

GTGCATTTCT AACAAGCTTT CCAGGCGATC CTATAGTAAG TCATCTGTGG ACTACTTTAA 120

GAAACTCTTC TATAGAGAAT GGAGTTGGAT TAATAATAGG TGATTTTTTA CACTGGACTG 180

ATTCACAAGA ACCTAAACAG TAGTCCATGA AGCTGCTCAT CTGTGGTAAC TATTTGGCCC 240

CGTCTCACTC TGAAAGCAGC AGGAGATGTT GTTTACTTTG TTTCTATCCC CTTTGTCTGG 300

AGATTAATTT TGGAATGAAA GTTTTTCTCT CTATGCCATT CCTGGTTCTT TTCCAAAGCC 360

TCATACAAGA GGATTAGGTC ACAATGCATG CATTACCTTT TAAAAGAATG CGATATTGAT 420

ACCGATGCTT ACTTTTTTTT TTTTTNACTA CTTGTTTTAT TCCTTCCAGN AAAGTATAGC 480

CCGCCTTTCT ATAGCATAGT TCTCTTTAGG TGGAATGATT CCTATAAGAT TTCTCATTAT 540

TAAATCATGC ATTTTTCAAG ATGGAATCAA TMTTTGATTT AATCTAAGCT GATATTCTCA 600

TTTGTTAGAA GAACAACCTA CATGCTAGAG AGAGAGGAGG AAATATACCC ACGACCACAC 660

AGCCAGTTAG TATCCAGTTG GTGCTGGACT CCAGCCAGGT GTCCTGCCTC ATGGTAGTTA 720

AATGATATAT AGAAAAGGTA AATTTTTAAA GAAATATTTA TTAATATATT CCTATAAAAC 780

ATTTTAAAGG TAACCACATA AAAATGGTTA ATTTTTCCAT TCCAAAGTAA ATGCTAAGCA 840

TGTTTATTAA TGAAGCAGTA CTTCTGATTA GTATATGACA TTCTGAAGTT AATTAAACTC 900

ATTGCACTAA ATGTGTCTTC CTTGGTATAG TGGAGGATTT GAGGATTGGA ATATAGAGTA 960

GAGTGCTTGC TTAAGCCTGG GAGCCCATCT TTATAGCTAT TTGATGTAAG AAAAGAGACA 1020

TGGNCCATTT CTAAACTATA TAAGGTGAGT GTGTCTATTC CCAGCAGATA TAAAGGAAAA 1080

AGGAAACTTT TTTGATTCCC ACCTTCCCAG CCTCACCTAG CCATCTTCCA GCCTCAAATA 1140

TAGAGATGTT AGTGCAAGGT CCTGGGCTCT AGGTGATCAT TTCATAAGTC CTTTACAGAT 1200

AAAGAAAAAG TAGTGTTTGT ATGTTTGTTT TTAAGTAACC CCAAAACAAA TTTATATTGT 1260

ATTCAGCAAA ATTGGAATTC AGGTGTTTAA TTTTAGAACA TGAAGTGCCT GCTGTTTTAA 1320

GCATTGACTT GTATAAAAAG AATTGCATGT CTCCAGTAAG CTTATGGGTT TTCTCATTTT 1380

TAGGTATATG GCTTTTAATC ATGTAAAGTG AAACATTAGT TTTCTTGCAT TTTATTACAG 1440

GTTCTTTGTT GCAATAAAGA TGCTGCTGAA ATTAATTGAA AAAAAAAAAA AAAAAAACTC 1500

GA 1502

(2) INFORMATION FOR SEQ ID NO: 178

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1637 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 178:

ATTTTCTAGC CCACAAGGAC TGAAGTTCAG ATCCAAAAGT TCACTTGCTA ATTATCTTCA 60

CAAAAATGGA GAGACTTCTC TTAAGCCAGA AGATTTTGAT TTTACTGTAC TTTCTAAAAG 120

GGGTATCAAG TCAAGATATA AAGACTGCAG CATGGCAGCC CTGACATCCC ATCTACAAAA 180

CCAAAGTAAC AATTCAAACT GGAACCTCAG GACCCGAAGC AAGTGCAAAA AGGATGTGTT 240

TATGCCGCCA AGTAGTAGTT CAGAGTTGCA GGAGAGCAGA GGACTCTCTA ACTTTACTTC 300

[illegible]

TAAAGCAGAT GCTGAAAGTG AACCTGTTGC ACAAAAAAGT CAGCTTGATA GAACTGTCTG 540

CATTTCTGAT GCTGGAGCAT GTGGTGAGAC CCTCAGTGTG ACCAGTGAAG AAAACAGCCT 600

TGTAAAAAAA AAAGAAAGAT CATTGAGTTC AGGATCAAAT TTTTGTTCTG AACAAAAAAC 660

TTCTGGCATC ATAAACAAAT TTTGTTCAGC CAAAGACTCA GAACACAACG AGAAGTATGA 720

GGATACCTTT TTAGAATCTG AAGAAATCGG AACAAAAGTA GAAGTTGTGG AAAGGAAAGA 780

ACATTTGCAT ACTGACATTT TAAAACGTGG CTCTGAAATG GACAACAACT GCTCACCAAC 840

CAGGAAAGAC TTCACTGAAG ATACCATCCC ACGGAACACA GATAGAAAGA AGGAAAACAA 900

GCCTGTATTT TTCCAGCAAA TATAACAAAG AAGCTCTTAG CCCCCCACGA CGTAAAGCCT 960

TTAAGAAATG GACACCTCCT CGGTCACCTT TTAATCTCGT TCAAGAAACA CTTTTTCATG 1020

ATCCATGGAA GCTTCTCATC GCTACTATAT TTCTCAATCG GACCTCAGGC AAAATGGCAA 1080

TACCTGTGCT TTGGAAGTTT CTGGAGAAGT ATCCTTCAGC TGAGGTAGCA AGAACCGCAG 1140

ACTGGAGAGA TGTGTCAGAA CTTCTTAAAC CTCTTGGTCT CTACGATCTT CGGGCAAAAA 1200

CCATTGTCAA GTTCTCAGAT GAATACCTGA CAAAGCAGTG GAAGTATCCA ATTGAGCTTC 1260

ATGGGATTGG TGCACCCTGA AGACCACAAA TTAAATAAAT ATCATGACTG GCTTTGGGAA 1320

AATCATGAAA AATTAAGTCT ATCTTAAACT CTGCAGCTTT CAAGCTCATC TGTTATGCAT 1380

AGCTTTGCAC TTCAAAAAAG CTTAATTAAG TACAACCAAC CACCTTTCCA GCCATAGAGA 1440

TTTTAATTAG CCCAACTAGA AGCCTAGTGT GTGTGCTTTC TTAATGTGTG TGCCAATGGT 1500

GGATCTTTGC TACTGAATGT GTTTGAACAT GTTTTGAGAT TTTTTTAAAA TAAATTATTA 1560

TTTGACAACA ATCCAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1620

AAAAAAAAAA AAAAAAA 1637

(2) INFORMATION FOR SEQ ID NO: 179:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2911 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179:

GGTGGTTTTT GTTCTGCAAT AGGCGGCTTA GAGGGAGGGG CTTTTTCGCC TATACCTACT 60

GTAGCTTCTC CACGTATGGA CCCTAAAGGC TACTGCTGCT ACTACGGGGC TAGACAGTTA 120

CTGTCTCAGC TCTAGGATGT GCGTTCTTCC ACTAGAAGCT CTTCTGAGGG AGGTAATTAA 180

AAAACAGTGG AATGGAAAAA CAGTGCTGTA GTCATCCTGT AATATGCTCC TTGTCAACAA 240

TGTATACATT CCTGCTAGGT GCCATATTCA TTGCTTTAAG CTCAAGTCGC ATCTTACTAG 300
TGAAGTATTC TGCCAATGAA GAAAACAAGT ATGATTATCT TCCAACTACT GTGAATGTGT 360
GCTCAGAACT GGTGAAGCTA GTTTTCTGTG TGCTTGTGTC ATTCTGTGTT ATAAAGAAAG 420
ATCATCAAAG TAGAAATTTG AAATATGCTT CCTGGAAGGA ATTCTCTGAT TTCATGAAGT 480
GGTCCATTCC TGCCTTTCTT TATTTCCTGG ATAACTTGAT TGTCTTCTAT GTCCTGTCCT 540
ATCTTCAACC AGCCATGGCT GTTATCTTCT CAAATTTTAG CATTATAACA ACAGCTCTTC 600
TATTCAGGAT AGTGCTGAAG ANGCGTCTAA ACTGGATCCA GTGGGCTTCC CTCCTGACTT 660
TATTTTTGTC TATTGTGGCC TTGACTGCCG GGACTAAAAC TTTACAGCAC AACTTGGCAG 720
GACGTGGATT TCATCACGAT GCCTTTTTCA GCCCTTCCAA TTCCTGCCTT CTTTTCAGAA 780
ATGAGTGTCC CAGAAAAGAC AATTGTACAG CAAAGGAATG GACTTTTCCT GAAGCTAAAT 840
GGAACACCAC AGCCAGAGTT TTCACTCACA TCCGTCTTGG CATGGGCCAT GTTCTTATTA 900
TAGTCCAGTG TTTTATTTCT TCAATGGCTA ATATCTATAA TGAAAAGATA CTGAAGGAAG 960
GGAACCAGCT CACTGAARGC ATCTTCATAC AGAACAGCAA ACTCTATTTC TTTGGCATTC 1020
TGTTTAATGG GCTGACTCTG GGCCTTCAGA GGAGTAACCG TGATCAGATT AAGAACTGTG 1080
GATTTTTTTA TGGCCACAGT GCATTTTCAG TAGCCCTTAT TTTTGTAACT GCATTCCAGG 1140
GCCTTTCAGT GGCTTTCATT CTGAAGTTCC TGGATAACAT GTTCCATGTC TTGATGGCCC 1200
AGGTTACCAC TGTCATTATC ACAACAGTGT CTGTCCTGGT CTTTGACTTC AGGCCCTCCC 1260
TGGAATTTTT CTTGGAAGCC CCATCAGTCC TTCTCTCTAT ATTTATTTAT AATGCCAGCA 1320
AGCCTCAAGT TCCGGAATAC GCACCTAGGC AAGAAAGGAT CCGAGATCTA AGTGGCAATC 1380
TTTGGGAGCG TTCCAGTGGG GATGGAGAAG AACTAGAAAG ACTTACCAAA CCCAAGAGTG 1440
ATGAGTCAGA TGAAGATACT TTCTAACTGG TACCCACATA GTTTGCAGCT CTCTTGAACC 1500
TTATTTTCAC ATTTTCAGTG TTTGTAATAT TTATCTTTTC ACTTTGATAA ACCAGAAATG 1560
TTTCTAAATC CTAATATTCT TTGCATATAT CTAGCTACTC CCTAAATGGT TCCATCCAAG 1620
GCTTAGAGTA CCCAAAGGCT AAGAAATTCT AAAGAACTGA TACAGGAGTA ACAATATGAA 1680
GAATTCATTA ATATCTCAGT ACTTGATAAA TCAGAAAGTT ATATGTGCAG ATTATTTTCC 1740
TTGGCCTTCA AGCTTCCAAA AAACTTGTAA TAATCATGTT AGCTATAGCT TGTATATACA 1800

[illegible]

TACCTGGCCA TACCATAGAT TTGGGATGAT GTAGTCTGTG CTAAATATTT TTCTGAAGAA 2040

GCAGTTTCTC AGACACAACA TCTCAGAATT TTAATTTTTA GAAATTCATG GGAAATTGGA 2100

TTTTTGTAAT AATCTTTTGA TGTTTTAAAC ATTGGTTCCC TAGTCACCAT AGTTACCACT 2160

TGTATTTTAA GTCATTTAAA CAAGCCACGG TGGGGCTTTT TTCTCCTCAG TTTGAGGAGA 2220

AAAATCTTGA TGTCATTACT CCTGAATTAT TACATTTTGG AGAATAAGAG GGCATTTTAT 2280

TTTATTAGTT ACTAATTCAA GCTGTGACTA TTGTATATCT TTCCAAGAGT TGAAATGCTG 2340

GCTTCAGAAT CATACCAGAT TGTCAGTGAA GCTGATGCCT AGGAACTTTT AAAGGGATCC 2400

TTTCAAAAGG ATCACTTAGC AAACACATGT TGACTTTTAA CTGATGTATG AATATTAATA 2460

CTCTAAAAAT AGAAAGACCA GTAATATATA AGTCACTTTA CAGTGCTACT TCACACTTAA 2520

AAGTGCATGG TATTTTTCAT GGTATTTTGC ATGCAGCCAG TTAACTCTCG TAGATAGAGA 2580

AGTCAGGTGA TAGATGATAT TAAAAATTAG CAAACAAAAG TGACTTGCTC AGGGTCATGC 2640

AGCTGGGTGA TGATAGAAGA GTGGGCTTTA ACTGGCAGGC CTGTATGTTT ACAGACTACC 2700

ATACTGTAAA TATGAGCTTT ATGGTGTCAT TCTCAGAAAC TTATACATTT CTGCTCTCCT 2760

TTCTCCTAAG TTTCATGCAG ATGAATATAA GGTAATATAC TATTATATAA TTCATTTGTG 2820

ATATCCACAA TAATATGACT GGCAAGAATT GGTGGAAATT TGTAATTAAA ATAATTATTA 2880

AACCTAAAAA AAAAAAAAAA AAAAACTCGA G 2911

(2) INFORMATION FOR SEQ ID NO: 180:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 519 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 180:

GGCACGAGCC CCAGGCCAGC CAGGGCCAGG CCTACTTTGG CCACCCTTAA ATTAGAATGT 60

GGGGTCAGGG GTCACAGAAA AGCCATTTCT CTGACCTAGT GTTTGGCGTC CGGGAACTCT 120

GTGCCCAACC TTCAGACCCT GGCAGTCCTC ACTGAGGCCA TTGGCCCAGA GCCCGCCATC 180

CCCCGARACC CCCGGGAGCC GCCTGTTGCC ACGTCCACAC CTGCCACACC CTCTGCCGGG 240

CCCCAGCCCC TCCCAACCGG GACCGTGCTG GTCCCTGGGG GTCCTGCCCC ACCTTGCCTT 300

GGGGAGGCAT GGGCCCTCCT CCTCCCACCC TGCCGGCCGT CACTCACCTC TTGCTTCTGG 360

TCCCCCAGGC CTAGCCCTTG GAAGGAGACA GGAGTCTAGG GAGGCTGAAG CCCACTCCCG 420

GGGAGGCCCG TGCTCCTCCA GCCCCAGGGA CAGCAAGGAA AAGAGAAGAG AGCAGAGCAT 480

TTCATGGCTC TAATAAAAAA AAAAAAAAAA AAAACTCGA 519

(2) INFORMATION FOR SEQ ID NO: 181:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 968 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 181:

```
TCCCCTTGGG GCCGGAAAAA GCGGGGTTGG CCTGNCCATT GGTTNTCCAT GCCGCCCGCC      60
CATGCCCCAG TACTAGCCTG CAGTCCCAAT GTAGCCCCTC CCTCYTCCMA GAGCCCYTCM     120
AACCGCCCCG STCANTTGTG ATTTCAGGAG GATTTGATGA AGATGTTAAA GCGAAAGTGG     180
AGAACCTTCT CGGGATTTCC AGCCTGGAAA AAACGGACCC TGTTAGGCAA GCACCCTGCA     240
GCCCTCCCTG TCCCCTTCTT CCCCTCCCCT TCYCCCGCCC GTGGAGACAG CTGTTYTCAG     300
CAGGGCTCTC CGCAGGGAGG GGGCCGGCTC CTTCCCTGGC AGCAACATCC TTGCCCTTGT     360
CACACAAGTC AGCCTCCATC TGCGCAGCTC TGTGGATGCG CTGCTGGAGG GCAACAGGTA     420
TGTCACTGGC TGGTTCAGCC CCTACCACCG CCAGCGGAAG CTCATCCACC CGGTCATGGT     480
TCAGCACATC CAGCCCGCAG CGCTCAGCCT CCTGGCACAG TGGAGCACCC TCGTGCAGGA     540
GCTGGAGGCT GCCCTGCAGC TGGCTTTCTA CCCCGATCCC GTGGAGGAGT GGCTGGAGGA     600
AAACGTGCAC CCCAGCCTGC AGCGGCTGCA ARCTCTGCTG CAGGACCTCA GCGAGGTGTC     660
TGCCCCCCCG CTGCCACCCA CCAGCCCTGG CAGGGACGTT GCTCAGGACC CCTGAGGGGA     720
GAGCTCATGC CAGGGGGCTC CTGCTGGAGG CTGGGGGGGC TCTGCWYTKY CWWWTGGCCT     780
CGGCAATACG GCCCACGTGG GCGTCGTGCC CTCTGGCCCA GCAGTGTCTT GCCCACACTC     840
AGTTCCTGAG GGCCCTGGGC AGCCCCTGGG GGAGAGACTA GAAAACACAG AAGGAAGCAG     900
CACAGGGAGA CCCCCTTTGT GATCTGCATG TGTGACACTG ATTCTTTGGA AATAAAGAGT     960
GGAAGCTG                                                              968
```

(2) INFORMATION FOR SEQ ID NO: 182:

STRANDEDNESS:
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 182:

```
TGTAAAAGTT ATCAGTAATC CTAATTCTTT TCCTGGGTTT TCCTTTTGTC ACTTATTAAT      60
CAGTTTTTGA AAGGACGAAT GAATTTAGAG ATGTACTCTG GAGCAGTATC ATGTTAAACC     120
AGGGGTATAT TAGAAAAATC ATCCTCATAA TCATTCTGGG AAGTTTTTCC TCCCCAAAAA     180
AAGCCATCCT GATGGGTTTT CAAAACCAGA AAAAAGCTCT TAATGAGGAA CAGACCACTG     240
GAGTACCCAT GAGCATCTCA GGAAAACTGA GACCCTCGAG AAGCCTTGAT TTCGTGCAAC     300
CCCCAAGGTT TCAGAGCCAG CAGCCCAGTG CTGTGGTTGA CAGACGTGGT TTTKTGGRGA     360
AAGCAGCCAG AGGCCAGGAA TTTTCAGAGT CGTGAGTCAC GRTYTCCCAC CCAAGATTAG     420
AGCAMAGATT AGCCATACTG AGATTTGGTA AAATCATTCT GTCTAAGCAA TGGAGGTGTG     480
TGCAMACCTG CAGTGCCTGT TCACAGGGGA TGCAGGCAGA TCSYGGGTTT AGGATGGGGR     540
AGGCCACCGC ACCCCCTTTC AYTGCTCTGC ACCTGCTCCC TCACGTGGAC ACTGTCCACA     600
ACTGTGGCTC TCACAGGACA GTTGCCCAAG GAGCTCATAT CTTATTGGAG ATAGGGGGTC     660
GTACAGGTGA CATTCATGAG CAGTGTGAGC CGGGTGACAT GGGGGTGTCA ACCCAGCATC     720
TGTCCAGGAG CTCCTCCTGC AGCGGCTCTG GCAGGTGGCC TGAGGCTCCT TTTTGAGAGA     780
GAACTGTTTG GCCTTCCTGT CTCCTCTCCT CTGATCTGTT CTTTCTTGGA ACACCACCCA     840
AGAACCTCAC CTCCTCCATC AGATTGTGAG CTCCTGGAGG GCAGGAGCTG TGTCCTTCTA     900
TTCATCTTCC TATCCCCAGA ACCTTGCACA GATCCTGGAA TGTGGTAGGT GCTCAGTAAA     960
TGTGTGTTGA ATAAATGAAT GAATGAATGA ACAAATGAAT GAATTTGCTT ACTTCAAGGC    1020
AAAAGAACCA TGAAACTGTA TTTTGAGTTT CTATGTTATA GCAGTCAGCA AATCCTATTA    1080
AATACTTTGT GTTTCCAAGC AAAAAAAAAA AAAAAAAAAA AAACTCGA                 1128
```

(2) INFORMATION FOR SEQ ID NO: 183:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2276 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 183:

```
CCGCGGCGTC TGACCTCATG GCGTAGAGCC TAGCAACAGC GCAGGCTCCC AGCCGAGTCC      60
GTTATGGCCG CTGCCGTCCC GAAGAGGATG AGGGGGCCAG CACAAGCGAA ACTGCTGCCC     120
GGGTCGGCCA TCCAAGCCCT TGTGGGGTTG GCGCGGCCGC TGGTCTTGGC GCTCCTGCTT     180
GTGTCCGCCG CTCTATCCAG TGTTGTATCA CGGACTGATT CACCGAGCCC AACCGTACTC     240
```

AACTCACATA TTTCTACCCC AAATGTGAAT GCTTTAACAC ATGAAAACCA AACCAAACCT 300
TCTATTTCCC AAATCAGCAC CACCCTCCCT CCCACGACGA GTACCAAGAA AAGTGGAGGA 360
GCATCTGTGG TCCCTCATCC CTCGCCTACT CCTCTGTCTC AAGAGGAAGC TGATAACAAT 420
GAAGATCCTA GTATAGAGGA GGAGGATCTT CTCATGCTGA ACAGTTCTCC ATCCACAGCC 480
AAAGACACTC TAGACAATGG CGATTATGGA GAACCAGACT ATGACTGGAC CACGGGCCCC 540
AGGGACGACG ACGAGTCTGA TGACACCTTG GAAGAAAACA GGGGTTACAT GGAAATTGAA 600
CAGTCAGTGA AATCTTTTAA GATGCCATCC TCAAATATAG AAGAGGAAGA CAGCCATTTC 660
TTTTTTCATC TTATTATTTT TGCTTTTTGC ATTGCTGTTG TTTACATTAC ATATCACAAC 720
AAAAGGAAGA TTTTTCTTCT GGTTCAAAGC AGGAAATGGC GTGATGGCCT TTGTTCCAAA 780
ACAGTGGAAT ACCATCGCCT AGATCAGAAT GTTAATGAGG CAATGCCTTC TTTGAAGATT 840
ACCAATGATT ATATTTTTTA AAGCACTGTG ATTTGAATTT GCTTATGTAA TTTTATTTGC 900
TTGACTTTTT ATATGATATT GTGCAAATGT TTGCCATACG CAATTGGTAC TTAAATGAGA 960
GGTGAGTCTC TCTTTTGCCT TGGTGCTTTG GAAATTAAAT GTCACAAACG AGTATATAAT 1020
TTTTTATCTG TACTTTTAGA GCTGAGTTTA ATCAGGTGTC CAAAATGTGA GTTAAACATT 1080
ACCTTATATT TACACTGTTA GTTTTTATTG TTTTAGATTT ATTATGCTTC TTCTGGAAGT 1140
ATTAGTGATG CTACTTTTAA AAGATCCCAA ACTTGTAACT AAATTCTGAC ATATCTGTTA 1200
CTGCTGACTC ACATTCATTC TCCGCCATTC AAATACTATT TTTTATCCAC ATTTTTTTTT 1260
GTTCCCAAAC TGTAATGTAC AAGGATATGT GTGATAATGC TTTGGATTTG AGTAATATTT 1320
TTTTTTCTTC CAAGAAAACT GCTTTGGATA TTTTTAGATA ATTTAAACAT AATTTAGGAT 1380
AATGATATTG CTCAATCTGA CCACAATTTT AGGTAAAACA TTAAATGTGT CAGAAATCTT 1440
GGCAACAGAG ACTCTGCAGC TTGCAGTGGA CATAGATAAA ATGTTACAGA GATACTATTT 1500
TTTTGGTTGG AATTACTATA TTAAATTTAG AAGCAGAAAC TGGTAAAATG TTAAATACAT 1560
GTACAATTGC TTTTAGTTAG CAATTCATTG TAGCATGCGT TCCTCCAAGG TTTCAAGCAA 1620
TGGGCAGAGT TTAAAATTAT ATCAGATTCG TTTACTTCGT TTATTATTTT ACAGTAAATT 1680
TGAATAAATC TTAGGGGTCA TTATCACTTA AATAATACTG TACCTAGGTC TTTCAAATTA 1740
AAATTATACC TGAATGAAGT TGTTTGTATA CATAAAGGAT ATTTGTGTAC AATTACCTTT 1800

TTTGAACTAT GTTTGACTTA [illegible] [illegible] [illegible] [illegible] [illegible]
TATTTTAACT AGGACCCGCG TGAGCCAGTG GGCTTG[illegible]T TTATTTAGAG CTGGAAGAAG 2040

GCCGTCCATC CTGTCTCTTG GGCGGACAGT GTACTTTCCT AATAGGGAAG GGAAGCACAA 2100

TGGAAATACC CCTGAACCGT TTTATTGCAG TAATTTTTTT CATATCTGAA ACTATTATTT 2160

AATATTTTGA ATAAGATTTT AAAAAATAAA TGGCAAAGAT ATAAATCTAA AAAAAAAAAA 2220

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAA 2276

(2) INFORMATION FOR SEQ ID NO: 184:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2500 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 184:

TCCAAGCTAC GCCACTCGGG CTGGGGCGTT GGGAGCGGGA GTGCAGAGCG TGGTCGTGGC 60

GGCGGCGGTG AGAAGAGCGA GGCGKAGGAG GGGGTGCCAT GGCCGGGCAG CAGTTCCAGT 120

ACGATGACAG TGGGAACACC TTCTTCTACT TCCTCACCTC CTTCGTGGGG CTCATCGTGA 180

TCCCGGCGAC ATACTACCTC TGGCCCCGAG ATCAGAATGC CGAGCAAATT CGATTAAAGA 240

ATATCAGAAA AGTATATGGA AGGTGTATGT GGTACGTTTA CGGTTATTAA AACCCCAGCC 300

AAATATTATT CCTACAGTAA AGAAAATAGT TCTGCTTGCA GGATGGGCAT TGTTCTTATT 360

CCTTGCATAT AAAGTTTCCA AAACAGACCG AGAATACCAA GAATACAATC CTTATGAAGT 420

ATTAAATTTG GATCCTGGAG CCACAGTAGC AGAAATTAAA AAACAATATC GTTTGCTGTC 480

ACTTAAATAT CATCCAGATA AAGGAGGTGA TGAGGTTATG TTCATGAGGA TAGCAAAAGC 540

TTATGCTGCT TTAACGGATG AAGAGTCCCG GAAAAATTGG GAAGAATTTG GAAATCCAGA 600

TGGGCCTCAA GCCACAAGCT TTGGAATTGC CCTGCCAGCT TGGATAGTTG ACCAGAAAAA 660

TTCAATTCTG GTTTTACTTG TATATGGATT GGCATTTATG GTTATCCTTC CAGTTGTTGT 720

GGGCTCTTGG TGGTATCGCT CAATACGCTA TAGTGGAGAC CAGATTCTAA TACGSACAAC 780

ACAGATTTAT ACATACTTTG TTTATAAAAC CCGAAATATG GATATGAAAC GTCTTATCAT 840

GGTTTTGGST GGAGCTTCTG AATTTGATCC TCAGTATAAT AAAGATGCCA CAAGCAGACC 900

AACGGATAAT ATTCTAATAC CACAGCTAAT CAGAGAAATT GGCAGCATTA ATTTAAAGAA 960

GAATGAGCCT CCACTTACCT GCCCATATAG CCTGAAGGCC AGAGTTCTTT TACTGTCTCA 1020

TCTTGCTAGA ATGAAAATTC CTGAGACCCT TGAAGAAGAT CAGCAATTCA TGCTAAAAAA 1080

GTGTCCTGCC CTACTTCAAG AAATGGTTAA TGTAATCTGC CAACTAATAG TAATGGCCCG 1140

GAACCGTGAA GAAAGGGAGT TTCGTGCTCC AACTTTGGCA TCCCTAGAAA ACTGCATGAA 1200

GCTTTCTCAG ATGGCCGTTC AGGGACTTCA GCAATTTAAG TCTCCCCTTC TGCAGCTCCC 1260

TCATATTGAA GAGGACAATC TTAGACGGGT TTCTAATCAT AAGAAGTATA AAATTAAAAC 1320

TATCCAGGAT TTGGTGAGTT TAAAAGAATC AGATCGTCAC ACTCTACTGC ACTTCCTTGA 1380

AGATGAAAAA TATGAAGAGG TTATGGCTGT CCTTGGGAGT TTTCCATATG TGACCATGGA 1440

TATAAAATCA CAGGTGTTAG ATGATGAACA TAGCAACAAC ATCACAGTAG GATCCTTAGT 1500

TACACTGTTG GTTAAGTTCA CAAGGTAAAC AATGGCTGAA GTATTTGAAA AGGAGCAGTC 1560

CATCTGTGCT GCAGAGGAAC AGCCAGCAGA AGATGGGCAG GGTGAAACTA ACAAGAACAG 1620

GACAAAAGGA GGATGGCAAC AGAAGAGTAA AGGACCCAAG AAAACTGCTA AATCAAAAAA 1680

AAAGAAACCT TTAAAAAAAA AACCTACACC TGTGCTATTA CCACAGTCAA AGCAACAGAA 1740

ACAAAAGCAG GCAAATGGAG TCGTTGGGAA TGAAGCTGCA GTAAAGGAAG ATGAAGAAGA 1800

AGTTTCAGAT AAGGGCAGTG ATTCTGAAGA AGAAGAAACC AATAGAGATT CCCAAAGTGA 1860

GAAAGATGAT GGTAGTGACA GAGACTCTGA TAGAGAGCAA GATGAAAAAC AAAACAAAGA 1920

TGATGAAGCA GAGTGGCAAG AATTACAACA AAGCATACAG CGAAAAGAGA GAGCTCTATT 1980

GGAAACCAAA TCAAAAATAA CACATCCTGT GTATAGCCTT TACTTTCCTG AGGAAAAACA 2040

AGAATGGTGG TGGCTTTACA TTGCAGATAG GAAGGAGCAG ACATTAATAT CCATGCCATA 2100

TCATGTGTGT ACGCTGAAAG ATACAGAGGA GGTAGAGCTG AAGTTTCCTG CACCAGGCAA 2160

GCCTGGAAAT TATCAGTATA CTGTGTTTCT GAGATCAGAC TCCTATATGG GTTTGGATCA 2220

GATTAAACCA TTGGAAGTTK GGAAGTTCAT GAGGCTGAAG CCTGTGCCAG AAAATCACCC 2280

ACAGTGGGAT ACAGCAATAG AGGGGGATGA AGACCAGGAG GACAGTGAGG GCTTTGAAGA 2340

TAGCTTTGAG GGAGGAAGAG GGAGGGAGGA AGGAAGGTGG TGGACTTAAG GCAGTTACTC 2400

TGGAATGGGA CCCACAGTGT TTTGCACCAT ATTTTGGCAA TTTTTTTTGC CCGTTTTTNG 2460

GAAGTGTTTT CCNTNAANCC CAGGAACCAT TACAGAACCG 2500

(2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 1337 base pairs

[illegible]

TCTCCCTGGC GTTTGGTCAC CTCTGCTTCA TTCTCCACCG CGCCTATGGT CCCTCTTGGA 120

GCCAGCGTGG CGGGCCTGGC GGCTCCCGGG TGGTGAGAGA GCGGTCCGGG AACGATGAAG 180

GCCTTGCAGT GCTGCTGCTG TCTCAGCCAC CTCTTGGCTT CCGTCCTCCT CCTGCTGTTG 240

CTGCCTGAAC TAAGCGGGYC CCTGGMAGTC CTGCTGCAGG CAGCCGAGGC CGCGCCAGGT 300

CTTGGGCCTC CTGACCCTAG ACCACGGACA TTACCGCCGC TGCCACCGGG CCCTACCCCT 360

GCCCAGCAGC CGGGCCGTGG TCTGGCTGAA GCTGCGGGGC CGCGGGGCTC CGAGGGAGGC 420

AATGGCAGCA ACCCTGTGGC CGGGCTTGAG ACGGACGATC ACGGAGGGAA GGCCGGGGAA 480

GGCTCGGTGG GTGGCGGCCT TGCTGTGAGC CCCAACCCTG GCGACAAGCC CATGACCCAG 540

CGGGCCCTGA CCGTGTTGAT GGTGGTGAGC GGCGCGGTGC TGGTGTACTT CGTGGTCAGG 600

ACGGTCAGGA TGAGAAGAAG AAACCGAAAG ACTAGGAGAT ATGGAGTTTT GGACACTAAC 660

ATAGAAAATA TGGAATTGAC ACCTTTAGAA CAGGATGATG AGGATGATGA CAACACGTTG 720

TTTGATGCCA ATCATCCTCG AAGATAAGAA TGTGCCTTTT GATGAAAGAA CTTTATCTTT 780

CTACAATGAA GAGTGGAATT TCTATGTTTA AGGAATAAGA AGCCACTATA TCAATGTTGG 840

GGGCGTATTT AAGTTACATA TATTTTAACA ACCTTTAATT TGCTGTTGCA ATAAATACCG 900

TATCCTTTTA TTATATCTTT ATATGTATAG AAGTACTCTR TTAATGGGCT CAGAGATGTT 960

GGGGATAAAG TATACTGTAA TAATTTATCT GTTTGAAAAT TACTATAAAA CGGTGTTTTC 1020

TGATCGGTTT TTGTTTCCTG CTTACCATAT GATTGTAAAT TGTTTTATGT ATTAATCAGT 1080

TAATGCTAAT TATTTTTGCT GATGTCATAT GTTAAAGAGC TATAAATTCC AACAACCAAC 1140

TGGTGTGTAA AAATAATTTA AAATTTCCTT TACTGAAAGG TATTTCCCAT TTTTGTGGGG 1200

AAAAGAAGCC AAATTTATTA CTTTGTGTTG GGGTTTTTAA AATATTAAGA AATGTCTAAG 1260

TTATTGTTTG CAAAACAATA AATATGATTT TAAATTCTCT TAAAAAAAAA AAAAAAAACC 1320

CCGGGGGGGG GCCCGGN 1337

(2) INFORMATION FOR SEQ ID NO: 186:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 941 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186:

GGCACGAGCC TGGACGCAGC AGCCACCGCC GCGTCCCTCT CTCCACGAGG CTGCCGGCTT 60

AGGACCCCCA GCTCCGACAT GTCGCCCTCT GGTCGCCTGT GTCTTCTCAC CATCGTTGGC 120

CTGATTCTCC CCACCAGAGG ACAGACGTTG AAAGATACCA CGTCCAGTTC TTCAGCAGAC 180

TCAACTATCA TGGACATTCA GGTCCCGACA CGAGCCCCAG ATGCAGTCTA CACAGAACTC 240

CAGCCCACCT CTCCAACCCC AACCTGGCCT GCTGATGAAA CACCACAACC CCAGACCCAG 300

ACCCAGCAAC TGGAAGGAAC GGATGGGCCT CTAGTGACAG ATCCAGAGAC ACACAAGAGC 360

ACCAAAGCAG CTCATCCCAC TGATGACACC ACGACGCTCT CTGAGAGACC ATCCCCAAGC 420

ACAGACGTCC AGACAGACCC CCAGACCCTC AAGCCATCTG GTTTTCATGA GGATGACCCC 480

TTCTTCTATG ATGAACACAC CCTCCGGAAA CGGGGGCTGT TGGTCGCAGC TGTGCTGTTC 540

ATCACAGGCA TCATCATCCT CACCAGTGGC AAGTGCAGGC AGCTGTCCCG GTTATGCCGG 600

AATCATTGCA GGTGAGTCCA TCAGAAACAG GAGCTGACAA CCYGCTGGGC ACCCGAAGAC 660

CAAGCCCCCT GCCAGCTCAC CGTGCCCAGC CTCCTGCATC CCCTCGAAGA GCCTGGCCAG 720

AGAGGGAAGA CACAGATGAT GAAGCTGGAG CCAGGGCTGC CGGTCCGAGT CTCCTACCTC 780

CCCCAACCCT GCCCGCCCCT GAAGGCTACC TGGCGCCTTG GGGGCTGTCC CTCAAGTTAT 840

CTCCTCTGYT AAGACAAAAA GTAAAGCACT GTGGTCTTTG CAAAAAAAAA AAAAAAAAAA 900

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAACTCG A 941

(2) INFORMATION FOR SEQ ID NO: 187:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 654 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 187:

GAATTCGGCA CGAGGCAGCT TGTGCTTTAA AGGAGGTGTT CAAAGCATGT CTGAGCAGAG 60

ACTTTTGGGC TCTGTTTTAA TTAATACTTT AAAATAATTC ATATTTAAAA TATCARATGT 120

TTCCATAAAG AGGAGGATGT TTAAATGCCT CCAGACTACA TTCCTTTTTA TTSCTTGATT 180

TTACCTGGGA GTCCAAAGTT CAATTCCCAT AAAGCAAGCG TTTTATTTGT CACTTTCAAT 240

ATACATCCGA TTGCCATGCT TAAGATGCAA TATGGCTGC GGAAATAGGT TAACCCACAG 300

[illegible] 360

[illegible]

TACTAAAAAT ACAAAAATTA GCCGGGCATG GT[illegible] [illegible] TA[illegible] 540

GGAGGCTGAG GCAGGAGAAT CGTTTGAATC TGGGAGTTGG AGGTTGTCAG TGAGCTGAGA 600

TCGCGCCACA GCACTCCAGC CTGGGTGACA GGGTGAGACT CTGTCTCAAA NAGA 654

(2) INFORMATION FOR SEQ ID NO: 188:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1848 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188:

GAAACTGGAC CGGAGAACCG GAGCGAAGCG AAGCGGAAGC CCGGAATGAG GCCGGACTGG 60

AAAGCCGGAG CGGGCCAGG CGGGCTCCC CAAAAGCCTG CCCCTTCATC CCAGCGGAAA 120

CCGCCGGCCC GGCCGAGCGC GGCGGCCGCT GCGATTGCAG TCGCGGCGGC GGAGGAAGAG 180

AGACGGCTCC GGCAGCGGAA CCGCCTGAGG CTGGAGGAGG ACAAACCGGC CGTGGAGCGG 240

TGCTTGGAGG AGCTGGTCTT CGGCGACGTC GAGAACGACG AGGACGCGTT GCTGCGGCGT 300

CTGCGAGGCC CGAGGGTTCA AGAACATGAA GACTCGGGTG ACTCAGAAGT GGAGAATGAA 360

GCAAAAGGTA ATTTTCCACC TCAAAAGAAG CCAGTTTGGG TCGATGAAGA AGATGAAGAT 420

GAGGAAATGG TTGACATGAT GAACAATCGG TTTCGGAAGG ATATGATGAA AAATGCTAGT 480

GAAAGTAAAC TTTCGAAAGA CAACCTTAAA AAGAGACTTA AAGAAGAATT CCAACATGCC 540

ATGGGAGGAG TACCTGCCTG GGCAGAGACT ACTAAGCGGA AAACATCTTC AGATGATGAA 600

AGTGAAGAGG ATGAAGATGA TTTGTTGCAA AGGACTGGGA ATTTCATATC CACATCAACT 660

TCTCTTCCAA GAGGCATCTT GAAGATGAAG AACTGCCAGC ATGCGAATGC TGAACGTCCT 720

ACTGTTGCTC GGATCTCCAT CTGTGCAGTT CCATCCCGGT GCACAGATTG TGATGGTTGC 780

TGGGATTAGA TAATGCTGTA TCACTATTTC AGGTTGATGG GAAAACAAAT CCTAAAATTC 840

AGAGCATCTA TTTGGAAAGG TTTCCAATCT TTAAGGCTTG TTTTAGTGCT AATGGGGAAG 900

AAGTTTTAGC CACGAGTACC CACAGCAAGG TTCTTTATGT CTATGACATG CTGGCTGGAA 960

AGTTAATTCC TGTGCATCAA GTGAGAGGTT TGAAAGAGAA GATAGTGAGG AGCTTTGAAG 1020

TCTCCCCAGA TGGGTCCTTC TTGCTCATAA ATGGCATTGC TGGATATTTG CATTTGCTAG 1080

CAATGAAGAC CAAAGAACTG ATTGGAAGCA TGAAAATTAA TGGAAGGGTT GCAGCATCCA 1140

CATTCTCTTC AGATAGTAAG AAAGTATACG CCTCTTCGGG GGATGGAGAA GTTTATGTTT 1200

GGGATGTGAA CTCAAGGAAG TGCCTTAACA GATTTGTTGA TGAAGGCAGT TTATATGGAT 1260

TAAGCATTGC CACATCTAGG AATGGACAGT ATGTTGCTTG TGGTTCTAAT TGTGGAGTGG 1320

TAAATATATA CAATCAAGAT TCTTGTCTCC AAGAAACAAA CCCAAAGCCA ATAAAAGCTA 1380

TAATGAACTT GGTTACAGGT GTTACTTCTC TGACCTTCAA TCCTACTACA GAAATCTTGG 1440

CAATTGCTTC AGAAAAAATG AAAGAAGCAG TCAGATTGGT TCATCTTCCT TCCTGTACAG 1500

TATTTTCAAA CTTCCCAGTC ATTAAAAATA AGAATATTTC TCATGTTCAT ACCATGGATT 1560

TTTCTCCGAG AAGTGGATAC TTTGCCTTGG GGAATGAAAA GGGCAAGGCC CTGATGTATA 1620

GGTTGCACCA TTACTCAGAC TTCTAAAGAG ACTATTTGAA GTCCAGTTGA GTCACAAGAG 1680

AAGCCTGTCT TGATATATCA TCTCAGAAAC TTTCCTGAAT ATGTGATAAT ATATGGAAAA 1740

TGATTTATAG ATCCAGCTGT GCTTAAGAGC CAGTAATGTC TTAATAAACA TGTGGCAGCT 1800

TTTGTTTGAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAACTCGA 1848

(2) INFORMATION FOR SEQ ID NO: 189:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1145 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 189:

AAAAAAAACC CAGGGGAACN TTGGGGGCCG CTTTNNNTTC CCCCTCCAGG CCATTGGGGA 60

ATTCTTCAAG TTAATCCTGC TTTGCTCTTG GCCAACAGGG CTTGTAGGGG GGAGAGACCC 120

ACGATCATCA AGGGGTTCGA GTGCAAGCCT CACTCCCAGC CCTGGCAGGC AGCCCTGTTC 180

GAGAAGACGC GGCTACTCTG TGGGGCGACG CTCATCGCCC CCAGATGGCT CCTGACAGCA 240

GCCCACTGCC TCAAGCCCCG CTACATAGTT CACCTGGGGC AGCACAACCT CCAGAAGGAG 300

GAGGGCTGTG AGCAGACCCG GACAGCCACT GAGTCCTTCC CCCACCCCGG CTTCAACAAC 360

AGCCTCCCCA ACAAAGACCA CCGCAATGAC ATCATGCTGG TGAAGATGGC ATCGCCAGTC 420

TCCATCACCT GGGCTGTGCG ACCCCTCACC CTCTCCTCAC GCTGTGTCAC TGCTGGCACC 480

AGCTGYCTCA TTTCCGGCTG GGGCAGMACG TCCAGCCCCC AGTTACGCCT GCCTCACACC 540

TTGSGATGCG CCAACATCAC CATCATTGAG CACCAGAAGT GTGAGAACGC CTACCCCGGC 600

[illegible] TTCCAGGAAG GGGGCAAGGA CTCCTGCCAG 660

[illegible]

GACTGGATCC AGGAGACCAT GAAGAACAAT TAGACTGGAC [illegible] 840

CCCTCCATTT CCACTTGGTG TTTGGTTTCT GTTCACTCTG TTAATAAGAA ACCCTAAGCC 900

AAGACCCTCT ACGAACATTC TTTGGGCCTC CTGGACTACA GGAGATGCTG TCACTTAATA 960

ATCAACCTGG GGTTCGAAAT CAGTGAGACC TGGATTCAAA TTCTGCCTTG AAATATTGTG 1020

ACTCTGGGAA TGACAACACC TGGTTTGTTC TCTGTTGTAT CCCCAGCCCC AAAGACAGCT 1080

CCTGGCCATA TATCAAGGTT TCAATAAATA TTTGCTAAAT GAAAAARAAA AAAAAAAAAA 1140

ACTCGA 1146

(2) INFORMATION FOR SEQ ID NO: 190:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 906 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 190:

ACTCCCTCAC CCAGGTCCCA GCCCTGGGAA CCACCTACCG TGAGCCCTTT TGCAGATATA 60

GACTCATTTC ATCCTCAGAT GGTCCTTCAA GGTAGGTACT TTAGTCCCAT TTTAGAGATG 120

AGACGATTGA GGCCAGAGGG GTGNNGTAAC TTGCCTGGGG GCTCACGAGC ACAAAAGGAG 180

CCGAGGCAGG ATCTGACCCT TGTTCTCTGG CCTCACTGCC CTCACTTTGC CATGACCCGA 240

AGTTATGTCC CTACAAAGCA ATGCATGGTC CAAGGYTCTT TTTATTGTAT TTTTATTTTT 300

AAGGGTCCTG TTCAAAACTG GTGTGAGCTC TGAGGAGTCC TGAACCCTGG GTGCAGCATC 360

CTAGCATCCT GGGAGTCCTT TTCTGCCCAC ACTGAGCTGG GCTCCTCGAG GGGTGGGGCT 420

GCTGTCCCTG GAAGCCTGGC AGCAGCACTG TATCGGGTTG GCTGAAGCTG ARCGCCGTGG 480

GGTGCAGGGC TCCMGGAATC CCCGTTTGGC TGAAGGGGTT CCCTGTAGCC MGGGATGTTT 540

ATGAGGTCTC TCTGATGCCC CAGGCGCAGG ACATGTGTGC GGGTGGAGAA AAGCAGGCCC 600

TTTCAGTGCC AGCTCCACTC AATTTCTATG TGGACCAAGA ACGATAAACT TAAAAAATTT 660

TTTTTCCTAA GGTATCTTCA GAATATGGTG TATTTTTATG TGGAAAAGAA AAGTTATGAA 720

GGCAGCTGTT ACTTTAAGAG AAAATTCATT AAAACTCCTC GAGGTATGAA GATGACGGCG 780

TGCTTCTCAA TCATTTTGGC ATAACTTGAT TGTGGCTGTA ATTTTTTTTT TTTTTTTTGT 840

CAAGCATGTC AGACAATAAA GTCTTTGTAA AAAGRGAAAA AAAAAAAAAA AAAAAAAAAA 900

ACTCGA 906

(2) INFORMATION FOR SEQ ID NO: 191:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1941 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 191:

```
CTTCAGCTGA AGCCCAGGGA CCCCTTTTCC ACCCTGGGCC CCAATGCCGT CCTTTCCCCG      60
CAGAGACTGG TCTTGGAAAC CCTCAGCAAA CTCAGCATCC AGGACAACAA TGTGGACCTG     120
ATTCTGGCCA CACCCCCCTT CAGCCGCCTG GAGAAGTTGT ATAGCACTAT GGTGCGCTTC     180
CTCAGTGACC GAAAGAACCC GGTGTGCCGG AGATGGCTGT GGTACTGCTG GCCAACCTGG     240
CTCAGGGGGA CAGCCTGGCA GCTCGTGCCA TTCCACTGCA GAAGGGCAGT ATCGGCAACC     300
TCCTGGGCTT CCTAGAGGAC AGCCTTGCCG CCACACAGTT CCAGCAGAGC CAGGCCAGCC     360
TCCTCCACAT GCAGAACCCA CCCTTTGAGC CAAYTAGTGT GGACATGATG CGGCGGGCTG     420
CCCGCGCCCT GCTTGCCTTG GCCAAGGTGG ACGAGAACCA CTCAGAGTTT ACTCTGTACG     480
AATCACGGCT GTTGGACATC TCGGTATCAC CGTTGATGAA CTCAKTGGTT TCACAAGTCA     540
TTTGTGATGT ACTGTTTTTG NATTGGCCAG TCATGACAGC CGTGGGACAC CTCCCCCCCC     600
CGTGTGTGTG TGCGTGTGTG GAGAACTTAG AAACTGACTG TTGCCCTTTA TTTATGCAAA     660
ACCACCTTAG AATCCAGTTT ACCCTGTGCT GTCCAGCTTC TCCCTTGGGA AAAAGTCTCT     720
CCTGTTTCTC TCTCCTCCTT CCACCTCCCC TCCCTCCATC ACCTCACGCC TTTCTGTTCC     780
TTGTCCTCAC CTTACTCCCC TCAGGACCCT ACCCCACCCT CTTTGAAAAG ACAAAGCTCT     840
GCCTACATAG AAGACTTTTT TTATTTTAAC CAAAGTTACT GTTGTTTACA GTGAGTTTGG     900
GGAAAAAAAA TAAAATAAAA ATGGCTTTCC CAGTCCTTCC ATCAACGGGA TGCCACATTT     960
CATAACTGTT TTTAATGGTA AAAAAAAAAA AAAAAAATAC AAAAAAAAAT TCTGAAGGAC    1020
AAAAAAGGTG ACTGCTGAAC TGTGTGTGGT TTATTGTTGT ACATTCACAA TCTTGCAGGA    1080
GCCAAGAAGT TCGCAGTTGT GAACAGACCC TGTTCACTGG AGAGGCCTGT GCAGTAGAGT    1140
GTAGACCCTT TCATGTACTG TACTGTACAC CTGATACTGT AAACATACTG TAATAATAAT    1200
GTCTCACATG GAAACAGAAA ACGCTGGGTC AGCAGCAAGC TGTAGTTTTT AAAAATGTTT    1260
[illegible] AAACTAT CATGTGTGAA                                        1320
[illegible]
GAGGTKGTAC ATTGCACATA CCCTTGGATC CCTACACTTK GGTCCTCCTC CCAGCTACC[illegible]  1500
```

CTTTATAGTA TGACGAGTTA ACAAGTTGGT GACCTGCACA AAGCGAGACA CAGCTATTTA 1560

ATCTCTTGCC CAGATATCGC CCCTCTTGGT GCGATGCTGT ACAGGTCTCT GTAAAAAGTC 1620

CTTGCTGTCT CAGCAGCCAA TCAACTTATA GTTTATTTTT TTCTGGGTTT TTGTTTTGTT 1680

TTGTTTTCTT TCTAATCGAG GTGTGAAAAA GTTCTAGGTT CAGTTGAAGT TCTGATGAAG 1740

AAACACAATT GAGATTTTTT CAGTGATAAA ATCTGCATAT TTGTATTTCA ACAATGTAGC 1800

TAAAACTTGA TGTAAATTCC TCCTTTTTTT CCTTTTTTGG CTTAATGAAT ATCATTTATT 1860

CAGTATGAAA TCTTTATACT ATATGTTCCA CGTGTTAAGA ATAAATGTAC ATTAAATCTT 1920

GGTAAGACTT TAAAAAAAAA A 1941

(2) INFORMATION FOR SEQ ID NO: 192:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2118 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192

AAATAATAAT AANAATAAAT AAAAATWAAG TGCTTAKTGT AACTCAGCGG ACAGGGCTCC 60

CAGCTGCTCT GGCACGTGGG ACACCYTCCA CCCTGCACAC AACAGGCATG CAAAGAGGAC 120

TGGATATGGT GGGGTAGAGT GCTTCTGGTG TGTTCACTTT AAGAAAACAT CTGCCAAGAG 180

AGAAGAGTGC CCAGGAAAGA CCAGGAAAAT ACAAGTACAT GGCTGCTTCA TACCATATAC 240

CCCAATTCTT TAAAGCAGCA AAAGGCACTT TTTTTTTCAG GCCAGAGTGA ATCTAAAACA 300

AACCTGGCTT TGCTTACAGG GAAGCTGTCC CAGAAGGACT GAGTGATGCC TCTTGTTCCC 360

TAAGGTCTGG AGAGTCTTTG CAAGTTTCCA ACGACATTTC CAACCAGGTG GGAGAGACCA 420

GCAGTTGACG AGACAAGTCA GACCCAAAAA ACGACGCCAA GGTAGTGAGT GGGTGCCTAT 480

TTGGGAGTAG GATGATTTGA GGAAAACAGG AAGAAAAACC GGTCAGAAAG TGGCACTTTG 540

GAAGTGGAAA GCTGTTTGCA AATAGCAACT CTGGCTAAAG CGAAAATGTT AATCAAGTAG 600

AAAGTAAAAT TCAGGATCTT AGAAGCTCAT CCTTCTGATG AGAACTATTT TTTTTTCCGT 660

GAAGGAACTA TTATTACTTT AAAAGTGAGG GTAATTTACA TATGGGGTGT ATATATTCTA 720

AAAATAGTAA TAAAAGTACC TTTTATAAGC AATGTTGTGT GGCTTGTAGA AGAAAGCAGG 780

GAGGAAAAAA AGGCAGGCAA AACTAGTCTA GGTCTAGGCC CTAAAAATGA GCTTCCTTCC 840

CACTTGACTG GAAACGCCCA TGTGATTTCT AGGCTGAAAA TAGGTAGGAT TTAACGAGTA 900

ACCTAGTTCC CTTCTGTCTC TGATTTCTGA TCAGCTGATG GAGCTGCTAG TAAGAGGGGC 960

CGATCATGCT CCCAGACGAG TCCTTTGGCC TCTTGCTCTC CATCCCAAGC CTGACTCCTT 1020

CAGCAGCAGC CCCCTCCTTC TGTGTCCATC TGATGCAGGC AAGCAGGAGC AGTAAGAGGG 1080

CATCCCATGT TCCAGTTCAC CTTCTATGGG GTGACTARGA GGTTCCCGGT AACTAGGGCA 1140

GCCCARGCCC AGCAGGTTGC AAAAGCAGCT GCAAGCTTCA GAAACCCACT TCCTCCAACA 1200

CCAGGGAGGT GGCAGAGAGC CCATCCAAAA GCCCACTGGG AGAGGCATAA GATTCTGTGC 1260

CAGGCCCCCA GGTCCCCTCT GTGTCAGGTA GGCTCTGCTA CTGGCCTCTG AAGTAAAGGC 1320

AAANACAAAC GGGCAGGGCA GGGTGGCAGG AATAAAAAAC TCTGGACAGA AACCCTTTTA 1380

ATAAAGGAAA TTCCACCCCT CCCAATCCTT CCATGGAAGG GTGAGACCTT AATGTGATGT 1440

AAGAGGAAGG TCTTCTCTGG CTTTCAGGGA AACAGCTGCA GCTGAAACTT AGGGGCCCAT 1500

TCCAGGGCAC TTTTCACCAC AGCCAGTGCA GCCGCTCCAA GTGCCACTGT CAGCCCCATC 1560

ACTGCCAATT TCACAAAGCG GTTGGTCCTT GGCTTGGTCA GGACATCTTT TGTTCGATCT 1620

TCAGGCCGCA GAAGTCCCCG AANATCGCTG CCGCAGCACC ATATCAGGCC TCTGCTGGGC 1680

TGATGCCAGC TCAAAGTCTT TGAAAGTAGA GGCTGCCGTC CTCTCAGCTT GCTGTTGGGC 1740

AGCGGCCTCC CGAGCAAGTT CGGATGGGGG AAACTGAACA AAAAGGTCTC CTGTCTGCTG 1800

ATCAGTGTCT CATAGGGCAA GTCCTGAGGG ATCTGGGACA ACAGGTGGTG GACCGAGGCC 1860

ATGTCACAGT CACAGTCCAG GACTTCCTGC TCGCGATACA ACACAATCAC GGCTGCAAAG 1920

TAAATCGGCA TCAGTGGGTG GCAGGCCAGG AAGAAGTCAT ATAACCGCAC GACGTGCCTG 1980

AAGTCAGACA GGACATGCCC AAACCAGGTG ATGAGCCAGC TGAGGGCAAA GATGGTCCCT 2040

ACCTCAGCAC TCTGCATGAA GTCATGGAGC TCTGGATTCA CCTGGTCAAT GATGGGCATC 2100

AGATAGTTTA ATATATGC 2118

(2) INFORMATION FOR SEQ ID NO: 193:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1538 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

[illegible]

[illegible]

GGCCAAGGCC GCTCTGTGCG CGGCCGNAGC TGGAGCCTTC TCCTTAGCTT [illegible] 180

```
GACGCGGAGG CACCTCTCGT CCCGAAACCG ACCAGAGGGC AAAGTGTTGG AGACAGTTGG    240
TGTGTTTGAG GTGCCAAAAC AGAATGGAAA ATATGAGACC GGGCAGCTTT TCCTTCATAG    300
CATTTTTGGC TACCGAGGTG TCGTCCTGTT TCCCTGGCAG GCCAGACTGT RTGACCGGGA    360
TGTGGCTTCT GCAGCTCCAG AAAAAGCAGA GAACCCTGCT GGCCATGGCT CCAAGGAGGT    420
GAAAGGCAAA ACTCACACTT ACTATCAGGT GCTGATTGAT GCTCGTGACT GCCCACATAT    480
ATCTCAGAGA TCTCAGACAG AAGCTGTGAC CTTCTTGGCT AACCATGATG ACAGTCGGGC    540
CCTCTATGCC ATCCCAGGCT TGGACTATGT CAGCCATGAA GACATCCTCC CCTACACCTC    600
CACTGATCAG GTTCCCATCC AACATGAACT CTTTGAAAGA TTTCTTCTGT ATGACCAGAC    660
AAAAGCACCT CCTTTTGTGG CTCGGGAGAC GCTAAGGGCC TGGCAAGAGA AGAATCACCC    720
CTGGCTGGAG CTCTCCGATG TTCATCGGGA AACAACTGAG AACATACGTG TCACTGTCAT    780
CCCCTTCTAC ATGGGCATGA GGGAAGCCCA GAATTCCCAC GTGTACTGGT GGCGCTACTG    840
TATCCGTTTG GAGAACCTTG ACAGTGATGT GGTACAGCTC CGGGAGCGGC ACTGGAGGAT    900
ATTCAGTCTC TCTGGCACCT TGGAGACAGT GCGAGGCCGA GGGGTAGTGG GCAGGGAACC    960
AGTGTTATCC AAGGAGCAGC CTGCGTTCCA GTATAGCAGC CACGTCTCGC TGCAGGCTTC   1020
CAGTGGGCAC ATGTGGGGCA CGTTCCGCTT TGAAAGACCT GATGGCTCCC ACTTTGATGT   1080
TCGGATTCCT CCCTTCTCCC TGGAAAGCAA TAAAGATGAG AAGACACCAC CCTCAGGCCT   1140
TCACTGGTAG GCCAGCTGAG GCCCCAACTG CCCAGGCTTG GTCACCGGGA AGAACAACTC   1200
TCATCCCACA ATTGCTGCAG AACTCTTCTC TCCCCATCAT GGGCCACAGT GGGTCTCTTA   1260
ATTTGATTGT GGGGTTCTTT TTGTGGGGAG GGTGGTATA ACTTTTCTTC AGAAGACCCA    1320
TGTGGGACAC CTCCAAGGCT GGCCTCCTCA TAAGCCCTGC CTACACCATG TTCCAGTAAA   1380
CCTCTCCACC AAGGAACTGT GTTCAGCTGC CACAGGCCTG GAGGAGTTTC CTGGCCTGTC   1440
ACGTGAGGTT TGATCAGTAA ACCAGTGCAS GYTTGGCCAA AAAAAAAAAA AAAAAAAAAA   1500
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAACTCGA                           1538
```

(2) INFORMATION FOR SEQ ID NO: 194:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1098 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 194:

AGACCCTGTC TCAAATAATA ATAATAATAA TAATCTTATT TTGGAGAATA AAGAGACCTS 60
TGGATTTGAG GTGCCATTTG GGTAGAAAGA AAAGACGTTT ACACCGAGAA ATAGTCTGTG 120
TTGCCCTGAA GGAGCAGAGG GATGCATCGC TGGAGGTGAC CTACAGTTGA AGAAGACTCA 180
TTATGACAGA CCTTGTCCTT CTTCCTTGTG GAAAGTGTTT CCTCTGCTCC TACTGCTCAT 240
GAGACTCTTC CCCCTCCCTG TCCCAGGGAA CCAAAGGGCT TTNCTACCAC ACCCTTTCTT 300
NGCCCCCCGC CTCCCATGTC TGCTGTGCCT TTGTACTCAG CAATTCTTNG TTTGCTCCCA 360
TTATCTTCCA GCCGGATACA GAGTGAATAG TTAACCACAC TTAGGTCAAA TAGGATCTAA 420
ATTTTTGTTC CTGCTCCNGT GTAAAGAGGC CAGTGTTTGT GTGTTGCAAG CAGCCTTGGA 480
ATAGTAACTC TTCTCATTTG TTTGGGATCT CGCCAMCAAG TTCCAGAATG ATACACGGAT 540
CAGTGCAGAA GTTCATCAGG CTCTCGGACC TTAGGGCTGT TGGAGAAGGC TTCAGCAGCA 600
GAACTGATGG TKAWKGYTCG TGTTCTCCAT CCTCAACTTT CTTTGCTTCG ATCATACACA 660
AGAATACATT TGGAAGGGCA AAAAATGAAC ACTGTTGTTC ATTGCAGCCG TGTTTTGTGA 720
CACAGATGCA CAGTCTGCTG TGAAGACCTT CTCTCAAGTG GSATYTGGGA GTCCATGCCA 780
GATCATGGTG CTTCATGAGA GACTGACAGC TATCAGGGGT TGTGGCACTT AGTGAGGACT 840
CTCCTCCCCC AGTGTGTGCT GATGACACAT ACACACCTGA CAATAGCTTG AGTCTTCTCT 900
GTTCCTTTTA CTCTGTAGCC AACATACACA TGATTTAAAA CCCTTTCTAA ATATCTATCA 960
TGGTTCATCC TTGTCCAAAT GCAGAGTCAG AGCTATTTGT ACTTCATTAT TATTTCCAAG 1020
GCGAATAGTT GGCTTTCTTT TTGCAAAAAT AATTAAAGTT TTTGTATGTT GCAAAAAAAA 1080
AAAAAAAAAA CTACGTAG 1098

(2) INFORMATION FOR SEQ ID NO: 195

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1001 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195:

GAATTCGGCA CGAGATACCT TGCATCTCAT CCCAGTAAAA CCACTTATTT ATAACATATC 60
[illegible]
[illegible]
AGACTGTCAT CACTGAGATT CAAACTCCCA GARTAATCAG CAAGAGTTTT CTAGAGACCA 300

AGGCCAGGCC TGATCCCTGA GGGATGCATG AGAAGGCTTG GAATCTCATT CTGCTATGGT 360

GGCTCTCTCT TGATCTTCTT GGAGTAGCAA AAACAGCAAT GTGGCCCCAA TGGTGTGGCC 420

TAAATGATCA CAAAGGTAAA TGAGTAAAGG GCTCAGCAGA TGAGTAAGGA GCCTTGTCCT 480

GAGAAATTAG CACTGGGCTC TGCATTCAGA AACATGTGAT AAGCATTGCC CATTGCACAT 540

TGCCTTTATT GTGTAAGGAC ATGAAATTCC AGTTTTGCAT AGCTAGTGAT GAATACCTGA 600

AGGGAATTGC AGACATATTT TATTTTATTT TTAATTGACA GATGGAATTG TATATATTTA 660

TCATGTACAT AATCATGCTT TAAAATATGT ACATTATGGA ATGGCTAAAT CAAACTAACC 720

TAGGCATTAT CTCATATAAT TGTCATTTTT GTGGCGAGAA GACTAAAAAT CTACCCTTTC 780

AGCATTTTTA AAGAATACAA TGTGTTTTAT TAACAACAGT CACCATTTGG TACACTAGAT 840

CTCTTGAACT TCTTCCTCTT ATCTAACTGA GATCTTGTAA CCTTTGATAA CAGCTCCCAA 900

GCCCTTCCCC AACCACTGCT CCACCCGTGG TAACCACCAT TCTATTCTCA ACTTCCTGGT 960

AATCACCATT CTAGACACAG GGAAGACTCT CTACCCTCTG A 1001

(2) INFORMATION FOR SEQ ID NO: 196:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1443 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 196:

ATAAACTGAA ATAGGTCATG CAAATATAAA ATATTATTTT TAAATTATTT GTCATAAGAA 60

ACGATGGTGG CCATATTTTG CTTTAATAAT GGAAAAAATG TGGTTAGCAT TCTKTGGAAG 120

GTGGTCATCA GATAGTAGAC ATTTTCTAGG ATTTATTTCT ACCTGCATAT GTGGAAATGT 180

GTACTACTTT AGATTTATWT AATGGCAGCT AACTCAGAGG CATCAAAATG TGCTAATGGT 240

GTAATATGGC CTTTGTCTTG CTGTYCTGTT TTGTARGCCT TCAATCAAGC ARGGGCAGGG 300

CCGTACAGTG AACTTGTCCT TTGSCAGACG CCAGCGTCTG CCCCTGACCC CGTCTCCACT 360

CTCTGTGTCC TGGAGGAGGA GCCCCTTGAT GCYTACCCTG ATTCACCTTC TGCGTGCCTT 420

GTACTGAACT GGGAAGAGCC GTGCAATAAC CGATCTGAAA TCCTTGCTTA CACCATTGAT 480

CTAGGAGACA CTAGCATTAC CGTGGGCAAC ACCACCATGC ATGTTATGAA AGATCTCCTT 540

CCAGAAACCA CCTACCGGTG AGTGCAAGGG AGTAGAAATC TGCATCAGCA CATCAGCACT 600

TGGGGATCTA AGTAAACCTC TCGGGGAAAA TGACCAAGTG GATGTCATCT CCCAGCTGTT 660

TCTAAGAGCC CAGATGTCCA GAGTATTGTC TCACCTTGAT CCCTCAGGCC AGAAGACCTG 720

TGAAAAAGCC ACACTGGTTC AGGGACTCAC TGGACGGTTT TGTGTCCACT TTAACTTGCA 780

CCGTCTCTAC CCCAGAGTGG ACTCARATCC TCAAGTCATC CTCTGAACAT TCRTCTCAGA 840

AATTATAAAA GGGCTTTGGC AATATGTTAG CCCAAGAATT TGGCTTCTTC CAGAAATTGT 900

GCCGACNTTA ACAGTGGCTT AAATGATGGT AAAACTTTTA AGATTTCTAA AAGGRTGGCA 960

TTGGAGATAC GTTGACTTTT ATTAAACMAC CTATAGTTGT TTAATGATTT CTAAAAAAAT 1020

ATCTGGAGCT CAGGGGTTCA ACTGAGGGAA CACATGTTGA GRATCATTGT TTACTAATTA 1080

AATGCCAGGT AACCCGTTGA AATTATCAAA AACATCTTCC ACGTACCAGA AAGTACCTCA 1140

GAGGATAGTT CTGTTATGGA GAAGATGAAA TGGTTTAGTA GTGTAGGAAC TATGGAAAGG 1200

TGAGCTTAGA TTTGGATAGT AAAACCTCAA GACCCTATTT AAAAAGTATT TTATGAATGC 1260

AGCATAAATA ATTTAATTCA GTGTTAANAT GCCAAGCCTA GTATATTGAG CTCAATGTGA 1320

AAAGAAACTC ACATTGGGAG AATGCCACCT TTTCCTTATA AGATAGCTTT GAAGATACCA 1380

TTTTAGACAG ATGGAAATTG AATAGCTTTA GAAAAGGCAA ATGTTTGATC TTGGGGAAAA 1440

AAA 1443

(2) INFORMATION FOR SEQ ID NO: 197:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1282 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 197:

GAAAAAAAAA AGTATGACCC AGTAGCTAGG CACCTGTGGC CCCGCCAAGT TCACACATAA 60

AATTAACTGT CACAGTATCA TCTTAGAAGT GAAAGAAGCC CCTTTATCCT GCAGTGCCCC 120

TCTACCACCA CCTACTGACA AAGAACATGG TGCTATCTGG CATGGGAGAA ATCTTCAGTT 180

TGCTATGGCT TGTATGTGTC CCCTCAAATT CAAGTGTTGC CAATGTGACA GCATCAAGAG 240

GTGGGGTCTT TAAGAGATCA CTAGGCCATG AGGGATTCTC TTAGGACTGG GATGAAGGCC 300

CATAATAAAA GAGGTTTCAG GGAGCATCCT GCTAGCTTGC CTTCTGTATG TCAGAACACA 360

[illegible] 420

[illegible]

[illegible]

AGGGCATAGG ATGAACAAGT TACTGCTAGA CCTCTCACAA TGCCACTAAT GGATAAGATT 660

GTATTTTCAT CATTNCTTGT CTCTTCGGAA GCTAACACCA TGCTATAATA GGAACTAAAT 720

AGATGTCTAA AAACACCTTA AGTATTTGTC TAGAAATCTG GTGCATTCTC CAGAAAGAAC 780

CAAAATTCMA AATAATTTCA AAGGGCCTAA AGAACTAKTT AATCMAAATT CATTAGTTTT 840

TAATGGTACT ACCACTCTCA AATTTAAAAT GTTATCTTAC GTTCCTCTTC CTGGCATTGG 900

ATTTATTGCT AAAACCTGGT AAACACTTTA ATCCTTTTCA ATTCCATTAC CACTGCTCTT 960

GTCCAGAATT ACTCGCAGAC TAATAGTCAC CTGACTTCTC CCCCTGCATC CCGATTTGCT 1020

GTCTAATTCT GGTTACAAAT AAGTAACTGC CAAACTAATC TTTCTAAAAA GCAAGACTGA 1080

TCTCGTCACT CCTTTGCTCA ACAATGTAAA ACCTCCCATT GTCTCCCAAA TAAAACCAGC 1140

TTTCCACTGT GTATACAATA CATCCATGAT CTGTATCCAG CATCATTTTG TATTTGCTCA 1200

CTTTATACAC CACCCCCCAT GCCACATCAA ATTAAATTAT CCTGATAAAT GCAACTGCAA 1260

AAAAAAAAAA AAAAAAACTC GA 1282

(2) INFORMATION FOR SEQ ID NO: 198

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 951 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 198.

ATTTCGGAAC GAGGACTGAA GTGGGAGCGG CGGCAGGGTA GAAGACAGAA GGGGGATCTA 60

TGTGGTAACT AAAGAATGTT TCTGTTTTGT TAATTATTGT GTGTGTGTGG TTTTATTGTT 120

TGCTTAAGAG AATCAAAAAC TGAAAAAAAT GAGAATACAG GAAATGGCTC TTGTTTATTT 180

TTTTGCTGTG TTTACAGCTT GTTAATGCTC TACTGTCTTT GTTTCAAGAG AGATTTGTTC 240

ACTGCCCAGC TCGTTTTGTG TCCTGAGCCC TATGCCCAGC CCACCTTATA AATCATGCCT 300

GTTTAGATGT TTGATTTTGT TCTGTTTGCT ATTGTTATCT TAAAGGTGTA TAACTCTGAC 360

ATGCCAGACA TCAAATTAAG CTCAAATTAA GCTCTCGTTT AAATGTTTAA ACACCTAATT 420

TATATTCTAA TTGATCCCAG CCACTGATGC ATGTACTTTA GCTACTTCTG CTAAATAAGC 480

ATATTAATTT TCCACATCAG GCCATCAGAT CTTGAGAACC AACAGTTATC TAGAATTCCG 540

TGTCTACTAA TGTTTCACCT GCATGCAGCC TTCATTAATT TTGTAGCAAA ATATAAGTG 600

ATCATTATGT AGTTTCTGGA TTAAAAAAAT TTGTGTGTGA AGTTGCTTTG TAAAGTGCAT 660

GTGGAATTAA TGGGACAGTG TGCCCTTTGT GTTAGATGTT AGAGCAAAAG AAAGGGCTTA 720

TAGTGTTAGT ATTGGAGCAC TTTGAAGATA GATATTTTCA GAAAAGATGT AGGATTTAAA 780

AGTTAAATTT TAAATTTTAG AAAAAGATAT GATGGCAATT GGAAATAGTC ACAATGAAGT 840

TCTTCATCCA GTAGGTGTTT AACAGTGTTA TTTTGCCACT GGTAATGTCT AAACTGTGAG 900

TGATTTACAA TAAATGATTA TGAATTCAAA AAAAAAAAAA AAAAAACTCG A 951

(2) INFORMATION FOR SEQ ID NO: 199:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1740 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199:

TTATTATAAT AATGATGATG ATTCCAAGGA AAAAACCTAC AGCGAATGTT CCATTTCTAC 60

CCCGCACGCA GACACTCTCC CTAACACTGA TAACCTGAGC CCCCAGCACT GGACGGAAGA 120

ATGCTGGCGT CTCCGTGTGT ACTGGTTCAG GGTTCTGGCC CCAGCCTTGT CAGGACCCCC 180

TGGTGTCCAG AGCCCCCACC CCTCCCGCAA CAAGCAGCTG ATGCCCCAGT GATTCTCTAT 240

ACATTTTTCA CCTCGGCCAA TATGTCCAGG AAAACTGCTT ACTTCTCTTT TCTTGCCTGG 300

AGCCTTCATT GTTCACCCTT ACGTTGCAAT ATAGGAATTA ATGCTACAAA ATAAAAGTAA 360

AGCTTACCTG AAAAGTGCAT AGTTTGGGGC AATGGTATCT ACATCTCCCA CTGTGGGAAA 420

ACCAGCAAAG CATCAAAACT CTCAATTCTC CTGTTACCCA ATGCAGATCT GAATTATAAG 480

ATGTTTATGT TTGACCATTG TTTCAACAAT GGGATTTTGT TACGAATTAT CCCTTTAACT 540

GAAACCCTCA GTTTTACTGT TTACATTATT AGGAAAACAG GGATATCTTT TGAATCTAAA 600

AATTTGATGT ACAGCATGTG ATTTTTGAAG TTTACATGTA AAGTCACAGT ATAGGTGAAA 660

TAACGTTTGT CATATTTTGA GACGTATCCT GCAGCCATGT TTTTACGTGA GTGTTTTAGT 720

CAAAGTACAT GGTAGACAGT CTTTCACAAT AAAAGGAAAA GGATTTTTTT TCCTCCAAAT 780

GTACATTTAT CAACCTAATG ATTGATTTTT TTAAAAAGAG ATTTCGCCCC AGTCTGGTTT 840

ATGAAAGTTC ATTGCCCTAA ACTGTGCTGA TTGTTTTTAA TCAAGTTATA AATTTCCAAC 900

[illegible]

TTTGTTTAAA A [illegible]

AAATCGACCC TTTAATTATT ACTTGCAACT CAACAGATCT [illegible]

CAGGAACTTT ACTTCAGGGC TGTCCAGATT GCAGTTGTGC CCCGTGTATG TGGATCTAGT 1200

TCACAGAGTC TTTGGAAGCC AGCAGTCGTG CCCTCCGTAT ACTGTCCACT CATTTTATGT 1260

AGATTTGGTA TCCTCAGCAG CCAGTGTTAA CACCACTGTC ACGTAGTTAN CAGATTCATC 1320

TTTTATGTAT TTAAAGTAAT CCATACTATG ATTTGGTTTT TCCCTGCACC ATTAATTCTG 1380

GCATCAGATC AGTTTTTGTG TTGTGAAGTT CTACTGTGGT TTGACCCAAG ACCACAACCA 1440

TGAGACCCTG AAGTAAAGAT AAGGTACACA TACATTATTT GAGTAACTGT TTCCTTGGGG 1500

GCCAATCTGT GTATGCTTTT AGAAGTTTAC AGAATGCTTT TATTTTTGTC TATAACAAAC 1560

AGTCTGTCAT TTATTTCTGT TGATAAACCA TTTGGACAGA GTGAGGACGT TTGCCCTGTT 1620

ATCTCCTAGT GCTAACAATA CACTCCAGTC ATGAGCCGGG CTTTACAAAT AAAGCACTTT 1680

TGATGACTCA MAAAAAAAAA AAAAAAAANC YCGGGGGGGG GCCGGTAACC CATTTTNCCC 1740

(2) INFORMATION FOR SEQ ID NO: 200:

(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 1707 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 200:

GCTTATAGAA GGGAGAGGAG CGAACATGGC AGCGCGTTGG CGGTTTTGGT GTGTCTCTGT 60

GACCATGGTG GTGGCGCTGC TCATCGTTTG CGACGTTCCC TCAGCCTCTG CCCAAAGAAA 120

GAAGGAGATG GTGTTATCTG AAAAGGTTAG TCAGCTGATG GAATGGACTA ACAAAAGACC 180

TGTAATAAGA ATGAATGGAG ACAAGTTCCG TCGCCTTGTG AAAGCCCCAC CGAGAAATTA 240

CTCCGTTATC GTCATGTTCA CTGCTCTCCA ACTGCATAGA CAGTGTGTCG TTTGCAAGCA 300

AGCTGATGAA GAATTCCAGA TCCTGGCAAA CTCCTGGCGA TACTCCAGTG CATTCACCAA 360

CAGGATATTT TTTGCCATGG TGGATTTTGA TGAAGGCTCT GATGTATTTC AGATGCTAAA 420

CATGAATTCA GCTCCAACTT TCATCAACTT TCCTGCAAAA GGGAAACCCA AACGGGGTGA 480

TACATATGAG TTACAGGTGC GGGGTTTTTC AGCTGAGCAG ATTGCCCGGT GGATCGCCGA 540

CAGAACTGAT GTCAATATTA GAGTGATTAG ACCCCCAAAT TATGCTGGTC CCCTTATGTT 600

GGGATTGCTT TTGGCTGTTA TTGGTGGACT TGTGTATCTT CGAAGAGTAA TATGGAATTT 660

CTCTTTAATA AAACTGGATG GGCTTTTGCA GCTTTGTGTT TTGTGCTTGC TATGACATCT 720

GGTCAAATGT GGAACCATAT AAGAGGACCA CCATATGCCC ATAAGAATCC CCACACGGGA 780

CATGTGAATT ATATCCATGG AAGCAGTCAA GCCCAGTTTG TAGCTGAAAC ACACATTGTT 840

CTTCTGTTTA ATGGTGGAGT TACCTTAGGA ATGGTGCTTT TATGTGAAGC TGCTACCTCT 900

GACATGGATA TTGGAAAGCG AAAGATAATG TGTGTGGCTG GTATTGGACT TGTTGTATTA 960

TTCTTCAGTT GGATGCTCTC TATTTTTAGA TCTAAATATC ATGGCTACCC ATACAGCTTT 1020

CTGATGAGTT AAAAAGGTCC CAGAGATATA TAGACACTGG AGTACTGGAA ATTGAAAAAC 1080

GAAAATCGTG TGTGTTTGAA AAGAAGAATG CAACTTGTAT ATTTTGTATT ACCTCTTTTT 1140

TTCAAGTGAT TTAAATAGTT AATCATTTAA CCAAAGAAGA TGTGTAGTGC CTTAACAAGC 1200

AATCCTCTGT CAAAATCTGA GGTATTTGAA AATAATTATC CTCTTAACCT TCTCTTCCCA 1260

GTGAACTTTA TGGAACATTT AATTTAGTAC AATTAAGTAT ATTATAAAAA TTGTAAAACT 1320

ACTACTTTGT TTTAGTTAGA ACAAACCTCA AAACTACTTT AGTTAACTTG GTCATCTGAT 1380

TTTATATTGC CTTATCCAAA GATGGGGAAA GTAACTCCTG ACCAGGTGTT CCCACATATG 1440

CCTGTTACAG ATAACTACAT TAGGAATTCA TTCTTAGCTT CTTCATCTTT GTGTGGATGT 1500

GTATACTTTA CGCATCTTTC CTTTTGAGTA GAGAAATTAT GTGTGTCATG TGGTCTTCTG 1560

AAAATGGAAC ACCATTCTTC AGAGCACACG TCTAGCCCTC AGCAAGACAG TTGTTTCTCC 1620

TCCTCCTTGC ATATTTCCTA CTGAAATACA GTGCTGTCTA TGATTGTTTT TGTTTTGTTG 1680

TTTTTTYGAG ATCACGYTAC TGGCTC 1707

(2) INFORMATION FOR SEQ ID NO: 201:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 779 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 201:

CTGTCCCCAG TGTTTCCAGG TAATGACTTG GCACTCCAGA GAAACTTTCA TRCTGTTGCG 60

TGTGGTGGCT CCAAGCCAAG CACCTGGCAT GCAGGTCAGC CCTTCCCAGC GGGCGTGGCG 120

TCGTCCTCTT CACAGATGCC ACGTTGCAGC CCCAAGGCCT CACCATTTTG CGTTTTTTAG 180

AAACCCATTT TCTTGGTCAT TTATAAAGCT GCTTTATAGA TATCTTTGAT CCTGGCATGC 240

[illegible]

[illegible] CTTTGATTCT CACAGAGCCC CCCGAATACT [illegible] [illegible] [illegible]

TAGGTGTCAT AAATTTTAAG AAACCTGCTT TTAAGTACTA TTTATAGGTT TTTCTGTTAT 540

ACTTGCAACC TAGTTTTAAA ATACATGAGG ATTTTATGAA AGCTTTATAC AGACATTTAT 600

AGGAAACTCA TTCTTTGATT TTAGGTGCCA TTTAAATTGA TAACACTTAC TTTATAAAAA 660

GATGCTTTTT GTCTGGATAG AGCCTTATAG TTTAAAATAT CTTCATATAT TGCCATTTGA 720

TCAAATAAAT TTCTTACTTA GAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAACTCGA 779

(2) INFORMATION FOR SEQ ID NO: 202:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1617 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 202:

GGCACAGCTT TCTGTCTCTT CCTCGCTCCC TCTCTTTCTC TCCTCCCTCT GCCTTCCCAG 60

TGCATAAAGT CTCTGTCGCT CCCGGAACTT GTTGGCAATG CCTATTTTTT GGCTTTCCCC 120

CGCGTTCTCT AAACTAACTA TTTAAAGGTC TGCGGTCGCA AATGGTTTGA CTAAACGTAG 180

GATGGGACTT AAGTTGAACG GCAGATATAT TTCACTGATC CTCGCGGTGC AAATAGCGTA 240

TCTGGTGCAG GCCGTGAGAG CAGCGGGCAA GTGCGATGCG GTCTTCAAGG GCTTTTCGGA 300

CTGTTTGCTC AAGCTGGGCG ACACATGGCC AACTACCCGC AGCCTGGGAC GACAAGACGA 360

ACATCAAGAC CGTGTGCACA TACTGGGAGG ATTTCCACAG CTGCACGGTC ACAGCCCTTA 420

CGGATTGCCA GGAAGGGGCG AAAGATATGT GGGATAAACT GAGAAAAGAA TCCAAAAACC 480

TCAACATCCA AGGCAGCTTA TTCGAACTCT GCGGCAGCGG CAACGGGGCG GCGGGGTCCC 540

TGCTCCCGGC GTTCCCGGTG CTCCTGGTGT CTCTCTCGGC AGCTTTAGCG ACCTGGCTTT 600

CCTTCTGAGC GTGGGGCCAG CTCCCCCCGC GCGCCCACCC ACACTCACTC CATGCTCCCG 660

GAAATCGAGA GGAAGATCCA TTAGTTCTTT GGGGACGTTG TGATTCTCTG TGATGCTGAA 720

AACACTCATA TAGGATTGTG GGAAATCCTG ATTTCTCTTT TTATTTCGTT TGATTTCTTG 780

TGTTTTATTT GCCAAATGTT ACCAATCAGT GAGCAAGCAA GCACAGCCAA AATCGGACCT 840

CAGCTTTAGT CCGTCTTCAC ACACAAATAA GAAAACGGCA AACCCACCCC ATTTTTTAAT 900

TTTATTATTA TTAATTTTTT TTGTTGGCAA AAGAATCTCA GGAACGGCCC TGGGCACCTA 960

CTATATTAAT CATGCTAGTA ACATGAAAAA TGATGGGCTC CTCCTAATAG GAAGGCGAGG 1020

AGAGGAGAAG GCCAGGGGAA TGAATTCAAG AGAGATGTCC ACGGACGAAA CATACGGTGA 1080

ATAATTCACG CTCACGTCGT TCTTCCACAG TATCTTGTTT TGATCATTTC CACTGCACAT 1140

TTCTCCTCAA GAAAAGCGAA AGGACAGACT GTTGGCTTTG TGTTTGGAGG ATAGGAGGGA 1200

GAGAGGGAAG GGGCTGAGGA AATCTCTGGG GTAAGAGTAA AGGCTTCCAG AAGACATGCT 1260

GCTATGGCTA CTGAGGGGTT AGCTTTATCT GCTGTTGTTG ATGCATCCCT CCAAGTTCAC 1320

TGCCTTTATT TTCCCTCCTC CCTCTTGTTT TAGCTGTTAC ACACACAGTA ATACCTGAAT 1380

ATCCAACCGT ATAGATCACA AGGGGGGGAT GTTAAATGTT AATCTAAAAT ATAGCTAAAA 1440

AAAGATTTTG ACATAAAAGA GCCTTGATTT TAAAAAAAAA AGAGAGAGAG ATGTAATTTA 1500

AAAAGTTTAT TATAAATTAA ATTCAGCAAA AAAACATTTG CTACAAACTA TAGAGAAGTA 1560

TAAAATAAAA GTTATTGTTT GAAAAAAAAA AAAAAAAAAW CTCGACCGCA AGGGAAT 1617

(2) INFORMATION FOR SEQ ID NO: 203:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1974 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 203:

GAATTCGGCA CGAGGCTGAG GGAGCTGCAG CGCAGCAGAG TATCTGACGG CGCCAGGTTG 60

CGTAGGTGCG GCACGAGGAG TTTTCCCGGC AGCCAGGAGG TCCTGAGCAG CATGGCCCGG 120

AGGAGCGGCT TCCCTGCCGC CGGGCTCTGG CTCTGGAGCA TCCTCCTGTG CCTGCTGGCA 180

CTGCGGGCGG AGGCCGGGCC GCCGCAGGAG GAGAGCCTGT ACCTATGGAT CGATGCTCAC 240

CAGGCAAGAG TACTCATAGG ATTTGAAGAA GATATCCTGA TTGTTTCAGA GGGGAAAATG 300

GCACCTTTTA CACATGATTT CAGAAAAGCG CAACAGAGAA TGCCAGCTAT TCCTGTCAAT 360

ATCCATTCCA TGAATTTTAC CTGGCAAGCT GCAGGGCAGG CAGAATACTT CTATGAATTC 420

CTGTCCTTGC GCTCCCTGGA TAAAGGCATC ATGGCAGATC CAACCGTCAA TGTCCCTCTG 480

CTGGGAACAG TGCCTCACAA GGCATCAGTT GTTCAAGTTG GTTTCCCATG TCTTGGAAAA 540

CAGGATGGGG TGGCAGCATT TGAAGTGGAT GTGATTGTTA TGAATTCTGA AGGCAACACC 600

ATTCTCCAAA CACCTCAAAA TGCTATCTTC TTTAAAACAT GTCAACAAGC TGAGTGCCCA 660

[illegible]

GCAAACTGCT CAAGCACCTG [illegible]TTTAATGGA GGGACCTGTT [illegible] AAAATGTATT [illegible]

TSCCCTCCAG GACTAGAGGG AGAGCAGTGT GAAATCAGCA AATGCCCACA ACCCTGTCGA 960

AATGGAGGTA AATGCATTGG TAAAAGCAAA TGTAAGTKTT CCAAAGGTTA CCAGGGAGAC 1020

CTCTGTTCAA AGCCTGTCTG CGAGCCTGGC TGTGGTGCAC ATGGAACCTG CCATGAACCC 1080

AACAAATGCC AATGTCAAGA AGGTTGGCAT GGAAGACACT GCAATAAAAG GTACGAAGCC 1140

AGCCTCATAC ATGCCCTGAG GCCAGCAGGC GCCCAGCTCA GGCAGCACAC GCCTTCACTT 1200

AAAAAGGCCG AGGAGCGGCG GGATCCACCT GAATCCAATT ACATCTGGTG AACTCCGACA 1260

TCTGAAACGT TTTAAGTTAC ACCAAGTTCA TAGCCTTTGT TAACCTTTCA TGTGTTGAAT 1320

GTTCAAATAA TGTTCATTAC ACTTAAGAAT ACTGGCCTGA ATTTTATTAG CTTCATTATA 1380

AATCACTGAG CTGATATTTA CTCTTCCTTT TAAGTTTTCT AAGTACGTCT GTAGCATGAT 1440

GGTATAGATT TTCTTGTTTC AGTGCTTTGG GACAGATTTT ATATTATGTC AATTGATCAG 1500

GTTAAAATTT TCAGTGTGTA GTTGGCAGAT ATTTTCAAAA TTACAATGCA TTTATGGTGT 1560

CTGGGGGCAG GGGAACATCA GAAAGGTTAA ATTGGGCAAA AATGCGTAAG TCACAAGAAT 1620

TTGGATGGTG CAGTTAATGT TGAAGTTACA GCATTTCAGA TTTTATTGTC AGATATTTAG 1680

ATGTTTGTTA CATTTTTAAA AATTGCTCTT AATTTTTAAA CTCTCAATAC AATATATTTT 1740

GACCTTACCA TTATTCCAGA GATTCAGTAT TAAAAAAAAA AAAATTACAC TGTGGTAGTG 1800

GCATTTAAAC AATATAATAT ATTCTAAACA CAATGAAATA GGGAATATAA TGTATGAACT 1860

TTTTGCATTG GCTTGAAGCA ATATAATATA TTGTAAACAA AACACAGCTC TTACCTAATA 1920

AACATTTTAT ACTGTTTGTA TGTATAAAAT AAAGGTGCTG CTTTAGTTTT CTGA 1974

(2) INFORMATION FOR SEQ ID NO: 204:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1057 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 204:

CGGCCTTCCG GGGCAACCGT TCGTCCCAAC NCGGGAAAGG GTCCTGGAGN CGGGAACTAG 60

GAGCCTCGGA AGTCCAAGGG CGGAGCGCCC TTTGCTAATA AGCCAATCAG AACGTGAGAC 120

GCTCCGGTGG GNCGGTGCCG TCGAGCGCGG GGTGGAGTCT GGGTGACTTG GCTGGCGGGA 180

TCAAGTGCAG CTGCTTCAGG CTGAGGTGGC AGATAGTGAG CGCTGGTGGC GGAGTTAAAG 240

TYAAAGCAGG AGAGTAATWA TGAATAGCGC AGCGGGATTC TCACACCTAG ACCGTCGCGA 300

GCGGGTTCTC AAGTTAGGGG AGAGTTTCGA GAAGCAGCCG CGCTGCGCTT CCACACTGTG 360

CGCTATGACT TCAAACCTGC TTCTATTGAC ACTTCTTCTG AAGGATACCT TGAGKTTGGC 420

GAAGKTGAAC AGKTGACCAT WACTCTGCCM AATATAGAAA GTTGAAGGAA GCAGTAAAAT 480

TCAGTATCGT AAAGAACAAC AGCAACAACA ATGTGGAATT CASCCAGGAC TCCCAATCTT 540

GTAAAACATT CTCCATCTGA AGATAAGATG TCCCCAGCAT CTCCAATAGA TGATATCGAA 600

AGAGAACTGA AGGCAGAAGC TAGTCTAATG GACCAGATGA GTAGTTGTGA TAGTTCATCA 660

GATTCCAAAA GTTCATCATC TTCAAGTAGT GAGGATAGTT CTAGTGACTC AGAAGATGAA 720

GATTGCAAAT CCTCTACTTC TGATACAGGG NAATTGTGTC TCAGGACATC CTACCATGAC 780

ACAGTACAGG ATTCCTGATA TAGATGCCAG TCATAATAGA TTTCGAGACA ACAGTGGCCT 840

TCTGATGAAT ACTTTAAGAA ATGATTTGCA GCTGAGTGAA TCAGGAAGTG ACAGTGATGA 900

CTGAAGAAAT ATTTAGCTAT AAATAAAAAT TTATACAGCA TGTATAATTT ATTTTGTATT 960

AACAATAAAA ATTCCTAAGA CTGAGGGAAA TATGTCTTAA CTTTTGATGA TAAAAGAAAT 1020

TAAATTTGAT TCAGAAAAAA AAAAAAAAAA AACTCGA 1057

(2) INFORMATION FOR SEQ ID NO: 205:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 721 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 205:

GAATTCGGCA CGAGTCATCC CTCTCCCTCT TTCACTCCCT TACTCTTACT CTGTTTTTTG 60

TGCTCCAGAC AGACAGACCC TACCTCTTTT GCTTCTTTTT TGTTTGTTTG TTTTGAGATG 120

GAGTGTCGCT CTTGTTGCCC AGGCTGGAGT GCAGTGGCGC AATCTCGGCT CACCACAACC 180

TCTGCCTCCC GGGTTCAAGC AATTCTCCTG CCTCAGCCTC CCGAGAAGCT GGGGATTACA 240

GGCATGCGCC ACCACACCCA GCTNAATTTT ATATTTTTAG TAGAGATGGT GTTTCTCCAT 300

GTTGGTCAGG CTGGCCTCAA ACTCCCAACC TCAGGTGATN CCGCCTGCTT TGGCCTCCCC 360

AAAGTGCTGG GATTACAGGC GTGAGCCACT GCCCCCAGCC TCTTTTGCTC CTTTATACTC 420

[illegible] 480

[illegible]

TGAAGTGGGA GGATCATTGA GCCCAGGAGT TGAGGTTGCA [illegible] 600

TACACTCAGC CTGGGCAATA GAGGGACATG TTGTCTCTAA AAAAAAAAAA AAAAAACTCG 720

A 721

(2) INFORMATION FOR SEQ ID NO: 206:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2465 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 206:

CCACCATTTA TCCAACTGAA GAGGAGTTAC AGGCAGTTCA GAAAATTGTT TCTATTACTG 60

AACGTGCTTT AAAACTCGTT TCAGACAGTT TGTCTGAACA TGAGAAGAAC AAGAACAAAG 120

AGGGAGATGA TAAGAAAGAG GGAGGTAAAG ACAGAGCTTT GAAAGGACTT TTGCGAGTGG 180

GAGTATTGGC AAAAGGATTA CTTCTCCGAG GAGATAGAAA TGTCAACCTT GTTTTGCTGT 240

GCTCAGAGAA ACCTTCAAAG ACATTATTAA GCCGTATTGC AGAAAACCTA CCCAAACAGC 300

TTGCTGTTAT AAGCCCTGAG AAGTATGACA TAAAATGTGC TGTATCTGAA GCGGCAATAA 360

TTTTGAATTC ATGTGTGGAA CCCAAAATGC AAGTCACTAT CACACTGACA TCTCCAATTA 420

TTCGAGAAGA GAACATGAGG GAAGGAGATG TAACCTCGGG TATGGTGAAA GACCCACCGG 480

ACGTCTTGGA CAGGCAAAAA TGCCTTGACG CTCTGGCTGC TCTACGCCAC GCTAAGTCGT 540

TCCAGGCTAG ACCTAATGGT CTGCAGTCCT GTGTGATTAT CATACGCATT CTTCGAGACC 600

TCTGTCAGCG AGTTCCAACT TGGTCTGATT TTCCAAGCTG GGCTATGGAG TTACTAGTAG 660

AGAAAGCAAT CAGCAGTGCT TCTAGCCCTC AGAGCCCTGG GGATGCACTG AGAAGAGTTT 720

TTGAATGCAT TTCTTCAGGG ATTATTCTTA AAGGTAGTCC TGGACTTCTG GATCCTTGTG 780

AAAAGGATCC CTTTGATACC TTGGCAACAA TGACTGACCA GCAGCGTGAA GACATCACAT 840

CCAGTGCACA GTTTGCATTG AGACTCCTTG CATTCCGCCA GATACACAAA GTTCTAGGCA 900

TGGATCCATT ACCGCAAATG AGCCAACGTT TTAACATCCA CAACAACAGG AAACGAAGAA 960

GAGATAGTGA TGGAGTTGAT GGATTTGAAG CTGAGGGGAA AAAAGACAAA AAAGATTATG 1020

ATAACTTTTA AAAAGTGTCT GTAAATCTTC AGTGTTAAAA AAACAGATGC CCATTTGTTG 1080

GCTGTTTTTC ATTCATAATA ATGTCTACAT TGAAAAATTT ATCAAGAATT TAAAGGATTT 1140

CATGGAAGAA CCAAGTTTTT CTATGATATT AAAAAATGTA CAGTGTTAGG TATTATTTGA 1200

ATGGAAAGAC ACCCAAAAAA AAAAATGTGC TCCGACTAGG GGGAAAACAG TAGTTCCGAT 1260

TTTTTCCCAT TATTTTTATT TTATTTTCTG GTTGCCCTAG CTTCCCCCCC TATTTTTGTG 1320

TCTTTTATTA ACTAGTGCAT TGTCTTATTA AATCTTCACT GTATTTAATG CAGGATGTGT 1380

GCTTCAGTTG CTCTGTGTAT TTTGATATTT TAATTTAGAG GTTTTGTTTG CTTTTTGACA 1440

CTAGTTGTAA GTTACTTTGT TATAGATGGT ATCCTTTACC CCTTCTTAAT ATTTTACAGC 1500

AGTACGTTTT TTTGTAACGT GAGACTGCAG AGTTTGTTTT TCTATATGTG AAGGATTACA 1560

ACACAAAAAG TTATCCTGCC ATTCGAGTGC TCAGAACTGA ATGTTTCTGC AGATCTTGTG 1620

GCATTTGTCT CTAGTGTGAT ATATAAAGGT GTAATTAAGA CAGAGTTCTG TTAATCTAAT 1680

CAAGTTTGCT GTTAGTTGTG CATTAGCACT ATAAAAGCTA ATATATACTA TATGGTCTTG 1740

CAACAGTTTT AAAGCCTCTG CATAATTGAT AATAAAAATG CATGACATTC TTGTTTTTAA 1800

TAGACTTTTA AAATCATAAT TTTAGGTTTA ACACGTAGAT CTTTGTACAG TTGACTTTTT 1860

GACATAGCAA GGCCAAAAAT AACTTTCTGA ATATTTTTTT CTTGTGTATA AGTGGAAAGG 1920

GCATTTTTCA CATATAAGTG GGCTAACCAA TATTTTCAAA AGAACTTCAT CATTGTACAA 1980

CTAACAACAG TAACTAGCCC TTAATTATGG TGACAGTTCC TTATTGGTGT GTGTGAGATT 2040

ACTCTAGCAA CTATTACAGT ATAACACAGA TGATCTTCTC CACACACCCC ATCACCCAGA 2100

TAATTTACAG TTCTGTTAAC AGTGAGGTTG ATAAAGTATT ACTGATAAAA AATTATCTAA 2160

GGAAAAAAAC AGAAAATTAT TTGGTGTGGC CATCTTACCT GCTTATGTCT CCTACACAAA 2220

GCTAAATATT CTAGCAGTGA TGTAATGAAA AATTACATCT TACTGTTGAT ATATGTATGC 2280

TCTGGTACAC AGATGTCATT TTGTTGTCAC AGCACTACAG TGAAATACAC AAAAAATGAA 2340

ATTCATATAA TGACTTAAAT GTATTATATG TTAGAATTGA CAACATAAAC TACTTTTGCT 2400

TTGAAATGAT GTATGCTTCA GTAAAATCAT ATTCAAATTT AAAAAAAAAA AAAAAAAAAA 2460

CTCGA 2465

(2) INFORMATION FOR SEQ ID NO: 207:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1480 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

[illegible]

TTCCGCTGCT GCTCGCCCCT TCTCCTGCAG GCGAAAGCAA GAAGATGACA [illegible] 1[illegible]

GCTGGCTGAA CGAGAGCAGG AAGAAGCCAT TGCTCAGTTC CCATATGTGG AATTCACCGG 240

GAGAGATAGC ATCACCTGTC TCACGTGCCA GGGGACAGGC TACATTCCAA CAGAGCAAGT 300

AAATGAGTTG GTGGCTTTGA TCCCACACAG TGATCAGACA TTGCGCCCTC AGCGAACTAA 360

GCAATATGTC CTCCTGTCCA TCCTGCTTTG TCTCCTGGCA TCTGGTTTGG TGGTTTTCTT 420

CCTGTTTCCG CATTCAGTCC TTGTGGATGA TGACGGCATC AAAGTGGTGA AAGTCACATT 480

TAATAAGCAA GACTCCCTTG TAATTCTCAC CATCATGGCC ACCCTGAAAA TCAGGAACTC 540

CAACTTCTAC ACGGTGGCAG TGACCAGCCT GTCCAGCCAG ATTCAGTACA TGAACACAGT 600

GGTGAATTTT ACCGGGAAGG CCGAGATGGG AGGACCGTTT TCCTATGTGT ACTTCTTCTG 660

CACGGTACCT GAGATCCTGG TCCACAACAT AGTGATCTTC ATGCGAACTT CAGTGAAGAT 720

TTCATACATT GGCCTCATGA CCCAGAGCTC CTTGGAGACA CATCACTATG TGGATTGTGG 780

AGGAAATTCC ACAGCTATTT AACAACTGCT ATTGGTTCTT CCACACAGCG CCTGTAGAAG 840

AGAGCACAGC ATATGTTCCC AAGGCCTGAG TTCTGGACCT ACCCCCACGT GGTGTAAGCA 900

GAGGAGGAAT TGGTTCACTT AACTCCCAGC AAACATCCTC CTGCCACTTA GGAGGAAACA 960

CCTCCCTATG GTACCATTTA TGTTTCTCAG AACCAGCAGA ATCAGTGCCT AGCCTGTGCC 1020

CAGCAAATAG TTGGCACTCA ATAAAGATTT GCAGAATTTA ATACAGATCT TTTCAGCTGT 1080

TCTTAGGGCA TTATAAATGG AAATCATAAC GTGGTTCTAG GTTATCAAAC CATGGAGTGA 1140

TGTGGAGCTA GGATTGTGAG TGACCTGCAG GCCATTATCA GTGCCTCATC TGTGCAGAAG 1200

TCGCAGCAGA GAGGGACCAT CCAAATACCT AAGAGAAAAC AGACCTAGTC AGGATATGAA 1260

TTTGTTTCAG CTGTTCCCAA AGGCCTGGGA GCTTTTTGAA AAGAAAGAAA AAAGTGTGTT 1320

GGCTTTTTTT TTTTTTAGAA AGTTAGAATT GTTTTTACCA AGAGTCTATG TGCGGCTTGA 1380

TTCACCCTTC ATCCATTGGC TGGAACATGG ATTGGGGATT TGATAGAAAA ATAAACCCTG 1440

CTTTTGATTC AAAAAAAAAA AAAAAAWAAA AAAAACTCGA 1480

(2) INFORMATION FOR SEQ ID NO: 208:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 872 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 208:

CAGTATTTCC CTCAGTACTG TAAGCAAAAG TGGTATGTTT TTCTTTCTTT ATGTCTACTC 60

TGTCCTCTGT GGCCTTCTGG TGTACCCCTC TCTTCCTAGC CATTCAGTCT CTCTAGTCAC 120

CTCCCTAGTA GCTAGTGCTC TCTAAGTTTT TATTTAATTA GAACAACTCC ATTTCCATTT 180

CAAGGTAGGT CAATGGGGGG AAAAGCCTCA TGATTTAAAC TGAAGTTAAC AACACAGCTT 240

TTAAAATGAA AACTCATACT CCAACTTCTA AAGTATATTT GAGCTGATTT GTTTCCAAAA 300

CAAAGATATG CTGTACCTAA AACTGCTAAA ACAAAAATAT AAAGACAAGG ACTAGGTGAT 360

TAAGGGGAGA GAAAAATCAT YTCTTTTCCA GGAAACCTTT GCTAAAATAA GCAAAACTTG 420

ANTCTATGCT TCATGGAAAC TGACACAAAG AAAAGAAACT GATGGATTGC ACAGGCCTTG 480

TTATAGAAAT AGATCTATAA AAAGATCTGT CCACAGGAAA TATACACCTT CTCCTGGTTC 540

TGAACTTCAA TGGGGATTTG TCAGCTAGGT CTCCATCTAT AGGAATACCT TCACATACCT 600

ATCTATTCAT GCACATATTC TGAAAACAGG TACATACAAA ATTACAACAA AGGAAAAAAA 660

TTCTATTGAA CACTTAAAAA TAGAAACAGG CCAGGCACGG TGGCTCATGC TGTAATCCCA 720

ACAATTTGGG AGGCTGAGGC TGGTGGATCA CCTGAGGTCA GGAGTGTGAG ACCAGCTTGG 780

CCAACATGGT GAAACCCCGT CACTACTAAA AATACAAAAA AAATTAGCCT GTGTGGTGGC 840

ACACTCNTAC AATCCNGGCT GACTCGGGAA AN 872

(2) INFORMATION FOR SEQ ID NO: 209:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1779 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 209:

AATTCCCAAG ACTGCACAAA ATTACAGTGC TAATGTATAT GGTTGCAGTT CACATAAAGA 60

CAAAAGCATC TGTTATGAAA TGAGTAGTAA TATTGGGTGG TTGATTTGTT CTTAGCAGAC 120

TTGGCTTCAT WTTGGTCTTG AGATAAAATG GCCAGCATAA ATGCTGTTTA TATTCACGTT 180

TTCCTAGGTG TGTGTGTGCA GGCCACAGCA GCATGCCCTT GGTGTAGTCA GTGCCGAAAS 240

GGGTCTGTTC CTTCTTGAGC CTGCCTGCAG GGATGGTCTC CTTTTAAAGC AGGTTGTGTG 300

CAGCATTCAG TACACTGAAG GTAAGCTAAA CCATCAACAT CTCTGGTGTT TTAAGATGTT 360

[illegible]

[illegible]

[illegible]

[illegible] TTATTAACTT TACTTTTTTT AAATCAACTT GCTATAGA[illegible]T TTATATACAT [illegible]

TTTGTTAAAT ATAGTTCCTA GTGACATAGA AACGATGCGT AGTTTTCATT TACTAATTAC 660

AAATGTTGAG GCCTAATTCT GAAAGTCCTC ATATTTAAAG GCTAGACAAC GTAATGAAAT 720

TTTTAACTAT TTGTATGTCA TTTTGAAAGT GTACTGCTTT ATGGTAAAAG TGTTTTTCAT 780

TTGTTCATTG TTTTCATTAT TTGTGATCAT GTTGTCTTTC AATACAGGCA TAAACCTTCC 840

ACTCTTGAAC AAAGCAGCTG CTTTTTAAAA GCGGTAATTG CTTCTTTACC TTTTATTTCT 900

TTTGTAAATG AAGCTTTTCT TTAAGAATGT GACTTTAAAG TGTTGTCTAT TGCATAAAAC 960

AGTTGACACT CACTTATTGT AAAGTGAAGA TTGTTCTACT GCATGTGAAG TGGACCATGC 1020

AGATTTCTGT ATGTTCTGAG TATGCATCAC TAGATAATAA AGTCTTTTGT GAACAAGGCA 1080

TTTGTAGCCA TTTTTAAAAG TTTTTGTCTT CAGTGCTGGT AAGTCAGGTA AACCATAAAT 1140

AGTTAAAAGC AACCTTTTGT TTTTTTCCTG AAAGTTTTTA ATTGAAAGTA TTATTAGTTA 1200

AAGATGTAAA CCTAGCCAAA ATTACCAGTT TATTAATAAT TAGGATCCTA ATTATTTCAA 1260

AAAATCCTAC AAATATTGTC AGCTTTCAGT GTAGTGAGAT TATTCCTGTA CGTTATGGGG 1320

TATAATTCAG GATTTAACTA ATGTTTCTGC TATTTTCTCA CTTTTCCTTT TGATGGTGCG 1380

GAAAGAGAAA AAGGAAAACG GGGCACAGGC CATTCGACGC CTTCTCCAAG GGGTCTGATT 1440

TGCTGAGACA CCAGCTTCAC CTTCTTAACA AGGCACCTAA TTACAACAAG CATGCACATT 1500

TTGGTGCATT CAAGAATGGA AAATCAGAAT AGCAGCATTG ATTCTTCTGG TGCAGCTCAG 1560

TGGAAGATGA TGACAACCAG AAGACATGAG CTAAGGGTAA GGGACTGTTC TGAAGAACCT 1620

TTCCATTTAG TGATCAAGAT ATGGAAGCTG ATTTCTGAAA ATGCTCAGTG TGTACTCTAA 1680

TTATTTATGG TACCATTTGA ATTGTAACTT GCATTTTAGC AGTGCATGTT TCTAATTGAC 1740

TTACTGGGAA ACTGAATAAA ATATGCCTCT TATTATCAA 1779

(2) INFORMATION FOR SEQ ID NO: 210:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2110 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210:

GCGGCCGCTG CAGCCCGGAG CTGAGCTAGC CGTCCGAGCC GAGCCGTCCG AGCCGGGGAA 60

GCCGGCGCGT GCTGCCGCTC GTGGCGGCCA GAGGAGAGGA GAGGCAGCAG CATGGCGAGT 120

GTCCTGTCCC GACGCCTTGG AAAGCGGTCC CTCCTGGGAG CCCGGGTGTT GGGACCCAGT 180

GCCTCGGAGG GGCCTCGGCT GCCCCACCCT CGGAGCCACT GCTAGAAGGG GCCGCTCCCC 240

AGCCTTTCAC CACCTCTGAT GACACCCCCT GCCAGGAGCA GCCCAAGGAA GTCCTTAAGG 300

CTCCCAGTAC CTCGGGCCTT CAGCAGGTGG CCTTTMAGCC TGGGCAGAAG GTTTATGTGT 360

GGTACGGGGG TCAAGAGTGC ACACGACTGG TGGWGCAGCA CAGCTGGATG GAGGGTCAGG 420

TGACCGTCTG GCTGCTGGAG CACAAGCTGC AGGTCTGCTG CAGGGTGGAG GAGGTGTGGC 480

TGGCAGAGCT GCAGGGCCCC TGTCCCCAGG CACCACCCCT GGAGCCGGGA GCCCAGGCCC 540

TGGCCTACAG GCCCGTCTCC ACGAACATCG ATGTCCCAAA GAGGAAGTCG GACGCATGGA 600

AATGGATGAG ATGATGGCGG CCATGGTGCT GACGTCCCTG TCCTGCAGCC CTGTTGTACA 660

GAGTCCTCCC GGGACCGAGG CCAACTTCTC TGCTTCCCGT GCGGCCTGCG ACCCATGGAA 720

GGAGAGTGGT GACATCTCGG ACAGCGGCAN CAGCACTACC AGCGGTCACT GGAGTGGGAG 780

CAGTCGTGTC TCCACCCCCT CGCCCCCCCA CCCCCAGGCC AGCCCCAAGT ATTTGGGGGA 840

TGCTTTTGGT TCTCCCCAAA CTGATCATGG CTTTGAGACC GATCCTGACC CTTTCCTGCT 900

GGACGAACCA GCTCCACGAA AAAGAAAGAA CTCTGTGAAG GTGATGTACA AGTGCCTGTG 960

GCCAAACTGT GGCAAAGTTC TGCGCTCCAT TGTGGGCATC AAACGACACG TCAAAGCCCT 1020

CCATCTGGGG GACACAGTGG ACTCTGATCA GTTCAAGCGG GAGGAGGATT TCTACTACAC 1080

AGAGGTGCAG CTGAAGGAGG AATCTGCTGC TGCTGCTGCT GCTGCTGCCG CAGACCCCCA 1140

GTCCCTGGCA CTCCCACCTC CGAGCCAGCT CCCACCCCCA GCATGACTGG CCTGCCTCTG 1200

TCTGCTCTTC CACCACCTCT GCACAAAGCC CAGTCCTCCG GCCCAGAACA TCCTGGCCCG 1260

GAGTCCTCCC TGCCCTCAGG GGCTCTCAGC AAGTCAGCTC CTGGGTCCTT CTGGCACATT 1320

CAGGCAGATC ATGCATACCA GGCTCTGCCA TCCTTCCAGA TCCCAGTCTC ACCACACATC 1380

TACACCAGTG TCAGCTGGGC TGCTGCCCCC TCCGCCGCCT GCTCTCTMTC TCCGGTCCGG 1440

AGCCGGTCGC TAAGCTTCAG CGAAGCCCCA GCAGCCAGCA CCTGCGATGA AATCTCATCT 1500

GATCGTCACT TCTCCACCCC GGGCCCAGAG TGGTGCCAGG AAAGCCCGAC GGGAGGCTAA 1560

GAAGTGCCGC AAGTGTATGG CATCGAGCAC CGGGACCAGT GGTGCACGGC CTGCCGGTGG 1620

AAGAAGGCCT GCCAGCGCTT TCTGGACTGA CCTGTGCTGC AGGTTCTACT CTGTTCCTGG 1680

CCCTGCCGGC AGCCACTGAC AAGAGGCCAG TGTGTCACCA GCCCTCAGCA GAAACCGAAA 1740

GAGAAAGAAC GGAAACACGG AGTTTGGGCT CTGTTGGCTA AGGTGTAACA CTTAAAGCAA 1800

GAATTAATTA [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

AAAAGAAGGA ACAGCTCGTT CTGCTTCCTG CTGAGTCGGT GAATTCTTTG CTTTCTAAAC 2040

TCTTCCAGAA AGGACTGTGA GCAAGATGAA TTTACTTTTC TTAAAAAAAA AAAAAAAAAA 2100

AAAAACTCGA 2110

(2) INFORMATION FOR SEQ ID NO: 211:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 938 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 211:

GGCACAGGAA AAAAAAGAAA AAAGAAAAAA GAAAAAAGTT TTTGTACCCA CAGATTAGCA 60

TTTTCTTGAT GTTTGAAAAA AGTTTAAGCT ATGTCCTAAT TTAAAAATGA GCACAAACTA 120

CTTAACAGAT GTCTGTTCCC TCTTCTCTTA CTTAAATTAT CTTTATTTTC ACCATCACCT 180

CCCAGTGCCG AACACCTGAN CTCTGTGTTT TGTGGTTGGA TCCTGGGTTG CCAAGTTCCT 240

ATTTGGTCAG TCCCTGGCCT GTGGGGCGGT CTCAGGAAGT GGCATGCTCT TCAMGRAGGA 300

TCGTTCATYT CCAGTATAAC CAWTTTGTTA ATAATAGTTG ATAATTCCCA GCTTTTACCA 360

GATGARTTTT GACTTATTTT TCCTCCTTTG ACCTGTTCAA AGCTAACATA TCTCGGTCAG 420

TTCGGAGAGG GTGGGGGATT TGAGAATGTG AGGAGGAGTG GGGTTAGAAT GGGTTTGCCT 480

ATCTGGGCAA GGAAAGAGTT CCTAGTCGAT TGGGCACAAT GACAAAATGA TTCCATGGAT 540

AGAATCGTCC CATGTTGCTG GAACACCTCA CGTGTTGTGA ACGCCTTAAA TTCCTGCCAT 600

CCCTTCTCTG ATTCCCCACC TCCCTGTAGT TTCCACAGGA TTTATCTCTC TGTACCCCCG 660

TCCTCCAACT CTACTCTGTC AGCCTCTCCT CCATCCCTTA CTTCCCTTCT AAATTCCAGG 720

AGATGACCTC ACTTTGCAAA GCAAATTGGA GCCACCAAAT TGTAGCTCTC CTCGGTGGAA 780

ACTGCATCTG TGCTCATCCC TGCACCTTCT TGCAGAAAGC CGCCCCCTCA GGCCAAGATG 840

AGTGCCTGGC CCCCATGGGA GACTCAGACA CTTTGACCCC TTGTGACTTC AGCATCTCCC 900

TCTTTAAAGA TTCTCTCCCA ACATTCAGTC GTGCTCGA 938

(2) INFORMATION FOR SEQ ID NO: 212:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1551 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 212:

AGGCTGGACT AAGCATAGAG AACCAGGAGA GAAAGAAAGA TTTAAGAGAC TGAGTAATAT 60

TTTTTGACAG ATCATTTAAG AAACTGAGTA ATTTTTTTTT TCTCCAAAAG GGCATGGGTT 120

TTTTTTTTGT TTTGTTTTTT CTCTATTTGG CACTTTCTAG GGATTGGTCT ATAAATTTTT 180

TGAAAGATCA TAGGATAAAT TTCTTTGTAG CAACTTCCTA TTTTAGTGTT TATGTTAGGG 240

GARCCCCARG TGTCCCTGCT GATACGCCAT TAGGGCCACT TCTCAGCCTC TGGCTACATC 300

ATAATGCTTT TTTTTCTATC TTGCCAAAGT TTCCMGAAAA TTKAKGTTTT CTAATTTTAA 360

AAAAATTGGT TGTGGAGATG GGATGGGACC TCTTTATAAG CCCTGAAAAT AAGTGATTTN 420

TTTTAAGTGC TATTCTGCTA TAAACCTGAT TCTCACTTTT TTCTGTAGAC AACAGTTTTT 480

TATAATATAT CTATTTTGTG TGGACATTAT TTCCTTTTAA CCAATACTGA AATTCCATAG 540

TGTAWACTTT CTCCACATTT TCTTTGATTA ATACTTYCTT AAAATAGACA CTTGGATTGG 600

CACCAGCTGT CACCAATAAA GCTGCCCTGA ACATTGTCAA TCAATCCTGT TAACCAATTT 660

GAGAATTTTT CTGGAATGCT TAGTTAGGGA TGAAATTGCT GGGTTATAGG TATGAGTATG 720

CTTGATATAC TTTTCTCCAG AATGTCTACA CCTGTGTGTA CACCACATCT CCAGAGATAG 780

GGGAATCTTA TGTCCCTGCT AACTGCTCTC GTTATTTAAT TTTCTGACAT TTGCCGCCGC 840

CGCCGCCCCC TGCCCCCAAC ACACACATGG TATAAAGTGG TAGTTTCTTG TTTTAAATTG 900

AACTTTTGAA TGATTTGAAT TTGGGCATTT CTTTGTATCC TGAGTTATTT TGGTTTCCCG 960

TTATGTGAAT ATCCTTTTCC TATGCTTTAA CTACTTTTCT AATTTGTCCC TTTTTTNGGT 1020

TATCAAATTC CAGGCCATTG TCTATTCCAT CGTCACTTTT GGGTATTGGA AACATCTTTC 1080

CATTCTGTAG CCTGTCTGTT GAACATAAAT CTTGATTTTT ATGTAATCAG ATTTTTCTCC 1140

TTACGGTTAT GTTCTTGGAA TTTTATTTAA GAAATCTTTT TCTATCCTGA GACCACAAAA 1200

ATGTCCCCAC CATTTTCTTC TGTTTCATAG TTTTGCCTTG TATGTTTAAT CCTTTAAGGC 1260

ATGTGTAGTT CATTTTATAT GGTGTGAAAT AGTTCTTATT CATTTATTCA ACACATATTG 1320

GTGGAGTGCC TGCTGATGGT AGTACTCTTC AGAGTACTTT GTATATATTT GTGAACACAT 1380

ATTCTTGCCC TGGAAGCTTA TGTTGTCNTT CAAGGTAGAT CCNTACTCGG TTTCCACCTG 1440

TTTTCTTCAG CCCTCAGGAT GAATTCCACA ATTTTACACA TAGCACCAGT TAAGGAATAG 1500

(2) INFORMATION FOR SEQ ID NO: 213:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 997 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 213:

AGAGAGTCCT CAACAGAACC TAATCATGCT GGCACCCTAA TCTCATACTT CTAGCCTCCA 60

GAACTGAGAG AACATAAACT CCAGTTGTTT AAGCTACCCA GTCTATGGTA TTTGTTATTA 120

TAGCCCAAGC TAAGTCAGGT GGAAAGGCAG AAATATTTTG AGAAGAATCA TTTCTACAAA 180

AACAGAGTTG TTCTAAATGA AATGGCCAGA TATTTCATCT TCTTCATACT AGTATTTATG 240

AAAGTTTCAT TAAACACCAC TTGGCCAGCA CCCAGGCCTG CCACCCTCAG AACGGCAAAC 300

AAAAGCAAAT GATTTGAGGA ACAAAAGAGT GGACACAGAG CCTCTCAGAA GATGGCTCCA 360

TCTTCTGAGA TGATCTTCTG AGATCATCAA TTTTCTGCAC CTGATGTCCT ACTCCAATTG 420

TAGTAGATAA GAGCAAAGAC ACTTCCTGAT CCTGTGGAAA ATGCTGGAGC CCTGCTGATG 480

GAGAGGCTGA CACTGGGACC AACAGAAGGC CGGACATTTA TTTGCTGCAG CCCTTCTGCA 540

CCTGGGCCCT CTTCAGGCCT TGTACCTTGC ACTCCCCATG CCACTGTAGC ACCTGGTAAG 600

CTGAAGTTAG GTATTTGAAG AGATAATTTG CCCCCAACAA AGAATTACTT AAAAGAAAAA 660

GGAAACCACT AAATTCCACT TGACAAACCA GTTTGTTCAG TTTTGACTTT TGCAAATTTG 720

AAACTTTCTC TTTGGCACCA TATGATTCTG TTACATTAGG GCTCATCAAT GCTAAGATAC 780

ACAGCTAGGT CTACCAGCTG CCAGTGGTCA AGAATGAAAG AACCTCTCAG AGAGAGATCA 840

GTTTCTAATA ACCTAACAGT TTTCCTTGGS TATTACMAAA AAAAAAAAAA TTAGAATAAA 900

ATGTCAGTGC CATGCAGGCA AGTACAGATA TGGAAATGAA AGCTCTGTCT ACAACTGCAA 960

GATTTGTTTG TTAATAAAAT TGATTGGGAT CACTCGA 997

(2) INFORMATION FOR SEQ ID NO: 214:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1496 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 214:

GAATTCGGCA CGAGTGACCA CAGATATCTT TGGCTTTCAG CCTCACCACA ATGCTGTCCA 60

CTATGTTTTT TTTAATCGAT TGACATTTCA TGAATCCACA AATTTAGCCG CTTTTCCATC 120

TTTTCCATCT TTGTCATAGC TTCATCACGC ACGATGGAGG TCACTTCAGC ACTATCCGGA 180

GCGGCCTCAC GGACAGATCR GTGAATTTCC TTTTCCTTTT TCTTGATGTA CCGGATTGTC 240

GACTCGTTAA CATTGAGCTC ATGGCCAACA GCACTGTAAC TCATGCCTGA TTGGAGCTTA 300

TCCAACACGC GGAMTTTCTC CGTAAGGSAM ATCAMGGTCT TCTTTCGCTT AGGAACACTG 360

GGCARARCTT AARCACTACG CTTGGGGGCC ATTTTAGAAA GCAAAACCAC CCACAAAAAG 420

CAGAAAAAAA AGTGTCAGTA AACAGACTGN NGANAGGACT CTTTGTTTAC AGCACAGGAG 480

CTGCGACTAG AAGGCGGCGC TTCTCCCCAG TTCAAACTTC AGCTGGGAAC CTTACCTCCG 540

CCAACTCCAA ATTTTCACCC TCTGCGCATG CCCGGGAAAS AAACCCCCAG AACAGTACCG 600

TGATGATTGA TTTTAGGGTT ACAAATACAT TTTAGCAAGT AAGTGAATTT GGCATTACGA 660

ATTAATGATT AATGAAGGTC ACCTGTATTT CCATAGATAT GTAATTTTAT TTAAGCAGGT 720

TTATTATATT AAGGCGGGGA GGCAGCGCCG AAGACTACAA GTTCCAGCAT GCACCGCGTC 780

CGGGCGGGTT CGGGCTCCCA GCGAGGGCTT CAGGGACGCC AGCCCGGAGG CATCGGCCGG 840

AAGTGTCGTA GGGCAACCAC GTAGTACTCT CTGCGCATGT GCAAAGCGCT GTCGGGGGCC 900

GCCCTAGCTG CCGTCGCCGC CGCCGGGGCT CTATGGTCTC TCCCTAGAGC TTTGCCGTTG 960

GAGGCGGCTG CTGCGGTCTT GTGAGTTTGA CCAGCGTCGA GCGGCAGCAA CATGGAGGAA 1020

TTCGACTCCG AAGACTTCTC TACGTCGGAG GAGGACGAGG ACTACGTGCC GTCGGGTGAG 1080

CGATTCCGCC TCAGGCGAGA AGCGAATTGC CCCGCCCCAC GCCTCACGTG AGGCCGCGTC 1140

TGTCCCCGCG GGCGTCTGCC CTGTGGCCCA GGTGGTCCAG GGGGGCTCCT GTTCTCGAGC 1200

GTCCGCTCCC TCAGGCCCCT CATGCTCGGC CGCTCCGGCC CGAGGCGTGT GCGCGTGGCG 1260

GTTCTGTGCT CCCCTCCCGT TGGGCAGCTC CGGCCGCCGC CCCCTCTTGC AGCGCGGGAA 1320

CGGCACATGG ACACGGCCCC TTGTCGCTAG GGACGCTCGT CGGTCAGCCC CGAACGACAA 1380

CGCTGCTTCA GAAGTCGGGG CGGCAGTTCG AGCCTTGGAA GTTTTTTTCA GCCCTGGCCC 1440

GAGAGAGCTG CTGGCCAACA ACCCGTCCAA GATAGAGCTG TCCGNTCTCC GNCTGG 1496

(2) INFORMATION FOR SEQ ID NO: 215:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1308 base pairs

[illegible]

CTGCCTTTGA CCCATCACAC CCCATTTCCT CCTCTTTCCC TCTCCCCGCT GCCAAAAAAA 120

AAAAAAAAGG AAACGTTTAT CATGAATCAA CAGGGTTTCA GTCCTTATCA AAGAGAGATG 180

TGGAAAGAGC TAAAGAAACC ACCCTTTGTT CCCAACTCCA CTTTACCCAT ATTTTATGCA 240

ACACAAACAC TGTCCTTTTG GGTCCCTTTC TTACAGATGG ACCTCTTGAG AAGAATTATC 300

GTATTCCACG TTTTTAGCCC TCAGGTTACC AAGATAAATA TATGTATATA TAACCTTTAT 360

TATTGCTATA TCTTTGTGGA TAATACATTC AGGTGGTGCT GGGTGATTTA TTATAATCTG 420

AACCTAGGTA TATCCTTTGG TCTTCCACAG TCATGTTGAG GTGGGCTCCC TGGTATGGTA 480

AAAAGCCAGG TATAATGTAA CTTCACCCCA GCCTTTGTAC TAAGCTCTTG ATAGTGGATA 540

TACTCTTTTA AGTTTAGCCC CAATATAGGG TAATGGAAAT TTCCTGCCCT CTGGGTTCCC 600

CATTTTTACT ATTAAGAAGA CCAGTGATAA TTTAATAATG CCACCAACTC TGGCTTAGTT 660

AAGTGAGAGT GTGAACTGTG TGGCAAGAGA GCCTCACACC TCACTAGGTG CAGAGAGCCC 720

AGGCCTTATG TTAAAATCAT GCACTTGAAA AGCAAACCTT AATCTGCAAA GACAGCAGCA 780

AGCATTATAC GGTCATCTTG AATGATCCCT TTGAAATTTT TTTTTTGTTT GTTTGTTTAA 840

ATCAAGCCTG AGGCTGGTGA ACAGTAGCTA CACACCCATA TTGTGTGTTC TGTGAATGCT 900

AGCTCTCTTG AATTTGGATA TTGGTTATTT TTTATAGAGT GTAAACCAAG TTTTATATTC 960

TGCAATGCGA ACAGGTACCT ATCTGTTTCT AAATAAAACT GTTTACATTC ATTATGGGGT 1020

ATGTATGACC TTCATTTTCC AAGAAATAGA ACTCTAGCTT AGAATTATGG ATGCTCTAAA 1080

ATGTCAGAAT GGGAACTCTC CTCGAAGTTC TCCCAAACTC AGAGACAGCA CTGCCTTCTC 1140

CTAAATGATT ATTCTTTTCT CCCTGTTTTC TGGTATTTTC TAGGCATCCT TCTCACCACA 1200

GCCATAACCC TTTTTTACTT CCATTAGGCC GTATAACTGG NGGGACNGCT GGTCGGTATA 1260

TAATACTGGT WCCAACAMAG GGGTTCTGGA TGTACACMAG GTTATCTT 1308

(2) INFORMATION FOR SEQ ID NO: 216:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1705 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 216:

TGGCCATGGA AGCGCTAGAA GGTTTAGATT TTGAAACAGC AAAGAAGGAT TTCCTTGGAT 60

CTGGAGACCC CAAAGAAACA AAGATGCTAA TCACCAAACA GGCTGACTGG GCCAGAAATA 120

TCAAGGAGCC CAAAGCCGCC GTGGAGATGT ACATCTCAGC AGGAGAGCAC GTCAAGGCCA 180

TCGAGATCTG TGGTGACCAT GGCTGGGTTG ACATGTTGAT CGACATCGCC CGCAAACTGG 240

ACAAGGCTGA GCGCGAGCCC CTGCTGCTGT GCGCTACCTA CCTCAAGAAG CTGGACAGCC 300

CTGGCTATGC TGCTGAGACC TACCTGAAGA TGGGTGACCT CAAGTCCCTG GTGCAGCTGC 360

AGTGGAGACC CAGCGCTGGG ATGAGGCCTT TGCTTTGGGT GAGAAGCATC CTGAGTTTAA 420

GGATGACATC TACATGCCGT ATGCTCAGTG GCTAGCAGAG AACGATCGCT TTGAGGAAGC 480

CCAGAAAGCG TTCCACAAGG CTGGCGACA GAGAGAAGCG GTCCAGCTGC TGGAGCAGCT 540

CACAAACAAT GCCGTGGCCG AGAGCAGGTT TAATGATGCT GCCTATTATT ACTGGATGCT 600

GTCCATGCAG TGCCTCGATA TAGCTCAAGA TCCTGCCCAG AAGGACACAA TGCTTGGCAA 660

GTTCTACCAC TTCCAGCGTT TGGCAGAGCT GTACCATGGT TACCATGCCA TCCATCGCCA 720

CACGGAAGAT CCGTTCAGTG TCCATCGTCC TGAAACTCTT TTCAACATCT CCAGGTTCCT 780

GCTGCACAGC CTGCCCAAGG ACACCCCCTC GGGCATCTCT AAAGTGAAAA TACTCTTCAC 840

CTTGGCCAAG CAGAGCAAGG CCCTCGGTGC CTACAGGCTG GCCCGGCACG CCTATGACAA 900

GCTGCGTGGC CTGTACATCC CTGCCAGATT CCAAAAGTCC ATTGAGCTGG GTACCCTGAC 960

CATCCGCGCC AAGCCCTTCC ACGACAGTGA GGAGTTGGTG CCCTTGTGCT ACCGCTGCTC 1020

CACCAACAAC CCGCTGCTCA ACAACCTGGG CAACGTCTGC ATCAACTGCC GCCAGCCCTT 1080

CATCTTCTCC GCCTCTTCCT ACGACGTGCT ACACCTGGTT GAGTTCTACC TGGAGGAAGG 1140

GATCACTGAT GAAGAAGCCA TCTCCCTCAT CGACCTGGAG GTGCTCAGAC CCAAGCGGGA 1200

TGACAGACAG CTAGAGATTT GCAAACAACA GCTCCCAGAT TCTTGCGGCT AGTGGGAGAC 1260

CAAGGGACTC CATCGGAGAT NAGGACCCGT TCACAGCTAA GCTRAGCTTT GAGCAAGGTG 1320

GCTCARAGTT CGTGCCAGTG GTGGTGAGCC GGCTGGTGCT GCGCTCCATG AGCCGCCGGG 1380

ATGTCCTCAT CAAGGGATGG CCCCCACCCC TGAGGTGGCA ATACTTCCGC TCACTGCTGC 1440

CTGACGGCTC CATTACCATG TGCCCCTCCT GCTTCCAGAT GTTCCATTCT GAGGACTATG 1500

ACTTGCTGGT GCTTCACCAT GGCTGCTGCC CCTACTGCCG CAGGTGCAAG GATGACCCTG 1560

GCCCATGACC AGCATCCTGG GGACGGCCTG CACCCTCTGC CCGCCTTGGG GTCTGCTGGG 1620

CTGTGAAGGA GAATAAAGAG TTAAACTGTC AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1680

AAAAAAAAAA AAAAAAAAAA AAANA 1705

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 999 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 217:

```
AGCAAATCAC CTTAACGATC TGGAATGAAA CTGTGACCAG TGCCGCCCTG GGTGGTTCTG    60
GAGAGACTGC CGTCTTCTTG TTTGGCCATA GGTGCTGGGG CCCCGGCTTC AGTCACTGTC   120
TCAGACAGKA GTCCCGATAA GCAGATCACC AGTCCTCCAC TGTCCTTCCT GTCGGCCTTG   180
CTGCATGAGA AGATAGCTGC TTCCTCCCTC TTTTCCTACA CTGTAAATTA TTGTTTTACA   240
ATTGAGTGYC TTAATAATAG TYTACAAATA CTATGTATTT ATGCAAAACT GTTAAAGTTC   300
TCATCTGTTA TGATTGGATA CTTGGTCTTG TCAGTAGTGG TCAGCATTGG GTTGTGAGCT   360
TGTCCTACTC CATACGTGTT TATCCTGCTA TGCATTTTAC ATTGTGTGTT CACATCTATT   420
CCAAGGAGCC TTGCTAGAAA CAACACTGGC GGTTCCTGCA GGCCAGGCAG GCATTGGCCC   480
ATGCTGTGTC CCATAGGAGC CAATGGAAAG AACGTAGCTT GGTCTGCTAG CCAGCCGTGG   540
GGTGGCGCAG GCCAGGCAGC CTCTGCACCA GAGTCCAGCA CCTGCCCATT CCCCAGTCAC   600
ACAATCATAC TCTTCTTTCA TAGAGATTTT ATTACCACCT AGACCACCCT AGTTTTCCTC   660
TCTGTTAGTG TCCTGAGCTC TTTTGCAACA AAATGTAGGT ACAGACCAAT CCCTGTCCCT   720
TCCCCAATCA GGAGGTCCAC ACCATGAGTT GTTTGGTTTT CCAGAAGCTG CCAGTGGGTT   780
CCCGTGAATT GCGGTTAAGAT ATCGATGATK TTTTTTATTG TTTTTCTTCT TGTTTTTTTA   840
AATAATATAT TTAAAGGCAG TATCTTTTGT ACTGTGAATT TGCAGTAGAA GATGCAGAAT   900
GCACTTTTTT TTTACTTCTG TTGGTGTGTA TTGTATATAG TGTGTGTGCT TCTTGTGATG   960
AAAATAAACT TTTTCTTTAT AAAAAAAAAA AAAAAAAAC                          999
```

(2) INFORMATION FOR SEQ ID NO: 218:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 941 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 218:

```
GGCACGAGTA GCATTTCATT TAATCTGCAG GTATATTCTC CCAACAGTTT ATTGTCATGT    60
GATGTCCTCA GCCAAGATTG TRAGGCAGAG AGGAGCTGTC CCAACCTACT ATACCACCGA   120
GGCTGGAGAG ATCATATTTT TGGTATTAAA CTGGAGTCTC TCCATCCTTC ACATTGTTGA   180
```

TGTCCTCTGT AGCAAACCGG AAAAGTCAGT GACAGAAGAT GCTGCTAGCG GTTTGAGCCA 240
GAGAATGACA GCTCTGGTTT GGAGAAAAGG GCCGGATGGT GGCTCTAGAA AGCCCATCCT 300
TCTGCTCTTC TTTTTTCTCC CCCTTATATT GTGCTTTCAT TCATTCATTC ATTCATCAAA 360
CATTTGTTGA GCACCTATTA TGTGTCAAGC TCTGTGCTAG CCTCTGGAAA ACCTGCCCTC 420
ATGTAGCTCA CTGTGGAGTA GGAGAAACAA TGACTACACT ATGATAAGCA CGGGTTGTCA 480
GGGTCTCACA GAGCAGTGGC CCCTCATCCA GACCGATGAG GTTAAAGAAG GCATCCAGGC 540
GAGGATGGTG TCAGAGCTAA CTGAAGAATG AGAGGGAGCT GCACCAGCAG GGGTTGGAAC 600
TGAAGGTGGC AGTGCCTGGA GTCTTGATTC CAGCAGAGGG AGAGCAGTCT GTGAAAAGGC 660
ACCAAGGGTG GGAGAGGGCA GAGCACATGG AGGAACTTCA GGTAGTTCTG GATGGCSCTG 720
GGGCAAAGCT AGAGAGGTAA GAAGAATCTA CAAATGTTCC TTGAGTTACA TGAACTTCCA 780
TCCCAATAAA CCCATTGGAA ACGAAAAATT TAAGTCAGAA GTGCATTTAA GGCTGGTCCG 840
AGTAGAATGA TTTTTACAAC GAATTGATCA CAACCAGTTA CAGATGTCTT TGTTCCTTCT 900
CCACTCCCAC TGCTTCACCT GACTAGCCTT TAAAAAAAAA A 941

(2) INFORMATION FOR SEQ ID NO: 219:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 575 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 219:

TAAGTGGAAT CCCCCGGGGT TGCAGGGAAT TCGGCACGAG GCATTCTGAG AAGCTTAAGA 60
CATACTTTGA AGACAACCCT AGGGACCTCC AGCTGCTGCG GCATGACCTA CCTTTGCACC 120
CCGCAGTGGT GAAGCCCCAC CTGGGCCATG TTCCTGACTA CCTGGTTCCT CCTGCTCTCC 180
GTGGCCTGGT RCGCCCTCAC AAGAAGCGGA AGAAGCTGTC TTCCTCTTGT AGGAAGGCCA 240
AGAGAGCAAA GTCCCAGAAC CCACTGCGCA GCTTCAAGCA CAAAGGAAAG AAATTCAGAC 300
CCACAGCCAA GCCCTCCTGA GGTTGTTGGG CCTCTCTGGA GCTGAGCACA TTGTGGAGCA 360
CAGGCTTACA CCCTTCGTGG ACAGGCGAGG CTCTGGTGCT TACTGCACAG CCTGAACAGA 420
[illegible] 480

(2) INFORMATION FOR SEQ ID NO: 220:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3018 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 220:

```
GCCAGCCTTA CAGGTTTTAC GTGAAATGAA AGCCATTGGA ATAGAACCCT CGCTTGCAAC    60
ATATCACCAT ATTATTCGCC TGTTTGATCA ACCTGGAGAC CCTTTAAAGA GATCATCCTT   120
CATCATTTAT GATATAATGA ATGAATTAAT GGGAAAGAGA TTTTCTCCAA AGGACCCGGA   180
TGATGATAAG TTTTTTCAGT CAGCCATGAG CATATGCTCA TCTCTCAGAG ATCTAGAACT   240
TGCCTACCAA GTACATGGCC TTTTAAAAAC CGGAGACAAC TGGAAATTCA TTGGACCTGA   300
TCAACATCGT AATTTCTATT ATTCCAAGTT CTTCGATTTG ATTTGTCTAA TGGAACAAAT   360
TGATGTTACC TTGAAGTGGT ATGAGGACCT GATACCTTCA GCCTACTTTC CCCACTCCCA   420
AACAATGATA CATCTTCTCC AAGCATTGGA TGTGGCCAAT CGGCTAGAAG TGATTCCTAA   480
AATTTGGGAA AGATAGTAAA GAATATGGTC ATACTTTCCG CAGTGACCTG AGAGAAGAGA   540
TCCTGATGCT CATGGCAAGG GACAAGCACC CACCAGAGCT TCAGGTGGCA TTTGCTGACT   600
GTGCTGCTGA TATCAAATCT GCGTATGAAA GCCAACCCAT CAGACAGACT GCTCAGGATT   660
GGCCAGCCAC CTCTCTCAAC TGTATAGCTA TCCTCTTTTT AAGGGCTGGG AGAACTCAGG   720
AAGCCTGGAA AATGTTGGGG CTTTTCAGGA AGCATAATAA GATTCCTAGA AGTGAGTTGC   780
TGAATGAGCT TATGGACAGT GCAAAAGTGT CTAACAGCCC TTCCCAGGCC ATTGAAGTAG   840
TAGAGCTGGC AAGTGCCTTC AGCTTACCTA TTTGTGAGGG CCTCACCCAG AGAGTAATGA   900
GTGATTTTGC AATCAACCAG GAACAAAAGG AAGCCCTAAG TAATCTAACT GCATTGACCA   960
GTGACAGTGA TACTGACAGC AGCAGTGACA GCGACAGTGA CACCAGTGAA GGCAAATGAA  1020
AGTGGAGATT CAGGAGCAGC AATGGTCTCA CCATAGCTGC TGGAATCACA CCTGAGAACT  1080
GAGATATACC AATATTTAAC ATTGTTACAA AGAAGAAAAG ATACAGATTT GGTGAATTTG  1140
TTACTGTGAG GTACAGTCAG TACACAGCTG ACTTATGTAG ATTTAAGCTG CTAATATGCT  1200
ACTTAACCAT CTATTAATGC ACCATTAAAG GCTTAGCATT TAAGTAGCAA CATTGCGGTT  1260
TTCAGACACA TGGTGAGGTC CATGGCTCTT GTCATCAGGA TAAGCCTGCA CACCTAGAGT  1320
GTCGGTGAGC TGACCTCACG ATGCTGTCCT CGTGCGATTG CCCTCTCCTG CTGCTGGACT  1380
TCTGCCTTTG TTGGCCTGAT GTGCTGCTGT GATGCTGGTC CTTCATCTTA GGTGTTCATG  1440
```

CAGTTCTAAC ACAGTTGGGG TTGGGTCAAT AGTTTCCCAA TTTCAGGATA TTTCGATGTC 1500

AGAAATAACG CATCTTAGGA ATGACTAAAC AAGATAATGG CAGTTTAGGC TGCACAACTG 1560

GTAAAATGAC TGTAGATAAA TGTTGTAATT AGTGTACACG TTTGTATTTT TGTTAATATA 1620

GCCGCTGCCA TAGTTTTCTA ACTTGAACAG CCATGAATGT TTCATGTCTC CCTTTTTTTT 1680

TTGTCTATAG CTGTTACCTA TTTTAGTGGT TGAAATGAGA GCTAGTGATG ACAGAAGGAT 1740

GTGGAATGTC TTCTTGACAT CATTGTGTAT TGCTGGTAAT CAAGTTGGTA ACCACTACTT 1800

CTAGCAGCTC TTACCACTAT GACTTAAGTG GTCCTGGAAG GCAGTAAGTG GACGTTTGCA 1860

GCATTCCTGC CTTCATGAGG GCTTCTACCA CTGACCACTT TGCACGTACC TGGCTCCCAG 1920

ATTTACTTAG GTACCCCACG AGTCGTCCAC ATAAGCAGCT TCATCTTTAC CTTGCCAGAG 1980

TTGACAATTA TGGGATACTC TAGTCTACTT ATACTTGTGT TCCCATCTGT CTGCCATCCT 2040

CTCAAGGCCA GGACCCAGTC ATACATCCTT AGAAACCAAA GTATGGTTTT TGTTTTCTCT 2100

TGGAATGTCA GGTCTTAAGG CATTTAATTG AGGGACAAAA AAAAAAAAAA GCCGATATAG 2160

TAGCTAGCTA CTTAAGCATC CATGGGTATT GCTCCATATC AAAGCAGATT TCCAGGACAG 2220

AAAGAGTAAA TTAGCCTTCA GTCTTGGTTT ACAGCTTCCA AGGAGAGCCT TGGCACCTG 2280

AAATGTTAAC TCGGTCCCTT CCTGTCTCTA GTTCATCAGC ACCTGCAGAT GCCTGACTCT 2340

TGTTAGCCTT ACTATTCAAT ACAGTCCTTA GATTCACGGT ATGCCTCTTC CTATCCAGGC 2400

ACCTATTCTG AATCACCATG TTGCTCTGCA GCTAGAGTTG ATAGGAGAAA ATCCATTTGG 2460

GTAGATGGCC TATGAATTTG TAGTAGACTT TCAAAATGAG TGATTTGTTA GCTTGGTACT 2520

TTTAAGTTTG TGGTACAGAT CCTCCAAACC CATACTCTGA GCAATTAACT GCCTTGAACA 2580

TAGAGAAAAA TTAAGGCCTC ACAGGATGAG TCTCCATTCT CTGTAAATGC TTATTTTATC 2640

ATAGTCTTTA GCCTCTAACT ATGAGTAAAA TGTTCTCTTC GGCCGGGTGT GGTGACTCAC 2700

ACCTGTAACC TCAGCACTTT GGGAGGCAGA GGTGGGAGGA TCACTTAGGT CCAGGAGTTC 2760

GAGACTAGCC TGGGCAACAT AGTGAGACAC CGGATCTACA AAAAAATAAA AAGCCAGACT 2820

GGTGGTATGT ATCTGTGTTC CAGCTAATTG GGAGGGTGAG ATGGGAGGAT TGTTTGAGCC 2880

TAGGAGAGGG AGGTTGCAGT GAGCCGTGAT CGCACCACTG CACTCCAGCC TGGGCAACAG 2940

AGCAAGACCC TGTCTTGGAG AAACCAGAAT TTTGGAAGAG CAAATGGGGC TGAGTGCAGT 3000

GCCTCATGCC TGTAATCC 3018

(2) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 968 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 221:

```
GGCACGAGGG CCGCGGGACA TCCACGGGGC GCGAGTGACA CGCGGGAGGG AGAGCAGTGT     60
TCTGCTGGAG CCGATGCCAA AAACCATGCA TTTCTTATTC AGATTCATTG TTTTCTTTTA    120
TCTGTGGGGC CTTTTTACTG CTCAGAGACA AAAGAAAGAG GAGAGCACCG AAGAAGTGAA    180
AATAGAAGTT TTGCATCGTC CAGAAAACTG CTCTAAGACA AGCAAGAAGG GAGACCTACT    240
NAAATGCCCA TTATGACGGC TACCTGGCTA AAGACGGCTC GAAATTCTAC TGCAGCCGGA    300
CACAAAATGA AGGCCACCCC AAATGGTTTG TTCTTGGTGT TGGGCAAGTC ATAAAAGGCC    360
TAGACATTGC TATGACAGAT ATGTGCCCTG GAGAAAAGCG AAAAGTAGTT ATACCCCCTT    420
CATTTGCATA CGGAAAGGAA GGCTATGCAG AAGGCAAGAT TCCACCGGAT GCTACATTGA    480
TTTTTGAGAT TGAACTTTAT GCTGTGACCA AAGGACCACG GAGCATTGAG ACATTTAAAC    540
AAATAGACAT GGACAATGAC AGGCAGCTCT CTAAAGCCGA GATAAACCTC TACTTGCAAA    600
GGGAATTTGA AAAAGATGAG AAGCCACGTG ACAAGTCATA TCAGGATGCA GTTTTAGAAG    660
ATATTTTTAA GAAGAATGAC CATGATGGTG ATGGCTTCAT TTCTCCCAAG GAATACAATG    720
TATACCAACA CGATGAACTA TAGCATATTT GTATTTCTAC TTTTTTTTTT TAGCTATTTA    780
CTGTACTTTA TGTATWAAAC AAAGTCMCTT TTCTCCMAGT TGKATTTGCT ATTTTTCCCC    840
TATGAGAAGA TATTTTGATC TCCCCAATAC ATTGATTTTG GTATAATAAA TGTGAGGCTG    900
TTTTGCAAAC TTAAAAAAAA ATTTAAAAAA ACTGGAGGGG GGCCCGTACC CAANTCGCCG    960
NATATGAT                                                             968
```

(2) INFORMATION FOR SEQ ID NO: 222:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1404 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 222:

```
CGTTTTCCGG CCGTGCGTTT GTGGCCGTCC GGCCTCCCTG ACATGCAGCC CTCTGGACCC     60
CGAGGTTGGA CCCTACTGTG ACACACCTAC CATGCGGACA CTCTTCAACC TCCTCTGGCT    120
TGCCCTGGCC TGCAGCCCTG TTCACACTAC CCTGTCAAAG TCAGATGCCA AAAAAGCCGC    180
```

CTCAAAGACG CTGCTGGAGA AGAGTCAGTT TTCAGATAAG CCGGTGCAAG ACCGGGGTTT 240

GGTGGTGACG GACCTCAAAG CTGAGAGTGT GGTTCTTGAG CATCGCAGCT ACTGCTCGGC 300

AAAGGCCCGG GACAGACACT TTGCTGGGGA TGTACTGGGC TATGTCACTC CATGGAACAG 360

CCATGGCTAC GATGTCACCA AGGTCTTTGG GAGCAAGTTC ACACAGATCT CACCCGTCTG 420

GCTGCAGCTG AAGAGACGTG GCCGTGAGAT GTTTGAGGTC ACGGGCCTCC ACGACGTGGA 480

CCAAGGGTGG ATGCGAGCTG TCAGGAAGCA TGCCAAGGGC CTGCACATAG TGCCTCGGCT 540

CCTGTTTGAG GACTGGACTT ACGATGATTT CCGGAACGTC TTAGACAGTG AGGATGAGAT 600

AGAGGAGCTG AGCAAGACCG TGGTCCAGGT GGCAAAGAAC CAGCATTTCG ATGGCTTCGT 660

GGTGGAGGTC TGGAACCAGC TGCTAAGCCA GAAGCGCGTG GGCCTCATCC ACATGCTCAC 720

CCACTTGGCC GAGGCTCTGC ACCAGGCCCG GCTGCTGGCC CTCCTGGTCA TCCCGCCTGC 780

CATCACCCCC GGGACCGACC AGCTGGGCAT GTTCACGCAC AAGGAGTTTG AGCAGCTGGC 840

CCCCGTGCTG GATGGTTTCA GCCTCATGAC CTACGACTAC TCTACAGCGC ATCAGCCTGG 900

CCCTAATGCA CCCCTGTCCT GGGTTCGAGC CTGCGTCCAG GTCCTGGACC CGAAGTCCAA 960

GTGGCGAAGC AAAATCCTCC TGGGGCTCAA CTTCTATGGT ATGGACTACG CGACCTCCAA 1020

GGATGCCCGT GAGCCTGTTG TCGGGGCCAG GTACATCCAG ACACTGAAGG ACCACAGGCC 1080

CCGGATGGTG TGGGACAGCC AGGYCTCAGA GCACTTCTTC GAGTACAAGA AGAGCCGCAG 1140

TGGGAGGCAC GTCGTCTTCT ACCCAACCCT GAAGTCCCTG CAGGTGCGGC TGGAGCTGGC 1200

CCGGGAGCTG GGCGTTGGGG TCTCTATCTG GGAGCTGGCC AGGGCCTGGA CTACTTCTAC 1260

GACCTGCTCT AGGTGGGCAT TGCGGCCTCC GCGGTGGACG TGTTCTTTTC TAAGCCATGG 1320

AGTGAGTGAG CAGGTGTGAA ATACAGGCCT NCACTCCGTT TGCTGTGAAA AAAAAAAAAA 1380

AAAAAAAAAA AAAAAAAAAA AAAA 1404

(2) INFORMATION FOR SEQ ID NO: 223:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 707 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 223:

CATGGAGCGG ATCAAGGAGG ACCGGCCCAT CACCATCAAG GACGAGAAGG GCAAGCTCAA 180

CCGCTGCATC GCAGACGTGG TCTCGCTCTT CATCACGGTC ATGGACAAGC TCCGCCTGGA 240

GATCCGCGCC ATGGATGAGA TCCAGCCCGA CCTGCGAGAG CTCATGGACA CCATGCACCG 300

CATGAGCCAC CTCCCACCCG ACTTTGAGGG CCGCCAGACG GTCAGCCAGT GGCTGCAGAC 360

CCTGAGCGGC ATGTCGGCGT CAGATGAGCT GGACGACTCA CAGGTGCCTC AGATGCTGTT 420

CGACCTGGAG TCAGCCTACA ACGCCTTCAA CCGCTTCCTG CATGCCTGAG CCCGGGGCAC 480

TAGCCCTTGC ACAGAAGGGC AGAGTCTGAG GCGATGGCTC CTGGTCCCCT GTCCGCCACA 540

CAGGCCGTGG TCATCCACAC AACTCACTGT TTGCAGCTGC CTGTCTGGTG TCTGTCTTTG 600

GTGTCAGAAC TTTTGGGCCG GGCCCCTCCC CACAATAAAG ATGCTCTCCG ACCTTCAAAA 660

AAAAAAAAAA AAAAACTCRG GGGGGGCCCG GTCCCAATCC CCCCNEEI 707

(2) INFORMATION FOR SEQ ID NO: 224:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1384 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 224:

GGGGAACTGC AGTGACAGCA GGAGTAAGAG TGGGAGGCAG GACAGAGCTG GGACACAGGT 60

ATGGAGAGGG GGTTCAGCGA GCCTAGAGAG CGCAGACTAT CAGGGTGCCG GCGGTGAGAA 120

TCCAGGGAGA GGAGCGGAAA CAGAAGAGGG GCAGAAGACC GGGGCACTTG TGGGTTGCAG 180

AGCCCCTCAG CCATGTTGGG AGCCAAGCCA CACTGGCTAC CAGGTCCCCT ACACAGTCCC 240

GGGCTGCCCT TGGTTCTGGT GCTTCTGGCC CTGGGGGCCG GGTGGGCCCA GGAGGGGTCA 300

GAGCCCGTCC TGCTGGAGGG GGAGTGCCTG GTGGTCTGTG AGCCTGGCCG AGTTGCTGCA 360

GGGGGGCCCG GGGGAGCAGC CCTGGGAGAG GCACCCCCTG GGCGAGTGGC ATTTGCTGCG 420

GTCCGAAGCC AMCACCATGA GCCAGCAGGG GAAACCGGCA ATGGCACCAK TGGGGCCATC 480

TACTTCGACC AGGTCCTGGT GAACGAGGGC GGTGGCTTTG ACCGGGCCTC TGGCTCCTTC 540

GTAGCCCCTG TCCGGGGTGT CTACAGCTTC CGGTTCCATG TGGTGAAGGT GTACAACCGC 600

CAAACTGTCC AGGTGAGCCT GATGCTGAAC ACGTGGCCTG TCATCTCAGC CTTTGCCAAT 660

GATCCTGACG TGACCCGGGA GGCAGCCACC AGCTCTGTGC TACTGCCCTT GGACCCTGGG 720

GACCGAGTGT CTCTGCGCCT GCGTCGGGGG AATCTACTGG GTGGTTGGAA ATACTCAAGT 780

TTCTCTGGCT TCCTCATCTT CCCTCTCTGA GGACCCAAGT YTTTCAAGCA CAAGAATCCA 840

GCCCCTGACA ACTTTCTTCT GCCCTCTCTT GCCCCAGAAA CAGCAGAGGC AGGAGAGAGA 900

CTCCCTCTGG YTCCTATCCC ACYTCTTTGC ATGGGAMCCT GTGCCAAACA CCCAAGTTTA 960

AGARAARARY ARARCTGWGG CAGGTATACA GAGCTGGAAG TGGACCATGG AAAACATSGA 1020

TAACCATGCA TCYTCTTGCT TGGCCACCTC CTGAAACTGT CCACCTTTGA AGTTTGAACT 1080

TTAGTCCCTC CAMACTCTGA CTGCTGCCTC CTTCCTCCCA GCTCTCTCAC TGAGTTATYT 1140

TCACTGTACC TGTTCCAGCA TATCCCCACT ATCTCTCTTT CTCCTGATCT GTGCTGTCTT 1200

ATTCTCCTCC TTAGGCTTCC TATTACCTGG GATTCCATGA TTCATTCCTT CAGACCCTCT 1260

CCTGCCAGTA TGCTAAACCC TCCCTCTCTC TTTCTTATCC CGCTGTCCCA TTGGCCCAGC 1320

CTGGATGAAT CTATCAATAA AACAACTAGA GAATGGTGGT CAAAAAAAAA AAAAAAAAAC 1380

TCCA 1384

(2) INFORMATION FOR SEQ ID NO: 225:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 760 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 225:

GGGTCGACCC ACGCGTCCGC TGACCAGTCC GTTATAGATA CTTCTTCCTA TACCAAAACT 60

GTTTAAACAG GTGCCACCAC AAGGGATGTC GTCCTTACTC TCTGCGGGTC TTCAAGCATC 120

CCTTTGTGGG AAARGTCTCT GGCCAAGCAC GTGGTATTTG GTCTGCTGCT TGCTTCCCTT 180

TTTCCACCAG GGATGTTGTG ATCATAAGTC AAAACAACAG TATATTCCAA ATCTCAAAAG 240

CTATTGTGGC CTGAGCACAA TTGAAATCTA GCAGAGTTTT TCCTATGTAG CTTTAGAGTA 300

ACTCTTCTGC TTCTCTGTCA CTTACAATTC AGGTTCTGCC TTTGCCTAAG AGCATGAGCA 360

GAAGAGTCCT CATGTGACGC TTAGTTCTAT TGCAGTCCTG GGTGAAACTA TTTAAGCWAT 420

GGGGCTGCTK CTCCCCANWT CCTCCCTAAC AATTCGTTGT GTGGACTTCT CATCTAAAAG 480

GTTAGTGGCT TTTGCTTGGG ATCAGTGCTC TCTATTGATG TTCTTGCTGG TCTCCAGACA 540

CATTCCTGTT GCATTAAGAC TTGAAAGACT TGTAGATGTG TGATGTTCAG GCACAGGATG 600

[illegible] [illegible] [illegible] [illegible] TTTGATACCA [illegible] 660

(2) INFORMATION FOR SEQ ID NO: 226:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2057 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 226:

CCGAGCCGGC TGCGCCGGGG GAATCCGTGC GGGCGCCTTC CGTCCCRGTC CCATCCTCGC 60

CGCGCTCCAG CACCTCTGAA GTTTTGCAGC GCCCAGAAAG GAGGCGAGGA AGGAGGGAGT 120

GTGTGAGAGG AGGGAGCAAA AAGCTCACCC TAAAACATTT ATTTCAAGGA GAAAAGAAAA 180

AGGGGGGCGG CAAAAATGGC TGGGGCAATT ATAGAAAACA TGAGCACCAA GAAGCTGTGC 240

ATTGTTGGTG GGATTCTGCT CGTGTTCCAA ATCATCGCCT TTCTGGTGGG AGGCTTGATT 300

GCTCCAGGGC CCACAACGGC AGTGTCCTAC ATGTCGGTGA AATGTGTGGA TGCCCGTAAG 360

AACCATCACA AGACAAAATG GTTCGTGCCT TGGGGACCCA ATCATTGTGA CAAGATCCGA 420

GACATTGAAG AGGCAATTCC AAGGGAAATT GAAGCCAATG ACATCGTGTT TTCTGTTCAC 480

ATTCCCCTCC CCCACATGGA GATGAGTCCT TGGTTCCAAT TCATGMTGTT TATCCTGCAG 540

CTGGACATTG CCTTCAAGCT AAACAACCAA ATCAGRGAAA ATGCAGAAGT CTCCATGGAC 600

GTTTCCCTGG CTTACCGTGA TGACGCGTTT GCTGAGTGGA CTGAAATGGC CCATGAAAGA 660

GTACCACGGA AACTCAAATG CACCTTCACA TCTCCCAAGA CTCCAGAGCA TGGAGGGCCG 720

GTTACTATGA ATGTGATGTC CTTCCTTTCA TGGAAATTGG GTCTGTGGCC CATGAAGTTT 780

TACCTTTTAA ACATCCGGCT GCCTGTGAAT GAGAAGAAGA AAATCAATGT GGGAATTGGG 840

GAGATAAAGG ATATCCGGTT GGTGGGGATC CACCAAAATG GAGGCTTCAC CAAGGTGTGG 900

TTTGCCATGA AGACCTTCCT TACGCCCAGC ATCTTCATCA TTATGGTGTG GTATTGGAGG 960

AGGATCACCA TGATGTCCCG ACCCCCAGTG CTTCTGGAAA AAGTCATCTT TGCCCTTGGG 1020

ATTTCCATGA CCTTTATCAA TATCCCAGTG GAATGGTTTT CCATCGGGTT TGACTGGACC 1080

TGGATGCTGC TGTTTGGTGA CATCCGACAG GCATCTTCTA TGCRATGCTT CTKTCCTTCT 1140

GGATCATCTT CTGTGGCGAG CACATGATGG ATCAGCACGA GCGGAACCAC ATCGCAGGGT 1200

ATTGGAAGCA AGTCGGACCC ATTGCCGTTG GTCCTTCTGC CTCTTCATAT TTGACATGTG 1260

TGAGAGAGGG GTACAACTCA CGAATCCCTT CTACAGTATC TGGACTACAG ACATTGGGAA 1320

CAGAGCTGGC CATGGCTTTC ATCATCGTGG CTGGAATCTG CCTCTGCCTC TAACTTCCTG 1380

TTTCTATGCT TCATGGTATT TCAGGTGTTT CGGAACATCA GTGGGAAGCA GTCCAGCCTG 1440

CCAGCTATGA GCAAAGTCCG GCGGCTACAC TATGAGGGGC TAATTTTTAG GTTCAAGTTC 1500

CTCATGCTTA TCACCTTGGC TTGCGCTGCC ATGACTGTCA TCTTCTTCAT CGTTAGTCAG 1560

GTAACGGAAG GCCATTGGGA AATGGGGCGG CGTCACAGTC CCAAGTGAAC AGTGCCTTTT 1620

TCACAGGCAT CTATGGGATG TGGAATCTGT ATGTCTTTGC TCTGATGTTC TTGTATGCAC 1680

CATCCCATAA AAACTATGGA GAAGACCAGT CCAATGGAAT GCAACTCCCA TGTAAATCGA 1740

GGCAAGATTG TGCTTTGTTT GTTTCGGAAC TTTATCAAGA ATTGTTCAGC GCTTCGAAAT 1800

ATTCCTTCAT CAATGACAAC GCAGCTTCTG GTATTTGAGT CAACAAGGCA ACACATGTTT 1860

ATCAGCTTTG CATTTGCAGT TGTCACAGTC ACATTGATTG TACTTGTATA CGCACACAAA 1920

TACACTCATT TAGCCTTTAT TTCAAAATGT TAAATATAAG GAAAAAAGCG TCAACAATAA 1980

ATATTCTTTG AGTATTGTCT TACTTCTCTT AAAAAAAAAA AAAAAAACTC GTGCCGAATT 2040

CGGCACGAGC GGCACCA 2057

(2) INFORMATION FOR SEQ ID NO: 227:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2084 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 227:

GGCAGAGGGC CATTTCCTGC AAAGAGCCAA ACCCCCATTC CTCTGTGCCC CTCCTCTCCC 60

ACCAAGTGCT TTATAAAAAT AGTTCTTGTT ACCGGAAATA ACTGTTCATT TTTCACTCCT 120

CCCTCCTAGG TCACACTTTT CAGAAAAAGA ATCTGCATCC TGGAAACCAG AAGAAAAATA 180

TGAGACGGGG AATCATCGTG TGATGTGTGT GCTGCCTTTG GCTGAGTGTG TGGAGTCCTG 240

CTCAGGTGTT AGGTACAGTG TGTTTGATCG TGGTGGCTTG AAGGGAACCG CTTGTTCAGA 300

GCTGTGACTG CGGCTGCACT GCAGAGAAGC TCCCCTTGGC TGCTCGTAGC GCCGGGCCTT 360

CTCTCCTCGT CATCATCCAG AGCAGCCAGT GTCCGGGAGG CAGAAGGTAC CGGGGCAGCT 420

ACTGGAGGAC TGTGCGGCCC TGCCTGGGCT GCCCCCTCCG CCGTGGGGCC CTGTTGCTGC 480

TGTCCATCTA TTTCTACTAC TCCCTCCCAA ATGCGGTCGG CCCGCCCTTC ACTTGGATGC 540

[illegible] TGGGCCTCAA GGGCCTGGCT 600

ACTTACAATT AGCATTAGAA [illegible] TGAGCCAA[illegible]TGTNATATT [illegible]

CTCCTCCCAT TGGACTGTGG GGTGCCTGAT AACCTGAGTA TGGCTGACCC CAACATTCGC 840

TTCCTGGATA AACTGCCCCA GCAGACCGGT GACCGTGCTG GCATCAAGGA TCGGGTTTAC 900

AGCAACAGCA TCTATGAGCT TCTGGAGAAC GGGCAGCGGG CGGGCACCTG TGTCCTGGAG 960

TACGCCACCC CCTTGCAGAC TTTGTTTGCC ATGTCACAAT ACAGTCAAGC TGGCTTTAGC 1020

GGGGAGGATA GGCTTGAGCA GGCCAAACTC TTCTGCCGGA CACTTGAGGA CATCCTGGCA 1080

GATGCCCCTG AGTCTCAGAA CAACTGCCGC CTCATTGCCT ACCAGGAACC TGCAGATGAC 1140

AGCAGCTTCT CGCTGTCCCA GGAGGTTCTC CGGCACCTGC GGCAGGAGGA AAAGGAAGAG 1200

GTTACTGTGG GCAGCTTGAA GACCTCAGCG GTGCCCAGTA CCTCCACGAT GTCCCAAGAG 1260

CCTGAGCTCC TCATCAGTGG AATGGAAAAG CCCCTCCCTC TCCGCACGGA TTTCTCTTGA 1320

GACCCAGGGT CACCAGGCCA GAGCCTCCAG TGGTCTCCAA GCCTCTGGAC TGGGGGCTCT 1380

CTTCAGTGGC TGAATGTCCA GCAGAGCTAT TTCCTTCCAC AGGGGGCCTT GCAGGGAAGG 1440

GTCCAGGACT TGACATCTTA AGATGCGTCT TGTCCCCTTG GGCCAGTCAT TTCCCCTCTC 1500

TGAGCCTCGG TGTCTTCAAC CTGTGAAATG GGATCATAAT CACTGCCTTA CCTCCCTCAC 1560

GGTTGTTGTG AGGACTGAGT GTGTGGAAGT TTTTCATAAA CTTTGGATGC TAGTGTACTT 1620

AGGGGGTGTG CCAGGTGTCT TTCATGGGGC CTTCCAGACC CACTCCCCAC CCTTCTCCCC 1680

TTCCTTTGCC CGGGGACGCC GAACTCTCTC AATGGTATCA ACAGGCTCCT TCGCCCTCTG 1740

GCTCCTGGTC ATGTTCCATT ATTGGGGAGC CCCAGCAGAA GAATGGAGAG GAGGAGGAGG 1800

CTGAGTTTGG GGTATTGAAT CCCCCGGCTC CCACCCTGCA GCATCAAGGT TGCTATGGAC 1860

TCTCCTGCCG GGCAACTCTT GCGTAATCAT GACTATCTCT AGGATTCTGG CACCACTTCC 1920

TTCCCTGGCC CCTTAAGCCT AGCTGTGTAT CGGCACCCCC ACCCCACTAG AGTACTCCCT 1980

CTCACTTGCG GTTTCCTTAT ACTCCACCCC TTTCTCAACG GTCCTTTTTT AAAGCACATC 2040

TCAGATTAAA AAAAAAAAAA AAAAAAAAAA AGGGGGGGCN GCNT 2084

(2) INFORMATION FOR SEQ ID NO: 228:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2143 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 228:

TCGACCCACG CGTCCGGTTG AATTCCTTGA CCTGCAAACA CATATTTATT AGCCTGACTC 60

AAACAATGAA GCTATTAAAA CTTCGGAGGA ACATTGTAAA ACTCTCTTTG TATCGGCATT 120

TCACCAACAC GCTTATTTTG GCAGTGGCAG CATCCATTGT GTTTATCATC TGGACAACCA 180

TGAAGTTCAG AATAGTGACA TGTCAGTCGG ACTGCCGGGA GCTGTGGGTA GACGATGCCA 240

TCTGGCGCTT GCTGTTCTCC ATGATCCTCT TTGTCATCAT GGTTCTCTGG CGACCATCTG 300

CAAACAACCA GAGGTTTGCC TTTTCACCAT TGTCTGAGGA AGAGGAGGAG GATGAACAAA 360

AGGAGCCTAT GCTGAAAGAA AGCTTTGAAG GAATGAAAAT GAGAAGTATC AAACAAGAAC 420

CCAATGGAAA TAGTAAAGTT AACAAAGCAC AGGAAGATGA TTTGAAGTGG GTAGAAGAGA 480

ATGTTCCTTC TTCTGTGACA GATGTAGCAC TTCCAGCCCT TCTGGATTCA GATGAGGAAC 540

GAATGATCAC ACACTTTGAA AGGTCCAAAA TGGAGTAAGG AATGGGAAGA TTTGCAGTTA 600

AAGATGGCTA CCATCAGGGA ACACATCAGC ATCTGTGTCA GTCTTCTGTA CGGCTCCATG 660

GGATTAAAGG AACCAATGAC ATCCTGATCT GTTCCTTGAT CTTTGGGCAT TGGAGTTGGC 720

GAGAGGTGTC AGAACAAAGA GAACATCTTA CTGAAAACAA GTTCATAAGA TGAGAAAAAT 780

CTACGAGCTT CTTATTTACA ACACTGCTGC CCCCTTTCCT CCCAGACTCT GACATGGATG 840

TTCATGCAAC TTAAGTGTGT TGTTCCTGAA CTTTCTGTAA TGTTTCATTT TTTAAATCTG 900

ACAAACTAAA AAGTTTAACG TCTTCTAAAA GATTGTCATC AACACCATAA TATGTAATCT 960

CCAGGAGCAA CTGCCTGTAA TTTTTATTTA TTTAGGGAGT TACATAGGTG ATGGCGGAAA 1020

TTGTTAACTA CCTTTCATTT TCCTGGGAAG TCAAGGTTAC ATCTTGCAGA GGTTGTTTTG 1080

AGAAAAAAGG GCCCTTCTGA GTTAAGGAGC CATAGTTCTA TCAATGATCA AAAGAAAAAA 1140

AAAAAAAAGA GAAACTGTTA CAGTATGATT CAGATCATTT AAAAAAGCAA AATCAAGTGC 1200

AATTTTGTTT ACAAATGGTG TATATTAAAG ATTTTTCTAT TTCAGATGTA CTTTAAAGAG 1260

AAATATTAGC TTAACTCTTT TGACATCTGC TATTGTGACA CATCCCATTG CTGGCAATGT 1320

GGTGCACACT CCGAAACTTT TAACTACTGT TTTGTAAGCC TCCAAGGGTG GCATTGCAGG 1380

GTCCTTAGGC AATGTTTTGT TTGCCTTTAT GCAGAGAGGT GCTCCAAGTG CTGTGATTGA 1440

GCACCGTGCT AGAGGAACTG TAATGCTTCA GAAGTTGTAG CTTATACAAA GGAAACAGGT 1500

CCTGCTGGCT TAATTTAAAC AGTTATTGCA TGAAGTAGCG TGGAGGCCCT GGACTGCTGC 1560

TCGTTCTTTA GGATGGACTG TTCTGGTATC TGGTATTGGT TTAGAGACTG TTAATAAGGG 1620

[illegible] [illegible] TCATTTGAAT [illegible]TCTATTT CTCTTTTAAT GCTTTTATCC 1680

TTCTGTCAAA CTCATGAAAA ATTTCTTTCT ATGCCTTTTA TT[illegible]TAGATT[illegible] T[illegible]TTATTTT[illegible] 1860

TGTTAAAACC AATGACCACA TGACCACAAT CTTCACTAAC TCATACTGCA GTGAAAGTGT 1920

TAACCCTTAG GTAGTTTCTC TACAACTCTT TGCTATGGTG ATTTTTAAAA AAGTTTCCTA 1980

GGGAAGTATC TCTGAGGGAA CAGGTAATCT GAAGGAACTG ACTATATTCT CCATGGCTAA 2040

GTCCATTAGG CCAAAAGNCT GGGTGGGTAT TGGTTGTTAN GCTGTCTATT GGCATATTAA 2100

AAACGTAGGC CGGANGGAAT AATTAGGTTG TNATGCCGGC GGG 2143

(2) INFORMATION FOR SEQ ID NO: 229:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1025 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 229:

CCTGGCCCAC ATTGCTTCAT TGGCCTGGCC ATGCGCCTGT ACTATGGCAG CCGCTAGTCC 60

CTGACAACTT CCACCCTGAT TCCGGACCCT GTAGATTGGG CGCCACCACC AGATCCCCCT 120

CCCAGGCCTT CCTCCCTCTC CCATCAGCAG CCCTGTAACA AGTGCCTTGT GAGAAAAGCT 180

GGAGAAGTGA GGGCAGCCAG GTTATTCTCT GGAGGTTGGT GGATGAAGGG GTACCCTAGG 240

AGATGTGAAG TGTGGGTTTG GTTAAGGAAA TGCTTACCAT CCCCCACCCC CAACCAAGTT 300

CTTCCAGACT AAAGAATTAA GGTAACATCA ATACCTAGGC CTGAGAAATA ACCCCATCCT 360

TGTTGGGCAG CTCCCTGCTT TGTCCTGCAT GAACAGAGTT GATGAAAGTG GGGTGTGGGC 420

AACAAGTGGC TTTCCTTGCC TACTTTAGTC ACCCAGCAGA GCCACTGGAG CTGGCTAGTC 480

CAGCCCAGCC ATGGTGCATG ACTCTTCCAT AAGGGATCCT CACCCTTCCA CTTTCATGCA 540

AGAAGGCCCA GTTGCCACAG ATTATACAAC CATTACCCAA ACCACTCTGA CAGTCTCCTC 600

CAGTTCCAGC AATGCCTAGA GACATGCTCC CTGCCCTCTC CACAGTGCTG CTCCCCACAC 660

CTAGCCTTTG TTCTGGAAAC CCCAGAGAGG GCTGGGCTTG ACTCATCTCA GGGAATGTAG 720

CCCCTGGGCC CTGGCTTAAG CCGACACTCC TGACCTCTCT GTTCACCCTG AGGGCTGTCT 780

TGAAGCCCGC TACCCACTCT GAGGCTCCTA GGAGGTACCA TGCTTCCCAC TCTGGGGCCT 840

GCCCCTGCCT AGCAGTCTCC CAGCTCCCAA CAGCCTGGGG AAGCTCTGCA CAGAGTGACC 900

TGAGACCAGG TACAGGAAAC CTGTAGCTCA ATCAGTGTCT CTTTAACTGC ATAAGCAATA 960

AGATCTTAAT AAAGTCTTCT AGGCTGTAGG GTGGTTCCTA CAACCACAGC CAAAAAAAAA 1020

AAAAA 1025

(2) INFORMATION FOR SEQ ID NO: 230:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1250 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 230:

```
GCCCACGCGT CCGCCCACGC GTCCGGCGGT GCGGAGTATG GGGCGCTGAT GGCCATGGAG      60
GGCTACTGGC GCTTCCTGGC GCYGCTGGGG TCGGCACTGC TCGTCGGCTT CCTGTCGGTG     120
ATSTTCGCCC TCGTCTGGGT CCTCCACTAC CGAGAGGGGC TTGGCTGGGA TGGGAGCGCA     180
CTAGAGTTTA ACTGGCACCC AGTGCTSATG GTCACCGGCT TCGTCTTCAT CCAGGGCATC     240
GCCATCATCGT CTACAGACTG CCGTGGACCT GGAAATGCAG CAAGCTCCTG ATGAAATCCA     300
TCCATGCAGG GTTAAATGCA GTTGCTGCCA TTCTTGCAAT TATCTCTGTG GTGGCCGTGT     360
TTGAGAACCA CAATGTTAAC AATATAGCCA ATATGTACAG TCTGCACAGC TGGGTTGGAC     420
TGATAGCTGT CATATGCTAT TTGTTACAGC TTCTTTCAGG TTTTTCAGTC TTTCTGCTTC     480
CATGGGCTCC GCTTTCTCTC CGAGCATTTC TCATGCCCAT ACATGTTTAT TCTGGAATTG     540
TCATCTTTGG AACAGTGATT GCAACAGCAC TTATGGGATT GACAGAGAAA CTGATTTTTT     600
CCCTGAGAGA TCCTGCATAC AGTACATTCC CGCCAGAAGG TGTTTTCGTA AATACGCTTG     660
GCCTTCTGAT CCTGGTGTTC GGGGCCCTCA TTTTTTGGAT AGTCACCAGA CCGCAATGGA     720
AACGTCCTAA GGAGCCAAAT TCTACCATTC TTCATCCAAA TGGAGGCACT GAACAGGGAG     780
CAAGAGGTTC CATGCCAGCC TACTCTGGCA ACAACATGGA CAAATCAGAT TCAGAGTTAA     840
ACARTGAAGT AGCAGCAAGG AAAAGAAACT TAGCTCTGGA TGAGGCTGGG CAGAGATCTA     900
CCATGTAAAA TGTTGTAGAG ATAGAGCCAT ATAACGTCAC GTTTCAAAAC TAGCTCTACA     960
GTTTTGCTTC TCCTATTAGC CATATGATAA TTGGGCTATG TAGTATCAAT ATTTACTTTA    1020
ATCACAAAGG ATGGTTTCTT GAAATAATTT GTATTGATTG AGGCCTATGA ACTGACCTGA    1080
ATTGGAAAGG ATGTGATTAA TATAAATAAT AGCAGATATA AATTGTGGTT ATGTTACCTT    1140
TATCTTGTTG AGGACCACAA CATTAGCACG GTGCCTTGTG CAKAATAGAT ACTCAATATG    1200
TGAATATGTG TCTACTAGTA GTTAATTGGA TAAACTGGCA GCATCCCTGA               1250
```

(2) INFORMATION FOR SEQ ID NO: 231:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1811 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 231:

```
CNGNCAGTAC CGGTCNGATT CCCGGGTCGA CCCACGCGTC CGCTGCATTC CAGGGCCTTT     60
CAGTGGCTTT CATTCTGAAG TTCCTGGATA ACATGTTCCA TGTCTTGATG GCCCAGGTTA    120
CCASTGTCAT TATCACAACA GTGTCTGTCC TGGTCTTTGA CTTCAGGCCC TCCCTGGAAT    180
TTTTCTTGGA AGCCSCATCA GTCSTYCTCT CTATATTTAT TTATAATGCC AGCAAGCCTC    240
AAGTTCCGGA ATACGCACCT AGGCAAGAAA GGATCCGAGA TCTAAGTGGC AATCTTTGGG    300
AGCGTTCCAG TGGGGATGGA GAAGAACTAG AAAGACTTAC CAAACCCAAG AGTGATGAGT    360
CAGATGAAGA TACTTTCTAA CTGGTACCCA CATAGTTTGC AGCTCTCTTG AACCTTATTT    420
TCACATTTTC AGTGTTTGTA ATATTTATCT TTTCACTTTG ATAAACCAGA AATGTTTCTA    480
AATCCTAATA TTCTTTGCAT ATATCTAGCT ACTCCCTAAA TGGTTCCATC CAAGGCTTAG    540
AGTACCCAAA GGCTAAGAAA TTCTAAAGAA CTGATACAGG AGTAACAATA TGAAGAATTC    600
ATTAATATCT CAGTACTTGA TAAATCAGAA AGTTATATGT GCAGATTATT TTCCTTGGCC    660
TTCAAGCTTC CAAAAAACTT GTAATAATCA TGTTAGCTAT AGCTTGTATA TACACATAGA    720
GATCAATTTG CCAAATATTC ACAATCATGT AGTTCTAGTT TACATGCCAA AGTCTTCCCT    780
TTTTAACATT ATAAAAGCTA GGTTGTCTCT TGAATTTTGA CGCCCTAGAG ATAGTCATTT    840
TGCAAGTAAA GAGCAACGGG ACCCTTTCTA AAAACGTTGG TTGAAGGACC TAAATACCTG    900
GCCATACCAT AGATTTGGGA TGATGTAGTC TGTGCTAAAT ATTTTGCTGA AGAAGCAGTT    960
TCTCAGACAC AACATCTCAG AATTTTAATT TTTAGAAATT CATGGGAAAT TGGATTTTTG   1020
TAATAATCTT TTGATGTTTT AAACATTGGT TCCCTAGTCA CCATAGTTAC CACTTGTATT   1080
TTAAGTCATT TAAACAAGCC ACGGTGGGGC TTTTTTCTCC TCAGTTTGAG GAGAAAAATC   1140
TTGATGTCAT TACTCCTGAA TTATTACATT TTGGAGAATA AGAGGGCATT TTATTTTATT   1200
AGTTACTAAT TCAAGCTGTG ACTATTGTAT ATCTTTCCAA GAGTTGAAAT GCTGGCTTCA   1260
GAATCATACC AGATTGTCAG TGAAGCTGAT GCCTAGGAAC TTTTAAAGGG ATCCTTTCAA   1320
AAGGATCACT TAGCAAACAC ATGTTGACTT TTAACTGATG TATGAATATT AATACTCTAA   1380
AAATAGAAAG ACCAGTAATA TATAAGTCAC TTTACAGTGC TACTTCACAC TTAAAAGTGC   1440
ATGGTATTTT TCATGGTATT TTGCATGCAG CCAGTTAACT CTCGTAGATA GAGAAGTCAG   1500
GTGATAGATG ATATTAAAAA TTAGCAAACA AAAGTGACTT GCTCAGGGTC ATGCAGCTGG   1560
GTGATGATAG AAGAGTGGGC TTTAACTGGC AGGCCTGTAT GTTTACAGAC TACCATACTG   1620
```

TAAATATGAG CTTTATGGTG TCATTCTCAG AAACTTATAC ATTTCTGCTC TCCTTTCTCC 1680

TAAGTTTCAT GCAGATGAAT ATAAGGTAAT ATACTATTAT ATAATTCATT TGTGATATCC 1740

ACAATAATAT GACTGGCAAG AATTGGTGCA AATTTGTAAT TAAAATAATT ATTAAACCTA 1800

AAAAAAAAAN N 1811

(2) INFORMATION FOR SEQ ID NO: 232:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2271 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 232:

CTGACCTCAT GGCGTAGAGC CTAGCAACAG CGCAGGCTCC CAGCCGAGTC CGTTATGGCC 60

GCTGCCGTCC CGAAGAGGAT GAGGGGGCCA GCACAAGCGA AACTGCTGCC CGGGTCGGCC 120

ATCCAAGCCC TTGTGGGGTT GGCGGGGCCG CTGGTCTTGG CGCTCCTGCT TGTGTCCGCC 180

GCTCTATCCA GTGTTGTATC ACGGACTGAT TCACCGAGCC CAACCGTACT CAACTCACAT 240

ATTTCTACCC CAAATGTGAA TGCTTTAACA CATGAAAACC AAACCAAACC TTCTATTTCC 300

CAAATCAGCA CCACCCTCCC TCCCACGACG AGTACCAAGA AAAGTGGAGG AGCATCTGTG 360

GTCCCTCATC CCTCGCCTAC TCCTCTGTCT CAAGAGGAAG CTGATAACAA TGAAGATCCT 420

AGTATAGAGG AGGAGGATCT TCTGATGCTG AACAGTTCTC CATCCACAGC CAAAGACACT 480

CTAGACAATG GCGATTATGG AGAACCAGAC TATGACTGGA CCACGGGCCC CAGGGACGAC 540

GACGAGTCTG ATNGACACCT TGGAAGAAAA CAGGGGTTAC ATGGAAATTG AACAGTCAGT 600

GAAATCTTTT AAGATGCCAT CCTCAAATAT AGAAGAGGAA GACAGCCATT TCTTTTTTCA 660

TCTTATTATT TTTGCTTTTT GCATTGCTGT TGTTTACATT ACATATCACA ACAAAAGGAA 720

GATTTTTCTT CTGGTTCAAA GCAGGAAATG GCGTGATGGC CTTTGTTCCA AAACAGTGGA 780

ATACCATCGC CTAGATCAGA ATGTTAATGA GGCAATGCCT TCTTTGAAGA TTACCAATGA 840

TTATATTTTT TAAAGCACTG TCATTTGAAT TTGCTTATGT AATTTTATTT GCTTGACTTT 900

[illegible] [illegible] [illegible] [illegible]CAATTGGT ACTTAAATGA GAGGTGAGTC 960

TTTACACTGT TAGTTTTTAT T[illegible]TTTAGAT TTATTATGCT [illegible]TTTCTAAAA [illegible]TATTATTGA 1140

TGCTACTTTT AAAAGATCCC AAACTTGTAA CTAAATTCTG ACATATCTGT TACTGCTGAC 1200
TCACATTCAT TCTCCGCCAT TCAAATACTA TTTTTTATCC ACATTTTTTT TTGTTCCCAA 1260
ACTGTAATGT ACAAGGATAT GTGTGATAAT GCTTTGGATT TGAGTAATAT TTTTTTTTCT 1320
TCCAAGAAAA CTGCTTTGGA TATTTTTAGA TAATTTAAAC ATAATTTAGG ATAATGATAT 1380
TGCTCAATCT GACCACAATT TTAGGTAAAA CATTAAATGT GTCAAGAAAT CTTGGCAACA 1440
GAGACTCTGC AGCTTGCAGT GGACATAGAT AAAATGTTAC AGAGATACTA TTTTTTTGGT 1500
TGGAATTACT ATATTAAATT TAGAAGCAGA AACTGGTAAA ATGTTAAATA CATGTACAAT 1560
TGCTTTTAGT TAGCAATTGA TTGTAGCATG GGTTCCTCCA AGGTTTCAAG CAATGGGCAG 1620
AGTTTAAAAT TATATCAGAT TCGTTTACTT CGTTTATTAT TTTACAGTAA ATTTGAATAA 1680
ATCTTAGGGG TCATTATCAC TTAAATAATA CTGTACCTAG GTCTTTCAAA TTAAAATTAT 1740
ACCTGAATGA AGTTGTTTGT ATACATAAAG GATATTTGTG TACAATTACC TTTTTTCCCC 1800
CACACTTGTT TTCTTTGTTT TTGTTTTTTA TGGCAACTGG AAAGTATTTA CTATGGGATT 1860
CATTTATGTC TGTCTTTCTA TCATAAAGAA TTGATCAATA TGTAAATATG TGATTTGAAC 1920
CATGGTTGAC TTACAAGTGT CACTACAGCT TTTTAGAAAA CATAGCCCTA ATATATGTTA 1980
AGCAGGACCC GGGTCAGCCA GTGGGCTTGC GCTTTATGTA GAGCTGGAAG AAGGCCGTCC 2040
ATCCTGTCTC TTGGCGGGAC AGTGTACTTT CCTAATAGGG AAGGGAAGCA CAATGGAAAT 2100
ACCCCTGAAC CGTTTTATTG CAGTAATTTT TTTCATATCT GAAACTATTA TTTAATATTT 2160
TGAATAAGAT TTTAAAAAAT AAATGGCAAA GATATAAATC TAAAAAAAAA AAAAAAAAAA 2220
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAANANA N 2271

(2) INFORMATION FOR SEQ ID NO: 233:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1338 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 233:

CTTCCGGTTC TCCGGGCAGC TGCCACTGCT GTAGCTTCTG CCACCTGCCA CGACCGGGCC 60
TCTCCCTGGC GTTTGGTCAC CTCTGCTTCA TTCTCCACCG CGCCTATGGT CCCTCTTGGA 120
GCCAGCGTGG CGNGCCTGGC GGCTCCCGGG TGGTGAGAGA GCGGTCCGGG AACGATGAAG 180
GCCTCGCAGT GCTGCTGCTG TCTCAGCCAC CTCTTGGCTT CCGTCCTCCT CCTGCTGTTG 240
CTGCCTGAAC TAAGCGGGYC CCTGGMAGTC CTGCTGCAGG CAGCCGAGGC CGCGCCAGGT 300

YTTGGGCCTC CTGACCCTAG ACCAGGACAT TACCGCCGCT GCCACCGGGC CCTWACCCCT 360

GCCCAGCAGC CGGGCCGTGG TCTGGCTGAA GCTGCGGGGG CCGCGGGGCT CCGAGGGAGG 420

CAATGGCAGC AACCCTGTGG CCGGGCTTGA GACGGACGAT CACGGAGGGA AGGCCGGGGA 480

ARGCTCGGTG GGTGGCGGCC TTGCTGTGAG CCCCAACCCT GGCGACAAGC CCATGACCCA 540

GCGGGCCCTG ACCGTGTTGA TGGTGGTGAG CGGCGCGGTG CTGGTGTACT TCGTGGTCAG 600

GACGGTCAGG ATGAGAACAA CAAACCGAAA GACTAGGAGA TATGGAGTTT TGGACACTAA 660

CATAGAAAAT ATGGAATTGA CACCTTTAGA ACAGGATGAT GAGGATGATG ACAACACGTT 720

GTTTGATGCC AATCATCCTC GAAGATAAGA ATGTGCCTTT TGATGAAAGA ACTTTATCTT 780

TCTACAATGA AGAGTGGAAT TTCTATGTTT AAGGAATAAG AAGCCACTAT ATCAATGTTG 840

GGGGGGTATT TAAGTTACAT ATATTTTAAC AACCTTTAAT TTGCTGTTGC AATAAAATACC 900

GTATCCTTTT ATTATATCTT TATATGTATA GAAGTACTCT GTTAATGGGC TCAGAGATGT 960

TGGGGATAAA GTATACTGTA ATAATTTATC TGTTTGAAAA TTACTATAAA ACGGTGTTTT 1020

CTGRTCGGTT TTTGTTTCCT GCTTACCATA TGATTGTAAA TTGTTTTATG TATTAATCAG 1080

TTAATGCTAA TTATTTTTGC TGATGTCATA TGTTAAAGAG CTATAAATTC CAACAACCAA 1140

CTGGTGTGTA AAAATAATTT AAAATYTCCT TTACTGAAAG GTATTTCCCA TTTTTGTGGG 1200

GAAAAGAAGC CAAATTTATT ACTTTGTGTT GGGGTTTTTA AAATATTAAG AAATGTCTAA 1260

GTTATTGTTT GCAAAACAAT AAATATGATT TTAAATTCTC TTAAAAAAAA AAAAAAAAAC 1320

CCCGGGGGGG GGCCCGGN 1338

(2) INFORMATION FOR SEQ ID NO: 234:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 234:

Met Leu Ser Thr Gly Ile Glu Val Ala Arg Pro Pro Ala Thr Leu Leu
1 5 10 15

Gly Leu Met Phe Val Leu Thr Gly Met Pro Arg Gly Leu Arg Xaa
20 25 30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 115 amino acids

(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 235:

```
Met Asn Val Val Ile Val Ile Ile Leu Phe Ser Phe Asp Ser Val Gly
 1               5                  10                  15

Thr Met Phe Ser Cys Asn Arg Ile Pro Lys Ile Thr Val Leu Asn Lys
            20                  25                  30

Leu Lys Phe Xaa Cys Glu Val Leu Leu Arg Ile Gln Thr Ile Gln Gly
        35                  40                  45

Phe Tyr Arg Cys Thr Arg Ile Ser Arg Tyr Lys Gly Ile Phe Pro Asp
    50                  55                  60

Phe Cys Gln Ser Gln Cys Met Gly Cys Asn Pro Glu Ser Xaa Met Ala
65                  70                  75                  80

Val Pro Ala Leu Val Thr Pro Ile Leu Ala His Arg Lys Lys Glu Lys
                85                  90                  95

Gly Met Cys Leu Phe Thr Leu Ile Ile Ala Pro Thr Arg Cys Thr His
            100                 105                 110

Tyr Phe Cys Xaa
        115
```

(2) INFORMATION FOR SEQ ID NO: 236:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 103 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 236:

```
Met Ser Ser Ala Lys Ile Val Arg Gln Arg Gly Ala Val Pro Thr Tyr
 1               5                  10                  15

Tyr Thr Thr Glu Ala Gly Glu Ile Ile Phe Leu Val Leu Asn Trp Ser
            20                  25                  30

Leu Ser Ile Leu His Ile Val Asp Val Leu Cys Ser Lys Pro Glu Lys
        35                  40                  45

Ser Val Thr Glu Asp Ala Ala Ser Gly Leu Ser Gln Arg Met Thr Ala
    50                  55                  60

Leu Val Trp Arg Lys Gly Pro Asp Gly Gly Ser Arg Lys Pro Ile Leu
65                  70                  75                  80

Leu Leu Phe Phe Phe Leu Pro Leu Ile Leu Cys Phe His Ser Phe Ile
                85                  90                  95

His Ser Ser Asn Ile Cys Xaa
            100
```

(2) INFORMATION FOR SEQ ID NO: 237:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 237:

Met Ile Leu Phe Pro Gln Xaa Ala Leu Arg Leu Gly Xaa Trp Pro Arg
1 5 10 15

Thr Trp Ser Ile Leu Xaa Lys Tyr Ser Val Asn Phe Phe Ser Ala Tyr
20 25 30

Ser Pro Met Gly Ala Val Gly Thr Glu Phe
35 40

(2) INFORMATION FOR SEQ ID NO: 238:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 238:

Met Ile Ile Leu Leu Leu Phe Met Leu Leu Asn Asn Val Val Leu Val
1 5 10 15

Gln Glu Asp Asn Cys Gln Arg Lys Asn Thr Val Gln Glu Arg Arg Xaa
20 25 30

Trp Ser Gln Trp Xaa
35

(2) INFORMATION FOR SEQ ID NO: 239:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 128 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 239:

Met Ala Ala Xaa Pro Pro Gly Cys Thr Pro Pro Xaa Leu Leu Asp Ile
1 5 10 15

Ser Trp Leu Thr Glu Ser Leu Gly Ala Gly Gln Pro Val Pro Val Glu
20 25 30

His His Asn Thr Gly Leu Ser Glu Leu Leu Glu His Gly Val Cys Gln

65 70 75 80

Glu Val Glu Arg Val Arg Arg Ser Glu Arg Tyr Gln Thr Met Lys Val
85 90 95

Arg Arg Ala Gly Leu Gly Pro Thr Pro Gly Met Ser Cys Pro Gly Asn
100 105 110

Asp Asn Thr Val His Thr Met His Gly Glu Ala Asn Arg Gly Ser Xaa
115 120 125

(2) INFORMATION FOR SEQ ID NO: 240:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 240:

Met Ser Ile Leu Cys Cys Pro Xaa Leu Cys Leu Phe Phe Ser Phe Cys
1 5 10 15

Ile Ser Ser Gly Ser Cys Pro Phe Ser His Val Ser Gln Leu Ser Phe
20 25 30

Ile Ala Thr Phe Ser Gln Ser Ser Pro Val Leu Leu Val Pro Ala Tyr
35 40 45

Asn Thr Tyr Leu Ser Phe Leu Ala Phe Leu Asp Cys Ala Ser Leu Thr
50 55 60

Ser Thr Xaa
65

(2) INFORMATION FOR SEQ ID NO: 241:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 69 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 241:

Met Ser Thr Phe Gln Leu Leu Leu Leu Ile Leu Ala Gln Ser Thr Tyr
1 5 10 15

Lys Ile Lys Ser Lys Pro Leu His Met Thr Asn His Thr Leu Leu Asn
20 25 30

Ser Pro Gly Leu Asn Pro Ser Ser Pro Thr Leu Asn Phe Lys Thr Gln
35 40 45

Gln His Glu Ser Val Ser Tyr Ala Cys Cys His Met Arg Ser Leu His
50 55 60

His Ala Phe Ala Xaa
65

(2) INFORMATION FOR SEQ ID NO: 242:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 242:

Met Val Ser Val Val Leu Ile Phe Ser Phe Leu Ser Leu Thr Ile Ser
1 5 10 15

Thr Thr Ala Ser Ala Tyr Asn Gly Asn Asp Thr Gln Gly Trp Asn Asp
20 25 30

Lys Phe His Xaa Xaa Ser Val Lys Thr Gln Thr Xaa
35 40

(2) INFORMATION FOR SEQ ID NO: 243:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 243:

Met Ile Ser Asp Ala Gly Ala Gly Phe Gly Val Phe Leu Leu Val Pro
1 5 10 15

Arg Ala Gly His Cys Trp Gly Ala Gly Lys Pro Leu Pro Ser Cys Pro
20 25 30

Ser Val Ala Ser Ile Pro Ser Trp Val Leu Pro Ser Phe Leu Glu Arg
35 40 45

Gly Arg Xaa
50

(2) INFORMATION FOR SEQ ID NO: 244:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

Phe Leu Leu Leu Leu Met Phe Glu Thr Leu Ser Leu Ala Pro Ala Thr
20 25 30

Leu Lys Pro Leu Arg Val Thr Ser His Ser Xaa
35 40

(2) INFORMATION FOR SEQ ID NO: 245:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 61 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 245:

Met Ile Leu Met Pro Gly Leu Gly Thr Ser Arg Gln Arg Ser Val Pro
1 5 10 15

Phe Val Pro Thr Leu Asn Ala Ser Thr Pro Gly Ala Met Thr Gly Pro
20 25 30

Thr Ala Thr Leu Thr Ser Cys Gln Trp Thr Thr Ala Cys Arg Val Ser
35 40 45

Trp Ala Asn Gly Trp Thr Ser Leu Arg Thr Phe Arg Xaa
50 55 60

(2) INFORMATION FOR SEQ ID NO: 246:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 246:

Met Ser His His Ala Gln Pro Arg Phe Leu Leu Ile Thr Met Leu Leu
1 5 10 15

Gln Glu Ala Lys Pro Val Ser Asn Ile Pro His Leu Leu Glu Ser Trp
20 25 30

Tyr Phe Gly Xaa
35

(2) INFORMATION FOR SEQ ID NO: 247:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 247:

Met Asn Ser Leu Phe Trp Met Ile Leu Leu Pro Val Ser Gln Asp Gln
1 5 10 15

Val Val Glu Gly Leu Gln Gly Gly Phe Ser Gln Ile His Met Arg Ile
20 25 30

Leu Arg Lys His Leu Xaa
35

(2) INFORMATION FOR SEQ ID NO: 248:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 211 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 248:

Met Ser Arg Ser Xaa Asp Val Thr Asn Thr Thr Phe Leu Leu Met Ala
1 5 10 15

Ala Ser Ile Tyr Leu His Asp Gln Asn Pro Asp Ala Ala Leu Arg Ala
20 25 30

Leu His Gln Gly Asp Ser Leu Glu Cys Thr Ala Met Thr Val Gln Ile
35 40 45

Leu Leu Lys Leu Asp Arg Leu Asp Leu Ala Arg Lys Glu Leu Lys Arg
50 55 60

Met Gln Asp Leu Asp Glu Asp Ala Thr Leu Thr Gln Leu Ala Thr Ala
65 70 75 80

Trp Val Ser Leu Ala Thr Gly Gly Glu Lys Leu Gln Asp Ala Tyr Tyr
85 90 95

Ile Phe Gln Glu Met Ala Asp Lys Cys Ser Pro Thr Leu Leu Leu Leu
100 105 110

Asn Gly Gln Ala Ala Cys His Met Ala Gln Gly Arg Trp Glu Ala Ala
115 120 125

Glu Gly Leu Leu Gln Glu Ala Leu Asp Lys Asp Ser Gly Tyr Pro Glu
130 135 140

Thr Leu Val Asn Leu Ile Val Leu Ser Gln His Leu Gly Lys Pro Pro
145 150 155 160

Glu Val Thr Asn Arg Tyr Leu Ser Gln Leu Lys Asp Ala His Arg Ser
165 170 175

His Pro Phe Ile Lys Glu Tyr Gln Ala Lys Glu Asn Asp Phe Asp Arg
180 185 190

Leu Val Leu Gln Tyr Ala Pro Ser Ala Glu Ala Gly Pro Glu Leu Ser
195 200 205

(2) INFORMATION FOR SEQ ID NO: 249:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 548 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 249:

Met Glu Asp Ser Glu Ala Leu Gly Phe Glu His Met Gly Leu Asp Pro
1 5 10 15

Arg Leu Leu Gln Ala Val Thr Asp Leu Gly Trp Ser Arg Pro Thr Leu
20 25 30

Ile Gln Glu Lys Ala Ile Pro Leu Ala Leu Glu Gly Lys Asp Leu Leu
35 40 45

Ala Arg Ala Arg Thr Gly Ser Gly Lys Thr Ala Ala Tyr Ala Ile Pro
50 55 60

Met Leu Gln Leu Leu Leu His Arg Lys Ala Thr Gly Pro Val Val Glu
65 70 75 80

Gln Ala Val Arg Gly Leu Val Leu Val Pro Thr Lys Glu Leu Ala Arg
85 90 95

Gln Ala Gln Ser Met Ile Gln Gln Leu Ala Thr Tyr Cys Ala Arg Asp
100 105 110

Val Arg Val Ala Asn Val Ser Ala Ala Glu Asp Ser Val Ser Gln Arg
115 120 125

Ala Val Leu Met Glu Lys Pro Asp Val Val Val Gly Thr Pro Ser Arg
130 135 140

Ile Leu Ser His Leu Gln Gln Asp Ser Leu Lys Leu Arg Asp Ser Leu
145 150 155 160

Glu Leu Leu Val Val Asp Glu Ala Asp Leu Leu Phe Ser Phe Gly Phe
165 170 175

Glu Glu Glu Leu Lys Ser Leu Leu Cys His Leu Pro Arg Ile Tyr Gln
180 185 190

Ala Phe Leu Met Ser Ala Thr Phe Asn Glu Asp Val Gln Ala Leu Lys
195 200 205

Glu Leu Ile Leu His Asn Pro Val Thr Leu Lys Leu Gln Glu Ser Gln
210 215 220

Leu Pro Gly Pro Asp Gln Leu Gln Gln Phe Gln Val Val Cys Glu Thr
225 230 235 240

Glu Glu Asp Lys Phe Leu Leu Leu Tyr Ala Leu Leu Lys Leu Ser Leu
245 250 255

Ile Arg Gly Lys Ser Leu Leu Phe Val Asn Thr Leu Glu Arg Ser Tyr
260 265 270

Arg Leu Arg Leu Phe Leu Glu Gln Phe Ser Ile Pro Thr Cys Val Leu
275 280 285

```
Asn Gly Glu Leu Pro Leu Arg Ser Arg Cys His Ile Ile Ser Gln Phe
    290                 295                 300

Asn Gln Gly Phe Tyr Asp Cys Val Ile Ala Thr Asp Ala Glu Val Leu
305                 310                 315                 320

Gly Ala Pro Val Lys Gly Lys Arg Arg Gly Arg Gly Pro Lys Gly Asp
                325                 330                 335

Lys Ala Ser Asp Pro Glu Ala Gly Val Ala Arg Gly Ile Asp Phe His
            340                 345                 350

His Val Ser Ala Val Leu Asn Phe Asp Leu Pro Pro Thr Pro Glu Ala
        355                 360                 365

Tyr Ile His Arg Ala Gly Arg Thr Ala Arg Ala Asn Asn Pro Gly Ile
    370                 375                 380

Val Leu Thr Phe Val Leu Pro Thr Glu Gln Phe His Leu Gly Lys Ile
385                 390                 395                 400

Glu Glu Leu Leu Ser Gly Glu Asn Arg Gly Pro Ile Leu Leu Pro Tyr
                405                 410                 415

Gln Phe Arg Met Glu Glu Ile Glu Gly Phe Arg Tyr Arg Cys Arg Asp
            420                 425                 430

Ala Met Arg Ser Val Thr Lys Gln Ala Ile Arg Glu Ala Arg Leu Lys
        435                 440                 445

Glu Ile Lys Glu Glu Leu Leu His Ser Glu Lys Leu Lys Thr Tyr Phe
    450                 455                 460

Glu Asp Asn Pro Arg Asp Leu Gln Leu Leu Arg His Asp Leu Pro Leu
465                 470                 475                 480

His Pro Ala Val Val Lys Pro His Leu Gly His Val Pro Asp Tyr Leu
                485                 490                 495

Val Pro Pro Ala Leu Arg Gly Leu Val Arg Pro His Lys Lys Arg Lys
            500                 505                 510

Lys Leu Ser Ser Ser Cys Arg Lys Ala Lys Arg Ala Lys Ser Gln Asn
        515                 520                 525

Pro Leu Arg Ser Phe Lys His Lys Gly Lys Lys Phe Arg Pro Thr Ala
    530                 535                 540

Lys Pro Ser Xaa
545
```

(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25[illegible]:

Met Thr Thr Val Pro Pro Ser Pro Arg Pro Met Ser Arg Pro Ser Glu
1 5 10 15

Arg Asn Met Arg Arg Pro Arg Gly Pro Ser Pro Leu Pro Ala Ser Pro
20 25 30

Arg Asn Ser Thr Pro Asp Glu Pro Asp Val His Phe Ser Lys Lys Phe
35 40 45

Leu Asn Val Phe Met Ser Gly Arg Ser Arg Ser Ser Ser Ala Glu Ser
50 55 60

Phe Gly Leu Phe Ser Cys Ile Ile Asn Gly Glu Glu Gln Glu Gln Thr
65 70 75 80

His Arg Ala Ile Phe Arg Phe Val Pro Arg His Glu Asp Glu Leu Glu
85 90 95

Leu Glu Val Asp Asp Pro Leu Leu Val Glu Leu Gln Ala Glu Asp Tyr
100 105 110

Trp Tyr Glu Ala Tyr Asn Met Arg Thr Gly Ala Arg Gly Val Phe Pro
115 120 125

Ala Tyr Tyr Ala Ile Glu Val Thr Lys Glu Pro Glu His Met Ala Ala
130 135 140

Leu Ala Lys Asn Ser Asp Trp Val Asp Gln Phe Arg Val Lys Phe Leu
145 150 155 160

Gly Ser Val Gln Val Pro Tyr His Lys Gly Asn Asp Val Leu Cys Ala
165 170 175

Ala Met Gln Lys Ile Ala Thr Thr Arg Arg Leu Thr Val His Phe Asn
180 185 190

Pro Pro Ser Ser Cys Val Leu Glu Ile Ser Val Arg Gly Val Lys Ile
195 200 205

Gly Val Lys Ala Asp Asp Ser Gln Glu Ala Lys Gly Asn Lys Cys Ser
210 215 220

His Phe Phe Gln Leu Lys Asn Ile Ser Phe Cys Gly Tyr His Pro Lys
225 230 235 240

Asn Asn Lys Tyr Phe Gly Phe Ile Thr Lys His Pro Ala Asp His Arg
245 250 255

Phe Ala Cys His Val Phe Val Ser Glu Asp Ser Thr Lys Ala Leu Ala
260 265 270

Glu Ser Val Gly Arg Ala Phe Gln Gln Phe Tyr Lys Gln Phe Val Glu
275 280 285

Tyr Thr Cys Pro Thr Glu Asp Ile Tyr Leu Glu
290 295

(2) INFORMATION FOR SEQ ID NO: 251:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 251:

Leu Leu Tyr Leu Leu Lys Val Xaa Val Ile Phe Val Phe Ser Ser Ser
1 5 10 15

Lys Gly Val Thr Leu Val Ser Met Asn Leu Thr Ser Phe Phe Val Ser
20 25 30

Ser Val Leu Ala Cys Phe Ser Xaa
35 40

(2) INFORMATION FOR SEQ ID NO: 252:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 594 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 252:

Met Pro Ala Ser Ser Leu Glu Ser Arg Ser Phe Leu Leu Ala Lys Lys
1 5 10 15

Ser Gly Glu Asn Val Ala Lys Phe Ile Ile Asn Ser Tyr Pro Lys Tyr
20 25 30

Phe Gln Lys Asp Ile Ala Glu Pro His Ile Pro Cys Leu Met Pro Glu
35 40 45

Tyr Phe Glu Pro Gln Ile Lys Asp Ile Ser Glu Ala Ala Leu Lys Glu
50 55 60

Arg Ile Glu Leu Arg Lys Val Lys Ala Ser Val Asp Met Phe Asp Gln
65 70 75 80

Leu Leu Gln Ala Gly Thr Thr Val Ser Leu Glu Thr Thr Asn Ser Leu
85 90 95

Leu Asp Xaa Leu Cys Tyr Tyr Gly Asp Gln Glu Pro Ser Thr Asp Tyr
100 105 110

His Phe Gln Gln Thr Gly Gln Ser Glu Ala Leu Glu Glu Glu Asn Asp
115 120 125

Glu Thr Ser Arg Arg Lys Ala Gly His Gln Phe Gly Val Thr Trp Arg
130 135 140

[illegible]
165 170 175

```
Tyr Glu Gln Ala Leu Asn Leu Tyr Thr Glu Leu Leu Asn Asn Arg Leu
            180                 185                 190

His Ala Asp Val Tyr Thr Phe Asn Ala Leu Ile Glu Ala Thr Val Cys
        195                 200                 205

Ala Ile Asn Glu Lys Phe Glu Glu Lys Trp Ser Lys Ile Leu Glu Leu
    210                 215                 220

Leu Arg His Met Val Ala Gln Lys Val Lys Pro Asn Leu Gln Thr Phe
225                 230                 235                     240

Asn Thr Ile Leu Lys Cys Leu Arg Arg Phe His Val Phe Ala Arg Ser
                245                 250                 255

Pro Ala Leu Gln Val Leu Arg Glu Met Lys Ala Ile Gly Ile Glu Pro
            260                 265                 270

Ser Leu Ala Thr Tyr His His Ile Ile Arg Leu Phe Asp Gln Pro Gly
        275                 280                 285

Asp Pro Leu Lys Arg Ser Ser Phe Ile Ile Tyr Asp Ile Met Asn Glu
    290                 295                 300

Leu Met Gly Lys Arg Phe Ser Pro Lys Asp Pro Asp Asp Asp Lys Phe
305                 310                 315                     320

Phe Gln Ser Ala Met Ser Ile Cys Ser Ser Leu Arg Asp Leu Glu Leu
                325                 330                 335

Ala Tyr Gln Val His Gly Leu Leu Lys Thr Gly Asp Asn Trp Lys Phe
            340                 345                 350

Ile Gly Pro Asp Gln His Arg Asn Phe Tyr Tyr Ser Lys Phe Phe Asp
        355                 360                 365

Leu Ile Cys Leu Met Glu Gln Ile Asp Val Thr Leu Lys Trp Tyr Glu
    370                 375                 380

Asp Leu Ile Pro Ser Ala Tyr Phe Pro His Ser Gln Thr Met Ile His
385                 390                 395                     400

Leu Leu Gln Ala Leu Asp Val Ala Asn Arg Leu Glu Val Ile Pro Lys
                405                 410                 415

Ile Trp Lys Asp Ser Lys Glu Tyr Gly His Thr Phe Arg Ser Asp Leu
            420                 425                 430

Arg Glu Glu Ile Leu Met Leu Met Ala Arg Asp Lys His Pro Pro Glu
        435                 440                 445

Leu Gln Val Ala Phe Ala Asp Cys Ala Ala Asp Ile Lys Ser Ala Tyr
    450                 455                 460

Glu Ser Gln Pro Ile Arg Gln Thr Ala Gln Asp Trp Pro Ala Thr Ser
465                 470                 475                     480

Leu Asn Cys Ile Ala Ile Leu Phe Leu Arg Ala Gly Arg Thr Gln Glu
                485                 490                 495
```